<?xml version="1.0" encoding="utf-8"?>
<documents>
  <document>
    <id>330278</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=330278]]&gt;</url>
    <title>2009 Annual Evidence Update on Alcoholic Liver Disease - Adverse effects</title>
    <publicationDate>2009-12-07T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,ALCOHOLIC LIVER DISEASE,RECENT ADDITIONS,DECEMBER 2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Alcoholic Liver Disease - Adverse effects&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;I&gt;Reviewed by Andrew Austin, Consultant Hepatologist, Royal Derby Hospital&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;
&lt;P style="COLOR: #306754"&gt;&lt;B&gt;Randomised controlled trials:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;As a junior house officer on a Liver Transplant Unit, I clearly remember the anxiety induced by the need to prescribe appropriate analgesia for patients after acute liver injury and my disbelief when first instructed to use paracetamol (acetaminophen) by senior colleagues. I soon learned that opiates and non-steroidal anti-inflammatory drugs were far more likely to lead to significant complications, but what evidence was this advice based upon? Recent studies in normal healthy subjects have reported hepatic enzyme elevations in one-third of subjects given 4g daily for up to two weeks. This has led to renewed uncertainty about the safety of therapeutic doses of paracetamol in recently abstinent alcoholics thought to be particularly vulnerable given high levels of CYP2E1 induction and low levels of glutathione. &lt;A href="#bartels"&gt;Bartels et al&lt;/A&gt; and &lt;A href="#kuffner"&gt;Kuffner et al&lt;/A&gt; have both studied patients entering rehabilitation using similar 3-5 days exposure to therapeutic doses or placebo and were unable to identify any increase in markers of liver injury indicating that short term use in this patient group is safe.&lt;/P&gt;
&lt;P&gt;When considering adjunctive therapy for patients in treatment for alcohol misuse then naltrexone is one of several options that have a modest beneficial effect. However, there have been reports of hepatotoxicity when high doses are administered orally. To address this concern with respect to a newer injectable once-monthly formulation, &lt;A href="#lucey"&gt;Lucey et al&lt;/A&gt; have published the hepatic safety data from the earlier RCT in detail and found no evidence of increased rates of liver toxicity compared with placebo.&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #306754"&gt;&lt;B&gt;List of articles:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=bartels&gt;&lt;/A&gt;Bartels S, Sivilotti M, Crosby D, Richard J. &lt;A href="nelh:330283:0" name=internalLink&gt;Are recommended doses of acetaminophen hepatotoxic for recently abstinent alcoholics? A randomized trial.&lt;/A&gt;&lt;/A&gt; &lt;I&gt;Clin Toxicol (Phila)&lt;/I&gt; 2008;46(3):243-9.&lt;/P&gt;
&lt;P&gt;&lt;A name=kuffner&gt;&lt;/A&gt;Kuffner EK, Green JL, Bogdan GM, Knox PC, Palmer RB, Heard K, Slattery, JT, Dart RC. &lt;A href="nelh:330284:0" name=internalLink&gt;The effect of acetaminophen (four grams a day for three consecutive days) on hepatic tests in alcoholic patients--a multicenter randomized study.&lt;/A&gt;&lt;/A&gt; &lt;I&gt;BMC Med&lt;/I&gt; 2007;5:13.&lt;/P&gt;
&lt;P&gt;&lt;A name=lucey&gt;&lt;/A&gt;Lucey MR, Silverman BL, Illeperuma A, O'Brien CP &lt;A href="nelh:330289:0" name=internalLink&gt;Hepatic safety of once-monthly injectable extended-release naltrexone administered to actively drinking alcoholics.&lt;/A&gt; &lt;I&gt;Alcohol Clin Exp Res&lt;/I&gt; 2008;32(3):498-504.&lt;/P&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #306754; COLOR: #ffffff"&gt;Alcoholic Liver Disease Annual Evidence Update 2009&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #addfff"&gt;
&lt;P&gt;&lt;A href="nelh:332182:0" name=internalLink&gt;Introduction&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:332194:0" name=internalLink&gt;General&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:332177:0" name=internalLink&gt;Diagnosis&lt;/A&gt; &lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:332178:0" name=internalLink&gt;Alcoholic hepatitis&lt;/A&gt; | &lt;A href="nelh:332183:0" name=internalLink&gt;Alcoholic cirrhosis&lt;/A&gt; | &lt;A href="nelh:332184:0" name=internalLink&gt;Other&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:330278:0" name=internalLink&gt;&lt;B&gt;Adverse effects&lt;/B&gt;&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:332185:0" name=internalLink&gt;Other&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:332195:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:332187:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:331666:0" name=internalLink&gt;Statistics, policy and links&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:332189:0" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>332177</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=332177]]&gt;</url>
    <title>2009 Annual Evidence Update on Alcoholic Liver Disease - Diagnosis</title>
    <publicationDate>2009-12-07T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,ALCOHOLIC LIVER DISEASE,DIAGNOSTIC PROCEDURES,BIOPSY,LIVER,BLOOD TESTS,RECENT ADDITIONS,DECEMBER 2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Alcoholic Liver Disease - Diagnosis&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;I&gt;Reviewed by Dermot Gleeson, Consultant in Hepatology, Liver Unit, Sheffield Teaching Hospitals, Royal Hallamshire Hospital&lt;/I&gt; &lt;/P&gt;
&lt;P style="COLOR: #306754"&gt;&lt;B&gt;Systematic reviews:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The paper by &lt;A href="#halfon"&gt;Halfon, Munteanu and Poynard&lt;/A&gt; is an extensive meta analysis of studies assessing the performance of the Fibrotest in four liver diseases: chronic hepatitis B (HBV) and C (HCV), alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD). The test is assessed first in regard to its correlation with liver biopsy in the assessment of fibrosis severity, and secondly in regard to its value in predicting survival. Most of the 38 studies included (and tabulated in detail) are in patients with HCV. Only two studies (from the same institution) are in ALD. For distinguishing mild (Metavir F0-1 from severe (F2-3) fibrosis on biopsy, the Fibrotest had an adjusted AUROC of 0.84-0.86 for HVB, ALD and NAFLD and 0.80 for HBV. For prediction of complications and mortality, Fibrotest was better than liver biopsy in patients with HCV. In patients with HBV, the combination of the Fibrotest and baseline viral load was highly predictive of 4 year survival. In ALD, Fibrotest gave similar results on fibrosis grade to liver biopsy in predicting mortality. &lt;/P&gt;
&lt;P&gt;The Fibrotest may be unreliable in Gilbert's syndrome, haemolysis and acute inflammation. Unfortunately, the relative accuracies of the Fibrotest and Transient Elastography (Fibroscan) in assessing fibrosis are not discussed. Nor is the potential influence of liver inflammation on Fibrotest values.&lt;/P&gt;
&lt;P&gt;The authors (two of whom have a declared financial interest in the manufacturer of the Fibrotest) advocate a moratorium on liver biopsy as a first line procedure in assessment chronic liver disease, where the aetiology is clear. The case for this seems compelling in HCV, but is, I believe, less so in HBV, NAFL and ALD, where the correlation and the relative prognostic accuracies of Fibrotest and liver biopsy probably need more comprehensive assessment. Also, in ALD, fibrosis severity (however assessed) may be less important prognostically than other parameters, such as severity of alcoholic hepatitis, severity ofliver dysfunction (as assessed by scores such as Child-Pugh, MELD and Glasgow) and subsequent drinking behaviour.&lt;/P&gt;
&lt;P&gt;&lt;A href="#poynard"&gt;Poynard et al.&lt;/A&gt; is a meta analysis of 30 studies, also assessing the performance of the Fibrotest in four liver diseases: HBV, HCV, ALD and NAFLD. The main question was the degree of correlation with liver biopsy in assessment of fibrosis severity. As well as a standard meta-analysis combining all published studies, the authors performed a second meta-analysis of an integrated database combining individual results from about half the patients, obtained from the authors of the individual studies. A process is discussed of adjusting AUROC values for the difference in mean fibrosis stages in the "advanced" and non advanced fibrosis groups. For the distinction between mild (Metavir F0-F1) and severe (F2-4) fibrosis, pooled adjusted AUROC values of 0.84-0.86 are found for the four liver diseases, with no significant differences between them.&lt;/P&gt;
&lt;P&gt;The authors also compared AUROC values for distinguishing between adjacent fibrosis stages. As expected values were lower than for those cited above for distinction of F01 for F2-4. AUROC for F0 vs F1 and F3 vs F4 (end of fibrosis spectrum) were similar to that for F1 vs Fr (middle of fibrosis spectrum). The authors feel that this refutes assertions that the Fibrotest is less useful in classification of the intermediate stages of fibrosis. &lt;/P&gt;
&lt;P&gt;This 2007 meta analysis adds little to the more up-to date and comprehensive later (2008) review (see above) and there is considerable (although not total) overlap between them.&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #306754"&gt;&lt;B&gt;List of articles:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=halfon&gt;&lt;/A&gt;Halfon P, Munteanu M, Poynard T. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=323814" target="_blank"&gt;FibroTest-ActiTest as a non-invasive marker of liver fibrosis.&lt;/A&gt; &lt;I&gt;Gastroenterol Clin Biol&lt;/I&gt; 2008;32(6 Suppl 1):22-39.&lt;/P&gt;
&lt;P&gt;&lt;A name=poynard&gt;&lt;/A&gt;Poynard T, Morra R, Halfon P, Castera L, Ratziu V, Imbert-Bismut F, Naveau S, Thabut D, Lebrec D, Zoulim F, Bourliere M, Cacoub P, Messous D, Munteanu M, de Ledinghen V. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=293837" target="_blank"&gt;Meta-analyses of FibroTest diagnostic value in chronic liver disease.&lt;/A&gt; &lt;I&gt;BMC Gastroenterol&lt;/I&gt; 2007;7:40.&lt;/P&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #306754; COLOR: #ffffff"&gt;Alcoholic Liver Disease Annual Evidence Update 2009&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #addfff"&gt;
&lt;P&gt;&lt;A href="nelh:332182:0" name=internalLink&gt;Introduction&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:332194:0" name=internalLink&gt;General&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:332177:0" name=internalLink&gt;&lt;B&gt;Diagnosis&lt;/B&gt;&lt;/A&gt; &lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:332178:0" name=internalLink&gt;Alcoholic hepatitis&lt;/A&gt; | &lt;A href="nelh:332183:0" name=internalLink&gt;Alcoholic cirrhosis&lt;/A&gt; | &lt;A href="nelh:332184:0" name=internalLink&gt;Other&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:330278:0" name=internalLink&gt;Adverse effects&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:332185:0" name=internalLink&gt;Other&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:332195:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:332187:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:331666:0" name=internalLink&gt;Statistics, policy and links&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:332189:0" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>332195</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=332195]]&gt;</url>
    <title>2009 Annual Evidence Update on Alcoholic Liver Disease - Foreign language articles</title>
    <publicationDate>2009-12-07T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,ALCOHOLIC LIVER DISEASE,RECENT ADDITIONS,DECEMBER 2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Alcoholic Liver Disease - Foreign language articles&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;The following articles were identified by the search as being potentially relevant to the AEU, but were not sent out for appraisal because the full text is in a language other than English. They are included here for interest, and for the sake of completeness.&lt;/P&gt;&lt;BR&gt; &lt;P&gt;Fernández-Rodríguez CM, Lledó JL, López-Serrano P, Gutiérrez ML, Alonso S, Pérez-Fernández MT, Fernández Gil M, Pazos R, Tolon R, Hernández T, Sanz P. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18942901" target="_blank"&gt;Effect of pentoxifylline on survival, cardiac function and both portal and systemic hemodynamics in advanced alcoholic cirrhosis--a randomized double-blind placebo-controlled trial.&lt;/A&gt; &lt;I&gt;Rev Esp Enferm Dig&lt;/I&gt; 2008;100(8):481-9.&lt;BR&gt;&lt;I&gt;&lt;B&gt;Language:&lt;/B&gt; Spanish&lt;/I&gt;&lt;/P&gt;&lt;BR&gt; &lt;P&gt;Lazebnik LB, Mikheeva OM, Toporkov AS, Komissarenko IA, Vasnev OS, Fedulenkova LV. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18389599" target="_blank"&gt;Correction of portal hypertension by beta-adrenoblockers (atenolol and metoprolol) and inhibitors of ACE (lisinopril and enalapril) in liver cirrhosis.&lt;/A&gt; &lt;I&gt;Eksp Klin Gastroenterol&lt;/I&gt; 2007;(5):57-6.&lt;BR&gt;&lt;I&gt;&lt;B&gt;Language:&lt;/B&gt; Russian &lt;/I&gt;&lt;/P&gt;&lt;BR&gt; &lt;P&gt;Lligoña A, Freixa N, Bataller R, Monràs M, Rimola A. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19232780" target="_blank"&gt;Clinical guideline for the evaluation of liver transplant candidates with addictions.&lt;/A&gt; &lt;I&gt;Gastroenterol Hepatol&lt;/I&gt; 2009;32(3):155-61.&lt;BR&gt;&lt;I&gt;&lt;B&gt;Language:&lt;/B&gt; Spanish &lt;/I&gt;&lt;/P&gt;&lt;BR&gt; &lt;P&gt;Yang YY. &lt;A href="http://www.jcimjournal.com/en/FullText2.aspx?articleID=167219772007030343" target="_blank"&gt;Clinical observation of treatment of alcoholic fatty liver by Gehua Jiejiu Xiaozhi Decoction.&lt;/A&gt; &lt;I&gt;Zhong Xi Yi Jie He Xue Bao&lt;/I&gt; 2007;5(3):343-5.&lt;BR&gt;&lt;I&gt;&lt;B&gt;Language:&lt;/B&gt; Chinese&lt;/I&gt;&lt;/P&gt;&lt;BR&gt; &lt;TABLE align=center&gt; &lt;TBODY&gt; &lt;TR&gt; &lt;TD style="COLOR: #ffffff; BACKGROUND-COLOR: #306754; TEXT-ALIGN: center"&gt;Alcoholic Liver Disease Annual Evidence Update 2009&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD style="BACKGROUND-COLOR: #addfff; TEXT-ALIGN: center"&gt; &lt;P&gt;&lt;A href="nelh:332182:0" name=internalLink&gt;Introduction&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:332194:0" name=internalLink&gt;General&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:332177:0" name=internalLink&gt;Diagnosis&lt;/A&gt; &lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:332178:0" name=internalLink&gt;Alcoholic hepatitis&lt;/A&gt; | &lt;A href="nelh:332183:0" name=internalLink&gt;Alcoholic cirrhosis&lt;/A&gt; | &lt;A href="nelh:332184:0" name=internalLink&gt;Other&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:330278:0" name=internalLink&gt;Adverse effects&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:332185:0" name=internalLink&gt;Other&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:332195:0" name=internalLink&gt;&lt;B&gt;Foreign language articles&lt;/B&gt;&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:332187:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:331666:0" name=internalLink&gt;Statistics, policy and links&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:332189:0" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>332194</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=332194]]&gt;</url>
    <title>2009 Annual Evidence Update on Alcoholic Liver Disease - General</title>
    <publicationDate>2009-12-07T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,ALCOHOLIC LIVER DISEASE,RECENT ADDITIONS,DECEMBER 2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Alcoholic Liver Disease - General&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;A general guideline from China on the diagnosis and treatment of alcoholic liver disease was published in 2008: &lt;/P&gt;
&lt;P&gt;Zeng MD, Li YM, Chen CW, Lu LG, Fan JG, Wang BY, Mao YM; Chinese National Consensus Workshop on Nonalcoholic Fatty Liver Disease. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=332193" target="_blank"&gt;Guidelines for the diagnosis and treatment of alcoholic liver disease.&lt;/A&gt; &lt;I&gt;J Dig Dis&lt;/I&gt; 2008;9(2):113-6.&lt;/P&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #306754; COLOR: #ffffff"&gt;Alcoholic Liver Disease Annual Evidence Update 2009&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #addfff"&gt;
&lt;P&gt;&lt;A href="nelh:332182:0" name=internalLink&gt;Introduction&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:332194:0" name=internalLink&gt;&lt;B&gt;General&lt;/B&gt;&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:332177:0" name=internalLink&gt;Diagnosis&lt;/A&gt; &lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:332178:0" name=internalLink&gt;Alcoholic hepatitis&lt;/A&gt; | &lt;A href="nelh:332183:0" name=internalLink&gt;Alcoholic cirrhosis&lt;/A&gt; | &lt;A href="nelh:332184:0" name=internalLink&gt;Other&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:330278:0" name=internalLink&gt;Adverse effects&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:332185:0" name=internalLink&gt;Other&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:332195:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:332187:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:331666:0" name=internalLink&gt;Statistics, policy and links&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:332189:0" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>332182</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=332182]]&gt;</url>
    <title>2009 Annual Evidence Update on Alcoholic Liver Disease - Introduction</title>
    <publicationDate>2009-12-07T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,ALCOHOLIC LIVER DISEASE,RECENT ADDITIONS,DECEMBER 2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Alcoholic Liver Disease - Introduction&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence Annual Evidence Updates (AEUs) attempt to draw together recently published, high quality evidence – focusing particularly on systematic reviews and published guidelines - which it is hoped will inform and enhance the decision making and planning of clinicians, commissioners and others involved in the process of health care. &lt;/P&gt; &lt;P&gt;Alcohol misuse produces a spectrum of liver injury ranging from simple fatty change through alcoholic hepatitis to cirrhosis and, in some 20% of individuals, to hepatocellular carcinoma. In this AEU, we present an overview of the best systematic reviews and selected primary research from the past two years, along with commentary from experts in the field.&amp;nbsp;A detailed literature search from 2008-2009 identified 715 potential pieces of evidence (see &lt;A href="nelh:332189:0" name=internalLink&gt;methods for retrieving and evaluating the evidence&lt;/A&gt; for more information). Following a process of filtering and peer review (with thanks to the reviewers listed below) 27 of these form the basis of this AEU. We also provide links to useful policy documents and other items of interest.&lt;/P&gt; &lt;P&gt;It is imperative that those involved in commissioning and delivering care are apprised of the best available evidence and guidelines against which to review their service. We hope that the AEU in alcoholic liver disease will provide a prime source of such evidence.&lt;/P&gt; &lt;P&gt;A summary of the methods used for retrieving and evaluating the evidence can be found &lt;A href="nelh:332189:0" name=internalLink&gt;&lt;A href="nelh:323984:0" name=internalLink&gt;here&lt;/A&gt;&lt;/A&gt;. The evidence has been split into sections as follows:&lt;/P&gt; &lt;UL&gt; &lt;LI&gt;&lt;A href="nelh:332194:0" name=internalLink&gt;General&lt;/A&gt;&lt;/LI&gt; &lt;LI&gt;&lt;A href="nelh:332177:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;/LI&gt; &lt;LI&gt;Treatment &lt;/LI&gt; &lt;UL&gt; &lt;LI&gt;&lt;A href="nelh:332178:0" name=internalLink&gt;Alcoholic hepatitis&lt;/A&gt;&lt;/LI&gt; &lt;LI&gt;&lt;A href="nelh:332183:0" name=internalLink&gt;Alcoholic cirrhosis&lt;/A&gt;&lt;/LI&gt; &lt;LI&gt;&lt;A href="nelh:332185:0" name=internalLink&gt;Other&lt;/A&gt;&lt;/LI&gt;&lt;BR&gt;&lt;/UL&gt; &lt;LI&gt;&lt;A href="nelh:330278:0" name=internalLink&gt;Adverse effects&lt;/A&gt;&lt;/LI&gt; &lt;LI&gt;&lt;A href="nelh:332185:0" name=internalLink&gt;Other&lt;/A&gt; &lt;/LI&gt;&lt;/UL&gt; &lt;P&gt;Click on the sections above to find links to critically appraised systematic reviews, expert commentaries and other information of interest, or download the &lt;A href="http://www.library.nhs.uk/SpecialistLibrarySearch/Download.aspx?resID=332182" target="_blank"&gt;pdf version&lt;/A&gt;.&lt;/P&gt; &lt;P&gt;We also have provided a list of &lt;A href="nelh:332187:0" name=internalLink&gt;&lt;A href="nelh:323978:0" name=internalLink&gt;treatment uncertainties&lt;/A&gt;&lt;/A&gt;, taken from the articles included in the AEU.&lt;/P&gt; &lt;P&gt;This year's update has been put together by the NHS Evidence - gastroenterology and liver diseases Project Team, with expert advice and commentaries provided by our liver disease topic leads. These are:&lt;/P&gt; &lt;UL&gt; &lt;LI&gt;Andrew Austin, Consultant Hepatologist, Royal Derby Hospital&lt;/LI&gt; &lt;LI&gt;Dermot Gleeson, Consultant in Hepatology, Liver Unit, Sheffield Teaching Hospitals, Royal Hallamshire Hospital &lt;/LI&gt; &lt;LI&gt;Marsha Morgan, Consultant Physician, Royal Free Hospital, London&lt;/LI&gt;&lt;/UL&gt; &lt;P&gt;&amp;nbsp;&lt;/P&gt; &lt;P&gt;We'd like to thank the topic leads for their generous help and support with this project.&lt;/P&gt; &lt;P&gt;&amp;nbsp;&lt;/P&gt; &lt;TABLE align=center&gt; &lt;TBODY&gt; &lt;TR&gt; &lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #306754; COLOR: #ffffff"&gt;Alcoholic Liver Disease Annual Evidence Update 2009&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #addfff"&gt; &lt;P&gt;&lt;A href="nelh:332182:0" name=internalLink&gt;&lt;B&gt;Introduction&lt;/B&gt;&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:332194:0" name=internalLink&gt;General&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:332177:0" name=internalLink&gt;Diagnosis&lt;/A&gt; &lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:332178:0" name=internalLink&gt;Alcoholic hepatitis&lt;/A&gt; | &lt;A href="nelh:332183:0" name=internalLink&gt;Alcoholic cirrhosis&lt;/A&gt; | &lt;A href="nelh:332184:0" name=internalLink&gt;Other&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:330278:0" name=internalLink&gt;Adverse effects&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:332185:0" name=internalLink&gt;Other&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:332195:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:332187:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:331666:0" name=internalLink&gt;Statistics, policy and links&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:332189:0" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>332189</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=332189]]&gt;</url>
    <title>2009 Annual Evidence Update on Alcoholic Liver Disease - Methods for retrieving and evaluating the evidence</title>
    <publicationDate>2009-12-07T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,ALCOHOLIC LIVER DISEASE,RECENT ADDITIONS,DECEMBER 2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Alcoholic Liver Disease - Methods for retrieving and evaluating the evidence&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;This is the first annual evidence update we have performed on the topic of alcoholic liver disease. We searched for material published since the beginning of 2007; future updates will be produced on a yearly basis to expand and update the content here. As is the normal practice with AEUs we searched for guidelines and systematic reviews, but because there are fewer articles written on this topic than there are in the other areas we produce AEUs for, we were able to extend our search in order to find randomised controlled trials as well. We were primarily looking for articles in English; however, foreign language articles were included in the search process. As translations for these articles were not available, the article titles have been listed separately. &lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #306754"&gt;&lt;B&gt;Search strategy:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The following resources were searched: 
&lt;UL&gt;
&lt;LI&gt;MEDLINE&lt;/LI&gt;
&lt;LI&gt;EMBASE&lt;/LI&gt;
&lt;LI&gt;CINAHL&lt;/LI&gt;
&lt;LI&gt;Web of Science&lt;/LI&gt;
&lt;LI&gt;PsycINFO&lt;/LI&gt;
&lt;LI&gt;AMED&lt;/LI&gt;
&lt;LI&gt;British Nursing Index&lt;/LI&gt;
&lt;LI&gt;National Library of Guidelines&lt;/LI&gt;
&lt;LI&gt;NHS Evidence Specialist Collections &lt;/LI&gt;
&lt;LI&gt;Database of Abstracts of Reviews of Effects &lt;/LI&gt;
&lt;LI&gt;NHS Economic Evaluation Database&lt;/LI&gt;
&lt;LI&gt;HTA Database&lt;/LI&gt;&lt;/UL&gt;The search strategy for MEDLINE, which was modified for the other resources, appears &lt;A href="#strategy"&gt;below&lt;/A&gt;. We combined this with a modified SIGN systematic review and randomised controlled trial &lt;A href="#filters"&gt;filters&lt;/A&gt; in all cases except the searches of the BNI (due to its small size) and the NLH, the Specialist Collections, DARE, NHS EED and HTA (because they consist entirely of the types of publication that we were interested in). 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;After de-duplication 715 articles were retrieved.&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #306754"&gt;&lt;B&gt;Inclusion and exclusion criteria:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Included articles had to meet the following criteria:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Publication types: systematic review, consensus report, guideline, protocol, care pathway, economic evaluation, health technology assessment, randomised controlled trial. &lt;/LI&gt;
&lt;LI&gt;Published in 2007, 2008 or 2009&lt;/LI&gt;
&lt;LI&gt;Main condition under investigation was fatty liver disease, hepatitis, cirrhosis, hepatocellular carcinoma, liver failure, ascites or fibrosis, or main procedure under investigation was liver resection or liver transplantation, and either: 
&lt;UL&gt;
&lt;LI&gt;Alcohol was the aetiology of liver disease in all patients under investigation&lt;/LI&gt;
&lt;LI&gt;Alcohol was the aetiology of liver disease in a significant proportion of patients under investigation&lt;/LI&gt;
&lt;LI&gt;The paper examined different aetiologies of liver disease separately, and alcohol was one of those aetiologies &lt;/LI&gt;&lt;/UL&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Once the inclusion criteria were applied, 41 articles were left. Of these, 4 were foreign language articles, 2 were Cochrane systematic reviews, and 2 were guidelines.&lt;/P&gt;
&lt;P&gt;The Cochrane systematic reviews and guidelines were automatically included in the Evidence Update. The foreign language studies were not sent out to reviewers because of translation difficulties, but are listed in a separate section of the Evidence Update. This left 33 articles to be sent to our reviewers for appraisal.&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #306754"&gt;&lt;B&gt;Critical appraisal process:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Before sending out, the articles were divided into categories as follows:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Diagnosis&lt;/LI&gt;
&lt;LI&gt;Treatment&lt;/LI&gt;
&lt;LI&gt;Adverse effects &lt;/LI&gt;
&lt;LI&gt;Risk factors and prognosis &lt;/LI&gt;
&lt;LI&gt;Other&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Using these categories as a guide, the papers were divided up and sent to our reviewers. The reviewers then appraised the articles for their validity, relevance and rigour. Following the receipt of their comments, we included in the Evidence Update 25 articles that were deemed to meet the standards.&lt;BR&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #306754"&gt;&lt;B&gt;AEU process flowchart:&lt;/B&gt;&lt;/P&gt;&lt;IMG src="https://rmsadmin.library.nhs.uk/libraryImages/gastroliver/contentID332189/nelhImp_0000_aldaeuflowchart.jpg"&gt;&lt;/IMG&gt;&lt;BR&gt;
&lt;P style="COLOR: #306754"&gt;&lt;B&gt;&lt;A name=strategy&gt;&lt;/A&gt;MEDLINE search strategy&lt;/B&gt;&lt;/P&gt;
&lt;TABLE style="TABLE-LAYOUT: fixed"&gt;
&lt;TBODY&gt;
&lt;TR style="FONT-FAMILY: Courier,monospace; FONT-SIZE: 7pt"&gt;
&lt;TD style="BORDER-BOTTOM: #000000 thin solid; BORDER-LEFT: #000000 thin solid; PADDING-BOTTOM: 5pt; PADDING-LEFT: 5pt; PADDING-RIGHT: 5pt; BORDER-TOP: #000000 thin solid; BORDER-RIGHT: #000000 thin solid; PADDING-TOP: 5pt" ?&gt;&lt;STRONG&gt;1&lt;/STRONG&gt; exp Liver Diseases, Alcoholic/&lt;BR&gt;&lt;STRONG&gt;2&lt;/STRONG&gt; Alcohol Drinking/&lt;BR&gt;&lt;STRONG&gt;3&lt;/STRONG&gt; alcohol*.ti,ab.&lt;BR&gt;&lt;STRONG&gt;4&lt;/STRONG&gt; achol*.ti,ab.&lt;BR&gt;&lt;STRONG&gt;5&lt;/STRONG&gt; alchol*.ti,ab.&lt;BR&gt;&lt;STRONG&gt;6&lt;/STRONG&gt; 3 or 2 or 4 or 5&lt;BR&gt;&lt;STRONG&gt;7&lt;/STRONG&gt; fatty liver/&lt;BR&gt;&lt;STRONG&gt;8&lt;/STRONG&gt; fatty liver.ti,ab.&lt;BR&gt;&lt;STRONG&gt;9&lt;/STRONG&gt; steatosis.ti,ab.&lt;BR&gt;&lt;STRONG&gt;10&lt;/STRONG&gt; hepatosteatosis.ti,ab.&lt;BR&gt;&lt;STRONG&gt;11&lt;/STRONG&gt; hepatitis/&lt;BR&gt;&lt;STRONG&gt;12&lt;/STRONG&gt; hepatitis, chronic/&lt;BR&gt;&lt;STRONG&gt;13&lt;/STRONG&gt; hepatitis.ti,ab.&lt;BR&gt;&lt;STRONG&gt;14&lt;/STRONG&gt; steatohepatitis.ti,ab.&lt;BR&gt;&lt;STRONG&gt;15&lt;/STRONG&gt; hepatitides.ti,ab.&lt;BR&gt;&lt;STRONG&gt;16&lt;/STRONG&gt; (liver adj3 inflamm*).ti,ab.&lt;BR&gt;&lt;STRONG&gt;17&lt;/STRONG&gt; Liver Cirrhosis/&lt;BR&gt;&lt;STRONG&gt;18&lt;/STRONG&gt; liver injur*.ti,ab.&lt;BR&gt;&lt;STRONG&gt;19&lt;/STRONG&gt; liver.ti,ab.&lt;BR&gt;&lt;STRONG&gt;20&lt;/STRONG&gt; hepat*.ti,ab.&lt;BR&gt;&lt;STRONG&gt;21&lt;/STRONG&gt; laennec*.ti,ab.&lt;BR&gt;&lt;STRONG&gt;22&lt;/STRONG&gt; 19 or 20 or 21&lt;BR&gt;&lt;STRONG&gt;23&lt;/STRONG&gt; cirrho*.ti,ab.&lt;BR&gt;&lt;STRONG&gt;24&lt;/STRONG&gt; fibros?s.ti,ab.&lt;BR&gt;&lt;STRONG&gt;25&lt;/STRONG&gt; ascites.ti,ab.&lt;BR&gt;&lt;STRONG&gt;26&lt;/STRONG&gt; Ascites/&lt;BR&gt;&lt;STRONG&gt;27&lt;/STRONG&gt; 23 or 24 or 25 or 26&lt;BR&gt;&lt;STRONG&gt;28&lt;/STRONG&gt; 27 and 22&lt;BR&gt;&lt;STRONG&gt;29&lt;/STRONG&gt; hepatofibrosis.ti,ab.&lt;BR&gt;&lt;STRONG&gt;30&lt;/STRONG&gt; exp Liver Failure/&lt;BR&gt;&lt;STRONG&gt;31&lt;/STRONG&gt; liver failure.ti,ab.&lt;BR&gt;&lt;STRONG&gt;32&lt;/STRONG&gt; hepatic failure.ti,ab.&lt;BR&gt;&lt;STRONG&gt;33&lt;/STRONG&gt; hepatic insufficiency.ti,ab.&lt;BR&gt;&lt;STRONG&gt;34&lt;/STRONG&gt; liver insufficiency.ti,ab.&lt;BR&gt;&lt;STRONG&gt;35&lt;/STRONG&gt; end stage liver disease.ti,ab.&lt;BR&gt;&lt;STRONG&gt;36&lt;/STRONG&gt; ESLD.ti,ab.&lt;BR&gt;&lt;STRONG&gt;37&lt;/STRONG&gt; Carcinoma, Hepatocellular/&lt;BR&gt;&lt;STRONG&gt;38&lt;/STRONG&gt; hepatocellular carcinom*.ti,ab.&lt;BR&gt;&lt;STRONG&gt;39&lt;/STRONG&gt; HCC.ti,ab.&lt;BR&gt;&lt;STRONG&gt;40&lt;/STRONG&gt; Liver transplantation/&lt;BR&gt;&lt;STRONG&gt;41&lt;/STRONG&gt; liver transplant*.ti,ab.&lt;BR&gt;&lt;STRONG&gt;42&lt;/STRONG&gt; liver resect*.ti,ab.&lt;BR&gt;&lt;STRONG&gt;43&lt;/STRONG&gt; hepat* transplant*.ti,ab.&lt;BR&gt;&lt;STRONG&gt;44&lt;/STRONG&gt; hepat* resect*.ti,ab.&lt;BR&gt;&lt;STRONG&gt;45&lt;/STRONG&gt; 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44&lt;BR&gt;&lt;STRONG&gt;46&lt;/STRONG&gt; 6 and 45&lt;BR&gt;&lt;STRONG&gt;47&lt;/STRONG&gt; 1 or 46 &lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;BR&gt;
&lt;P style="COLOR: #306754"&gt;&lt;B&gt;&lt;A name=filters&gt;&lt;/A&gt;Search filters:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;These is modified from the SIGN filters, which can be found at &lt;A href="http://www.sign.ac.uk/methodology/filters.html" target="_blank"&gt;http://www.sign.ac.uk/methodology/filters.html&lt;/A&gt;. They shown below as used for the MEDLINE search (small adaptations were made for other databases).&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Systematic review filter&lt;/B&gt;&lt;/P&gt;
&lt;TABLE style="BORDER-BOTTOM: #000000 thin solid; BORDER-LEFT: #000000 thin solid; FONT-FAMILY: Courier,serif; FONT-SIZE: 7pt; BORDER-TOP: #000000 thin solid; BORDER-RIGHT: #000000 thin solid"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="PADDING-BOTTOM: 5pt; PADDING-LEFT: 5pt; PADDING-RIGHT: 5pt; PADDING-TOP: 5pt"&gt;&lt;STRONG&gt;1&lt;/STRONG&gt; Meta-Analysis as Topic/&lt;BR&gt;&lt;STRONG&gt;2&lt;/STRONG&gt; Meta-Analysis/&lt;BR&gt;&lt;STRONG&gt;3&lt;/STRONG&gt; metaanaly*.mp. &lt;BR&gt;&lt;STRONG&gt;4&lt;/STRONG&gt; meta analy*.mp. &lt;BR&gt;&lt;STRONG&gt;5&lt;/STRONG&gt; (systematic adj (review* or overview*)).mp.&lt;BR&gt;&lt;STRONG&gt;6&lt;/STRONG&gt; exp Review Literature as Topic/&lt;BR&gt;&lt;STRONG&gt;7&lt;/STRONG&gt; 1 or 2 or 3 or 4 or 5 or 6&lt;BR&gt;&lt;STRONG&gt;8&lt;/STRONG&gt; Cochrane.ab.&lt;BR&gt;&lt;STRONG&gt;9&lt;/STRONG&gt; Embase.ab.&lt;BR&gt;&lt;STRONG&gt;10&lt;/STRONG&gt; Medline.ab.&lt;BR&gt;&lt;STRONG&gt;11&lt;/STRONG&gt; Pubmed.ab.&lt;BR&gt;&lt;STRONG&gt;12&lt;/STRONG&gt; (psychlit or psyclit).ab.&lt;BR&gt;&lt;STRONG&gt;13&lt;/STRONG&gt; (psychinfo or psycinfo).ab.&lt;BR&gt;&lt;STRONG&gt;14&lt;/STRONG&gt; (cinahl or cinhal).ab.&lt;BR&gt;&lt;STRONG&gt;15&lt;/STRONG&gt; science citation index.ab.&lt;BR&gt;&lt;STRONG&gt;16&lt;/STRONG&gt; bids.ab.&lt;BR&gt;&lt;STRONG&gt;17&lt;/STRONG&gt; cancerlit.ab.&lt;BR&gt;&lt;STRONG&gt;18&lt;/STRONG&gt; 11 or 9 or 17 or 12 or 15 or 14 or 8 or 16 or 10 or 13&lt;BR&gt;&lt;STRONG&gt;19&lt;/STRONG&gt; reference list$.ab.&lt;BR&gt;&lt;STRONG&gt;20&lt;/STRONG&gt; bibliograph$.ab.&lt;BR&gt;&lt;STRONG&gt;21&lt;/STRONG&gt; hand-search$.ab.&lt;BR&gt;&lt;STRONG&gt;22&lt;/STRONG&gt; relevant journals.ab.&lt;BR&gt;&lt;STRONG&gt;23&lt;/STRONG&gt; manual search$.ab.&lt;BR&gt;&lt;STRONG&gt;24&lt;/STRONG&gt; 22 or 21 or 23 or 19 or 20&lt;BR&gt;&lt;STRONG&gt;25&lt;/STRONG&gt; selection criteria.ab.&lt;BR&gt;&lt;STRONG&gt;26&lt;/STRONG&gt; data extraction.ab.&lt;BR&gt;&lt;STRONG&gt;27&lt;/STRONG&gt; 25 or 26&lt;BR&gt;&lt;STRONG&gt;28&lt;/STRONG&gt; review/&lt;BR&gt;&lt;STRONG&gt;29&lt;/STRONG&gt; 27 and 28&lt;BR&gt;&lt;STRONG&gt;30&lt;/STRONG&gt; Comment/&lt;BR&gt;&lt;STRONG&gt;31&lt;/STRONG&gt; Letter/&lt;BR&gt;&lt;STRONG&gt;32&lt;/STRONG&gt; editorial/&lt;BR&gt;&lt;STRONG&gt;33&lt;/STRONG&gt; 32 or 30 or 31&lt;BR&gt;&lt;STRONG&gt;34&lt;/STRONG&gt; 18 or 24 or 7 or 29&lt;BR&gt;&lt;STRONG&gt;35&lt;/STRONG&gt; 34 not 33&lt;BR&gt;&lt;STRONG&gt;36&lt;/STRONG&gt; limit 35 to animals&lt;BR&gt;&lt;STRONG&gt;37&lt;/STRONG&gt; limit 35 to (animals and humans)&lt;BR&gt;&lt;STRONG&gt;38&lt;/STRONG&gt; 36 not 37&lt;BR&gt;&lt;STRONG&gt;39&lt;/STRONG&gt; 35 not 38 &lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;BR&gt;
&lt;P&gt;&lt;B&gt;Randomised controlled trial filter&lt;/B&gt;&lt;/P&gt;
&lt;TABLE style="BORDER-BOTTOM: #000000 thin solid; BORDER-LEFT: #000000 thin solid; FONT-FAMILY: Courier,serif; FONT-SIZE: 7pt; BORDER-TOP: #000000 thin solid; BORDER-RIGHT: #000000 thin solid"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="PADDING-BOTTOM: 5pt; PADDING-LEFT: 5pt; PADDING-RIGHT: 5pt; PADDING-TOP: 5pt"&gt;&lt;STRONG&gt;1&lt;/STRONG&gt; Randomized controlled trials as Topic/&lt;BR&gt;&lt;STRONG&gt;2&lt;/STRONG&gt; Randomized controlled trial/&lt;BR&gt;&lt;STRONG&gt;3&lt;/STRONG&gt; Random allocation/&lt;BR&gt;&lt;STRONG&gt;4&lt;/STRONG&gt; Double blind method/&lt;BR&gt;&lt;STRONG&gt;5&lt;/STRONG&gt; Single blind method/&lt;BR&gt;&lt;STRONG&gt;6&lt;/STRONG&gt; Clinical trial/&lt;BR&gt;&lt;STRONG&gt;7&lt;/STRONG&gt; exp Clinical Trials as Topic/&lt;BR&gt;&lt;STRONG&gt;8&lt;/STRONG&gt; 1 or 2 or 3 or 4 or 5 or 6 or 7&lt;BR&gt;&lt;STRONG&gt;9&lt;/STRONG&gt; (random* adj2 trial*).ti,ab.&lt;BR&gt;&lt;STRONG&gt;10&lt;/STRONG&gt; (clinic* adj trial*).mp.&lt;BR&gt;&lt;STRONG&gt;11&lt;/STRONG&gt; ((singl* or doubl* or treb* or tripl*) adj (blind* or mask*)).mp.&lt;BR&gt;&lt;STRONG&gt;12&lt;/STRONG&gt; Placebos/&lt;BR&gt;&lt;STRONG&gt;13&lt;/STRONG&gt; Placebo*.mp.&lt;BR&gt;&lt;STRONG&gt;14&lt;/STRONG&gt; (allocat* adj2 random*).mp.&lt;BR&gt;&lt;STRONG&gt;15&lt;/STRONG&gt; 9 or 12 or 14 or 11 or 10 or 13&lt;BR&gt;&lt;STRONG&gt;16&lt;/STRONG&gt; 8 or 15&lt;BR&gt;&lt;STRONG&gt;17&lt;/STRONG&gt; Case report.mp.&lt;BR&gt;&lt;STRONG&gt;18&lt;/STRONG&gt; Case Reports.pt.&lt;BR&gt;&lt;STRONG&gt;19&lt;/STRONG&gt; Letter.pt.&lt;BR&gt;&lt;STRONG&gt;20&lt;/STRONG&gt; Historical Article.pt.&lt;BR&gt;&lt;STRONG&gt;21&lt;/STRONG&gt; 19 or 20 or 17 or 18&lt;BR&gt;&lt;STRONG&gt;22&lt;/STRONG&gt; 16 not 21&lt;BR&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #306754; COLOR: #ffffff"&gt;Alcoholic Liver Disease Annual Evidence Update 2009&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #addfff"&gt;
&lt;P&gt;&lt;A href="nelh:332182:0" name=internalLink&gt;Introduction&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:332194:0" name=internalLink&gt;General&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:332177:0" name=internalLink&gt;Diagnosis&lt;/A&gt; &lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:332178:0" name=internalLink&gt;Alcoholic hepatitis&lt;/A&gt; | &lt;A href="nelh:332183:0" name=internalLink&gt;Alcoholic cirrhosis&lt;/A&gt; | &lt;A href="nelh:332184:0" name=internalLink&gt;Other&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:330278:0" name=internalLink&gt;Adverse effects&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:332185:0" name=internalLink&gt;Other&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:332195:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:332187:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:331666:0" name=internalLink&gt;Statistics, policy and links&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:332189:0" name=internalLink&gt;&lt;B&gt;Methods&lt;/B&gt;&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>332185</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=332185]]&gt;</url>
    <title>2009 Annual Evidence Update on Alcoholic Liver Disease - Other</title>
    <publicationDate></publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,ALCOHOLIC LIVER DISEASE,RECENT ADDITIONS,DECEMBER 2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Alcoholic Liver Disease - Other&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P style="COLOR: #306754"&gt;&lt;B&gt;Studies on hepatocellular carcinoma screening in cirrhosis:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;Reviewed by Andrew Austin, Consultant Hepatologist, Royal Derby Hospital&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;Many centres undertake surveillance for hepatoma in cirrhosis as part of their local standard of care often using combinations of ultrasound and alpha fetoprotein (AFP). However, this is often an adhoc arrangement and has not been subjected to rigorous cost-effectiveness analysis. &lt;A href="#tcoon1"&gt;Thompson Coon et al.&lt;/A&gt; undertook an economic analysis as part of an NIHR funded Health Technology Assessment, &lt;A href="#tcoon2"&gt;also published&lt;/A&gt; in the British Journal of Cancer. The modelling suggests that although a combination of AFP and ultrasound every six months is the most clinically effective strategy for the detection of treatable disease, it may not be cost-effective in all forms of cirrhosis. High treatment costs including liver transplantation lead to overall costs per QALY far exceeding the standard £30,000 willingness to pay threshold.&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #306754"&gt;&lt;B&gt;Other studies:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="#dew"&gt;Dew et al.: Meta-analysis of risk for relapse to substance use after transplantation of the liver or other solid organs.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Conclusions (from abstract): &lt;/B&gt;Average alcohol relapse rates (examined only in liver studies) were 5.6 cases per 100 patients per year (PPY) for relapse to any alcohol use and 2.5 cases per 100 PPY for relapse with heavy alcohol use. Illicit drug relapse averaged 3.7 cases per 100 PPY, with a significantly lower rate in liver vs. other recipients (1.9 vs. 6.1 cases). Average rates in other areas (tobacco use, immunosuppressant and clinic appointment nonadherence) were 2 to 10 cases per 100 PPY.&lt;/P&gt;&lt;BR&gt;&lt;A href="#singal"&gt;Singal &amp;amp; Anand: Mechanisms of synergy between alcohol and hepatitis C. 
&lt;P&gt;&lt;/P&gt;&lt;/A&gt;
&lt;P&gt;&lt;B&gt;Conclusions (from abstract):&lt;/B&gt; Alcoholics with HCV infection have more severe liver disease compared with nondrinkers. Patients should be encouraged to enroll in rehabilitation programs so as to improve treatment adherence and response.&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;A href="#szabo"&gt;Szabo &amp;amp; Mandrekar: A recent perspective on alcohol, immunity and host defense&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Conclusions (from abstract):&lt;/B&gt; Altered inflammatory cell and adaptive immune responses after alcohol consumption result in increased incidence and poor outcome of infections and other organ-specific immune-mediated effects.&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;A href="#tome"&gt;Tome et al.: Quality of life after liver transplantation: a systematic review&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Conclusions (from abstract):&lt;/B&gt; This review suggests that whereas general QOL improves after LT, when compared with healthy controls, LT patients have significant deficits in QOL. Consequently, the previously reported QOL benefits after LT may have been overstated.&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #306754"&gt;&lt;B&gt;List of articles:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=dew&gt;&lt;/A&gt;Dew MA, DiMartini AF, Steel J, De Vito Dabbs A, Myaskovsky L, Unruh M, Greenhouse J. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=330614" target="_blank"&gt;Meta-analysis of risk for relapse to substance use after transplantation of the liver or other solid organs.&lt;/A&gt; &lt;I&gt;Liver Transpl&lt;/I&gt; 2008;14(2):159-72.&lt;/P&gt;
&lt;P&gt;&lt;A name=singal&gt;&lt;/A&gt;Singal AK, Anand BS. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=330629" target="_blank"&gt;Mechanisms of synergy between alcohol and hepatitis C virus.&lt;/A&gt; &lt;I&gt;J Clin Gastroenterol&lt;/I&gt; 2007;41(8):761-72.&lt;/P&gt;
&lt;P&gt;&lt;A name=szabo&gt;&lt;/A&gt;Szabo G, Mandrekar P. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=330631" target="_blank"&gt;A recent perspective on alcohol, immunity, and host defense.&lt;/A&gt; &lt;I&gt;Alcohol Clin Exp Res&lt;/I&gt; 2009;33(2):220-32.&lt;/P&gt;
&lt;P&gt;&lt;A name=tcoon1&gt;&lt;/A&gt;Thompson Coon J, Rogers G, Hewson P, Wright D, Anderson R, Cramp M, Jackson S, Ryder S, Price A, Stein K. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=330290" target="_blank"&gt;Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis.&lt;/A&gt; &lt;I&gt;Health Technol Assess&lt;/I&gt; 2007;11(34):1-206.&lt;/P&gt;
&lt;P&gt;&lt;A name=tcoon2&gt;&lt;/A&gt;Thompson Coon J, Rogers G, Hewson P, Wright D, Anderson R, Jackson S, Ryder S, Cramp M, Stein K. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=330292" target="_blank"&gt;Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis.&lt;/A&gt; &lt;I&gt;Br J Cancer&lt;/I&gt; 2008;98(7):1166-75.&lt;/P&gt;
&lt;P&gt;&lt;A name=tome&gt;&lt;/A&gt;Tome S, Wells JT, Said A, Lucey MR. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=330636" target="_blank"&gt;Quality of life after liver transplantation. A systematic review.&lt;/A&gt; &lt;I&gt;J Hepatol&lt;/I&gt; 2008;48(4):567-77.&lt;/P&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #306754; COLOR: #ffffff"&gt;Alcoholic Liver Disease Annual Evidence Update 2009&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #addfff"&gt;
&lt;P&gt;&lt;A href="nelh:332182:0" name=internalLink&gt;Introduction&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:332194:0" name=internalLink&gt;General&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:332177:0" name=internalLink&gt;Diagnosis&lt;/A&gt; &lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:332178:0" name=internalLink&gt;Alcoholic hepatitis&lt;/A&gt; | &lt;A href="nelh:332183:0" name=internalLink&gt;Alcoholic cirrhosis&lt;/A&gt; | &lt;A href="nelh:332184:0" name=internalLink&gt;Other&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:330278:0" name=internalLink&gt;Adverse effects&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:332185:0" name=internalLink&gt;&lt;B&gt;Other&lt;/B&gt;&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:332195:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:332187:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:331666:0" name=internalLink&gt;Statistics, policy and links&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:332189:0" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>331666</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=331666]]&gt;</url>
    <title>2009 Annual Evidence Update on Alcoholic Liver Disease - Statistics, policy documents and other useful links</title>
    <publicationDate>2009-12-07T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,ALCOHOLIC LIVER DISEASE,RECENT ADDITIONS,DECEMBER 2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Alcoholic Liver Disease - Statistics, policy documents and other useful links&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P style="COLOR: #306754"&gt;&lt;B&gt;Statistics:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:301426:0" name=internalLink&gt;Statistics on Alcohol, England 2009&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:331668:0" name=internalLink&gt;Alcohol related deaths in the United Kingdom&lt;/A&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #306754"&gt;&lt;B&gt;Policy documents:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:331673:0" name=internalLink&gt;Department of Health Alcohol publications&lt;/A&gt;&lt;BR&gt;The National Plan for Liver Services 2009: &lt;A href="nelh:328388:0" name=internalLink&gt;A time to act: improving liver health and outcomes in liver disease&lt;/A&gt;&lt;BR&gt;NICE guidance forthcoming (expected date of publication May 2010): &lt;A href="http://guidance.nice.org.uk/CG/Wave15/77" target="_blank"&gt;Alcohol-use disorders in adults and young people - clinical management&lt;/A&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #306754"&gt;&lt;B&gt;Media:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:328175:0" name=internalLink&gt;Alcohol is worse than cigarettes&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:328177:0" name=internalLink&gt;Department of Health to develop National Liver Strategy&lt;/A&gt;&lt;BR&gt;&lt;A href="http://www.britishlivertrust.org.uk/home/media-centre/campaigns/national-liver-strategy.aspx" target="_blank"&gt;British Liver Trust press release on the National Liver Strategy&lt;/A&gt;&lt;BR&gt;&lt;A href="http://www.bsg.org.uk/press/press-releases/map-of-booze-britain.html" target="_blank"&gt;BSG press release: Map of booze Britain&lt;/A&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #306754"&gt;&lt;B&gt;Patient information:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:156357:0" name=internalLink&gt;Alcohol and liver disease&lt;/A&gt; (British Liver Trust)&lt;BR&gt;&lt;A href="nelh:320260:0" name=internalLink&gt;Alcohol and liver disease&lt;/A&gt; (Patient UK)&lt;BR&gt;&lt;A href="nelh:320186:0" name=internalLink&gt;Liver disease (alcoholic)&lt;/A&gt; (NHS Choices)&lt;/P&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #306754; COLOR: #ffffff"&gt;Alcoholic Liver Disease Annual Evidence Update 2009&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #addfff"&gt;
&lt;P&gt;&lt;A href="nelh:332182:0" name=internalLink&gt;Introduction&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:332194:0" name=internalLink&gt;General&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:332177:0" name=internalLink&gt;Diagnosis&lt;/A&gt; &lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:332178:0" name=internalLink&gt;Alcoholic hepatitis&lt;/A&gt; | &lt;A href="nelh:332183:0" name=internalLink&gt;Alcoholic cirrhosis&lt;/A&gt; | &lt;A href="nelh:332184:0" name=internalLink&gt;Other&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:330278:0" name=internalLink&gt;Adverse effects&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:332185:0" name=internalLink&gt;Other&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:332195:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:332187:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:331666:0" name=internalLink&gt;&lt;B&gt;Statistics, policy and links&lt;/B&gt;&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:332189:0" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>332183</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=332183]]&gt;</url>
    <title>2009 Annual Evidence Update on Alcoholic Liver Disease - Treatment | Alcoholic cirrhosis</title>
    <publicationDate>2009-12-07T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,ALCOHOLIC LIVER DISEASE,ALCOHOLIC CIRRHOSIS,RECENT ADDITIONS,CIRRHOSIS,ALCOHOLIC,DECEMBER 2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Alcoholic Liver Disease - Treatment | Alcoholic cirrhosis&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;I&gt;Reviewed by Dermot Gleeson, Consultant in Hepatology, Liver Unit, Sheffield Teaching Hospitals, Royal Hallamshire Hospital&lt;/I&gt; &lt;/P&gt;
&lt;P style="COLOR: #306754"&gt;&lt;B&gt;Systematic reviews:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The review by &lt;A href="#triantos"&gt;Triantos, Nikolopoulou, and Burroughs&lt;/A&gt; is a detailed update on the usefulness of Hepatic Venous Pressure Gradient (HVPG) measurement in the management of portal hypertension and its complications. In most liver diseases HVPG correlates well with portal vein pressure. The review summarises the accumulating evidence that reduction of portal pressure in cirrhosis has widespread benefits: not only reducing the risk of variceal bleeding but also that of ascites, encephalopathy and death. Furthermore, these benefits of reducing portal pressure may be independent of improvements in hepatocellular function. There is a useful discussion of the mutually enhancing effects of both bacterial infection and gastrointestinal bleeding, each on the risk of the other. &lt;/P&gt;
&lt;P&gt;Undoubtedly, HVPG measurements give useful prognostic information. The question remains however whether such information can lead to changes in management which will confer evidence-based benefit. About 40% of patients are non responders to beta blockers, in that they do not achieve an adequate reduction of HVPG; and these patients are more likely to rebleed and to die. However there is a lack of controlled studies comparing different treatment strategies in this group of non responders, in both primary and secondary prophylaxis. As the authors discuss, not all non responders subsequently bleed, suggesting that the beta blocker may still confer some protection, even without an "adequate" fall in HVPG. Trials comparing beta blockade alone, banding ligation and TIPPS in such patients are needed. &lt;/P&gt;
&lt;P&gt;The reviewers discuss one study in which HVPG was measured following an acute variceal bleed and patients with high pressures randomised to TIPPS or sclerotherapy. Rebleeding and mortality rates were low in the low pressure group and in the high-pressure group, were lower in those randomised to TIPPs than in those randomised to sclerotherapy, apparently justifying routing HVPG measurement in acute variceal bleeding. Whilst this study is convincing, sclerotherapy might no longer be regarded as a first lint treatment, and this study needs to be complimented by others comparing TIPPS with combination of beta blockers and banding ligation.&lt;/P&gt;
&lt;P&gt;Thus, although this is an excellent review, I was not entirely convinced regarding the author's conclusion that HVPG measurement should now be part of everyday clinical practice. &lt;BR&gt;&lt;/P&gt;
&lt;P style="COLOR: #306754"&gt;&lt;BR&gt;&lt;B&gt;Randomised controlled trials:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Urodilatin is a member of the Atrial Naturetic peptide family and impairs sodium absorption in the distal tubule, possibly by increasing cyclic GMP in renal tubular epithelial cells. &lt;A href="#carstens"&gt;Carstens et al.&lt;/A&gt; report on a randomised single blind cross-over study of its effects in promoting sodium excretion in seven patients with diuretic-resistant ascites. Patients were infused for 90 minutes with Urodilatin or saline in random sequence with a 2-3 day washout period between the two infusions. Diuretics (stable doses of Spironolactione and/or Frusemide) were stopped on the day of the infusions but given on all other days. Urodilatin resulted in a significant (although transient) increase in urine sodium excretion (compared to placebo) and also an increase in urine flow (not quite reaching significance). Urodilation markedly increased serum cGMP as expected, but did not affect blood pressure or serum renin, angiotensin 2 or aldosterone. Despite similar cGMP responses, the natiuretic effect of urodilation was much smaller than the authors found in previous studies of patients without major sodium and water retention, possibly due to the high serum levels of renin angiotensin and aldosterone in the present patients, and high proximal sodium absorption, with consequently, relatively low sodium delivery to the distal tubule. The authors indicate that in their previous studies, urodilation also reduced sodium absorption in the proximal tubule (assessed using lithium clearance) but this was not addressed in the present study. &lt;/P&gt;
&lt;P&gt;This is a carefully performed study with a focused question and clear results, albeit in a small number of patients. It is however, difficult to see, given its short half-life, need for infusion and limited natiuretic and diuretic efficacy, how urodilation can be of much clinical use. However, orally active and more stable inhibitors of cGMP might prove to be more useful in ascites resistant to conventional diuretics. &lt;/P&gt;&lt;BR&gt;
&lt;P&gt;The efficacy of TACE in HCC is still not established. Two recent randomised trials and two meta analyses have demonstrated a survival benefit, whereas a third meta analysis has not. The multi centre RCT by &lt;A href="#doeffel"&gt;Doffoel et al.&lt;/A&gt; compared Tamoxifen alone with Tamoxifen plus TACE in cirrhotics with unresectable HCC. Patients with Child-Pugh Stage 3 disease, advanced HCC (Okuda stage III or extra hepatic metastases), portal vein thrombosis, or renal impairment (GFR 80) were excluded. TACE (Lipiodol plus Epirubicin) was given a 2 month intervals until stabilisation or death (median 2.8 times). The trial was powered to demonstrate an improvement from 20 to 40% in 2 yr survival (Okuda stage 1) or 1 year survival (Okuda stage II). &lt;/P&gt;
&lt;P&gt;Unfortunately, there was no difference in survival between patients receiving TACE plus Tamoxifen and those receiving Tamoxifen alone, either overall, or in subgroups defined by Okuda stage. The authors note that the "negative" trials of TACE included high proportions of patients with alcoholic cirrhosis, whereas in the trials that showed a survival benefit, more than 80% of patients have chronic viral hepatitis. &lt;/P&gt;
&lt;P&gt;This is a well-conducted trial, which casts doubt on the clinical efficacy of TACE in HCC, especially in patients with alcoholic cirrhosis.&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;The study by &lt;A href="#laleman"&gt;Laleman et al.&lt;/A&gt;, in 18 patients with biopsy proven alcoholic hepatitis and cirrhosis, compared the effects of 2 liver support devices (6 patients each) with standard medical therapy (6 patients). The devices were used for 6 hours on each of 3 successive days. The Prometheus device (fractionated plasma separation, adsorption and dialysis) was more effective than MARS in reducing serum bilirubin and bile acids and may have also reduced inflammatory mediators as evidence by a slight falls in CRP and WCC (not reaching significance). The MARS device resulted in smaller falls in bilirubin and bile acids and unchanged CRP and WCC. However MARS reduced increased mean arterial pressure (MAP) and reduced systemic vascular resistance (SVR). It also reduced serum renin aldosterone, norepinephrine and nitrate/nitrate. Nitrate/nitrite (but not rennin) was detected in the dialysate and the authors proposed that MARS improved haemodnamic parameters by reducing vasoconstictor production as a result of removing nitric oxide. In contrast, the Prometheus device did not alter haemodynamic parameters, serum vasoconstrictors or serum nitrate/nitrite and lower nitrate/nitrite levels were detectable in the dialysate. &lt;/P&gt;
&lt;P&gt;The study has detected interesting and possibly important differences in how these devices operate. However it would be premature based on these small numbers of patients to draw any conclusions about the clinical efficacy of these devices, compared to either one another or to standard in clearly defined patients groups and with mortality as an end point.&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;The indications for and the optimal timing of liver transplantation for Alcoholic Liver Disease (ALD) require further clarification, especially in those with severe disease but who have been abstinent for short periods (or not at all). Aside from the ethical issues surrounding allocation of scarce organs to such patients, there is the real possibility of recovery of liver function with continued abstinence. &lt;/P&gt;
&lt;P&gt;Previous studies have compared survival of patients with decompensated ALD (Child-Pugh Grade B or C) who undergo liver transplantation with predicted survival of this cohort using a French prognostic model (Beclere model). A clear survival advantage could be shown in transplanted patients with Child Stage C but not in Child Stage B disease. &lt;/P&gt;
&lt;P&gt;Thus, in an important multicentre trial by &lt;A href="#vanlemmens"&gt;Vanlemmens et al.&lt;/A&gt;, patients with Child-Pugh Stage B alcoholic cirrhosis (median MELD score 14.5) were randomised to immediate listing for transplantation or to standard care. Exclusion criteria included Childs C disease but patients who had recovered from previous Child stage C disease were included. A power calculation was not reported. Interestingly, neither alcohol dependence nor continued alcohol consumption were exclusion criteria, and of the 120 patients, 18 had drunk alcohol within 3 months, and 7 were still drinking (3 heavily).&lt;/P&gt;
&lt;P&gt;41 of the 60 patients randomised to transplantation underwent transplantation after (median) 4.8 months. The others died on the waiting list or were removed because of improvement or subsequently meeting exclusion criteria. 15 of the 60 randomised to standard care underwent transplantation (after median of 12 months) because of worsening to Child stage C. Perhaps surprisingly, of the 56 explanted livers only one showed alcoholic hepatitis. &lt;/P&gt;
&lt;P&gt;Median follow up was 42 months and no patients were lost to follow up. In those randomised to listing for transplantation, 5 year mortality (total and liver-related) was (non-significantly) higher in those randomised to listing for transplantation compared to standard care. Cancer (both total and extra hepatic) developed more frequently and cancer free survival was significantly lower in those randomised to transplantation. Independent predictors of mortality were continued alcohol consumption (the frequency of this is unfortunately not reported), a Child score of more than 7 and absence of prior Child stage C disease (something which presumably suggests ongoing recovery of liver function).&lt;/P&gt;
&lt;P&gt;The inclusion of patients (15% of the total) with alcohol dependence or who were abstinent for&amp;nbsp;&amp;lt;3 months might have resulted in a high recidivism rate (unfortunately not reported) and this might have resulted in some deaths. However this controlled trial clearly shows that liver transplantation in patients with Child-Pugh Stage B ALD does not improve survival and (confirming previous observational studies: Liver Transpl. 2002 May;8(5):488-90) increases the risk of cancer. This study was difficult to do because of ethical concerns about randomisation to liver transplantation. It is a landmark study, likely to influence clinical practice and unlikely to be repeated. &lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #306754"&gt;&lt;B&gt;List of articles:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=carstens&gt;&lt;/A&gt;Carstens J, Gronbaek H, Larsen HK, Pedersen EB, Vilstrup H. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=330578" target="_blank"&gt;Effects of urodilatin on natriuresis in cirrhosis patients with sodium retention.&lt;/A&gt; &lt;I&gt;BMC Gastroenterol&lt;/I&gt; 2007;7:1.&lt;/P&gt;
&lt;P&gt;&lt;A name=doeffel&gt;&lt;/A&gt;Doffoël M, Bonnetain F, Bouché O, Vetter D, Abergel A, Fratté S, Grangé JD, Stremsdoerfer N, Blanchi A, Bronowicki JP, Caroli-Bosc FX, Causse X, Masskouri F, Rougier P, Bedenne L; Fédération Francophone de Cancérologie Digestive. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=330579" target="_blank"&gt;Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402).&lt;/A&gt; &lt;I&gt;Eur J Cancer&lt;/I&gt; 2008;44(4):528-38.&lt;/P&gt;
&lt;P&gt;&lt;A name=laleman&gt;&lt;/A&gt;Laleman W, Wilmer A, Evenepoel P, Elst IV, Zeegers M, Zaman Z, Verslype C, Fevery J, Nevens F. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=330597" target="_blank"&gt;Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure.&lt;/A&gt; &lt;I&gt;Crit Care&lt;/I&gt; 2006;10(4):R108.&lt;/P&gt;
&lt;P&gt;&lt;A name=triantos&gt;&lt;/A&gt;Triantos CK, Nikolopoulou V, Burroughs AK. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=330598" target="_blank"&gt;Review article: the therapeutic and prognostic benefit of portal pressure reduction in cirrhosis.&lt;/A&gt; &lt;I&gt;Aliment Pharmacol Ther&lt;/I&gt; 2008;28(8):943-52.&lt;/P&gt;
&lt;P&gt;&lt;A name=vanlemmens&gt;&lt;/A&gt;Vanlemmens C, Di Martino V, Milan C, Messner M, Minello A, Duvoux C, Poynard T, Perarnau JM, Piquet MA, Pageaux GP, Dharancy S, Silvain C, Hillaire S, Thiefin G, Vinel JP, Hillon P, Collin E, Mantion G, Miguet JP; TRANSCIAL Study Group. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=330580" target="_blank"&gt;Immediate listing for liver transplantation versus standard care for Child-Pugh stage B alcoholic cirrhosis: a randomized trial.&lt;/A&gt; &lt;I&gt;Ann Intern Med&lt;/I&gt; 2009;150(3):153-61.&lt;/P&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #306754; COLOR: #ffffff"&gt;Alcoholic Liver Disease Annual Evidence Update 2009&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #addfff"&gt;
&lt;P&gt;&lt;A href="nelh:332182:0" name=internalLink&gt;Introduction&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:332194:0" name=internalLink&gt;General&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:332177:0" name=internalLink&gt;Diagnosis&lt;/A&gt; &lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:332178:0" name=internalLink&gt;Alcoholic hepatitis&lt;/A&gt; | &lt;A href="nelh:332183:0" name=internalLink&gt;&lt;B&gt;Alcoholic cirrhosis&lt;/B&gt;&lt;/A&gt; | &lt;A href="nelh:332184:0" name=internalLink&gt;Other&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:330278:0" name=internalLink&gt;Adverse effects&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:332185:0" name=internalLink&gt;Other&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:332195:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:332187:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:331666:0" name=internalLink&gt;Statistics, policy and links&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:332189:0" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>332178</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=332178]]&gt;</url>
    <title>2009 Annual Evidence Update on Alcoholic Liver Disease - Treatment | Alcoholic hepatitis</title>
    <publicationDate>2009-12-07T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,ALCOHOLIC LIVER DISEASE,ALCOHOLIC HEPATITIS,STEATOHEPATITIS,ALCOHOLIC,RECENT ADDITIONS,DECEMBER 2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Alcoholic Liver Disease - Treatment | Alcoholic hepatitis&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;I&gt;Reviewed by Marsha Morgan, Consultant Physician, Royal Free Hospital, London&lt;/I&gt;&lt;/P&gt;
&lt;P style="COLOR: #306754"&gt;&lt;B&gt;Guidelines and systematic reviews:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Alcohol misuse produces a spectrum of liver injury ranging from simple fatty change through alcoholic hepatitis to cirrhosis and, in some 20% of individuals, to hepatocellular carcinoma. In the majority of individuals alcoholic hepatitis is silent but, in an unknown minority, its presence is associated with florid hepatic failure and a mortality rate of 35 to 50%. The exact pathogenesis of alcoholic hepatitis is unknown although a cytokine-induced acute inflammatory response, endotoxaemia, oxidative stress and immune mechanisms are all thought to play a role; the absence of an exact pathogenesis means that treatment can not be specifically directed and so remains controversial.&lt;/P&gt;
&lt;P&gt;Corticosteroids have anti-inflammatory and immunosuppressive properties and are used to treat patients with alcoholic hepatitis although their use is invariably restricted to those with severe disease. However, many clinicians remain sceptical about the efficacy of corticosteroids in this setting, in part at least, because previous systematic reviews and meta-analyses of the available randomised, placebo-controlled trials have produced conflicting results. Two recent publications have done little, at least at first glance, to clarify the situation. Thus a recent Cochrane systematic review, including meta-analyses of randomized trials, (&lt;A href="#rambaldi1"&gt;Rambaldi et al.&lt;/A&gt;) concluded that the current evidence base does not support the use of corticosteroids in alcoholic hepatitis. In contrast, a meta-analysis undertaken under the auspices of &lt;A href="#nice"&gt;NICE&lt;/A&gt; concluded that in patients with severe alcoholic hepatitis, defined as a Maddrey Discriminant Function = 32 or spontaneous hepatic encephalopathy, use of corticosteroids is associated with a significant reduction in both all-cause mortality and liver–related mortality at one month and six month and, importantly, with no increase in the rates of infection or gastrointestinal bleeding. Why these discrepant results? &lt;/P&gt;
&lt;P&gt;The 11 trials selected for inclusion in the NICE meta-analysis were undertaken in patients with severe alcoholic hepatitis or else contained an identifiable subpopulation of patients with severe disease whose data could be separately extracted. No such selection was exercised in the Cochrane meta-analysis; the patients in the 15 trials selected for inclusion had alcoholic hepatitis of varying severity and, in addition, two were not peer reviewed, two used inappropriate drug regimens and one included patients with only mild to moderate disease; in addition one appropriate trial was omitted. However, the Cochrane authors also reported that in a subgroup analysis of six trials in patients with severe alcoholic hepatitis, defined as a Maddrey Discriminant Function = 32 or spontaneous hepatic encephalopathy, use of corticosteroids was associated with a significant reduction in mortality although whether this was all-cause or liver-related mortality and at which time point(s) was not specified.&lt;/P&gt;
&lt;P&gt;Thus, although not immediately apparent, there is consensus that patients with severe alcoholic hepatitis benefit from treatment with corticosteroids in terms of mortality. However, only the most discerning of readers will glean this information from the Cochrane systematic review which might have significant implications for clinical practice.&lt;/P&gt;
&lt;P&gt;One of the hallmarks of the inflammatory response in alcoholic hepatitis is the observed increase in circulating TNF-a levels. Pentoxifylline, a xanthine inhibitor, inhibits TNF synthesis and in an initial study (Akriviadis et al., 2000) was shown to confer benefit in patients with alcoholic hepatitis although this related more to the prevention of hepato-renal syndrome rather than to a direct effect on liver function. A recent Cochrane systematic review, including a meta-analysis and trial sequential analysis of five relatively small randomized trials (&lt;A href="#whitfield"&gt;Whitfield et al.&lt;/A&gt;) concluded that the current evidence base neither supports nor rejects the use of pentoxifylline to treat severe alcoholic hepatitis. However, four of the five trials included in the meta-analysis were only published in abstract form and therefore have a high risk of bias making it is difficult to judge the worth of this review. &lt;/P&gt;
&lt;P&gt;(A Cochrane review on milk thistle in liver disease, including alcoholic hepatitis, was also published in the period making it eligible for inclusion in this Annual Evidence Update (&lt;A href="#rambaldi2"&gt;Raimbaldi, Jacobs and Gluud&lt;/A&gt;).)&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #306754"&gt;&lt;B&gt;Randomised controlled trials:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;In a recent, well-conducted, randomized trial of pentoxifylline vs prednisolone, undertaken in 68 patients with severe alcoholic hepatitis, the 3-month mortality rate was significantly lower in the pentoxifylline-treated patients (14.7 vs 35.3%; p = 0.04) (&lt;A href="#de"&gt;De et al.&lt;/A&gt;). This reduction in mortality rate was attributable, at least in part, to the renoprotective of pentoxifylline. The six deaths from hepatorenal syndrome in the prednisolone-treated group occurred within 3 month of the trial onset but no further details are supplied; these data would have allowed better interpretation of the findings given that the prednisolone dosage was tapered from week four to week 11 whereas the pentoxifylline was given in full dosage for 12 weeks. The incidence of hepatic encephalopathy was higher in the pentoxifylline group which is probably why the authors state that pentoxifylline is at least as efficacious as prednisolone rather than claiming greater efficacious. The results of a large French study, currently underway, comparing the efficacy of corticosteroids, with and without adjuvant pentoxifylline, in severe alcoholic hepatitis, may help clarify the role of pentoxifylline further.&lt;/P&gt;
&lt;P&gt;Etanercept is an agent which binds and neutralizes unbound serum TNF-a. In a recent randomized, double-blind, placebo-controlled trial, involving 48 patients with moderate to severe alcoholic hepatitis, the 6-month mortality rate was significantly higher in the etanercept group compared with placebo (57.6 vs. 22.7%; p = 0.17); the rate of serious infection was also higher in the etanercept group (&lt;A href="#boetticher"&gt;Boetticher et al.&lt;/A&gt;). Further trials with this agent or other agents that neutralize or modulate circulating TNF-a are not warranted.&lt;/P&gt;
&lt;P&gt;Finally, although oxidative stress is thought to play a major role in the genesis of alcohol-related liver injury, treatment with an antioxidant cocktail which included N-acetylcysteine, multiple vitamins and trace elements and Coenzyme Q, did not improve the 6-month survival rate in patients with severe alcohol hepatitis whether given alone or in combination with corticosteroids (&lt;A href="#stewart"&gt;Stewart et al.&lt;/A&gt;).&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #306754"&gt;&lt;B&gt;List of articles:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=boetticher&gt;&lt;/A&gt;Boetticher NC, Peine CJ, Kwo P, Abrams GA, Patel T, Aqel B, Boardman L, Gores GJ, Harmsen WS, McClain CJ, Kamath PS, Shah VH. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=330638" target="_blank"&gt;A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis.&lt;/A&gt; &lt;I&gt;Gastroenterology&lt;/I&gt; 2008;135(6):1953-60.&lt;/P&gt;
&lt;P&gt;&lt;A name=de&gt;&lt;/A&gt;De BK, Gangopadhyay S, Dutta D, Baksi SD, Pani A, Ghosh P. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=330640" target="_blank"&gt;Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial.&lt;/A&gt;&lt;I&gt; World J Gastroenterol&lt;/I&gt; 2009;15(13):1613-9.&lt;/P&gt;
&lt;P&gt;&lt;A name=nice&gt;&lt;/A&gt;National Institute for Health and Clinical Excellence. Alcohol use disorders: diagnosis and clinical management of alcohol-related physical complications (NICE guideline draft for consultations). Available from &lt;A href="http://www.nice.org.uk/nicemedia/pdf/AlcoholNICEVersionForConsultation.pdf" target="_blank"&gt;http://www.nice.org.uk/nicemedia/pdf/AlcoholNICEVersionForConsultation.pdf&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=rambaldi2&gt;&lt;/A&gt;Rambaldi A, Jacobs BP, Gluud C. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=237980" target="_blank"&gt;Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases.&lt;/A&gt; &lt;I&gt;Cochrane Database of Systematic Reviews&lt;/I&gt; 2007, Issue 4. Art. No.: CD003620.&lt;/P&gt;
&lt;P&gt;&lt;A name=rambaldi1&gt;&lt;/A&gt;Rambaldi A, Saconato HH, Christensen E, Thorlund K, Wetterslev J, Gluud C. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=330643" target="_blank"&gt;Systematic review: glucocorticosteroids for alcoholic hepatitis--a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials.&lt;/A&gt; &lt;I&gt;Aliment Pharmacol Ther&lt;/I&gt; 2008;27(12):1167-78.&lt;/P&gt;
&lt;P&gt;&lt;A name=stewart&gt;&lt;/A&gt;Stewart S, Prince M, Bassendine M, Hudson M, James O, Jones D, Record C, Day CP. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=330647" target="_blank"&gt;A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis.&lt;/A&gt; &lt;I&gt;J Hepatol&lt;/I&gt; 2007;47(2):277-83.&lt;/P&gt;
&lt;P&gt;&lt;A name=whitfield&gt;&lt;/A&gt;Whitfield K, Rambaldi A, Wetterslev J, Gluud C. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=327222" target="_blank"&gt;Pentoxifylline for alcoholic hepatitis.&lt;/A&gt; &lt;I&gt;Cochrane Database of Systematic Reviews&lt;/I&gt; 2009, Issue 4. Art. No.: CD007339.&lt;/P&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #306754; COLOR: #ffffff"&gt;Alcoholic Liver Disease Annual Evidence Update 2009&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #addfff"&gt;
&lt;P&gt;&lt;A href="nelh:332182:0" name=internalLink&gt;Introduction&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:332194:0" name=internalLink&gt;General&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:332177:0" name=internalLink&gt;Diagnosis&lt;/A&gt; &lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:332178:0" name=internalLink&gt;&lt;B&gt;Alcoholic hepatitis&lt;/B&gt;&lt;/A&gt; | &lt;A href="nelh:332183:0" name=internalLink&gt;Alcoholic cirrhosis&lt;/A&gt; | &lt;A href="nelh:332184:0" name=internalLink&gt;Other&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:330278:0" name=internalLink&gt;Adverse effects&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:332185:0" name=internalLink&gt;Other&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:332195:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:332187:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:331666:0" name=internalLink&gt;Statistics, policy and links&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:332189:0" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>332184</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=332184]]&gt;</url>
    <title>2009 Annual Evidence Update on Alcoholic Liver Disease - Treatment | Other</title>
    <publicationDate>2009-12-07T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,ALCOHOLIC LIVER DISEASE,RECENT ADDITIONS,DECEMBER 2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Alcoholic Liver Disease - Treatment | Other&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;I&gt;Reviewed by Andrew Austin, Consultant Hepatologist, Royal Derby Hospital&lt;/I&gt;&lt;/P&gt;
&lt;P style="COLOR: #306754"&gt;&lt;B&gt;Randomised controlled trials:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Carvedilol, a non-cardioselective vasodilating betablocker, is more effective in reducing portal pressure than propranolol in haemodynamic studies. In the primary prevention trial from &lt;A href="#tripathi"&gt;Tripathi et al.&lt;/A&gt;, carvedilol prevented more bleeds (10% vs 23%) but mortality was similar (35% vs 37%) compared to variceal band ligation (VBL). Meta-analysis has previously suggested VBL is more effective than propranolol but is clearly more expensive. A cost-effectiveness analysis may now be required to guide best use of limited resources in this area. &lt;/P&gt;
&lt;P style="COLOR: #306754"&gt;&lt;B&gt;List of articles:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=tripathi&gt;&lt;/A&gt;Tripathi D, Ferguson JW, Kochar N, Leithead JA, Therapondos G, McAvoy NC, Stanley AJ, Forrest EH, Hislop WS, Mills PR, Hayes PC. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=330327" target="_blank"&gt;Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed.&lt;/A&gt; &lt;I&gt;Hepatology&lt;/I&gt; 2009;50(3):825-33.&lt;/P&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #306754; COLOR: #ffffff"&gt;Alcoholic Liver Disease Annual Evidence Update 2009&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #addfff"&gt;
&lt;P&gt;&lt;A href="nelh:332182:0" name=internalLink&gt;Introduction&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:332177:0" name=internalLink&gt;Diagnosis&lt;/A&gt; &lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:332178:0" name=internalLink&gt;Alcoholic hepatitis&lt;/A&gt; | &lt;A href="nelh:332183:0" name=internalLink&gt;Alcoholic cirrhosis&lt;/A&gt; | &lt;A href="nelh:332184:0" name=internalLink&gt;&lt;B&gt;Other&lt;/B&gt;&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:330278:0" name=internalLink&gt;Adverse effects&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:332185:0" name=internalLink&gt;Other&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:332195:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:332187:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:331666:0" name=internalLink&gt;Statistics, policy and links&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:332189:0" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>332187</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=332187]]&gt;</url>
    <title>2009 Annual Evidence Update on Alcoholic Liver Disease - Uncertainties</title>
    <publicationDate>2009-12-07T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,ALCOHOLIC LIVER DISEASE,RECENT ADDITIONS,DECEMBER 2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Alcoholic Liver Disease - Uncertainties&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;As part of the process of conducting this Annual Evidence Update, we examined the included papers for treatment uncertainties that could be added to the UK Database of Uncertainties about the Effects of Treatments (&lt;A href="http://www.library.nhs.uk/duets/" target="_blank"&gt;UK DUETs&lt;/A&gt;), a project aimed at creating a central database of such uncertainties. The following list, which has been submitted to the database, is the results of our search. Click on each title for more information.&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=332229" target="_blank"&gt;Glucocorticosteroids for alcoholic hepatitis&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=330528" target="_blank"&gt;Hepatotoxic effects of acetaminophen in alcoholics when taken for more than a few days&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=302506" target="_blank"&gt;Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=327694" target="_blank"&gt;Pentoxifylline for alcoholic hepatitis&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #306754; COLOR: #ffffff"&gt;Alcoholic Liver Disease Annual Evidence Update 2009&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #addfff"&gt;
&lt;P&gt;&lt;A href="nelh:332182:0" name=internalLink&gt;Introduction&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:332194:0" name=internalLink&gt;General&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:332177:0" name=internalLink&gt;Diagnosis&lt;/A&gt; &lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:332178:0" name=internalLink&gt;Alcoholic hepatitis&lt;/A&gt; | &lt;A href="nelh:332183:0" name=internalLink&gt;Alcoholic cirrhosis&lt;/A&gt; | &lt;A href="nelh:332184:0" name=internalLink&gt;Other&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:330278:0" name=internalLink&gt;Adverse effects&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:332185:0" name=internalLink&gt;Other&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:332195:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:332187:0" name=internalLink&gt;&lt;B&gt;Uncertainties&lt;/B&gt;&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:331666:0" name=internalLink&gt;Statistics, policy and links&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:332189:0" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>323954</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=323954]]&gt;</url>
    <title>2009 Annual Evidence Update on Hepatitis B and C - Diagnosis</title>
    <publicationDate>2009-09-07T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ LIVER,GASTROENTEROLOGY &amp; LIVER DISEASES,HEPATITIS B,HEPATITIS C,HEPATITIS,DIAGNOSTIC PROCEDURES,BLOOD TESTS,RECENT ADDITIONS,SEPTEMBER 2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Hepatitis B and C - Diagnosis&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Articles:&lt;/B&gt;&lt;/P&gt; &lt;P&gt;&lt;A name=halfon&gt;&lt;/A&gt;Halfon P, Munteanu M, Poynard T. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=323814" target="_blank"&gt;FibroTest-ActiTest as a non-invasive marker of liver fibrosis.&lt;/A&gt; &lt;I&gt;Gastroenterol Clin Biol&lt;/I&gt; 2008 Sep;32(6:Suppl 1):Suppl-39.&lt;/P&gt; &lt;P&gt;&lt;A name=leroy&gt;&lt;/A&gt;Leroy V, Halfon P, Bacq Y, Boursier J, Rousselet MC, Bourliere M, et al. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=323831" target="_blank"&gt;Diagnostic accuracy, reproducibility and robustness of fibrosis blood tests in chronic hepatitis C: a meta-analysis with individual data.&lt;/A&gt; &lt;I&gt;Clin Biochem&lt;/I&gt; 2008 Nov;41(16-17):1368-76.&lt;/P&gt;&lt;BR&gt; &lt;TABLE align=center&gt; &lt;TBODY&gt; &lt;TR&gt; &lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #99cc00"&gt;Hepatitis B and C Annual Evidence Update 2009&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #33cccc"&gt; &lt;P&gt;&lt;A href="nelh:323995:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323959:0" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323956:0" name=internalLink&gt;Economics&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323953:0" name=internalLink&gt;Prevention&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323954:0" name=internalLink&gt;&lt;B&gt;Diagnosis&lt;/B&gt;&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:323962:0" name=internalLink&gt;Hepatitis B&lt;/A&gt; | &lt;A href="nelh:323961:0" name=internalLink&gt;Hepatitis C&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:323963:0" name=internalLink&gt;Risk factors&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:323952:0" name=internalLink&gt;Foreign articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323978:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323984:0" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>323956</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=323956]]&gt;</url>
    <title>2009 Annual Evidence Update on Hepatitis B and C - Economics</title>
    <publicationDate>2009-09-07T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ HEPATITIS,HEPATITIS C,HEPATITIS B,GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,VACCINATION,DISEASE PREVENTION,SEPTEMBER 2009,RECENT ADDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Hepatitis B and C - Economics&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;I&gt;Reviewed by Steven Ryder, Consultant Physician and Hepatologist, Queen's Medical Centre, Nottingham&lt;/I&gt;&lt;/P&gt; &lt;P&gt;Health state utilities may sound about as exciting as watching paint dry, but are important. Understanding the health benefits of an intervention requires assessment of the value of a particular health state. A &lt;A href="#mclernon"&gt;systematic review of heath state utilities&lt;/A&gt; has shown there are relatively few good quality studies in this area, but was able to provide pooled mean health state utility estimates for 4 areas in patients with hepatitis C (moderate, compensated cirrhosis, decompensated cirrhosis and post-transplant). This will help researchers interested in cost-effectiveness analysis (a key area with the advent of new and likely highly expensive therapies for HCV). It also provides a good clear summary of what is know about heath state utility in other liver diseases, although limited data is available and hence the statistical certainty is less.&lt;/P&gt; &lt;P&gt;Access to therapy for hepatitis C infection is a major challenge; lifestyle issues associated with injecting drugs make access to healthcare a challenge. Treatment can potentially be delivered in the prison system. A &lt;A href="#tan"&gt;pharmaco-economic model of therapy in prisons&lt;/A&gt; (based on US data) concludes that therapy is cost effective using available data on genotype, response rates to therapy and even allowing for a very high rate of re-infection. While there are obviously considerable differences in the populations from US to UK prisons, such as high rates of genotype 1 and numbers of HCV infected Black people in the US, most of these differences would suggest that a UK population would be even more cost effective to treat.&lt;/P&gt; &lt;P&gt;Many clinicians in the UK and Ireland regard the lack of universal hepatitis B vaccination as a major failing in public health policy. The argument against vaccination has always been economic, taking the view that with low prevalence, the cost is too high for the benefit to be worth the investment. A &lt;A href="#tilson"&gt;cost-effectiveness analysis&lt;/A&gt; based on the Irish population took data on the increasing number of chronic HBV cases notified in Ireland and produced a Markov model of progression of disease in those who would be infected. They show that the cost-effectiveness of universal infant vaccination was acceptable at 37,000 Euros per life year gained. This provides initial evidence that in a population previously a low incidence area for HBV, migration and the higher rates of HBV infection will probably make a change in vaccination policy both desirable and cost effective.&lt;/P&gt; &lt;P&gt;Treating chronic HBV is expensive with potentially life-long therapy required. Two cost effectiveness analyses have been published looking at various treatment strategies, one in &lt;A href="#spackman"&gt;e positive&lt;/A&gt; and the other in &lt;A href="#spackman"&gt;e negative&lt;/A&gt; disease. While these models are complex, the headlines are that potent oral anti-viral therapy in e antigen negative HBV infection with abnormal ALT is likely to be the most cost effective strategy over a 4-5 year period. In e positive disease a similar benefit was seen for Entecavir and interferon therapy. Although Tenofovir was not included in these analyses, given its greater potency and lower cost compared to Adefovir, it is likely that this drug will be cost-effective. &lt;/P&gt;&lt;BR&gt; &lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Articles:&lt;/B&gt;&lt;/P&gt; &lt;P&gt;&lt;A name=mclernon&gt;&lt;/A&gt;McLernon DJ, Dillon J, Donnan PT. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=323557" target="_blank"&gt;Health-state utilities in liver disease: a systematic review.&lt;/A&gt; &lt;I&gt;Med Decis Making&lt;/I&gt; 2008 Jul;28(4):582-92.&lt;/P&gt; &lt;P&gt;&lt;A name=tan&gt;&lt;/A&gt;Tan JA, Joseph TA, Saab S. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=323561" target="_blank"&gt;Treating hepatitis C in the prison population is cost-saving.&lt;/A&gt; &lt;I&gt;Hepatology&lt;/I&gt; 2008;48(5):1387-95.&lt;/P&gt; &lt;P&gt;&lt;A name=tilson&gt;&lt;/A&gt;Tilson L, Thornton L, O'Flanagan D, Johnson H, Barry M. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=323564" target="_blank"&gt;Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation.&lt;/A&gt; &lt;I&gt;Eur J Public Health&lt;/I&gt; 2008;18(3):275-82.&lt;/P&gt; &lt;P&gt;&lt;A name=spackman&gt;&lt;/A&gt;Spackman DE, Veenstra DL. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=323570" target="_blank"&gt;A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B.&lt;/A&gt; &lt;I&gt;Pharmacoeconomics&lt;/I&gt; 2008;26(11):937-49.&lt;/P&gt; &lt;P&gt;&lt;A name=spackman&gt;&lt;/A&gt;Veenstra DL, Spackman DE, Bisceglie A, Kowdley K, V, Gish RG. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=323573" target="_blank"&gt;Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis.&lt;/A&gt; &lt;I&gt;Aliment Pharmacol Ther&lt;/I&gt; 2008;27(12):1240-52.&lt;/P&gt; &lt;P&gt;&lt;A name=spackman&gt;&lt;/A&gt;You JH, Chan FW. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=323573" target="_blank"&gt;Pharmacoeconomics of entecavir treatment for chronic hepatitis B.&lt;/A&gt; &lt;I&gt;Expert Opin Pharmacother&lt;/I&gt; 2008 Oct;9(15):2673-81.&lt;/P&gt;&lt;BR&gt; &lt;TABLE align=center&gt; &lt;TBODY&gt; &lt;TR&gt; &lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #99cc00"&gt;Hepatitis B and C Annual Evidence Update 2009&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #33cccc"&gt; &lt;P&gt;&lt;A href="nelh:323995:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323959:0" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323956:0" name=internalLink&gt;&lt;B&gt;Economics&lt;/B&gt;&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323953:0" name=internalLink&gt;Prevention&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323954:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:323962:0" name=internalLink&gt;Hepatitis B&lt;/A&gt; | &lt;A href="nelh:323961:0" name=internalLink&gt;Hepatitis C&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:323963:0" name=internalLink&gt;Risk factors&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:323952:0" name=internalLink&gt;Foreign articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323978:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323984:0" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>323959</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=323959]]&gt;</url>
    <title>2009 Annual Evidence Update on Hepatitis B and C - Epidemiology</title>
    <publicationDate>2009-09-07T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ LIVER,GASTROENTEROLOGY &amp; LIVER DISEASES,HEPATITIS B,HEPATITIS C,HEPATITIS,RECENT ADDITIONS,SEPTEMBER 2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Hepatitis B and C - Epidemiology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;I&gt;Reviewed by Janice Main, Reader in Infectious Diseases and General Medicine, Imperial College at St Mary's Hospital, London&lt;/I&gt;&lt;/P&gt; &lt;P style="COLOR: #99cc00; FONT-SIZE: 12pt"&gt;&lt;B&gt;Hepatitis B virus&lt;/B&gt;&lt;/P&gt; &lt;P&gt;The availability of hepatitis B virus (HBV) vaccine for health care workers should limit the risk of patients acquiring HBV infection in the health care setting. &lt;A href="#lanini"&gt;Lanini et al&lt;/A&gt; review reports of outbreaks in this setting between 1992 and 2007. As a result of the outbreaks described, 471 patients acquired HBV infection and 16 patients died. Dialysis units accounted for 30.3% of the outbreaks and the main breaches in clinical practice were the use of multi-vial drugs, non-disposable multi-patient capillary blood sampling devices and transvenous endomyocardial biopsy procedures. In 9.1% of the outbreaks there were multiple deficiencies in clinical practice. One outbreak followed contamination of stem cells which had been stored in liquid nitrogen but the authors point out that most of these outbreaks were avoidable and many of the infected patients were particularly vulnerable to severe hepatitis or increased HBV chronicity rates because of existing co-morbidities such as chronic renal failure, diabetes mellitus, malignancy, immunosuppression, transplantation, etc. &lt;/P&gt; &lt;P&gt;Most patients with chronic HBV infection are asymptomatic and several studies have looked at possible predictors for more severe disease such as cirrhosis, liver failure and hepatocellular carcinoma. &lt;A href="#taylor"&gt;Taylor et al&lt;/A&gt; reviewed 41 articles and confirmed that cirrhosis, higher HBV DNA level and male sex were the main risk factors for risk of death and liver cancer. Some of the studies from the Far East, for example, included data on several thousand patients. Overall there were limited data on HBV genotype, or coinfection with HCV, HIV and hepatitis D virus (HDV). These studies are useful in developing clinical guidelines for antiviral treatment and screening for HCC. It is also very useful to help identify the patients with the low risk of severe disease so that they can be reassured and appropriately monitored.&lt;/P&gt;&lt;BR&gt; &lt;P style="COLOR: #99cc00; FONT-SIZE: 12pt"&gt;&lt;B&gt;Hepatitis C virus&lt;/B&gt;&lt;/P&gt; &lt;P&gt;Several studies have investigated the incidence and prevalence of hepatitis C virus (HCV) among injecting drug users (IDUs). In the clinic when evaluating a patient with a new diagnosis of HCV infection we ask the patient when they started injecting drugs assuming they acquired their HCV infection early in their injecting “career” and that this then gives us an idea of chronicity of infection.&lt;/P&gt; &lt;P&gt;&lt;A href="#hagan"&gt;Hagan et al&lt;/A&gt; describe the results of a meta-regression of HCV infection in relation to the onset of injecting behaviour and report that over time this has changed in developed countries with delayed acquisition of infection. In developed countries after 1995 the mean fitted prevalence was 32.02% at 1 year of injection and 53.01% at 5 years compared with 59.13% at 1 year in developing/transitional countries. The authors discuss whether this may relate to the evolution and availability of public health resources. &lt;/P&gt; &lt;P&gt;In a further study of HCV infection among IDUs &lt;A href="#lelutiu"&gt;Lelutiu-Weinberger et al&lt;/A&gt; reviewed 29 prevalence and 11 incidence studies comparing the incidence and prevalence of HCV infection among racial/ethnic minority groups versus those of the majority status in a number of countries. Clear differences were noted in Canadian and Australian aboriginal populations with high levels of prevalence and incidence of HCV infection compared with the local white population. In the US, compared to the white population high levels of HCV prevalence were reported among the Hispanic group but not the African-Americans. The authors discuss whether these differences relate to social behaviour and access to health care.&lt;/P&gt;&lt;BR&gt; &lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Articles:&lt;/B&gt;&lt;/P&gt; &lt;P&gt;&lt;A name=hagan&gt;&lt;/A&gt;Hagan H, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger C. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=323508" target="_blank"&gt;Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place.&lt;/A&gt; &lt;I&gt;Am J Epidemiol&lt;/I&gt; 2008;168:1099-1109.&lt;/P&gt; &lt;P&gt;&lt;A name=lanini&gt;&lt;/A&gt;Lanini S, Puro V, Lauria FN, Fusco FM, Nisii C, Ippolito G. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=323517" target="_blank"&gt;Patient to patient transmission of hepatitis B virus: a systematic review of reports on outbreaks between 1992 and 2007.&lt;/A&gt; &lt;I&gt;BMC Med&lt;/I&gt; 2009:7:15.&lt;/P&gt; &lt;P&gt;&lt;A name=lelutiu&gt;&lt;/A&gt;Lelutiu-Weinberger C, Pouget ER, Des Jarlais DC, Cooper HL, Scheinmann R, Stern R, Strauss S, Hagan H. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=323521" target="_blank"&gt;A meta-analysis of the hepatitis C virus distribution in diverse racial/ethnic drug injector groups.&lt;/A&gt; &lt;I&gt;Soc Sci Med&lt;/I&gt; 2009;68:579-90.&lt;/P&gt; &lt;P&gt;&lt;A name=taylor&gt;&lt;/A&gt;Taylor BC, Yuan J-M, Shamliyan TA, Shaukat A, Kane RL, Wilt TJ. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=323523" target="_blank"&gt;Clinical outcomes in adults with chronic hepatitis B in association with patient and viral characteristics: a systematic review of evidence.&lt;/A&gt; &lt;I&gt;Hepatology&lt;/I&gt; 2009;49:S85-S95.&lt;/P&gt;&lt;BR&gt; &lt;TABLE align=center&gt; &lt;TBODY&gt; &lt;TR&gt; &lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #99cc00"&gt;Hepatitis B and C Annual Evidence Update 2009&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #33cccc"&gt; &lt;P&gt;&lt;A href="nelh:323995:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323959:0" name=internalLink&gt;&lt;B&gt;Epidemiology&lt;/B&gt;&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323956:0" name=internalLink&gt;Economics&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323953:0" name=internalLink&gt;Prevention&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323954:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:323962:0" name=internalLink&gt;Hepatitis B&lt;/A&gt; | &lt;A href="nelh:323961:0" name=internalLink&gt;Hepatitis C&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:323963:0" name=internalLink&gt;Risk factors&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:323952:0" name=internalLink&gt;Foreign articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323978:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323984:0" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>323952</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=323952]]&gt;</url>
    <title>2009 Annual Evidence Update on Hepatitis B and C - Foreign articles</title>
    <publicationDate>2009-09-07T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ LIVER,GASTROENTEROLOGY &amp; LIVER DISEASES,HEPATITIS C,HEPATITIS B,HEPATITIS,HEPATOCELLULAR CARCINOMA,DISEASE PREVENTION,HIV / AIDS,SCREENING,VACCINATION,RECENT ADDITIONS,SEPTEMBER 2009,CANCER]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Hepatitis B and C - Foreign articles&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;The following articles were identified by the search as being potentially relevant to the AEU, but were not sent out for appraisal because the full text is in a language other than English. They are included here for interest, and for the sake of completeness.&lt;/P&gt;&lt;BR&gt; &lt;P&gt;Bai SL, Hu XY, Zhong S. &lt;A href="http://d.wanfangdata.com.cn/Periodical_zhlxbx200812017.aspx" target="_blank"&gt;Evaluation on HBeAg conversion time when treating chronic hepatitis B patients with combination of lamivudine and traditional Chinese medicine.&lt;/A&gt; &lt;I&gt;Zhonghua Liu Xing Bing Xue Za Zhi&lt;/I&gt; 2008 Dec;29(12):1243-7.&lt;BR&gt;&lt;I&gt;&lt;B&gt;Language:&lt;/B&gt; Chinese&lt;/I&gt;&lt;/P&gt; &lt;P&gt;Hwang SH, Oh HB, Choi SE, Kim HH, Chang CL, Lee EY, Son HC. &lt;A href="http://www.kslm.org/english/catalog.php?page=160&amp;amp;vol=28&amp;amp;year=2008" target="_blank"&gt;Meta-analysis for the pooled sensitivity and specificity of hepatitis B surface antigen rapid tests.&lt;/A&gt; &lt;I&gt;Korean J Lab Med&lt;/I&gt; 2008 Apr;28(2):160-8.Click here to read &lt;BR&gt;&lt;I&gt;&lt;B&gt;Language:&lt;/B&gt; Korean&lt;/I&gt;&lt;/P&gt; &lt;P&gt;Jin H-L, Shi B-Y. &lt;A href="http://d.wanfangdata.com.cn/Periodical_xdkf200818042.aspx" target="_blank"&gt;Hepatitis B virus recurrence and YMDD variation after liver transplantation: A review.&lt;/A&gt; &lt;I&gt;J Clin Rehab Tissue Eng Res&lt;/I&gt; 2008;12(18), 3527-31.&lt;BR&gt;&lt;I&gt;&lt;B&gt;Language:&lt;/B&gt; Chinese&lt;/I&gt;&lt;/P&gt; &lt;P&gt;Li L, He Q, Yang D-G, Zhong B-L, Zeng X-M. &lt;A href="http://www.cjebm.org.cn/OA/pdfdow.aspx?Type=pdf&amp;amp;FileName=c5420873-f007-47fc-9a42-fce5600495a3.pdf" target="_blank"&gt;Effectiveness and safety of Fuzheng Huayu capsule for liver fibrosis of chronic hepatitis B: A systematic review.&lt;/A&gt; &lt;I&gt;Chin J Evid Based Med&lt;/I&gt; 2008;8(10):892-7.&lt;BR&gt;&lt;I&gt;&lt;B&gt;Language:&lt;/B&gt; Chinese&lt;/I&gt;&lt;/P&gt; &lt;P&gt;Margusino Framiñán L, Suárez López F, Martín Herranz I. &lt;A href="http://www.elsevier.es/revistas/ctl_servlet?_f=7017&amp;amp;articuloid=13121232&amp;amp;revistaid=121" target="_blank"&gt;The prophylaxis and treatment of c virus liver disease in the liver transplantation setting. Narrative review.&lt;/A&gt; &lt;I&gt;Farm Hosp&lt;/I&gt; 2008 Mar-Apr;32(2):102-12.&lt;BR&gt;&lt;I&gt;&lt;B&gt;Language:&lt;/B&gt; Spanish&lt;/I&gt;&lt;/P&gt; &lt;P&gt;Mincis M, Mincis R, Calichman S. &lt;A href="http://bases.bireme.br/cgi-bin/wxislind.exe/iah/online/?IsisScript=iah/iah.xis&amp;amp;src=google&amp;amp;base=LILACS&amp;amp;lang=p&amp;amp;nextAction=lnk&amp;amp;exprSearch=505721&amp;amp;indexSearch=ID" target="_blank"&gt;Acute hepatitis A, B, C, D and E.&lt;/A&gt; &lt;I&gt;Rev Bras Med&lt;/I&gt; 2008;65(11):351-61.&lt;BR&gt;&lt;I&gt;&lt;B&gt;Language:&lt;/B&gt; Portuguese&lt;/I&gt;&lt;/P&gt; &lt;P&gt;Morillo Verdugo R, Madrazo Berenguer A, Gil Navarro MV, Suárez García E. &lt;A href="http://www.elsevier.es/revistas/ctl_servlet?_f=7064&amp;amp;ip=195.195.96.216&amp;amp;articuloid=13130933&amp;amp;revistaid=121" target="_blank"&gt;Drugs treatment of hepatitis B.&lt;/A&gt; &lt;I&gt;Farm Hosp&lt;/I&gt; 2008 Jul-Aug;32(4):234-48.&lt;BR&gt;&lt;I&gt;&lt;B&gt;Language:&lt;/B&gt; Spanish&lt;/I&gt;&lt;/P&gt; &lt;P&gt;Schramm F, Moenne-Loccoz R, Fafi-Kremer S, Soulier E, Royer C, Weitten T, Brignon N, Ellero B, Woehl-Jaegle ML, Meyer C, Wolf P, Doffoel M, Baumert TF, Gut JP, Stoll-Keller F, Schvoerer E. &lt;A href="http://dx.doi.org/10.1016/j.patbio.2008.07.007" target="_blank"&gt;Study of hepatitis C virus leukotropism by characterization of viral quasispecies in the liver transplantation setting.&lt;/A&gt; &lt;I&gt;Pathol Biol (Paris)&lt;/I&gt; 2008 Nov-Dec;56(7-8):487-91.&lt;BR&gt;&lt;I&gt;&lt;B&gt;Language:&lt;/B&gt; French&lt;/I&gt;&lt;/P&gt; &lt;P&gt;Takedai M, Takatani A, Funato T, Ino K, Nakayama T, Nomura F, Miyachi H, Noboru T, Ueda K. &lt;A href="http://ci.nii.ac.jp/naid/40016330198/" target="_blank"&gt;HCV-RNA test in hepatitis C virus infection--a systematic review.&lt;/A&gt; &lt;I&gt;Rinsho Byori&lt;/I&gt; 2008 Oct;56(10):868-76.&lt;BR&gt;&lt;I&gt;&lt;B&gt;Language:&lt;/B&gt; Japanese&lt;/I&gt;&lt;/P&gt;&lt;BR&gt; &lt;P&gt;In addition, the following English-language articles were identified by the search but not sent out for review because they were studies of foreign populations:&lt;/P&gt;&lt;BR&gt; &lt;P&gt;Alavian SM, Hajarizadeh B, Ahmadzad-Asl M, Kabir A, Bagheri-Lankarani K. &lt;A href="http://hepmon.com/pdf/Hepatitis_B_Virus_Infection_in_Iran_A_Sy.pdf" target="_blank"&gt;Hepatitis B virus infection in Iran: a systematic review.&lt;/A&gt; &lt;I&gt;Hepat Mon&lt;/I&gt; 2008;8(4):868-76.&lt;/P&gt; &lt;P&gt;Ali SA, Donahue RM, Qureshi H, Vermund SH. &lt;A href="http://dx.doi.org/10.1016/j.ijid.2008.06.019" target="_blank"&gt;Hepatitis B and hepatitis C in Pakistan: prevalence and risk factors.&lt;/A&gt; &lt;I&gt;Int J Infect Dis&lt;/I&gt; 2009 Jan;13(1):9-19. &lt;/P&gt; &lt;P&gt;Bajubair MA, Elrub AA, Bather G. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18521468" target="_blank"&gt;Hepatic viral infections in Yemen between 2000--2005.&lt;/A&gt; &lt;I&gt;Saudi Med J&lt;/I&gt; 2008 Jun;29(6):871-4.&lt;/P&gt; &lt;P&gt;Bao YP, Liu ZM. &lt;A href="http://dx.doi.org/10.1258/ijsa.2008.008362" target="_blank"&gt;Systematic review of HIV and HCV infection among drug users in China.&lt;/A&gt; &lt;I&gt;Int J STD AIDS&lt;/I&gt; 2009 Jun;20(6):399-405.&lt;/P&gt; &lt;P&gt;Campos LN, Guimarães MD, Carmo RA, Melo AP, Oliveira HN, Elkington K, McKinnon K. &lt;A href="https://rmsadmin.library.nhs.uk/admin/wizards/articles/dx.doi.org/10.1590/S0102-311X2008001600012" target="_blank"&gt;HIV, syphilis, and hepatitis B and C prevalence among patients with mental illness: a review of the literature.&lt;/A&gt; &lt;I&gt;Cad Saude Publica&lt;/I&gt; 2008;24 Suppl 4:s607-20.&lt;/P&gt; &lt;P&gt;Hu KQ. &lt;A href="http://dx.doi.org/10.1111/j.1572-0241.2008.01878.x" target="_blank"&gt;Hepatitis B virus (HBV) infection in Asian and Pacific Islander Americans (APIAs): how can we do better for this special population?&lt;/A&gt; &lt;I&gt;Am J Gastroenterol&lt;/I&gt; 2008 Jul;103(7):1824-33.&lt;/P&gt; &lt;P&gt;Lacey L, Chien RN, Chuang WL, Pwu RF. &lt;A href="http://dx.doi.org/10.1111/j.1440-1746.2008.05360.x" target="_blank"&gt;Economic evaluation of chronic hepatitis B treatments in Taiwan.&lt;/A&gt; &lt;I&gt;J Gastroenterol Hepatol&lt;/I&gt; 2008 Apr;23(4):571-9.&lt;/P&gt; &lt;P&gt;Lehman EM, Wilson ML. &lt;A href="http://dx.doi.org/10.1002/ijc.23937" target="_blank"&gt;Epidemiology of hepatitis viruses among hepatocellular carcinoma cases and healthy people in Egypt: a systematic review and meta-analysis.&lt;/A&gt; &lt;I&gt;Int J Cancer&lt;/I&gt; 2009 Feb 1;124(3):690-7. &lt;/P&gt; &lt;P&gt;Nakamura J, Terajima K, Aoyagi Y, Akazawa K. &lt;A href="https://rmsadmin.library.nhs.uk/admin/wizards/articles/dx.doi.org/10.1620/tjem.215.33" target="_blank"&gt;Cost-effectiveness of the national screening program for hepatitis C virus in the general population and the high-risk groups.&lt;/A&gt; &lt;I&gt;Tohoku J Exp Med&lt;/I&gt; 2008 May;215(1):33-42.&lt;/P&gt; &lt;P&gt;Puliyel JM, Rastogi P, Mathew JL. Hepatitis B in India: &lt;A href="http://www.icmr.nic.in/ijmr/2008/may/0513.pdf" target="_blank"&gt;Systematic review &amp;amp; report of the 'IMA sub-committee on immunization'.&lt;/A&gt; &lt;I&gt;Indian J Med Res&lt;/I&gt; 2008 May;127(5):494-7.&lt;/P&gt; &lt;P&gt;Raja NS, Janjua KA. &lt;A href="http://www.jmii.org/content/pdf/v41n1p4.pdf" target="_blank"&gt;Epidemiology of hepatitis C virus infection in Pakistan.&lt;/A&gt; &lt;I&gt;J Microbiol Immunol Infect&lt;/I&gt; 2008 Feb;41(1):4-8.&lt;/P&gt; &lt;P&gt;Roman S, Panduro A, Aguilar-Gutierrez Y, Maldonado M, Vazquez-Vandyck M, Martinez-Lopez E, Ruiz-Madrigal B, Hernandez-Nazara Z. &lt;A href="http://dx.doi.org/10.1007/s12072-008-9115-9" target="_blank"&gt;A low steady HBsAg seroprevalence is associated with a low incidence of HBV-related liver cirrhosis and hepatocellular carcinoma in Mexico: a systematic review.&lt;/A&gt; &lt;I&gt;Hepatol Int&lt;/I&gt; 2009 Jun;3(2):343-55. &lt;P&gt;Veenstra DL, Sullivan SD, Lai MY, Lee CM, Tsai CM, Patel KK. &lt;A href="http://dx.doi.org/10.1111/j.1524-4733.2007.00221.x" target="_blank"&gt;HBeAg-negative chronic hepatitis B: cost-effectiveness of peginterferon alfa-2a compared to lamivudine in Taiwan.&lt;/A&gt; &lt;I&gt;Value Health&lt;/I&gt; 2008 Mar-Apr;11(2):131-8.&lt;/P&gt; &lt;P&gt;Xia X, Luo J, Bai J, Yu R. &lt;A href="http://dx.doi.org/10.1016/j.puhe.2008.01.014" target="_blank"&gt;Epidemiology of hepatitis C virus infection among injection drug users in China: systematic review and meta-analysis.&lt;/A&gt; &lt;I&gt;Public Health&lt;/I&gt; 2008 Oct;122(10):990-1003.&lt;/P&gt; &lt;P&gt;Zhao S, Liu E, Yu H, Yang H, Xun M, Xue X, Song J, Xu K, Chu Y. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18705326" target="_blank"&gt;Comparison of peginterferon and interferon in treating Chinese patients with chronic hepatitis C.&lt;/A&gt; &lt;I&gt;Hepatogastroenterology&lt;/I&gt; 2008 May-Jun;55(84):1047-54.&lt;/P&gt; &lt;P&gt;Zhou YH, Wu C, Zhuang H. &lt;A href="http://cmj.org/periodical/PDF/20091556325330.pdf" target="_blank"&gt;Vaccination against hepatitis B: the Chinese experience.&lt;/A&gt; &lt;I&gt;Chin Med J (Engl)&lt;/I&gt; 2009 Jan 5;122(1):98-102.&lt;/P&gt;&lt;BR&gt; &lt;TABLE align=center&gt; &lt;TBODY&gt; &lt;TR&gt; &lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #99cc00"&gt;Hepatitis B and C Annual Evidence Update 2009&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #33cccc"&gt; &lt;P&gt;&lt;A href="nelh:323995:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323959:0" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323956:0" name=internalLink&gt;Economics&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323953:0" name=internalLink&gt;Prevention&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323954:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:323962:0" name=internalLink&gt;Hepatitis B&lt;/A&gt; | &lt;A href="nelh:323961:0" name=internalLink&gt;Hepatitis C&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:323963:0" name=internalLink&gt;Risk factors&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:323952:0" name=internalLink&gt;&lt;B&gt;Foreign articles&lt;/B&gt;&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323978:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323984:0" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>323995</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=323995]]&gt;</url>
    <title>2009 Annual Evidence Update on Hepatitis B and C - Introduction</title>
    <publicationDate>2009-09-07T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,HEPATITIS C,RECENT ADDITIONS,SEPTEMBER 2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Hepatitis B and C - Introduction&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence Annual Evidence Updates (AEUs) attempt to draw together recently published, high quality evidence – focusing particularly on systematic reviews and published guidelines - which it is hoped will inform and enhance the decision making and planning of clinicians, commissioners and others involved in the process of health care. &lt;/P&gt;
&lt;P&gt;For this Hepatitis B and C AEU updating last year's work, a detailed literature search from 2008-2009 identified 408 potential pieces of evidence (see methods for retrieving and evaluating the evidence for more information). Following a process of filtering and peer review (with thanks to the reviewers listed below) 46 of these form the basis of this AEU.&lt;/P&gt;
&lt;P&gt;It is imperative that those involved in commissioning and delivering care are apprised of the best available evidence and guidelines against which to review their service. We hope that the AEU in Hepatitis B and C will provide a prime source of such evidence.&lt;/P&gt;
&lt;P&gt;A summary of the methods used for retrieving and evaluating the evidence can be found &lt;A href="nelh:323984:0" name=internalLink&gt;here&lt;/A&gt;. The evidence has been split into sections as follows:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:323959:0" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:323956:0" name=internalLink&gt;Economics&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:323953:0" name=internalLink&gt;Prevention&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:323954:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Treatment: 
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:323962:0" name=internalLink&gt;Hepatitis B&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:323961:0" name=internalLink&gt;Hepatitis C&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;BR&gt;
&lt;LI&gt;&lt;A href="nelh:323963:0" name=internalLink&gt;Risk factors&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:323952:0" name=internalLink&gt;Articles in foreign languages and on foreign populations&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Click on the sections above to find links to critically appraised systematic reviews, expert commentaries and other information of interest, or download the &lt;A href="http://www.library.nhs.uk/SpecialistLibrarySearch/Download.aspx?resID=323995" target="_blank"&gt;pdf version&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;We also have provided a list of &lt;A href="nelh:323978:0" name=internalLink&gt;treatment uncertainties&lt;/A&gt;, taken from the articles included in the AEU.&lt;/P&gt;
&lt;P&gt;This year's update has been put together by the NHS Evidence - gastroenterology and liver diseases Project Team, with expert advice and commentaries provided by our liver disease topic leads. These are:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Andrew Austin, Consultant Hepatologist, Royal Derby Hospital&lt;/LI&gt;
&lt;LI&gt;Jane Collier, Consultant Hepatologist, John Radcliffe Hospital, Oxford&lt;/LI&gt;
&lt;LI&gt;Jan Freeman, Consultant Hepatologist and Lead Clinician for Gastroenterology and Hepatology, Royal Derby Hospital&lt;/LI&gt;
&lt;LI&gt;Martin James, Consultant Hepatologist and Gastroenterologist, Queen's Medical Centre, Nottingham&lt;/LI&gt;
&lt;LI&gt;Lynda Greenslade, Clinical Nurse Specialist in Hepatology, Royal Free Hampstead NHS Trust, London&lt;/LI&gt;
&lt;LI&gt;Janice Main, Reader in Infectious Diseases and General Medicine, Imperial College at St Mary's Hospital, London&lt;/LI&gt;
&lt;LI&gt;Steven Ryder, Consultant Physician and Hepatologist, Queen's Medical Centre, Nottingham&lt;/LI&gt;&lt;/UL&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BACKGROUND-COLOR: #99cc00; TEXT-ALIGN: center"&gt;Hepatitis B and C Annual Evidence Update 2009&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BACKGROUND-COLOR: #33cccc; TEXT-ALIGN: center"&gt;
&lt;P&gt;&lt;A href="nelh:323995:0" name=internalLink&gt;&lt;B&gt;Introduction&lt;/B&gt;&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323959:0" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323956:0" name=internalLink&gt;Economics&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323953:0" name=internalLink&gt;Prevention&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323954:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:323962:0" name=internalLink&gt;Hepatitis B&lt;/A&gt; | &lt;A href="nelh:323961:0" name=internalLink&gt;Hepatitis C&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:323963:0" name=internalLink&gt;Risk factors&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:323952:0" name=internalLink&gt;Foreign articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323978:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323984:0" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>323984</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=323984]]&gt;</url>
    <title>2009 Annual Evidence Update on Hepatitis B and C - Methods for retrieving and evaluating the evidence</title>
    <publicationDate>2009-09-07T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ HEPATITIS,HEPATITIS B,HEPATITIS C,GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,SEPTEMBER 2009,RECENT ADDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Hepatitis B and C - Methods for retrieving and evaluating the evidence&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;The last Annual Evidence Update for Hepatitis B and C was carried out in August 2008. This AEU serves as an update to that one, and includes articles published in 2008 and 2009. As the Specialist Library focuses only on secondary information of use to NHS staff and patients, our update was focused on guidelines and systematic reviews written in English. However, foreign language articles were included in the search process. As translations for these articles were not available, the article titles have been listed separately. Our search also recovered a large number of studies of viral hepatitis in foreign populations; as these are of limited relevance to UK practice we did not send these out to our reviewers for appraisal, but we have again listed them separately. &lt;/P&gt;&lt;BR&gt; &lt;P style="COLOR: #99cc00; FONT-SIZE: 13pt"&gt;&lt;B&gt;&lt;U&gt;Search strategy&lt;/U&gt;&lt;/B&gt;&lt;/P&gt; &lt;P&gt;Our search strategy has been updated from last year. The following resources were searched: &lt;UL&gt; &lt;LI&gt;MEDLINE&lt;/LI&gt; &lt;LI&gt;EMBASE&lt;/LI&gt; &lt;LI&gt;CINAHL&lt;/LI&gt; &lt;LI&gt;Web of Science&lt;/LI&gt; &lt;LI&gt;PsycINFO&lt;/LI&gt; &lt;LI&gt;AMED&lt;/LI&gt; &lt;LI&gt;British Nursing Index&lt;/LI&gt; &lt;LI&gt;National Library of Guidelines&lt;/LI&gt; &lt;LI&gt;NHS Evidence Specialist Collections &lt;/LI&gt; &lt;LI&gt;Database of Abstracts of Reviews of Effects &lt;/LI&gt; &lt;LI&gt;NHS Economic Evaluation Database&lt;/LI&gt; &lt;LI&gt;HTA Database&lt;/LI&gt;&lt;/UL&gt;The search strategy for MEDLINE, which was modified for the other resources, appears &lt;A href="#strategy"&gt;below&lt;/A&gt;. We combined this with a &lt;A href="#filter"&gt;modified SIGN systematic review&lt;/A&gt; filter in all cases except the searches of the BNI (due to its small size) and the NLH, the Specialist Collections, DARE, NHS EED and HTA (because they consist entirely of the types of publication that we were interested in). &lt;P&gt;&lt;/P&gt; &lt;P&gt;After de-duplication 408 articles were retrieved.&lt;/P&gt;&lt;BR&gt; &lt;P style="COLOR: #99cc00; FONT-SIZE: 13pt"&gt;&lt;B&gt;&lt;U&gt;Inclusion and exclusion criteria&lt;/U&gt;&lt;/B&gt;&lt;/P&gt; &lt;P&gt;Included articles had to meet the following criteria:&lt;/P&gt; &lt;UL&gt; &lt;LI&gt;Publication types: systematic review, consensus report, guideline, protocol, care pathway, economic evaluation, health technology assessment&lt;/LI&gt; &lt;LI&gt;Published in 2008 or 2009&lt;/LI&gt; &lt;LI&gt;Main condition under investigation was hepatitis B or C virus infection &lt;/LI&gt;&lt;/UL&gt; &lt;P&gt;Once the inclusion criteria were applied, 80 articles were left. Of these, 9 were foreign language articles, 2 were Cochrane systematic reviews, 4 were guidelines, and 16 were studies of specific foreign populations. &lt;/P&gt; &lt;P&gt;The Cochrane systematic reviews and guidelines were automatically included in the Evidence Update. The foreign language and foreign population studies were not sent out to reviewers because of translation difficulties and limited relevance to UK practice, but are listed in a separate section of the Evidence Update. This left 49 articles to be sent to our reviewers for appraisal.&lt;/P&gt;&lt;BR&gt; &lt;P style="COLOR: #99cc00; FONT-SIZE: 13pt"&gt;&lt;B&gt;&lt;U&gt;Critical appraisal process&lt;/U&gt;&lt;/B&gt;&lt;/P&gt; &lt;P&gt;Before sending out, the articles were divided into categories as follows:&lt;/P&gt; &lt;UL&gt; &lt;LI&gt;Epidemiology&lt;/LI&gt; &lt;LI&gt;Economics&lt;/LI&gt; &lt;LI&gt;Prevention&lt;/LI&gt; &lt;LI&gt;Diagnosis&lt;/LI&gt; &lt;LI&gt;Treatment&lt;/LI&gt; &lt;LI&gt;Risk factors&lt;/LI&gt; &lt;LI&gt;Other&lt;/LI&gt;&lt;/UL&gt; &lt;P&gt;Using these categories as a guide, the papers were divided up and sent to our ? reviewers. The reviewers then appraised the articles for their validity, relevance and rigour. Following the receipt of their comments, we included in the Evidence Update ? articles that were deemed to meet the standards.&lt;BR&gt;&lt;/P&gt;&lt;BR&gt; &lt;P style="COLOR: #99cc00; FONT-SIZE: 13pt"&gt;&lt;B&gt;&lt;U&gt;AEU process flowchart&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;&lt;IMG src="https://rmsadmin.library.nhs.uk/libraryImages/gastroliver/contentID323984/nelhImp_0002_hbcflowchart.jpg"&gt;&lt;/IMG&gt;&lt;BR&gt; &lt;P style="COLOR: #99cc00; FONT-SIZE: 13pt"&gt;&lt;B&gt;&lt;U&gt;&lt;A name=strategy&gt;&lt;/A&gt;MEDLINE search strategy&lt;/U&gt;&lt;/B&gt;&lt;/P&gt; &lt;TABLE style="TABLE-LAYOUT: fixed"&gt; &lt;TBODY&gt; &lt;TR style="FONT-FAMILY: Courier,monospace; FONT-SIZE: 7pt"&gt; &lt;TD style="BORDER-BOTTOM: #000000 thin solid; BORDER-LEFT: #000000 thin solid; PADDING-BOTTOM: 5pt; PADDING-LEFT: 5pt; PADDING-RIGHT: 5pt; BORDER-TOP: #000000 thin solid; BORDER-RIGHT: #000000 thin solid; PADDING-TOP: 5pt" ?&gt;&lt;STRONG&gt;1&lt;/STRONG&gt; exp Hepatitis B/&lt;BR&gt;&lt;STRONG&gt;2&lt;/STRONG&gt; Hepatitis B Virus/&lt;BR&gt;&lt;STRONG&gt;3&lt;/STRONG&gt; exp Hepatitis B Antigens/&lt;BR&gt;&lt;STRONG&gt;4&lt;/STRONG&gt; Hepatitis B Vaccines/&lt;BR&gt;&lt;STRONG&gt;5&lt;/STRONG&gt; "Hepatitis B".ti,ab.&lt;BR&gt;&lt;STRONG&gt;6&lt;/STRONG&gt; "Hep B".ti,ab.&lt;BR&gt;&lt;STRONG&gt;7&lt;/STRONG&gt; HBV.ti,ab.&lt;BR&gt;&lt;STRONG&gt;8&lt;/STRONG&gt; HBSAG.ti,ab.&lt;BR&gt;&lt;STRONG&gt;9&lt;/STRONG&gt; HBCAG.ti,ab.&lt;STRONG&gt;&lt;BR&gt;10&lt;/STRONG&gt; HBEAG.ti,ab.&lt;BR&gt;&lt;STRONG&gt;11&lt;/STRONG&gt; exp Hepatitis C/&lt;BR&gt;&lt;STRONG&gt;12&lt;/STRONG&gt; Hepacivirus/&lt;BR&gt;&lt;STRONG&gt;13&lt;/STRONG&gt; Hepatitis C Antigens/&lt;BR&gt;&lt;STRONG&gt;14&lt;/STRONG&gt; "Hepatitis C".ti,ab.&lt;BR&gt;&lt;STRONG&gt;15&lt;/STRONG&gt; "Hep C".ti,ab.&lt;BR&gt;&lt;STRONG&gt;16&lt;/STRONG&gt; HCV.ti,ab.&lt;BR&gt;&lt;STRONG&gt;17&lt;/STRONG&gt; AGHCV.ti,ab.&lt;BR&gt;&lt;STRONG&gt;18&lt;/STRONG&gt; (Hepatitis adj ("non a" adj "non b")).ti,ab.&lt;BR&gt;&lt;STRONG&gt;19&lt;/STRONG&gt; Hepacivirus.ti,ab.&lt;BR&gt;&lt;STRONG&gt;20&lt;/STRONG&gt; Pt-nanbh.ti,ab.&lt;BR&gt;&lt;STRONG&gt;21&lt;/STRONG&gt; 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 &lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;BR&gt; &lt;P style="COLOR: #99cc00; FONT-SIZE: 13pt"&gt;&lt;B&gt;&lt;U&gt;&lt;A name=filter&gt;&lt;/A&gt;Systematic review filter&lt;/U&gt;&lt;/B&gt;&lt;/P&gt; &lt;P&gt;This is modified from the SIGN filter, which can be found at &lt;A href="http://www.sign.ac.uk/methodology/filters.html" target="_blank"&gt;http://www.sign.ac.uk/methodology/filters.html&lt;/A&gt;. It shown below as used for the MEDLINE search (small adaptations were made for other databases).&lt;/P&gt; &lt;TABLE style="BORDER-BOTTOM: #000000 thin solid; BORDER-LEFT: #000000 thin solid; FONT-FAMILY: Courier,serif; FONT-SIZE: 7pt; BORDER-TOP: #000000 thin solid; BORDER-RIGHT: #000000 thin solid"&gt; &lt;TBODY&gt; &lt;TR&gt; &lt;TD style="PADDING-BOTTOM: 5pt; PADDING-LEFT: 5pt; PADDING-RIGHT: 5pt; PADDING-TOP: 5pt"&gt;&lt;STRONG&gt;1&lt;/STRONG&gt; Meta-Analysis as Topic/&lt;BR&gt;&lt;STRONG&gt;2&lt;/STRONG&gt; Meta-Analysis/&lt;BR&gt;&lt;STRONG&gt;3&lt;/STRONG&gt; metaanaly*.mp. &lt;BR&gt;&lt;STRONG&gt;4&lt;/STRONG&gt; meta analy*.mp. &lt;BR&gt;&lt;STRONG&gt;5&lt;/STRONG&gt; (systematic adj (review* or overview*)).mp.&lt;BR&gt;&lt;STRONG&gt;6&lt;/STRONG&gt; exp Review Literature as Topic/&lt;BR&gt;&lt;STRONG&gt;7&lt;/STRONG&gt; 1 or 2 or 3 or 4 or 5 or 6&lt;BR&gt;&lt;STRONG&gt;8&lt;/STRONG&gt; Cochrane.ab.&lt;BR&gt;&lt;STRONG&gt;9&lt;/STRONG&gt; Embase.ab.&lt;BR&gt;&lt;STRONG&gt;10&lt;/STRONG&gt; Medline.ab.&lt;BR&gt;&lt;STRONG&gt;11&lt;/STRONG&gt; Pubmed.ab.&lt;BR&gt;&lt;STRONG&gt;12&lt;/STRONG&gt; (psychlit or psyclit).ab.&lt;BR&gt;&lt;STRONG&gt;13&lt;/STRONG&gt; (psychinfo or psycinfo).ab.&lt;BR&gt;&lt;STRONG&gt;14&lt;/STRONG&gt; (cinahl or cinhal).ab.&lt;BR&gt;&lt;STRONG&gt;15&lt;/STRONG&gt; science citation index.ab.&lt;BR&gt;&lt;STRONG&gt;16&lt;/STRONG&gt; bids.ab.&lt;BR&gt;&lt;STRONG&gt;17&lt;/STRONG&gt; cancerlit.ab.&lt;BR&gt;&lt;STRONG&gt;18&lt;/STRONG&gt; 11 or 9 or 17 or 12 or 15 or 14 or 8 or 16 or 10 or 13&lt;BR&gt;&lt;STRONG&gt;19&lt;/STRONG&gt; reference list$.ab.&lt;BR&gt;&lt;STRONG&gt;20&lt;/STRONG&gt; bibliograph$.ab.&lt;BR&gt;&lt;STRONG&gt;21&lt;/STRONG&gt; hand-search$.ab.&lt;BR&gt;&lt;STRONG&gt;22&lt;/STRONG&gt; relevant journals.ab.&lt;BR&gt;&lt;STRONG&gt;23&lt;/STRONG&gt; manual search$.ab.&lt;BR&gt;&lt;STRONG&gt;24&lt;/STRONG&gt; 22 or 21 or 23 or 19 or 20&lt;BR&gt;&lt;STRONG&gt;25&lt;/STRONG&gt; selection criteria.ab.&lt;BR&gt;&lt;STRONG&gt;26&lt;/STRONG&gt; data extraction.ab.&lt;BR&gt;&lt;STRONG&gt;27&lt;/STRONG&gt; 25 or 26&lt;BR&gt;&lt;STRONG&gt;28&lt;/STRONG&gt; review/&lt;BR&gt;&lt;STRONG&gt;29&lt;/STRONG&gt; 27 and 28&lt;BR&gt;&lt;STRONG&gt;30&lt;/STRONG&gt; Comment/&lt;BR&gt;&lt;STRONG&gt;31&lt;/STRONG&gt; Letter/&lt;BR&gt;&lt;STRONG&gt;32&lt;/STRONG&gt; editorial/&lt;BR&gt;&lt;STRONG&gt;33&lt;/STRONG&gt; 32 or 30 or 31&lt;BR&gt;&lt;STRONG&gt;34&lt;/STRONG&gt; 18 or 24 or 7 or 29&lt;BR&gt;&lt;STRONG&gt;35&lt;/STRONG&gt; 34 not 33&lt;BR&gt;&lt;STRONG&gt;36&lt;/STRONG&gt; limit 35 to animals&lt;BR&gt;&lt;STRONG&gt;37&lt;/STRONG&gt; limit 35 to (animals and humans)&lt;BR&gt;&lt;STRONG&gt;38&lt;/STRONG&gt; 36 not 37&lt;BR&gt;&lt;STRONG&gt;39&lt;/STRONG&gt; 35 not 38 &lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;BR&gt; &lt;TABLE align=center&gt; &lt;TBODY&gt; &lt;TR&gt; &lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #99cc00"&gt;Hepatitis B and C Annual Evidence Update 2009&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #33cccc"&gt; &lt;P&gt;&lt;A href="nelh:323995:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323959:0" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323956:0" name=internalLink&gt;Economics&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323953:0" name=internalLink&gt;Prevention&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323954:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:323962:0" name=internalLink&gt;Hepatitis B&lt;/A&gt; | &lt;A href="nelh:323961:0" name=internalLink&gt;Hepatitis C&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:323963:0" name=internalLink&gt;Risk factors&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:323952:0" name=internalLink&gt;Foreign articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323978:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323984:0" name=internalLink&gt;&lt;B&gt;Methods&lt;/B&gt;&lt;/A&gt;&lt;/P&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>323953</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=323953]]&gt;</url>
    <title>2009 Annual Evidence Update on Hepatitis B and C - Prevention</title>
    <publicationDate>2009-09-07T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ HEPATITIS,HEPATITIS A,HEPATITIS B,GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,VACCINATION,DISEASE PREVENTION,SEPTEMBER 2009,RECENT ADDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Hepatitis B and C - Prevention&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P style="COLOR: #99cc00; FONT-SIZE: 12pt"&gt;&lt;B&gt;Cochrane reviews&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The following Cochrane review was updated this year: &lt;/P&gt;
&lt;P&gt;Mathew JL, El DR, Mathew PJ, Boxall EH, Brok J. &lt;A href="http://www.library.nhs.uk/GASTROLIVER/ViewResource.aspx?resID=293684" target="_blank"&gt;Hepatitis B immunisation in persons not previously exposed to hepatitis B or with unknown exposure status.&lt;/A&gt; &lt;I&gt;Cochrane Database of Systematic Reviews&lt;/I&gt; 2008;(3):CD006481.&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00; FONT-SIZE: 12pt"&gt;&lt;B&gt;Other reviews&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;Reviewed by Andrew Austin, Consultant Hepatologist, Royal Derby Hospital&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="#steele"&gt;Steele et al&lt;/A&gt; address the issue of immunisation against hepatitis A and B of paediatric patients with inherited bleeding disorders. The discrepancies between a range of national and international guidelines are discussed and recommendations made. Existing UK advice (references nos. 21 and 24) are included and should be the first source of advice for UK-based doctors. &lt;/P&gt;
&lt;P&gt;The comprehensive systematic review and meta-analysis by &lt;A href="#sangare"&gt;Sangare et al&lt;/A&gt; compares intradermal and intramuscular hepatitis B vaccination. The pooled meta-analysis of five homogeneous RCTs (each including small numbers - less than 250 subjects) identified a significantly lower rate of sero-protection using the intradermal route which may be related to male sex or older age at time of vaccination. A single study comparing two intradermal doses demonstrated equivalent rates of sero-protection to the intramuscular route where the higher intradermal dose was used. The immunological mechanisms vary by route of administration and there is no data to indicate whether this difference in sero-protection rates translates into a greater or longer term risk of infection.&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Articles:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=sangare&gt;&lt;/A&gt;Sangare L, Manhart L, Zehrung D, Wang CC. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=323553" target="_blank"&gt;Intradermal hepatitis B vaccination: a systematic review and meta-analysis.&lt;/A&gt; &lt;I&gt;Vaccine&lt;/I&gt; 2009 Mar 13;27(12):1777-86.&lt;/P&gt;
&lt;P&gt;&lt;A name=steele&gt;&lt;/A&gt;Steele M, Cochrane A, Wakefield C, Stain A-M, Ling S, Blanchette V, et al. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=323555" target="_blank"&gt;Hepatitis A and B immunization for individuals with inherited bleeding disorders.&lt;/A&gt; &lt;I&gt;Haemophilia&lt;/I&gt; 2009;15(2):437-47.&lt;/P&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #99cc00"&gt;Hepatitis B and C Annual Evidence Update 2009&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #33cccc"&gt;
&lt;P&gt;&lt;A href="nelh:323995:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323959:0" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323956:0" name=internalLink&gt;Economics&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323953:0" name=internalLink&gt;&lt;B&gt;Prevention&lt;/B&gt;&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323954:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:323962:0" name=internalLink&gt;Hepatitis B&lt;/A&gt; | &lt;A href="nelh:323961:0" name=internalLink&gt;Hepatitis C&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:323963:0" name=internalLink&gt;Risk factors&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:323952:0" name=internalLink&gt;Foreign articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323978:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323984:0" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>323963</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=323963]]&gt;</url>
    <title>2009 Annual Evidence Update on Hepatitis B and C - Risk factors</title>
    <publicationDate>2009-09-07T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ HEPATITIS,HEPATITIS B,HEPATITIS C,GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATOCELLULAR CARCINOMA,HIV / AIDS,SEPTEMBER 2009,CANCER,RECENT ADDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Hepatitis B and C - Risk factors&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P style="COLOR: #99cc00; FONT-SIZE: 12pt"&gt;&lt;B&gt;Fibrosis and hepatocellular carcinoma&lt;/B&gt;&lt;/P&gt; &lt;P&gt;The following articles were approved for inclusion on these topics. Citations for them are at the bottom of this section.&lt;/P&gt; &lt;UL&gt; &lt;LI&gt;&lt;A href="#raimondi"&gt;Raimondi et al&lt;/A&gt;&lt;/LI&gt; &lt;LI&gt;&lt;A href="#sung"&gt;Sung et al&lt;/A&gt;&lt;/LI&gt; &lt;LI&gt;&lt;A href="#thein2"&gt;Thein et al&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt; &lt;P style="COLOR: #99cc00; FONT-SIZE: 12pt"&gt;&lt;B&gt;HCV and diabetes&lt;/B&gt;&lt;/P&gt; &lt;P&gt;&lt;I&gt;Reviewed by Lynda Greenslade, Clinical Nurse Specialist in Hepatology, Royal Free Hampstead NHS Trust, London&lt;/I&gt;&lt;/P&gt; &lt;P&gt;Identifying risk factors and comorbidities in patients with Hepatitis C virus (HCV) is clearly important for those clinicians and nurses involved in identifying and treating it. The impact of new onset diabetes mellitus (NODM) in HCV patients including those post-liver and renal transplant, which is examined in three studies, is important for long term follow up and risk factors for other comorbidities. Three other studies (&lt;A href="#hiv"&gt;see below&lt;/A&gt;) also used meta-analysis to look at the impact of HCV infection on those co-infected with HIV and the effects this has on kidney function and the effectiveness of highly active antiretroviral therapy (HAART). Both groups of papers add to the literature but also identify gaps in our knowledge that need to be answered in prospective papers, including economic factors, long term follow up, the impact of early treatment of HCV infection, and the impact of treatment in post-transplantation and coinfected patients. In all the papers many of the studies identified were not of high quality, with incomplete information on some risk factors.&lt;/P&gt; &lt;P&gt;&lt;A href="#chen"&gt;Chen et al&lt;/A&gt; confirm links between HCV infection and persistent NODM post-liver transplant. The papers looked at in this meta-analysis were based on retrospective studies and the authors suggest the need for larger prospective studies to look further at effects of immunosuppressant regimes, recurrent HCV infection, long term follow up and management of persistent NODM.&lt;/P&gt; &lt;P&gt;The paper by &lt;A href="#fabrizi"&gt;Fabrizi et al&lt;/A&gt; is a meta-analysis of observational studies, which looks at the increase in HCV+ patients developing NODM post-renal transplant and the increased mortality in HCV+ patients from liver disease and hepatocellular carcinoma (HCC) after renal transplant. In the United States diabetes mellitus (DM) is a risk factor for HCC. This paper raises the issue of the lack of data on post renal transplant treatment for HCV and on the effects of donors' HCV status.&lt;/P&gt; &lt;P&gt;&lt;A href="#white"&gt;White, Ratziu and El-Serag&lt;/A&gt; have conducted the first meta-analysis that specifically examines the association between HCV infection and the risk of DM in the general population, as well as in the sub-groups at particularly increased risk of chronic liver disease. There was not enough data to suggest an excess risk of DM in patients coinfected with HIV and HCV compared to those with HIV only, so this can only be considered as suggestive as this point in time. This meta-analysis suggests an impact on practice; increased surveillance of glucose abnormalities in patients with HCV infection is recommended. The increased incidence of DM adds to the overall burden of disease in chronic HCV.&lt;/P&gt;&lt;BR&gt;&lt;A name=hiv&gt;&lt;/A&gt; &lt;P style="COLOR: #99cc00; FONT-SIZE: 12pt"&gt;&lt;B&gt;HCV/HIV coinfection&lt;/B&gt;&lt;/P&gt; &lt;P&gt;&lt;I&gt;Reviewed by Lynda Greenslade&lt;/I&gt;&lt;/P&gt; &lt;P&gt;These three papers are all meta-analyses that look at different aspects of coinfection of HCV and HIV. &lt;A href="#deng"&gt;Deng et al&lt;/A&gt; look at the effect of HIV infection on the course of HCV infection, to see what the effects on progressive liver disease would be, examine any possible heterogeneity and identify the potential confounding variables in the studies identified. The authors were unable to include the impact of the pre-HAART and HAART eras in looking at the progression of HCV infection due to a lack of data and this remains an important aspect to be considered in future studies, along with accurate data about alcohol consumption and duration of HCV infection.&lt;/P&gt; &lt;P&gt;&lt;A href="#thein"&gt;Thein et al&lt;/A&gt; consider some of the concerns raised in the previous paper by examining the natural history of coinfection and the impact of HIV on HCV-related liver disease in the era of HAART. It looks at the rate of fibrosis progression in coinfected individuals and concluded that this seems to be constant across stages of fibrosis, and that the outcomes for coinfected patients are worse than those for patients with hepatitis C alone. Over the study period (from January 1990 to September 2007), HAART did not appear to fully correct the adverse effect of HIV infection on HCV prognosis.&lt;/P&gt; &lt;P&gt;The final meta-analysis by &lt;A href="#wyatt"&gt;Wyatt et al&lt;/A&gt; looks at the impact of HCV coinfection on HIV related kidney disease and shows that there was an association between coinfection and an increased risk of kidney disease when compared to infection with HIV alone. There was some missing data in some of the studies included which would be important in interpreting the findings, such as race, and variability in the kidney disease outcomes measured. The authors suggest this provides the basis for future studies to explore this in more depth. &lt;/P&gt;&lt;BR&gt; &lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Articles:&lt;/B&gt;&lt;/P&gt; &lt;P&gt;&lt;A name=chen&gt;&lt;/A&gt;Chen T, Jia H, Li J, Chen X, Zhou H, Tian H. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=323525" target="_blank"&gt;New onset diabetes mellitus after liver transplantation and hepatitis C virus infection: meta-analysis of clinical studies.&lt;/A&gt; &lt;I&gt;Transpl Int&lt;/I&gt; 2009 Apr;22(4):408-15.&lt;/P&gt; &lt;P&gt;&lt;A name=deng&gt;&lt;/A&gt;Deng LP, Gui XE, Zhang YX, Gao SC, Yang RR. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=323527" target="_blank"&gt;Impact of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis.&lt;/A&gt; &lt;I&gt;World J Gastroenterol&lt;/I&gt; 2009 Feb 28;15(8):996-1003.&lt;/P&gt; &lt;P&gt;&lt;A name=fabrizi&gt;&lt;/A&gt;Fabrizi F, Messa P, Martin P, Takkouche B. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=323531" target="_blank"&gt;Hepatitis C virus infection and post-transplant diabetes mellitus among renal transplant patients: a meta-analysis.&lt;/A&gt; &lt;I&gt;Int J Artif Organs&lt;/I&gt; 2008 Aug;31(8):675-82.&lt;/P&gt; &lt;P&gt;&lt;A name=raimondi&gt;&lt;/A&gt;Raimondi S, Bruno S, Mondelli MU, Maisonneuve P. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=323800" target="_blank"&gt;Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis.&lt;/A&gt; &lt;I&gt;J Hepatol&lt;/I&gt; 2009 Jun;50(6):1142-54.&lt;/P&gt; &lt;P&gt;&lt;A name=sung&gt;&lt;/A&gt;Sung JJ, Tsoi KK, Wong VW, Li KC, Chan HL. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=323808" target="_blank"&gt;Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma.&lt;/A&gt; &lt;I&gt;Aliment Pharmacol Ther&lt;/I&gt; 2008 Nov 1;28(9):1067-77.&lt;/P&gt; &lt;P&gt;&lt;A name=thein&gt;&lt;/A&gt;Thein HH, Yi Q, Dore GJ, Krahn MD. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=323538" target="_blank"&gt;Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis.&lt;/A&gt; &lt;I&gt;AIDS&lt;/I&gt; 2008 Oct 1;22(15):1979-91.&lt;/P&gt; &lt;P&gt;&lt;A name=thein2&gt;&lt;/A&gt;Thein HH, Yi Q, Dore GJ, Krahn MD. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=323795" target="_blank"&gt;Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression.&lt;/A&gt; &lt;I&gt;Hepatology&lt;/I&gt; 2008 Aug;48(2):418-31.&lt;/P&gt; &lt;P&gt;&lt;A name=white&gt;&lt;/A&gt;White DL, Ratziu V, El-Serag HB. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=323540" target="_blank"&gt;Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis.&lt;/A&gt; &lt;I&gt;J Hepatol&lt;/I&gt; 2008 Nov;49(5):831-44.&lt;/P&gt; &lt;P&gt;&lt;A name=wyatt&gt;&lt;/A&gt;Wyatt CM, Malvestutto C, Coca SG, Klotman PE, Parikh CR. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=323541" target="_blank"&gt;The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis.&lt;/A&gt; &lt;I&gt;AIDS&lt;/I&gt; 2008 Sep 12;22(14):1799-807.&lt;/P&gt;&lt;BR&gt; &lt;TABLE align=center&gt; &lt;TBODY&gt; &lt;TR&gt; &lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #99cc00"&gt;Hepatitis B and C Annual Evidence Update 2009&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #33cccc"&gt; &lt;P&gt;&lt;A href="nelh:323995:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323959:0" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323956:0" name=internalLink&gt;Economics&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323953:0" name=internalLink&gt;Prevention&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323954:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:323962:0" name=internalLink&gt;Hepatitis B&lt;/A&gt; | &lt;A href="nelh:323961:0" name=internalLink&gt;Hepatitis C&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:323963:0" name=internalLink&gt;&lt;B&gt;Risk factors&lt;/B&gt;&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:323952:0" name=internalLink&gt;Foreign articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323978:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323984:0" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>323962</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=323962]]&gt;</url>
    <title>2009 Annual Evidence Update on Hepatitis B and C - Treatment | Hepatitis B</title>
    <publicationDate>2009-09-07T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ LIVER,GASTROENTEROLOGY &amp; LIVER DISEASES,NON-ALCOHOLIC,HEPATITIS B,HEPATITIS,HEPATOCELLULAR CARCINOMA,RECENT ADDITIONS,CIRRHOSIS,CANCER,SEPTEMBER 2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Hepatitis B and C - Treatment | Hepatitis B&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P style="COLOR: #99cc00; FONT-SIZE: 12pt"&gt;&lt;B&gt;Guidelines&lt;/B&gt;&lt;/P&gt; &lt;P&gt;The following guidelines were released this year: &lt;/P&gt; &lt;P&gt;European Association for the Study of the Liver. &lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=296198" target="_blank"&gt;EASL clinical practice guidelines: management of chronic hepatitis B.&lt;/A&gt; [Online] 2008 Oct 1.&lt;/P&gt; &lt;P&gt;National Institute for Health and Clinical Excellence. &lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=293043" target="_blank"&gt;Entecavir for the treatment of chronic hepatitis B.&lt;/A&gt; [Online] 2008 Aug.&lt;/P&gt; &lt;P&gt;National Institute for Health and Clinical Excellence. &lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=293052" target="_blank"&gt;Telbivudine for the treatment of chronic hepatitis B.&lt;/A&gt; [Online] 2008 Aug.&lt;/P&gt; &lt;P&gt;World Gastroenterology Organisation. &lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=307175" target="_blank"&gt;Hepatitis B.&lt;/A&gt; [Online] 2008 Sept.&lt;/P&gt;&lt;BR&gt; &lt;P style="COLOR: #99cc00; FONT-SIZE: 12pt"&gt;&lt;B&gt;Reviews of general management&lt;/B&gt;&lt;/P&gt; &lt;P&gt;&lt;I&gt;Reviewed by Jane Collier, Consultant Hepatologist, John Radcliffe Hospital, Oxford&lt;/I&gt;&lt;/P&gt; &lt;P&gt;Despite the increasing number of anti-virals now licensed for chronic hepatitis B infection, the timing of treatment and long term efficacy remains controversial. This is mainly due to lack of prospective large long term natural history data on the course of hepatitis B in various subpopulations and the design of drug treatment studies. This is illustrated in a independent systematic review resulting in a NIH consensus statement and two reviews of the literature resulting in a treatment algorithm by a panel of US hepatologists.&lt;/P&gt; &lt;P&gt;The NIH commissioned an independent systematic review of antiviral therapy for chronic hepatitis B, published by &lt;A href="#wilt"&gt;Wilt at al&lt;/A&gt; as a Technology Assessment, which was then discussed at a NIH consensus conference, the results of which are reported in detail by &lt;A href="#Shamliyan"&gt;Shamliyan et al&lt;/A&gt; and summarised by &lt;A href="#sorrell"&gt;Sorrell et al&lt;/A&gt;. This comprehensive meta-analysis concluded that treatment is definitely indicated for patients with decompensated cirrhosis, compensated cirrhosis and those on immunosuppressive therapy including cancer chemotherapy. There was less evidence to support the use in patients with lesser degrees of liver fibrosis who were in the immune active phase and this was because none of the clinical trials have been powered to look at the effects of treatment on mortality.&lt;/P&gt; &lt;P&gt;However in clinical practice this patient group are usually considered for therapy and &lt;A href="#keeffe"&gt;Keeffe et al&lt;/A&gt; in their systematic review discuss in more detail the drugs of choice for treating this patient group. The oral nucleoside analogues, lamivudine, telbuvidine and entecavir, are reviewed separately to the nucleotide analogues of adefovir and tenofovir and to the immunomodulator pegylated alpha interferon. Keefe et al also clearly define the stages of chronic hepatitis B infection, based on ALT, serology and HBV DNA levels which are relevant to treatment and give useful guidance on the follow-up of patients who are not candidates for treatment, immunotolerant and inactive carriers. They discuss the evidence for the duration of therapy in HBe antigen positive and HBe antigen negative chronic hepatitis and the roles of combination therapy versus sequential drug therapy. They also review evidence for different drug combinations in HIV co-infected patients and the timing and the length of therapy in patients receiving cancer chemotherapy. The increasing new evidence for a role of antiviral therapy in a subgroup of women with a high viral load during pregnancy to prevent fetal transmission is helpful and likely to change clinical practice. &lt;A href="#ayoub"&gt;Ayoub and Keeffe&lt;/A&gt; in their systematic review give a clear practically applicable roadmap on how to assess response to antiviral therapy, and the indication for switching to other drug therapy . They have also adapted the AASLD and US algorithm giving clear practical guidance on how to monitor and manage drug resistance.&lt;/P&gt; &lt;P&gt;&lt;/P&gt;&lt;BR&gt; &lt;P style="COLOR: #99cc00; FONT-SIZE: 12pt"&gt;&lt;B&gt;Reviews of specific drugs &lt;/B&gt;&lt;/P&gt; &lt;P&gt;&lt;I&gt;Reviewed by Jan Freeman, Consultant Hepatologist and Lead Clinician for Gastroenterology and Hepatology, Royal Derby Hospital &lt;/I&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="#hann"&gt;Hann et al&lt;/A&gt; provide a good review of definitions and overview of problems determining HBV drug resistance. They conclude that study methodology and the definition of resistance used can dramatically influence results.&lt;/P&gt; &lt;P&gt;&lt;A href="#miyake"&gt;Miyake, Kobashi and Yamamoto&lt;/A&gt; is a good meta-analysis of the effect of interferon on HCC development, but relates mainly to Asian populations. Studies included different treatment regimes, with two using PEG interferon as compared to all the others using standard interferon. Only two of the included studies were RCTs.&lt;/P&gt; &lt;P&gt;&lt;A href="#wilt"&gt;Yang et al&lt;/A&gt; is another good meta-analysis of interferon, with inclusion of European studies making it valid for European readers.&lt;/P&gt; &lt;P&gt;The &lt;A href="#nash"&gt;Nash&lt;/A&gt; article is an excellent review of telbivudine, presenting good evidence against its use as a first line agent. The author points out that high resistance and side effects are concerns. In addition she highlights ineffective cost analysis.&lt;/P&gt;&lt;BR&gt; &lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Articles:&lt;/B&gt;&lt;/P&gt; &lt;P&gt;&lt;A name=ayoub&gt;&lt;/A&gt;Ayoub WS, Keeffe EB. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=323584" target="_blank"&gt;Review article: current antiviral therapy of chronic hepatitis B.&lt;/A&gt; &lt;I&gt;Aliment Pharmacol Ther&lt;/I&gt; 2008 Jul;28(2):167-77.&lt;/P&gt; &lt;P&gt;&lt;A name=hann&gt;&lt;/A&gt;Hann H-W, Gregory VL, Dixon JS, Barker KF. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=323624" target="_blank"&gt;A review of the one-year incidence of resistance to lamivudine in the treatment of chronic hepatitis B.&lt;/A&gt; &lt;I&gt;Hepatol Int&lt;/I&gt; 2008;2(4):440-56.&lt;/P&gt; &lt;P&gt;&lt;A name=keeffe&gt;&lt;/A&gt;Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, et al. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=323577" target="_blank"&gt;A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update.&lt;/A&gt; &lt;I&gt;Clin Gastroenterol Hepatol&lt;/I&gt; 2008;6(12):1315-41.&lt;/P&gt; &lt;P&gt;&lt;A name=miyake&gt;&lt;/A&gt;Miyake Y, Kobashi H, Yamamoto K. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=323627" target="_blank"&gt;Meta-analysis: the effect of interferon on development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.&lt;/A&gt; &lt;I&gt;J Gastroenterol&lt;/I&gt; 2009;44(5):470-5.&lt;/P&gt; &lt;P&gt;&lt;A name=nash&gt;&lt;/A&gt;Nash K. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=323640" target="_blank"&gt;Telbivudine in the treatment of chronic hepatitis B.&lt;/A&gt; &lt;I&gt;Adv Ther&lt;/I&gt; 2009 Feb;26(2):155-69.&lt;/P&gt; &lt;P&gt;&lt;A name=Shamliyan&gt;&lt;/A&gt;Shamliyan TA, MacDonald R, Shaukat A, Taylor BC, Yuan JM, Johnson JR, et al. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=323587" target="_blank"&gt;Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health Consensus Development Conference.&lt;/A&gt; &lt;I&gt;Ann Intern Med&lt;/I&gt; 2009 Jan 20;150(2):111-24.&lt;/P&gt; &lt;P&gt;&lt;A name=sorrell&gt;&lt;/A&gt;Sorrell MF, Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM, et al. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=323579" target="_blank"&gt;National Institutes of Health consensus development conference statement: Management of hepatitis B.&lt;/A&gt; &lt;I&gt;Ann Intern Med&lt;/I&gt; 2009;150(2):104-10.&lt;/P&gt; &lt;P&gt;&lt;A name=wilt&gt;&lt;/A&gt;Wilt TJ, Shamliyan T, Shaukat A, Taylor BC, MacDonald R, Yuan JM, et al. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=323582" target="_blank"&gt;Management of chronic hepatitis B.&lt;/A&gt; &lt;I&gt;Evid Rep Technol Assess (Full Rep)&lt;/I&gt; 2008 Oct;(174):1-671.&lt;/P&gt; &lt;P&gt;&lt;A name=wilt&gt;&lt;/A&gt;Yang YF, Zhao W, Zhong YD, Xia HM, Shen L, Zhang N. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=323641" target="_blank"&gt;Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis.&lt;/A&gt; &lt;I&gt;J Viral Hepat&lt;/I&gt; 2009 Apr;16(4):265-71.&lt;/P&gt;&lt;BR&gt; &lt;TABLE align=center&gt; &lt;TBODY&gt; &lt;TR&gt; &lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #99cc00"&gt;Hepatitis B and C Annual Evidence Update 2009&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #33cccc"&gt; &lt;P&gt;&lt;A href="nelh:323995:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323959:0" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323956:0" name=internalLink&gt;Economics&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323953:0" name=internalLink&gt;Prevention&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323954:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:323962:0" name=internalLink&gt;&lt;B&gt;Hepatitis B&lt;/B&gt;&lt;/A&gt; | &lt;A href="nelh:323961:0" name=internalLink&gt;Hepatitis C&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:323963:0" name=internalLink&gt;Risk factors&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:323952:0" name=internalLink&gt;Foreign articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323978:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323984:0" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>323961</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=323961]]&gt;</url>
    <title>2009 Annual Evidence Update on Hepatitis B and C - Treatment | Hepatitis C</title>
    <publicationDate>2009-09-07T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ HEPATITIS,HEPATITIS C,NON-ALCOHOLIC,GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HIV / AIDS,SEPTEMBER 2009,CIRRHOSIS,RECENT ADDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Hepatitis B and C - Treatment | Hepatitis C&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;I&gt;Reviewed by Martin James, Consultant Hepatologist and Gastroenterologist, Queen's Medical Centre, Nottingham&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;Advances in combination antiviral therapy over the past decade has improved outcomes in chronic hepatitis C infection, with successful treatment depending on viral and patient characteristics. This annual update focuses on studies of different types of interferon therapy in chronic hepatitis C and on treatment in circumstances which make sustained virological response (SVR) and histological and clinical endpoints more challenging to achieve.&lt;/P&gt;
&lt;P&gt;&lt;A href="#chou"&gt;Chou, Carson and Chan&lt;/A&gt; performed an indirect analysis of pegylated interferon (PEG-IFN) alpha-2a or alpha-2b from 16 studies where original comparisons were between PEG-IFN and standard interferon. Derived estimates found no difference in SVR or tolerability between PEG-IFN alpha-2a or alpha-2b. This is supported by a large direct study comparing combination weekly 1.0mcg/kg PEG-IFN alpha-2b, 1.5mcg/kg PEG-IFN alpha-2b or PEG-IFN alpha-2a 180mcg together with daily ribavirin in 3000 patients chronically infected with genotype 1 HCV (HCV-1) infection (SVR rates 39.8%, 38.0% and 40.9% respectively; p=ns) with similar safety and tolerability (&lt;A href="#mchutchinson"&gt;McHutchison et al&lt;/A&gt;). &lt;/P&gt;
&lt;P&gt;Novel fusion proteins of recombinant human albumin and IFN alpha-2b (Albinterferon alpha-2b; alb-IFN) offer longer dosing intervals of 2-4 weeks which may improve compliance and tolerability. Phase 2 studies of different doses and intervals using alb-IFN were reviewed by &lt;A href="#rustgi"&gt;Rustgi&lt;/A&gt;. Subsequently, phase 3 multicentre studies in genotype 1 (Achieve-1) and genotype 2/3 infection (Achieve-2/3) have commenced with 2-weekly alb-IFN doses from 900µg to 1200µg compared to weekly PEG-IFN alpha-2a 180µg, all with ribavirin co-therapy.&lt;/P&gt;
&lt;P&gt;The exact mechanism of action of ribavirin is unclear; it has effects on HCV as a nucleoside analogue blocking viral replication via RNA polymerase, and on host immunity increasing T-cell expression of ?-interferon and enhancing expression of antiviral response genes. Although ineffective as monotherapy, maximising tolerated dose of oral ribavirin in combination with PEG-IFN remains a crucial component in achieving SVR. &lt;A href="#martin"&gt;Martin and Jensen&lt;/A&gt; found significant differences in SVR according to dose. In genotype 1 infection, SVR with ribavirin dose compliance &amp;gt;80% compared to 0-60% was 62% vs 33%. Dose adjustments, monitoring levels in renal dysfunction and strategies to manage common adverse effects such as haemolytic anaemia using s/c erythropoietin were discussed.&lt;/P&gt;
&lt;P&gt;HCV viral genotype is perhaps the most important determinant of SVR. &lt;A href="#andriulli"&gt;Andriulli et al&lt;/A&gt; examined whether there was a difference in SVR in treating genotypes 2 (HCV-2) or 3 (HCV-3) infection. Meta-analysis of studies of 24 (n=8) or 12-16 (n=4) weeks concluded that overall SVR was higher for HCV-2 rather than HCV-3 (SVR 74% vs 68%; OR 1.49 (1.23-1.80)), especially with viral loads &amp;gt;600,000IU/mL (SVR 75% vs 58%; OR 2.36 (1.80-3.09)), but not with low viral loads (SVR 79% vs 75%; OR 1.50 (1.08-2.09)) or where there was a rapid virological response (RVR) at week 4 (83% vs 84%; OR 0.94 (0.66-1.36)). 24 weeks therapy should be given to HCV-2 and low viraemic HCV-3, while high viraemic HCV-3 may require longer duration treatment. Both HCV-2 and HCV-3 patients with RVR may have 12-16 weeks treatment without reducing SVR.&lt;/P&gt;
&lt;P&gt;Treating patients waiting for or who have received liver transplantation (OLT) is challenging because of the risks of decompensation, tolerability and the potential for graft rejection. Two systematic reviews and a Cochrane review addressed treatment in this patient population. &lt;A href="#xirouchakis"&gt;Xirouchakis et al&lt;/A&gt; found that combination therapy pre-OLT with PEG-IFN and ribavirin in 3 studies had a disappointing median SVR of 19.6%; 7-32% for HCV-1 and 43.5-72% for HCV-2 and HCV-3. Treatment post-OLT was successful in achieving median SVR of 41% with full dose PEG-IFN and ribavirin but lower (median SVR 9.2%) if treated with lower dose PEG-IFN combination, or PEG-IFN monotherapy. &lt;A href="#berenguer"&gt;Berenguer&lt;/A&gt; reviewed 19 studies of treatment 1-3 years post-OLT. Mean SVR was 30.2%, often using lower starting doses of ribavirin supported by growth factors, but 70% required dose reduction and 28% discontinued therapy. &lt;A href="#gurusamy"&gt;Gurusamy et al&lt;/A&gt; studied 11 RCTs including 389 patients comparing antiviral therapy post-OLT. 78% were genotype 1 patients and no difference in mortality, graft rejection or re-transplantation was found. Although often retrospective, these studies support the view that patients pre- and post transplantation remain challenging to treat.&lt;/P&gt;
&lt;P&gt;Other patients difficult to treat are those with HCV/HIV co-infection. HCV co-infection in patients with HIV varies from 30-50% in Europe, and HCV is responsible for 10% of all deaths in HIV patients in France. &lt;A href="#zhao"&gt;Zhao et al&lt;/A&gt; performed a meta-analysis of six studies (1800 patients) of combination therapy in HCV/HIV co-infection and found SVR higher with PEG-IFN and ribavirin than standard interferon and ribavirin, but lower than monoinfected patients; SVR 26% for HCV-1 and HCV-4 and 55% for HCV-2 and HCV-3. &lt;/P&gt;
&lt;P&gt;Easier to treat patients may be those with mild HCV. &lt;A href="#hartwell"&gt;Hartwell and Shepherd&lt;/A&gt; identified 10 RCTs examining HCV treatment in mild disease (F0-F2 metavir or &amp;lt; Ishak 4). SVR and tolerability is similar to those with advanced fibrosis across genotypes, with duration of treatment determined by genotype. However, studies included a proportion of patients (up to 30%) with moderate or severe hepatitis C, which may result in an underestimation of SVR rates in mild disease. NICE has approved treatment for mild disease, however estimates of the cost-effectiveness were not reported. &lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Articles:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=andriulli&gt;&lt;/A&gt;Andriulli A, Mangia A, Iacobellis A, Ippolito A, Leandro G, Zeuzem S. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=323646" target="_blank"&gt;Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis.&lt;/A&gt; &lt;I&gt;Aliment Pharmacol Ther&lt;/I&gt; 2008 Aug 15;28(4):397-404.&lt;/P&gt;
&lt;P&gt;&lt;A name=berenguer&gt;&lt;/A&gt;Berenguer M. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=323677" target="_blank"&gt;Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin.&lt;/A&gt; &lt;I&gt;J Hepatol&lt;/I&gt; 2008 Aug;49(2):274-87.&lt;/P&gt;
&lt;P&gt;&lt;A name=chou&gt;&lt;/A&gt;Chou R, Carson S, Chan BKS. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=323678" target="_blank"&gt;Pegylated interferons for chronic hepatitis C virus infection: An indirect analysis of randomized trials.&lt;/A&gt; &lt;I&gt;J Viral Hepat&lt;/I&gt; 2008;15(8):551-70.&lt;/P&gt;
&lt;P&gt;&lt;A name=gurusamy&gt;&lt;/A&gt;Gurusamy KS, Osmani B, Xirouchakis E, Burroughs AK, Davidson BR. &lt;A href="http://www.library.nhs.uk/GASTROLIVER/ViewResource.aspx?resID=304927" target="_blank"&gt;Antiviral therapy for recurrent liver graft infection with hepatitis C virus.&lt;/A&gt; &lt;I&gt;Cochrane Database of Systematic Reviews&lt;/I&gt; 2009;(1):CD006803.&lt;/P&gt;
&lt;P&gt;&lt;A name=hartwell&gt;&lt;/A&gt;Hartwell D, Shepherd J. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=323695" target="_blank"&gt;Pegylated and non-pegylated interferon-alfa and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and meta-analysis.&lt;/A&gt; &lt;I&gt;Int J Technol Assess Health Care&lt;/I&gt; 2009 Jan;25(1):56-62.&lt;/P&gt;
&lt;P&gt;&lt;A name=martin&gt;&lt;/A&gt;Martin P, Jensen DM. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=323697" target="_blank"&gt;Ribavirin in the treatment of chronic hepatitis C.&lt;/A&gt; &lt;I&gt;J Gastroenterol Hepatol&lt;/I&gt; 2008 Jun;23(6):844-55.&lt;/P&gt;
&lt;P&gt;&lt;A name=mchutchinson&gt;&lt;/A&gt;McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. &lt;A href="http://dx.doi.org/10.1056/NEJMoa0808010" target="_blank"&gt;Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.&lt;/A&gt; &lt;I&gt;N Engl J Med&lt;/I&gt; 2009 Aug 6;361(6):580-93. (Although a randomised controlled trial, this article was selected as worthy of attention for the AEU by our reviewer.) &lt;/P&gt;
&lt;P&gt;&lt;A name=rustgi&gt;&lt;/A&gt;Rustgi VK. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=323700" target="_blank"&gt;Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis C.&lt;/A&gt; &lt;I&gt;Curr Med Res Opin&lt;/I&gt; 2009 Apr;25(4):991-1002.&lt;/P&gt;
&lt;P&gt;&lt;A name=xirouchakis&gt;&lt;/A&gt;Xirouchakis E, Triantos C, Manousou P, Sigalas A, Calvaruso V, Corbani A, et al. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=323699" target="_blank"&gt;Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies.&lt;/A&gt; &lt;I&gt;J Viral Hepat&lt;/I&gt; 2008 Oct;15(10):699-709.&lt;/P&gt;
&lt;P&gt;&lt;A name=zhao&gt;&lt;/A&gt;Zhao S, Cheng D, Liu E, Yu H, Yang H, Xue X, et al. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=323701" target="_blank"&gt;Peginterferon vs. interferon in the treatment of different HCV genotype infections in HIV patients.&lt;/A&gt; &lt;I&gt;Eur J Clin Microbiol Infect Dis&lt;/I&gt; 2008 Dec;27(12):1183-92.&lt;/P&gt;
&lt;P style="COLOR: #99cc00; FONT-SIZE: 12pt"&gt;&lt;/P&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #99cc00"&gt;Hepatitis B and C Annual Evidence Update 2009&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #33cccc"&gt;
&lt;P&gt;&lt;A href="nelh:323995:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323959:0" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323956:0" name=internalLink&gt;Economics&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323953:0" name=internalLink&gt;Prevention&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323954:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:323962:0" name=internalLink&gt;Hepatitis B&lt;/A&gt; | &lt;A href="nelh:323961:0" name=internalLink&gt;&lt;B&gt;Hepatitis C&lt;/B&gt;&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:323963:0" name=internalLink&gt;Risk factors&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:323952:0" name=internalLink&gt;Foreign articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323978:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323984:0" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>323978</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=323978]]&gt;</url>
    <title>2009 Annual Evidence Update on Hepatitis B and C - Uncertainties</title>
    <publicationDate>2009-09-07T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ LIVER,GASTROENTEROLOGY &amp; LIVER DISEASES,HEPATITIS C,HEPATITIS B,HEPATITIS,RECENT ADDITIONS,SEPTEMBER 2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Hepatitis B and C - Uncertainties&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;As part of the process of conducting this Annual Evidence Update, we examined the included papers for treatment uncertainties that could be added to the UK Database of Uncertainties about the Effects of Treatments (&lt;A href="http://www.library.nhs.uk/duets/" target="_blank"&gt;UK DUETs&lt;/A&gt;), a project aimed at creating a central database of such uncertainties. The following list, which has been submitted to the database, is the results of our search. Click on each title for more information.&lt;/P&gt; &lt;UL&gt; &lt;LI&gt;&lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=323436" target="_blank"&gt;Antiviral therapy for hepatitis C patients without rapid virological response&lt;/A&gt;&lt;/LI&gt; &lt;LI&gt;&lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=323340" target="_blank"&gt;Antiviral therapy for recurrent liver graft infection with hepatitis C virus&lt;/A&gt;&lt;/LI&gt; &lt;LI&gt;&lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=323342" target="_blank"&gt;Antiviral therapy in patients with Hepatitis B virus DNA levels of &gt;=20,000 IU/mL and normal ALT levels&lt;/A&gt;&lt;/LI&gt; &lt;LI&gt;&lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=323404" target="_blank"&gt;Combination therapies in hepatitis B patients with decompensated cirrhosis&lt;/A&gt;&lt;/LI&gt; &lt;LI&gt;&lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=323468" target="_blank"&gt;Interferon alpha-2b and ribavirin maintenance therapy for halting hepatitis C disease progression in liver-transplanted patients&lt;/A&gt;&lt;/LI&gt; &lt;LI&gt;&lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=323418" target="_blank"&gt;Long-term results of antiviral treatment for chronic hepatitis B&lt;/A&gt;&lt;/LI&gt; &lt;LI&gt;&lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=323461" target="_blank"&gt;Optimal antiviral therapy of chronic hepatitis B&lt;/A&gt;&lt;/LI&gt; &lt;LI&gt;&lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=323385" target="_blank"&gt;Optimal duration of therapy in HBeAg-negative hepatitis B patients&lt;/A&gt;&lt;/LI&gt; &lt;LI&gt;&lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=323472" target="_blank"&gt;Pegylated interferon alpha-2a plus ribavirin vs pegylated interferon alpha-2b plus ribavirin for chronic hepatitis C&lt;/A&gt;&lt;/LI&gt; &lt;LI&gt;&lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=323480" target="_blank"&gt;Pegylated interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis&lt;/A&gt;&lt;/LI&gt; &lt;LI&gt;&lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=323477" target="_blank"&gt;Role of ribavirin in reducing bone mineral density in chronic hepatitis C patients&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt; &lt;TABLE align=center&gt; &lt;TBODY&gt; &lt;TR&gt; &lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #99cc00"&gt;Hepatitis B and C Annual Evidence Update 2009&lt;/TD&gt;&lt;/TR&gt; &lt;TR&gt; &lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #33cccc"&gt; &lt;P&gt;&lt;A href="nelh:323995:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323959:0" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323956:0" name=internalLink&gt;Economics&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323953:0" name=internalLink&gt;Prevention&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323954:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:323962:0" name=internalLink&gt;Hepatitis B&lt;/A&gt; | &lt;A href="nelh:323961:0" name=internalLink&gt;Hepatitis C&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:323963:0" name=internalLink&gt;Risk factors&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:323952:0" name=internalLink&gt;Foreign articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323978:0" name=internalLink&gt;&lt;B&gt;Uncertainties&lt;/B&gt;&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:323984:0" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>308889</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=308889]]&gt;</url>
    <title>2009 Annual Evidence Update on Inflammatory Bowel Disease - Adverse effects and risk factors | Adverse effects of medication</title>
    <publicationDate>2009-03-23T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Inflammatory Bowel Disease - Adverse effects and risk factors | Adverse effects of medication&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;I&gt;Reviewed by Andrew Cole, Consultant Gastroenterologist, Derby City General Hospital&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;Adverse drug side effects are an important concern in the treatment of IBD, particularly with anti-TNF drugs, but also with older therapies such as corticosteroids and thiopurines. Safety in special situations such as pregnancy is important and merits further investigation. Safety issues surrounding surgery have also received attention.&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;One review (&lt;A href="#theis"&gt;Theis et al.&lt;/A&gt;) addressed the important question of minimizing the risk of activating latent TB during anti-TNF therapy. The majority of the data relates to rheumatoid arthritis and mixed populations but also includes 2 large series in Crohn’s (3350 patients). The relative risk of TB in anti-TNF treated US populations is approximately 4 times (24/100,000) the general population risk. The relative risk is higher in other populations such as Spain (1113/100,000 patients, RR 90.1), but limited data suggest a lower risk in the generally younger IBD cohort. There is a higher proportion of extrapulmonary disease, (46 to 94%) than in control populations. Quantiferon Gold or T-spot TB tests offer improved sensitivity to detect latent TB in some groups of immunosuppressed patients, though formal data in IBD is not available. Chemoprophylaxis of latent TB with isoniazid reduces the rate of developing TB by 70%.&lt;BR&gt;&lt;B&gt;Bottom line conclusion:&lt;/B&gt; Increased risk of TB in anti-TNF treated populations varies, but there is a high proportion of extrapulmonary TB when it occurs and TB chemoprophylaxis is not fully effective.&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;Demyelination is a labelled risk of anti-TNF therapy. &lt;A href="#andersen"&gt;Andersen et al.&lt;/A&gt; reviewed the data on the risk of this in the IBD population and with anti-TNF therapy. The ascertained risk is 1.1 to 3.7 times the general population risk. Only series and case report data are available for IBD patients treated with anti-TNF therapy. Further research is needed.&lt;BR&gt;&lt;B&gt;Bottom line conclusion:&lt;/B&gt; There is an increased incidence of demyelination in the IBD population and anti-TNF therapy is reported to be associated with a risk of developing demyelination but the relative risk in this population is not known.&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;Thiopurines can cause severe myelotoxicity. This is a serious complication of this drug in the treatment of IBD. The meta-analysis of &lt;A href="#gisbert"&gt;Gisbert and Gomollon&lt;/A&gt; indicates a rate of 3% per patient per year (biased towards the start of therapy). Severe myelotoxicity occurs less often (less than 1%/pt/y and the risk of death is less than 0.1.%/pt/y).&lt;BR&gt;&lt;B&gt;Bottom line conclusion:&lt;/B&gt; Death from severe myelotoxicity due to thiopurine therapy occurs less often than 0.1% per patient per year).&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;The combination of pregnancy, IBD and the risk of adverse drug effects is a clinical challenge. A meta-analysis (&lt;A href="#rahimi"&gt;Rahimi et al.&lt;/A&gt;) has analysed the outcomes of 642 women taking 5-ASA drugs compared with 2200 not taking them. No significant differences in outcome were observed but with wide confidence intervals indicating a need for more data.&lt;BR&gt;&lt;B&gt;Bottom line conclusion:&lt;/B&gt; No clear evidence of adverse effects on pregnancy outcomes of 5-ASA drugs taken during pregnancy.&lt;/B&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;Evidence about the use of anti-TNF therapy in pregnancy comes from two small series of 10 and 12 women (&lt;A href="#odonnell"&gt;O’Donnell et al.&lt;/A&gt;). No excess of adverse outcomes has been detected. Opinion leans towards avoiding infliximab in the third trimester because of transplacental transfer of infliximab to the infant. Again more data would be valuable.&lt;BR&gt;&lt;B&gt;Bottom line conclusion:&lt;/B&gt; Infliximab has been used particularly in the first two trimesters of pregnancy in small numbers of patients without adverse effects.&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;The influence of steroids on the outcome of surgery for IBD (1714 patients) is the subject of a recent meta-analysis (&lt;A href="#subramanian"&gt;Subramanian et al.&lt;/A&gt;). Whist vulnerable to confounding factors the analysis indicates that pre-operative steroid use is associates with an odds ration of 1.68 (1.24-2.28) for infectious complications.&lt;BR&gt;&lt;B&gt;Bottom line conclusion:&lt;/B&gt; Pre-operative corticosteroids increase post operative infection risk.&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Articles:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=andersen&gt;&lt;/A&gt;Andersen, N. N., Caspersen, S., Jess, T., &amp;amp; Munkholm, P. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=309222" target="_blank"&gt;Occurrence of demyelinating diseases after anti-TNFalpha treatment of inflammatory bowel disease: A Danish Crohn Colitis Database study.&lt;/A&gt; &lt;I&gt;Journal of Crohn's and Colitis&lt;/I&gt;, 2(4), 304-309.&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;B&gt;Reviewer's comments:&lt;/B&gt; This paper is a review of data on demyelinating disease complicating IBD both in patients not treated with anti-TNF therapy and in those treated. Included are new data on the Danish Cohort. The risk of demyelination in IBD not treated with anti-TnF therapy appears increased in four separate studies the largest of which showed OR for demyelinating disease of 1.75 for UC and 1.54 for CD. The Danish Cohort had a standard morbidity ratio for demyelination of 4.2 (0.1 to 23). This is an important issue but more data is needed.&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;A name=gisbert&gt;&lt;/A&gt;Gisbert, J. P. &amp;amp; Gomollon, F. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=309224" target="_blank"&gt;Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review.&lt;/A&gt; &lt;I&gt;American Journal of Gastroenterology&lt;/I&gt;, 103(7):1783-1800.&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;B&gt;Reviewer's comments:&lt;/B&gt; This is a formal meta-analysis of thiopurine myelotoxicity in IBD which indicates a rate of 3% per patient per year though with reactions biased towards the start of therapy. Severe myelotoxicity occurs less often (less than 1%) and the risk of death is less than 0.1%.&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;A name=odonnell&gt;&lt;/A&gt;O'Donnell, S. &amp;amp; O'Morain, C. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=309230" target="_blank"&gt;Review article: use of antitumour necrosis factor therapy in inflammatory bowel disease during pregnancy and conception.&lt;/A&gt; &lt;I&gt;Alimentary Pharmacology &amp;amp; Therapeutics&lt;/I&gt;, 27(10):885-894.&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;B&gt;Reviewer's comments:&lt;/B&gt; This review addresses the use of anti-TNF therapy in pregnancy. There is limited data from series of 10 and 12 pregnant women treated with anti-TNF therapy and from registry data. This data has not indicated any sign of excess foetal or maternal morbidity. The limited data indicate placental transfer of infliximab to the foetus especially in the third trimester. When pregnancy arises through a man treated with infliximab there is little data on outcomes but what there is has not shown any increase in miscarriage or foetal malformation&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;A name=rahimi&gt;&lt;/A&gt;Rahimi, R., Nikfar, S., Rezaie, A., &amp;amp; Abdollahi, M. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=309233" target="_blank"&gt;Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis.&lt;/A&gt; &lt;I&gt;Reproductive Toxicology&lt;/I&gt;, 25(2):271-275.&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;B&gt;Reviewer's comments:&lt;/B&gt; This systematic meta-analysis looked at the adverse pregnancy outcomes of a total of 642 women taking 5-ASA drugs in pregnancy and 2200 not taking them. Of the literature identified 7 cohort studies were included. No randomised studies were identified. Outcomes analysed were congenital abnormalities, still birth, spontaneous abortion, preterm delivery and low birth weight. None of the studied adverse outcomes occurred significantly more often in the 5-ASA treated patients than controls, though confidence intervals were wide. For example the OR for congenital abnormalities was 1.16 (CI:0.76 to 1.77), and the OR for still birth was 2.38 (0.65-8.72).&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;A name=subramanian&gt;&lt;/A&gt;Subramanian, V., Saxena, S., Kang, J. Y., &amp;amp; Pollok, R. C. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=309235" target="_blank"&gt;Preoperative steroid use and risk of postoperative complications in patients with inflammatory bowel disease undergoing abdominal surgery.&lt;/A&gt; &lt;I&gt;American Journal of Gastroenterology&lt;/I&gt;, 103(9):2373-2381.&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;B&gt;Reviewer's comments:&lt;/B&gt; This is an important meta-analysis of the risks with preoperative steroid therapy of post operative complications in patients with IBD having abdominal surgery. The analysis is of retrospective and prospective observational studies of 1,714 patients in total. Whilst it is vulnerable to confounding factors inherent in the observational studies drawn on, the data indicate that associated with pre-operative steroid use there is a 1.68 fold odds ratio (1.24 to 2.28) for infections complications either in hospital or up to 30 days post op.&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;A name=theis&gt;&lt;/A&gt;Theis, V. S. &amp;amp; Rhodes, J. M. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=281274" target="_blank"&gt;Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease.&lt;/A&gt; &lt;I&gt;Alimentary Pharmacology &amp;amp; Therapeutics&lt;/I&gt;, 27(1):19-30.&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;B&gt;Reviewer's comments:&lt;/B&gt; This review addresses the important question of minimizing the risk of activating latent TB during anti-TNF therapy. Papers on TB rates in treated and control population are reviewed. The majority of the data is related to rheumatoid arthritis and mixed populations but also include 2 large case series in Crohn's (2850 patients TREAT registry, and 500 Mayo clinic). The risk of TB in anti-TNF treated US populations is increased approximately 4 times (24/100,000) with a higher proportion of extrapulmonary disease, but the relative risk appears much higher in other populations such as Spain (1113/100,000 patients, RR 90.1). Quantiferon Gold or T-spot TB tests offer improved sensitivity to detect latent TB in some groups of immunosuppressed patients though formal data in Crohn’s is not available. Chemoprophylaxis of latent TB with isoniazid reduces the rate of developing TB by 70% but the timing of anti-TNF therapy has not been formally studied.&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #33cccc"&gt;Inflammatory Bowel Disease Annual Evidence Update 2009&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #99cc00" ?&gt;
&lt;P&gt;&lt;A href="nelh:309257:1" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308811:1" name=internalLink&gt;Aetiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308884:1" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:308897:1" name=internalLink&gt;Aminosalicylates&lt;/A&gt; | &lt;A href="nelh:308900:1" name=internalLink&gt;Biotics and nutritional therapies&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308904:1" name=internalLink&gt;Corticosteroids and immunosuppressants&lt;/A&gt; | &lt;A href="nelh:308916:1" name=internalLink&gt;Other interventions&lt;/A&gt; | &lt;A href="nelh:308924:1" name=internalLink&gt;General and miscellaneous&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;Adverse events and risk factors &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:308889:1" name=internalLink&gt;&lt;B&gt;Medication&lt;/B&gt;&lt;/A&gt; | &lt;A href="nelh:308957:1" name=internalLink&gt;Other&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:308891:1" name=internalLink&gt;Miscellaneous&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308947:1" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:309258:1" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:309001:1" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>308957</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=308957]]&gt;</url>
    <title>2009 Annual Evidence Update on Inflammatory Bowel Disease - Adverse effects and risk factors | Other adverse effects and risk factors</title>
    <publicationDate>2009-03-23T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CANCER,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Inflammatory Bowel Disease - Adverse effects and risk factors | Other adverse effects and risk factors&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;I&gt;Reviewed by Isobel Mason, Endoscopy Nurse Specialist, Royal Free Hospital, London&lt;/I&gt;&lt;/P&gt;
&lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Articles:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Lutgens, M. W. M. D., Vleggaar, F. P., Schipper, M. E. I., Stokkers, P. C. F., van der Woude, C. J., Hommes, D. W., de Jong, D. J., Dijkstra, G., van Bodegraven, A. A., Oldenburg, B., &amp;amp; Samsom, M. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=309241" target="_blank"&gt;High frequency of early colorectal cancer in inflammatory bowel disease.&lt;/A&gt; &lt;I&gt;Gut&lt;/I&gt;, 57(9):1246-1251.&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;B&gt;Reviewer's comments:&lt;/B&gt; This paper aims to assess the time interval between the onset of IBD and CRC and evaluate the number of patients developing cancer before recommended surveillance (8-10 years after diagnosis for extensive colitis and 10-15 years for left sided colitis). 149 patients were identified from the Dutch IBD database. These included patients with UC, Crohn’s colitis and PSC (19). 74% of patients had extensive colitis. 9% of patients had been diagnosed with CRC. 17% of these had been diagnosed on screening colonoscopy. 22% of CRC had occurred before screening commenced. The paper discusses the limitations of previous meta-analyses that have led to the recommended guidelines for surveillance. It recommends that guidelines should be less rigid and that criteria for surveillance should include other risk factors including disease severity, early age onset, family history and psuedopolyps. It is suggested that existing guidelines may lead to a delay on diagnosis in 20% of patients.&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;Nakase, H., Matsumura, K., Yoshino, T., &amp;amp; Chiba, T. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=309245" target="_blank"&gt;Systematic review: cytomegalovirus infection in inflammatory bowel disease.&lt;/A&gt; &lt;I&gt;Journal of Gastroenterology&lt;/I&gt;, 43(10):735-740.&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;B&gt;Reviewer's comments:&lt;/B&gt; This is a review article that discusses the role of CMV infection in IBD; the paper discusses diagnosis (serology, histopathology, antigenemia, endoscopy, polymerase and viral culture). 2 studies also suggest that CMV detection in the blood may not reflect colonic mucosa activation. Mucosal PCR and histological examination is reported as the important diagnostic test. It reviews the case reports of CMV, particularly in UC. 1 study of antiviral therapy in patients in whom CMV infection was identified showed no alteration in disease course with patients still requiring surgery. The paper identifies that the method of CMV activation and replication is unclear. Prospective studies to assess diagnostic modalities for early CMV screening and optimal, timely therapy are recommended.&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;Reese, G. E., Nanidis, T., Borysiewicz, C., Yamamoto, T., Orchard, T., &amp;amp; Tekkis, P. P. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=309249" target="_blank"&gt;The effect of smoking after surgery for Crohn's disease: a meta-analysis of observational studies.&lt;/A&gt; &lt;I&gt;International Journal of Colorectal Disease&lt;/I&gt;, 23(12):1213-1221.&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;B&gt;Reviewer's comments:&lt;/B&gt; This meta-analysis aims to quantify the risk of disease recurrence in smokers with Crohn’s disease post operatively. 16 papers were included (3 non randomised) published between 1997 and 2007. Assessment for heterogeneity is limited due to a lack of comparable data. There was no comparable data on disease phenotype or time to recurrence. Smokers were found to have significantly higher surgical recurrence at 5 and 10 year follow up. A 2.5 fold increased risk of surgical recurrence is stated. The paper discusses the role of smoking cessation, but only 1 study showed outcomes of this intervention with a ‘quit rate’ of only 12%. The authors recommend counseling for patients about the risks of smoking in the context of their illness.&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;Simillis, C., Yamamoto, T., Reese, G. E., Umegae, S., Matsumoto, K., Darzi, A. W., &amp;amp; Tekkis, P. P. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=281270" target="_blank"&gt;A meta-analysis comparing incidence of recurrence and indication for reoperation after surgery for perforating versus nonperforating Crohn's disease.&lt;/A&gt; &lt;I&gt;American Journal of Gastroenterology&lt;/I&gt;, 103(1):196-205.&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;B&gt;Reviewer's comments:&lt;/B&gt; This meta-analysis compares studies published between 1988 and 2005 of perforating versus non perforating Crohn’s disease following a first operation. Perforation and sticturoplasty were excluded. 13 studies were included. Heterogeneity was assessed, but no significant heterogeneity was found. The indications for reoperation were found to be closely dependent on the indication for the primary operation with recurrence significantly higher in the perforated group. The paper discusses the significant difference and the potential role for prophylactic treatment (immunosuppression or biologic) in patients with perforating disease postoperatively.&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #33cccc"&gt;Inflammatory Bowel Disease Annual Evidence Update 2009&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #99cc00" ?&gt;
&lt;P&gt;&lt;A href="nelh:309257:1" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308811:1" name=internalLink&gt;Aetiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308884:1" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:308897:1" name=internalLink&gt;Aminosalicylates&lt;/A&gt; | &lt;A href="nelh:308900:1" name=internalLink&gt;Biotics and nutritional therapies&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308904:1" name=internalLink&gt;Corticosteroids and immunosuppressants&lt;/A&gt; | &lt;A href="nelh:308916:1" name=internalLink&gt;Other interventions&lt;/A&gt; | &lt;A href="nelh:308924:1" name=internalLink&gt;General and miscellaneous&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;Adverse events and risk factors &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:308889:1" name=internalLink&gt;Medication&lt;/A&gt; | &lt;A href="nelh:308957:1" name=internalLink&gt;&lt;B&gt;Other&lt;/B&gt;&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:308891:1" name=internalLink&gt;Miscellaneous&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308947:1" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:309258:1" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:309001:1" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>308811</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=308811]]&gt;</url>
    <title>2009 Annual Evidence Update on Inflammatory Bowel Disease - Aetiology</title>
    <publicationDate>2009-03-23T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,STOMACH,SMALL INTESTINE,COLON &amp; RECTUM,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE,APPENDICITIS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Inflammatory Bowel Disease - Aetiology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;I&gt;Reviewed by Stephen Grainger, Consultant Physician and Gastroenterologist, King George Hospital, Essex&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Overall Comments:&lt;/B&gt; In general, there is little convincing evidence presented that exogenous factors that might perturb the intestinal environment influence the development of IBD, despite much speculation. This series of papers is rather disappointing - the quality being diminished by poor English, heterogeneity of pooled studies, publication bias and studies of very limited size.&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Articles:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Cornish, J. A., Tan, E., Simillis, C., Clark, S. K., Teare, J., &amp;amp; Tekkis, P. P. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=309028" target="_blank"&gt;The risk of oral contraceptives in the etiology of inflammatory bowel disease: a meta-analysis.&lt;/A&gt; &lt;I&gt;American Journal of Gastroenterology&lt;/I&gt;, 103(9):2394-2400.&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;B&gt;Reviewer's comments:&lt;/B&gt; The paper shows that the risk of developing Crohn's disease is related to duration of oral contraceptive use. Its further attempt to relate the risk to the contraceptive dose is flawed by lack of data and the presumption that contraceptive doses would be lower after 2000 - without data being provided to demonstrate this.&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;Jones, D. T., Osterman, M. T., Bewtra, M., &amp;amp; Lewis, J. D. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=309031" target="_blank"&gt;Passive smoking and inflammatory bowel disease: a meta-analysis.&lt;/A&gt; &lt;I&gt;American Journal of Gastroenterology&lt;/I&gt;, 103(9):2382-2393.&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;B&gt;Reviewer's comments:&lt;/B&gt; The paper demonstrated no measurable effect of passive smoking on the development of IBD. There is a hundred-fold difference between the number of cases included in the various studies, and the largest study showed no effect. There was also generally no matching of cases to control subjects.&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;Kaplan, G. G., Jackson, T., Sands, B. E., Frisch, M., Andersson, R. E., &amp;amp; Korzenik, J. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=309034" target="_blank"&gt;The risk of developing Crohn's disease after an appendectomy: a meta-analysis.&lt;/A&gt; &lt;I&gt;American Journal of Gastroenterology&lt;/I&gt;, 103(11):2925-31.&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;B&gt;Reviewer's comments:&lt;/B&gt; There was significant heterogeneity amongst the included studies in this paper. It suggests that, in contrast to the situation for ulcerative colitis, appendectomy increases the likelihood of a diagnosis of Crohn's disease within 4 years of the operation, but that this is partly due to diagnostic error.&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;Koloski, N. A., Bret, L., &amp;amp; Radford-Smith, G. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=309039" target="_blank"&gt;Hygiene hypothesis in inflammatory bowel disease: A critical review of the literature.&lt;/A&gt; &lt;I&gt;World Journal of Gastroenterology&lt;/I&gt;, 14(2):165-173.&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;B&gt;Reviewer's comments:&lt;/B&gt; This paper provides a useful collection of references on a "popular" hypothesis, but is ultimately only speculation with no definitive conclusions.&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;Maunder, R. G. &amp;amp; Levenstein, S. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=309042" target="_blank"&gt;The role of stress in the development and clinical course of inflammatory bowel disease: epidemiological evidence.&lt;/A&gt; &lt;I&gt;Current Molecular Medicine&lt;/I&gt;, 8(4):247-52.&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;B&gt;Reviewer's comments:&lt;/B&gt; There may be an association between psychological factors and IBD, but interventions do not help, sadly.&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;Porter, C. K., Tribble, D. R., Aliaga, P. A., Halvorson, H. A., &amp;amp; Riddle, M. S. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=309048" target="_blank"&gt;Infectious gastroenteritis and risk of developing inflammatory bowel disease.&lt;/A&gt; &lt;I&gt;Gastroenterology&lt;/I&gt;, 135(3):781-786.&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;B&gt;Reviewer's comments:&lt;/B&gt; This is a large US military personnel study showing that infectious gastroenteritis increased the risk of subsequently developing IBD. Even so, 93% of military personnel that developed IBD had no preceding infection.&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;Waddell, L. A., Rajic, A., Sargeant, J., Harris, J., Amezcua, R., Downey, L., Read, S., &amp;amp; McEwen, S. A. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=309053" target="_blank"&gt;The zoonotic potential of Mycobacterium avium spp. paratuberculosis: a systematic review.&lt;/A&gt; &lt;I&gt;Canadian Journal of Public Health/Revue Canadienne de Sante Publique&lt;/I&gt;, 99(2):145-55.&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;B&gt;Reviewer's comments:&lt;/B&gt; Myobacterium avium spp. paratuberculosus (MAP) is present in milk, but the evidence is not convincing that it is harmful to man.&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #33cccc"&gt;Inflammatory Bowel Disease Annual Evidence Update 2009&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #99cc00" ?&gt;
&lt;P&gt;&lt;A href="nelh:309257:1" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308811:1" name=internalLink&gt;&lt;B&gt;Aetiology&lt;/B&gt;&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308884:1" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:308897:1" name=internalLink&gt;Aminosalicylates&lt;/A&gt; | &lt;A href="nelh:308900:1" name=internalLink&gt;Biotics and nutritional therapies&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308904:1" name=internalLink&gt;Corticosteroids and immunosuppressants&lt;/A&gt; | &lt;A href="nelh:308916:1" name=internalLink&gt;Other interventions&lt;/A&gt; | &lt;A href="nelh:308924:1" name=internalLink&gt;General and miscellaneous&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;Adverse events and risk factors &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:308889:1" name=internalLink&gt;Medication&lt;/A&gt; | &lt;A href="nelh:308957:1" name=internalLink&gt;Other&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:308891:1" name=internalLink&gt;Miscellaneous&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308947:1" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:309258:1" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:309001:1" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>308884</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=308884]]&gt;</url>
    <title>2009 Annual Evidence Update on Inflammatory Bowel Disease - Diagnosis</title>
    <publicationDate>2009-03-23T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,DIAGNOSTIC PROCEDURES,GASTROINTESTINAL ENDOSCOPY,NUCLEAR MEDICINE,ULTRASOUND,MRI,CT / CAT SCAN,CAPSULE ENDOSCOPY,STOOL TESTING,RADIOLOGY]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Inflammatory Bowel Disease - Diagnosis&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;I&gt;Reviewed by Marcus Harbord, Consultant Gastroenterologist, Chelsea and Westminster Hospital, London&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;Despite the tremendous advances in molecular biology, the clinical diagnosis of inflammatory bowel disease, particularly Crohn’s disease (CD), still poses problems for clinicians. This is, in part, due to flaws in study design inherent in much of the published literature that is illustrated in a recent meta-analysis and two recent systematic reviews.&lt;/P&gt;
&lt;P&gt;&lt;A href="#horsthuis"&gt;Horsthuis et al.&lt;/A&gt; have provided the first comprehensive meta-analysis comparing the various radiological techniques available to diagnose IBD. This helpfully concluded that we should use non-ionising studies, magnetic resonance (MR) or ultrasound (US), where possible. It did not provide support for a particular technique, as US, MR, scintigraphy and computerised tomography (CT) scanning all had diagnostic sensitivities and specificities greater than 85%, although CT performed less well compared to MR or scintigraphy. However, the conclusions have to be viewed with some scepticism: first, it included reports from 1993, some of which may now be irrelevant given technical advances; the majority of the studies were performed in patients with “IBD”, which comprises two very different diseases radiologically; few studies were blinded; often, the gold standard was itself imperfect, such as small bowel follow-through (now known to be much inferior to capsule endoscopy); and most studies were inadequately powered, for example of 33 included studies, only three included more than 100 patients. More large randomised-controlled trials please! The paper revealed several interesting facts, for example that the sensitivity of MR in small bowel disease is increased from 84% to 96% using enteroclysis; that bowel wall thickness using US =/&amp;gt; 4 mm is &amp;gt; 90 % sensitive for IBD; and that CT is used proportionally more in the United States than Europe. I suspect that whether one uses US or MR would depend on local expertise, and availability.&lt;/P&gt;
&lt;P&gt;&lt;A href="#varela"&gt;Varela Lema &amp;amp; Ruano-Ravina&lt;/A&gt; provided a systematic review evaluating nine other systematic reviews and 28 original papers on the use of capsule endoscopy in diagnosing small bowel diseases. They concluded that it has a pre-emptive role in assessing obscure GI bleeding or diagnosing CD. Again however, the gold standard was limited. For example, only one study used intra-operative enteroscopy as a comparator. The discussion helpfully alluded to the relevance (or non-relevance) of lesions seen, which in part explains the heterogeneity of results across the studies.&lt;/P&gt;
&lt;P&gt;Faecal bio-markers are increasingly used in research and clinical practice. &lt;A href="#sutherland"&gt;Sutherland et al.&lt;/A&gt; provide a review and up-to-date list of references. They emphasise their increasing role in monitoring disease activity, particularly in ulcerative colitis (UC), for example one study cited describes a two- and 14-fold increase in relapse risk respectively for those patients with CD and UC in clinical remission with faecal Calprotectin &amp;gt;150 µg/g. Their role will become more pertinent in tailoring therapies, recently underscored in the (French) STORI study which examined factors associated with a successful withdrawal of Infliximab in patients with CD. They also likely will have an increasing role in preventing inappropriate investigations in patients with irritable bowel without alarm features.&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Articles:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=horsthuis&gt;&lt;/A&gt;Horsthuis, K., Bipat, S., Bennink, R. J., &amp;amp; Stoker, J. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=309073" target="_blank"&gt;Inflammatory bowel disease diagnosed with US, MR, scintigraphy, and CT: meta-analysis of prospective studies.&lt;/A&gt; &lt;I&gt;Radiology&lt;/I&gt;, 247(1):64-79.&lt;/P&gt;
&lt;P&gt;&lt;A name=Sutherland&gt;&lt;/A&gt;Sutherland, A. D., Gearry, R. B., &amp;amp; Frizelle, F. A. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=309076" target="_blank"&gt;Review of fecal biomarkers in inflammatory bowel disease.&lt;/A&gt; &lt;I&gt;Diseases of the Colon &amp;amp; Rectum&lt;/I&gt;, 51(8):1283-1291.&lt;/P&gt;
&lt;P&gt;&lt;A name=Varela&gt;&lt;/A&gt;Varela Lema, L. &amp;amp; Ruano-Ravina, A. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=309078" target="_blank"&gt;Effectiveness and safety of capsule endoscopy in the diagnosis of small bowel diseases.&lt;/A&gt; &lt;I&gt;Journal of Clinical Gastroenterology&lt;/I&gt;, 42(5):466-470.&lt;/P&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #33cccc"&gt;Inflammatory Bowel Disease Annual Evidence Update 2009&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #99cc00" ?&gt;
&lt;P&gt;&lt;A href="nelh:309257:1" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308811:1" name=internalLink&gt;Aetiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308884:1" name=internalLink&gt;&lt;B&gt;Diagnosis&lt;/B&gt;&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:308897:1" name=internalLink&gt;Aminosalicylates&lt;/A&gt; | &lt;A href="nelh:308900:1" name=internalLink&gt;Biotics and nutritional therapies&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308904:1" name=internalLink&gt;Corticosteroids and immunosuppressants&lt;/A&gt; | &lt;A href="nelh:308916:1" name=internalLink&gt;Other interventions&lt;/A&gt; | &lt;A href="nelh:308924:1" name=internalLink&gt;General and miscellaneous&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;Adverse events and risk factors &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:308889:1" name=internalLink&gt;Medication&lt;/A&gt; | &lt;A href="nelh:308957:1" name=internalLink&gt;Other&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:308891:1" name=internalLink&gt;Miscellaneous&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308947:1" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:309258:1" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:309001:1" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>308947</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=308947]]&gt;</url>
    <title>2009 Annual Evidence Update on Inflammatory Bowel Disease - Foreign language articles</title>
    <publicationDate>2009-03-23T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Inflammatory Bowel Disease - Foreign language articles&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;The following articles were identified by the search as being potentially relevant to the AEU, but were not sent out for appraisal because the full text is in a language other than English. They are included here for interest, and for the sake of completeness.&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;Basque Office for Health Technology Assessment &amp;amp; Health Department. (2008) &lt;I&gt;Establishing standards, records and analytical procedures for the treatment of ulcerative colitis.&lt;/I&gt; [Online] Available from: &lt;A href="http://www9.euskadi.net/sanidad/osteba/datos/e_06_05_Aferesis.pdf" target="_blank"&gt;http://www9.euskadi.net/sanidad/osteba/datos/e_06_05_Aferesis.pdf&lt;/A&gt;&lt;BR&gt;&lt;I&gt;&lt;B&gt;Language:&lt;/B&gt; Spanish&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;Beaugerie, L. (2008) &lt;A href="http://dx.doi.org/10.1007/s101900800018" target="_blank"&gt;Inflammatory bowel disease (IBD): what is the role of conventional treatments?&lt;/A&gt; &lt;I&gt;Acta Endoscopica&lt;/I&gt;, 38(4), 359-374.&lt;BR&gt;&lt;I&gt;&lt;B&gt;Language:&lt;/B&gt; French&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;Calderon, J. &amp;amp; Gongora, A. (2008) &lt;A href="http://apps.unicordoba.edu.co/revistas/revistamvz/mvz-131/V13N1A13.pdf" target="_blank"&gt;Clinical and pathological similarities between paratuberculosis and Crohn's disease: a possible zoonotic link?&lt;/A&gt; &lt;I&gt;Revista MVZ Cordoba&lt;/I&gt;, 13(1), 1226-1239.&lt;BR&gt;&lt;I&gt;&lt;B&gt;Language:&lt;/B&gt; Spanish&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;Hoffmann, J.C., Autschbach, F., Bokemeyer, B., Buhr, H.J., Herrlinger, K., Hohne, W., Krieglstein, C., Kruis, W., Moser, G., Preiss, J. C., Reinshagen, M., Rogler, G., Schreiber, S., Schreyer, A.G., Siegmund, B., Stallmach, A., Stange, E.F., &amp;amp; Zeitz, M. (2008) &lt;A href="http://dx.doi.org/10.1055/s-0028-1085580" target="_blank"&gt;Short version of the updated German S3 (level 3) guideline on diagnosis and treatment of Crohn's disease.&lt;/A&gt; &lt;I&gt;Deutsche Medizinische Wochenschrift&lt;/I&gt;, 133(38), 1924-1929.&lt;BR&gt;&lt;I&gt;&lt;B&gt;Language:&lt;/B&gt; German&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;Huang, M.-L., Ran, Z.-H., Tong, J.-L., Lu, L.-H., &amp;amp; Xiao, S.-D. (2008) &lt;A href="http://scholar.ilib.cn/A-QCode~hrxhzz200803019.html" target="_blank"&gt;Effects of topical administration of budesonide and traditional glucocorticosteroids on active distal ulcerative colitis or proctitis.&lt;/A&gt; &lt;I&gt;World Chinese Journal of Digestology&lt;/I&gt;, 16(3), 326-331.&lt;BR&gt;&lt;I&gt;&lt;B&gt;Language:&lt;/B&gt; Chinese&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;Wu, Q.-R., Zhou, J., He, J.-D., Wang, Y.-P., Yang, X.-R., &amp;amp; Zhang, L. (2008) Probiotic agents for ulcerative colitis: A systematic review. &lt;I&gt;Chinese Journal of Evidence-Based Medicine&lt;/I&gt;, 8(5), 315-321.&lt;BR&gt;&lt;I&gt;&lt;B&gt;Language:&lt;/B&gt; Chinese&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;Wu, X.J., He, X.S., Zhou, X.Y., Zou, Y.F., &amp;amp; Lan, P. (2008) &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18803038" target="_blank"&gt;Safety and feasibility of laparoscopic surgery and open surgery in ulcerative colitis: a meta-analysis.&lt;/A&gt; &lt;I&gt;Zhonghua Weichang Waike Zazhi&lt;/I&gt;, 11(5), 408-413.&lt;BR&gt;&lt;I&gt;&lt;B&gt;Language:&lt;/B&gt; Chinese&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #33cccc"&gt;Inflammatory Bowel Disease Annual Evidence Update 2009&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #99cc00" ?&gt;
&lt;P&gt;&lt;A href="nelh:309257:1" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308811:1" name=internalLink&gt;Aetiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308884:1" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:308897:1" name=internalLink&gt;Aminosalicylates&lt;/A&gt; | &lt;A href="nelh:308900:1" name=internalLink&gt;Biotics and nutritional therapies&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308904:1" name=internalLink&gt;Corticosteroids and immunosuppressants&lt;/A&gt; | &lt;A href="nelh:308916:1" name=internalLink&gt;Other interventions&lt;/A&gt; | &lt;A href="nelh:308924:1" name=internalLink&gt;General and miscellaneous&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;Adverse events and risk factors &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:308889:1" name=internalLink&gt;Medication&lt;/A&gt; | &lt;A href="nelh:308957:1" name=internalLink&gt;Other&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:308891:1" name=internalLink&gt;Miscellaneous&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308947:1" name=internalLink&gt;&lt;B&gt;Foreign language articles&lt;/B&gt;&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:309258:1" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:309001:1" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>309257</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=309257]]&gt;</url>
    <title>2009 Annual Evidence Update on Inflammatory Bowel Disease - Introduction</title>
    <publicationDate>2009-03-23T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Inflammatory Bowel Disease - Introduction&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;It is a pleasure to introduce this year’s annual evidence update for Inflammatory Bowel Disease. This update highlights the best peer reviewed guidelines and systematic reviews on the area and I must thank our topic advisors for their help in finalising the list and for their pertinent comments. Those topic advisors include Dr Andrew Cole, Dr Stephen Grainger, Dr Marcus Harbord, Dr Brian McKaig, Dr Richard Makins, Ms Isobel Mason and Dr Tim Orchard. In addition this update has allowed us to scrutinize those areas of “uncertainties” in the management of IBD still not answered by the current literature and this has become part of the UK Database of Uncertainties about the Effects of Treatment (DUETS). I would like to make special mention of Sara Clarke (Project Manager of GLDSL) and Matthew Hall (Information Specialist for GLDSL), their hard work has enabled the success of the library and development of this annual evidence update.&lt;/P&gt;
&lt;P&gt;We welcome any comments and hope you find the GLDSL a useful contribution to your practice.&lt;/P&gt;
&lt;P&gt;MARTYN CAPLIN&lt;/P&gt;
&lt;P&gt;Consultant Gastroenterologist &amp;amp; Clinical Lead GLDSL&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;A summary of the methods used for retrieving and evaluating the evidence can be found &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=309001" target="_blank"&gt;here&lt;/A&gt;. The evidence has been split into sections as follows:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:308811:1" name=internalLink&gt;Aetiology&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:308884:1" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Treatment: 
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:308897:1" name=internalLink&gt;Aminosalicylates&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:308900:1" name=internalLink&gt;Biotics and nutritional therapies&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:308904:1" name=internalLink&gt;Corticosteroids and immunosuppressants&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:308916:1" name=internalLink&gt;Other interventions&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:308924:1" name=internalLink&gt;General reviews and miscellaneous topics in treatment&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;BR&gt;
&lt;LI&gt;Adverse effects and risk factors 
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:308889:1" name=internalLink&gt;Adverse effects of medication&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:308957:1" name=internalLink&gt;Other adverse effects and risk factors&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;BR&gt;
&lt;LI&gt;&lt;A href="nelh:308891:1" name=internalLink&gt;Miscellaneous&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:308947:1" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Click on the sections above to find links to critically appraised systematic reviews, expert commentaries and other information of interest, or download the &lt;A href="http://www.library.nhs.uk/SpecialistLibrarySearch/Download.aspx?resID=309257" target="_blank"&gt;pdf version&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;We also have provided a list of &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=309258" target="_blank"&gt;treatment uncertainties&lt;/A&gt;, taken from the articles included in the AEU.&lt;/P&gt;
&lt;P&gt;This year's update has been put together by the Gastroenterology &amp;amp; Liver Diseases Specialist Library Project Team, with expert advice and commentaries provided by our IBD topic leads. These are:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Andrew Cole, Consultant Gastroenterologist, Derby City General Hospital&lt;/LI&gt;
&lt;LI&gt;Stephen Grainger, Consultant Physician and Gastroenterologist, King George Hospital, Essex&lt;/LI&gt;
&lt;LI&gt;Marcus Harbord, Consultant Gastroenterologist, Chelsea and Westminster Hospital, London&lt;/LI&gt;
&lt;LI&gt;Brian McKaig, Consultant Gastroenterologist, New Cross Hospital, Wolverhampton&lt;/LI&gt;
&lt;LI&gt;Richard Makins, Consultant Gastroenterologist, Cheltenham General Hospital, Gloucestershire&lt;/LI&gt;
&lt;LI&gt;Isobel Mason, Endoscopy Nurse Specialist, Royal Free Hospital, London&lt;/LI&gt;
&lt;LI&gt;Tim Orchard, Consultant Gastroenterologist, St Mary's Hospital London and Reader in Gastroenterology, Imperial College London&lt;/LI&gt;&lt;/UL&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #33cccc"&gt;Inflammatory Bowel Disease Annual Evidence Update 2009&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #99cc00" ?&gt;
&lt;P&gt;&lt;B&gt;&lt;A href="nelh:309257:1" name=internalLink&gt;Introduction&lt;/A&gt;&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:308811:1" name=internalLink&gt;Aetiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308884:1" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:308897:1" name=internalLink&gt;Aminosalicylates&lt;/A&gt; | &lt;A href="nelh:308900:1" name=internalLink&gt;Biotics and nutritional therapies&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308904:1" name=internalLink&gt;Corticosteroids and immunosuppressants&lt;/A&gt; | &lt;A href="nelh:308916:1" name=internalLink&gt;Other interventions&lt;/A&gt; | &lt;A href="nelh:308924:1" name=internalLink&gt;General and miscellaneous&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;Adverse events and risk factors &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:308889:1" name=internalLink&gt;Medication&lt;/A&gt; | &lt;A href="nelh:308957:1" name=internalLink&gt;Other&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:308891:1" name=internalLink&gt;Miscellaneous&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308947:1" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:309258:1" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:309001:1" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>309001</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=309001]]&gt;</url>
    <title>2009 Annual Evidence Update on Inflammatory Bowel Disease - Methods for retrieving and evaluating the evidence</title>
    <publicationDate>2009-03-23T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Inflammatory Bowel Disease - Methods for retrieving and evaluating the evidence&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;The last Annual Evidence Update for IBD was carried out in March 2008. This AEU serves as an update to that one, and includes articles published in 2008 and 2009. As the Specialist Library focuses only on secondary information of use to NHS staff and patients, our update was focused on guidelines and systematic reviews written in English. However, foreign language articles were included in the search process. As translations for these articles were not available, the article titles have been listed separately.&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00; FONT-SIZE: 13pt"&gt;&lt;B&gt;&lt;U&gt;Search strategy&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Our search strategy has been updated from last year. The following resources were searched: 
&lt;UL&gt;
&lt;LI&gt;MEDLINE&lt;/LI&gt;
&lt;LI&gt;EMBASE&lt;/LI&gt;
&lt;LI&gt;CINAHL&lt;/LI&gt;
&lt;LI&gt;Web of Science&lt;/LI&gt;
&lt;LI&gt;PsycINFO&lt;/LI&gt;
&lt;LI&gt;AMED&lt;/LI&gt;
&lt;LI&gt;British Nursing Index&lt;/LI&gt;
&lt;LI&gt;NHS Economic Evaluation Database&lt;/LI&gt;
&lt;LI&gt;HTA Database&lt;/LI&gt;&lt;/UL&gt;The search strategy for MEDLINE, which was modified for the other resources, appears &lt;A href="#strategy"&gt;below&lt;/A&gt;. We combined this with a &lt;A href="#filter"&gt;modified SIGN systematic review&lt;/A&gt; filter in all cases except the searches of the BNI (due to its small size) and NHS EED and HTA (because they consist entirely of the types of publication that we were interested in). 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;After de-duplication 350 articles were retrieved.&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00; FONT-SIZE: 13pt"&gt;&lt;B&gt;&lt;U&gt;Inclusion and exclusion criteria&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Included articles had to meet the following criteria:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Publication types: systematic review, consensus report, guideline, protocol, care pathway, economic evaluation, health technology assessment&lt;/LI&gt;
&lt;LI&gt;Published in 2008 or 2009&lt;/LI&gt;
&lt;LI&gt;Main condition under investigation was IBD, Crohn’s disease, ulcerative colitis, colitis&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Once the inclusion criteria were applied, 74 articles were left. Of these, 7 were foreign language articles, 9 were Cochrane systematic reviews, and 1 was a health technology assessment (which was also in a foreign language).&lt;/P&gt;
&lt;P&gt;The Cochrane systematic reviews were automatically included in the Evidence Update. While we were not able to find reviewers for them, the titles of the foreign language articles are included in a separate section of the Evidence Update. This left 58 articles to be sent to our reviewers for appraisal.&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00; FONT-SIZE: 13pt"&gt;&lt;B&gt;&lt;U&gt;Critical appraisal process&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Before sending out, the articles were divided into categories as follows:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Aetiology&lt;/LI&gt;
&lt;LI&gt;Diagnosis&lt;/LI&gt;
&lt;LI&gt;Treatment&lt;/LI&gt;
&lt;LI&gt;Adverse effects and risk factors&lt;/LI&gt;
&lt;LI&gt;Other&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Using these categories as a guide, the papers were divided up and sent to our seven reviewers. The reviewers then appraised the articles for their validity, relevance and rigour. Following the receipt of their comments, we included in the Evidence Update 47 articles that were deemed to meet the standards.&lt;/P&gt;
&lt;P&gt;After the articles had been sent out, our RSS alerts continued to highlight articles that matched the search criteria. The Clinical Lead reviewed these and recommended that four be included in the final AEU, bringing the total to 51 articles in all.&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00; FONT-SIZE: 13pt"&gt;&lt;B&gt;&lt;U&gt;AEU process flowchart&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="COLOR: #99cc00; FONT-SIZE: 13pt"&gt;&lt;IMG src="https://rmsadmin.library.nhs.uk/libraryImages/gastroliver/contentID309001/nelhImp_0004_aeuflowchartrevised.jpg"&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00; FONT-SIZE: 13pt"&gt;&lt;B&gt;&lt;U&gt;&lt;A name=strategy&gt;&lt;/A&gt;MEDLINE search strategy&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;TABLE style="TABLE-LAYOUT: fixed"&gt;
&lt;TBODY&gt;
&lt;TR style="FONT-FAMILY: Courier,monospace; FONT-SIZE: 7pt"&gt;
&lt;TD style="BORDER-BOTTOM: #000000 thin solid; BORDER-LEFT: #000000 thin solid; PADDING-BOTTOM: 5pt; PADDING-LEFT: 5pt; PADDING-RIGHT: 5pt; BORDER-TOP: #000000 thin solid; BORDER-RIGHT: #000000 thin solid; PADDING-TOP: 5pt" ?&gt;&lt;STRONG&gt;1&lt;/STRONG&gt; exp colitis/ &lt;BR&gt;&lt;STRONG&gt;2&lt;/STRONG&gt; exp inflammatory bowel diseases/ &lt;BR&gt;&lt;STRONG&gt;3&lt;/STRONG&gt; exp enteritis/ &lt;BR&gt;&lt;STRONG&gt;4&lt;/STRONG&gt; exp proctitis/&lt;BR&gt;&lt;STRONG&gt;5&lt;/STRONG&gt; (inflammat* adj5 bowel*).mp.&lt;BR&gt;&lt;STRONG&gt;6&lt;/STRONG&gt; (inflammat* adj5 colon*).mp.&lt;BR&gt;&lt;STRONG&gt;7&lt;/STRONG&gt; (inflammat* adj5 intestin*).mp.&lt;BR&gt;&lt;STRONG&gt;8&lt;/STRONG&gt; (inflammat* adj5 ile*).mp.&lt;BR&gt;&lt;STRONG&gt;9&lt;/STRONG&gt; crohn*.mp.&lt;BR&gt;&lt;STRONG&gt;10&lt;/STRONG&gt; colitis.mp.&lt;BR&gt;&lt;STRONG&gt;11&lt;/STRONG&gt; ileitis.mp.&lt;BR&gt;&lt;STRONG&gt;12&lt;/STRONG&gt; enteritis.mp.&lt;BR&gt;&lt;STRONG&gt;13&lt;/STRONG&gt; proctitis.mp.&lt;BR&gt;&lt;STRONG&gt;14&lt;/STRONG&gt; enterocolitis.mp.&lt;BR&gt;&lt;STRONG&gt;15&lt;/STRONG&gt; proctocolitis.mp.&lt;BR&gt;&lt;STRONG&gt;16&lt;/STRONG&gt; cd.mp.&lt;BR&gt;&lt;STRONG&gt;17&lt;/STRONG&gt; ibd.mp.&lt;BR&gt;&lt;STRONG&gt;18&lt;/STRONG&gt; uc.mp.&lt;BR&gt;&lt;STRONG&gt;19&lt;/STRONG&gt; 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 &lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00; FONT-SIZE: 13pt"&gt;&lt;B&gt;&lt;U&gt;&lt;A name=filter&gt;&lt;/A&gt;Systematic review filter&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This is modified from the SIGN filter, which can be found at &lt;A href="http://www.sign.ac.uk/methodology/filters.html" target="_blank"&gt;http://www.sign.ac.uk/methodology/filters.html&lt;/A&gt;. It shown below as used for the MEDLINE search (small adaptations were made for other databases).&lt;/P&gt;
&lt;TABLE style="BORDER-BOTTOM: #000000 thin solid; BORDER-LEFT: #000000 thin solid; FONT-FAMILY: Courier,serif; FONT-SIZE: 7pt; BORDER-TOP: #000000 thin solid; BORDER-RIGHT: #000000 thin solid"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="PADDING-BOTTOM: 5pt; PADDING-LEFT: 5pt; PADDING-RIGHT: 5pt; PADDING-TOP: 5pt"&gt;&lt;STRONG&gt;1&lt;/STRONG&gt; Meta-Analysis as Topic/&lt;BR&gt;&lt;STRONG&gt;2&lt;/STRONG&gt; Meta-Analysis/&lt;BR&gt;&lt;STRONG&gt;3&lt;/STRONG&gt; metaanaly*.mp. &lt;BR&gt;&lt;STRONG&gt;4&lt;/STRONG&gt; meta analy*.mp. &lt;BR&gt;&lt;STRONG&gt;5&lt;/STRONG&gt; (systematic adj (review* or overview*)).mp.&lt;BR&gt;&lt;STRONG&gt;6&lt;/STRONG&gt; exp Review Literature as Topic/&lt;BR&gt;&lt;STRONG&gt;7&lt;/STRONG&gt; 1 or 2 or 3 or 4 or 5 or 6&lt;BR&gt;&lt;STRONG&gt;8&lt;/STRONG&gt; Cochrane.ab.&lt;BR&gt;&lt;STRONG&gt;9&lt;/STRONG&gt; Embase.ab.&lt;BR&gt;&lt;STRONG&gt;10&lt;/STRONG&gt; Medline.ab.&lt;BR&gt;&lt;STRONG&gt;11&lt;/STRONG&gt; Pubmed.ab.&lt;BR&gt;&lt;STRONG&gt;12&lt;/STRONG&gt; (psychlit or psyclit).ab.&lt;BR&gt;&lt;STRONG&gt;13&lt;/STRONG&gt; (psychinfo or psycinfo).ab.&lt;BR&gt;&lt;STRONG&gt;14&lt;/STRONG&gt; (cinahl or cinhal).ab.&lt;BR&gt;&lt;STRONG&gt;15&lt;/STRONG&gt; science citation index.ab.&lt;BR&gt;&lt;STRONG&gt;16&lt;/STRONG&gt; bids.ab.&lt;BR&gt;&lt;STRONG&gt;17&lt;/STRONG&gt; cancerlit.ab.&lt;BR&gt;&lt;STRONG&gt;18&lt;/STRONG&gt; 11 or 9 or 17 or 12 or 15 or 14 or 8 or 16 or 10 or 13&lt;BR&gt;&lt;STRONG&gt;19&lt;/STRONG&gt; reference list$.ab.&lt;BR&gt;&lt;STRONG&gt;20&lt;/STRONG&gt; bibliograph$.ab.&lt;BR&gt;&lt;STRONG&gt;21&lt;/STRONG&gt; hand-search$.ab.&lt;BR&gt;&lt;STRONG&gt;22&lt;/STRONG&gt; relevant journals.ab.&lt;BR&gt;&lt;STRONG&gt;23&lt;/STRONG&gt; manual search$.ab.&lt;BR&gt;&lt;STRONG&gt;24&lt;/STRONG&gt; 22 or 21 or 23 or 19 or 20&lt;BR&gt;&lt;STRONG&gt;25&lt;/STRONG&gt; selection criteria.ab.&lt;BR&gt;&lt;STRONG&gt;26&lt;/STRONG&gt; data extraction.ab.&lt;BR&gt;&lt;STRONG&gt;27&lt;/STRONG&gt; 25 or 26&lt;BR&gt;&lt;STRONG&gt;28&lt;/STRONG&gt; review/&lt;BR&gt;&lt;STRONG&gt;29&lt;/STRONG&gt; 27 and 28&lt;BR&gt;&lt;STRONG&gt;30&lt;/STRONG&gt; Comment/&lt;BR&gt;&lt;STRONG&gt;31&lt;/STRONG&gt; Letter/&lt;BR&gt;&lt;STRONG&gt;32&lt;/STRONG&gt; editorial/&lt;BR&gt;&lt;STRONG&gt;33&lt;/STRONG&gt; 32 or 30 or 31&lt;BR&gt;&lt;STRONG&gt;34&lt;/STRONG&gt; 18 or 24 or 7 or 29&lt;BR&gt;&lt;STRONG&gt;35&lt;/STRONG&gt; 34 not 33&lt;BR&gt;&lt;STRONG&gt;36&lt;/STRONG&gt; limit 35 to animals&lt;BR&gt;&lt;STRONG&gt;37&lt;/STRONG&gt; limit 35 to (animals and humans)&lt;BR&gt;&lt;STRONG&gt;38&lt;/STRONG&gt; 36 not 37&lt;BR&gt;&lt;STRONG&gt;39&lt;/STRONG&gt; 35 not 38 &lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #33cccc"&gt;Inflammatory Bowel Disease Annual Evidence Update 2009&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #99cc00" ?&gt;
&lt;P&gt;&lt;A href="nelh:309257:1" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308811:1" name=internalLink&gt;Aetiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308884:1" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:308897:1" name=internalLink&gt;Aminosalicylates&lt;/A&gt; | &lt;A href="nelh:308900:1" name=internalLink&gt;Biotics and nutritional therapies&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308904:1" name=internalLink&gt;Corticosteroids and immunosuppressants&lt;/A&gt; | &lt;A href="nelh:308916:1" name=internalLink&gt;Other interventions&lt;/A&gt; | &lt;A href="nelh:308924:1" name=internalLink&gt;General and miscellaneous&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;Adverse events and risk factors &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:308889:1" name=internalLink&gt;Medication&lt;/A&gt; | &lt;A href="nelh:308957:1" name=internalLink&gt;Other&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:308891:1" name=internalLink&gt;Miscellaneous&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308947:1" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:309258:1" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:309001:1" name=internalLink&gt;&lt;B&gt;Methods&lt;/B&gt;&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>308891</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=308891]]&gt;</url>
    <title>2009 Annual Evidence Update on Inflammatory Bowel Disease - Miscellaneous</title>
    <publicationDate>2009-03-23T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Inflammatory Bowel Disease - Miscellaneous&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;I&gt;Reviewed by Marcus Harbord, Consultant Gastroenterologist, Chelsea and Westminster Hospital, London&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;Consensus is the cornerstone of complex medical care. Consequently, it is encouraging that an ECCO consensus has been published looking at quality of care issues in inflammatory bowel disease (&lt;A href="#elkjaer"&gt;Elkjaer et al.&lt;/A&gt;). This relatively brief article should be read by all those keen on improving their IBD Service. The consensus was derived following detailed review of 76 articles. Experts from 13 countries, including the UK, agreed on several issues. Briefly, they promoted: better patient information; the importance of compliance with medication; the need for IBD specialists to better link with primary care and for this dynamic to be better studied; the use of psychological support within treatment protocols; specialist IBD clinics, including the use of specialist nurse-led telephone or e-mail helplines; the requirement for specialist paediatric transition clinics.&lt;/P&gt;
&lt;P&gt;The BRIDGe group, a collection of 12 relatively young IBD specialists from four continents published a consensus document examining current controversies in IBD (&lt;A href="#sparrow"&gt;Sparrow et al.&lt;/A&gt;). This paper is interesting for the more personal nature of the conclusions. The group concluded that there was very little evidence for the use of amino-salicylate therapy in CD, which was rather ironic since their funding was provided by Procter &amp;amp; Gamble. None had yet adopted an early “top down” approach for CD, interesting given the strong pharmaceutical drive for this approach. Some of their conclusions were a bit dated given the rapid advances in biological therapies, for example they preferred scheduled maintenance monotherapy with anti-TNF-alpha, since they met before results of the SONIC trial were available. I look forward to further papers from the group, since their personal, educated views will no doubt be stimulating.&lt;/P&gt;
&lt;P&gt;The paper by &lt;A href="#yu"&gt;Yu et al.&lt;/A&gt; on the costs of Crohn's disease provides a rationale for including out-of-hospital costs, especially in European practice, which is very relevant given the role of managed health care.&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Articles:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=elkjaer&gt;&lt;/A&gt;Elkjaer, M., Moser, G., Reinisch, W., Durovicova, D., Lukas, M., Vucelic, B., Wewer, V., Frederic, C. J., Shuhaibar, M., O'Morain, C., Politi, P., Odes, S., Bernklev, T., Oresland, T., Nikulina, I., Belousova, E., Van, d. E., I, &amp;amp; Munkholm, P. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=309251" target="_blank"&gt;IBD patients need in health quality of care: ECCO consensus.&lt;/A&gt; &lt;I&gt;Journal of Crohn's and Colitis&lt;/I&gt;, 2(2):181-188.&lt;/P&gt;
&lt;P&gt;Smith, G.D., Watson, R., &amp;amp; Thompson, D.R. (2008) &lt;A href="http://www.library.nhs.uk/GASTROLIVER/ViewResource.aspx?resID=310840" target="_blank"&gt;Older people and inflammatory bowel disease: a systematic review.&lt;/A&gt; &lt;EM&gt;Journal of Clinical Nursing&lt;/EM&gt;, 17(11c):400-406.&lt;/P&gt;
&lt;P&gt;&lt;A name=sparrow&gt;&lt;/A&gt;Sparrow, M. P., Irving, P. M., Baidoo, L., Bressler, B., Cheifetz, A. S., Devlin, S. M., Harrell, L. E., Jones, J., Kozuch, P. L., Melmed, G. Y., Velayos, F. S., &amp;amp; Siegel, C. A. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=309254" target="_blank"&gt;Current controversies in Crohn's disease: A roundtable discussion of the BRIDGe group.&lt;/A&gt; &lt;I&gt;Gastroenterology and Hepatology&lt;/I&gt;, 4(10):713-720.&lt;/P&gt;
&lt;P&gt;&lt;A name=yu&gt;&lt;/A&gt;Yu, A. P., Cabanilla, L. A., Wu, E. Q., Mulani, P. M., &amp;amp; Chao, J. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=309256" target="_blank"&gt;The costs of Crohn's disease in the United States and other Western countries: a systematic review.&lt;/A&gt; &lt;I&gt;Current Medical Research &amp;amp; Opinion&lt;/I&gt;, 24(2):319-328.&lt;/P&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #33cccc"&gt;Inflammatory Bowel Disease Annual Evidence Update 2009&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #99cc00" ?&gt;
&lt;P&gt;&lt;A href="nelh:309257:1" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308811:1" name=internalLink&gt;Aetiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308884:1" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:308897:1" name=internalLink&gt;Aminosalicylates&lt;/A&gt; | &lt;A href="nelh:308900:1" name=internalLink&gt;Biotics and nutritional therapies&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308904:1" name=internalLink&gt;Corticosteroids and immunosuppressants&lt;/A&gt; | &lt;A href="nelh:308916:1" name=internalLink&gt;Other interventions&lt;/A&gt; | &lt;A href="nelh:308924:1" name=internalLink&gt;General and miscellaneous&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;Adverse events and risk factors &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:308889:1" name=internalLink&gt;Medication&lt;/A&gt; | &lt;A href="nelh:308957:1" name=internalLink&gt;Other&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:308891:1" name=internalLink&gt;&lt;B&gt;Miscellaneous&lt;/B&gt;&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308947:1" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:309258:1" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:309001:1" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>308897</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=308897]]&gt;</url>
    <title>2009 Annual Evidence Update on Inflammatory Bowel Disease - Treatment | Aminosalicylates</title>
    <publicationDate>2009-03-23T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Inflammatory Bowel Disease - Treatment | Aminosalicylates&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;I&gt;Reviewed by Brian McKaig, Consultant Gastroenterologist, New Cross Hospital, Wolverhampton&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;5-ASA agents are the mainstay of treatment for ulcerative colitis. Over the past few years there has been focus on maximising dose for active disease (&lt;A href="http://gut.bmj.com/cgi/content/full/54/suppl_2/a1" target="_blank"&gt;ASCEND I &amp;amp; II&lt;/A&gt;: Marion JF et al. (2006) &lt;EM&gt;Gut,&lt;/EM&gt; 55(Suppl 2):Abstract 140) along with combination of oral and rectal therapy for moderate to severe disease (&lt;A href="http://dx.doi.org/10.1136/gut.2004.060103%20" target="_blank"&gt;PINCE&lt;/A&gt;: Marteau et al. (2005) &lt;EM&gt;Gut&lt;/EM&gt;, 54(7):960-5). These recent studies highlight the importance of maximising drug concentration where the mucosa is actively inflamed.&lt;/P&gt;
&lt;P&gt;It is well recognised that compliance of 5-ASA therapy in UC is poor with rates of around 40-60% reported (&lt;A href="http://dx.doi.org/10.1111/j.1572-0241.2001.04683.x" target="_blank"&gt;Kane et al&lt;/A&gt;. (2001) &lt;EM&gt;American Journal of Gastroenterology&lt;/EM&gt;, 96(10):2929-33). Several factors contribute to this including number of tablets and multiple daily dosing regimes. The net effect of this is to reduce drug concentrations and potentially lead to higher relapse rates. Unsurprisingly, there is now considerable attention to simplifying dosing regimes with 5-ASA therapy. MMX mesalazine (Mesavant) has recently been approved in Europe for induction and maintenance of remission in adult patients with active mild to moderate UC (&lt;A href="http://dx.doi.org/10.1111/j.1365-2036.2006.03082.x" target="_blank"&gt;D’Haens et al&lt;/A&gt;. (2006) &lt;EM&gt;Alimentary Pharmacology and Therapeutics&lt;/EM&gt;, 24(7):1087-97). MMX mesalazine uses a novel multi matrix drug delivery system which allows once daily dosing with a high dose formulation of 1.2g mesalazine per tablet. Recent studies demonstrate higher compliance with once daily dosing using MMX mesalazine and this offers a positive step forward in our treatment of UC.&lt;/P&gt;
&lt;P&gt;Should we therefore switch all our patients to once daily MMX mesalazine? There have no comparative studies of once daily MMX mesalazine with conventional bd or tds therapies. Additionally manufacturers of alternative 5-ASA compounds have either completed or are running clinical trials to compare efficacy of once daily dosing with pentasa and asacol versus conventional therapy. Pentasa 2g od has recently been licensed for maintenance of remission in UC (&lt;A href="http://gut.bmj.com/content/vol57/Suppl_1/" target="_blank"&gt;PODIUM&lt;/A&gt;: Dignass &amp;amp;amp; Veerman (2008) &lt;EM&gt;Gut&lt;/EM&gt;, 57(Supp. 1):A1).&lt;/P&gt;
&lt;P&gt;In summary, 5-ASA therapy should be given in high dose (4g) in active disease and to improve compliance in both inducing and maintaining remission, and once daily therapy is virtually upon us.&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Articles:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Hu, M. Y. &amp;amp; Peppercorn, M. A. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=309081" target="_blank"&gt;MMX mesalamine: a novel high-dose, once-daily 5-aminosalicylate formulation for the treatment of ulcerative colitis.&lt;/A&gt; &lt;I&gt;Expert Opinion on Pharmacotherapy&lt;/I&gt;, 9(6):1049-1058.&lt;/P&gt;
&lt;P&gt;Kale-Pradhan, P. B., Pradhan, R. S., &amp;amp; Wilhelm, S. M. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=309083" target="_blank"&gt;Multi-matrix system mesalamine: to use or not to use.&lt;/A&gt; &lt;I&gt;Annals of Pharmacotherapy&lt;/I&gt;, 42(2):265-269.&lt;/P&gt;
&lt;P&gt;Lakatos, P. L. &amp;amp; Lakatos, L. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=309168" target="_blank"&gt;Once daily 5-aminosalicylic acid for the treatment of ulcerative colitis: are we there yet?&lt;/A&gt; &lt;I&gt;Pharmacological Research&lt;/I&gt;, 58(3-4):190-195.&lt;/P&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #33cccc"&gt;Inflammatory Bowel Disease Annual Evidence Update 2009&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #99cc00" ?&gt;
&lt;P&gt;&lt;A href="nelh:309257:1" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308811:1" name=internalLink&gt;Aetiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308884:1" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:308897:1" name=internalLink&gt;&lt;B&gt;Aminosalicylates&lt;/B&gt;&lt;/A&gt; | &lt;A href="nelh:308900:1" name=internalLink&gt;Biotics and nutritional therapies&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308904:1" name=internalLink&gt;Corticosteroids and immunosuppressants&lt;/A&gt; | &lt;A href="nelh:308916:1" name=internalLink&gt;Other interventions&lt;/A&gt; | &lt;A href="nelh:308924:1" name=internalLink&gt;General and miscellaneous&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;Adverse events and risk factors &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:308889:1" name=internalLink&gt;Medication&lt;/A&gt; | &lt;A href="nelh:308957:1" name=internalLink&gt;Other&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:308891:1" name=internalLink&gt;Miscellaneous&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308947:1" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:309258:1" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:309001:1" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>308900</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=308900]]&gt;</url>
    <title>2009 Annual Evidence Update on Inflammatory Bowel Disease - Treatment | Biotics and nutritional therapies</title>
    <publicationDate>2009-03-23T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COMMON CLINICAL PRESENTATIONS,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE,ENTERAL,THERAPEUTIC NUTRITION]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Inflammatory Bowel Disease - Treatment | Biotics and nutritional therapies&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P style="COLOR: #99cc00; FONT-SIZE: 13pt"&gt;&lt;B&gt;&lt;U&gt;Cochrane reviews:&lt;/U&gt;&lt;/B&gt; 
&lt;P&gt;The following Cochrane review was published this year:&lt;/P&gt;
&lt;P&gt;Butterworth, A.D., Thomas, A.G., &amp;amp; Akobeng, A.K. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=293648" target="_blank"&gt;Probiotics for induction of remission in Crohn's disease.&lt;/A&gt; &lt;I&gt;Cochrane Database of Systematic Reviews&lt;/I&gt; 2008, Issue 3. Art. No.: CD006634. DOI: 10.1002/14651858.CD006634.pub2.&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00; FONT-SIZE: 13pt"&gt;&lt;B&gt;&lt;U&gt;Other reviews:&lt;/U&gt;&lt;/B&gt; 
&lt;P style="COLOR: #33cccc; FONT-SIZE: 12pt"&gt;&lt;B&gt;Probiotics&lt;/B&gt; 
&lt;P&gt;&lt;I&gt;Reviewed by Richard Makins, Consultant Gastroenterologist, Cheltenham General Hospital, Gloucestershire&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;The side-effect profile of biologic therapy and potential for toxicity when used long term makes alternatives attractive. Much attention has been paid to probiotic therapies although there is no evidence that they confer any benefit over placebo in maintaining remission and prevention of endoscopic or clinical relapse in Crohn’s disease (&lt;A href="#rahimi1"&gt;Rahimi, 2008a&lt;/A&gt;). In UC probiotics may be useful as alternative to mesalasine in maintaining remission (&lt;A href="https://rmsadmin.library.nhs.uk/admin/wizards/articles/rahimi2" target="_blank"&gt;Rahimi, 2008b&lt;/A&gt;). They are potentially most valuable in the prevention and treatment of pouchitis but long term efficacy is yet to be determined (&lt;A href="https://rmsadmin.library.nhs.uk/admin/wizards/articles/elahi" target="_blank"&gt;Elahi&lt;/A&gt;).&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Articles:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=elahi&gt;&lt;/A&gt;Elahi, B., Nikfar, S., Derakhshani, S., Vafaie, M., &amp;amp; Abdollahi, M. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=309181" target="_blank"&gt;On the benefit of probiotics in the management of pouchitis in patients underwent ileal pouch anal anastomosis: a meta-analysis of controlled clinical trials.&lt;/A&gt; &lt;I&gt;Digestive Diseases &amp;amp; Sciences&lt;/I&gt;, 53(5):1278-1284.&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;B&gt;Reviewer's comments:&lt;/B&gt; The use of probiotics, in particular VSL#3, show promise in the prevention and treatment of pouchitis, but further trials are needed to determine long term efficacy&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;A name=rahimi1&gt;&lt;/A&gt;Rahimi, R., Nikfar, S., Rahimi, F., Elahi, B., Derakhshani, S., Vafaie, M., &amp;amp; Abdollahi, M. (2008a) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=309186" target="_blank"&gt;A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease.&lt;/A&gt; &lt;I&gt;Digestive Diseases &amp;amp; Sciences&lt;/I&gt;, 53(9):2524-2531.&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;B&gt;Reviewer's comments:&lt;/B&gt; Probiotics confer no benefit over placebo in maintaining remission and prevention of endoscopic or clinical relapse in Crohn’s disease.&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;A name=rahimi2&gt;Rahimi, R., Nikfar, S., Rezaie, A., &amp;amp; Abdollahi, M. (2008b) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=309187" target="_blank"&gt;A meta-analysis of the benefit of probiotics in maintaining remission of human ulcerative colitis: Evidence for prevention of disease relapse and maintenance of remission.&lt;/A&gt; &lt;I&gt;Archives of Medical Science&lt;/I&gt;, 4(2):185-190.&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;B&gt;Reviewer's comments:&lt;/B&gt; This study includes a meta-analysis of two RCTs looking at probiotics vs. placebo for maintenance of remission in UC. The studies had different dosing regimens and treatment durations, and very small numbers of patients. It also has a meta-analysis of four RCTs looking at probiotics vs. mesalazine for maintenance of remission; these also have different study characteristics. Probiotics may be useful alternative for maintenance therapy in UC compared to mesalazine, but they were not superior.&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #33cccc; FONT-SIZE: 12pt"&gt;&lt;B&gt;Enteral nutrition&lt;/B&gt; 
&lt;P&gt;&lt;I&gt;Reviewed by Richard Makins&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;Widely used in the paediatric population with Crohn’s disease, enteral nutrition may also have unsuspected benefits in adults such as lower rate of relapse, reduction of post operative recurrence and improved response to infliximab (&lt;A href="#day"&gt;Day&lt;/A&gt;).&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Articles:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=day&gt;&lt;/A&gt;Day, A. S., Whitten, K. E., Sidler, M., &amp;amp; Lemberg, D. A. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=281296" target="_blank"&gt;Systematic review: nutritional therapy in paediatric Crohn's disease.&lt;/A&gt; &lt;I&gt;Alimentary Pharmacology &amp;amp; Therapeutics&lt;/I&gt;, 27(4):293-307.&lt;BR&gt;&lt;/P&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #33cccc"&gt;Inflammatory Bowel Disease Annual Evidence Update 2009&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #99cc00" ?&gt;
&lt;P&gt;&lt;A href="nelh:309257:1" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308811:1" name=internalLink&gt;Aetiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308884:1" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:308897:1" name=internalLink&gt;Aminosalicylates&lt;/A&gt; | &lt;A href="nelh:308900:1" name=internalLink&gt;&lt;B&gt;Biotics and nutritional therapies&lt;/B&gt;&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308904:1" name=internalLink&gt;Corticosteroids and immunosuppressants&lt;/A&gt; | &lt;A href="nelh:308916:1" name=internalLink&gt;Other interventions&lt;/A&gt; | &lt;A href="nelh:308924:1" name=internalLink&gt;General and miscellaneous&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;Adverse events and risk factors &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:308889:1" name=internalLink&gt;Medication&lt;/A&gt; | &lt;A href="nelh:308957:1" name=internalLink&gt;Other&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:308891:1" name=internalLink&gt;Miscellaneous&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308947:1" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:309258:1" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:309001:1" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>308904</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=308904]]&gt;</url>
    <title>2009 Annual Evidence Update on Inflammatory Bowel Disease - Treatment | Corticosteroids and immunosuppressants</title>
    <publicationDate>2009-03-23T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Inflammatory Bowel Disease - Treatment | Corticosteroids and immunosuppressants&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P style="COLOR: #99cc00; FONT-SIZE: 13pt"&gt;&lt;B&gt;&lt;U&gt;Cochrane reviews:&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The following Cochrane reviews were published or updated this year:&lt;/P&gt;
&lt;P&gt;Baumgart, D.C., MacDonald, J.K., &amp;amp; Feagan, B. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=293697" target="_blank"&gt;Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis.&lt;/A&gt; &lt;I&gt;Cochrane Database of Systematic Reviews&lt;/I&gt; 2008, Issue 3. Art. No.: CD007216. DOI: 10.1002/14651858.CD007216.&lt;/P&gt;
&lt;P&gt;Behm, B.W &amp;amp; Bickston, S.J. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=279187" target="_blank"&gt;Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.&lt;/A&gt; &lt;I&gt;Cochrane Database of Systematic Reviews&lt;/I&gt; 2008, Issue 1. Art. No.: CD006893. DOI: 10.1002/14651858.CD006893.&lt;/P&gt;
&lt;P&gt;Benchimol, E.I., Seow, C.H., Otley, A.R., &amp;amp; Steinhart, A.H. (2009) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=237919" target="_blank"&gt;Budesonide for maintenance of remission in Crohn's disease.&lt;/A&gt; &lt;I&gt;Cochrane Database of Systematic Reviews&lt;/I&gt; 2009, Issue 1. Art. No.: CD002913. DOI: 10.1002/14651858.CD002913.pub2.&lt;/P&gt;
&lt;P&gt;Benchimol, E,I., Seow, C.H., Steinhart, A.H., &amp;amp; Griffiths, A.M. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=283719" target="_blank"&gt;Traditional corticosteroids for induction of remission in Crohn's disease.&lt;/A&gt; &lt;I&gt;Cochrane Database of Systematic Reviews&lt;/I&gt; 2008, Issue 2. Art. No.: CD006792. DOI: 10.1002/14651858.CD006792.pub2.&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00; FONT-SIZE: 13pt"&gt;&lt;B&gt;&lt;U&gt;Other reviews:&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="COLOR: #33cccc; FONT-SIZE: 12pt"&gt;&lt;B&gt;Thiopurines&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;Reviewed by Richard Makins, Consultant Gastroenterologist, Cheltenham General Hospital, Gloucestershire&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;Corticosteroids and 5-aminosalicylates are frequently utilised as first line therapy to achieve remission in both ulcerative colitis (UC) and Crohn’s disease. When patients fail to respond to such therapy, or become steroid resistant or steroid dependent, immunomodulatory drugs are often considered as an alternative. The thiopurines, azathioprine and 6-mercaptopurine are the most commonly used in this setting and their clinical usefulness and enviable safety profile was confirmed in a recent retrospective study from Italy (&lt;A href="#saibeni"&gt;Saibeni et al.&lt;/A&gt;). &lt;/P&gt;
&lt;P&gt;This approach was challenged when only modest efficacy was demonstrated in patients with UC (&lt;A href="https://rmsadmin.library.nhs.uk/admin/wizards/articles/leung" target="_blank"&gt;Leung et al.&lt;/A&gt;). However as these drugs have been available for more than 30 years, clinical use and experience has reached far beyond published experience, and consequently the available evidence to date along with expert opinion and clinical experience continue to promote an active role for thiopurines in steroid dependent or resistant UC.&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Articles:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=leung&gt;&lt;/A&gt;Leung, Y., Panaccione, R., Hemmelgarn, B., &amp;amp; Jones, J. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=281248" target="_blank"&gt;Exposing the weaknesses: a systematic review of azathioprine efficacy in ulcerative colitis.&lt;/A&gt; &lt;I&gt;Digestive Diseases &amp;amp; Sciences&lt;/I&gt;, 53(6):1455-1461.&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;B&gt;Reviewer's comments:&lt;/B&gt; There have been few randomised controlled trials looking at thiopurine use in UC, and as this meta-analysis of the more robust trials shows, pooled results show modest efficacy only. However, as these drugs have been available for more than 30 years, clinical use and experience has reached far beyond published experience. Consequently the available evidence to date along with expert opinion and clinical experience continue to promote an active role for azathioprine and 6-MP in steroid dependent or resistant UC.&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;A name=saibeni&gt;&lt;/A&gt;Saibeni, S., Virgilio, T., D'Inca, R., Spina, L., Bortoli, A., Paccagnella, M., Peli, M., Sablich, R., Meucci, G., Colombo, E., Benedetti, G., Girelli, C. M., Casella, G., Grasso, G., de Franchis, R., &amp;amp; Vecchi, M. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=309190" target="_blank"&gt;The use of thiopurines for the treatment of inflammatory bowel diseases in clinical practice.&lt;/A&gt; &lt;I&gt;Digestive and Liver Disease&lt;/I&gt;, 40(10):814-820.&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;B&gt;Reviewer's comments:&lt;/B&gt; The thiopurines, mercaptopurine and azathioprine, remain some of the most commonly prescribed drugs in IBD with good medium term safety profiles and desirable efficacy. Widely used in patients for steroid resistance or dependence they represent the mainstay of second line IBD therapy.&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #33cccc; FONT-SIZE: 12pt"&gt;&lt;B&gt;Tumour necrosis factor antagonists&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;Reviewed by Richard Makins&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;Whilst the experience of thiopurines is based on long term clinical use, the biologic agents, particularly the tumour necrosis factor antagonists such as infliximab and adalimumab, are relatively new to gastroenterological practice. With an established role in Crohn’s disease, and being superior to placebo for the induction and maintenance of remission and steroid free remission, these agents are widely used as third line therapy. The benefits are less clear in fistulising disease at induction but useful in maintenance. Despite initial concerns, there is no clear increased risk in infection related morbidity although long term risk of malignancy remains to be defined (&lt;A href="#peyrin"&gt;Peyrin-Biroulet et al.&lt;/A&gt;). The long term data for anti-TNF therapy in UC are less convincing and it is not currently recommended (&lt;A href="https://rmsadmin.library.nhs.uk/admin/wizards/articles/wilhelm" target="_blank"&gt;Wilhelm&lt;/A&gt;).&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Articles:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=peyrin&gt;&lt;/A&gt;Peyrin-Biroulet, L., Deltenre, P., de, S. N., Branche, J., Sandborn, W. J., &amp;amp; Colombel, J. F. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=309191" target="_blank"&gt;Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials.&lt;/A&gt; &lt;I&gt;Clinical Gastroenterology &amp;amp; Hepatology&lt;/I&gt;. 6(6):644-653.&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;B&gt;Reviewer's comments:&lt;/B&gt; Anti-TNF therapy is superior to placebo for induction and maintenance of remission and steroid free remission in Crohn’s disease. In fistulising disease the benefit is less in the short term but it is superior to placebo as maintenance. There is no increase in mortality associated with anti-TNF use or morbidity from serious infections; the risk of later malignancy remains unclear.&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;A name=wilhelm&gt;&lt;/A&gt;Wilhelm, S. M., McKenney, K. A., Rivait, K. N., &amp;amp; Kale-Pradhan, P. B. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=309192" target="_blank"&gt;A review of infliximab use in ulcerative colitis.&lt;/A&gt; &lt;I&gt;Clinical Therapeutics&lt;/I&gt;, 30(2):223-30.&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;B&gt;Reviewer's comments:&lt;/B&gt; Initial small scale studies showed no benefit for use of infliximab in moderate to severe steroid refractory UC. The ACT 1 &amp;amp; 2 studies demonstrated benefit over placebo but long term follow up data is lacking currently. NICE have not recommended the use of infliximab in this setting.&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #33cccc"&gt;Inflammatory Bowel Disease Annual Evidence Update 2009&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #99cc00" ?&gt;
&lt;P&gt;&lt;A href="nelh:309257:1" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308811:1" name=internalLink&gt;Aetiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308884:1" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:308897:1" name=internalLink&gt;Aminosalicylates&lt;/A&gt; | &lt;A href="nelh:308900:1" name=internalLink&gt;Biotics and nutritional therapies&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308904:1" name=internalLink&gt;&lt;B&gt;Corticosteroids and immunosuppressants&lt;/B&gt;&lt;/A&gt; | &lt;A href="nelh:308916:1" name=internalLink&gt;Other interventions&lt;/A&gt; | &lt;A href="nelh:308924:1" name=internalLink&gt;General and miscellaneous&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;Adverse events and risk factors &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:308889:1" name=internalLink&gt;Medication&lt;/A&gt; | &lt;A href="nelh:308957:1" name=internalLink&gt;Other&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:308891:1" name=internalLink&gt;Miscellaneous&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308947:1" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:309258:1" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:309001:1" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>308924</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=308924]]&gt;</url>
    <title>2009 Annual Evidence Update on Inflammatory Bowel Disease - Treatment | General reviews and miscellaneous topics in treatment</title>
    <publicationDate>2009-03-23T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,MICROSCOPIC COLITIS,CROHN'S DISEASE,PROCTITIS &amp; DISTIL COLITIS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Inflammatory Bowel Disease - Treatment | General reviews and miscellaneous topics in treatment&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P style="COLOR: #99cc00; FONT-SIZE: 13pt"&gt;&lt;B&gt;&lt;U&gt;Cochrane reviews:&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The following Cochrane reviews were updated this year:&lt;/P&gt;
&lt;P&gt;Chande, N., McDonald, J.W.D., &amp;amp; MacDonald, J.K. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=238087" target="_blank"&gt;Interventions for treating collagenous colitis.&lt;/A&gt; &lt;I&gt;Cochrane Database of Systematic Reviews&lt;/I&gt; 2008, Issue 2. Art. No.: CD003575. DOI: 10.1002/14651858.CD003575.pub5.&lt;/P&gt;
&lt;P&gt;Chande, N., McDonald, J.W.D., &amp;amp; MacDonald, J.K. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=239251" target="_blank"&gt;Interventions for treating lymphocytic colitis.&lt;/A&gt; &lt;I&gt;Cochrane Database of Systematic Reviews&lt;/I&gt; 2008, Issue 2. Art. No.: CD006096. DOI: 10.1002/14651858.CD006096.pub3.&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00; FONT-SIZE: 13pt"&gt;&lt;B&gt;&lt;U&gt;Others:&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;Reviewed by Dr Tim Orchard, Consultant Gastroenterologist, St Mary's Hospital London and Reader in Gastroenterology, Imperial College London.&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;Advances in the treatment of IBD have focused on new ways to use current drug therapies, maximizing patient adherence, new treatment algorithms and emerging treatments, many of which are biologic. &lt;A href="#hawthorne"&gt;Hawthorne et al.&lt;/A&gt; have highlighted the importance of adherence and the factors that may be altered, including dosing regimens and allowing patients more control by using self-management plans. In addition they highlight the importance of a patient’s health beliefs in determining adherence, and speculate that methods of altering this may be successful in increasing adherence.&lt;/P&gt;
&lt;P&gt;&lt;A href="#hommel"&gt;Hommel et al.&lt;/A&gt; look at the adherence problem in paediatric populations where there appears to be poor data. They acknowledge the importance of adherence in IBD treatment and point out the need for further work, in particular to see how adherence changes in children with time and into adolescence. They also highlight the need for more formal and validated methods of measuring adherence. &lt;A href="#heuschkel"&gt;Heuschkel et al.&lt;/A&gt; reviewed the important subject of optimizing growth in children with IBD, and conclude that the best way of doing this is optimizing management of the underlying IBD. This should include regular measurement of growth along with strategies to avoid steroid use such as using exclusive elemental diets and early use of immune modulators and biological therapy.&lt;/P&gt;
&lt;P&gt;The standard management of Crohn’s disease, including the place of biological therapy and the importance of well set up infrastructure, are highlighted by &lt;A href="#cummings"&gt;Cummings et al.&lt;/A&gt;, whilst &lt;A href="#lakatos"&gt;Lakatos and Lakatos&lt;/A&gt; concentrate on the subject of ulcerative proctitis (UP) – an important subset of ulcerative colitis patients. They conclude that topical therapy is most effective for both induction and maintenance of remission, although long term use of rectal therapies is often compromised by poor adherence. 5-ASA is the standard first line drug, although steroids, immune modulators and surgery may be required. There is little evidence specifically in UP patients for the efficacy of immune modulators and biologics although it seems logical to use them. &lt;A href="#panaccione"&gt;Panaccione et al.&lt;/A&gt; demonstrate how the era of biological therapy has changed the treatment paradigms in IBD, with mucosal healing becoming a major goal. This has lead to the concept of top-down therapy where biologics and immune suppressants are used early. The problem with this is that a number of patients may be significantly overtreated, and so a strategy to select patients at high risk is suggested. &lt;A href="#ng"&gt;Ng and Kamm&lt;/A&gt; discuss the current and future biologic and other treatments in a comprehensive review of future directions highlighting, in addition to current therapies, new biological drugs and other therapeutic avenues including probiotics and drugs to alter gut barrier function. &lt;A href="#irving"&gt;Irving et al.&lt;/A&gt; point out the importance of potential interactions between medications in IBD, and have devised a very useful classification based on the frequency and importance of the major interactions seen.&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Articles:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Chande, N., Macdonald, J.K., &amp;amp; MacDonald, J.W.D. (2009) &lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=310848" target="_blank"&gt;Interventions for treating microscopic colitis: a Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Review Group systematic review of randomized trials.&lt;/A&gt; &lt;EM&gt;American Journal of Gastroenterology&lt;/EM&gt;, 104(1):235-241.&lt;/P&gt;
&lt;P&gt;&lt;A name=cummings&gt;&lt;/A&gt;Cummings, J., Keshav, S., &amp;amp; Travis, S. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=309202" target="_blank"&gt;Medical management of Crohn's disease.&lt;/A&gt; &lt;I&gt;BMJ&lt;/I&gt;, 336(7652):1062-1066.&lt;/P&gt;
&lt;P&gt;&lt;A name=hawthorne&gt;&lt;/A&gt;Hawthorne, A. B., Rubin, G., &amp;amp; Ghosh, S. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=281300" target="_blank"&gt;Review article: medication non-adherence in ulcerative colitis - strategies to improve adherence with mesalazine and other maintenance therapies.&lt;/A&gt; &lt;I&gt;Alimentary Pharmacology &amp;amp; Therapeutics&lt;/I&gt;, 27(12):1157-1166.&lt;/P&gt;
&lt;P&gt;&lt;A name=heuschkel&gt;&lt;/A&gt;Heuschkel, R., Salvestrini, C., Beattie, R. M., Hildebrand, H., Walters, T., &amp;amp; Griffiths, A. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=309206" target="_blank"&gt;Guidelines for the management of growth failure in childhood inflammatory bowel disease.&lt;/A&gt; &lt;I&gt;Inflammatory Bowel Diseases&lt;/I&gt;, 14(6):839-849.&lt;/P&gt;
&lt;P&gt;Higgins, P.D.R., Rubin, D.T., Kaulback, K., Schoenfield, P.S., &amp;amp; Kane, S.V. (2009) &lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=310844" target="_blank"&gt;Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares.&lt;/A&gt; &lt;EM&gt;Alimentary Pharmacology &amp;amp; Therapeutics&lt;/EM&gt;, 29(3):247-257.&lt;/P&gt;
&lt;P&gt;&lt;A name=hommel&gt;&lt;/A&gt;Hommel, K. A., Mackner, L. M., Denson, L. A., &amp;amp; Crandall, W. V. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=309208" target="_blank"&gt;Treatment regimen adherence in pediatric gastroenterology.&lt;/A&gt; &lt;I&gt;Journal of Pediatric Gastroenterology &amp;amp; Nutrition&lt;/I&gt;, 47(5):526-543.&lt;/P&gt;
&lt;P&gt;&lt;A name=irving&gt;&lt;/A&gt;Irving, P. M., Shanahan, F., &amp;amp; Rampton, D. S. (2008)&lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=309211" target="_blank"&gt; Drug interactions in inflammatory bowel disease&lt;/A&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=309211" target="_blank"&gt;.&lt;/A&gt; &lt;I&gt;American Journal of Gastroenterology&lt;/I&gt;, 103(1):207-219.&lt;/P&gt;
&lt;P&gt;&lt;A name=lakatos&gt;&lt;/A&gt;Lakatos, P. L. &amp;amp; Lakatos, L. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=309212" target="_blank"&gt;Ulcerative proctitis: a review of pharmacotherapy and management.&lt;/A&gt; &lt;I&gt;Expert Opinion on Pharmacotherapy&lt;/I&gt;, 9(5):741-749.&lt;/P&gt;
&lt;P&gt;Lichtenstein, G.R., Hanauer, S.B., Sandborn, W.J., &amp;amp; The Practice Parameters Committee of the American College of Gastroenterology (2009) &lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=310832" target="_blank"&gt;Management of Crohn's disease in adults.&lt;/A&gt; &lt;EM&gt;American Journal of Gastroenterology&lt;/EM&gt;, 104(2):465-483.&lt;/P&gt;
&lt;P&gt;&lt;A name=ng&gt;&lt;/A&gt;Ng, S. C. &amp;amp; Kamm, M. A. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=309215" target="_blank"&gt;Review article: new drug formulations, chemical entities and therapeutic approaches for the management of ulcerative colitis.&lt;/A&gt; &lt;I&gt;Alimentary Pharmacology &amp;amp; Therapeutics&lt;/I&gt;, 28(7):815-829.&lt;/P&gt;
&lt;P&gt;&lt;A name=panaccione&gt;&lt;/A&gt;Panaccione, R., Rutgeerts, P., Sandborn, W. J., Feagan, B., Schreiber, S., &amp;amp; Ghosh, S. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=309216" target="_blank"&gt;Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease.&lt;/A&gt; &lt;I&gt;Alimentary Pharmacology &amp;amp; Therapeutics&lt;/I&gt;, 28(6):674-688.&lt;/P&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #33cccc"&gt;Inflammatory Bowel Disease Annual Evidence Update 2009&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #99cc00" ?&gt;
&lt;P&gt;&lt;A href="nelh:309257:1" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308811:1" name=internalLink&gt;Aetiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308884:1" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:308897:1" name=internalLink&gt;Aminosalicylates&lt;/A&gt; | &lt;A href="nelh:308900:1" name=internalLink&gt;Biotics and nutritional therapies&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308904:1" name=internalLink&gt;Corticosteroids and immunosuppressants&lt;/A&gt; | &lt;A href="nelh:308916:1" name=internalLink&gt;Other interventions&lt;/A&gt; | &lt;A href="nelh:308924:1" name=internalLink&gt;&lt;B&gt;General and miscellaneous&lt;/B&gt;&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;Adverse events and risk factors &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:308889:1" name=internalLink&gt;Medication&lt;/A&gt; | &lt;A href="nelh:308957:1" name=internalLink&gt;Other&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:308891:1" name=internalLink&gt;Miscellaneous&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308947:1" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:309258:1" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:309001:1" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>308916</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=308916]]&gt;</url>
    <title>2009 Annual Evidence Update on Inflammatory Bowel Disease - Treatment | Other interventions</title>
    <publicationDate>2009-03-23T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Inflammatory Bowel Disease - Treatment | Other interventions&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P style="COLOR: #99cc00; FONT-SIZE: 13pt"&gt;&lt;B&gt;&lt;U&gt;Cochrane reviews:&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The following Cochrane reviews were updated this year:&lt;/P&gt;
&lt;P&gt;Chande, N., McDonald, J.W.D., &amp;amp; MacDonald, J.K. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=283718" target="_blank"&gt;Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis.&lt;/A&gt; &lt;I&gt;Cochrane Database of Systematic Reviews&lt;/I&gt; 2008, Issue 2. Art. No.: CD006774. DOI: 10.1002/14651858.CD006774.pub2.&lt;/P&gt;
&lt;P&gt;Seow, C.H., Benchimol, E.I., Griffiths, A.M., Steinhart, A.H. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=293665" target="_blank"&gt;Type I interferons for induction of remission in ulcerative colitis.&lt;/A&gt; &lt;I&gt;Cochrane Database of Systematic Reviews&lt;/I&gt; 2008, Issue 3. Art. No.: CD006790. DOI: 10.1002/14651858.CD006790.pub2.&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00; FONT-SIZE: 13pt"&gt;&lt;B&gt;&lt;U&gt;Other reviews:&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P style="COLOR: #33cccc; FONT-SIZE: 12pt"&gt;&lt;B&gt;Placebo response&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;Reviewed by Brian McKaig, Consultant Gastroenterologist, New Cross Hospital, Wolverhampton&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;These studies highlight the problems with trials in UC with a very variable placebo response. Care should be taken to examine the placebo response when interpreting clinical trials in UC, as there is significant variation in response with no reliable identifiable variables to predict outcome.&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Articles:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Garud, S., Brown, A., Cheifetz, A., Levitan, E. B., &amp;amp; Kelly, C. P. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=281300" target="_blank"&gt;Meta-analysis of the placebo response in ulcerative colitis.&lt;/A&gt; &lt;I&gt;Digestive Diseases &amp;amp; Sciences&lt;/I&gt;, 53(4):875-891.&lt;/P&gt;
&lt;P&gt;Pascua, M., Su, C., Lewis, J. D., Brensinger, C., &amp;amp; Lichtenstein, G. R. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=309196" target="_blank"&gt;Meta-analysis: factors predicting post-operative recurrence with placebo therapy in patients with Crohn's disease.&lt;/A&gt; &lt;I&gt;Alimentary Pharmacology &amp;amp; Therapeutics&lt;/I&gt;, 28(5):545-556.&lt;/P&gt;
&lt;P&gt;Renna, S., Camma, C., Modesto, I., Cabibbo, G., Scimeca, D., Civitavecchia, G., Mocciaro, F., Orlando, A., Enea, M., &amp;amp; Cottone, M. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=309199" target="_blank"&gt;Meta-analysis of the placebo rates of clinical relapse and severe endoscopic recurrence in postoperative Crohn's disease.&lt;/A&gt; &lt;I&gt;Gastroenterology&lt;/I&gt;, 135(5):1500-1509.&lt;/P&gt;
&lt;P&gt;Tine, F., Rossi, F., Sferrazza, A., Orlando, A., Mocciaro, F., Scimeca, D., Olivo, M., &amp;amp; Cottone, M. (2008) &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=309201" target="_blank"&gt;Meta-analysis: remission and response from control arms of randomized trials of biological therapies for active luminal Crohn's disease.&lt;/A&gt; &lt;I&gt;Alimentary Pharmacology &amp;amp; Therapeutics&lt;/I&gt;, 27(12):1210-1223.&lt;/P&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #33cccc"&gt;Inflammatory Bowel Disease Annual Evidence Update 2009&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #99cc00" ?&gt;
&lt;P&gt;&lt;A href="nelh:309257:1" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308811:1" name=internalLink&gt;Aetiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308884:1" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:308897:1" name=internalLink&gt;Aminosalicylates&lt;/A&gt; | &lt;A href="nelh:308900:1" name=internalLink&gt;Biotics and nutritional therapies&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308904:1" name=internalLink&gt;Corticosteroids and immunosuppressants&lt;/A&gt; | &lt;A href="nelh:308916:1" name=internalLink&gt;&lt;B&gt;Other interventions&lt;/B&gt;&lt;/A&gt; | &lt;A href="nelh:308924:1" name=internalLink&gt;General and miscellaneous&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;Adverse events and risk factors &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:308889:1" name=internalLink&gt;Medication&lt;/A&gt; | &lt;A href="nelh:308957:1" name=internalLink&gt;Other&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:308891:1" name=internalLink&gt;Miscellaneous&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308947:1" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:309258:1" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:309001:1" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>309258</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=309258]]&gt;</url>
    <title>2009 Annual Evidence Update on Inflammatory Bowel Disease - Uncertainties</title>
    <publicationDate>2009-03-23T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,MICROSCOPIC COLITIS,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Inflammatory Bowel Disease - Uncertainties&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;As part of the process of conducting this Annual Evidence Update, we examined the included papers for treatment uncertainties that could be added to the UK Database of Uncertainties about the Effects of Treatments (&lt;A href="http://www.library.nhs.uk/duets/" target="_blank"&gt;UK DUETs&lt;/A&gt;), a new project to create a central database of such uncertainties. The following list, which has been submitted to the database, is the results of our search. Click on each title for more information.&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/duets/ViewResource.aspx?resID=309666" target="_blank"&gt;Analimumab for fistulizing Crohn's disease&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/duets/ViewResource.aspx?resID=309676" target="_blank"&gt;Anti-TNF therapy in inflammatory bowel disease during conception&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/duets/ViewResource.aspx?resID=309632" target="_blank"&gt;Bismuth subsalicylate for lymphocytic colitis or collagenous colitis&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/duets/ViewResource.aspx?resID=309615" target="_blank"&gt;Budesonide for lymphocytic colitis&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/duets/ViewResource.aspx?resID=309636" target="_blank"&gt;Cholestyramine for lymphocytic colitis or collagenous colitis&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/duets/ViewResource.aspx?resID=309668" target="_blank"&gt;Comparison of the efficacy of different anti-TNF agents in Crohn's disease&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/duets/ViewResource.aspx?resID=309671" target="_blank"&gt;Infliximab for induction of remission of ulcerative colitis&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/duets/ViewResource.aspx?resID=309645" target="_blank"&gt;Mesalamine for lymphocytic colitis or collagenous colitis&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/duets/ViewResource.aspx?resID=309627" target="_blank"&gt;Prednisolone for collagenous colitis&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/duets/ViewResource.aspx?resID=309703" target="_blank"&gt;Risk of postoperative complications in patients with inflammatory bowel disease undergoing abdominal surgery after treatment with steroids or biological agents&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/duets/ViewResource.aspx?resID=309594" target="_blank"&gt;Tacrolimus for induction of remission in refractory ulcerative colitis&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/duets/ViewResource.aspx?resID=309678" target="_blank"&gt;Treatment compliance in ulcerative colitis patients treated with MMX mesalamine&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/duets/ViewResource.aspx?resID=309605" target="_blank"&gt;Tumour necrosis factor-alpha antibody for early Crohn's disease&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/duets/ViewResource.aspx?resID=309601" target="_blank"&gt;Tumour necrosis factor-alpha antibody for maintenance of remission in Crohn's disease in paediatric patients&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/duets/ViewResource.aspx?resID=309604" target="_blank"&gt;Tumour necrosis factor-alpha antibody for maintenance of remission in Crohn's disease in pregnant patients&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #33cccc"&gt;Inflammatory Bowel Disease Annual Evidence Update 2009&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #99cc00" ?&gt;
&lt;P&gt;&lt;A href="nelh:309257:1" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308811:1" name=internalLink&gt;Aetiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308884:1" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:308897:1" name=internalLink&gt;Aminosalicylates&lt;/A&gt; | &lt;A href="nelh:308900:1" name=internalLink&gt;Biotics and nutritional therapies&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308904:1" name=internalLink&gt;Corticosteroids and immunosuppressants&lt;/A&gt; | &lt;A href="nelh:308916:1" name=internalLink&gt;Other interventions&lt;/A&gt; | &lt;A href="nelh:308924:1" name=internalLink&gt;General and miscellaneous&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;Adverse events and risk factors &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:308889:1" name=internalLink&gt;Medication&lt;/A&gt; | &lt;A href="nelh:308957:1" name=internalLink&gt;Other&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:308891:1" name=internalLink&gt;Miscellaneous&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:308947:1" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:309258:1" name=internalLink&gt;&lt;B&gt;Uncertainties&lt;/B&gt;&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:309001:1" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>395141</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=395141]]&gt;</url>
    <title>2010 Annual Evidence Update on Alcoholic Liver Disease - Adverse effects</title>
    <publicationDate>2010-12-06T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,ALCOHOLIC LIVER DISEASE,RECENT ADDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Alcoholic Liver Disease - Adverse effects&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;I&gt;Reviewed by Andrew Austin, Consultant Hepatologist, Royal Derby Hospital&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Randomised controlled trials:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:396343:0" name=internalLink&gt;Dart et al.&lt;/A&gt; explore the concerns previously expressed mainly in North America about the safety of paracetamol in therapeutic doses in patients with liver disease.&amp;nbsp; They identified a group thought to be at the highest risk of paracetamol toxicity given their recent alcohol consumption.&amp;nbsp; No patients had decompensated liver disease but liver histology was not a requirement.&amp;nbsp; Some patients had concomitant hepatitis C infection.&amp;nbsp; Both newly abstinent alcohol misusers and controls experienced minor elevations of ALT over the 5 days study period but no changes in INR or bilirubin.&amp;nbsp; The authors conclude that paracetamol is safe for short term administration in this group of at risk patients.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;List of articles:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Dart, R. C., Green, J. L., Kuffner, E. K., Heard, K., Sproule, B., &amp;amp; Brands, B. 2010. &lt;A href="nelh:396343:0" name=internalLink&gt;The effects of paracetamol (acetaminophen) on hepatic tests in patients who chronically abuse alcohol - a randomized study&lt;/A&gt;. &lt;EM&gt;Alimentary Pharmacology &amp;amp; Therapeutics&lt;/EM&gt; 32(3) 478-486.&lt;/P&gt;
&lt;P&gt;&lt;A name=bartels&gt;&lt;/A&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="COLOR: #ffffff; BACKGROUND-COLOR: #306754; TEXT-ALIGN: center"&gt;Alcoholic Liver Disease Annual Evidence Update 2010&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BACKGROUND-COLOR: #addfff; TEXT-ALIGN: center"&gt;
&lt;P&gt;&lt;A href="nelh:395097:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:395151:0" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:395145:0" name=internalLink&gt;Treatment&lt;/A&gt; &lt;BR&gt;&lt;B&gt;Adverse effects&lt;/B&gt; &lt;BR&gt;&lt;A href="nelh:395155:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:396443:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:395153:0" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>395151</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=395151]]&gt;</url>
    <title>2010 Annual Evidence Update on Alcoholic Liver Disease - Epidemiology</title>
    <publicationDate>2010-12-06T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,ALCOHOLIC LIVER DISEASE,RECENT ADDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Alcoholic Liver Disease - Epidemiology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;I&gt;Reviewed by Andrew Austin, Consultant Hepatologist, Royal Derby Hospital&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:396346:0" name=internalLink&gt;Marcos et al.&lt;/A&gt; report a systematic evaluation (metananalysis) of the risk of alcoholic liver disease or alcoholism related to possession of the A allele of both the -238G&amp;gt;A and -308G&amp;gt;A polymorphism of the tumour necrosis factor alpha (TNFA) gene.&amp;nbsp; Both alleles have been linked to higher TNFA production, a cytokine implicated in the pathogenesis of severe alcoholic hepatitis.&amp;nbsp;&amp;nbsp;The former but not the latter change was associated with an increased risk of alcoholic liver disease.&amp;nbsp; Although an important observation, at present therapies aimed at reducing production of (pentoxifylline) or neutralising (infliximab) TNFA have shown only limited clinical efficacy.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;List of articles:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Marcos, M., Gomez-Munuera, M., Pastor, I., Gonzalez-Sarmiento, R., &amp;amp; Laso, F. J. (2009). &lt;A href="nelh:396346:0" name=internalLink&gt;Tumor necrosis factor polymorphisms and alcoholic liver disease: a HuGE review and meta-analysis&lt;/A&gt;. &lt;EM&gt;American Journal of Epidemiology&lt;/EM&gt; 170(8): 948-956.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;A name=bartels&gt;&lt;/A&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="COLOR: #ffffff; BACKGROUND-COLOR: #306754; TEXT-ALIGN: center"&gt;Alcoholic Liver Disease Annual Evidence Update 2010&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BACKGROUND-COLOR: #addfff; TEXT-ALIGN: center"&gt;
&lt;P&gt;&lt;A href="nelh:395097:0" name=internalLink&gt;Introduction&lt;/A&gt; &lt;BR&gt;&lt;STRONG&gt;Epidemiology&lt;/STRONG&gt;&lt;BR&gt;&lt;A href="nelh:395145:0" name=internalLink&gt;Treatment&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:395141:0" name=internalLink&gt;Adverse effects&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:395155:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:396443:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:395153:0" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>395155</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=395155]]&gt;</url>
    <title>2010 Annual Evidence Update on Alcoholic Liver Disease - Foreign language articles</title>
    <publicationDate>2010-12-06T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,ALCOHOLIC LIVER DISEASE,RECENT ADDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Alcoholic Liver Disease - Foreign language articles&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;The following articles were identified by the search as being potentially relevant to the AEU, but were not sent out for appraisal because the full text is in a language other than English. They are included here for interest, and for the sake of completeness.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Chae, H. B. (2009). &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19458463" target="_blank"&gt;Alcoholic liver disease&lt;/A&gt;. &lt;EM&gt;Korean Journal of Gastroenterology/Taehan Sohwagi Hakhoe Chi&lt;/EM&gt; 53(5): 275-282.&lt;BR&gt;&lt;STRONG&gt;Language:&lt;/STRONG&gt; Korean&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Mathurin, P. (2009). &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19729258" target="_blank"&gt;Alcohol and the liver&lt;/A&gt;. &lt;EM&gt;Gastroenterologie Clinique et Biologique&lt;/EM&gt; 33(8-9): 840-849. &lt;BR&gt;&lt;STRONG&gt;Language:&lt;/STRONG&gt; French&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="COLOR: #ffffff; BACKGROUND-COLOR: #306754; TEXT-ALIGN: center"&gt;Alcoholic Liver Disease Annual Evidence Update 2010&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BACKGROUND-COLOR: #addfff; TEXT-ALIGN: center"&gt;
&lt;P&gt;&lt;A href="nelh:395097:0" name=internalLink&gt;Introduction&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:395151:0" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:395145:0" name=internalLink&gt;Treatment&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:395141:0" name=internalLink&gt;Adverse effects&lt;/A&gt; &lt;BR&gt;&lt;B&gt;Foreign language articles&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:396443:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:395153:0" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>395097</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=395097]]&gt;</url>
    <title>2010 Annual Evidence Update on Alcoholic Liver Disease - Introduction</title>
    <publicationDate>2010-12-06T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ MENTAL HEALTH,ADULT CONDITIONS,ALCOHOL MISUSE,GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,ALCOHOLIC LIVER DISEASE,RECENT ADDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Alcoholic Liver Disease - Introduction&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;The 2010 Annual Evidence Update on Alcoholic Liver Disease, our second on this topic, highlights knowledge published since the 2009 Update on the diagnosis, treatment and management of alcoholic liver disease. By presenting this information in an easily accessible format and with additional expert commentary, we will provide busy healthcare professionals with the information they need to keep up to date. &lt;/P&gt;
&lt;P&gt;A summary of the methods used for retrieving and evaluating the evidence can be found &lt;A href="nelh:332189:0" name=internalLink&gt;&lt;/A&gt;&lt;A href="nelh:395153:0" name=internalLink&gt;here&lt;/A&gt;&lt;/A&gt;. The evidence has been split into sections as follows:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:395151:0" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:395145:0" name=internalLink&gt;Treatment &lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:395141:0" name=internalLink&gt;Adverse effects&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Click on the sections above to find links to critically appraised systematic reviews, expert commentaries and other information of interest, or download the &lt;A href="http://www.library.nhs.uk/SpecialistLibrarySearch/Download.aspx?resID=395097" target="_blank"&gt;pdf version&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;We also have provided a list of &lt;A href="nelh:332187:0" name=internalLink&gt;&lt;/A&gt;treatment uncertainties&lt;/A&gt;, taken from the articles included in the AEU. These also feature in the &lt;A href="http://www.library.nhs.uk/duets/" target="_blank"&gt;UK DUETs &lt;/A&gt;database.&lt;/P&gt;
&lt;P&gt;This year's update has been put together by the NHS Evidence - gastroenterology and liver diseases Project Team, with expert advice and commentaries provided by our liver disease topic advisors. These are:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Andrew Austin, Consultant Hepatologist, Royal Derby Hospital&lt;/LI&gt;
&lt;LI&gt;Marsha Morgan, Consultant Physician, Royal Free Hospital, London&lt;/LI&gt;
&lt;LI&gt;Martyn Caplin, Clinical Lead for the Gastroenterology &amp;amp; Liver Diseases specialist collection&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;We would&amp;nbsp;like to thank the topic advisors for their generous help and support with this project.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="COLOR: #ffffff; BACKGROUND-COLOR: #306754; TEXT-ALIGN: center"&gt;Alcoholic Liver Disease Annual Evidence Update 2010&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BACKGROUND-COLOR: #addfff; TEXT-ALIGN: center"&gt;
&lt;P&gt;&lt;B&gt;Introduction&lt;/B&gt;&amp;nbsp;&lt;BR&gt;&lt;A href="nelh:395151:0" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:395145:0" name=internalLink&gt;Treatment&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:395141:0" name=internalLink&gt;Adverse effects&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:395155:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:396443:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:395153:0" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>395153</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=395153]]&gt;</url>
    <title>2010 Annual Evidence Update on Alcoholic Liver Disease - Methods for retrieving and evaluating the evidence</title>
    <publicationDate>2010-12-06T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,ALCOHOLIC LIVER DISEASE,RECENT ADDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Alcoholic Liver Disease - Methods for retrieving and evaluating the evidence&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;This is the second annual evidence update we have performed on the topic of alcoholic liver disease. We searched for material published since the date of the last review. We searched for guidelines and systematic reviews and randomised controlled trials. We were primarily looking for articles in English; however, foreign language articles were included in the search process. As translations for these articles were not available, the article titles have been listed separately. &lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #306754"&gt;&lt;B&gt;Search strategy:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The following resources were searched: 
&lt;UL&gt;
&lt;LI&gt;MEDLINE&lt;/LI&gt;
&lt;LI&gt;EMBASE&lt;/LI&gt;
&lt;LI&gt;CINAHL&lt;/LI&gt;
&lt;LI&gt;PsycINFO&lt;/LI&gt;
&lt;LI&gt;AMED&lt;/LI&gt;
&lt;LI&gt;NHS Evidence&lt;/LI&gt;
&lt;LI&gt;NHS Evidence Specialist Collections &lt;/LI&gt;
&lt;LI&gt;Database of Abstracts of Reviews of Effects &lt;/LI&gt;
&lt;LI&gt;NHS Economic Evaluation Database&lt;/LI&gt;
&lt;LI&gt;HTA Database&lt;/LI&gt;&lt;/UL&gt;The search strategy for MEDLINE, which was modified for the other resources, appears &lt;A href="#strategy"&gt;below&lt;/A&gt;. We combined this with modified SIGN systematic review and randomised controlled trial &lt;A href="#filters"&gt;filters&lt;/A&gt; in all cases except the searches of NHS Evidence, the Specialist Collections, DARE, NHS EED and HTA (because they consist entirely of the types of publication that we were interested in). 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;After de-duplication 474 articles were retrieved.&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #306754"&gt;&lt;B&gt;Inclusion and exclusion criteria:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Included articles had to meet the following criteria:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Publication types: systematic review, consensus report, guideline, protocol, care pathway, economic evaluation, health technology assessment, randomised controlled trial. &lt;/LI&gt;
&lt;LI&gt;Published since the date of the previous review&lt;/LI&gt;
&lt;LI&gt;Main condition under investigation was fatty liver disease, hepatitis, cirrhosis, hepatocellular carcinoma, liver failure, ascites or fibrosis, or main procedure under investigation was liver resection or liver transplantation, and either: 
&lt;UL&gt;
&lt;LI&gt;Alcohol was the aetiology of liver disease in all patients under investigation&lt;/LI&gt;
&lt;LI&gt;Alcohol was the aetiology of liver disease in a significant proportion of patients under investigation&lt;/LI&gt;
&lt;LI&gt;The paper examined different aetiologies of liver disease separately, and alcohol was one of those aetiologies &lt;/LI&gt;&lt;/UL&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Once the inclusion criteria were applied, 14 articles were left. Of these, 2 were foreign language articles and 2 were guidelines.&lt;/P&gt;
&lt;P&gt;The&amp;nbsp;guidelines were automatically included in the Evidence Update. The foreign language studies were not sent out to reviewers because of translation difficulties, but are listed in a separate section of the Evidence Update. This left&amp;nbsp;10 articles to be sent to our reviewers for appraisal.&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #306754"&gt;&lt;B&gt;Critical appraisal process:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Before sending out, the articles were divided into categories as follows:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Epidemiology&lt;/LI&gt;
&lt;LI&gt;Treatment&lt;/LI&gt;
&lt;LI&gt;Adverse effects &lt;/LI&gt;
&lt;LI&gt;Risk factors and prognosis &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Using these categories as a guide, the papers were divided up and sent to our reviewers. The reviewers then appraised the articles for their validity, relevance and rigour. Following the receipt of their comments, we included in the Evidence Update&amp;nbsp;5 articles that were deemed to meet the standards.&lt;BR&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #306754"&gt;&lt;B&gt;AEU process flowchart:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;/IMG&gt;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/gastroliver/contentID395153/nelhImp_0000_Flowchart.JPG" name=nelh_tempImage0&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P style="COLOR: #306754"&gt;&lt;B&gt;&lt;A name=strategy&gt;&lt;/A&gt;MEDLINE search strategy&lt;/B&gt;&lt;/P&gt;
&lt;TABLE style="TABLE-LAYOUT: fixed"&gt;
&lt;TBODY&gt;
&lt;TR style="FONT-SIZE: 7pt; FONT-FAMILY: Courier,monospace"&gt;
&lt;TD style="BORDER-RIGHT: #000000 thin solid; PADDING-RIGHT: 5pt; BORDER-TOP: #000000 thin solid; PADDING-LEFT: 5pt; PADDING-BOTTOM: 5pt; BORDER-LEFT: #000000 thin solid; PADDING-TOP: 5pt; BORDER-BOTTOM: #000000 thin solid" ?&gt;&lt;STRONG&gt;1&lt;/STRONG&gt; exp Liver Diseases, Alcoholic/&lt;BR&gt;&lt;STRONG&gt;2&lt;/STRONG&gt; Alcohol Drinking/&lt;BR&gt;&lt;STRONG&gt;3&lt;/STRONG&gt; alcohol*.ti,ab.&lt;BR&gt;&lt;STRONG&gt;4&lt;/STRONG&gt; achol*.ti,ab.&lt;BR&gt;&lt;STRONG&gt;5&lt;/STRONG&gt; alchol*.ti,ab.&lt;BR&gt;&lt;STRONG&gt;6&lt;/STRONG&gt; 3 or 2 or 4 or 5&lt;BR&gt;&lt;STRONG&gt;7&lt;/STRONG&gt; fatty liver/&lt;BR&gt;&lt;STRONG&gt;8&lt;/STRONG&gt; fatty liver.ti,ab.&lt;BR&gt;&lt;STRONG&gt;9&lt;/STRONG&gt; steatosis.ti,ab.&lt;BR&gt;&lt;STRONG&gt;10&lt;/STRONG&gt; hepatosteatosis.ti,ab.&lt;BR&gt;&lt;STRONG&gt;11&lt;/STRONG&gt; hepatitis/&lt;BR&gt;&lt;STRONG&gt;12&lt;/STRONG&gt; hepatitis, chronic/&lt;BR&gt;&lt;STRONG&gt;13&lt;/STRONG&gt; hepatitis.ti,ab.&lt;BR&gt;&lt;STRONG&gt;14&lt;/STRONG&gt; steatohepatitis.ti,ab.&lt;BR&gt;&lt;STRONG&gt;15&lt;/STRONG&gt; hepatitides.ti,ab.&lt;BR&gt;&lt;STRONG&gt;16&lt;/STRONG&gt; (liver adj3 inflamm*).ti,ab.&lt;BR&gt;&lt;STRONG&gt;17&lt;/STRONG&gt; Liver Cirrhosis/&lt;BR&gt;&lt;STRONG&gt;18&lt;/STRONG&gt; liver injur*.ti,ab.&lt;BR&gt;&lt;STRONG&gt;19&lt;/STRONG&gt; liver.ti,ab.&lt;BR&gt;&lt;STRONG&gt;20&lt;/STRONG&gt; hepat*.ti,ab.&lt;BR&gt;&lt;STRONG&gt;21&lt;/STRONG&gt; laennec*.ti,ab.&lt;BR&gt;&lt;STRONG&gt;22&lt;/STRONG&gt; 19 or 20 or 21&lt;BR&gt;&lt;STRONG&gt;23&lt;/STRONG&gt; cirrho*.ti,ab.&lt;BR&gt;&lt;STRONG&gt;24&lt;/STRONG&gt; fibros?s.ti,ab.&lt;BR&gt;&lt;STRONG&gt;25&lt;/STRONG&gt; ascites.ti,ab.&lt;BR&gt;&lt;STRONG&gt;26&lt;/STRONG&gt; Ascites/&lt;BR&gt;&lt;STRONG&gt;27&lt;/STRONG&gt; 23 or 24 or 25 or 26&lt;BR&gt;&lt;STRONG&gt;28&lt;/STRONG&gt; 27 and 22&lt;BR&gt;&lt;STRONG&gt;29&lt;/STRONG&gt; hepatofibrosis.ti,ab.&lt;BR&gt;&lt;STRONG&gt;30&lt;/STRONG&gt; exp Liver Failure/&lt;BR&gt;&lt;STRONG&gt;31&lt;/STRONG&gt; liver failure.ti,ab.&lt;BR&gt;&lt;STRONG&gt;32&lt;/STRONG&gt; hepatic failure.ti,ab.&lt;BR&gt;&lt;STRONG&gt;33&lt;/STRONG&gt; hepatic insufficiency.ti,ab.&lt;BR&gt;&lt;STRONG&gt;34&lt;/STRONG&gt; liver insufficiency.ti,ab.&lt;BR&gt;&lt;STRONG&gt;35&lt;/STRONG&gt; end stage liver disease.ti,ab.&lt;BR&gt;&lt;STRONG&gt;36&lt;/STRONG&gt; ESLD.ti,ab.&lt;BR&gt;&lt;STRONG&gt;37&lt;/STRONG&gt; Carcinoma, Hepatocellular/&lt;BR&gt;&lt;STRONG&gt;38&lt;/STRONG&gt; hepatocellular carcinom*.ti,ab.&lt;BR&gt;&lt;STRONG&gt;39&lt;/STRONG&gt; HCC.ti,ab.&lt;BR&gt;&lt;STRONG&gt;40&lt;/STRONG&gt; Liver transplantation/&lt;BR&gt;&lt;STRONG&gt;41&lt;/STRONG&gt; liver transplant*.ti,ab.&lt;BR&gt;&lt;STRONG&gt;42&lt;/STRONG&gt; liver resect*.ti,ab.&lt;BR&gt;&lt;STRONG&gt;43&lt;/STRONG&gt; hepat* transplant*.ti,ab.&lt;BR&gt;&lt;STRONG&gt;44&lt;/STRONG&gt; hepat* resect*.ti,ab.&lt;BR&gt;&lt;STRONG&gt;45&lt;/STRONG&gt; 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44&lt;BR&gt;&lt;STRONG&gt;46&lt;/STRONG&gt; 6 and 45&lt;BR&gt;&lt;STRONG&gt;47&lt;/STRONG&gt; 1 or 46 &lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;BR&gt;
&lt;P style="COLOR: #306754"&gt;&lt;B&gt;&lt;A name=filters&gt;&lt;/A&gt;Search filters:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;These&amp;nbsp;are modified from the SIGN filters, which can be found at &lt;A href="http://www.sign.ac.uk/methodology/filters.html" target="_blank"&gt;http://www.sign.ac.uk/methodology/filters.html&lt;/A&gt;. They are shown below as used for the MEDLINE search (small adaptations were made for other databases).&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Systematic review filter&lt;/B&gt;&lt;/P&gt;
&lt;TABLE style="BORDER-RIGHT: #000000 thin solid; BORDER-TOP: #000000 thin solid; FONT-SIZE: 7pt; BORDER-LEFT: #000000 thin solid; BORDER-BOTTOM: #000000 thin solid; FONT-FAMILY: Courier,serif"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="PADDING-RIGHT: 5pt; PADDING-LEFT: 5pt; PADDING-BOTTOM: 5pt; PADDING-TOP: 5pt"&gt;&lt;STRONG&gt;1&lt;/STRONG&gt; Meta-Analysis as Topic/&lt;BR&gt;&lt;STRONG&gt;2&lt;/STRONG&gt; Meta-Analysis/&lt;BR&gt;&lt;STRONG&gt;3&lt;/STRONG&gt; metaanaly*.mp. &lt;BR&gt;&lt;STRONG&gt;4&lt;/STRONG&gt; meta analy*.mp. &lt;BR&gt;&lt;STRONG&gt;5&lt;/STRONG&gt; (systematic adj (review* or overview*)).mp.&lt;BR&gt;&lt;STRONG&gt;6&lt;/STRONG&gt; exp Review Literature as Topic/&lt;BR&gt;&lt;STRONG&gt;7&lt;/STRONG&gt; 1 or 2 or 3 or 4 or 5 or 6&lt;BR&gt;&lt;STRONG&gt;8&lt;/STRONG&gt; Cochrane.ab.&lt;BR&gt;&lt;STRONG&gt;9&lt;/STRONG&gt; Embase.ab.&lt;BR&gt;&lt;STRONG&gt;10&lt;/STRONG&gt; Medline.ab.&lt;BR&gt;&lt;STRONG&gt;11&lt;/STRONG&gt; Pubmed.ab.&lt;BR&gt;&lt;STRONG&gt;12&lt;/STRONG&gt; (psychlit or psyclit).ab.&lt;BR&gt;&lt;STRONG&gt;13&lt;/STRONG&gt; (psychinfo or psycinfo).ab.&lt;BR&gt;&lt;STRONG&gt;14&lt;/STRONG&gt; (cinahl or cinhal).ab.&lt;BR&gt;&lt;STRONG&gt;15&lt;/STRONG&gt; science citation index.ab.&lt;BR&gt;&lt;STRONG&gt;16&lt;/STRONG&gt; bids.ab.&lt;BR&gt;&lt;STRONG&gt;17&lt;/STRONG&gt; cancerlit.ab.&lt;BR&gt;&lt;STRONG&gt;18&lt;/STRONG&gt; 11 or 9 or 17 or 12 or 15 or 14 or 8 or 16 or 10 or 13&lt;BR&gt;&lt;STRONG&gt;19&lt;/STRONG&gt; reference list$.ab.&lt;BR&gt;&lt;STRONG&gt;20&lt;/STRONG&gt; bibliograph$.ab.&lt;BR&gt;&lt;STRONG&gt;21&lt;/STRONG&gt; hand-search$.ab.&lt;BR&gt;&lt;STRONG&gt;22&lt;/STRONG&gt; relevant journals.ab.&lt;BR&gt;&lt;STRONG&gt;23&lt;/STRONG&gt; manual search$.ab.&lt;BR&gt;&lt;STRONG&gt;24&lt;/STRONG&gt; 22 or 21 or 23 or 19 or 20&lt;BR&gt;&lt;STRONG&gt;25&lt;/STRONG&gt; selection criteria.ab.&lt;BR&gt;&lt;STRONG&gt;26&lt;/STRONG&gt; data extraction.ab.&lt;BR&gt;&lt;STRONG&gt;27&lt;/STRONG&gt; 25 or 26&lt;BR&gt;&lt;STRONG&gt;28&lt;/STRONG&gt; review/&lt;BR&gt;&lt;STRONG&gt;29&lt;/STRONG&gt; 27 and 28&lt;BR&gt;&lt;STRONG&gt;30&lt;/STRONG&gt; Comment/&lt;BR&gt;&lt;STRONG&gt;31&lt;/STRONG&gt; Letter/&lt;BR&gt;&lt;STRONG&gt;32&lt;/STRONG&gt; editorial/&lt;BR&gt;&lt;STRONG&gt;33&lt;/STRONG&gt; 32 or 30 or 31&lt;BR&gt;&lt;STRONG&gt;34&lt;/STRONG&gt; 18 or 24 or 7 or 29&lt;BR&gt;&lt;STRONG&gt;35&lt;/STRONG&gt; 34 not 33&lt;BR&gt;&lt;STRONG&gt;36&lt;/STRONG&gt; limit 35 to animals&lt;BR&gt;&lt;STRONG&gt;37&lt;/STRONG&gt; limit 35 to (animals and humans)&lt;BR&gt;&lt;STRONG&gt;38&lt;/STRONG&gt; 36 not 37&lt;BR&gt;&lt;STRONG&gt;39&lt;/STRONG&gt; 35 not 38 &lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;BR&gt;
&lt;P&gt;&lt;B&gt;Randomised controlled trial filter&lt;/B&gt;&lt;/P&gt;
&lt;TABLE style="BORDER-RIGHT: #000000 thin solid; BORDER-TOP: #000000 thin solid; FONT-SIZE: 7pt; BORDER-LEFT: #000000 thin solid; BORDER-BOTTOM: #000000 thin solid; FONT-FAMILY: Courier,serif"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="PADDING-RIGHT: 5pt; PADDING-LEFT: 5pt; PADDING-BOTTOM: 5pt; PADDING-TOP: 5pt"&gt;&lt;STRONG&gt;1&lt;/STRONG&gt; Randomized controlled trials as Topic/&lt;BR&gt;&lt;STRONG&gt;2&lt;/STRONG&gt; Randomized controlled trial/&lt;BR&gt;&lt;STRONG&gt;3&lt;/STRONG&gt; Random allocation/&lt;BR&gt;&lt;STRONG&gt;4&lt;/STRONG&gt; Double blind method/&lt;BR&gt;&lt;STRONG&gt;5&lt;/STRONG&gt; Single blind method/&lt;BR&gt;&lt;STRONG&gt;6&lt;/STRONG&gt; Clinical trial/&lt;BR&gt;&lt;STRONG&gt;7&lt;/STRONG&gt; exp Clinical Trials as Topic/&lt;BR&gt;&lt;STRONG&gt;8&lt;/STRONG&gt; 1 or 2 or 3 or 4 or 5 or 6 or 7&lt;BR&gt;&lt;STRONG&gt;9&lt;/STRONG&gt; (random* adj2 trial*).ti,ab.&lt;BR&gt;&lt;STRONG&gt;10&lt;/STRONG&gt; (clinic* adj trial*).mp.&lt;BR&gt;&lt;STRONG&gt;11&lt;/STRONG&gt; ((singl* or doubl* or treb* or tripl*) adj (blind* or mask*)).mp.&lt;BR&gt;&lt;STRONG&gt;12&lt;/STRONG&gt; Placebos/&lt;BR&gt;&lt;STRONG&gt;13&lt;/STRONG&gt; Placebo*.mp.&lt;BR&gt;&lt;STRONG&gt;14&lt;/STRONG&gt; (allocat* adj2 random*).mp.&lt;BR&gt;&lt;STRONG&gt;15&lt;/STRONG&gt; 9 or 12 or 14 or 11 or 10 or 13&lt;BR&gt;&lt;STRONG&gt;16&lt;/STRONG&gt; 8 or 15&lt;BR&gt;&lt;STRONG&gt;17&lt;/STRONG&gt; Case report.mp.&lt;BR&gt;&lt;STRONG&gt;18&lt;/STRONG&gt; Case Reports.pt.&lt;BR&gt;&lt;STRONG&gt;19&lt;/STRONG&gt; Letter.pt.&lt;BR&gt;&lt;STRONG&gt;20&lt;/STRONG&gt; Historical Article.pt.&lt;BR&gt;&lt;STRONG&gt;21&lt;/STRONG&gt; 19 or 20 or 17 or 18&lt;BR&gt;&lt;STRONG&gt;22&lt;/STRONG&gt; 16 not 21&lt;BR&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="COLOR: #ffffff; BACKGROUND-COLOR: #306754; TEXT-ALIGN: center"&gt;Alcoholic Liver Disease Annual Evidence Update 2010&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BACKGROUND-COLOR: #addfff; TEXT-ALIGN: center"&gt;
&lt;P&gt;&lt;A href="nelh:395097:0" name=internalLink&gt;Introduction&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:395151:0" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:395145:0" name=internalLink&gt;Treatment&lt;BR&gt;&lt;/A&gt;&lt;A href="nelh:395141:0" name=internalLink&gt;Adverse effects&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:395155:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:396443:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;B&gt;Methods&lt;/B&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>395145</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=395145]]&gt;</url>
    <title>2010 Annual Evidence Update on Alcoholic Liver Disease - Treatment</title>
    <publicationDate>2010-12-06T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,ALCOHOLIC LIVER DISEASE,RECENT ADDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Alcoholic Liver Disease - Treatment&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;EM&gt;Reviewed by Marsha Morgan, Consultant Physician, Royal Free Hospital, London &lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Only a small number of publications relating to the treatment of alcohol-related liver disease and its complications have appeared since the last review but the data reported are both valuable and of significance. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Alcoholic hepatitis&lt;/EM&gt;&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;One of the most important recommendations of a recent NICE guideline on Alcohol Use Disorders (NICE clinical guideline 100; 2010), was that corticosteroids should be offered to individuals with severe acute alcohol-related hepatitis with a discriminant function (DF) of = 32*. Surprisingly this was not one of the key recommendations made despite the strength of the evidence provided from an excellent meta-analysis of selected RCTs. The recommendation to treat severe alcoholic hepatitis with corticosteroids was also made by the American Association for the Study of Liver Diseases (AASLD) and the American College of Gastroenterology (O’Shea et al., 2010) in their guideline on alcoholic liver disease. Both bodies, while acknowledging that the supporting evidence was weak, recommended that patients with alcoholic hepatitis should receive nutritional support and favoured the enteral route. &lt;/P&gt;
&lt;P&gt;&lt;FONT size=0&gt;*Maddrey’s discriminant function (DF): DF = 4.6 x (Prothrombin time –control time [s]) + bilirubin [mmol/l]/ 17.1 (&lt;A href="http://www.mdcalc.com/maddreys-discriminant-function-for-alcoholic-hepatitis" target="_blank"&gt;www.mdcalc.com/maddreys-discriminant-function-for-alcoholic-hepatitis&lt;/A&gt;) &lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Antioxidant supplementation&lt;/EM&gt;&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;Oxidative stress is thought to play a role in the genesis of liver disease; antioxidant supplements may, therefore, have a preventative/protective role. A meta-analysis of the efficacy of a variety of antioxidant supplements, used singly or in combination, in patients with alcohol-related liver disease showed no beneficial effects on all-cause or liver specific mortality (Bjelakovic et al, 2010). The use of these supplements was not associated with an excess of adverse events although significant increases in serum gamma glutamyl tranferase (GGT) activity were observed in the two studies, one short-term and one long-term, in which it was monitored. &lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Variceal bleeding&lt;/STRONG&gt;&lt;/EM&gt; &lt;/P&gt;
&lt;P&gt;Acute variceal bleeding is a major cause of death in patients with cirrhosis. Standard treatment with vasoactive drugs, antibiotics and endoscopic intervention fails in about 10-15% of patients. The results of a multicentre RCT (Garcia-Pagán et al., 2010) showed that in patients admitted with acute variceal bleeding, who were at high risk for conventional treatment failure, early intervention with a transjugular intrahepatic portalsystemic shunt (TIPS) was associated with a significant reduction in both treatment failure and mortality. Surprisingly there was no increase in the 1-year actuarial probability of hepatic encephalopathy in the early-TIPS group. However, longer follow-up is required to assess the true occurrence of this important side-effect. &lt;/P&gt;
&lt;P&gt;This study has one significant failing. Two-thirds of the patients had alcohol-related cirrhosis, 50% of whom were actively abusing alcohol at the time of their inclusion into the study. Both the risk of rebleeding and survival in these patients is likely to have been influenced by their subsequent drinking behaviour but no follow-up data were provided and no mention was made of the possible confounding effect of this important variable. While it is unlikely that subsequent drinking behaviour will have varied significantly between the groups, failure to take it into account was an important omission. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Hepatorenal syndrome&lt;/EM&gt;&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;Hepatorenal syndrome (HRS) is a feature of advanced liver disease and has a poor prognosis. Vasoconstrictor agents such as terlipressin, if given with albumin, have been shown, in observational studies, to effectively reverse type 1 i.e. rapidly progressive, HRS in patients treated for a minimum of 3 days. A recent meta-analysis of four good quality RCTs in which patients with cirrhosis and type 1 HRS received between 3 to 15 days treatment with terlipressin and albumin or albumin with or without a placebo, showed that use of terlipressin was associated with significantly greater reversal of HRS and a significant increase in transplant-free survival at 90 days (Sagi et al, 2010). However, the assessment of longer-term outcomes was limited by the paucity of follow-up data in the reported trials. Information is still needed, however, on the optimal dose and duration of treatment as this varied substantially in the considered trials. &amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Guidelines:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;NICE Clinical Guideline 100: &lt;A href="nelh:377415:0" name=internalLink&gt;Alcohol-use disorders: diagnosis and clinical management of alcohol-related physical complications &lt;/A&gt;(June 2010). &lt;/P&gt;
&lt;P&gt;O'Shea, R.S. et al. 2010. &lt;A href="nelh:345202:0" name=internalLink&gt;Alcoholic liver disease&lt;/A&gt;. &lt;EM&gt;Hepatology&lt;/EM&gt; 51(1): 307-328. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Systematic reviews:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=tripathi&gt;&lt;/A&gt;Bjelakovic G, Gluud LL, Nikolova D, Bjelakovic M, Nagorni A, Gluud C.&amp;nbsp; &lt;A href="nelh:384927:0" name=internalLink&gt;Meta-analysis: antioxidant supplements for liver disease - the Cochrane Hepato-Biliary Group&lt;/A&gt;.&amp;nbsp; &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2010: 32: 356-367.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Sagi SV, Mittal S, Kasturi KS, Sood GK.&amp;nbsp; &lt;A href="nelh:396510:0" name=internalLink&gt;Terlipressin therapy for reversal of type 1 hepatorenal syndrome: A meta-analysis of randomized controlled trials&lt;/A&gt;.&amp;nbsp; &lt;EM&gt;J Gastroenterol Hepatol&lt;/EM&gt; 2010: 25; 880-885.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Randomised controlled trials:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Garcia-Pagán JC, Caca K, Bureau C, Laleman W, Appemrodt B, Luca A, et al.&amp;nbsp; &lt;A href="nelh:396512:0" name=internalLink&gt;Early use of TIPS in patients with cirrhosis and variceal bleeding&lt;/A&gt;.&amp;nbsp; &lt;EM&gt;N Engl J Med&lt;/EM&gt; 2010; 362: 2370-2379. &lt;/P&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="COLOR: #ffffff; BACKGROUND-COLOR: #306754; TEXT-ALIGN: center"&gt;Alcoholic Liver Disease Annual Evidence Update 2010&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BACKGROUND-COLOR: #addfff; TEXT-ALIGN: center"&gt;
&lt;P&gt;&lt;A href="nelh:395097:0" name=internalLink&gt;Introduction&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:395151:0" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;BR&gt;&lt;STRONG&gt;Treatment&lt;/STRONG&gt;&lt;BR&gt;&lt;A href="nelh:395141:0" name=internalLink&gt;Adverse effects&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:395155:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:396443:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:395153:0" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>396443</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=396443]]&gt;</url>
    <title>2010 Annual Evidence Update on Alcoholic Liver Disease - Uncertainties</title>
    <publicationDate>2010-12-06T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,ALCOHOLIC LIVER DISEASE]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Alcoholic Liver Disease - Uncertainties&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;As part of the process of conducting this Annual Evidence Update, we examined the included papers for treatment uncertainties that could be added to the UK Database of Uncertainties about the Effects of Treatments (&lt;A href="http://www.library.nhs.uk/duets/" target="_blank"&gt;UK DUETs&lt;/A&gt;), a project aimed at creating a central database of such uncertainties. The following list, which has been submitted to the database, is the results of our search. Click on each title for more information.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:396434:0" name=internalLink&gt;Antioxidant supplements for liver diseases&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:396432:0" name=internalLink&gt;Antioxidants as adjuvants to other drugs in liver diseases&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:396426:0" name=internalLink&gt;Treatment duration and optimal dose of terlipressin therapy in Type 1 hepatorenal syndrome (HRS)&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="COLOR: #ffffff; BACKGROUND-COLOR: #306754; TEXT-ALIGN: center"&gt;Alcoholic Liver Disease Annual Evidence Update 2010&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BACKGROUND-COLOR: #addfff; TEXT-ALIGN: center"&gt;
&lt;P&gt;&lt;A href="nelh:395097:0" name=internalLink&gt;Introduction&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:395151:0" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:395145:0" name=internalLink&gt;Treatment&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:395141:0" name=internalLink&gt;Adverse effects&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:395155:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;BR&gt;&lt;B&gt;Uncertainties&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:395153:0" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>381477</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=381477]]&gt;</url>
    <title>2010 Annual Evidence Update on Hepatitis B and C - Adverse effects</title>
    <publicationDate>2010-07-26T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,HEPATITIS C,DISEASE PREVENTION,VACCINATION,RECENT ADDITIONS,CHRONIC HEPATITIS C,JULY 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Hepatitis B and C - Adverse effects&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;I&gt;Reviewed by Janice Main, Reader in Infectious Diseases and General Medicine, Imperial College at St Mary's Hospital, London&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="#frankel"&gt;Frankel et al&lt;/A&gt; published a consensus document on treatment issues in patients with psoriasis and hepatitis C virus (HCV) infection. Interferon alpha can exacerbate psoriasis and there are concerns that immunomodulatory therapy used for more severe cases of psoriasis may cause more rapid disease progression of hepatitis C. There are additional issues with drugs such as methotrexate which can cause hepatotoxicity. The authors conclude that data are limited and, where possible, topical therapy should be used.&lt;/P&gt;
&lt;P&gt;&lt;A href="#slavenburg"&gt;Slavenburg, Heijdra and Drenth&lt;/A&gt; describe a case of pneumonitis in a patient with HCV receiving peginterferon and ribavirin and then review the relevant literature. Although pneumonitis is a very rare side effect of therapy it is important that this is recognized quickly as it can be fatal. Cessation of antiviral therapy is advised and steroid therapy&amp;nbsp;is recommended.&lt;/P&gt;
&lt;P&gt;Thyroiditis is a much more common side effect of interferon based therapy and &lt;A href="#tran"&gt;Tran et al&lt;/A&gt; describe their experience with 11 patients. All patients subsequently had a sustained virological response (SVR). However larger studies have not demonstrated such a high SVR in these patients. The authors conclude that with this side effect it is reasonable to treat the thyroiditis and to continue with antiviral therapy. &lt;/P&gt;
&lt;P&gt;Hepatitis B vaccination generally appears very safe but &lt;A href="#fraunfelder"&gt;Fraunfelder, Suhler and Fraunfelder&lt;/A&gt; highlight 32 case reports of uveitis and possible links to HBV vaccination.&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Articles:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=frankel&gt;&lt;/A&gt;Frankel AJ, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Bebo BF Jr, Gottlieb AB, National Psoriasis Foundation. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=380730" target="_blank"&gt;Treatment of psoriasis in patients with hepatitis C: from the Medical Board of the National Psoriasis Foundation.&lt;/A&gt; &lt;I&gt;J Am Acad Dermatol&lt;/I&gt; 2009;61(6):1044-55.&lt;/P&gt;
&lt;P&gt;&lt;A name=fraunfelder&gt;&lt;/A&gt;Fraunfelder FW, Suhler EB, Fraunfelder FT. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=380733" target="_blank"&gt;Hepatitis B vaccine and uveitis: an emerging hypothesis suggested by review of 32 case reports.&lt;/A&gt; &lt;I&gt;Cutan Ocul Toxicol&lt;/I&gt; 2010;29(1):26-9.&lt;/P&gt;
&lt;P&gt;&lt;A name=slavenburg&gt;&lt;/A&gt;Slavenburg S, Heijdra YF, Drenth JP. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=380739" target="_blank"&gt;Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature.&lt;/A&gt; &lt;I&gt;Dig Dis Sci&lt;/I&gt; 2010;55(3):579-85.&lt;/P&gt;
&lt;P&gt;&lt;A name=tran&gt;&lt;/A&gt;Tran HA, Malcolm Reeves GE, Gibson R, Attia JR. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=380745" target="_blank"&gt;Development of thyroid diseases in the treatment of chronic hepatitis C with alpha-interferon may be a good prognosticator in achieving a sustained virological response: a meta-analysis.&lt;/A&gt; &lt;I&gt;J Gastroenterol Hepatol&lt;/I&gt; 2009;24(7):1163-8.&lt;/P&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #99cc00"&gt;Hepatitis B and C Annual Evidence Update 2010&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #33cccc"&gt;
&lt;P&gt;&lt;A href="nelh:381482:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381479:0" name=internalLink&gt;Economics&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381480:0" name=internalLink&gt;Prevention&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381478:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:381474:0" name=internalLink&gt;Hepatitis B&lt;/A&gt; | &lt;A href="nelh:381475:0" name=internalLink&gt;Hepatitis C&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:381477:0" name=internalLink&gt;&lt;B&gt;Adverse effects&lt;/B&gt;&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381476:0" name=internalLink&gt;Risk factors&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:381471:0" name=internalLink&gt;Other&lt;/B&gt;&lt;/A&gt;&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:381473:0" name=internalLink&gt;Foreign articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381483:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381481:0" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>381478</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=381478]]&gt;</url>
    <title>2010 Annual Evidence Update on Hepatitis B and C - Diagnosis</title>
    <publicationDate>2010-07-26T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,DIAGNOSTIC PROCEDURES,ULTRASOUND,MRI,BLOOD TESTS,BREATH TESTS,RECENT ADDITIONS,RADIOLOGY,CHRONIC HEPATITIS C,JULY 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Hepatitis B and C - Diagnosis&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;I&gt;Reviewed by Graeme Alexander, Consultant Hepatologist, Addenbrooke's Hospital, Cambridge &lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="#smith"&gt;Smith and Sterling&lt;/A&gt; is a fair review of non invasive methods of assessing fibrosis in chronic hepatitis C virus infection. It has many aspects to commend it, including a comprehensive review, fair assessment with fair conclusions and this is an area that is particularly topical at present. &lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Articles:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=smith&gt;&lt;/A&gt;Smith JO, Sterling RK. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=326238" target="_blank"&gt;Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C.&lt;/A&gt; &lt;I&gt;Aliment Pharmacol Ther&lt;/I&gt; 2009;30(6):557-76.&lt;/P&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #99cc00"&gt;Hepatitis B and C Annual Evidence Update 2010&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #33cccc"&gt;
&lt;P&gt;&lt;A href="nelh:381482:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381479:0" name=internalLink&gt;Economics&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381480:0" name=internalLink&gt;Prevention&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381478:0" name=internalLink&gt;&lt;B&gt;Diagnosis&lt;/B&gt;&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:381474:0" name=internalLink&gt;Hepatitis B&lt;/A&gt; | &lt;A href="nelh:381475:0" name=internalLink&gt;Hepatitis C&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:381477:0" name=internalLink&gt;Adverse effects&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381476:0" name=internalLink&gt;Risk factors&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:381471:0" name=internalLink&gt;Other&lt;/B&gt;&lt;/A&gt;&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:381473:0" name=internalLink&gt;Foreign articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381483:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381481:0" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>381479</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=381479]]&gt;</url>
    <title>2010 Annual Evidence Update on Hepatitis B and C - Economics</title>
    <publicationDate>2010-07-26T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,HEPATITIS C,DIAGNOSTIC PROCEDURES,DISEASE PREVENTION,LIVER TRANSPLANTATION,SCREENING,RECENT ADDITIONS,CHRONIC HEPATITIS B,CHRONIC HEPATITIS C,SURGERY,JULY 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Hepatitis B and C - Economics&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;I&gt;Reviewed by Graeme Alexander, Consultant Hepatologist, Addenbrooke's Hospital, Cambridge and Andrew Austin, Consultant Hepatologist, Royal Derby Hospital&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Graeme Alexander:&lt;/B&gt; The paper by &lt;A href="#sroczynski"&gt;Sroczynski et al&lt;/A&gt;, which is pertinent to the UK, indicates that there is an economic benefit in screening for hepatitis C when the prevalence is sufficiently high. The only failing of this paper is that it doesn’t really define clearly what an adequate prevalence is to make studies cost effective, but it is one of the better papers in the field and the cost of screening and the cost of treatment are very important issues for the UK.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Andrew Austin:&lt;/B&gt; With the advent of a number of effective oral antiviral treatments for chronic hepatitis B, both clinical and cost-effectiveness need to be considered. The latest EASL guidelines recommend pegylated interferon, entecavir and tenofovir as first-line treatment for both HBeAg-positive and HBeAg-negative patients with chronic hepatitis B. &lt;A href="#buti"&gt;Buti et al&lt;/A&gt; used a Markov model to project lifetime costs in cohorts of 40 year old HBeAg-positive and HBeAg-negative patients treated with six different first-line and two second-line management strategies. Costs were assessed using Spanish data. The analysis found that tenofovir is the most cost-effective oral therapy for both groups of patients. Entecavir was the second most effective strategy and the difference is determined primarily by the difference in purchase price in Spain. When the pricing is similar the two drugs are equally cost-effective and it would be important to check on the real drug cost in your area. Furthermore, longer term modelling (&amp;gt; 5 years) is based on scant data and may be effected by changing resistance patterns, local cost of managing complications of chronic liver disease and unforeseen treatment side effects.&lt;/P&gt;
&lt;P&gt;&lt;A href="#deuffic"&gt;Deuffic-Burban et al&lt;/A&gt; compare different approaches to the detection of occupational hepatitis C infection in healthcare workers using a decision-analysis model. In France in 2004, a staggering 41,276 accidental blood exposures occurred in hospitals, 58.7% of which were percutaneous injuries. Of these 6.2% occurred to anti-HCV antibody-positive source patients. The authors compared three existing follow-up strategies from Europe and USA using combinations of ALT and anti-HCV antibody tests with a strategy based on early HCV RNA testing one month after exposure. The study found that although the HCV RNA testing strategy is more expensive than the other strategies examined, it is reasonably cost-effective and the study recommends its use. Given the advantage of early treatment of acute hepatitis C and the likely quality of life benefits from an earlier “all clear”, such a bland conclusion is surprising. I suspect that most clinicians who have been able to confirm the donor is HCV-positive will recommend an early HCV RNA test at one month using a highly sensitive assay for HCV RNA.&lt;/P&gt;
&lt;P&gt;&lt;A href="#grishchenko"&gt;Grishchenko et al&lt;/A&gt; have used similar methodology to estimate the lifetime cost per quality-adjusted life-year (QALY) of antiviral treatment compared to no treatment for chronic HCV infection. However, rather than using estimates of sustained virological response, costs and transitional probabilities from registration trials, they have drawn estimates from the Trent HCV database, a large representative sample of UK cases. The authors found that pegylated interferon and ribavirin is generally cost-effective when provided in routine clinical practice. Treatment appears cost saving for patients with non-1, and has low costs per QALY for most patients with genotype 1. However, treatment is less effective in older patients with genotype 1 and cirrhosis whose chance of achieving an SVR may be less than 10%. As a member of the Trent HCV cohort study I declare an interest in this paper.&lt;/P&gt;
&lt;P&gt;&lt;A href="#saab"&gt;Saab et al&lt;/A&gt; use retrospective data to compare switching from HBIG to adefovir one year after successful liver transplantation versus continuing with HBIG/lamivudine. The authors report that the switching strategy leads to significant cost-savings. However, looking to the future it seems unlikely that many patients will come to transplantation who are treatment-naive with respect to either tenofovir or entecavir and the result may be of mainly historical interest.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Articles:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=buti&gt;&lt;/A&gt;Buti M, Brosa M, Casado MA, Rueda M, Esteban R. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=380668" target="_blank"&gt;Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B.&lt;/A&gt; &lt;I&gt;J Hepatol&lt;/I&gt; 2009;51(4):640-6.&lt;/P&gt;
&lt;P&gt;&lt;A name=deuffic&gt;&lt;/A&gt;Deuffic-Burban S, Abiteboul D, Lot F, Branger M, Bouvet E, Yazdanpanah Y. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=380684" target="_blank"&gt;Costs and cost-effectiveness of different follow-up schedules for detection of occupational hepatitis C virus infection.&lt;/A&gt; &lt;I&gt;Gut&lt;/I&gt; 2009;58(1):105-10.&lt;/P&gt;
&lt;P&gt;&lt;A name=grishchenko&gt;&lt;/A&gt;Grishchenko M, Grieve RD, Sweeting MJ, De Angelis D, Thomson BJ, Ryder SD, Irving WL, Trent HCV Study Group. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=380685" target="_blank"&gt;Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice.&lt;/A&gt; &lt;I&gt;Int J Technol Assess Health Care&lt;/I&gt; 2009;25(2):171-80.&lt;/P&gt;
&lt;P&gt;&lt;A name=saab&gt;&lt;/A&gt;Saab S, Ham MY, Stone MA, Holt C, Tong M. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=380687" target="_blank"&gt;Decision analysis model for hepatitis B prophylaxis one year after liver transplantation.&lt;/A&gt; &lt;I&gt;Liver Transpl&lt;/I&gt; 2009;15(4):413-20.&lt;/A&gt; 
&lt;P&gt;&lt;A name=sroczynski&gt;&lt;/A&gt;Sroczynski G, Esteban E, Conrads-Frank A, Schwarzer R, Mühlberger N, Wright D, Zeuzem S, Siebert U. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=380707" target="_blank"&gt;Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection.&lt;/A&gt; &lt;I&gt;Eur J Public Health&lt;/I&gt; 2009;19(3):245-53.&lt;/P&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #99cc00"&gt;Hepatitis B and C Annual Evidence Update 2010&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #33cccc"&gt;
&lt;P&gt;&lt;A href="nelh:381482:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381479:0" name=internalLink&gt;&lt;B&gt;Economics&lt;/B&gt;&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381480:0" name=internalLink&gt;Prevention&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381478:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:381474:0" name=internalLink&gt;Hepatitis B&lt;/A&gt; | &lt;A href="nelh:381475:0" name=internalLink&gt;Hepatitis C&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:381477:0" name=internalLink&gt;Adverse effects&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381476:0" name=internalLink&gt;Risk factors&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:381471:0" name=internalLink&gt;Other&lt;/B&gt;&lt;/A&gt;&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:381473:0" name=internalLink&gt;Foreign articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381483:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381481:0" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>381473</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=381473]]&gt;</url>
    <title>2010 Annual Evidence Update on Hepatitis B and C - Foreign articles</title>
    <publicationDate>2010-07-26T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,HEPATITIS C,DISEASE PREVENTION,VACCINATION,RECENT ADDITIONS,CHRONIC HEPATITIS B,CHRONIC HEPATITIS C,JULY 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Hepatitis B and C - Foreign articles&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;The following articles were identified by the search as being potentially relevant to the AEU, but were not sent out for appraisal because the full text is in a language other than English. They are included here for interest, and for the sake of completeness.&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;Almeida AM, Silva DI, Guerra AA Jr, Silva GD, Acurcio Fde A. &lt;A href="http://dx.doi.org/10.1590/S0102-311X2009000800003" target="_blank"&gt;Efficacy of interferon (conventional, pegylated) and lamivudine for treatment of chronic hepatitis B: a systematic review.&lt;/A&gt; &lt;I&gt;Cad Saude Publica&lt;/I&gt; 2009;25(8):1667-77.&lt;BR&gt;&lt;I&gt;&lt;B&gt;Language:&lt;/B&gt; Spanish&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;Hu H-B, Xu T, Cheng K, Su N, Tang Y. &lt;A href="http://www.cjebm.org.cn/oa/pdfdow.aspx?Type=pdf&amp;amp;FileName=5b001c39-3b20-4973-8100-67278d5fe117.pdf" target="_blank"&gt;Lamivudine versus lamivudine-thymosin alpha-1 combination therapy for HBeAg positive chronic hepatitis B: A systematic review.&lt;/A&gt; &lt;I&gt;Chin J Evid-based Med&lt;/I&gt; 2009;9(8):904-9.&lt;BR&gt;&lt;I&gt;&lt;B&gt;Language:&lt;/B&gt; Chinese&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;Isken LD, Zaaijer HL, van Steenbergen JE. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19900310" target="_blank"&gt;Hepatitis B revaccination not indicated, even for those at increased risk.&lt;/A&gt; &lt;I&gt;Ned Tijdschr Geneeskd&lt;/I&gt; 2009;153:A415.&lt;BR&gt;&lt;I&gt;&lt;B&gt;Language:&lt;/B&gt; Dutch&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;Qin XK, Han M, Liu JP. &lt;A href="http://dx.doi.org/10.3736/jcim20091003" target="_blank"&gt;Compound Chinese herbal medicines, Chinese herbal drugs and their active extracts for treatment of chronic hepatitis C: a systematic review and meta-analysis of randomized clinical trials.&lt;/A&gt; &lt;I&gt;Zhong Xi Yi Jie He Xue Bao&lt;/I&gt; 2009;7(10):913-28.&lt;BR&gt;&lt;I&gt;&lt;B&gt;Language:&lt;/B&gt; Chinese&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;Takács IG, Demetrovics Z. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19949245" target="_blank"&gt;The efficacy of needle exchange programs in the prevention of HIV and hepatitis infection among injecting drug users.&lt;/A&gt; &lt;I&gt;Psychiatr Hung&lt;/I&gt; 2009;24(4):264-81.&lt;BR&gt;&lt;I&gt;&lt;B&gt;Language:&lt;/B&gt; Hungarian&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;Wang Y-F, Wang Y-X, Yu Q-H. Efficacy of peginterferon alpha-2a in HBeAg positive chronic hepatitis B: Meta-analysis study. &lt;I&gt;Chin J Evid-based Med&lt;/I&gt; 2009;9(10):1080-6.&lt;BR&gt;&lt;I&gt;&lt;B&gt;Language:&lt;/B&gt; Chinese&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;Zhao SH, Liu EQ, Cheng DX, Xue X, Chu YL. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19504643" target="_blank"&gt;Meta-analysis on peginterferon plus ribavirin in treatment of hepatitis C virus genotype 1 or 4 infection in HIV patients.&lt;/A&gt; &lt;I&gt;Zhejiang Da Xue Xue Bao Yi Xue Ban&lt;/I&gt; 2009;38(3):315-9.&lt;BR&gt;&lt;I&gt;&lt;B&gt;Language:&lt;/B&gt; Chinese&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;&lt;BR&gt;
&lt;P&gt;In addition, the following English-language articles were identified by the search but not sent out for review because they were studies of foreign populations:&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;Alavian SM, Ahmadzad-Asl M, Lankarani KB, Shahbabaie MA, Ahmadi AB, Kabir A. &lt;A href="http://hepmon.com/pdf/Hepatitis_C_Infection_in_the_General_Pop.pdf?mobify=0" target="_blank"&gt;Hepatitis C infection in the general population of Iran: a systematic review.&lt;/A&gt; &lt;I&gt;Hepat Mon&lt;/I&gt; 2009;9(3):211-23.&lt;/P&gt;
&lt;P&gt;Ali SA, Donahue RM, Qureshi H, Vermund SH. &lt;A href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2651958/" target="_blank"&gt;Hepatitis B and hepatitis C in Pakistan: prevalence and risk factors.&lt;/A&gt; &lt;I&gt;Int J Infect Dis&lt;/I&gt; 2009;13(1):9-19.&lt;/P&gt;
&lt;P&gt;Batham A, Gupta MA, Rastogi P, Garg S, Sreenivas V, Puliyel JM. &lt;A href="http://dx.doi.org/10.1007/s12098-009-0246-3" target="_blank"&gt;Calculating prevalence of hepatitis B in India: using population weights to look for publication bias in conventional meta-analysis.&lt;/A&gt; &lt;I&gt;Indian J Pediatr&lt;/I&gt; 2009;76(12):1247-57.&lt;/P&gt;
&lt;P&gt;Hung HF, Chen TH. &lt;A href="http://dx.doi.org/10.1016/j.vaccine.2009.08.082" target="_blank"&gt;Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence.&lt;/A&gt; &lt;I&gt;Vaccine&lt;/I&gt; 2009;27(48):6770-6.&lt;/P&gt;
&lt;P&gt;Jayaraman S, Chalabi Z, Perel P, Guerriero C, Roberts I. &lt;A href="http://dx.doi.org/10.1111/j.1537-2995.2009.002402.x" target="_blank"&gt;The risk of transfusion-transmitted infections in sub-Saharan Africa.&lt;/A&gt; &lt;I&gt;Transfusion&lt;/I&gt; 2010;50(2):433-42.&lt;/P&gt;
&lt;P&gt;Lehman EM, Wilson ML. &lt;A href="http://dx.doi.org/10.1111/j.1365-2893.2009.01115.x" target="_blank"&gt;Epidemic hepatitis C virus infection in Egypt: estimates of past incidence and future morbidity and mortality.&lt;/A&gt; &lt;I&gt;J Viral Hepat&lt;/I&gt; 2009;16(9):650-8.&lt;/P&gt;
&lt;P&gt;Sun J, Yu R, Zhu B, Wu J, Larsen S, Zhao W. &lt;A href="http://dx.doi.org/10.1080/08860220903003446" target="_blank"&gt;Hepatitis C infection and related factors in hemodialysis patients in china: systematic review and meta-analysis.&lt;/A&gt; &lt;I&gt;Ren Fail&lt;/I&gt; 2009;31(7):610-20.&lt;/P&gt;
&lt;P&gt;Tu HA, Woerdenbag HJ, Kane S, Riewpaiboon A, van Hulst M, Postma MJ. &lt;A href="http://dx.doi.org/10.1586/erv.09.53" target="_blank"&gt;Economic evaluations of hepatitis B vaccination for developing countries.&lt;/A&gt; &lt;I&gt;Expert Rev Vaccines&lt;/I&gt; 2009;8(7):907-20.&lt;/P&gt;
&lt;P&gt;Umar M, Khaar HT, Khurram M, Hasan Z. &lt;A href="http://www.pakmedinet.com/14542/c" target="_blank"&gt;Anti-HCV antibody positivity of various sections of Pakistani patients.&lt;/A&gt; &lt;I&gt;J Coll Physicians Surg Pak&lt;/I&gt; 2009;19(11):737-41.&lt;/P&gt;
&lt;P&gt;Waheed Y, Shafi T, Safi SZ, Qadri I. &lt;A href="http://dx.doi.org/10.3748/wjg.15.5647" target="_blank"&gt;Hepatitis C virus in Pakistan: a systematic review of prevalence, genotypes and risk factors.&lt;/A&gt; &lt;I&gt;World J Gastroenterol&lt;/I&gt; 2009;15(45):5647-53.&lt;/P&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #99cc00"&gt;Hepatitis B and C Annual Evidence Update 2010&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #33cccc"&gt;
&lt;P&gt;&lt;A href="nelh:381482:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381479:0" name=internalLink&gt;Economics&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381480:0" name=internalLink&gt;Prevention&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381478:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:381474:0" name=internalLink&gt;Hepatitis B&lt;/A&gt; | &lt;A href="nelh:381475:0" name=internalLink&gt;Hepatitis C&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:381477:0" name=internalLink&gt;Adverse effects&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381476:0" name=internalLink&gt;Risk factors&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:381471:0" name=internalLink&gt;Other&lt;/B&gt;&lt;/A&gt;&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:381473:0" name=internalLink&gt;&lt;B&gt;Foreign articles&lt;/B&gt;&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381483:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381481:0" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>381482</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=381482]]&gt;</url>
    <title>2010 Annual Evidence Update on Hepatitis B and C - Introduction</title>
    <publicationDate>2010-07-26T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,HEPATITIS C,RECENT ADDITIONS,JULY 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Hepatitis B and C - Introduction&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;NHS Evidence Annual Evidence Updates (AEUs) attempt to draw together recently published, high quality evidence – focusing particularly on systematic reviews and published guidelines - which it is hoped will inform and enhance the decision making and planning of clinicians, commissioners and others involved in the process of health care. &lt;/P&gt;
&lt;P&gt;For this Hepatitis B and C AEU updating last year's work, a detailed literature search from 2009-2010 identified 246 potential pieces of evidence (see methods for retrieving and evaluating the evidence for more information). Following a process of filtering and peer review (with thanks to the reviewers listed below) 61 of these form the basis of this AEU.&lt;/P&gt;
&lt;P&gt;It is imperative that those involved in commissioning and delivering care are apprised of the best available evidence and guidelines against which to review their service. We hope that the AEU in Hepatitis B and C will provide a prime source of such evidence.&lt;/P&gt;
&lt;P&gt;A summary of the methods used for retrieving and evaluating the evidence can be found &lt;A href="nelh:381481:0" name=internalLink&gt;here&lt;/A&gt;. The evidence has been split into sections as follows:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:381479:0" name=internalLink&gt;Economics&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:381480:0" name=internalLink&gt;Prevention&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:381478:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Treatment: 
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:381474:0" name=internalLink&gt;Hepatitis B&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:381475:0" name=internalLink&gt;Hepatitis C&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;BR&gt;
&lt;LI&gt;&lt;A href="nelh:381477:0" name=internalLink&gt;Adverse effects&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:381476:0" name=internalLink&gt;Risk factors&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:381471:0" name=internalLink&gt;Other&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:381473:0" name=internalLink&gt;Articles in foreign languages and on foreign populations&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Click on the sections above to find links to critically appraised systematic reviews, expert commentaries and other information of interest, or download the &lt;A href="http://www.library.nhs.uk/SpecialistLibrarySearch/Download.aspx?resID=381482" target="_blank"&gt;PDF version&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;We have also provided a list of &lt;A href="nelh:381483:0" name=internalLink&gt;treatment uncertainties&lt;/A&gt;, taken from the articles included in the AEU.&lt;/P&gt;
&lt;P&gt;This year's update has been put together by the NHS Evidence - gastroenterology and liver diseases Project Team, with expert advice and commentaries provided by our liver disease topic leads. These are:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Graeme Alexander, Consultant Hepatologist, Addenbrooke's Hospital, Cambridge&lt;/LI&gt;
&lt;LI&gt;Andrew Austin, Consultant Hepatologist, Royal Derby Hospital&lt;/LI&gt;
&lt;LI&gt;Jane Collier, Consultant Hepatologist, John Radcliffe Hospital, Oxford&lt;/LI&gt;
&lt;LI&gt;Jan Freeman, Consultant Hepatologist and Lead Clinician for Gastroenterology and Hepatology, Royal Derby Hospital&lt;/LI&gt;
&lt;LI&gt;Martin James, Consultant Hepatologist and Gastroenterologist, Queen's Medical Centre, Nottingham&lt;/LI&gt;
&lt;LI&gt;Lynda Greenslade, Clinical Nurse Specialist in Hepatology, Royal Free Hampstead NHS Trust, London&lt;/LI&gt;
&lt;LI&gt;Janice Main, Reader in Infectious Diseases and General Medicine, Imperial College at St Mary's Hospital, London&lt;/LI&gt;
&lt;LI&gt;Steven Ryder, Consultant Physician and Hepatologist, Queen's Medical Centre, Nottingham&lt;/LI&gt;&lt;/UL&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BACKGROUND-COLOR: #99cc00; TEXT-ALIGN: center"&gt;Hepatitis B and C Annual Evidence Update 2010&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BACKGROUND-COLOR: #33cccc; TEXT-ALIGN: center"&gt;
&lt;P&gt;&lt;A href="nelh:381482:0" name=internalLink&gt;&lt;B&gt;Introduction&lt;/B&gt;&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381479:0" name=internalLink&gt;Economics&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381480:0" name=internalLink&gt;Prevention&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381478:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:381474:0" name=internalLink&gt;Hepatitis B&lt;/A&gt; | &lt;A href="nelh:381475:0" name=internalLink&gt;Hepatitis C&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:381477:0" name=internalLink&gt;Adverse effects&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381476:0" name=internalLink&gt;Risk factors&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:381471:0" name=internalLink&gt;Other&lt;/B&gt;&lt;/A&gt;&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:381473:0" name=internalLink&gt;Foreign articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381483:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381481:0" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>381481</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=381481]]&gt;</url>
    <title>2010 Annual Evidence Update on Hepatitis B and C - Methods for retrieving and evaluating the evidence</title>
    <publicationDate>2010-07-26T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,HEPATITIS C,RECENT ADDITIONS,JULY 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Hepatitis B and C - Methods for retrieving and evaluating the evidence&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;The last Annual Evidence Update for Hepatitis B and C was published in September 2009. This AEU serves as an update to that one, and includes articles published in 2009 and 2010. As the Specialist Collection focuses only on secondary information of use to NHS staff and patients, our update was focused on guidelines and systematic reviews written in English. However, foreign language articles were included in the search process. As translations for these articles were not available, the article titles have been listed separately. Our search also recovered a large number of studies of viral hepatitis in foreign populations; as these are of limited relevance to UK practice we did not send these out to our reviewers for appraisal, but we have again listed them separately. &lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00; FONT-SIZE: 13pt"&gt;&lt;B&gt;&lt;U&gt;Search strategy&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Our search strategy has been updated from last year. The following resources were searched: 
&lt;UL&gt;
&lt;LI&gt;MEDLINE&lt;/LI&gt;
&lt;LI&gt;EMBASE&lt;/LI&gt;
&lt;LI&gt;CINAHL&lt;/LI&gt;
&lt;LI&gt;PsycINFO&lt;/LI&gt;
&lt;LI&gt;AMED&lt;/LI&gt;
&lt;LI&gt;National Library of Guidelines&lt;/LI&gt;
&lt;LI&gt;NHS Evidence Specialist Collections &lt;/LI&gt;
&lt;LI&gt;The Cochrane Library &lt;/LI&gt;
&lt;LI&gt;Database of Abstracts of Reviews of Effects &lt;/LI&gt;
&lt;LI&gt;NHS Economic Evaluation Database&lt;/LI&gt;
&lt;LI&gt;HTA Database&lt;/LI&gt;&lt;/UL&gt;The search strategy for MEDLINE, which was modified for the other resources, appears &lt;A href="#strategy"&gt;below&lt;/A&gt;. We combined this with a &lt;A href="#filter"&gt;modified SIGN systematic review&lt;/A&gt; filter in all cases except the searches of the NLG, the Specialist Collections, DARE, NHS EED and HTA (because they consist entirely of the types of publication that we were interested in). 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;After de-duplication 246 articles were retrieved.&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00; FONT-SIZE: 13pt"&gt;&lt;B&gt;&lt;U&gt;Inclusion and exclusion criteria&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Included articles had to meet the following criteria:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Publication types: systematic review, consensus report, guideline, protocol, care pathway, economic evaluation, health technology assessment&lt;/LI&gt;
&lt;LI&gt;Published in 2009 or 2010&lt;/LI&gt;
&lt;LI&gt;Main condition under investigation was hepatitis B or C virus infection&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Once the inclusion criteria were applied, 93 articles were left. Of these, 7 were foreign language articles, 7 were Cochrane systematic reviews, 5 were guidelines, and 10 were studies of specific foreign populations. &lt;/P&gt;
&lt;P&gt;The Cochrane systematic reviews and guidelines were automatically included in the Evidence Update. The foreign language and foreign population studies were not sent out to reviewers because of translation difficulties and limited relevance to UK practice, but are listed in a separate section of the Evidence Update. This left 64 articles to be sent to our reviewers for appraisal.&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00; FONT-SIZE: 13pt"&gt;&lt;B&gt;&lt;U&gt;Critical appraisal process&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Before sending out, the articles were divided into categories as follows:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Epidemiology&lt;/LI&gt;
&lt;LI&gt;Economics&lt;/LI&gt;
&lt;LI&gt;Prevention&lt;/LI&gt;
&lt;LI&gt;Diagnosis&lt;/LI&gt;
&lt;LI&gt;Treatment&lt;/LI&gt;
&lt;LI&gt;Adverse effects &lt;/LI&gt;
&lt;LI&gt;Risk factors&lt;/LI&gt;
&lt;LI&gt;Other&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Using these categories as a guide, the papers were divided up and sent to our 8 reviewers. The reviewers then appraised the articles for their validity, relevance and rigour. Following the receipt of their comments, we included in the Evidence Update 49 articles that were deemed to meet the standards.&lt;BR&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00; FONT-SIZE: 13pt"&gt;&lt;B&gt;&lt;U&gt;AEU process flowchart&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;&lt;IMG src="https://rmsadmin.library.nhs.uk/libraryImages/gastroliver/contentID381481/nelhImp_0000_hbcaeuflowchart.png"&gt;&lt;/IMG&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00; FONT-SIZE: 13pt"&gt;&lt;B&gt;&lt;U&gt;&lt;A name=strategy&gt;&lt;/A&gt;MEDLINE search strategy&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;TABLE style="TABLE-LAYOUT: fixed"&gt;
&lt;TBODY&gt;
&lt;TR style="FONT-FAMILY: Courier,monospace; FONT-SIZE: 7pt"&gt;
&lt;TD style="BORDER-BOTTOM: #000000 thin solid; BORDER-LEFT: #000000 thin solid; PADDING-BOTTOM: 5pt; PADDING-LEFT: 5pt; PADDING-RIGHT: 5pt; BORDER-TOP: #000000 thin solid; BORDER-RIGHT: #000000 thin solid; PADDING-TOP: 5pt" ?&gt;&lt;STRONG&gt;1&lt;/STRONG&gt; exp Hepatitis B/&lt;BR&gt;&lt;STRONG&gt;2&lt;/STRONG&gt; Hepatitis B Virus/&lt;BR&gt;&lt;STRONG&gt;3&lt;/STRONG&gt; exp Hepatitis B Antigens/&lt;BR&gt;&lt;STRONG&gt;4&lt;/STRONG&gt; Hepatitis B Vaccines/&lt;BR&gt;&lt;STRONG&gt;5&lt;/STRONG&gt; "Hepatitis B".ti,ab.&lt;BR&gt;&lt;STRONG&gt;6&lt;/STRONG&gt; "Hep B".ti,ab.&lt;BR&gt;&lt;STRONG&gt;7&lt;/STRONG&gt; HBV.ti,ab.&lt;BR&gt;&lt;STRONG&gt;8&lt;/STRONG&gt; HBSAG.ti,ab.&lt;BR&gt;&lt;STRONG&gt;9&lt;/STRONG&gt; HBCAG.ti,ab.&lt;STRONG&gt;&lt;BR&gt;10&lt;/STRONG&gt; HBEAG.ti,ab.&lt;BR&gt;&lt;STRONG&gt;11&lt;/STRONG&gt; exp Hepatitis C/&lt;BR&gt;&lt;STRONG&gt;12&lt;/STRONG&gt; Hepacivirus/&lt;BR&gt;&lt;STRONG&gt;13&lt;/STRONG&gt; Hepatitis C Antigens/&lt;BR&gt;&lt;STRONG&gt;14&lt;/STRONG&gt; "Hepatitis C".ti,ab.&lt;BR&gt;&lt;STRONG&gt;15&lt;/STRONG&gt; "Hep C".ti,ab.&lt;BR&gt;&lt;STRONG&gt;16&lt;/STRONG&gt; HCV.ti,ab.&lt;BR&gt;&lt;STRONG&gt;17&lt;/STRONG&gt; AGHCV.ti,ab.&lt;BR&gt;&lt;STRONG&gt;18&lt;/STRONG&gt; (Hepatitis adj ("non a" adj "non b")).ti,ab.&lt;BR&gt;&lt;STRONG&gt;19&lt;/STRONG&gt; Hepacivirus.ti,ab.&lt;BR&gt;&lt;STRONG&gt;20&lt;/STRONG&gt; Pt-nanbh.ti,ab.&lt;BR&gt;&lt;STRONG&gt;21&lt;/STRONG&gt; 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 &lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00; FONT-SIZE: 13pt"&gt;&lt;B&gt;&lt;U&gt;&lt;A name=filter&gt;&lt;/A&gt;Systematic review filter&lt;/U&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This is modified from the SIGN filter, which can be found at &lt;A href="http://www.sign.ac.uk/methodology/filters.html" target="_blank"&gt;http://www.sign.ac.uk/methodology/filters.html&lt;/A&gt;. It is shown below as used for the MEDLINE search (small adaptations were made for other databases).&lt;/P&gt;
&lt;TABLE style="BORDER-BOTTOM: #000000 thin solid; BORDER-LEFT: #000000 thin solid; FONT-FAMILY: Courier,serif; FONT-SIZE: 7pt; BORDER-TOP: #000000 thin solid; BORDER-RIGHT: #000000 thin solid"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="PADDING-BOTTOM: 5pt; PADDING-LEFT: 5pt; PADDING-RIGHT: 5pt; PADDING-TOP: 5pt"&gt;&lt;STRONG&gt;1&lt;/STRONG&gt; Meta-Analysis as Topic/&lt;BR&gt;&lt;STRONG&gt;2&lt;/STRONG&gt; Meta-Analysis/&lt;BR&gt;&lt;STRONG&gt;3&lt;/STRONG&gt; metaanaly*.mp. &lt;BR&gt;&lt;STRONG&gt;4&lt;/STRONG&gt; meta analy*.mp. &lt;BR&gt;&lt;STRONG&gt;5&lt;/STRONG&gt; (systematic adj (review* or overview*)).mp.&lt;BR&gt;&lt;STRONG&gt;6&lt;/STRONG&gt; exp Review Literature as Topic/&lt;BR&gt;&lt;STRONG&gt;7&lt;/STRONG&gt; 1 or 2 or 3 or 4 or 5 or 6&lt;BR&gt;&lt;STRONG&gt;8&lt;/STRONG&gt; Cochrane.ab.&lt;BR&gt;&lt;STRONG&gt;9&lt;/STRONG&gt; Embase.ab.&lt;BR&gt;&lt;STRONG&gt;10&lt;/STRONG&gt; Medline.ab.&lt;BR&gt;&lt;STRONG&gt;11&lt;/STRONG&gt; Pubmed.ab.&lt;BR&gt;&lt;STRONG&gt;12&lt;/STRONG&gt; (psychlit or psyclit).ab.&lt;BR&gt;&lt;STRONG&gt;13&lt;/STRONG&gt; (psychinfo or psycinfo).ab.&lt;BR&gt;&lt;STRONG&gt;14&lt;/STRONG&gt; (cinahl or cinhal).ab.&lt;BR&gt;&lt;STRONG&gt;15&lt;/STRONG&gt; science citation index.ab.&lt;BR&gt;&lt;STRONG&gt;16&lt;/STRONG&gt; bids.ab.&lt;BR&gt;&lt;STRONG&gt;17&lt;/STRONG&gt; cancerlit.ab.&lt;BR&gt;&lt;STRONG&gt;18&lt;/STRONG&gt; 11 or 9 or 17 or 12 or 15 or 14 or 8 or 16 or 10 or 13&lt;BR&gt;&lt;STRONG&gt;19&lt;/STRONG&gt; reference list$.ab.&lt;BR&gt;&lt;STRONG&gt;20&lt;/STRONG&gt; bibliograph$.ab.&lt;BR&gt;&lt;STRONG&gt;21&lt;/STRONG&gt; hand-search$.ab.&lt;BR&gt;&lt;STRONG&gt;22&lt;/STRONG&gt; relevant journals.ab.&lt;BR&gt;&lt;STRONG&gt;23&lt;/STRONG&gt; manual search$.ab.&lt;BR&gt;&lt;STRONG&gt;24&lt;/STRONG&gt; 22 or 21 or 23 or 19 or 20&lt;BR&gt;&lt;STRONG&gt;25&lt;/STRONG&gt; selection criteria.ab.&lt;BR&gt;&lt;STRONG&gt;26&lt;/STRONG&gt; data extraction.ab.&lt;BR&gt;&lt;STRONG&gt;27&lt;/STRONG&gt; 25 or 26&lt;BR&gt;&lt;STRONG&gt;28&lt;/STRONG&gt; review/&lt;BR&gt;&lt;STRONG&gt;29&lt;/STRONG&gt; 27 and 28&lt;BR&gt;&lt;STRONG&gt;30&lt;/STRONG&gt; Comment/&lt;BR&gt;&lt;STRONG&gt;31&lt;/STRONG&gt; Letter/&lt;BR&gt;&lt;STRONG&gt;32&lt;/STRONG&gt; editorial/&lt;BR&gt;&lt;STRONG&gt;33&lt;/STRONG&gt; 32 or 30 or 31&lt;BR&gt;&lt;STRONG&gt;34&lt;/STRONG&gt; 18 or 24 or 7 or 29&lt;BR&gt;&lt;STRONG&gt;35&lt;/STRONG&gt; 34 not 33&lt;BR&gt;&lt;STRONG&gt;36&lt;/STRONG&gt; limit 35 to animals&lt;BR&gt;&lt;STRONG&gt;37&lt;/STRONG&gt; limit 35 to (animals and humans)&lt;BR&gt;&lt;STRONG&gt;38&lt;/STRONG&gt; 36 not 37&lt;BR&gt;&lt;STRONG&gt;39&lt;/STRONG&gt; 35 not 38 &lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #99cc00"&gt;Hepatitis B and C Annual Evidence Update 2010&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #33cccc"&gt;
&lt;P&gt;&lt;A href="nelh:381482:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381479:0" name=internalLink&gt;Economics&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381480:0" name=internalLink&gt;Prevention&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381478:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:381474:0" name=internalLink&gt;Hepatitis B&lt;/A&gt; | &lt;A href="nelh:381475:0" name=internalLink&gt;Hepatitis C&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:381477:0" name=internalLink&gt;Adverse effects&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381476:0" name=internalLink&gt;Risk factors&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:381471:0" name=internalLink&gt;Other&lt;/B&gt;&lt;/A&gt;&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:381473:0" name=internalLink&gt;Foreign articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381483:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381481:0" name=internalLink&gt;&lt;B&gt;Methods&lt;/B&gt;&lt;/A&gt;&lt;/P&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>381471</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=381471]]&gt;</url>
    <title>2010 Annual Evidence Update on Hepatitis B and C - Other</title>
    <publicationDate>2010-07-26T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,HEPATITIS C,NON-ALCOHOLIC,LIVER TRANSPLANTATION,RECENT ADDITIONS,CIRRHOSIS,CHRONIC HEPATITIS C,SURGERY,JULY 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Hepatitis B and C - Other&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;I&gt;Reviewed by Lynda Greenslade, Clinical Nurse Specialist in Hepatology, Royal Free Hampstead NHS Trust, London&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;Accessing healthcare is currently an important issue for all health care providers and government who are trying to ensure that the current health service ensures that the general public receive equitable quality care. HCV is a case where it is essential for the health service to identify and offer if appropriate treatment in order to reduce the long term burden of HCV disease on the health service in the future. &lt;A href="#treloar"&gt;Treloar and Rhodes&lt;/A&gt; look at the lived experience of hepatitis C and its treatment among injecting drug users (IDUs) and has several messages for health care professionals about how to engage with IDUs in order to redesign services and pathways that are inclusive and that uses IDUs own experiences of trying and failing to access healthcare so as to avoid current pitfalls and shortcomings in future patient centred services. This review looked at 25 published articles and generated themes that are uniquely drawing on the perspectives of drug injectors rather than others living with hepatitis C. The analysis of the themes using the thoughts and words of the drug injectors themselves challenges our more traditional health care professional views where past personal adversity such as dealing with drug addiction and withdrawal meant that the drug injector was resilient and able to draw on some of the previously used coping mechanisms to get through their hepatitis C treatment. It shows that often drug injectors felt they were not given enough and appropriate information about treatment and were being hurried through as if to get them out of the system and on to someone deemed to be more worthy. This review is important reading for those of us working with patients with HCV and involved in trying to think out of the box when designing pathways to engage all those who need access to testing and treatment. It also shows that there is a need for more research on the lived experiences of coping with not just HCV but all viral hepatitis.&lt;/P&gt;
&lt;P&gt;A second paper by &lt;A href="#fabrizi"&gt;Fabrizi, Messa and Martin&lt;/A&gt; looked at health related quality of life (HRQOL) in dialysis patients with hepatitis c infection which is linked to a reduced mortality in patients with end stage renal disease. Interestingly it discussed possible links with HCV infection and depression in patients on dialysis and how this was poorly understood. Depression can be seen in any patients being treated with HCV infection and this paper reminds us that HRQOL screening and assessment for the development of depression throughout treatment for HCV infection remains an important part of the role of HCP looking after patients on treatment.&lt;/P&gt;
&lt;P&gt;The paper by &lt;A href="#Cholongitas"&gt;Cholongitas, Papatheodoridis and Burroughs&lt;/A&gt; also reviews the evidence for using liver grafts from anti-hepatitis B core positive donors, and gives clear guidance that these livers can be safely used and this should be added to any future practice guidelines.&lt;/P&gt;
&lt;P&gt;Also included in this AEU are reviews by &lt;A href="#hosseini"&gt;Hosseini-Moghaddam et al&lt;/A&gt; on delta hepatitis in haemodialysis patients, and by &lt;A href="#kapp"&gt;Kapp, Tilley and Curtis&lt;/A&gt; on the effects of hormonal contraceptives in women with viral hepatitis or cirrhosis. &lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Articles:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=Cholongitas&gt;&lt;/A&gt;Cholongitas E, Papatheodoridis GV, Burroughs AK. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=378384" target="_blank"&gt;Liver grafts from anti-hepatitis B core positive donors: a systematic review.&lt;/A&gt; &lt;I&gt;J Hepatol&lt;/I&gt; 2010;52(2):272-9.&lt;/P&gt;
&lt;P&gt;&lt;A name=fabrizi&gt;&lt;/A&gt;Fabrizi F, Messa P, Martin P. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=381427" target="_blank"&gt;Health-related quality of life in dialysis patients with HCV infection.&lt;/A&gt; &lt;I&gt;Int J Artif Organs&lt;/I&gt; 2009;32(8):473-481.&lt;/P&gt;
&lt;P&gt;&lt;A name=hosseini&gt;&lt;/A&gt;Hosseini-Moghaddam SM, Imani AA, Rizzetto M, Alavian SM. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=381428" target="_blank"&gt;Viral hepatitis D among hemodialysis patients: a worldwide underestimated problem.&lt;/A&gt; &lt;I&gt;Hepat Mon&lt;/I&gt; 2009;9(4):305-9.&lt;/P&gt;
&lt;P&gt;&lt;A name=kapp&gt;&lt;/A&gt;Kapp N, Tilley IB, Curtis KM. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=381429" target="_blank"&gt;The effects of hormonal contraceptive use among women with viral hepatitis or cirrhosis of the liver: a systematic review.&lt;/A&gt; &lt;I&gt;Contraception&lt;/I&gt; 2009;80(4):381-6.&lt;/P&gt;
&lt;P&gt;&lt;A name=treloar&gt;&lt;/A&gt;Treloar C, Rhodes T. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=381430" target="_blank"&gt;The lived experience of hepatitis C and its treatment among injecting drug users: qualitative synthesis.&lt;/A&gt; &lt;I&gt;Qual Health Res&lt;/I&gt; 2009;19(9):1321-34.&lt;/P&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #99cc00"&gt;Hepatitis B and C Annual Evidence Update 2010&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #33cccc"&gt;
&lt;P&gt;&lt;A href="nelh:381482:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381479:0" name=internalLink&gt;Economics&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381480:0" name=internalLink&gt;Prevention&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381478:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:381474:0" name=internalLink&gt;Hepatitis B&lt;/A&gt; | &lt;A href="nelh:381475:0" name=internalLink&gt;Hepatitis C&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:381477:0" name=internalLink&gt;Adverse effects&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381476:0" name=internalLink&gt;Risk factors&lt;/A&gt; &lt;BR&gt;&lt;B&gt;&lt;A href="nelh:381471:0" name=internalLink&gt;&lt;B&gt;Other&lt;/B&gt;&lt;/A&gt;&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:381473:0" name=internalLink&gt;Foreign articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381483:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381481:0" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>381480</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=381480]]&gt;</url>
    <title>2010 Annual Evidence Update on Hepatitis B and C - Prevention</title>
    <publicationDate>2010-07-26T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,DISEASE PREVENTION,VACCINATION,RECENT ADDITIONS,JULY 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Hepatitis B and C - Prevention&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P style="COLOR: #99cc00; FONT-SIZE: 12pt"&gt;&lt;B&gt;Cochrane reviews&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The following Cochrane reviews were released or updated this year:&lt;/P&gt;
&lt;P&gt;Bar-On ES, Goldberg E, Fraser A, Vidal L, Hellmann S, Leibovici L. &lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=320759" target="_blank"&gt;Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB).&lt;/A&gt; &lt;I&gt;Cochrane Database of Systematic Reviews&lt;/I&gt; 2009, Issue 3. Art. No.: CD005530. DOI: 10.1002/14651858.CD005530.pub2.&lt;/P&gt;
&lt;P&gt;Katz LH, Tur-Kaspa R, Guy DG, Paul M. &lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=380420" target="_blank"&gt;Lamivudine or adefovir dipivoxil alone or combined with immunoglobulin for preventing hepatitis B recurrence after liver transplantation.&lt;/A&gt; &lt;I&gt;Cochrane Database of Systematic Reviews&lt;/I&gt; 2010, Issue 7. Art. No.: CD006005. DOI: 10.1002/14651858.CD006005.pub2.&lt;/P&gt;
&lt;P&gt;McIntyre PG, Tosh K, McGuire W. &lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=239155" target="_blank"&gt;Caesarean section versus vaginal delivery for preventing mother to infant hepatitis C virus transmission.&lt;/A&gt; &lt;I&gt;Cochrane Database of Systematic Reviews&lt;/I&gt; 2006, Issue 4. Art. No.: CD005546. DOI: 10.1002/14651858.CD005546.pub2.&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00; FONT-SIZE: 12pt"&gt;&lt;B&gt;Other reviews&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;Reviewed by Janice Main, Reader in Infectious Diseases and General Medicine, Imperial College at St Mary's Hospital, London&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;The paper by &lt;A href="#alavian"&gt;Alavian and Tabatabaei&lt;/A&gt; reviews the problems of the reduced efficacy of hepatitis B vaccination in patients with end-stage renal disease. Various strategies have been suggested for this group of patients and the authors performed a meta-analysis of controlled clinical trials of levamisole, an immune modulator, in this setting. They identified four studies which suggest a beneficial response and highlight the need for larger randomized clinical trials.&lt;/P&gt;
&lt;P&gt;Poorolajal et al have published two meta-analyses (&lt;A href="#poorolajal1"&gt;1&lt;/A&gt;, &lt;A href="#poorolajal2"&gt;2&lt;/A&gt;) on the long term protection of HBV vaccination and the effects of booster doses. Their analyses suggest that although, with time, protective antibodies gradually decrease the risk of subsequent infection is low and, in healthy individuals with a good response to the initial vaccine course, booster doses of vaccine are not required.&lt;/P&gt;
&lt;P&gt;&lt;A href="#saab"&gt;Saab et al&lt;/A&gt; review 13 studies comparing lamivudine monotherapy with lamivudine/hepatitis B immune globulin (HBIG) after liver transplantation from a hepatitis B core antibody donor. Their analysis suggests that both strategies are effective and that lamivudine monotherapy is as effective as the combination approach.&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Articles:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=alavian&gt;&lt;/A&gt;Alavian SM, Tabatabaei SV. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=380715" target="_blank"&gt;Effects of oral levamisole as an adjuvant to hepatitis B vaccine in adults with end-stage renal disease: a meta-analysis of controlled clinical trials.&lt;/A&gt; &lt;I&gt;Clin Ther&lt;/I&gt; 2010;32(1):1-10.&lt;/P&gt;
&lt;P&gt;&lt;A name=poorolajal1&gt;&lt;/A&gt;Poorolajal J, Mahmoodi M, Majdzadeh R, Nasseri-Moghaddam S, Haghdoost A, Fotouhi A. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=380718" target="_blank"&gt;Long-term protection provided by hepatitis B vaccine and need for booster dose: a meta-analysis.&lt;/A&gt; &lt;I&gt;Vaccine&lt;/I&gt; 2010;28(3):623-31.&lt;/P&gt;
&lt;P&gt;&lt;A name=poorolajal2&gt;&lt;/A&gt;Poorolajal J, Mahmoodi M, Majdzadeh R, Nasseri-Moghaddam S, Haghdoost A, Ghalichi L, Fotouhi A. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=380716" target="_blank"&gt;Seroprotection of hepatitis B vaccine and need for booster dose: a meta-analysis.&lt;/A&gt; &lt;I&gt;Hepat Mon&lt;/I&gt; 2009;9(4):293-304.&lt;/P&gt;
&lt;P&gt;&lt;A name=saab&gt;&lt;/A&gt;Saab S, Waterman B, Chi AC, Tong MJ. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=380728" target="_blank"&gt;Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody-positive donors: a systematic review.&lt;/A&gt; &lt;I&gt;Liver Transpl&lt;/I&gt; 2010;16(3):300-7.&lt;/P&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #99cc00"&gt;Hepatitis B and C Annual Evidence Update 2010&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #33cccc"&gt;
&lt;P&gt;&lt;A href="nelh:381482:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381479:0" name=internalLink&gt;Economics&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381480:0" name=internalLink&gt;&lt;B&gt;Prevention&lt;/B&gt;&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381478:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:381474:0" name=internalLink&gt;Hepatitis B&lt;/A&gt; | &lt;A href="nelh:381475:0" name=internalLink&gt;Hepatitis C&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:381477:0" name=internalLink&gt;Adverse effects&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381476:0" name=internalLink&gt;Risk factors&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:381471:0" name=internalLink&gt;Other&lt;/B&gt;&lt;/A&gt;&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:381473:0" name=internalLink&gt;Foreign articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381483:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381481:0" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>381476</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=381476]]&gt;</url>
    <title>2010 Annual Evidence Update on Hepatitis B and C - Risk factors</title>
    <publicationDate>2010-07-26T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,HEPATITIS C,HEPATOCELLULAR CARCINOMA,HIV / AIDS,RECENT ADDITIONS,CANCER,CHRONIC HEPATITIS B,CHRONIC HEPATITIS C,JULY 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Hepatitis B and C - Risk factors&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;I&gt;Reviewed by Graeme Alexander, Consultant Hepatologist, Addenbrooke's Hospital, Cambridge, and Martin James, Consultant Hepatologist and Gastroenterologist, Queen's Medical Centre, Nottingham&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Graeme Alexander:&lt;/B&gt; &lt;A href="#chen"&gt;Chen et al&lt;/A&gt; is a solid meta-analysis of 37 studies, with well selected patients from two different eras which demonstrate clearly that hepatitis C co-infection with HIV increases mortality. There is not much more that a meta-analysis can conclude but the message here is clear.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Martin James:&lt;/B&gt; The link between HBV infection and the development of hepatocellular carcinoma has been well established previously with studies such as the REVEAL cohort study conducted in Taiwan (JAMA 2006), but the proportion of HCC cases related to chronic viral hepatitis (HBV or HCV) elsewhere in the world varies considerably &lt;/P&gt;
&lt;P&gt;&lt;A href="#franceschi"&gt;Franchesci and Raza&lt;/A&gt; conducted a meta-analysis of 90 studies including nearly 28,000 cases of HCC from 36 countries to study the worldwide variation in attributable risk of viral hepatitis in causation of HCC. In addition, they attempted to examine and describe the implementation and impact of HBV vaccination programmes and on HCC development.&lt;/P&gt;
&lt;P&gt;As expected, most HCC cases (66%) were from Asia and the rest from the Americas (15%), Europe (12%) with relatively few from Africa (7%; over half of these patients originated from Egypt), probably due to difficulties in accurate recording and publication. There was substantial variation in HBVsAg and anti-HCV antibodies in HCC cases across and within different continents. The highest rates of HBV positivity (over 50%) was in Taiwan, China, Korea, Thailand, Vietnam and Turkey. Conversely, the countries with a higher proportion of HCV positivity in HCC cases were Japan (68%), Pakistan (45%) and Mongolia (40%). &lt;/P&gt;
&lt;P&gt;In Europe, all countries apart from Greece had a higher proportion of HCC cases positive for HCV (approximately 45%) than for HBV. In Greece, 56% had HBVsAg positivity. HBV/HCV co-infection was relatively uncommon (3%), whereas absence of any chronic viral hepatitis in some northern European countries was common (80% in the study from Sweden). The majority of American studies came from the US, with 22% anti-HCV positive and only 9% positive for HBVsAg. The relatively low level of viral positivity in Western countries suggests that other aetiologies, principally alcoholic liver disease, are likely to be the cause of cirrhosis and predisposition for HCC, although these data were not presented directly.&lt;/P&gt;
&lt;P&gt;HBV vaccines were first licensed in 1981 and are now mostly produced by recombinant DNA technology. HBV vaccination programmes were introduced into highly endemic areas such as Taiwan in 1984; this resulted in a substantial fall in HCC in the following two decades and other studies in Gambia and Qidong China are due to report soon. The debate continues in the UK and other low HBV endemic countries whether universal vaccination should be introduced or to continue with targeting high risk individuals. However, with increased immigration from highly endemic areas, the falling price of HBV vaccines and the serious consequences and high cost of treating HCC, the balance may have shifted enough to reconsider this approach to favour universal vaccination.&lt;/P&gt;
&lt;P&gt;&lt;A href="#liu"&gt;Liu et al&lt;/A&gt; performed a meta-analysis of the association between different HBV mutations and the risk of HCC using 43 studies mostly from East Asia, including over 11,000 patients with HBV infection, and 2800 with HCC. HBV PreS mutations (C1653T, T1753V) and A1762T/G1764A were associated with an increased risk of developing HCC (summary odds ratio of approximately 3-4). These mutations also became more prevalent with increasing duration of infection and were proposed as potential biomarkers for subsequent HCC development. This raises the potential for confounding of duration of infection and presumably the likelihood of increasing liver fibrosis. In addition, not all patients included in the studies had HBV mutation analysis, which may introduce selection bias for those with higher HBV DNA levels, which has been demonstrated to be an important independent risk for future HCC development (REVEAL; JAMA 2006). The precore mutations G1896A and C1858T were not associated with HCC risk in this meta-analysis. &lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Articles:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=chen&gt;&lt;/A&gt;Chen TY, Ding EL, Seage Iii GR, Kim AY. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=380699" target="_blank"&gt;Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression.&lt;/A&gt; &lt;I&gt;Clin Infect Dis&lt;/I&gt; 2009;49(10):1605-15.&lt;/P&gt;
&lt;P&gt;&lt;A name=franceschi&gt;&lt;/A&gt;Franceschi S, Raza SA. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=380694" target="_blank"&gt;Epidemiology and prevention of hepatocellular carcinoma.&lt;/A&gt; &lt;I&gt;Cancer Lett&lt;/I&gt; 2009;286(1):5-8.&lt;/P&gt;
&lt;P&gt;&lt;A name=liu&gt;&lt;/A&gt;Liu S, Zhang H, Gu C, Yin J, He Y, Xie J, Cao G. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=380695" target="_blank"&gt;Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis.&lt;/A&gt; &lt;I&gt;J Natl Cancer Inst&lt;/I&gt; 2009;101(15):1066-82.&lt;/P&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #99cc00"&gt;Hepatitis B and C Annual Evidence Update 2010&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #33cccc"&gt;
&lt;P&gt;&lt;A href="nelh:381482:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381479:0" name=internalLink&gt;Economics&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381480:0" name=internalLink&gt;Prevention&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381478:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:381474:0" name=internalLink&gt;Hepatitis B&lt;/A&gt; | &lt;A href="nelh:381475:0" name=internalLink&gt;Hepatitis C&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:381477:0" name=internalLink&gt;Adverse effects&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381476:0" name=internalLink&gt;&lt;B&gt;Risk factors&lt;/B&gt;&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:381471:0" name=internalLink&gt;Other&lt;/B&gt;&lt;/A&gt;&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:381473:0" name=internalLink&gt;Foreign articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381483:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381481:0" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>381474</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=381474]]&gt;</url>
    <title>2010 Annual Evidence Update on Hepatitis B and C - Treatment | Hepatitis B</title>
    <publicationDate>2010-07-26T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,LIVER TRANSPLANTATION,RECENT ADDITIONS,CHRONIC HEPATITIS B,SURGERY,JULY 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Hepatitis B and C - Treatment | Hepatitis B&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;I&gt;Reviewed by Steven Ryder, Consultant Physician and Hepatologist, Queen's Medical Centre, Nottingham&lt;/I&gt;&lt;/P&gt;
&lt;P style="COLOR: #99cc00; FONT-SIZE: 12pt"&gt;&lt;B&gt;Guidelines&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;NICE has revisited HBV therapies and &lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=321031" target="_blank"&gt;guidance&lt;/A&gt; is available which should be seen in the context of the EASL guidelines for treatment, an excellent and thoughtful document.&lt;/P&gt;
&lt;P&gt;Also released this year were revised &lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=343575" target="_blank"&gt;AASLD guidelines&lt;/A&gt; on chronic hepatitis B &lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00; FONT-SIZE: 12pt"&gt;&lt;B&gt;Other reviews&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;There has been a revolution in the therapy of HBV infection with oral agents proving highly effective. Older therapies such as interferon remain an important part of the armoury. In South Asia there have been a number of studies of thymosin alpha. A meta analysis of trials of lamivudine and thymosin (&lt;A href="#zhang3"&gt;Zhang et al&lt;/A&gt;) suggest better outcomes in e antigen positive patients. It is a therapy which we have not seen used in the Western world but the contrast with interferon where combination therapy shows no benefit, is interesting. The effectiveness of interferon alpha treatment in hepatitis B was confirmed and the magnitude of the effect on e antigen seroconversion and surface antigen loss quantified in a meta-analysis of 7 trials (&lt;A href="#yang"&gt;Yang et al&lt;/A&gt;), the relative risk of e antigen loss was 0.66 and of surface antigen loss 0.28 over 3-7 years post therapy. A further study confirms that interferon therapy slows progression of hepatic fibrosis (&lt;A href="#poynard"&gt;Poynard et al&lt;/A&gt;). Another Eastern perspective on HBV is provided by Zhang et al. This summarises the trials of traditional Chinese medicines (TCM) used for HBV as compared to interferon and Lamivudine. The headline was that TCM has greater effect on ALT values than conventional therapies. A health warning concerning the quality of the studies is included but a further view eastwards for effective therapies may be indicated.&lt;/P&gt;
&lt;P&gt;Combination therapy seemed the likely best option for long term therapy of hepatitis B with oral agents in the era of relatively weak agents with high resistance rates, the effectiveness of combining adefovir and lamivudine was confirmed in a meta-analysis (&lt;A href="#chen"&gt;Chen et al&lt;/A&gt;) but with the newer more potent agents such a strategy may not be so compelling or necessary.&lt;/P&gt;
&lt;P&gt;Reactivation of HBV in patients undergoing cancer chemotherapy has been a significant problem, and a &lt;A href="#ziakas"&gt;meta-analysis&lt;/A&gt; suggests that lamivudine prophylaxis reduces the risk of reactivation and showed a trend towards reduced mortality. It gives some concrete figures which are useful in discussions with patients (1/1000 mortality given prophylaxis versus 25/1000 if not).&lt;/P&gt;
&lt;P&gt;Children with chronic hepatitis B are frequently in the immunotolerant phase of infection which has limited effectiveness of therapy in the relatively small studies which have been undertaken. A summary of the data is included in a review (&lt;A href="#giacchino"&gt;Giacchino and Cappelli&lt;/A&gt;). There are studies of the more modern oral agents ongoing in adolescents but a limited evidence base for other therapies.&lt;/P&gt;
&lt;P&gt;Replicating chronic hepatitis B was a contraindication to liver transplantation 15 years ago but the advances in therapeutics have totally reversed this with HBV now a good indication for transplantation with very low recurrence rates. &lt;A href="#zhang1"&gt;Zhang, Zhou and Zheng&lt;/A&gt; provide a concise summary of the evidence for effectiveness of therapy and the history of improvements in outcomes. A review article summarises the current best practice in prevention of recurrent HBV (&lt;A href="#Papatheodoridis"&gt;Papatheodoridis et al&lt;/A&gt;). &lt;/P&gt;
&lt;P&gt;Also included in this AEU is a health technology assessment on adefovir dipivoxil and pegylated interferon alpha for chronic hepatitis B by &lt;A href="#jones"&gt;Jones et al&lt;/A&gt;. &lt;BR&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Articles:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=chen&gt;&lt;/A&gt;Chen EQ, Wang LC, Lei J, Xu L, Tang H. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=381381" target="_blank"&gt;Meta-analysis: adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus.&lt;/A&gt; &lt;I&gt;Virol J&lt;/I&gt; 2009;6:163.&lt;/P&gt;
&lt;P&gt;&lt;A name=giacchino&gt;&lt;/A&gt;Giacchino R, Cappelli B. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=381391" target="_blank"&gt;Treatment of viral hepatitis B in children.&lt;/A&gt; &lt;I&gt;Expert Opin Pharmacother&lt;/I&gt; 2010;11(6):889-903.&lt;/P&gt;
&lt;P&gt;&lt;A name=jones&gt;&lt;/A&gt;Jones J, Shepherd J, Baxter L, Gospodarevskaya E, Hartwell D, Harris P, Price A. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=381419" target="_blank"&gt;Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation.&lt;/A&gt; &lt;I&gt;Health Technol Assess&lt;/I&gt; 2009;13(35):1-172, iii.&lt;/A&gt; 
&lt;P&gt;&lt;A name=Papatheodoridis&gt;&lt;/A&gt;Papatheodoridis GV, Cholongitas E, Archimandritis AJ, Burroughs AK. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=381413" target="_blank"&gt;Current management of hepatitis B virus infection before and after liver transplantation.&lt;/A&gt; &lt;I&gt;Liver Int&lt;/I&gt; 2009;29(9):1294-305. &lt;/P&gt;
&lt;P&gt;&lt;A name=poynard&gt;&lt;/A&gt;Poynard T, Massard J, Rudler M, Varaud A, Lebray P, Moussalli J, Munteanu M, Ngo Y, Thabut D, Benhamou Y, Ratziu V. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=381274" target="_blank"&gt;Impact of interferon-alpha treatment on liver fibrosis in patients with chronic hepatitis B: an overview of published trials.&lt;/A&gt; &lt;I&gt;Gastroenterol Clin Biol&lt;/I&gt; 2009;33(10-11):916-22.&lt;/P&gt;
&lt;P&gt;&lt;A name=yang&gt;&lt;/A&gt;Yang YF, Zhao W, Xia HM, Zhong YD, Huang P, Wen J. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=381273" target="_blank"&gt;Long-term efficacy of interferon alpha therapy on hepatitis B viral replication in patients with chronic hepatitis B: a meta-analysis.&lt;/A&gt; &lt;I&gt;Antiviral Res&lt;/I&gt; 2010;85(2):361-5.&lt;/P&gt;
&lt;P&gt;&lt;A name=zhang1&gt;&lt;/A&gt;Zhang J, Zhou L, Zheng SS. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=381392" target="_blank"&gt;Clinical management of hepatitis B virus infection correlated with liver transplantation.&lt;/A&gt; &lt;I&gt;Hepatobiliary Pancreat Dis Int&lt;/I&gt; 2010;9(1):15-21.&lt;/P&gt;
&lt;P&gt;&lt;A name=zhang2&gt;&lt;/A&gt;Zhang L, Wang G, Hou W, Li P, Dulin A, Bonkovsky HL. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=381275" target="_blank"&gt;Contemporary clinical research of traditional Chinese medicines for chronic hepatitis B in China: an analytical review.&lt;/A&gt; &lt;I&gt;Hepatology&lt;/I&gt; 2010;51(2):690-8.&lt;/P&gt;
&lt;P&gt;&lt;A name=zhang3&gt;&lt;/A&gt;Zhang YY, Chen EQ, Yang J, Duan YR, Tang H. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=381272" target="_blank"&gt;Treatment with lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B patients: a meta-analysis.&lt;/A&gt; &lt;I&gt;Virol J&lt;/I&gt; 2009;6:63.&lt;/P&gt;
&lt;P&gt;&lt;A name=ziakas&gt;&lt;/A&gt;Ziakas PD, Karsaliakos P, Mylonakis E. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=381386" target="_blank"&gt;Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance.&lt;/A&gt; &lt;I&gt;Haematologica&lt;/I&gt; 2009;94(7):998-1005.&lt;/P&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #99cc00"&gt;Hepatitis B and C Annual Evidence Update 2010&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #33cccc"&gt;
&lt;P&gt;&lt;A href="nelh:381482:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381479:0" name=internalLink&gt;Economics&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381480:0" name=internalLink&gt;Prevention&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381478:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:381474:0" name=internalLink&gt;&lt;B&gt;Hepatitis B&lt;/B&gt;&lt;/A&gt; | &lt;A href="nelh:381475:0" name=internalLink&gt;Hepatitis C&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:381477:0" name=internalLink&gt;Adverse effects&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381476:0" name=internalLink&gt;Risk factors&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:381471:0" name=internalLink&gt;Other&lt;/B&gt;&lt;/A&gt;&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:381473:0" name=internalLink&gt;Foreign articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381483:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381481:0" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>381475</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=381475]]&gt;</url>
    <title>2010 Annual Evidence Update on Hepatitis B and C - Treatment | Hepatitis C</title>
    <publicationDate>2010-07-26T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,HIV / AIDS,RECENT ADDITIONS,CHRONIC HEPATITIS C,JULY 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Hepatitis B and C - Treatment | Hepatitis C&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P style="COLOR: #99cc00; FONT-SIZE: 12pt"&gt;&lt;B&gt;Guidelines&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The following guidelines were published this year:&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=343595" target="_blank"&gt;Diagnosis, management, and treatment of hepatitis C: an update&lt;/A&gt; (American Association for the Study of Liver Diseases)&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=343359" target="_blank"&gt;British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=328731" target="_blank"&gt;Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program&lt;/A&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00; FONT-SIZE: 12pt"&gt;&lt;B&gt;Cochrane reviews&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The following Cochrane reviews were released or updated this year:&lt;/P&gt;
&lt;P&gt;Brok J, Gluud LL, Gluud C. &lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=239148" target="_blank"&gt;Ribavirin monotherapy for chronic hepatitis C.&lt;/A&gt; &lt;I&gt;Cochrane Database of Systematic Reviews&lt;/I&gt; 2009, Issue 4. Art. No.: CD005527. DOI: 10.1002/14651858.CD005527.pub2.&lt;/P&gt;
&lt;P&gt;Brok J, Gluud LL, Gluud C. &lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=239176" target="_blank"&gt;Ribavirin plus interferon versus interferon for chronic hepatitis C.&lt;/A&gt; &lt;I&gt;Cochrane Database of Systematic Reviews&lt;/I&gt; 2010, Issue 1. Art. No.: CD005445. DOI: 10.1002/14651858.CD005445.pub2.&lt;/P&gt;
&lt;P&gt;Gurusamy KS, Tsochatzis E, Xirouchakis E, Burroughs AK, Davidson BR. &lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=304927" target="_blank"&gt;Antiviral therapy for recurrent liver graft infection with hepatitis C virus.&lt;/A&gt; &lt;I&gt;Cochrane Database of Systematic Reviews&lt;/I&gt; 2010, Issue 1. Art. No.: CD006803. DOI: 10.1002/14651858.CD006803.pub3.&lt;/P&gt;
&lt;P&gt;Iorio A, Marchesini E, Awad T, Gluud LL. &lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=341713" target="_blank"&gt;Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus.&lt;/A&gt; &lt;I&gt;Cochrane Database of Systematic Reviews&lt;/I&gt; 2010, Issue 1. Art. No.: CD004888. DOI: 10.1002/14651858.CD004888.pub2.&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00; FONT-SIZE: 12pt"&gt;&lt;B&gt;Other reviews&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;Reviewed by Jane Collier, Consultant Hepatologist, John Radcliffe Hospital, Oxford and Jan Freeman, Consultant Hepatologist and Lead Clinician for Gastroenterology and Hepatology, Royal Derby Hospital &lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Jane Collier:&lt;/B&gt; The current recommended treatment of hepatitis C is pegylated interferon and ribavirin, but very few Chinese patients were included in the large phase 3 trials of this. &lt;A href="#zhao"&gt;Zhao et al&lt;/A&gt; have reviewed 7 studies, including a total of 398 Chinese patients, comparing this with standard interferon and ribavirin, confirming that the former is superior to the standard combination, with a relative risk of 1.76 (95% confidence interval 1.21 to 2.56). &lt;/P&gt;
&lt;P&gt;A recent randomised trial has shown no difference between the efficacy of pegylated interferon 2a and pegylated interferon 2b. In a meta-analysis by &lt;A href="#awad"&gt;Awad et al&lt;/A&gt;, 12 studies comparing these 2 drugs were pooled. Although pegylated interferon 2a was superior with a sustained virological response (SVR) experienced by 47% of participants, compared with 41% in pegylated interferon 2b, with a risk ratio (RR) of 1.11, the studies included were heterogeneous: different genotypes were included and not all patients were naïve or given weight based ribavirin. There were also not enough adverse events recorded to conclude a difference between the two drugs. The length of current treatment is dependent on genotype and viral kinetics, and as these drugs are expensive, recent research has been aimed at individualising length of treatment. A recent large study (ACCELERATE) in genotype 2 and 3 patients showed significant lower SVR with 16 weeks versus the conventional 24 weeks of therapy, even in those patients with a rapid virological response (RVR) (i.e. those who were HCV PCR negative at 4 weeks). The meta-analysis by &lt;A href="#slavenburg"&gt;Slavenburg et al&lt;/A&gt; looked at 8 studies comparing 24 weeks with 16 weeks treatment. 3 studies were randomised at the start of treatment (as per ACCELERATE) and 5 randomised at 4 weeks in those achieving a RVR. Although SVR were higher in those randomised to 2 weeks at baseline, RR 0.8, the SVR was similar in those patients who were HCV negative at 4 weeks and given 16 weeks compared to 24 weeks (82% versus 83%; RR 1.00). Patients who are not tolerating treatment at 16 weeks with an RVR could stop treatment with a good chance of an SVR. The role of a favourable interferon lambda genotype in identifying which of those with a RVR will achieve at SVR is currently unknown. &lt;/P&gt;
&lt;P&gt;In a meta-analysis looking at the cost-effectiveness of 24 weeks of treatment for genotype 2/3 and 48 weeks for genotype 1, &lt;A href="#sroczynski"&gt;Sroczynski et al&lt;/A&gt; showed treatment to be cost effective as defined by a 84700 Euro/QALY with a 3-4 year life, excluding patients with mild disease (normal LFTs). This study did not assess if costs could be reduced by individualising treatment, which was done by &lt;A href="#siebert"&gt;Siebert et al&lt;/A&gt;. They looked at the cost-effectiveness of German guidelines, which include 24 weeks treatment for genotype 2/3 and stopping treatment at 12 weeks in patients with genotype 1 who had &amp;lt; 2 log drop, and use weight based ribavirin dosing. Pegylated interferon and ribavirin increased undiscounted life expectancy by 5 life-years and individualisation of treatment dose was cheaper with a cost saving of 17000 Euros/per QALY. Similar studies will need to be performed when the protease inhibitors become licensed as they are likely to be significantly more costly. A meta-analysis by &lt;A href="#singal1"&gt;Singal et al&lt;/A&gt; has confirmed improved survival in patients with advanced fibrosis following a SVR with less liver related mortality (RR 0.23). None of the above studies were able to assess reduced liver related mortality in non-cirrhotics with a SVR due to lack of sufficient long-term follow-up data in patients with and without a SVR.&lt;/P&gt;
&lt;P&gt;Ribavirin is associated with haemolysis and dose reduction. Ribavirin dose reduction may not lead to poorer outcomes as a recent trial comparing ribavirin with the prodrug taribavirin which, although causing less anaemia, did not lead to a increased SVR. &lt;A href="#chan"&gt;Chan, Partovi and Ensom&lt;/A&gt; looked at whether therapeutic drug monitoring (TDM) for ribavirin is warranted in clinical practice. In a review of literature showed not clear that good relationship between drug levels and degree of anaemia, In 53 small studies, 12 in HIV infection and 5 in renal failure, there was no clear relationship between ribavirin concentration and virological response. There are no studies comparing ribavirin TDM versus dose reduction using Hb on SVR. Overall, there is no clear evidence for use of TDM.&lt;/P&gt;
&lt;P&gt;Adherence to therapy (compliance) is important in HCV treatment and will continue to be once direct antiviral therapy, i.e. protease inhibitors, are licensed, as poor compliance may lead to drug resistance. &lt;A href="#weiss"&gt;Weiss et al&lt;/A&gt; identified 8 studies assessing adherence with interferon/ribavirin combinations. 5 studies with pegylated interferon reported missed doses with adherence rates between 74%-92% in the first 12 weeks, falling towards end of treatment, with only 1 reporting effect on SVR. Three further studies, which combined adherence with dose reductions for medical reasons, showed that taking at least 80% of the initial prescribed dose of interferon/ribavirin for 80% of the recommended duration of treatment was associated with increased SVR. Thus these studies show non-adherence is common, but the effects on SVR for PEG-IFN/ribavirin are unknown. &lt;/P&gt;
&lt;P&gt;&lt;A href="#gentile"&gt;Gentile et al&lt;/A&gt; have reviewed the phase 2 data on the protease inhibitor telepravir combined with pegylated interferon and ribavirin for naïve genotype 1 patients and this together with the phase 2 study in treatment experienced patients both show improved SVR over current standard therapy (ie peg-interferon and ribavirin). Telepravir was given at different time points and different length during treatment and the ongoing phase 3 study will dictate the optimum dosing regimen and confirm efficacy data.&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;B&gt;Jan Freeman:&lt;/B&gt; &lt;A href="#camma"&gt;Camma et al&lt;/A&gt; address the issue of retreatment in non-responders, giving good advice on who to select for retreatment rather than indiscriminate treatment of all non-responders. Modest efficacy (16% SVR) of retreatment is achieved in genotype 2 or 3, in the non-obese, and by use of a 24 week stopping rule in those who fail to seroconvert.&lt;/P&gt;
&lt;P&gt;&lt;A href="#fabrizi"&gt;Fabrizi et al&lt;/A&gt; show that the use of Pegylated interferon does not add any benefit to standard interferon mono-therapy in patients undergoing dialysis.&lt;/P&gt;
&lt;P&gt;&lt;A href="#gluud"&gt;Gluud, Marchesini and Iorio&lt;/A&gt; confirm the utility of PEG interferon and ribavirin in co-infected patients although the study shows that adverse events are more common.&lt;/P&gt;
&lt;P&gt;&lt;A href="#gordon"&gt;Gordon et al&lt;/A&gt; demonstrate factors which give more favourable outcomes in Hepatitis C patients undergoing dialysis – these include the use of larger doses of interferon (greater than 3 million units thrice weekly), treatment completion rates, female gender and early virological negativity.&lt;/P&gt;
&lt;P&gt;&lt;A href="#hellard"&gt;Hellard, Sacks-Davis and Gold&lt;/A&gt; support the active treatment of patients who continue to abuse drugs intravenously as comparable treatment outcomes can be achieved to those who are former IV drug users.&lt;/P&gt;
&lt;P&gt;&lt;A href="#moreno"&gt;Moreno et al&lt;/A&gt;'s meta-analysis shows that only HCV-1 patients with a low base line HCV-RNA (less than 50IU/ml) at 4 weeks of therapy do not lose a chance of a sustained virological response if they are treated for 24 weeks - all others should be given 48 weeks of therapy.&lt;/P&gt;
&lt;P&gt;In &lt;A href="#singal2"&gt;Singal et al&lt;/A&gt;, pooled data shows a reduced risk of hepatocellular carcinoma in HCV treated patients (RR 0.43) who achieved a sustained virological response, but maintenance interferon therapy in those who failed to achieve a SVR did not reduce the risk of HCC. 
&lt;P&gt;&lt;A href="#zanini"&gt;Zanini and Lanzini&lt;/A&gt; is a good review of strategies to prevent HCV infection and disease progression, attitude and access to therapy amongst IV drug abusers.&lt;/P&gt;&lt;/B&gt;
&lt;P&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Articles:&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=awad&gt;&lt;/A&gt;Awad T, Thorlund K, Hauser G, Stimac D, Mabrouk M, Gluud C. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=371934" target="_blank"&gt;Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials.&lt;/A&gt; &lt;I&gt;Hepatology&lt;/I&gt; 2010;51(4):1176-84.&lt;/P&gt;
&lt;P&gt;&lt;A name=camma&gt;&lt;/A&gt;Cammà C, Cabibbo G, Bronte F, Enea M, Licata A, Attanasio M, Andriulli A, Craxì A. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=380755" target="_blank"&gt;Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: a meta-analysis.&lt;/A&gt; &lt;I&gt;J Hepatol&lt;/I&gt; 2009;51(4):675-81.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=chan&gt;&lt;/A&gt;Chan AH, Partovi N, Ensom MH. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=380650" target="_blank"&gt;The utility of therapeutic drug monitoring for ribavirin in patients with chronic hepatitis C--a critical review.&lt;/A&gt; &lt;I&gt;Ann Pharmacother&lt;/I&gt; 2009;43(12):2044-63.&lt;/P&gt;
&lt;P&gt;&lt;A name=fabrizi&gt;&lt;/A&gt;Fabrizi F, Dixit V, Messa P, Martin P. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=380759" target="_blank"&gt;Pegylated interferon monotherapy of chronic hepatitis C in dialysis patients: Meta-analysis of clinical trials.&lt;/A&gt; &lt;I&gt;J Med Virol&lt;/I&gt; 2010;82(5):768-75.&lt;/P&gt;
&lt;P&gt;&lt;A name=gentile&gt;&lt;/A&gt;Gentile I, Carleo MA, Borgia F, Castaldo G, Borgia G. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=380653" target="_blank"&gt;The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus.&lt;/A&gt; &lt;I&gt;Expert Opin Investig Drugs&lt;/I&gt; 2010;19(1):151-9.&lt;/P&gt;
&lt;P&gt;&lt;A name=gluud&gt;&lt;/A&gt;Gluud LL, Marchesini E, Iorio A. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=325168" target="_blank"&gt;Peginterferon plus ribavirin for chronic hepatitis C in patients with human immunodeficiency virus.&lt;/A&gt; &lt;I&gt;Am J Gastroenterol&lt;/I&gt; 2009;104(9):2335-41.&lt;/P&gt;
&lt;P&gt;&lt;A name=gordon&gt;&lt;/A&gt;Gordon CE, Uhlig K, Lau J, Schmid CH, Levey AS, Wong JB. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=380764" target="_blank"&gt;Interferon for hepatitis C virus in hemodialysis--an individual patient meta-analysis of factors associated with sustained virological response.&lt;/A&gt; &lt;I&gt;Clin J Am Soc Nephrol&lt;/I&gt; 2009;4(9):1449-58.&lt;/P&gt;
&lt;P&gt;&lt;A name=hellard&gt;&lt;/A&gt;Hellard M, Sacks-Davis R, Gold J. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=380770" target="_blank"&gt;Hepatitis C treatment for injection drug users: a review of the available evidence.&lt;/A&gt; &lt;I&gt;Clin Infect Dis&lt;/I&gt; 2009;49(4):561-73.&lt;/P&gt;
&lt;P&gt;&lt;A name=moreno&gt;&lt;/A&gt;Moreno C, Deltenre P, Pawlotsky JM, Henrion J, Adler M, Mathurin P. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=373099" target="_blank"&gt;Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis.&lt;/A&gt; &lt;I&gt;J Hepatol&lt;/I&gt; 2010;52(1):25-31.&lt;/P&gt;
&lt;P&gt;&lt;A name=siebert&gt;&lt;/A&gt;Siebert U, Sroczynski G, Aidelsburger P, Rossol S, Wasem J, Manns MP, McHutchison JG, Wong JB. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=380656" target="_blank"&gt;Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines.&lt;/A&gt; &lt;I&gt;Pharmacoeconomics&lt;/I&gt; 2009;27(4):341-54.&lt;/P&gt;
&lt;P&gt;&lt;A name=singal1&gt;&lt;/A&gt;Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=380658" target="_blank"&gt;A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus.&lt;/A&gt; &lt;I&gt;Clin Gastroenterol Hepatol&lt;/I&gt; 2010;8(3):280-8.&lt;/P&gt;
&lt;P&gt;&lt;A name=singal2&gt;&lt;/A&gt;Singal AK, Singh A, Jaganmohan S, Guturu P, Mummadi R, Kuo YF, Sood GK. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=380773" target="_blank"&gt;Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis.&lt;/A&gt; &lt;I&gt;Clin Gastroenterol Hepatol&lt;/I&gt; 2010;8(2):192-9. 
&lt;P&gt;&lt;A name=slavenburg&gt;&lt;/A&gt;Slavenburg S, Weggelaar I, van Oijen MG, Drenth JP. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=380659" target="_blank"&gt;Optimal length of antiviral therapy in patients with hepatitis C virus genotypes 2 and 3: a meta-analysis.&lt;/A&gt; &lt;I&gt;Antivir Ther&lt;/I&gt; 2009;14(8):1139-48.&lt;/P&gt;
&lt;P&gt;&lt;A name=sroczynski&gt;&lt;/A&gt;Sroczynski G, Esteban E, Conrads-Frank A, Schwarzer R, Mühlberger N, Wright D, Zeuzem S, Siebert U. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=380661" target="_blank"&gt;Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis.&lt;/A&gt; C. &lt;I&gt;J Viral Hepat&lt;/I&gt; 2010;17(1):34-50.&lt;/P&gt;
&lt;P&gt;&lt;A name=weiss&gt;&lt;/A&gt;Weiss JJ, Bräu N, Stivala A, Swan T, Fishbein D. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=380662" target="_blank"&gt;Review article: adherence to medication for chronic hepatitis C - building on the model of human immunodeficiency virus antiretroviral adherence research.&lt;/A&gt; &lt;I&gt;Aliment Pharmacol Ther&lt;/I&gt; 2009;30(1):14-27.&lt;/P&gt;
&lt;P&gt;&lt;A name=zanini&gt;&lt;/A&gt;Zanini B, Lanzini A. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=380775" target="_blank"&gt;Antiviral treatment for chronic hepatitis C in illicit drug users: a systematic review.&lt;/A&gt; &lt;I&gt;Antivir Ther&lt;/I&gt; 2009;14(4):467-79.&lt;/P&gt;
&lt;P&gt;&lt;A name=zhao&gt;&lt;/A&gt;Zhao SH, Chu YL, Cheng DX, Waqar AB, Yu Q, Yang PH, Xue X, Yang HJ, Liu EQ. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=380664" target="_blank"&gt;Treatment with peginterferon plus ribavirin vs. interferon plus ribavirin for 48 weeks in Chinese patients with chronic hepatitis C.&lt;/A&gt; &lt;I&gt;Int J Clin Pract&lt;/I&gt; 2009;63(9):1334-9.&lt;/P&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #99cc00"&gt;Hepatitis B and C Annual Evidence Update 2010&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="TEXT-ALIGN: center; BACKGROUND-COLOR: #33cccc"&gt;
&lt;P&gt;&lt;A href="nelh:381482:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381479:0" name=internalLink&gt;Economics&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381480:0" name=internalLink&gt;Prevention&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381478:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:381474:0" name=internalLink&gt;Hepatitis B&lt;/A&gt; | &lt;A href="nelh:381475:0" name=internalLink&gt;&lt;B&gt;Hepatitis C&lt;/B&gt;&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:381477:0" name=internalLink&gt;Adverse effects&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381476:0" name=internalLink&gt;Risk factors&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:381471:0" name=internalLink&gt;Other&lt;/B&gt;&lt;/A&gt;&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:381473:0" name=internalLink&gt;Foreign articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381483:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381481:0" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>381483</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=381483]]&gt;</url>
    <title>2010 Annual Evidence Update on Hepatitis B and C - Uncertainties</title>
    <publicationDate>2010-07-26T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,HEPATITIS C,RECENT ADDITIONS,JULY 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Hepatitis B and C - Uncertainties&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;As part of the process of conducting this Annual Evidence Update, we examined the included papers for treatment uncertainties that could be added to the UK Database of Uncertainties about the Effects of Treatments (&lt;A href="http://www.library.nhs.uk/duets/" target="_blank"&gt;UK DUETs&lt;/A&gt;), a project aimed at creating a central database of such uncertainties. The following list, which has been submitted to the database, is the results of our search. Click on each title for more information.&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=382751" target="_blank"&gt;Antiviral therapy for chronic hepatitis C in injecting drug users&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=382748" target="_blank"&gt;Antiviral therapy for chronic hepatitis C in patients coinfected with HBV&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=382747" target="_blank"&gt;Antiviral therapy for chronic hepatitis C in patients coinfected with HIV&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=382117" target="_blank"&gt;Antiviral therapy for chronic hepatitis C in patients who did not respond to treatment with peginterferon plus ribavirin or relapsed following it&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=382749" target="_blank"&gt;Antiviral therapy for chronic hepatitis C in patients with haemophilia&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=382746" target="_blank"&gt;Antiviral therapy for chronic hepatitis C in patients with histologically mild disease&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=382745" target="_blank"&gt;Antiviral therapy for chronic hepatitis C in patients with normal ALT levels&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/GASTROLIVER/ViewResource.aspx?resID=323340" target="_blank"&gt;Antiviral therapy for recurrent liver graft infection with hepatitis C virus&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=382775" target="_blank"&gt;Combination therapy with newer nucleoside analogues for chronic hepatitis B&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=328574" target="_blank"&gt;Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccine for primary prevention of hepatitis B&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=382774" target="_blank"&gt;Interventions for treatment of chronic hepatitis B in lamivudine-resistant patients&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=382771" target="_blank"&gt;Interventions for treatment of psoriasis in patients with hepatitis C&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=381495" target="_blank"&gt;Lamivudine or adefovir dipivoxil alone or combined with immunoglobulin for preventing hepatitis B recurrence after liver transplantation&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=382779" target="_blank"&gt;Lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=343281" target="_blank"&gt;Optimal duration of pegatheron plus ribavirin therapy for chronic hepatitis C in patients with HIV&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=378454" target="_blank"&gt;Optimal ribivirin dose for chronic hepatitis C when taking in combination with pegylated interferon alpha-2a or alpha-2b&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=382763" target="_blank"&gt;Oral levamisole as an adjuvant to vaccination for hepatitis B virus seroprotection&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=343278" target="_blank"&gt;Peginterferon plus ribavirin versus no treatment for chronic hepatitis C in patients with HIV&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=382754" target="_blank"&gt;Prolonged retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=382758" target="_blank"&gt;Rate of adverse events in dialysis patients receiving interferon therapy for chronic hepatitis C versus those not on antiviral therapy&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=343285" target="_blank"&gt;Rate of serious adverse events in antiviral treatment for chronic hepatitis C in patients with HIV&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=343291" target="_blank"&gt;Relationship between treatment and clinical outcomes in antiviral treatment for chronic hepatitis C in patients with HIV&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=343373" target="_blank"&gt;Traditional Chinese medicines for chronic hepatitis B&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BACKGROUND-COLOR: #99cc00; TEXT-ALIGN: center"&gt;Hepatitis B and C Annual Evidence Update 2010&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BACKGROUND-COLOR: #33cccc; TEXT-ALIGN: center"&gt;
&lt;P&gt;&lt;A href="nelh:381482:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381479:0" name=internalLink&gt;Economics&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381480:0" name=internalLink&gt;Prevention&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381478:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:381474:0" name=internalLink&gt;Hepatitis B&lt;/A&gt; | &lt;A href="nelh:381475:0" name=internalLink&gt;Hepatitis C&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:381477:0" name=internalLink&gt;Adverse effects&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381476:0" name=internalLink&gt;Risk factors&lt;/A&gt; &lt;BR&gt;&lt;A href="nelh:381471:0" name=internalLink&gt;Other&lt;/B&gt;&lt;/A&gt;&lt;/B&gt;&lt;BR&gt;&lt;A href="nelh:381473:0" name=internalLink&gt;Foreign articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381483:0" name=internalLink&gt;&lt;B&gt;Uncertainties&lt;/B&gt;&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:381481:0" name=internalLink&gt;Methods&lt;/A&gt;&lt;/P&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>346217</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=346217]]&gt;</url>
    <title>2010 Annual Evidence Update on Inflammatory Bowel Disease - Adverse effects and risk factors</title>
    <publicationDate>2010-03-22T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CANCER,INFECTIONS,CROHN'S DISEASE,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Inflammatory Bowel Disease - Adverse effects and risk factors&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Guidelines&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The following guidelines were published this year:&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=345642" target="_blank"&gt;AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease&lt;/A&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=317992" target="_blank"&gt;European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease&lt;/A&gt; (ECCO)&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Other reviews&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Reviewed by Mark Hamilton, Consultant Gastroenterologist, Royal Free Hospital, London, and Isobel Mason, Endoscopy Nurse Specialist, Royal Free Hospital, London&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Mark Hamilton: &lt;/STRONG&gt;The focus of several of these papers is on the safety and use of anti-TNF strategies in the management of inflammatory bowel disease. As early move to the use of biologic strategies increases in the management of IBD, this clearly needs to be balanced against evidence regarding the safety of these. In the paper from &lt;A href="#siegel"&gt;Siegel et al&lt;/A&gt;, a careful analysis of the rate and risk of lymphoma is evaluated. Overall there were a total of 13 lymphomas in 21,178 patient years of observation, yielding a rate of 6.1 NHLs per 10,000 patient years. This, when compared to the expected rate of NHL in all age groups, gives an SIR of 3.23. The paper points out that although there is a statistically significant increase in risk, the absolute risk remains small at 6.1 per 10,000 patient years and when compared to patients with Crohn’s disease taking immunomodulators alone, there is a non-statistically significant increased rate of NHL for those exposed to anti-TNF agents.&lt;/P&gt;
&lt;P&gt;&lt;A href="#fiorino"&gt;Fiorino et al&lt;/A&gt; review further that other conditions, perhaps with an immune basis, may be related to anti-TNF treatment including the emergence of rare findings such as psoriasis.&lt;/P&gt;
&lt;P&gt;&lt;A href="#colombel"&gt;Colombel et al&lt;/A&gt; review the safety of adalimumab in global clinical trials of patients with Crohn’s disease. Approximately 1% of patients treated developed a malignant neoplasm. However, evaluation of safety data from global clinical trials of adalimumab in Crohn’s disease with a large database of 3,160 patients, representing 3,401.9 patient years of adalimumab exposure, demonstrated that this is generally safe and well tolerated in treatment of patients with moderately to severe active Crohn’s disease. Types and frequency of serious adverse events were similar to placebo during induction and maintenance periods. These data compare with recent meta-analyses of placebo-controlled trials of adalimumab, infliximab and other TNF antagonists, which overall did not increase the risk of serious infection, malignancy or mortality in patients with Crohn’s disease. Lupus-related disorders and demyelinating disorders, although uncommon, occurred in patients treated with adalimumab.&lt;/P&gt;
&lt;P&gt;&lt;A href="#kefalakes"&gt;Kefalakes et al&lt;/A&gt; evaluate the evidence for NSAIDs in causing flares of activity in inflammatory bowel disease and whether or not COX-2 inhibitors are safe in patients with IBD. A further examination of this issue seems required, however available data remain contradictory and confusing and it remains uncertain as to whether COX-2 inhibitors are safer than NSAIDs in IBD. &lt;/P&gt;
&lt;P&gt;&lt;A href="#difabio"&gt;Di Fabio et al&lt;/A&gt; look at the issue regarding venous and vascular thrombosis associated with inflammatory bowel disease. They examine this issue in the context of recognised procoagulant tendencies and the relation between activity, disease and intervention with common and less common thrombotic events such as portal venous thrombosis. They point out that venous and arterial thromboembolism in association with IBD is a serious event that requires a high degree of vigilance and early intervention will reduce the risk of thrombosis-associated complications.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Isobel Mason: &lt;/STRONG&gt;The effects on quality of life of all chronic illnesses, including IBD, are well acknowledged. However, the impact is increased in adolescence as it can be a challenging life phase with significant psychological and physical changes. Chronic illness can make this change even more turbulent. &lt;A href="#karwowksi"&gt;Karwowksi, Keljo and Szigethy&lt;/A&gt; performed a systematic review on strategies to improve quality of life for adolescents with IBD.&lt;/P&gt;
&lt;P&gt;Several quality of life instruments are discussed; generic scores (e.g. short form SF-36), disease-specific instruments (e.g. IBDQ) and the IMPACT questionnaire, designed for children aged &amp;gt;10. Several factors affecting health quality of life are reviewed, including: 
&lt;UL&gt;
&lt;LI&gt;Disease characteristics&lt;/LI&gt;
&lt;LI&gt;Comorbid irritable bowel syndrome&lt;/LI&gt;
&lt;LI&gt;Patient characteristics (age, gender, socioeconomic status, ethnicity and culture)&lt;/LI&gt;
&lt;LI&gt;Psychosocial / Psychological factors&lt;/LI&gt;
&lt;LI&gt;Personality traits&lt;/LI&gt;
&lt;LI&gt;Coping strategies&lt;/LI&gt;
&lt;LI&gt;Illness perception&lt;/LI&gt;
&lt;LI&gt;Family and social support&lt;/LI&gt;&lt;/UL&gt;The review describes small studies undertaken in adults that have shown mixed results in a wide range of interventions in improving quality of life. However, the quality of the studies is not discussed and all have different quality of life measures. Those interventions showing positive outcomes include; education and self-management, moderate exercise, good sleep patterns, hypnotherapy and social support. Those showing mixed results included psychotherapy and better medication adherence. 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Only two areas have been studied specifically in adolescence; two studies show social support, with open communication from families and peers to be beneficial. Taking medication daily can adversely affect quality of life, however, nonadherence is related to poorer physical health and quality of life and increases in adolescents with depression and family dysfunction.&lt;/P&gt;
&lt;P&gt;The review acknowledges the limitations in quality of life measures and interventional studies and recommends further research including parental quality of life, the affects of adherence and the development of more comprehensive assessment tools.&lt;/P&gt;
&lt;P&gt;Also included in this update is the review on causes of IBS flares by &lt;A href="#singh"&gt;Singh, Graff and Bernstein&lt;/A&gt;.&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Articles&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=colombel&gt;&lt;/A&gt;Colombel JF, Sandborn WJ, Panaccione R, Robinson AM, Lau W, Li J, Cardoso AT. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=346143" target="_blank"&gt;Adalimumab safety in global clinical trials of patients with Crohn's disease.&lt;/A&gt; &lt;I&gt;Inflamm Bowel Dis&lt;/I&gt; 2009;15(9):1308-19.&lt;/P&gt;
&lt;P&gt;&lt;A name=difabio&gt;&lt;/A&gt;Di Fabio F, Obrand D, Satin R, Gordon PH. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=346145" target="_blank"&gt;Intra-abdominal venous and arterial thromboembolism in inflammatory bowel disease.&lt;/A&gt; &lt;I&gt;Dis Colon Rectum&lt;/I&gt; 2009;52(2):336-42.&lt;/P&gt;
&lt;P&gt;&lt;A name=fiorino&gt;&lt;/A&gt;Fiorino G, Allez M, Malesci A, Danese S. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=346146" target="_blank"&gt;Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease.&lt;/A&gt; &lt;I&gt;Aliment Pharmacol Ther&lt;/I&gt; 2009;29(9):921-7.&lt;/P&gt;
&lt;P&gt;&lt;A name=karwowksi&gt;&lt;/A&gt;Karwowski CA, Keljo D, Szigethy E. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=345613" target="_blank"&gt;Strategies to improve quality of life in adolescents with inflammatory bowel disease.&lt;/A&gt; &lt;I&gt;Inflamm Bowel Dis&lt;/I&gt; 2009;15(11):1755-64.&lt;/P&gt;
&lt;P&gt;&lt;A name=kefalakes&gt;&lt;/A&gt;Kefalakes H, Stylianides TJ, Amanakis G, Kolios G. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=346147" target="_blank"&gt;Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality?&lt;/A&gt; &lt;I&gt;Eur J Clin Pharmacol&lt;/I&gt; 2009;65(10):963-70.&lt;/P&gt;
&lt;P&gt;&lt;A name=siegel&gt;&lt;/A&gt;Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=346149" target="_blank"&gt;Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis.&lt;/A&gt; &lt;I&gt;Clin Gastroenterol Hepatol&lt;/I&gt; 2009;7(8):874-81.&lt;/P&gt;
&lt;P&gt;&lt;A name=singh&gt;&lt;/A&gt;Singh S, Graff LA, Bernstein CN. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=345634" target="_blank"&gt;Do NSAIDs, antibiotics, infections, or stress trigger flares in IBD?&lt;/A&gt; &lt;I&gt;Am J Gastroenterol&lt;/I&gt; 2009;104(5):1298-313.&lt;/P&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BACKGROUND-COLOR: #33cccc; TEXT-ALIGN: center"&gt;Inflammatory Bowel Disease Annual Evidence Update 2010&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BACKGROUND-COLOR: #99cc00; TEXT-ALIGN: center"&gt;
&lt;P&gt;&lt;A href="nelh:346211:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346221:0" name=internalLink&gt;Aetiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346222:0" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346218:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:346219:0" name=internalLink&gt;Aminosalicylates&lt;/A&gt; | &lt;A href="nelh:346216:0" name=internalLink&gt;Immunosuppressants&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346215:0" name=internalLink&gt;Other interventions&lt;/A&gt; | &lt;A href="nelh:346214:0" name=internalLink&gt;General and miscellaneous&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:346217:0" name=internalLink&gt;&lt;B&gt;Adverse effents and risk factors&lt;/B&gt;&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346213:0" name=internalLink&gt;Economics&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346212:0" name=internalLink&gt;Other&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346223:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346224:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346220:0" name=internalLink&gt;Methods&lt;/A&gt; &lt;/P&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>346221</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=346221]]&gt;</url>
    <title>2010 Annual Evidence Update on Inflammatory Bowel Disease - Aetiology</title>
    <publicationDate>2010-03-22T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Inflammatory Bowel Disease - Aetiology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;I&gt;Reviewed by Andrew Cole, Consultant Gastroenterologist, Derby City General Hospital&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;The aetiology of IBD is probably a complex interplay between host and environmental factors including luminal organisms.&lt;/P&gt;
&lt;P&gt;Four meta-analyses of studies of genetic polymorphisisms associated with IBD are included in this update. &lt;/P&gt;
&lt;P&gt;The first susceptibility gene identified for Crohn’s disese was NOD2/CARD15. Genetic variants are associated with altered innate immune responses to bacterial cell wall products. &lt;A href="#yazdanyar"&gt;Yasandanyer, Weischer and Nodestgaard&lt;/A&gt;’s analysis of three main genetic variants in Caucasians showed an odds ratio (OR) of 2.2 (95% confidence interval (CI) 2.0-2.6) to 3.3 (2.8-3.8) for heterozygotes with one variant and a much higher odds ratio for compound heterozygotes for these common disease associated variants (OR 9 (6.0-13.5))&lt;/P&gt;
&lt;P&gt;Autophagy is the process whereby intracellular bacteria are engulfed in an autophagosome and subsequently lysed following fusion with a lysosome. Genetic variants in genes encoding proteins involved in autophagy have been clearly associated with Crohn’s in WCCC and other studies. ATG16L1 encodes a protein that is involved in the formation of the autophagosome. IRGM is immunity related guanosine triphosphatase. It is a GTP binding protein that induces autophagy. Three meta-analyses have looked at these genes associated with Autophagy. The analaysis of &lt;A href="#marquez"&gt;Marquez et al&lt;/A&gt; has shown a consistent finding of ATG 16L1 thr300ala polymorphism in European Caucasian populations of Crohn’s patients (OR 1.33 for disease ) which is independent of the CARD15/NOD2 and IL23R genetic variants associated with Crohn’s. &lt;A href="#zhang"&gt;Zhang et al&lt;/A&gt; similarly found consistent influence of the G allele of ATG16L1 T300A polymorphism (OR 1.33 for the heterozygote) but this effect was not seen in one study of an Asian population. &lt;A href="#palomino"&gt;Palomino-Morales et al&lt;/A&gt;'s meta-analysis of ATG16L1 and IRGM polymorphisms equally confirm an association of these with Crohn’s but also suggest an association of these genetic variants with ulcerative colitis (ATG16L1 OR 1.08 (95% CI 1.03-1.12); IRGM rs13361189 OR 1.16 (1.04-1.30); and IRGM rs4958847 1.13 (1.02-1.24)).&lt;/P&gt;
&lt;P&gt;&lt;A href="#rowan"&gt;Rowan et al&lt;/A&gt; have reviewed the evidence suggesting a possible role of sulphate reducing bacteria (SRB) in causing ulcerative colitis. Whilst there is evidence of greater faecal carriage of SRB in UC the significance of this remains unproven and interest in focused on whether mucosa/mucous gel layer associated SRB may be important.&lt;/P&gt;
&lt;P&gt;&lt;A href="#ayre"&gt;Ayre et al&lt;/A&gt; have reviewed the role of CMV in severe and steroid resistant UC. A distinction is made between CMV disease confirmed by colonic biopsy and immunohistochemistry and CMV infection. CMV disease may be present in up to 36% of steroid refractory patients and probably increases the severity of colitis and may be the cause acute severe colitis in 3-5% of acute severe colitis. The role of antiviral therapy in this context need adequately powered placebo controlled studies.&lt;/P&gt;
&lt;P&gt;&lt;A href="#barclay"&gt;Barclay et al&lt;/A&gt; have reviewed the role of breast milk in paediatric IBD. This meta-analysis of 7 studies has shown a protective effect (OR 0.69 (95% CI 0.51 to 0.94)) of breast milk though this is subject to possible recall bias, suggesting that prospective studies are warranted.&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Articles&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=ayre&gt;&lt;/A&gt;Ayre K, Warren BF, Jeffery K, Travis SPL. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=345471" target="_blank"&gt;The role of CMV in steroid-resistant ulcerative colitis: A systematic review.&lt;/A&gt; &lt;I&gt;J Crohn's Colitis&lt;/I&gt; 2009;3(3):141-8.&lt;/P&gt;
&lt;P&gt;&lt;A name=barclay&gt;&lt;/A&gt;Barclay AR, Russell RK, Wilson ML, Gilmour WH, Satsangi J, Wilson DC. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=345481" target="_blank"&gt;Systematic review: the role of breastfeeding in the development of pediatric inflammatory bowel disease.&lt;/A&gt; &lt;I&gt;J Pediatr&lt;/I&gt; 2009;155(3):421-6.&lt;/P&gt;
&lt;P&gt;&lt;A name=marquez&gt;&lt;/A&gt;Márquez A, Núñez C, Martínez A, Mendoza JL, Taxonera C, Fernández-Arquero M, Díaz-Rubio M, de la Concha EG, Urcelay E. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=345480" target="_blank"&gt;Role of ATG16L1 Thr300Ala polymorphism in inflammatory bowel disease: a Study in the Spanish population and a meta-analysis.&lt;/A&gt; &lt;I&gt;Inflamm Bowel Dis&lt;/I&gt; 2009;15(11):1697-704.&lt;/P&gt;
&lt;P&gt;&lt;A name=palomino&gt;&lt;/A&gt;Palomino-Morales RJ, Oliver J, Gómez-García M, López-Nevot MA, Rodrigo L, Nieto A, Alizadeh BZ, Martín J. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=345484" target="_blank"&gt;Association of ATG16L1 and IRGM genes polymorphisms with inflammatory bowel disease: a meta-analysis approach.&lt;/A&gt; &lt;I&gt;Genes Immun&lt;/I&gt; 2009;10(4):356-64.&lt;/P&gt;
&lt;P&gt;&lt;A name=rowan&gt;&lt;/A&gt;Rowan FE, Docherty NG, Coffey JC, O'Connell PR. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=345507" target="_blank"&gt;Sulphate-reducing bacteria and hydrogen sulphide in the aetiology of ulcerative colitis.&lt;/A&gt; &lt;I&gt;Br J Surg&lt;/I&gt; 2009;96(2):151-8.&lt;/P&gt;
&lt;P&gt;&lt;A name=yazdanyar&gt;&lt;/A&gt;Yazdanyar S, Weischer M, Nordestgaard BG. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=345508" target="_blank"&gt;Genotyping for NOD2 genetic variants and Crohn disease: a metaanalysis.&lt;/A&gt; &lt;I&gt;Clin Chem&lt;/I&gt; 2009;55(11):1950-7.&lt;/P&gt;
&lt;P&gt;&lt;A name=zhang&gt;&lt;/A&gt;Zhang HF, Qiu LX, Chen Y, Zhu WL, Mao C, Zhu LG, Zheng MH, Wang Y, Lei L, Shi J. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=345511" target="_blank"&gt;ATG16L1 T300A polymorphism and Crohn's disease susceptibility: evidence from 13,022 cases and 17,532 controls.&lt;/A&gt; &lt;I&gt;Hum Genet&lt;/I&gt; 2009;125(5-6):627-31.&lt;/P&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BACKGROUND-COLOR: #33cccc; TEXT-ALIGN: center"&gt;Inflammatory Bowel Disease Annual Evidence Update 2010&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BACKGROUND-COLOR: #99cc00; TEXT-ALIGN: center"&gt;
&lt;P&gt;&lt;A href="nelh:346211:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346221:0" name=internalLink&gt;&lt;B&gt;Aetiology&lt;/B&gt;&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346222:0" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346218:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:346219:0" name=internalLink&gt;Aminosalicylates&lt;/A&gt; | &lt;A href="nelh:346216:0" name=internalLink&gt;Immunosuppressants&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346215:0" name=internalLink&gt;Other interventions&lt;/A&gt; | &lt;A href="nelh:346214:0" name=internalLink&gt;General and miscellaneous&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:346217:0" name=internalLink&gt;Adverse effents and risk factors&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346213:0" name=internalLink&gt;Economics&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346212:0" name=internalLink&gt;Other&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346223:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346224:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346220:0" name=internalLink&gt;Methods&lt;/A&gt; &lt;/P&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>346218</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=346218]]&gt;</url>
    <title>2010 Annual Evidence Update on Inflammatory Bowel Disease - Diagnosis</title>
    <publicationDate>2010-03-22T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,DIAGNOSTIC PROCEDURES,GASTROINTESTINAL ENDOSCOPY,ENTEROSCOPY,NUCLEAR MEDICINE,MRI,CROHN'S DISEASE,RECENT ADDITIONS,RADIOLOGY,PET,MARCH 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Inflammatory Bowel Disease - Diagnosis&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Guidelines&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The following guidelines were published this year:&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=345159" target="_blank"&gt;Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED–ECCO consensus&lt;/A&gt; &lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Other reviews&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Reviewed by Isobel Mason, Endoscopy Nurse Specialist, Royal Free Hospital, London&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Horsthuis K, Bipat S, Stokkers PC, Stoker J. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=345606" target="_blank"&gt;Magnetic resonance imaging for evaluation of disease activity in Crohn's disease: a systematic review.&lt;/A&gt; &lt;I&gt;Eur Radiol&lt;/I&gt; 2009;19(6):1450-60.&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;B&gt;Reviewer's summary&lt;/B&gt;: This paper presents a systematic review of accuracy of MRI in staging disease activity in CD. MRI was found to be highly accurate for diagnosing patients with frank disease activity in CD. With mild disease, there was inaccuracy and this was felt to be due to inexperience and a lack of parameters in interpreting the differences in bowel thickening and bowel wall enhancement between mild and moderate disease. The authors also point out the differences between endoscopic evaluation and MRI evaluation may occur as endoscopic&amp;nbsp;and histological assessment only interprets mucosal disease, whereas MRI evaluates the entire bowel wall with all its layers. The paper recommends that more research on the reproducibility of MRI for the evaluation of CD should be carried out before implementation into clinical practice and that clear staging criteria need to be agreed to allow standardisation.&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;Spier BJ, Perlman SB, Reichelderfer M. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=345608" target="_blank"&gt;FDG-PET in inflammatory bowel disease.&lt;/A&gt; &lt;I&gt;Q J Nucl Med Mol Imaging&lt;/I&gt; 2009;53(1):64-71.&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;B&gt;Reviewer's summary&lt;/B&gt;: This review aims to highlight the use of PET in IBD. It describes a reported 3% incidence of unsuspected gastrointestinal findings on PET imaging in patients (over 6000) having imaging for other pathologic processes. 3 small studies have shown that PET can successfully identify active intestinal inflammation in suspected IBD. However, differentiating types of inflammation (ischaemia, infection and IBD) is a challenge. There are few well-constructed studies evaluating PET in known IBD. PET appears to have excellent sensitivity for detecting active inflammation, however specificity is low. PET is particularly useful in children where completing colonoscopy or other invasive tests may be difficult. PET alone appears to be sufficient in UC, but PET/CT seems necessary for accurate bowel segment detection in CD. The paper suggests that PET is en emerging technique that can be recommended in children and for the evaluation of strictures (fibrostenotic vs inflammatory), but further studies are required to define its role.&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BACKGROUND-COLOR: #33cccc; TEXT-ALIGN: center"&gt;Inflammatory Bowel Disease Annual Evidence Update 2010&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BACKGROUND-COLOR: #99cc00; TEXT-ALIGN: center"&gt;
&lt;P&gt;&lt;A href="nelh:346211:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346221:0" name=internalLink&gt;Aetiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346222:0" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346218:0" name=internalLink&gt;&lt;B&gt;Diagnosis&lt;/B&gt;&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:346219:0" name=internalLink&gt;Aminosalicylates&lt;/A&gt; | &lt;A href="nelh:346216:0" name=internalLink&gt;Immunosuppressants&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346215:0" name=internalLink&gt;Other interventions&lt;/A&gt; | &lt;A href="nelh:346214:0" name=internalLink&gt;General and miscellaneous&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:346217:0" name=internalLink&gt;Adverse effents and risk factors&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346213:0" name=internalLink&gt;Economics&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346212:0" name=internalLink&gt;Other&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346223:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346224:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346220:0" name=internalLink&gt;Methods&lt;/A&gt; &lt;/P&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>346213</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=346213]]&gt;</url>
    <title>2010 Annual Evidence Update on Inflammatory Bowel Disease - Economics</title>
    <publicationDate>2010-03-22T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Inflammatory Bowel Disease - Economics&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;I&gt;Reviewed by Richard Makins, Consultant Gastroenterologist, Cheltenham General Hospital, Gloucestershire&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;Decisions concerning the use of medicines are made at various levels in the UK. Nationally NICE, the All Wales Medicines Strategy Group and the Scottish Medicines Consortium provide guidance whilst locally the role is taken by PCT or hospital trust drug and therapeutics committees. Decisions have to be made depending on both clinical effectiveness and cost-effectiveness. The latter informs of the balance between costs and potential health benefits. A form of cost-effectiveness analysis is the quality-adjusted life year (QALY). These are determined by estimating the total life years gained from a treatment with a score of 0 for death and 1 for full health. QALYs incorporate quality and quantity of life allowing comparison of treatments. NICE considers a medicine to be cost-effective if each additional QALY gained costs less than £30,000.&lt;/P&gt;
&lt;P&gt;5-aminosalicylic acid/mesalazine is effective in inducing and maintaining remission in ulcerative colitis and remains standard first line therapy. High dose mesalazine improves efficacy without adversely affecting the side effect profile and appears cost effective, in the short term, over standard dosing regimes by improving QALY and reducing the need for hospitalisation, intravenous regimens and surgery. Although the latter numbers may be small the cost savings are significant (&lt;A href="#buckland"&gt;Buckland and Bodger&lt;/A&gt;). Once daily versus twice daily dosing may, however, be more cost-effective (&lt;A href="#connolly"&gt;Connolly et al&lt;/A&gt;). In contrast, although continued mesalazine therapy is effective in maintaining remission in the longer term, Markov modelling, a form of economic model which can be used in modelling the progression of chronic disease, suggests that the QALY gains are not cost-effective when standard therapy is compared to treatment with mesalazine during flares only (&lt;A href="#yen"&gt;Yen, Kane and Ladabaum&lt;/A&gt;). This, however, does not consider the longer term benefits of continued therapy such as colorectal cancer prevention. Indeed with the need for regular colonoscopic surveillance, maintenance mesalazine could reduce costs by permitting the time intervals between surveillance examinations to be increased (&lt;A href="#rubenstein"&gt;Rubenstein et al&lt;/A&gt;).&lt;/P&gt;
&lt;P&gt;Biological therapy is now widely used to treat Crohn’s disease and in certain circumstances, ulcerative colitis. These treatments, however, represent a significant portion of a hospital drug budget and in the current financial climate the cost-effectiveness of therapy is paramount. The long term clinical effectiveness of infliximab (IFX) and adalimumab (ADM) has been extrapolated from clinical trials, although there are no long term data as yet, the cost-effectiveness remains to be seen. Pharmaceutical company sponsored research suggests cost-effectiveness is maintained after 5 years when treating luminal or fistulising disease, although the quoted costs are more than that recommended by NICE for perceived QALY gains (&lt;A href="#lindsay"&gt;Lindsay et al&lt;/A&gt;). Although effective in initial responders in the first 2 to 4 years of therapy projected long term use using Markov modelling suggests no benefit over standard therapy (aminosalicylates, immunosuppressants, steroids, antibiotics, surgery, etc.) (&lt;A href="#bodger"&gt;Bodger, Kikuch and Hughesi&lt;/A&gt;). The use of IFX in moderate to severe ulcerative colitis is not supported by NICE and is not cost-effective (&lt;A href="#tsai"&gt;Tsai et al&lt;/A&gt;). If medical therapy fails and surgery is required, if local expertise allows, laparoscopic techniques are more cost-effective than open mainly due to lower complication rates and shortened length of inpatient episode (&lt;A href="#lesperance"&gt;Lesperance et al&lt;/A&gt;).&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Articles&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=bodger&gt;&lt;/A&gt;Bodger K, Kikuchi T, Hughes D. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=345566" target="_blank"&gt;Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data.&lt;/A&gt; &lt;I&gt;Aliment Pharmacol Ther&lt;/I&gt; 2009;30(3):265-74.&lt;/P&gt;
&lt;P&gt;&lt;A name=buckland&gt;&lt;/A&gt;Buckland A, Bodger K. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=345570" target="_blank"&gt;The cost-utility of high dose oral mesalazine for moderately active ulcerative colitis.&lt;/A&gt; &lt;I&gt;Aliment Pharmacol Ther&lt;/I&gt; 2008;28(11-12):1287-96.&lt;/P&gt;
&lt;P&gt;&lt;A name=connolly&gt;&lt;/A&gt;Connolly MP, Nielsen SK, Currie CJ, Poole CD, Travis SPL. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=345571" target="_blank"&gt;An economic evaluation comparing once daily with twice daily mesalazine for maintaining remission based on results from a randomised controlled clinical trial.&lt;/A&gt; &lt;I&gt;J Crohn's Colitis&lt;/I&gt; 2009;3(1):32-7.&lt;/P&gt;
&lt;P&gt;&lt;A name=lesperance&gt;&lt;/A&gt;Lesperance K, Martin MJ, Lehmann R, Brounts L, Steele SR. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=345575" target="_blank"&gt;National trends and outcomes for the surgical therapy of ileocolonic Crohn's disease: a population-based analysis of laparoscopic vs. open approaches.&lt;/A&gt; &lt;I&gt;J Gastrointest Surg&lt;/I&gt; 2009;13(7):1251-9.&lt;/P&gt;
&lt;P&gt;&lt;A name=lindsay&gt;&lt;/A&gt;Lindsay J, Punekar YS, Morris J, Chung-Faye G. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=345578" target="_blank"&gt;Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease--modelling outcomes in active luminal and fistulizing disease in adults.&lt;/A&gt; &lt;I&gt;Aliment Pharmacol Ther&lt;/I&gt; 2008;28(1):76-87.&lt;/P&gt;
&lt;P&gt;&lt;A name=rubenstein&gt;&lt;/A&gt;Rubenstein JH, Waljee AK, Jeter JM, Velayos FS, Ladabaum U, Higgins PD. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=325169" target="_blank"&gt;Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates.&lt;/A&gt; &lt;I&gt;Am J Gastroenterol&lt;/I&gt; 2009;104(9):2222-32.&lt;/P&gt;
&lt;P&gt;&lt;A name=tsai&gt;&lt;/A&gt;Tsai HH, Punekar YS, Morris J, Fortun P. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=345581" target="_blank"&gt;A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis.&lt;/A&gt; &lt;I&gt;Aliment Pharmacol Ther&lt;/I&gt; 2008;28(10):1230-9. &lt;/P&gt;
&lt;P&gt;&lt;A name=yen&gt;&lt;/A&gt;Yen EF, Kane SV, Ladabaum U. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=345583" target="_blank"&gt;Cost-effectiveness of 5-aminosalicylic acid therapy for maintenance of remission in ulcerative colitis.&lt;/A&gt; &lt;I&gt;Am J Gastroenterol&lt;/I&gt; 2008;103(12):3094-105. &lt;/P&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BACKGROUND-COLOR: #33cccc; TEXT-ALIGN: center"&gt;Inflammatory Bowel Disease Annual Evidence Update 2010&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BACKGROUND-COLOR: #99cc00; TEXT-ALIGN: center"&gt;
&lt;P&gt;&lt;A href="nelh:346211:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346221:0" name=internalLink&gt;Aetiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346222:0" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346218:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:346219:0" name=internalLink&gt;Aminosalicylates&lt;/A&gt; | &lt;A href="nelh:346216:0" name=internalLink&gt;Immunosuppressants&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346215:0" name=internalLink&gt;Other interventions&lt;/A&gt; | &lt;A href="nelh:346214:0" name=internalLink&gt;General and miscellaneous&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:346217:0" name=internalLink&gt;Adverse effents and risk factors&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346213:0" name=internalLink&gt;&lt;B&gt;Economics&lt;/B&gt;&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346212:0" name=internalLink&gt;Other&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346223:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346224:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346220:0" name=internalLink&gt;Methods&lt;/A&gt; &lt;/P&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>346222</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=346222]]&gt;</url>
    <title>2010 Annual Evidence Update on Inflammatory Bowel Disease - Epidemiology</title>
    <publicationDate>2010-03-22T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Inflammatory Bowel Disease - Epidemiology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;EM&gt;Reviewed by Mark Hamilton, Consultant Gastroenterologist, Royal Free Hospital, London&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Two papers, one from &lt;A href="#thia"&gt;Thia et al&lt;/A&gt; and another &lt;A href="#hou"&gt;Hou, El-Serag and Thirumurthi&lt;/A&gt;, look at issues related to the epidemiology of inflammatory bowel disease. &lt;A href="#thia"&gt;Thia et al&lt;/A&gt; describe a rising incidence of IBD associated with different genotypes across Asia.&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Articles&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=hou&gt;&lt;/A&gt;Hou JK, El-Serag H, Thirumurthi S. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=346150" target="_blank"&gt;Distribution and manifestations of inflammatory bowel disease in Asians, Hispanics, and African Americans: a systematic review.&lt;/A&gt; &lt;I&gt;Am J Gastroenterol&lt;/I&gt; 2009;104(8):2100-9.&lt;/P&gt;
&lt;P&gt;&lt;A name=thia&gt;&lt;/A&gt;Thia KT, Loftus EV Jr, Sandborn WJ, Yang SK. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=346151" target="_blank"&gt;An update on the epidemiology of inflammatory bowel disease in Asia.&lt;/A&gt; &lt;I&gt;Am J Gastroenterol&lt;/I&gt; 2008;103(12):3167-82. &lt;/P&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BACKGROUND-COLOR: #33cccc; TEXT-ALIGN: center"&gt;Inflammatory Bowel Disease Annual Evidence Update 2010&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BACKGROUND-COLOR: #99cc00; TEXT-ALIGN: center"&gt;
&lt;P&gt;&lt;A href="nelh:346211:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346221:0" name=internalLink&gt;Aetiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346222:0" name=internalLink&gt;&lt;B&gt;Epidemiology&lt;/B&gt;&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346218:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:346219:0" name=internalLink&gt;Aminosalicylates&lt;/A&gt; | &lt;A href="nelh:346216:0" name=internalLink&gt;Immunosuppressants&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346215:0" name=internalLink&gt;Other interventions&lt;/A&gt; | &lt;A href="nelh:346214:0" name=internalLink&gt;General and miscellaneous&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:346217:0" name=internalLink&gt;Adverse effents and risk factors&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346213:0" name=internalLink&gt;Economics&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346212:0" name=internalLink&gt;Other&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346223:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346224:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346220:0" name=internalLink&gt;Methods&lt;/A&gt; &lt;/P&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>346223</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=346223]]&gt;</url>
    <title>2010 Annual Evidence Update on Inflammatory Bowel Disease - Foreign language articles</title>
    <publicationDate>2010-03-22T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Inflammatory Bowel Disease - Foreign language articles&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;The following articles were identified by the search as being potentially relevant to the AEU, but were not sent out for appraisal because the full text is in a language other than English. They are included here for interest, and for the sake of completeness.&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;Chang SY. &lt;A href="http://www.koreamed.org/SearchBasic.php?DT=1&amp;amp;RID=514736" target="_blank"&gt;Controversies in Pouch Surgery for Ulcerative Colitis.&lt;/A&gt; &lt;I&gt;J Korean Soc Coloproctol&lt;/I&gt; 2009;25(3):207-11.&lt;BR&gt;&lt;I&gt;&lt;B&gt;Language:&lt;/B&gt; Korean&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;Fornaro R, Frascio M, Denegri A, Stabilini C, Impenatore M, Mandolfino F, Lazzara F, Gianetta E. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19681293" target="_blank"&gt;Chron's disease and cancer.&lt;/A&gt; &lt;I&gt;Ann Ital Chir&lt;/I&gt; 2009;80(2):119-25.&lt;BR&gt;&lt;I&gt;&lt;B&gt;Language:&lt;/B&gt; Italian&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;Jahnsen J, Røseth AG, Aadland E. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19373299" target="_blank"&gt;Measurement of calprotectin in faeces.&lt;/A&gt; &lt;I&gt;Tidsskr Nor Laegeforen&lt;/I&gt; 2009;129(8):743-5.&lt;BR&gt;&lt;I&gt;&lt;B&gt;Language:&lt;/B&gt; Norwegian&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;Lakatos PL, Lakatos L. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19228568" target="_blank"&gt;Effectiveness of new, once-daily 5-aminosalicylic acid in the treatment of ulcerative colitis.&lt;/A&gt; &lt;I&gt;Orv Hetil&lt;/I&gt; 2009;150(9):397-404.&lt;BR&gt;&lt;I&gt;&lt;B&gt;Language:&lt;/B&gt; Hungarian&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;Polle SW, van Koperen PJ, van Berge Henegouwen MI, Slors JF, Stokkers PC, Bemelman WA. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19785860" target="_blank"&gt;Laparoscopic surgery for inflammatory bowel disease; an update.&lt;/A&gt; &lt;I&gt;Ned Tijdschr Geneeskd&lt;/I&gt; 2009;153:B284.&lt;BR&gt;&lt;I&gt;&lt;B&gt;Language:&lt;/B&gt; Dutch&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;Stein JM, Hartmann F, Cordes HJ, Dignass AU. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19197827" target="_blank"&gt;Pathophysiological-based diagnosis and therapy of iron-deficient anaemia in inflammatory bowel disease&lt;/A&gt; &lt;I&gt;Z Gastroenterol&lt;/I&gt; 2009;47(2):228-36.&lt;BR&gt;&lt;I&gt;&lt;B&gt;Language:&lt;/B&gt; German&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;Zheng L-P, Lv Z-S, Zhang J, Cao X-C, Wang X-L. &lt;A href="http://wjg.wjgnet.com/1009-3079/17/2217.asp" target="_blank"&gt;A meta-analysis of extraintestinal manifestations of inflammatory bowel disease in Mainland China&lt;/A&gt; &lt;I&gt;Shi Jie Hua Ren Xiao Hua Za Zhi&lt;/I&gt; 2009;17(21):2217-20.&lt;BR&gt;&lt;I&gt;&lt;B&gt;Language:&lt;/B&gt; Chinese&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;Zimmerer T, Siegmund SV, Singer MV. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19551607" target="_blank"&gt;The problems of compliance and adherence, using the example of chronic inflammatory bowel disease.&lt;/A&gt; &lt;I&gt;Dtsch Med Wochenschr&lt;/I&gt; 2009;134(27):1417-24.&lt;BR&gt;&lt;I&gt;&lt;B&gt;Language:&lt;/B&gt; German&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BACKGROUND-COLOR: #33cccc; TEXT-ALIGN: center"&gt;Inflammatory Bowel Disease Annual Evidence Update 2010&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BACKGROUND-COLOR: #99cc00; TEXT-ALIGN: center"&gt;
&lt;P&gt;&lt;A href="nelh:346211:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346221:0" name=internalLink&gt;Aetiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346222:0" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346218:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:346219:0" name=internalLink&gt;Aminosalicylates&lt;/A&gt; | &lt;A href="nelh:346216:0" name=internalLink&gt;Immunosuppressants&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346215:0" name=internalLink&gt;Other interventions&lt;/A&gt; | &lt;A href="nelh:346214:0" name=internalLink&gt;General and miscellaneous&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:346217:0" name=internalLink&gt;Adverse effents and risk factors&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346213:0" name=internalLink&gt;Economics&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346212:0" name=internalLink&gt;Other&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346223:0" name=internalLink&gt;&lt;B&gt;Foreign language articles&lt;/B&gt;&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346224:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346220:0" name=internalLink&gt;Methods&lt;/A&gt; &lt;/P&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>346211</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=346211]]&gt;</url>
    <title>2010 Annual Evidence Update on Inflammatory Bowel Disease - Introduction</title>
    <publicationDate>2010-03-22T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,DIAGNOSTIC PROCEDURES,GASTROINTESTINAL ENDOSCOPY,ENTEROSCOPY,NUCLEAR MEDICINE,DISEASE PREVENTION,MRI,PROBIOTICS,MICROSCOPIC COLITIS,CANCER,INFECTIONS,CROHN'S DISEASE,DIETARY SUPPLEMENTS,RECENT ADDITIONS,RADIOLOGY,PET,MARCH 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Inflammatory Bowel Disease - Introduction&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;It is a pleasure to introduce this year’s annual evidence update for Inflammatory Bowel Disease. This update highlights the best peer reviewed guidelines and systematic reviews on the area and I must thank our topic advisors for their help in finalising the list and for their pertinent comments. Those topic advisors include Dr Andrew Cole, Dr Stephen Grainger, Dr Mark Hamilton, Dr Marcus Harbord, Dr Brian McKaig, Dr Richard Makins and Ms Isobel Mason. In addition this update has allowed us to scrutinize those areas of “uncertainties” in the management of IBD still not answered by the current literature and this has become part of the UK Database of Uncertainties about the Effects of Treatment (DUETS). I would like to make special mention of&amp;nbsp;Matthew Hall&amp;nbsp;(Information Specialist of NHS Evidence - gastroenterology and liver diseases) and Sara Clarke (Project Manager), their hard work has enabled the success of the library and development of this annual evidence update.&lt;/P&gt;
&lt;P&gt;We welcome any comments and hope you find the Specialist Collection a useful contribution to your practice.&lt;/P&gt;
&lt;P&gt;MARTYN CAPLIN&lt;/P&gt;
&lt;P&gt;Consultant Gastroenterologist &amp;amp; Clinical Lead, NHS Evidence - gastroenterology and liver diseases &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;A summary of the methods used for retrieving and evaluating the evidence can be found &lt;A href="nelh:346220:0" name=internalLink&gt;here&lt;/A&gt;. The evidence has been split into sections as follows:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:346221:0" name=internalLink&gt;Aetiology&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:346222:0" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:346218:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Treatment: 
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:346219:0" name=internalLink&gt;Aminosalicylates&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:346216:0" name=internalLink&gt;Immunosuppressants&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:346215:0" name=internalLink&gt;Other interventions&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:346214:0" name=internalLink&gt;General reviews and miscellaneous topics in treatment&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;BR&gt;
&lt;LI&gt;&lt;A href="nelh:346217:0" name=internalLink&gt;Adverse effects and risk factors&lt;/A&gt; 
&lt;LI&gt;&lt;A href="nelh:346213:0" name=internalLink&gt;Economics&lt;/A&gt; 
&lt;LI&gt;&lt;A href="nelh:346212:0" name=internalLink&gt;Other&lt;/A&gt; 
&lt;LI&gt;&lt;A href="nelh:346223:0" name=internalLink&gt;Foreign language articles&lt;/A&gt; &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Click on the sections above to find links to critically appraised systematic reviews, expert commentaries and other information of interest, or download the &lt;A href="http://www.library.nhs.uk/SpecialistLibrarySearch/Download.aspx?resID=346211" target="_blank"&gt;PDF version&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;We also have provided a list of &lt;A href="nelh:346224:0" name=internalLink&gt;treatment uncertainties&lt;/A&gt;, taken from the articles included in the AEU.&lt;/P&gt;
&lt;P&gt;This year's update has been put together by the Gastroenterology &amp;amp; Liver Diseases Specialist&amp;nbsp;Collection Project Team, with expert advice and commentaries provided by our IBD topic leads. These are:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Andrew Cole, Consultant Gastroenterologist, Derby City General Hospital&lt;/LI&gt;
&lt;LI&gt;Stephen Grainger, Consultant Physician and Gastroenterologist, King George Hospital, Essex&lt;/LI&gt;
&lt;LI&gt;Mark Hamilton, Consultant Gastroenterologist, Royal Free Hospital, London &lt;/LI&gt;
&lt;LI&gt;Marcus Harbord, Consultant Gastroenterologist, Chelsea and Westminster Hospital, London&lt;/LI&gt;
&lt;LI&gt;Brian McKaig, Consultant Gastroenterologist, New Cross Hospital, Wolverhampton&lt;/LI&gt;
&lt;LI&gt;Richard Makins, Consultant Gastroenterologist, Cheltenham General Hospital, Gloucestershire&lt;/LI&gt;
&lt;LI&gt;Isobel Mason, Lead Nurse for Gastroenterology, Royal Free Hospital, London&lt;/LI&gt;&lt;/UL&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BACKGROUND-COLOR: #33cccc; TEXT-ALIGN: center"&gt;Inflammatory Bowel Disease Annual Evidence Update 2010&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BACKGROUND-COLOR: #99cc00; TEXT-ALIGN: center"&gt;
&lt;P&gt;&lt;A href="nelh:346211:0" name=internalLink&gt;&lt;B&gt;Introduction&lt;/B&gt;&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346221:0" name=internalLink&gt;Aetiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346222:0" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346218:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:346219:0" name=internalLink&gt;Aminosalicylates&lt;/A&gt; | &lt;A href="nelh:346216:0" name=internalLink&gt;Immunosuppressants&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346215:0" name=internalLink&gt;Other interventions&lt;/A&gt; | &lt;A href="nelh:346214:0" name=internalLink&gt;General and miscellaneous&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:346217:0" name=internalLink&gt;Adverse effents and risk factors&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346213:0" name=internalLink&gt;Economics&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346212:0" name=internalLink&gt;Other&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346223:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346224:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346220:0" name=internalLink&gt;Methods&lt;/A&gt; &lt;/P&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>346220</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=346220]]&gt;</url>
    <title>2010 Annual Evidence Update on Inflammatory Bowel Disease - Methods for retrieving and evaluating the evidence</title>
    <publicationDate>2010-03-22T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Inflammatory Bowel Disease - Methods for retrieving and evaluating the evidence&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;The last Annual Evidence Update for IBD was completed in March 2009. This AEU serves as an update to that one, and includes articles published in 2009 and 2010. As the Specialist&amp;nbsp;Collection focuses only on secondary information of use to NHS staff and patients, our update was focused on guidelines, systematic reviews, and economic evaluations written in English. However, foreign language articles were included in the search process. As translations for these articles were not available, the article titles have been listed separately.&lt;/P&gt;&lt;BR&gt;
&lt;P style="FONT-SIZE: 13pt; COLOR: #99cc00"&gt;&lt;B&gt;Search strategy&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Our search strategy has been updated from last year. The following resources were searched: 
&lt;UL&gt;
&lt;LI&gt;MEDLINE&lt;/LI&gt;
&lt;LI&gt;EMBASE&lt;/LI&gt;
&lt;LI&gt;CINAHL&lt;/LI&gt;
&lt;LI&gt;PsycINFO&lt;/LI&gt;
&lt;LI&gt;AMED&lt;/LI&gt;
&lt;LI&gt;DARE&lt;/LI&gt;
&lt;LI&gt;NHS Economic Evaluation Database&lt;/LI&gt;
&lt;LI&gt;HTA Database&lt;/LI&gt;
&lt;LI&gt;The Cochrane Library&lt;/LI&gt;
&lt;LI&gt;NHS Evidence - gastroenterology and liver diseases&lt;/LI&gt;&lt;/UL&gt;The search strategy for MEDLINE, which was modified for the other resources, appears &lt;A href="#strategy"&gt;below&lt;/A&gt;. We combined this with a &lt;A href="#filter"&gt;modified SIGN systematic review&lt;/A&gt; filter in all cases except the searches of the Cochrane Library, DARE, NHS EED, the HTA Database and the Specialist Collection itself (because they consist entirely of the types of publication that we were interested in). 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;After de-duplication 644 articles were retrieved.&lt;/P&gt;&lt;BR&gt;
&lt;P style="FONT-SIZE: 13pt; COLOR: #99cc00"&gt;&lt;B&gt;Inclusion and exclusion criteria&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Included articles had to meet the following criteria:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Publication types: systematic review, consensus report, guideline, protocol, care pathway, economic evaluation, health technology assessment&lt;/LI&gt;
&lt;LI&gt;Published in 2009 or 2010&lt;/LI&gt;
&lt;LI&gt;Main condition under investigation was Crohn’s disease, ulcerative colitis, or another form of inflammatory bowel disease &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Once the inclusion criteria were applied, 87 articles were left. Of these, 8 were foreign language articles, 11 were Cochrane systematic reviews, and 7 were guidelines. &lt;/P&gt;
&lt;P&gt;The Cochrane systematic reviews and guidelines were automatically included in the Evidence Update. The foreign language studies were not sent out to reviewers because of translation difficulties and limited relevance to UK practice, but are listed in a separate section of the Evidence Update. This left 59 articles to be sent to our reviewers for appraisal.&lt;/P&gt;&lt;BR&gt;
&lt;P style="FONT-SIZE: 13pt; COLOR: #99cc00"&gt;&lt;B&gt;Critical appraisal process&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Before sending out, the articles were divided into categories as follows:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Aetiology&lt;/LI&gt;
&lt;LI&gt;Epidemiology&lt;/LI&gt;
&lt;LI&gt;Diagnosis&lt;/LI&gt;
&lt;LI&gt;Treatment&lt;/LI&gt;
&lt;LI&gt;Adverse effects and risk factors&lt;/LI&gt;
&lt;LI&gt;Economics&lt;/LI&gt;
&lt;LI&gt;Other&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Using these categories as a guide, the papers were divided up and sent to our seven reviewers. The reviewers then appraised the articles for their validity, relevance and rigour. Following the receipt of their comments, we included in the Evidence Update 45 articles that were deemed to meet the standards.&lt;/P&gt;
&lt;P&gt;We later added one Cochrane review and three guidelines which were released subsequently to our initial search. &lt;/P&gt;&lt;BR&gt;
&lt;P style="FONT-SIZE: 13pt; COLOR: #99cc00"&gt;&lt;B&gt;AEU process flowchart&lt;/B&gt;&lt;/P&gt;
&lt;P style="FONT-SIZE: 13pt; COLOR: #99cc00"&gt;&lt;IMG src="https://rmsadmin.library.nhs.uk/libraryImages/gastroliver/contentID346220/nelhImp_0000_ibdaeuflowchart2010.jpg"&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="FONT-SIZE: 13pt; COLOR: #99cc00"&gt;&lt;B&gt;&lt;A name=strategy&gt;&lt;/A&gt;MEDLINE search strategy&lt;/B&gt;&lt;/P&gt;
&lt;TABLE style="TABLE-LAYOUT: fixed"&gt;
&lt;TBODY&gt;
&lt;TR style="FONT-SIZE: 7pt; FONT-FAMILY: Courier,monospace"&gt;
&lt;TD style="BORDER-RIGHT: #000000 thin solid; PADDING-RIGHT: 5pt; BORDER-TOP: #000000 thin solid; PADDING-LEFT: 5pt; PADDING-BOTTOM: 5pt; BORDER-LEFT: #000000 thin solid; PADDING-TOP: 5pt; BORDER-BOTTOM: #000000 thin solid" ?&gt;&lt;STRONG&gt;1&lt;/STRONG&gt; exp colitis/ &lt;BR&gt;&lt;STRONG&gt;2&lt;/STRONG&gt; exp inflammatory bowel diseases/ &lt;BR&gt;&lt;STRONG&gt;3&lt;/STRONG&gt; exp enteritis/ &lt;BR&gt;&lt;STRONG&gt;4&lt;/STRONG&gt; exp proctitis/&lt;BR&gt;&lt;STRONG&gt;5&lt;/STRONG&gt; (inflammat* adj5 bowel*).mp.&lt;BR&gt;&lt;STRONG&gt;6&lt;/STRONG&gt; (inflammat* adj5 colon*).mp.&lt;BR&gt;&lt;STRONG&gt;7&lt;/STRONG&gt; (inflammat* adj5 intestin*).mp.&lt;BR&gt;&lt;STRONG&gt;8&lt;/STRONG&gt; (inflammat* adj5 ile*).mp.&lt;BR&gt;&lt;STRONG&gt;9&lt;/STRONG&gt; crohn*.mp.&lt;BR&gt;&lt;STRONG&gt;10&lt;/STRONG&gt; colitis.mp.&lt;BR&gt;&lt;STRONG&gt;11&lt;/STRONG&gt; ileitis.mp.&lt;BR&gt;&lt;STRONG&gt;12&lt;/STRONG&gt; enteritis.mp.&lt;BR&gt;&lt;STRONG&gt;13&lt;/STRONG&gt; proctitis.mp.&lt;BR&gt;&lt;STRONG&gt;14&lt;/STRONG&gt; enterocolitis.mp.&lt;BR&gt;&lt;STRONG&gt;15&lt;/STRONG&gt; proctocolitis.mp.&lt;BR&gt;&lt;STRONG&gt;16&lt;/STRONG&gt; cd.mp.&lt;BR&gt;&lt;STRONG&gt;17&lt;/STRONG&gt; ibd.mp.&lt;BR&gt;&lt;STRONG&gt;18&lt;/STRONG&gt; uc.mp.&lt;BR&gt;&lt;STRONG&gt;19&lt;/STRONG&gt; 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 &lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;BR&gt;
&lt;P style="FONT-SIZE: 13pt; COLOR: #99cc00"&gt;&lt;B&gt;&lt;A name=filter&gt;&lt;/A&gt;Systematic review filter&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This is modified from the SIGN filter, which can be found at &lt;A href="http://www.sign.ac.uk/methodology/filters.html" target="_blank"&gt;http://www.sign.ac.uk/methodology/filters.html&lt;/A&gt;. It shown below as used for the MEDLINE search (small adaptations were made for other databases).&lt;/P&gt;
&lt;TABLE style="BORDER-RIGHT: #000000 thin solid; BORDER-TOP: #000000 thin solid; FONT-SIZE: 7pt; BORDER-LEFT: #000000 thin solid; BORDER-BOTTOM: #000000 thin solid; FONT-FAMILY: Courier,serif"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="PADDING-RIGHT: 5pt; PADDING-LEFT: 5pt; PADDING-BOTTOM: 5pt; PADDING-TOP: 5pt"&gt;&lt;STRONG&gt;1&lt;/STRONG&gt; Meta-Analysis as Topic/&lt;BR&gt;&lt;STRONG&gt;2&lt;/STRONG&gt; Meta-Analysis/&lt;BR&gt;&lt;STRONG&gt;3&lt;/STRONG&gt; metaanaly*.mp. &lt;BR&gt;&lt;STRONG&gt;4&lt;/STRONG&gt; meta analy*.mp. &lt;BR&gt;&lt;STRONG&gt;5&lt;/STRONG&gt; (systematic adj (review* or overview*)).mp.&lt;BR&gt;&lt;STRONG&gt;6&lt;/STRONG&gt; exp Review Literature as Topic/&lt;BR&gt;&lt;STRONG&gt;7&lt;/STRONG&gt; 1 or 2 or 3 or 4 or 5 or 6&lt;BR&gt;&lt;STRONG&gt;8&lt;/STRONG&gt; Cochrane.ab.&lt;BR&gt;&lt;STRONG&gt;9&lt;/STRONG&gt; Embase.ab.&lt;BR&gt;&lt;STRONG&gt;10&lt;/STRONG&gt; Medline.ab.&lt;BR&gt;&lt;STRONG&gt;11&lt;/STRONG&gt; Pubmed.ab.&lt;BR&gt;&lt;STRONG&gt;12&lt;/STRONG&gt; (psychlit or psyclit).ab.&lt;BR&gt;&lt;STRONG&gt;13&lt;/STRONG&gt; (psychinfo or psycinfo).ab.&lt;BR&gt;&lt;STRONG&gt;14&lt;/STRONG&gt; (cinahl or cinhal).ab.&lt;BR&gt;&lt;STRONG&gt;15&lt;/STRONG&gt; science citation index.ab.&lt;BR&gt;&lt;STRONG&gt;16&lt;/STRONG&gt; bids.ab.&lt;BR&gt;&lt;STRONG&gt;17&lt;/STRONG&gt; cancerlit.ab.&lt;BR&gt;&lt;STRONG&gt;18&lt;/STRONG&gt; 11 or 9 or 17 or 12 or 15 or 14 or 8 or 16 or 10 or 13&lt;BR&gt;&lt;STRONG&gt;19&lt;/STRONG&gt; reference list$.ab.&lt;BR&gt;&lt;STRONG&gt;20&lt;/STRONG&gt; bibliograph$.ab.&lt;BR&gt;&lt;STRONG&gt;21&lt;/STRONG&gt; hand-search$.ab.&lt;BR&gt;&lt;STRONG&gt;22&lt;/STRONG&gt; relevant journals.ab.&lt;BR&gt;&lt;STRONG&gt;23&lt;/STRONG&gt; manual search$.ab.&lt;BR&gt;&lt;STRONG&gt;24&lt;/STRONG&gt; 22 or 21 or 23 or 19 or 20&lt;BR&gt;&lt;STRONG&gt;25&lt;/STRONG&gt; selection criteria.ab.&lt;BR&gt;&lt;STRONG&gt;26&lt;/STRONG&gt; data extraction.ab.&lt;BR&gt;&lt;STRONG&gt;27&lt;/STRONG&gt; 25 or 26&lt;BR&gt;&lt;STRONG&gt;28&lt;/STRONG&gt; review/&lt;BR&gt;&lt;STRONG&gt;29&lt;/STRONG&gt; 27 and 28&lt;BR&gt;&lt;STRONG&gt;30&lt;/STRONG&gt; Comment/&lt;BR&gt;&lt;STRONG&gt;31&lt;/STRONG&gt; Letter/&lt;BR&gt;&lt;STRONG&gt;32&lt;/STRONG&gt; editorial/&lt;BR&gt;&lt;STRONG&gt;33&lt;/STRONG&gt; 32 or 30 or 31&lt;BR&gt;&lt;STRONG&gt;34&lt;/STRONG&gt; 18 or 24 or 7 or 29&lt;BR&gt;&lt;STRONG&gt;35&lt;/STRONG&gt; 34 not 33&lt;BR&gt;&lt;STRONG&gt;36&lt;/STRONG&gt; limit 35 to animals&lt;BR&gt;&lt;STRONG&gt;37&lt;/STRONG&gt; limit 35 to (animals and humans)&lt;BR&gt;&lt;STRONG&gt;38&lt;/STRONG&gt; 36 not 37&lt;BR&gt;&lt;STRONG&gt;39&lt;/STRONG&gt; 35 not 38 &lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BACKGROUND-COLOR: #33cccc; TEXT-ALIGN: center"&gt;Inflammatory Bowel Disease Annual Evidence Update 2010&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BACKGROUND-COLOR: #99cc00; TEXT-ALIGN: center"&gt;
&lt;P&gt;&lt;A href="nelh:346211:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346221:0" name=internalLink&gt;Aetiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346222:0" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346218:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:346219:0" name=internalLink&gt;Aminosalicylates&lt;/A&gt; | &lt;A href="nelh:346216:0" name=internalLink&gt;Immunosuppressants&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346215:0" name=internalLink&gt;Other interventions&lt;/A&gt; | &lt;A href="nelh:346214:0" name=internalLink&gt;General and miscellaneous&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:346217:0" name=internalLink&gt;Adverse effents and risk factors&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346213:0" name=internalLink&gt;Economics&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346212:0" name=internalLink&gt;Other&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346223:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346224:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346220:0" name=internalLink&gt;&lt;B&gt;Methods&lt;/B&gt;&lt;/A&gt; &lt;/P&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>346212</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=346212]]&gt;</url>
    <title>2010 Annual Evidence Update on Inflammatory Bowel Disease - Other</title>
    <publicationDate>2010-03-22T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Inflammatory Bowel Disease - Other&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Guidelines&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The following guidelines were published this year:&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=308840" target="_blank"&gt;Quality care: service standards for the healthcare of people who have Inflammatory Bowel Disease (IBD)&lt;/A&gt; (IBD Standards Group)&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=320430" target="_blank"&gt;Sexual and reproductive health for individuals with inflammatory bowel disease&lt;/A&gt; (RCOG)&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Other reviews&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Also included in this update is a review by &lt;A href="#rangwalla"&gt;Rangwalla, Waljee and Higgins&lt;/A&gt; proposing and investigating "voting with their feet", the percentage of subjects leaving a randomized controlled trial arm for lack of efficacy, as an alternative endpoint for trials of 5-ASA in ulcerative colitis. &lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Articles&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=rangwalla&gt;&lt;/A&gt;Rangwalla SC, Waljee AK, Higgins PD. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=345632" target="_blank"&gt;Voting With their Feet (VWF) endpoint: a meta-analysis of an alternative endpoint in clinical trials, using 5-ASA induction studies in ulcerative colitis.&lt;/A&gt; &lt;I&gt;Inflamm Bowel Dis&lt;/I&gt; 2009;15(3):422-8.&lt;/P&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BACKGROUND-COLOR: #33cccc; TEXT-ALIGN: center"&gt;Inflammatory Bowel Disease Annual Evidence Update 2010&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BACKGROUND-COLOR: #99cc00; TEXT-ALIGN: center"&gt;
&lt;P&gt;&lt;A href="nelh:346211:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346221:0" name=internalLink&gt;Aetiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346222:0" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346218:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:346219:0" name=internalLink&gt;Aminosalicylates&lt;/A&gt; | &lt;A href="nelh:346216:0" name=internalLink&gt;Immunosuppressants&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346215:0" name=internalLink&gt;Other interventions&lt;/A&gt; | &lt;A href="nelh:346214:0" name=internalLink&gt;General and miscellaneous&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:346217:0" name=internalLink&gt;Adverse effents and risk factors&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346213:0" name=internalLink&gt;Economics&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346212:0" name=internalLink&gt;&lt;B&gt;Other&lt;/B&gt;&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346223:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346224:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346220:0" name=internalLink&gt;Methods&lt;/A&gt; &lt;/P&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>346219</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=346219]]&gt;</url>
    <title>2010 Annual Evidence Update on Inflammatory Bowel Disease - Treatment | Aminosalicylates</title>
    <publicationDate>2010-03-22T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Inflammatory Bowel Disease - Treatment | Aminosalicylates&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;EM&gt;Reviewed by Stephen Grainger, Consultant Physician and Gastroenterologist, King George Hospital, Essex, and Isobel Mason, Endoscopy Nurse Specialist, Royal Free Hospital, London&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Stephen Grainger:&lt;/B&gt; Up to 25% of patients with inflammatory bowel disease take both a 5-ASA and an immunosuppressant. Is disease control better than with the immunosuppressant alone? It is unproven, but probably not according to &lt;A href="#andrews"&gt;Andrews et al&lt;/A&gt;. Co-administration of the 5-ASA also raises the levels of active thiopurine metabolites and might increase toxicity. However, co-administration of the 5-ASA is likely to reduce the risk of colorectal cancer, not just by mechanisms dependent on reducing colonic inflammation. To prevent one cancer will cost at least 153 times the annual cost of 5-ASA treatment.&lt;/P&gt;
&lt;P&gt;Sulphasalazine is cheap. Is it as good as sulphur-free 5-ASAs? Yes, when compared with doses of 5-ASAs now considered sub-optimal for treatment of active ulcerative colitis. The paper by &lt;A href="#nikfar"&gt;Nikfar et al&lt;/A&gt; has become outdated because of the move to using higher doses of 5-ASA containing drugs. &lt;A href="#rahimi"&gt;Rahimi et al&lt;/A&gt; report that balsalazide 4-5g-6.75g per day is 1.23 times more likely to put a UC patient into remission than conventional doses of 5-ASA (2.4g per day). So use it or you might try to get more out of other 5-ASA by using the high doses (up to 4.8g per day) now favoured. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Isobel Mason:&lt;/B&gt; The systematic review by Higgins et al revealed two studies comparing adherence and frequency of UC flares. Two were small, prospective, comparative studies. Both defined adherence as a rate of medication consumption &amp;gt;80% of the prescribed regimen. Follow up was 6-12 months. Both showed a significant increase in UC flares in the non adherent group (39-40% of patients).&lt;/P&gt;
&lt;P&gt;The review demonstrates that relatively little robust data is available about the impact of nonadherence on UC management. This highlights the difficulty of measuring adherence. It points out that gathering data through prospective RCT’s is likely to include artificially high adherence rates and that more real-world maintenance studies are needed.&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Articles&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=andrews&gt;&lt;/A&gt;Andrews JM, Travis SP, Gibson PR, Gasche C. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=345518" target="_blank"&gt;Systematic review: does concurrent therapy with 5-ASA and immunomodulators in inflammatory bowel disease improve outcomes?&lt;/A&gt; &lt;I&gt;Aliment Pharmacol Ther&lt;/I&gt; 2009;29(5):459-69.&lt;/P&gt;
&lt;P&gt;&lt;A name=higgins&gt;&lt;/A&gt;Higgins PD, Rubin DT, Kaulback K, Schoenfield PS, Kane SV. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=310844" target="_blank"&gt;Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares.&lt;/A&gt; &lt;I&gt;Aliment Pharmacol Ther&lt;/I&gt; 2009;29(3):247-57. 
&lt;P&gt;&lt;A name=nikfar&gt;&lt;/A&gt;Nikfar S, Rahimi R, Rezaie A, Abdollahi M. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=345524" target="_blank"&gt;A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis.&lt;/A&gt; &lt;I&gt;Dig Dis Sci&lt;/I&gt; 2009;54(6):1157-70.&lt;/P&gt;
&lt;P&gt;&lt;A name=rahimi&gt;&lt;/A&gt;Rahimi R, Nikfar S, Rezaie A, Abdollahi M. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=345527" target="_blank"&gt;Comparison of mesalazine and balsalazide in induction and maintenance of remission in patients with ulcerative colitis: a meta-analysis.&lt;/A&gt; &lt;I&gt;Dig Dis Sci&lt;/I&gt; 2009;54(4):712-21.&lt;/P&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BACKGROUND-COLOR: #33cccc; TEXT-ALIGN: center"&gt;Inflammatory Bowel Disease Annual Evidence Update 2010&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BACKGROUND-COLOR: #99cc00; TEXT-ALIGN: center"&gt;
&lt;P&gt;&lt;A href="nelh:346211:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346221:0" name=internalLink&gt;Aetiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346222:0" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346218:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:346219:0" name=internalLink&gt;&lt;B&gt;Aminosalicylates&lt;/B&gt;&lt;/A&gt; | &lt;A href="nelh:346216:0" name=internalLink&gt;Immunosuppressants&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346215:0" name=internalLink&gt;Other interventions&lt;/A&gt; | &lt;A href="nelh:346214:0" name=internalLink&gt;General and miscellaneous&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:346217:0" name=internalLink&gt;Adverse effents and risk factors&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346213:0" name=internalLink&gt;Economics&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346212:0" name=internalLink&gt;Other&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346223:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346224:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346220:0" name=internalLink&gt;Methods&lt;/A&gt; &lt;/P&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>346214</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=346214]]&gt;</url>
    <title>2010 Annual Evidence Update on Inflammatory Bowel Disease - Treatment | General reviews and miscellaneous topics in treatment</title>
    <publicationDate>2010-03-22T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,DIAGNOSTIC PROCEDURES,GASTROINTESTINAL ENDOSCOPY,MICROSCOPIC COLITIS,CROHN'S DISEASE,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Inflammatory Bowel Disease - Treatment | General reviews and miscellaneous topics in treatment&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Guidelines&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The following guidelines were published this year:&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resID=317963" target="_blank"&gt;ACG practice guidelines: management of Crohn's disease in adults&lt;/A&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=344774" target="_blank"&gt;Inflammatory bowel disease: a global perspective&lt;/A&gt; (WGO) &lt;/A&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=319980" target="_blank"&gt;Maintenance treatment of inflammatory bowel disease: a summary of new treatment options and implications for patient adherence and current practice&lt;/A&gt; (PCSG)&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Cochrane reviews&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The following Cochrane review was published this year:&lt;/P&gt;
&lt;P&gt;Doherty G, Bennett G, Patil S, Cheifetz A, Moss AC. &lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=327195" target="_blank"&gt;Interventions for prevention of post-operative recurrence of Crohn's disease.&lt;/A&gt; &lt;I&gt;Cochrane Database of Systematic Reviews&lt;/I&gt; 2009, Issue 4. Art. No.: CD006873. DOI: 10.1002/14651858.CD006873.pub2.&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Other reviews&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Reviewed by Stephen Grainger, Consultant Physician and Gastroenterologist, King George Hospital, Essex&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="#chande"&gt;Chande et al&lt;/A&gt; add four more years evidence to Cochrane reviews of treatment of collagenous and lymphocytic colitis. The data confirms the effectiveness of budesonide but there is sparse information on other approaches to treatment of these increasingly diagnosed disorders.&lt;/P&gt;
&lt;P&gt;Achieving mucosal healing is intuitively attractive as a goal of treatment in Crohn’s disease. &lt;A href="#pimentel"&gt;Pimentel-Nunes et al&lt;/A&gt; systematically review the increasing effectiveness of steroids, diet, immunosuppressants and infliximab (greatest) at securing endoscopic remission. But it is not clear, yet, whether mucosal healing confirms a better long term outcome. More studies and a universally accepted definition of endoscopic remission are needed. &lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Articles&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=chande&gt;&lt;/A&gt;Chande N, MacDonald JK, McDonald JW. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=310848" target="_blank"&gt;Interventions for treating microscopic colitis: a Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Review Group systematic review of randomized trials.&lt;/A&gt; &lt;I&gt;Am J Gastroenterol&lt;/I&gt; 2009;104(1):235-41&lt;/P&gt;
&lt;P&gt;&lt;A name=pimentel&gt;&lt;/A&gt;Pimentel-Nunes P, Dinis-Ribeiro M, Magro F. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=345530" target="_blank"&gt;Systematic review on drug and diet-induced endoscopic remission in Crohn's disease.&lt;/A&gt; &lt;I&gt;Eur J Gastroenterol Hepatol&lt;/I&gt; 2009;21(5):491-503.&lt;/P&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BACKGROUND-COLOR: #33cccc; TEXT-ALIGN: center"&gt;Inflammatory Bowel Disease Annual Evidence Update 2010&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BACKGROUND-COLOR: #99cc00; TEXT-ALIGN: center"&gt;
&lt;P&gt;&lt;A href="nelh:346211:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346221:0" name=internalLink&gt;Aetiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346222:0" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346218:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:346219:0" name=internalLink&gt;Aminosalicylates&lt;/A&gt; | &lt;A href="nelh:346216:0" name=internalLink&gt;Immunosuppressants&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346215:0" name=internalLink&gt;Other interventions&lt;/A&gt; | &lt;A href="nelh:346214:0" name=internalLink&gt;&lt;B&gt;General and miscellaneous&lt;/B&gt;&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:346217:0" name=internalLink&gt;Adverse effents and risk factors&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346213:0" name=internalLink&gt;Economics&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346212:0" name=internalLink&gt;Other&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346223:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346224:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346220:0" name=internalLink&gt;Methods&lt;/A&gt; &lt;/P&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>346216</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=346216]]&gt;</url>
    <title>2010 Annual Evidence Update on Inflammatory Bowel Disease - Treatment | Immunosuppressants</title>
    <publicationDate>2010-03-22T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Inflammatory Bowel Disease - Treatment | Immunosuppressants&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Guidelines&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The following guidelines were published this year:&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resID=317960" target="_blank"&gt;CAG clinical practice guidelines: the use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease&lt;/A&gt; &lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Cochrane reviews&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The following Cochrane reviews were published or updated this year:&lt;/P&gt;
&lt;P&gt;Akobeng AK, Stokkers PC. &lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=312239" target="_blank"&gt;Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease.&lt;/A&gt; &lt;I&gt;Cochrane Database of Systematic Reviews&lt;/I&gt; 2009, Issue 2. Art. No.: CD007351. DOI: 10.1002/14651858.CD007351.pub2.&lt;/P&gt;
&lt;P&gt;El-Matary W, Vandermeer B, Griffiths AM. &lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=320813" target="_blank"&gt;Methotrexate for maintenance of remission in ulcerative colitis.&lt;/A&gt; &lt;I&gt;Cochrane Database of Systematic Reviews&lt;/I&gt; 2009, Issue 3. Art. No.: CD007560. DOI: 10.1002/14651858.CD007560.pub2.&lt;/P&gt;
&lt;P&gt;Patel V, MacDonald JK, McDonald JWD, Chande N. &lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=327196" target="_blank"&gt;Methotrexate for maintenance of remission in Crohn's disease.&lt;/A&gt; &lt;I&gt;Cochrane Database of Systematic Reviews&lt;/I&gt; 2009, Issue 4. Art. No.: CD006884. DOI: 10.1002/14651858.CD006884.pub2.&lt;/P&gt;
&lt;P&gt;Prefontaine E, MacDonald JK, Sutherland LR. &lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=236347" target="_blank"&gt;Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.&lt;/A&gt; &lt;I&gt;Cochrane Database of Systematic Reviews&lt;/I&gt; 2009, Issue 4. Art. No.: CD000545. DOI: 10.1002/14651858.CD000545.pub2.&lt;/P&gt;
&lt;P&gt;Prefontaine E, Sutherland LR, MacDonald JK, Cepoiu M. &lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=236347" target="_blank"&gt;Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease.&lt;/A&gt; &lt;I&gt;Cochrane Database of Systematic Reviews&lt;/I&gt; 2009, Issue 1. Art. No.: CD000067. DOI: 10.1002/14651858.CD000067.pub2.&lt;/P&gt;
&lt;P&gt;Srinivasan R, Akobeng AK. &lt;A href="http://www.library.nhs.uk/Gastroliver/ViewResource.aspx?resID=312238" target="_blank"&gt;Thalidomide and thalidomide analogues for induction of remission in Crohn's disease.&lt;/A&gt; &lt;I&gt;Cochrane Database of Systematic Reviews&lt;/I&gt; 2009, Issue 2. Art. No.: CD007350. DOI: 10.1002/14651858.CD007350.pub2.&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Other reviews&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Reviewed by Marcus Harbord, Consultant Gastroenterologist, Chelsea and Westminster Hospital, London&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;These reviews and meta-analyses of treatment in IBD focus on anti-TNF drugs and azathioprine. They provide insights into what can be quite a confusing area. Let us look at a few of topical issues:&lt;/P&gt;
&lt;P&gt;&lt;I&gt;Immuno-modulators in Crohn’s&lt;/I&gt; A well conducted meta-analysis by &lt;A href="#peyrin"&gt;Peyrin-Biroulet et al&lt;/A&gt; reviewed the 4 main trials assessing azathioprine and mercaptopurine to prevent post-operative recurrence in Crohn’s disease. They comprised only 198 treated patients. At one year, the number needed to treat (NNT) to prevent clinical recurrence is 7- 13; and 7 for severe endoscopic recurrence. TOPIC, currently recruiting across the UK, will hopefully provide more robust data to determine who should receive thiopurines post-operatively.&lt;/P&gt;
&lt;P&gt;&lt;I&gt;Immuno-modulators in UC&lt;/I&gt; &lt;A href="#gisbert2"&gt;Gisbert et al&lt;/A&gt;’s meta-analysis shows efficacy (NNT = 5) for remission maintenance versus placebo but not remission induction. However, only three controlled trials compared against placebo, in total comprising 73 treated patients. Meta-analysis of 3 similar sized studies comparing immunomodulators to 5-ASA was not significant.&lt;/P&gt;
&lt;P&gt;&lt;I&gt;Need for concomitant therapy – are the biologics similar?&lt;/I&gt; Post SONIC, you might think this is no longer debatable. However, there are differences. For example, the detailed, comprehensive review of certolizumab by &lt;A href="#rivkin"&gt;Rivkin&lt;/A&gt;, a drug denied a licence by European authorities, notes that this pegylated, humanised antibody does not require co-treatment with azathioprine. The same is true of the other humanised antibody, adalimumab (Karmiris K et.al. 2009); but not so for the chimaeric antibody infliximab as shown in SONIC. Interestingly, &lt;A href="#cassinotti"&gt;Cassinotti, Ardizzone and Porro&lt;/A&gt;’s review describes a post-hoc analysis of GAIN that suggests co-therapy with steroids and Adalimumab provides greater disease remission. This needs a prospective trial.&lt;/P&gt;
&lt;P&gt;&lt;I&gt;Significance of infliximab antibodies&lt;/I&gt; &lt;A href="#cassinotti2"&gt;Cassinotti and Travis&lt;/A&gt;’ excellent review of anti-infliximab antibodies gives a very clear message: their heterogeneity precludes clinical use. Measuring drug levels is much more useful.&lt;/P&gt;
&lt;P&gt;&lt;I&gt;Loss of response to infliximab and dose escalation&lt;/I&gt; &lt;A href="#gisbert"&gt;Gisbert and Panés&lt;/A&gt; review loss of response to first line therapy. This occurs in about half the patients during the first year, with dose adjustment successful in about 80%. This is currently cost-effective given the paucity of other therapies, however there is little data beyond one year. &lt;A href="#ma"&gt;Ma et al&lt;/A&gt; describe similar loss of response rates in those treated with adalimumab after infliximab failure, but dose escalation only salvages 61%.&lt;/P&gt;
&lt;P&gt;&lt;I&gt;Adalimumab as second line therapy?&lt;/I&gt; &lt;A href="#ma"&gt;Ma et al&lt;/A&gt; review the use of adalimumab in primary and secondary non-responders to infliximab. In essence, remission can be obtained, but not quite as often as de novo treatment. At 1 year, it occurs in 19% to 68%, the range illustrating the heterogeneous populations studied. The review is useful for clarifying adalimumab’s efficacy in primary non-responders. Five studies included such patients, including the CARE open label extension that demonstrated 26-week remission rates of 36%. &lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Articles&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=cassinotti&gt;&lt;/A&gt;Cassinotti A, Ardizzone S, Porro GB. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=345586" target="_blank"&gt;Adalimumab for the treatment of Crohn's disease.&lt;/A&gt; &lt;I&gt;Biologics&lt;/I&gt; 2008;2(4):763-77.&lt;/P&gt;
&lt;P&gt;&lt;A name=cassinotti2&gt;&lt;/A&gt;Cassinotti A, Travis S. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=345589" target="_blank"&gt;Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review.&lt;/A&gt; &lt;I&gt;Inflamm Bowel Dis&lt;/I&gt; 2009;15(8):1264-75.&lt;/P&gt;
&lt;P&gt;&lt;A name=gisbert&gt;&lt;/A&gt;Gisbert JP, Panés J. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=345593" target="_blank"&gt;Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review.&lt;/A&gt; &lt;I&gt;Am J Gastroenterol&lt;/I&gt; 2009;104(3):760-7.&lt;/P&gt;
&lt;P&gt;&lt;A name=gisbert2&gt;&lt;/A&gt;Gisbert JP, Linares PM, McNicholl AG, Maté J, Gomollón F. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=324068" target="_blank"&gt;Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis.&lt;/A&gt; &lt;I&gt;Aliment Pharmacol Ther&lt;/I&gt; 2009;30(2):126-37.&lt;/P&gt;
&lt;P&gt;&lt;A name=ma&gt;&lt;/A&gt;Ma C, Panaccione R, Heitman SJ, Devlin SM, Ghosh S, Kaplan GG. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=345595" target="_blank"&gt;Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab.&lt;/A&gt; &lt;I&gt;Aliment Pharmacol Ther&lt;/I&gt; 2009;30(10):977-86.&lt;/P&gt;
&lt;P&gt;&lt;A name=peyrin&gt;&lt;/A&gt;Peyrin-Biroulet L, Deltenre P, Ardizzone S, D'Haens G, Hanauer SB, Herfarth H, Lémann M, Colombel JF. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=322935" target="_blank"&gt;Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis.&lt;/A&gt; &lt;I&gt;Am J Gastroenterol&lt;/I&gt; 2009;104(8):2089-96.&lt;/P&gt;
&lt;P&gt;&lt;A name=rivkin&gt;&lt;/A&gt;Rivkin A. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=345599" target="_blank"&gt;Certolizumab pegol for the management of Crohn's disease in adults.&lt;/A&gt; &lt;I&gt;Clin Ther&lt;/I&gt; 2009;31(6):1158-76.&lt;/P&gt;
&lt;P&gt;&lt;A name=shao&gt;&lt;/A&gt;Shao LM, Chen MY, Cai JT. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=345601" target="_blank"&gt;Meta-analysis: the efficacy and safety of certolizumab pegol in Crohn's disease.&lt;/A&gt; &lt;I&gt;Aliment Pharmacol Ther&lt;/I&gt; 2009 Mar 15;29(6):605-14.&lt;/P&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BACKGROUND-COLOR: #33cccc; TEXT-ALIGN: center"&gt;Inflammatory Bowel Disease Annual Evidence Update 2010&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BACKGROUND-COLOR: #99cc00; TEXT-ALIGN: center"&gt;
&lt;P&gt;&lt;A href="nelh:346211:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346221:0" name=internalLink&gt;Aetiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346222:0" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346218:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:346219:0" name=internalLink&gt;Aminosalicylates&lt;/A&gt; | &lt;A href="nelh:346216:0" name=internalLink&gt;&lt;B&gt;Immunosuppressants&lt;/B&gt;&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346215:0" name=internalLink&gt;Other interventions&lt;/A&gt; | &lt;A href="nelh:346214:0" name=internalLink&gt;General and miscellaneous&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:346217:0" name=internalLink&gt;Adverse effents and risk factors&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346213:0" name=internalLink&gt;Economics&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346212:0" name=internalLink&gt;Other&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346223:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346224:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346220:0" name=internalLink&gt;Methods&lt;/A&gt; &lt;/P&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>346215</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=346215]]&gt;</url>
    <title>2010 Annual Evidence Update on Inflammatory Bowel Disease - Treatment | Other interventions</title>
    <publicationDate>2010-03-22T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,DISEASE PREVENTION,PROBIOTICS,CROHN'S DISEASE,DIETARY SUPPLEMENTS,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Inflammatory Bowel Disease - Treatment | Other interventions&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Guidelines&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The following guidelines were published this year:&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resID=307089" target="_blank"&gt;Extracorporeal photopheresis for Crohn's disease&lt;/A&gt; (NICE) &lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Cochrane reviews&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The following Cochrane review was published this year:&lt;/P&gt;
&lt;P&gt;Ahmed Ali U, Keus F, Heikens JT, Bemelman WA, Berdah SV, Gooszen HG, van Laarhoven CJHM. &lt;A href="http://www.library.nhs.uk/GASTROLIVER/ViewResource.aspx?resID=304911" target="_blank"&gt;Open versus laparoscopic (assisted) ileo pouch anal anastomosis for ulcerative colitis and familial adenomatous polyposis.&lt;/A&gt; &lt;I&gt;Cochrane Database of Systematic Reviews&lt;/I&gt; 2009, Issue 1. Art. No.: CD006267. DOI: 10.1002/14651858.CD006267.pub2.&lt;/P&gt;
&lt;P&gt;Behm BW, Bickston SJ. &lt;A href="http://www.library.nhs.uk/GASTROLIVER/ViewResource.aspx?resID=304978" target="_blank"&gt;Humanized antibody to the alpha4beta7 integrin for induction of remission in ulcerative colitis.&lt;/A&gt; &lt;I&gt;Cochrane Database of Systematic Reviews&lt;/I&gt; 2009, Issue 1. Art. No.: CD007571. DOI: 10.1002/14651858.CD007571.&lt;/P&gt;
&lt;P&gt;Belling R, McLaren S, Woods L. &lt;A href="http://www.library.nhs.uk/GASTROLIVER/ViewResource.aspx?resID=327212" target="_blank"&gt;Specialist nursing interventions for inflammatory bowel disease.&lt;/A&gt; &lt;I&gt;Cochrane Database of Systematic Reviews&lt;/I&gt; 2009, Issue 4. Art. No.: CD006597. DOI: 10.1002/14651858.CD006597.pub2.&lt;/P&gt;
&lt;P&gt;Turner D, Zlotkin SH, Shah PS, Griffiths AM. &lt;A href="http://www.library.nhs.uk/GASTROLIVER/ViewResource.aspx?resID=260031" target="_blank"&gt;Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease.&lt;/A&gt; &lt;I&gt;Cochrane Database of Systematic Reviews&lt;/I&gt; 2009, Issue 1. Art. No.: CD006320. DOI: 10.1002/14651858.CD006320.pub3.&lt;/P&gt;&lt;BR&gt;
&lt;P style="COLOR: #99cc00"&gt;&lt;B&gt;Other reviews&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Reviewed by Brian McKaig, Consultant Gastroenterologist, New Cross Hospital, Wolverhampton&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Heriot AG, Lynch AC. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=345637" target="_blank"&gt;Ileal pouch anal anastomosis: meta-analysis and comparison of outcomes between techniques.&lt;/A&gt; &lt;I&gt;Semin Col Rect Surg&lt;/I&gt; 2009;20(2):88-92.&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;B&gt;Reviewer's comments:&lt;/B&gt; Meta-analysis of complications and functional outcomes of different standard types of IPAA. The authors correctly identify the potential shortcomings of this type of analysis but have presented reasonable evidence to suggest that a stapled anastamosis provides better functional outcome with less incontinence than hand sewn anastamosis with mucosectomy without compromising the incidence of neoplastic transformation (with the caveat of short follow up). The paper also suggests that a J pouch provides on balance a better outcome with lower complication rates following surgery offset with some increased stool frequency but less need for pouch intubation to facilitate evacuation.&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;Li Y, Tian Y, Yu C, Zhu W, Li J. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=345640" target="_blank"&gt;A systematic review and meta-analysis of anti-adhesion molecule therapy in patients with active Crohn's disease.&lt;/A&gt; &lt;I&gt;Scand J Gastroenterol&lt;/I&gt; 2009;44(12):1435-42.&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;B&gt;Reviewer's comments:&lt;/B&gt; Meta-analysis of anti-adhesion molecule therapy in Crohn’s disease demonstrating that these molecules appear to be safe and well tolerated. Concern does remain however over the development of progressive multifocal leukoencephalopathy which has been reported with the use of natalizumab. They have proven, if modest, efficacy in inducing clinical remission (RR 1.31; 95% CI 1.12–1.52; p = 0.0005) and clinical response Crohn’s disease (RR 1.26; 95% CI 1.05–1.17, p=0.01) by reducing leukocyte recruitment to the inflamed gut. Anti-adhesion molecules therefore deserve further study, but as yet do not have a defined role in the treatment of Crohn’s disease in clinical practice.&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;Shen J, Ran HZ, Yin MH, Zhou TX, Xiao DS. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=345641" target="_blank"&gt;Meta-analysis: the effect and adverse events of Lactobacilli versus placebo in maintenance therapy for Crohn disease.&lt;/A&gt; &lt;I&gt;Intern Med J&lt;/I&gt; 2009;39(2):103-9.&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;B&gt;Reviewer's comments:&lt;/B&gt; There is much interest in the use of probiotics in the therapy of IBD. This meta-analysis on the use of &lt;/I&gt;Lactobacilli&lt;I&gt; as maintenance therapy for Crohn’s disease suggests that administration of &lt;/I&gt;L. Rhamnosus&lt;I&gt; strain GG may increase the relapse rate and that &lt;/I&gt;L. Johnsonii&lt;I&gt; demonstrates no efficacy in reducing the rate of relapse.&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;Teeuwen PH, Stommel MW, Bremers AJ, van der Wilt GJ, de Jong DJ, Bleichrodt RP. &lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=345643" target="_blank"&gt;Colectomy in patients with acute colitis: a systematic review.&lt;/A&gt; &lt;I&gt;J Gastrointest Surg&lt;/I&gt; 2009;13(4):676-86.&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;B&gt;Reviewer's comments:&lt;/B&gt; Interesting review of alterations in practice and outcomes of colectomy in patients with acute severe UC. Despite the recognised limitations of retrospective studies it is clear that colectomy is now being performed much more commonly as an urgent intervention for severe UC resistant to medical therapy (16.5% in 1975-1984 vs 58% in 1995-2005) rather than as an emergency procedure for toxic megacolon (71% in 1975-1984 vs 21.6% in 1995-2005). This reflects in the significant reduction in mortality between these time periods (10% to 1.8%). It is likely that greater interaction between gastroenterologists and colorectal surgeons allows decisions regarding surgery to be made in a timely manner. The morbidity of these procedures remains high (&amp;gt;40%) with infections (wound site and distant), surgical complications, and thromboembolic complications being most common. There is the possibility that the more widespread introduction of laparoscopic colectomy may help to reduce the former and greater vigilance surrounding thromboprophylaxis perhaps impacting on the latter.&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BACKGROUND-COLOR: #33cccc; TEXT-ALIGN: center"&gt;Inflammatory Bowel Disease Annual Evidence Update 2010&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BACKGROUND-COLOR: #99cc00; TEXT-ALIGN: center"&gt;
&lt;P&gt;&lt;A href="nelh:346211:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346221:0" name=internalLink&gt;Aetiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346222:0" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346218:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:346219:0" name=internalLink&gt;Aminosalicylates&lt;/A&gt; | &lt;A href="nelh:346216:0" name=internalLink&gt;Immunosuppressants&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346215:0" name=internalLink&gt;&lt;B&gt;Other interventions&lt;/B&gt;&lt;/A&gt; | &lt;A href="nelh:346214:0" name=internalLink&gt;General and miscellaneous&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:346217:0" name=internalLink&gt;Adverse effents and risk factors&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346213:0" name=internalLink&gt;Economics&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346212:0" name=internalLink&gt;Other&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346223:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346224:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346220:0" name=internalLink&gt;Methods&lt;/A&gt; &lt;/P&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>346224</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=346224]]&gt;</url>
    <title>2010 Annual Evidence Update on Inflammatory Bowel Disease - Uncertainties</title>
    <publicationDate>2010-03-22T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Inflammatory Bowel Disease - Uncertainties&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;As part of the process of conducting this Annual Evidence Update, we and our reviewers examined the included papers for treatment uncertainties that could be added to the UK Database of Uncertainties about the Effects of Treatments (&lt;A href="http://www.library.nhs.uk/duets/" target="_blank"&gt;UK DUETs&lt;/A&gt;), a project to create a central database of such uncertainties. The following list, which has been submitted to the database, is the results of our search. Click on each title for more information.&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=346052" target="_blank"&gt;Anti-adhesion molecules for Crohn's disease&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=345989" target="_blank"&gt;Anti-cytomegalovirus treatment in patients with ulcerative colitis&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=327688" target="_blank"&gt;Anti-TNF agents for prevention of post-operative recurrence of Crohn's disease&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=345980" target="_blank"&gt;Azathioprine or 6-mercaptopurine to induce mucosal healing in Crohn's disease&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=345981" target="_blank"&gt;Azathioprine or 6-mercaptopurine for induction of remission in fistulizing Crohn's disease&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=346048" target="_blank"&gt;Balsalazide versus mesalazine for maintenance of remission in ulcerative colitis&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=346049" target="_blank"&gt;Balsalazide versus sulfasalazine for induction and maintenance of remission in ulcerative colitis&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=346047" target="_blank"&gt;Certolizumab pegol for Crohn's disease&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=346033" target="_blank"&gt;Concomitant adalimumab and immunosuppressants for induction and maintenance of other remission in Crohn's disease&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=346032" target="_blank"&gt;Concomitant corticosteroids and&amp;nbsp;adalimumab for induction and maintenance of remission in Crohn's disease&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=327689" target="_blank"&gt;Cost-effectiveness analysis of mesalamine for prevention of post-operative recurrence of Crohn's disease&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=346054" target="_blank"&gt;Lactobacilli for maintenance of remission for Crohn's disease in children&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=345976" target="_blank"&gt;Methotrexate for maintenance of remission in Crohn's disease&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=328632" target="_blank"&gt;Methotrexate for maintenance of remission in ulcerative colitis&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=345966" target="_blank"&gt;MLN-02 for induction of remission in ulcerative colitis&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=345988" target="_blank"&gt;Omega 3 fatty acids for maintenance of remission in Crohn's disease&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=345964" target="_blank"&gt;Open versus laparoscopic ileo pouch anal anastomosis for ulcerative colitis and familial adenomatous polyposis&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=327725" target="_blank"&gt;Specialist nursing interventions for inflammatory bowel disease&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=313198" target="_blank"&gt;Thalidomide analogues for induction of remission in Crohn's disease&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resid=313199" target="_blank"&gt;Thalidomide analogues for maintenance of remission in Crohn's disease&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;BR&gt;
&lt;TABLE align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BACKGROUND-COLOR: #33cccc; TEXT-ALIGN: center"&gt;Inflammatory Bowel Disease Annual Evidence Update 2010&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BACKGROUND-COLOR: #99cc00; TEXT-ALIGN: center"&gt;
&lt;P&gt;&lt;A href="nelh:346211:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346221:0" name=internalLink&gt;Aetiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346222:0" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346218:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Treatment &lt;FONT style="FONT-SIZE: 8pt"&gt;(&lt;A href="nelh:346219:0" name=internalLink&gt;Aminosalicylates&lt;/A&gt; | &lt;A href="nelh:346216:0" name=internalLink&gt;Immunosuppressants&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346215:0" name=internalLink&gt;Other interventions&lt;/A&gt; | &lt;A href="nelh:346214:0" name=internalLink&gt;General and miscellaneous&lt;/A&gt;)&lt;/FONT&gt;&lt;BR&gt;&lt;A href="nelh:346217:0" name=internalLink&gt;Adverse effents and risk factors&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346213:0" name=internalLink&gt;Economics&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346212:0" name=internalLink&gt;Other&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346223:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346224:0" name=internalLink&gt;&lt;B&gt;Uncertainties&lt;/B&gt;&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:346220:0" name=internalLink&gt;Methods&lt;/A&gt; &lt;/P&gt;&lt;/TD&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>281303</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17243140]]&gt;</url>
    <title>5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review</title>
    <publicationDate>2008-03-10T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Gisbert, JP. &lt;SPAN title="Inflammatory bowel diseases."&gt;&lt;A href="#javascript:AL_get(this," ?jour?, ?Inflamm Bowel Dis.?);?&gt;Inflamm Bowel Dis.&lt;/A&gt;&lt;/SPAN&gt; 2007 May;13(5):629-38.&lt;/P&gt;
&lt;P class=abstract&gt;Nephrotoxicity has been described in some patients with inflammatory bowel disease (IBD) treated with 5-aminosalicylic acid (5-ASA). Studies with 5-ASA treatment in which serum creatinine or creatinine clearance was measured regularly show that nephrotoxicity is exceptional (mean rate of only 0.26% per patient-year). There have been several case reports, including 46 patients, of renal disease associated with 5-ASA treatment in patients with IBD. 5-ASA treatment-related nephrotoxicity is reported most often within the first 12 months, but also delayed presentation after several years has been shown. The absence of a clear relationship between 5-ASA dose and the risk of nephrotoxicity suggests that this complication is idiosyncratic rather than dose-related. Most of the patients with renal disease associated with 5-ASA treatment suffered interstitial nephritis, with symptoms and signs being nonspecific, which may delay detection for many months. The nephrotoxicity potential of mesalazine and sulfasalazine seems to be similar. The risk with different oral preparations of 5-ASA is probably too small to influence the choice of agent. Mesalazine should be withdrawn when renal impairment manifests in a patient with IBD; if this does not result in a fall in serum creatinine, then renal biopsy should be considered. A trial of high-dose steroid may be recommended in patients whose renal function does not respond to drug withdrawal. The optimal monitoring schedule of serum creatinine in patients receiving 5-ASA treatment remains to be established, as there is no evidence to date that either the test, or the frequency of testing, improves patient outcomes.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>251166</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1463-1318.2005.00903.x]]&gt;</url>
    <title>A comparison of segmental vs subtotal/total colectomy for colonic Crohn's disease: a meta-analysis</title>
    <publicationDate>2006-02-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE,COLON]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Using meta-analytical techniques the present study evaluated differences in short-term and long-term outcomes of adult patients with colonic Crohn's disease who underwent either colectomy with ileorectal anastomosis (IRA) or segmental colectomy (SC)</description>
    <body>&lt;![CDATA[ &lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Tekkis PP, Purkayastha S, Lanitis S et al. 2006; Colorectal Diseases&amp;nbsp;8 (2) pp. 82-90&amp;nbsp; 
&lt;H2&gt;Original article abstract:&lt;/H2&gt;
&lt;P&gt;OBJECTIVE: Using meta-analytical techniques the present study evaluated differences in short-term and long-term outcomes of adult patients with colonic Crohn's disease who underwent either colectomy with ileorectal anastomosis (IRA) or segmental colectomy (SC). METHODS: Comparative studies published between 1988 and 2002, of subtotal/total colectomy and ileorectal anastomosis vs segmental colectomy, were used. The study end points included were surgical and overall recurrence, time to recurrence, postoperative morbidity and incidence of permanent stoma. Random and fixed-effect meta-analytical models were used to evaluate the study outcomes. Sensitivity analysis, funnel plot and meta-regressive techniques were carried out to explain the heterogeneity and selection bias between the studies. RESULTS: Six studies, consisting of a total of 488 patients (223 IRA and 265 SC) were included. Analysis of the data suggested that there was no significant difference between IRA and SC in recurrence of Crohn's disease. Time to recurrence was longer in the IRA group by 4.4 years (95% CI: 3.1-5.8), P &amp;lt; 0.001. There was no difference between the incidence of postoperative complications (OR = 1.4., 95% CI 0.16-12.74) or the need for a permanent stoma between the two groups (OR = 2.75, 95% CI 0.78-9.71). Patients with two or more colonic segments involved were associated with lower re-operation rate in the IRA group, a difference which did not reach statistical significance (P = 0.177). CONCLUSIONS: Both procedures were equally effective as treatment options for colonic Crohn's disease however, patients in the SC group exhibited recurrence earlier than those in the IRA group. The choice of operation is dependent on the extent of colonic disease, with a trend towards better outcomes with IRA for two or more colonic segments involved. Since no prospective randomised study has been undertaken, a clear view about which approach is more suitable for localised colonic Crohn's disease cannot be obtained.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;This article is &lt;STRONG&gt;not&lt;/STRONG&gt; available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323570</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18850763]]&gt;</url>
    <title>A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>Adis Data Information</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,RECENT ADDITIONS,AUGUST 2009,CHRONIC HEPATITIS B]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;
&lt;P&gt;&lt;/P&gt;&lt;STRONG&gt;Background:&lt;/STRONG&gt; A variety of pharmaceuticals are currently approved for the treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB), but their relative economic value is unclear. The goal of this analysis was to compare the cost effectiveness of adefovir, entecavir, lamivudine, pegylated interferon and telbivudine. 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; We conducted a cost-utility analysis from a US payer perspective over a lifetime time horizon using a Markov model, in a hypothetical population with HBeAg-positive CHB and a mean age of 35 years. Disease progression probabilities, costs and quality-of-life data were derived from the literature. We assumed a treatment duration of 4 years, with the use of combination therapy for drug resistance. Nonresponders to pegylated interferon were assumed to receive entecavir in years 3-4. Sensitivity analyses, including probabilistic sensitivity analysis, were conducted to evaluate uncertainty in the results. All costs were valued in $US, year 2008 values. Costs and outcomes were discounted at 3% per anum.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The 10-year cumulative incidence of cirrhosis for no treatment was 26.1%, and ranged from 19.7% to 23.8% with treatment; undiscounted life-years were 36.2 for no treatment, or ranged from 36.82 to 37.54 with treatment. Initiation with entecavir (18.70 QALYs) and pegylated interferon (18.64 QALYs) provided the largest treatment benefits overall, followed by telbivudine (18.55 QALYs). The probabilities of the interventions being cost effective at a threshold of $US50 000 per QALY were 57%, 37% and 2% for initiation with entecavir, pegylated interferon and telbivudine, respectively. The results were dependent on baseline seroconversion rate and the effect of viral suppression on cirrhosis risk.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; Initiation of treatments for HBeAg-positive CHB with a favourable combination of seroconversion, viral suppression and resistance profile appear to offer the greatest clinical and economic value.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;See also: &lt;/STRONG&gt;&lt;A href="nelh:343074:0" name=internalLink&gt;NHS EED record&lt;/A&gt; for this article/&lt;/P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Spackman DE, Veenstra DL. A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B. &lt;EM&gt;Pharmacoeconomics &lt;/EM&gt;2008;26(11):937-49.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314800</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1038/ajg.2009.129]]&gt;</url>
    <title>A global, evidence-based consensus on the definition of gastroesophageal reflux disease in the pediatric population</title>
    <publicationDate>2009-03-31T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,OESOPHAGUS,GASTRO-OESOPHAGEAL REFLUX]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Method: &lt;/STRONG&gt;The objective was to develop an international consensus on the definition of gastroesophageal reflux disease (GERD) in the pediatric population.&amp;nbsp;Using the Delphi process, a set of statements was developed and voted on by an international panel of eight pediatric gastroenterologists. Statements were based on systematic literature searches using Medline, EMBASE, and CINAHL. Voting was conducted using a six-point scale, with consensus defined, &lt;I&gt;a priori&lt;/I&gt;, as agreed by 75% of the group. The strength of each statement was assessed using the GRADE system.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Consensus items of particular note were: (i) GERD is present when reflux of gastric contents causes troublesome symptoms and/or complications, but this definition is complicated by unreliable reporting of symptoms in children under the age of approximately 8 years; (ii) histology has limited use in establishing or excluding a diagnosis of GERD; its primary role is to exclude other conditions; (iii) Barrett's esophagus should be defined as esophageal metaplasia that is intestinal metaplasia positive or negative; and (iv) extraesophageal conditions may be associated with GERD, but for most of these conditions causality remains to be established.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Sherman PM, Hassall E, Fagundes-Neto U, Gold BD, Kato S, Koletzko S, Orenstein S, Rudolph C, Vakil N, Vandeplas Y. A global, evidence-based consensus on the definition of gastroesophageal reflux disease in the pediatric population. Am J Gastroenterol 2009;104(5):1278-95.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>126586</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.hepctrust.org.uk/Resources/HepC/Migrated%20Resources/Documents/Other/280_A%20MATTER%20OF%20CHANCE%2023-5-06.pdf]]&gt;</url>
    <title>A matter of chance: an audit of the Department of Health 2004 Hepatitis C Action Plan for England</title>
    <publicationDate>2006-05-01T00:00:00</publicationDate>
    <publisher>Hepatitis C Trust</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The authors of this report are extremely disappointed with the local NHS response to hepatitis C.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Primary Care Trusts and NHS Hospital Trusts were surveyed in order to audit their actions to fulfil the &lt;A href="nelh:126589:0" name=internalLink&gt;&lt;A disabled href="nelh:126589:0" name=internalLink&gt;Hepatitis C Action Plan's&lt;/A&gt;&lt;/A&gt; requirement that 'Chief Executives of Primatry Care Trusts and NHS Hospital Trusts should be able to demonstarte that there are adequate services and partnerships at local level to enable models of vest clinical practice to be followed, as set out by the &lt;A href="nelh:126588:0" name=internalLink&gt;&lt;A href="http://www.dh.gov.uk/assetRoot/04/05/95/10/04059510.pdf" target="_blank"&gt;Hepatitis C Strategy for England&lt;/A&gt;&lt;/A&gt;&lt;/A&gt;.'&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Executive Conclusion: &lt;/B&gt;The All-Party Parliamentary Hepatology Group is extremely disappointed by the local NHS response to hepatitis C. The Department of Health’s Hepatitis C Action Plan for England is not working because it is not being implemented. &lt;/P&gt;
&lt;P align=justify&gt;Unless vastly more vigorous efforts are made now at local level by PCTs, encouraged by targets and a timetable set out nationally by the Department of Health, we predict that hepatitis C will in the future become a crushing burden to our health service and that we will look back and know that we could have prevented that happening."&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Audience:&lt;/STRONG&gt;&amp;nbsp;All those affected by hepatitis C care&amp;nbsp;within the NHS,&amp;nbsp;especially&amp;nbsp;healthcare professionals and&amp;nbsp;managers.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Related links:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:126588:0" name=internalLink&gt;&lt;A href="nelh:126589:0" name=internalLink&gt;&lt;A href="nelh:126589:0" name=internalLink&gt;&lt;A href="nelh:126589:0" name=internalLink&gt;Hepatitis C Action Plan&lt;/A&gt;&lt;A href="nelh:126589:0" name=internalLink&gt;&amp;nbsp;for England&lt;/A&gt;&lt;A href="nelh:126589:0" name=internalLink&gt;&lt;/A&gt;&lt;/A&gt;&lt;/A&gt;, Department&amp;nbsp;of Health.&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:126588:0" name=internalLink&gt;&lt;A href="nelh:126588:0" name=internalLink&gt;&lt;A href="http://www.dh.gov.uk/assetRoot/04/05/95/10/04059510.pdf" target="_blank"&gt;Hepatitis C Strategy for England&lt;/A&gt;&lt;A href="http://www.dh.gov.uk/assetRoot/04/05/95/10/04059510.pdf" target="_blank"&gt;&lt;/A&gt;&lt;/A&gt;&lt;A href="http://www.dh.gov.uk/assetRoot/04/05/95/10/04059510.pdf" target="_blank"&gt;&lt;/A&gt;&lt;/A&gt;&lt;A href="http://www.dh.gov.uk/assetRoot/04/05/95/10/04059510.pdf" target="_blank"&gt;&lt;/A&gt;&lt;/A&gt;, Department&amp;nbsp;of Health.&lt;/P&gt;
&lt;P&gt;Full report &lt;A href="nelh:126678:0" name=internalLink&gt;&lt;A href="nelh:126678:0" name=internalLink&gt;The UK vs. Europe: ready to fight back?&lt;/A&gt;&lt;/A&gt; The Hepatitis C Trust and University of Southampton.&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:126590:0" name=internalLink&gt;&lt;/A&gt;Interim report &lt;A href="nelh:126590:0" name=internalLink&gt;&lt;A href="http://www.hepcuk.info/data/news/213_The%20UK%20vs.%20Europe.pdf" target="_blank"&gt;The UK vs. Europe: Losing the fight against Hepatitis C&lt;/A&gt;&lt;/A&gt;&lt;A href="http://www.hepcuk.info/data/news/213_The%20UK%20vs.%20Europe.pdf" target="_blank"&gt;&lt;/A&gt;&lt;/A&gt;. The Hepatitis C Trust and University of Southampton.&lt;/P&gt;
&lt;P&gt;&lt;A&gt;&lt;/A&gt;&lt;A href="http://www.hepcuk.info/data/usercontentroot/home/" target="_blank"&gt;The Hepatitis C Trust&lt;/A&gt;&lt;A href="http://www.hepcuk.info/data/usercontentroot/home/" target="_blank"&gt;&lt;/A&gt;&lt;/A&gt;&lt;A href="http://www.hepcuk.info/data/usercontentroot/home/" target="_blank"&gt;&lt;/A&gt;&lt;/A&gt; website.&lt;/FONT&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281270</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1572-0241.2007.01548.x]]&gt;</url>
    <title>A meta-analysis comparing incidence of recurrence and indication for reoperation after surgery for perforating versus nonperforating Crohn's disease</title>
    <publicationDate>2008-03-10T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The indication for reoperation in CD tends to be the same as the primary operation, &lt;I&gt;i.e.&lt;/I&gt;, perforating disease tends to re-present as perforating disease, and nonperforating as nonperforating. Also, perforating CD appears to be associated with a higher recurrence rate compared with nonperforating CD. However, because of significant HG among studies, further studies should be undertaken to confirm this finding.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Comparative studies published between 1988 and 2005 of perforating &lt;I&gt;versus&lt;/I&gt; nonperforating CD were included. Using a random effects model, end points evaluated were recurrence of CD given as reoperation, and the indication for reoperation, &lt;I&gt;i.e.&lt;/I&gt;, perforating or nonperforating. Heterogeneity (HG) was assessed and a sensitivity analysis was performed to account for bias in patient selection.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Thirteen studies (12 nonrandomized retrospective, 1 nonrandomized prospective) reported on 3,044 patients, of which 1,337 (43.9%) had perforating indications (P group) and 1,707 (56.1%) had nonperforating indications (NP group) for surgery. The recurrence was found to be significantly higher in the P group compared to the NP group (HR 1.50, &lt;I&gt;P&lt;/I&gt; = 0.002), with significant HG among studies (&lt;I&gt;P&lt;/I&gt; &amp;lt; 0.001). The recurrence remained significantly higher in the P group compared with the NP group during sensitivity analysis of high-quality studies (HR 1.47, &lt;I&gt;P&lt;/I&gt; = 0.005) and more recent studies (HR 1.51, &lt;I&gt;P&lt;/I&gt; = 0.05), but still demonstrating significant HG (&lt;I&gt;P&lt;/I&gt; = 0.08 and &lt;I&gt;P&lt;/I&gt; &amp;lt; 0.001, respectively). At reoperation, concordance was found in the disease type of those patients re-presenting with perforating disease (OR 5.93, &lt;I&gt;P&lt;/I&gt; &amp;lt; 0.001, without significant HG among studies &lt;I&gt;P&lt;/I&gt; = 0.15) and those with nonperforating disease (OR 5.73, &lt;I&gt;P&lt;/I&gt; &amp;lt; 0.001, with significant HG among studies &lt;I&gt;P&lt;/I&gt; &amp;lt; 0.001). Concordance in disease type remained when considering only high-quality studies (P: OR 7.48, &lt;I&gt;P&lt;/I&gt; &amp;lt; 0.001; NP: OR 7.48, &lt;I&gt;P&lt;/I&gt; &amp;lt; 0.001) and more recent studies (P: OR 5.95, &lt;I&gt;P&lt;/I&gt; &amp;lt; 0.001; NP: OR 5.95, &lt;I&gt;P&lt;/I&gt; &amp;lt; 0.001), both not associated with HG among studies (&lt;I&gt;P&lt;/I&gt; = 0.47 and &lt;I&gt;P&lt;/I&gt; = 0.60, respectively).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Simillis, C., Yamamoto, T., Reese, G. E., Umegae, S., Matsumoto, K., Darzi, A. W., &amp;amp; Tekkis, P. P. (2008) A meta-analysis comparing incidence of recurrence and indication for reoperation after surgery for perforating versus nonperforating Crohn's disease. &lt;I&gt;American Journal of Gastroenterology&lt;/I&gt;, 103(1):196-205.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in January 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281252</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17415632]]&gt;</url>
    <title>A meta-analysis of antibiotic therapy for active ulcerative colitis</title>
    <publicationDate>2008-03-10T00:00:00</publicationDate>
    <publisher>Harvey Whitney Books Co.</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;SPAN title="Digestive diseases and sciences."&gt;Rahimi, R. &lt;A href="#javascript:AL_get(this," ?jour?, ?Dig Dis Sci.?);?&gt;Dig Dis Sci.&lt;/A&gt;&lt;/SPAN&gt; 2007 Nov;52(11):2920-5. Epub 2007 Apr 6.&lt;/P&gt;
&lt;P class=abstract&gt;To systematically evaluate the efficacy of antibacterial therapy in ulcerative colitis, we carried out a meta-analysis of controlled clinical trials. Within the time period 1966 through September 2006, PUBMED, EMBASE, and SCOPUS were searched for clinical trial studies that investigated the efficacy of antibiotics in ulcerative colitis. We considered clinical remission as our key outcome of interest. Of 122 studies, 10 randomized placebo-controlled clinical trials matched our criteria and were included in the analysis (530 patients). All the studies used antibiotics as an adjunct therapy to conventional treatment of ulcerative colitis (i.e., corticosteroids and 5-aminosalycilic acid). Pooling of these trials yielded odds ratio (OR) of 2.14 (95% confidence interval [CI], 1.48-3.09; P&amp;lt;0.0001) in favor of antimicrobial therapy. Meta-analysis of short-term trials (5-14 days) showed a higher rate of clinical remission in patients treated with antibiotics (OR, 2.02; 95% CI, 1.36-3). These results suggest that adjunctive antibacterial therapy is effective for induction of clinical remission in ulcerative colitis.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>385066</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1002/hep.23623]]&gt;</url>
    <title>A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease</title>
    <publicationDate>2010-07-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,NON-ALCOHOLIC,STEATOHEPATITIS,NON-ALCOHOLIC,RECENT ADDITIONS,FATTY LIVER,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Well-designed randomised controlled trials (RCTs) of adequate size and duration, with histological endpoints, are needed to assess long-term safety and efficacy of proposed treatments on patient-oriented clinical outcomes in nonalcoholic fatty liver disease (NAFLD).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; NAFLD encompasses a histological spectrum ranging from simple steatosis to nonalcoholic steatohepatitis (NASH). NAFLD carries a higher risk of cardio-metabolic and liver-related complications, the latter being confined to NASH and demanding specific treatment.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We assessed the efficacy of proposed treatments for NAFLD/NASH by reviewing reports of RCTs on online databases and national and international meeting abstracts through January 2010. Primary outcome measure was histological improvement; secondary outcome was biochemical improvement; improvement in radiological steatosis was also evaluated. Two reviewers extracted articles using predefined quality indicators, independently and in duplicate. Main outcomes of randomized controlled trials (RCTs) were pooled using random-effects or fixed-effects models. Publication bias was assessed by funnel plots.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Forty-nine RCTs (30 in NASH) were included: 23 RCTs (22 in NASH, 1 in NAFLD) had post-treatment histology. Most RCTs were small and did not exceed 1-year duration. Weight loss, thiazolidinediones (especially pioglitazone), and antioxidants were most extensively evaluated. Weight loss was safe and dose-dependently improved histological disease activity in NASH, but more than 50% of patients failed to achieve target weight loss. Thiazolidinediones improved steatosis and inflammation but yielded significant weight gain. RCTs with antioxidants yielded conflicting results and were heterogeneous with respect to type and dose of drug, duration, implementation of lifestyle intervention. Among the other agents, pentoxifylline, telmisartan and L-carnitine improved liver histology in at least 1 RCT in NASH; polyunsaturated fatty acid (PUFA) ameliorated biochemical and radiological markers of NAFLD. Other approaches yielded negative results.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. &lt;EM&gt;Hepatology&lt;/EM&gt; 2010;52(1):79-104.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>371933</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1002/hep.23485]]&gt;</url>
    <title>A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma</title>
    <publicationDate>2010-04-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATOCELLULAR CARCINOMA,RECENT ADDITIONS,CANCER,APRIL 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; This meta-analysis confirms the heterogeneity of behavior of untreated hepatocellular carcinoma (HCC) and provides a sound basis for stratifying patients with HCC according to expected survival in future trials of new anti-cancer agents.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Knowing the spontaneous outcome of HCC is important for designing randomized controlled trials (RCTs) of new therapeutic approaches; however, survival of patients in the absence of treatment is highly variable, and prognostic factors influencing outcomes are incompletely defined. The aims of this meta-analysis were to estimate the 1-year and 2-year survival rates of untreated HCC patients enrolled in RCTs of palliative treatments, and to identify prognostic factors.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; RCTs evaluating therapies for HCC with placebo or no-treatment arms were identified on MEDLINE through April 2009. Data were combined in a random effect model. Primary outcomes were 1-year and 2-year survival. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Thirty studies met the inclusion criteria. The pooled estimates of the survival rates were 17.5% at 1 year (95% confidence interval [95%CI], 11%-27%; range, 0%-75%) and 7.3% at 2 years (95%CI, 3.9%-13%; range, 0%-50%). Heterogeneity among studies was highly significant (P &amp;lt; 0.0001) both for 1-year and 2-year survival, and persisted when RCTs were stratified according to all patient and study features. Through meta-regression, impaired performance status, Child-Pugh B-C class, and presence of portal vein thrombosis were all independently associated with shorter survival. Ascites was strongly linked to a worse outcome in intermediate/advanced Barcelona Clinic Liver Cancer stages.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Cabibbo G, Enea M, Attanasio M, Bruix J, Craxì A, Cammà C. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. &lt;EM&gt;Hepatology&lt;/EM&gt; 2010;51(4):1274-83.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309187</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.termedia.pl/showpdf.php?article_id=10671&amp;filename=a%20metaanalysis.pdf&amp;priority=1]]&gt;</url>
    <title>A meta-analysis of the benefit of probiotics in maintaining remission of human ulcerative colitis: evidence for prevention of disease relapse and maintenance of remission</title>
    <publicationDate>2008-06-27T00:00:00</publicationDate>
    <publisher>Termedia &amp; Banach</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Probiotics are effective in maintaining remission and their effect in preventing relapse is comparable with mesalazine.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; PubMed, Embase, and Cochrane Central Register of Controlled Trials were searched for studies investigating the efficacy of probiotics in maintaining remission of ulcerative colitis. Relapse rate was the key outcome of interest. Data were searched within the time period of 1966 to January 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Two controlled trials which determined the efficacy of probiotics and 4 which compared the efficacy of probiotics with mesalazine in preventing relapse of ulcerative colitis met our criteria and were included in the metaanalysis. Pooling of 2 trials for the efficacy of probiotics yielded a significant odds ratio of 0.0269 [95% confidence interval (CI) 0.0049-0.1478, P&amp;lt;0.0001). The odds ratio for 4 studies which compared the efficacy of probiotics with mesalazine was 0.99 (95% CI 0.67-1.48, P=0.9419), a non-significant odds ratio.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Rahimi, R., Nikfar, S., Rezaie, A., &amp;amp; Abdollahi, M. (2008) A meta-analysis of the benefit of probiotics in maintaining remission of human ulcerative colitis: Evidence for prevention of disease relapse and maintenance of remission. &lt;I&gt;Archives of Medical Science&lt;/I&gt;, 4(2):185-190.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317082</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1038/ajg.2009.86]]&gt;</url>
    <title>A meta-analysis of the diagnostic accuracy of esophageal capsule endoscopy for Barrett's esophagus in patients with gastroesophageal reflux disease</title>
    <publicationDate>2009-06-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,OESOPHAGUS,DIAGNOSTIC PROCEDURES,GASTROINTESTINAL ENDOSCOPY,UPPER ENDOSCOPY,BARRETT'S OESOPHAGUS,CAPSULE ENDOSCOPY,GASTRO-OESOPHAGEAL REFLUX,RECENT ADDITIONS,JUNE 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt;&amp;nbsp;Capsule endoscopy of esophagus has a moderate sensitivity and specificity for the diagnosis of Barrett's esophagus (BE)&amp;nbsp;in patients with gastro-esophagal reflux disease (GERD). Esophagogastroduodenoscopy (EGD)&amp;nbsp;remains the modality of choice for evaluation of suspected BE.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Literature was searched for blinded studies evaluating the diagnostic accuracy of ECE for BE in patients with GERD. Meta-analysis was carried out to calculate pooled sensitivity and specificity of ECE for diagnosis of BE. Subgroup analysis was also carried out based on the reference standard used.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Nine studies comprising a total of 618 patients met the inclusion criteria. The pooled sensitivity and specificity of ECE for the diagnosis of BE for all studies were 77 and 86% respectively. The pooled sensitivity and specificity of ECE for the diagnosis of BE using EGD as the reference standard were 78 and 90%, respectively; using histologically confirmed intestinal metaplasia (IM) as the reference standard pooled sensitivity and specificity were 78 and 73%, respectively. Statistical heterogeneity was not evident among studies for sensitivity results (P=0.270, I2=19), but heterogeneity was present for specificity results (P&amp;lt;0.001, I2=74). There was no evidence of publication bias. The ECE was found to be safe and had a high rate of patient preference.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Bhardwaj A, Hollenbeak CS, Pooran N, Mathew A. A meta-analysis of the diagnostic accuracy of esophageal capsule endoscopy for Barrett's esophagus in patients with gastroesophageal reflux disease. &lt;EM&gt;Am J Gastroenterol&lt;/EM&gt; 2009;104(6):1533-9.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345524</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1007/s10620-008-0481-x]]&gt;</url>
    <title>A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis</title>
    <publicationDate>2009-06-01T00:00:00</publicationDate>
    <publisher>Springer</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Sulfasalazine (SSZ) does not differ from mesalamine or olsalazine in terms of efficacy and tolerability in ulcerative colitis (UC). Withdrawal from study due to adverse events was significantly lower for balsalazide compared with SSZ. Convincing conclusions on the comparison of effectiveness and safety of balsalazide and SSZ in UC remains to be elucidated by further clinical trials. Considering the lower cost of treatment with SSZ and the equal rate of adverse events with other 5-aminosalicylates (5-ASAs), it is not surprising to suggest SSZ as a first-choice treatment for UC and reserve 5-ASAs for when SSZ intolerability occurs.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Historically, SSZ and 5-ASAs have been a mainstay of mild-to-moderate UC remission induction and maintenance therapy. Considering the pivotal role of intestinal microbial flora in pathophysiology of UC and antimicrobial activity of sulfapyridine, we hypothesized that SSZ might be more effective than 5-ASAs in the management of UC. AIM: To compare the efficacy and tolerability of SSZ with each of the 5-ASAs (mesalamine, olsalazine, and balsalazide) by a meta-analysis technique.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Pubmed, Embase, Scopus, Web of Science, and Cochrane Central Register of Controlled Trials were searched for studies compared efficacy and/or tolerability of SSZ with 5-ASAs in the management of UC. The search terms were: "sulfasalazine" or "sulfasalazine" and "5-aminosalicylic acid," "mesalazine," "mesalamine," "olsalazine" or "balsalazide" and "ulcerative colitis." Data were collected from 1966 to April 2008. There was no language restriction. "Overall improvement," "relapse rate," "total adverse events," and "withdrawals because of adverse events" were the key outcomes of interest.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Twenty randomized placebo controlled trials met our criteria and were included in the meta-analysis. Comparison of SSZ with mesalamine yielded a nonsignificant relative risk (RR) of 1.04 (95% confidence interval of 0.89-1.21, P = 0.63) for overall improvement, a nonsignificant RR of 0.98 (95% CI 0.78-1.23, P = 0.85) for relapse, a nonsignificant RR of 0.76 (95% CI 0.54-1.07, P = 0.11) for any adverse events, and a nonsignificant RR of 0.78 (95% CI 0.46-1.3, P = 0.33) for withdrawals due to adverse events. Comparison of SSZ with olsalazine yielded a nonsignificant RR of 1.14 (95% CI 0.91-1.43, P = 0.25) for overall improvement, a nonsignificant RR of 0.93 (95% CI 0.77-1.12, P = 0.42) for relapse, a nonsignificant RR of 1.21 (95% CI 0.9-1.61, P = 0.20) for any adverse events, and a nonsignificant RR of 1.53 (95% CI 0.93-2.52, P = 0.09) for withdrawals due to adverse events. Comparison of SSZ with balsalazide yielded a nonsignificant RR of 1.3 (95% CI 0.93-1.81, P = 0.12) for overall improvement, and a significant RR of 0.17 (95% CI 0.06-0.49, P = 0.001) for withdrawals because of adverse events. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Nikfar S, Rahimi R, Rezaie A, Abdollahi M. A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis.&lt;EM&gt; Dig Dis Sci &lt;/EM&gt;2009;54(6):1157-70. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323521</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.socscimed.2008.10.011]]&gt;</url>
    <title>A meta-analysis of the hepatitis C virus distribution in diverse racial/ethnic drug injector groups</title>
    <publicationDate>2009-02-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,RECENT ADDITIONS,AUGUST 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The findings suggest that certain minority groups have elevated&amp;nbsp;hepatitis C virus (HCV)&amp;nbsp;rates in comparison to other injecting drug users (IDUs), which may be a consequence of stigma, discrimination, different risk behaviors or decreased access to health care, services and preventive education.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; This paper used meta-analytic methods to assess whether HCV prevalence and incidence varied across different racial/ethnic groups of injection drug users (IDUs) sampled internationally.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The 29 prevalence and 11 incidence studies identified as part of the HCV Synthesis Project were categorized into subgroups based on similar racial/ethnic comparisons. The effect estimate used was the odds or risk ratio comparing HCV prevalence or incidence rates in racial/ethnic minority groups versus those of majority status. For prevalence studies, the clearest disparity in HCV status was observed in the Canadian and Australian Aboriginal versus White comparison, followed by the US non-White versus White categories. Overall, Hispanic IDUs had greater HCV prevalence, and HCV prevalence in African-Americans was not significantly greater than that of Whites in the US. Aboriginal groups showed higher HCV seroconversion rates when compared to others, and African-Americans had lower seroconversion rates compared to other IDUs in the US.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Lelutiu-Weinberger C, Pouget ER, Des Jarlais DC, Cooper HL, Scheinmann R, Stern R, Strauss S, Hagan H. A meta-analysis of the hepatitis C virus distribution in diverse racial/ethnic drug injector groups. &lt;EM&gt;Soc Sci Med&lt;/EM&gt; 2009;68:579-90.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281272</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17258720]]&gt;</url>
    <title>A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis</title>
    <publicationDate>2008-03-10T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;:&lt;/P&gt;
&lt;P&gt;&lt;SPAN title=Gastroenterology.&gt;Su, C. &lt;A href="#javascript:AL_get(this," ?jour?, ?Gastroenterology.?);?&gt;Gastroenterology.&lt;/A&gt;&lt;/SPAN&gt; 2007 Feb;132(2):516-26. Epub 2006 Dec 20.&lt;/P&gt;
&lt;P class=abstract&gt;BACKGROUND &amp;amp; AIMS: Knowledge of the placebo outcomes and understanding specific study features that influence these outcomes is important for designing future clinical trials evaluating therapy of ulcerative colitis (UC). The aims of this study were to estimate the placebo rates of remission and response in placebo-controlled, randomized clinical trials for active UC and to identify factors influencing these rates. METHODS: We performed a systematic review and meta-analysis of placebo-controlled, randomized clinical trials evaluating therapies for active UC identified from MEDLINE from 1966 through 2005. RESULTS: Forty studies met the inclusion criteria. The pooled estimates of the placebo rates of remission and response were 13% (95% confidence interval, 9%-18%; range, 0%-40%; median, 12%) and 28% (95% confidence interval, 23%-33%; range, 0%-67%; median, 30%), respectively, both with significant heterogeneity. Studies that used more stringent definitions of outcomes had lower placebo rates of remission and response. Study duration, number of study visits, disease duration, baseline composite and rectal bleeding scores of the disease activity index, and inclusion of endoscopic mucosal healing as the remission definition all were associated with the placebo remission rate. CONCLUSIONS: Rates of remission in the placebo arm of UC clinical trials ranges from 0% to 40%. The placebo remission rates are influenced by the trial length, number of study visits, use of stricter remission definitions, and design features that enroll patients with more active disease. These factors should be considered when designing future placebo-controlled clinical trials in patients with active UC.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Gastroenterology is the official journal of the American Gastroenterological Association Institute. It publishes reports on the latest treatments for diseases, and has an exculusive correspondence section.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>251172</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?orig_db=PubMed&amp;db=PubMed&amp;cmd=Search&amp;term=%22The+American+journal+of+gastroenterology%22%5BJour%5D+AND+101%5Bvolume%5D+AND+954%5Bpage%5D+AND+2006%5Bpdat%5D]]&gt;</url>
    <title>A meta-analysis of the yield of capsule endoscopy compared to other diagnostic modalities in patients with non-stricturing small bowel Crohn's disease</title>
    <publicationDate>2006-05-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,DIAGNOSTIC PROCEDURES,GASTROINTESTINAL ENDOSCOPY,CAPSULE ENDOSCOPY,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Capsule endoscopy (CE) allows for direct evaluation of the small bowel mucosa in patients with Crohn's disease (CD). A number of studies have revealed significantly improved yield for CE over other modalities for the diagnosis of CD, but as sample sizes have been small, the true degree of benefit is uncertain. Additionally, it is not clear whether patients with a suspected initial presentation of CD and those with suspected recurrent disease are equally likely to benefit from CE. The aim of this study was to evaluate the yield of CE compared with other modalities in symptomatic patients with suspected or established CD using meta-analysis.</description>
    <body>&lt;![CDATA[ &lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Triester SL, Leighton JA, Leontiadis GI et al. 2006; American Journal of Gastroenterology 101 (5) pp. 954-964 
&lt;H2&gt;Original article abstract:&lt;/H2&gt;
&lt;P&gt;OBJECTIVES: Capsule endoscopy (CE) allows for direct evaluation of the small bowel mucosa in patients with Crohn's disease (CD). A number of studies have revealed significantly improved yield for CE over other modalities for the diagnosis of CD, but as sample sizes have been small, the true degree of benefit is uncertain. Additionally, it is not clear whether patients with a suspected initial presentation of CD and those with suspected recurrent disease are equally likely to benefit from CE. The aim of this study was to evaluate the yield of CE compared with other modalities in symptomatic patients with suspected or established CD using meta-analysis. METHODS: We performed a recursive literature search of prospective studies comparing the yield of CE to other modalities in patients with suspected or established CD. Data on yield among various modalities were extracted, pooled, and analyzed. Incremental yield (IY) (yield of CE--yield of comparative modality) and 95% confidence intervals (95% CI) of CE over comparative modalities were calculated. Subanalyses of patients with a suspected initial presentation of CD and those with suspected recurrent disease were also performed. RESULTS: Nine studies (n = 250) compared the yield of CE with small bowel barium radiography for the diagnosis of CD. The yield for CE versus barium radiography for all patients was 63% and 23%, respectively (IY = 40%, p &amp;lt; 0.001, 95% CI = 28-51%). Four trials compared the yield of CE to colonoscopy with ileoscopy (n = 114). The yield for CE versus ileoscopy for all patients was 61% and 46%, respectively (IY = 15%, p= 0.02, 95% CI = 2-27%). Three studies compared the yield of CE to computed tomography (CT) enterography/CT enteroclysis (n = 93). The yield for CE versus CT for all patients was 69% and 30%, respectively (IY = 38%, p= 0.001, 95% CI = 15-60%). Two trials compared CE to push enteroscopy (IY = 38%, p &amp;lt; 0.001, 95% CI = 26-50%) and one trial compared CE to small bowel magnetic resonance imaging (MRI) (IY = 22%, p= 0.16, 95% CI =-9% to 53%). Subanalysis of patients with a suspected initial presentation of CD showed no statistically significant difference between the yield of CE and barium radiography (p= 0.09), colonoscopy with ileoscopy (p= 0.48), CT enterography (p= 0.07), or push enteroscopy (p= 0.51). Subanalysis of patients with established CD with suspected small bowel recurrence revealed a statistically significant difference in yield in favor of CE compared with all other modalities (barium radiography (p &amp;lt; 0.001), colonoscopy with ileoscopy (p= 0.002), CT enterography (p &amp;lt; 0.001), and push enteroscopy (p &amp;lt; 0.001)). CONCLUSIONS: In study populations, CE is superior to all other modalities for diagnosing non-stricturing small bowel CD, with a number needed to test (NNT) of 3 to yield one additional diagnosis of CD over small bowel barium radiography and NNT = 7 over colonoscopy with ileoscopy. These results are due to a highly significant IY with CE over all other modalities in patients with established non-stricturing CD being evaluated for a small bowel recurrence. While there was no significant difference seen between CE and alternate modalities for diagnosing small bowel CD in patients with a suspected initial presentation of CD, the trend toward significance for a number of modalities suggests the possibility of a type II error. Larger studies are needed to better establish the role of CE for diagnosing small bowel CD in patients with a suspected initial presentation of CD.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;This article is &lt;STRONG&gt;not&lt;/STRONG&gt; available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309186</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1007/s10620-007-0171-0]]&gt;</url>
    <title>A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease.</title>
    <publicationDate>2008-09-01T00:00:00</publicationDate>
    <publisher>Springer</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; This meta-analysis fails to demonstrate the efficacy of probiotics in maintaining remission and preventing clinical and endoscopic recurrence in CD. It is suggested to use probiotic preparations containing a mixture of lactobacillus with &lt;I&gt;E. coli&lt;/I&gt; or &lt;I&gt;Saccharomyces&lt;/I&gt;. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; PUBMED and Cochrane Central Register of Controlled Trials were searched for clinical trial studies investigated the efficacy of probiotics for the maintenance of remission in Crohn’s disease. Clinical relapse and endoscopic relapse were the key outcomes of interest. Data were searched within the time period of 1966 through may 2007.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Eight randomized placebo-controlled clinical trials met our criteria and were included in the analysis. Seven determined clinical relapse and three evaluated endoscopic relapse among patients with CD received probiotics for maintenance of remission. Pooling of seven trials for the outcome of clinical relapse yielded an odds ratio of 0.92 (95% confidence interval of 0.52–1.62, &lt;I&gt;P&lt;/I&gt;&amp;nbsp;=&amp;nbsp;0.8853), a nonsignificant odds ratio. The odds ratio for three studies for the outcome of endoscopic relapse was 0.97 (95% confidence interval of 0.54–1.78, &lt;I&gt;P&lt;/I&gt;&amp;nbsp;=&amp;nbsp;0.93), a nonsignificant odds ratio.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Rahimi, R., Nikfar, S., Rahimi, F., Elahi, B., Derakhshani, S., Vafaie, M., &amp;amp; Abdollahi, M. (2008a) A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease. &lt;I&gt;Digestive Diseases &amp;amp; Sciences&lt;/I&gt;, 53(9):2524-2531.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;See also: &lt;/STRONG&gt;&lt;A href="nelh:319454:0" name=internalLink&gt;DARE record&lt;/A&gt; for this article.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in September 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281294</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17185356]]&gt;</url>
    <title>A meta-analysis on the influence of inflammatory bowel disease on pregnancy</title>
    <publicationDate>2008-03-10T00:00:00</publicationDate>
    <publisher>British Society of Gastroenterology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Cornish, J.&amp;nbsp; &lt;SPAN title=Gut.&gt;&lt;A href="#javascript:AL_get(this," ?jour?, ?Gut.?);?&gt;Gut.&lt;/A&gt;&lt;/SPAN&gt; 2007 Jun;56(6):830-7. Epub 2006 Dec 21&lt;/P&gt;
&lt;P&gt;BACKGROUND: Inflammatory bowel disease (IBD) has a typical onset during the peak reproductive years. Evidence of the risk of adverse pregnancy outcomes in IBD is important for the management of pregnancy to assist in its management. AIM: To provide a clear assessment of risk of adverse outcomes during pregnancy in women with IBD. DESIGN: The Medline literature was searched to identify studies reporting outcomes of pregnancy in patients with IBD. Random-effect meta-analysis was used to compare outcomes between women with IBD and normal controls. Patients and SETTING: A total of 3907 patients with IBD (Crohn's disease 1952 (63%), ulcerative colitis 1113 (36%)) and 320 531 controls were reported in 12 studies that satisfied the inclusion criteria. RESULTS: For women with IBD, there was a 1.87-fold increase in incidence of prematurity (&amp;lt;37 weeks gestation; 95% CI 1.52 to 2.31; p&amp;lt;0.001) compared with controls. The incidence of low birth weight (&amp;lt;2500 g) was over twice that of normal controls (95% CI 1.38 to 3.19; p&amp;lt;0.001). Women with IBD were 1.5 times more likely to undergo caesarean section (95% CI 1.26 to 1.79; p&amp;lt;0.001), and the risk of congenital abnormalities was found to be 2.37-fold increased (95% CI 1.47 to 3.82; p&amp;lt;0.001). CONCLUSION: The study has shown a higher incidence of adverse pregnancy outcomes in patients with IBD. Further studies are required to clarify which women are at higher risk, as this was not determined in the present study. This has an effect on the management of patients with IBD during pregnancy, who should be treated as a potentially high-risk group.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Gut is an international peer reviewed journal on gastroenterology, which is published monthly. The journal regularly includes new research papers, reports on the latest treatments, review articles and commentaries in its contents.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is &lt;STRONG&gt;not&lt;/STRONG&gt; available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>148781</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/16456576]]&gt;</url>
    <title>A methodologic analysis of chemoprevention and cancer prevention strategies for gastrointestinal cancer</title>
    <publicationDate>2006-02-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,OESOPHAGUS,CANCER,STOMACH,CANCER,SMALL INTESTINE,CANCER,COLON &amp; RECTUM,CANCER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This review systematically assess the evidence for various cancer prevention strategies, especially chemoprevention, and highlights the obstacles to further exploitation of this knowledge.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Abstract: &lt;/STRONG&gt;Gastroenterology lags behind other specialties such as cardiology in the&amp;nbsp;quality of its evidence base for clinical practice. One area where this is particularly evident is in cancer prevention, despite developments in chemoprevention strategies for high-risk patients. For chemoprevention strategies to be successful, we need appropriate clinical networks and translational science infrastructures, model chemoprevention agents and multiple, large, flexible and randomized clinical trials. Translational science must also be embedded into large-scale, long-term, randomized clinical trials that have hard endpoints, so that irrefutable evidence of the longevity of treatment efficacy can be gathered. We also need to be able to identify an individual's cancer risk using valid global patient populations, so that medical benefits can be applied to all, regardless of ethnicity, sex, economic status, age and comorbidities. The future success of gastrointestinal chemoprevention relies on fostering a closer link between basic pharmaceutical research and clinical applications, in a 'bench to bedside and back' manner. In this review we systematically assess the evidence for various cancer prevention strategies, especially chemoprevention, and highlight the obstacles to further exploitation of this knowledge base.&lt;/P&gt;
&lt;P&gt;Nature Clinical Practice Gastroenterology &amp;amp; Hepatology. 2006 Feb;3(2):101-11&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Audience:&lt;/STRONG&gt; Health care professionals.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is &lt;STRONG&gt;not &lt;/STRONG&gt;available freely or&amp;nbsp;via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext this journal. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345581</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2008.03839.x]]&gt;</url>
    <title>A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Eight-week&amp;nbsp;scheduled maintenance treatment (SMC)&amp;nbsp;with&amp;nbsp;infliximab (IFC)&amp;nbsp;appears to be a cost-effective treatment option for adult patients suffering from moderate to severe ulcerative colitis (UC).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt;&amp;nbsp;IFX has been shown to be efficacious in moderate-severe UC. The aim of this study was to evaluate the cost-effectiveness of a SMT with IFX in moderate-severe UC patients.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A Markov model was constructed to simulate the progression of a cohort of moderate-severe UC patients treated with IFX (5 mg/kg) SMT. Transitions were estimated from two phase III trials of IFX (ACT I and ACT II). Standard care, comprising immunomodulators and/or corticosteroids was used as a comparator. Two separate treatment strategies were evaluated – continued treatment in IFX responders and continued treatment in IFX patients achieving remission. The dose of IFX was estimated for a 73 kg typical UC patient in the UK. The results were calculated over 10 years using a discount rate of 3.5% for costs and outcomes. The outcome measure was quality-adjusted life years (QALYs) estimated using EQ-5D. Sensitivity analyses explored the uncertainty around the results.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The incremental cost effectiveness ratio (ICER) for IFX was £27,424 in the responder strategy and £19,696 in the remission strategy at 10 years. In sensitivity analysis, the ICER for IFX in the responder strategy ranged from £21,066 to £86,322 and in the remission strategy ranged from £14,728 to £46,765. The model time horizon and patient body weight were important factors affecting results.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Tsai HH, Punekar YS, Morris J, Fortun P. A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2008;28(10):1230-9. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;See also: &lt;/STRONG&gt;&lt;A href="nelh:314336:0" name=internalLink&gt;NHS EED record&lt;/A&gt; for this article.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>330647</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17532088]]&gt;</url>
    <title>A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis</title>
    <publicationDate>2007-08-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>RANDOMISED CONTROLLED TRIAL</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,ALCOHOLIC LIVER DISEASE,ALCOHOLIC HEPATITIS,STEATOHEPATITIS,ALCOHOLIC,RECENT ADDITIONS,NOVEMBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Antioxidant therapy, alone or in combination with corticosteroids, does not improve 6-month survival in severe alcoholic hepatitis.&lt;/P&gt;
&lt;P&gt;&lt;!-- articleText --&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Oxidative stress is putatively involved in the pathogenesis of alcohol-induced liver injury. This trial was devised to determine whether antioxidant therapy, alone or as an adjunct to corticosteroids, improved survival in patients with acute alcoholic hepatitis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Patients with a severe alcoholic hepatitis were stratified by sex and steroid use, and then randomized. The active group received &lt;I&gt;N&lt;/I&gt;-acetylcysteine for one week, and vitamins A–E, biotin, selenium, zinc, manganese, copper, magnesium, folic acid and Coenzyme Q daily for 6 months. The trial was double blinded and placebo controlled. The primary end-point was mortality within 6 months.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Thirty-six (20 male, 16 female; mean discriminant function (DF) 86.6) received active drug, and 34 (18 male, 16 female; mean DF 76.4) received placebo. 180-day survival was not significantly different between patients receiving drug and placebo (52.8% vs. 55.8%, &lt;I&gt;p&lt;/I&gt;&amp;nbsp;=&amp;nbsp;0.699). This was not affected by stratification for steroid use or sex. The only predictors of survival in multivariate analysis were initial bilirubin (&lt;I&gt;p&lt;/I&gt;&amp;nbsp;=&amp;nbsp;0.017), white cell count (&lt;I&gt;p&lt;/I&gt;&amp;nbsp;=&amp;nbsp;0.016) and age (&lt;I&gt;p&lt;/I&gt;&amp;nbsp;=&amp;nbsp;0.037). Treatment allocation did not affect survival in multivariate analysis (&lt;I&gt;p&lt;/I&gt;&amp;nbsp;=&amp;nbsp;0.830).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Stewart S, Prince M, Bassendine M, Hudson M, James O, Jones D, Record C, Day CP. A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. &lt;EM&gt;J Hepatol&lt;/EM&gt; 2007 Aug;47(2):277-83.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>330638</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18848937]]&gt;</url>
    <title>A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis.</title>
    <publicationDate>2008-12-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>RANDOMISED CONTROLLED TRIAL</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,ALCOHOLIC LIVER DISEASE,ALCOHOLIC HEPATITIS,STEATOHEPATITIS,ALCOHOLIC,RECENT ADDITIONS,NOVEMBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt;&amp;nbsp;In patients with moderate to severe alcoholic hepatitis, etanercept was associated with a significantly higher mortality rate after 6 months, indicating that etanercept is not effective for the treatment of patients with alcoholic hepatitis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Alcoholic hepatitis is a cause of major morbidity and mortality that lacks effective therapies. Both experimental and clinical evidence indicate that the multifunctional cytokine tumor necrosis factor-alpha (TNF-alpha) contributes to pathogenesis and clinical sequelae of alcoholic hepatitis. A pilot study demonstrated that the TNF-alpha-neutralizing molecule etanercept could be an effective treatment for patients with alcoholic hepatitis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Forty-eight patients with moderate to severe alcoholic hepatitis (Model for End-Stage Liver Disease score &amp;gt; or = 15) were enrolled and randomized to groups that were given up to 6 subcutaneous injections of either etanercept or placebo for 3 weeks. Primary study end points included mortality at 1- and 6-month time points.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; There were no significant baseline differences between the placebo and etanercept groups in demographics or disease severity parameters including age, gender, and Model for End-Stage Liver Disease score. The 1-month mortality rates of patients receiving placebo and etanercept were similar on an intention-to-treat basis (22.7% vs 36.4%, respectively; OR, 1.8; 95% CI, 0.5-6.5). The 6-month mortality rate was significantly higher in the etanercept group compared with the placebo group (57.7% vs 22.7%, respectively; OR, 4.6; 95% CI, 1.3-16.4; P = .017). Rates of infectious serious adverse events were significantly higher in the etanercept group compared with the placebo group (34.6% vs 9.1%, respectively, P = .04). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Boetticher NC, Peine CJ, Kwo P, Abrams GA, Patel T, Aqel B, Boardman L, Gores GJ, Harmsen WS, McClain CJ, Kamath PS, Shah VH.&amp;nbsp;A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. &lt;EM&gt;Gastroenterology &lt;/EM&gt;2008 Dec;135(6):1953-60.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>330631</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1530-0277.2008.00842.x]]&gt;</url>
    <title>A recent perspective on alcohol, immunity, and host defense</title>
    <publicationDate>2009-02-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,PANCREAS,LIVER,HEPATITIS,HEPATITIS B,HEPATITIS C,ALCOHOLIC LIVER DISEASE,HIV / AIDS,PANCREATITIS,RECENT ADDITIONS,NOVEMBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Altered inflammatory cell and adaptive immune responses after alcohol consumption result in increased incidence and poor outcome of infections and other organ-specific immune-mediated effects.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Multiple line of clinical and experimental evidence demonstrates that both acute, moderate, and chronic, excessive alcohol use result in various abnormalities in the functions of the immune system.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Medline and PubMed databases were used to identify published reports with particular interest in the period of 2000-2008 in the subject of alcohol use, infection, inflammation, innate, and adaptive immunity. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; This review article summarizes recent findings relevant to acute or chronic alcohol use-induced immunomodulation and its consequences on host defense against microbial pathogens and tissue injury. Studies with in vivo and in vitro alcohol administration are both discussed. The effects of alcohol on lung infections, trauma and burn injury, liver, pancreas, and cardiovascular diseases are evaluated with respect to the role of immune cells. Specific changes in innate immune response and abnormalities in adaptive immunity caused by alcohol intake are detailed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Szabo G, Mandrekar P. A recent perspective on alcohol, immunity, and host defense. &lt;EM&gt;Alcohol Clin Exp Res&lt;/EM&gt; 2009 Feb;33(2):220-32.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309192</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.clinthera.2008.02.014]]&gt;</url>
    <title>A review of infliximab use in ulcerative colitis</title>
    <publicationDate>2008-02-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Current data suggest that infliximab is an effective alternative treatment option for patients with moderate to severe UC with an inadequate response to conventional glucocorticoid treatment. Further trials are needed to assess infliximab's impact on the treatment and progression of UC, the HRQL of patients with UC, and the economic impact on the health care system.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A search of MEDLINE was conducted (1950–November 2007). Key terms included, but were not limited to, &lt;I&gt;infliximab, inflammatory bowel disease, ulcerative colitis, cost&lt;/I&gt;, and &lt;I&gt;quality of life&lt;/I&gt;. Studies included for review were limited to English-language, full-text, randomized, double-blind, placebo-controlled trials. Clinical trials were reviewed and summarized.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Four controlled clinical trials of infliximab in the treatment of steroid-refractory UC were found and assessed. In a double-blind, randomized, controlled trial in 43 patients with moderately severe, glucocorticoid-resistant UC, infliximab and placebo were not significantly different with respect to clinical and sigmoidoscopic remission or quality of life 2 and 6 weeks after infliximab treatment. In a multicenter, randomized, double-blind, placebo-controlled study in 45 patients with moderately severe to severe glucocorticoid-resistant UC, infliximab was associated with a significantly reduced need for colectomy compared with placebo (29% vs 67%; &lt;I&gt;P&lt;/I&gt;=0.017). The Active Ulcerative Colitis Trials (ACT) 1 and 2 together included 728 patients with moderate to severe glucocorticoid-resistant UC. The primary outcome, the rate of clinical response at 8 weeks, was significantly higher with infliximab compared with placebo (5 mg/kg: ACT 1, 69.4%, ACT 2, 64.5%; 10 mg/kg: ACT 1, 61.5%, ACT 2, 69.2%; placebo: ACT 1, 37.2%;, ACT 2, 29.3%; all, &lt;I&gt;P&lt;/I&gt; &amp;lt; 0.001 vs placebo). Based on the data from ACT 1 and 2, infliximab was associated with improved health-related quality-of-life (HRQOL) scores based on the Inflammatory Bowel Disease Questionnaire and the 36-item Short Form Health Survey.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Wilhelm, S. M., McKenney, K. A., Rivait, K. N., &amp;amp; Kale-Pradhan, P. B. (2008) A review of infliximab use in ulcerative colitis. &lt;I&gt;Clinical Therapeutics&lt;/I&gt;, 30(2):223-30.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in February 2008&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>330008</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19775771]]&gt;</url>
    <title>A review of quality of life instruments used in liver transplantation</title>
    <publicationDate>2009-11-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,TRANSPLANTATION,RECENT ADDITIONS,NOVEMBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion: &lt;/STRONG&gt;No available instruments allow for the precise and reliable assessment of the quality of life (QOL) impact of liver transplantation.&amp;nbsp; The development of a QOL instrument specifically for liver transplant recipients will improve QOL assessment in this population leading to a more nuanced understanding of the factors that influence transplant recipients' well-being.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We conducted a systematic review of the MEDLINE database and Cochrane library.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Our review identified 128 relevant articles utilizing more than 50 different QOL instruments. Generic health status instruments are the most commonly used, and among them the Medical Outcomes Study Short Form-36 (SF-36), the Hospital Anxiety and Depression Scale (HADS), and the Beck Depression Inventory (BDI) are the most prevalent. Few studies (16%) included targeted, disease-specific instruments. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Quality of Life questionnaire, the Liver Disease Quality of Life questionnaire, and the Chronic Liver Disease questionnaire are the most frequently employed targeted instruments; however, these instruments have been designed to assess QOL in patients with chronic liver disease rather than patients after liver transplantation.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Jay CL, Butt Z, Ladner DP, Skaro AI, Abecassis MM. A review of quality of life instruments used in liver transplantation. &lt;EM&gt;J Hepatol&lt;/EM&gt; 2009 Nov;51(5):949-59.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323624</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1007/s12072-008-9105-y]]&gt;</url>
    <title>A review of the one-year incidence of resistance to lamivudine in the treatment of chronic hepatitis B</title>
    <publicationDate>2008-12-01T00:00:00</publicationDate>
    <publisher>Springer</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,RECENT ADDITIONS,AUGUST 2009,CHRONIC HEPATITIS B]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; &lt;SPAN class=AbstractSectionHeading&gt;&lt;/SPAN&gt;It is important when comparing resistance rates to antiviral drugs in&amp;nbsp;chronic hepatitis B (CHB)&amp;nbsp;to consider the methodology and definition of resistance used because this can dramatically influence the results.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt;&amp;nbsp;Studies reporting one-year resistance rates to lamivudine in CHB were analyzed for methodologic differences and their influence on reported resistance rates. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt;&amp;nbsp;&lt;SPAN class=AbstractSectionHeading&gt;&lt;/SPAN&gt;Studies using only a genotypic definition of resistance reported one-year rates ranging from 14% to 32%. Studies assessing genotypic resistance in patients with evidence of virologic breakthrough reported much lower one-year resistance rates of 6.4–15.4%.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Hann H-W, Gregory VL, Dixon JS, Barker KF. A review of the one-year incidence of resistance to lamivudine in the treatment of chronic hepatitis B. &lt;EM&gt;Hepatol Int&lt;/EM&gt; 2008;2(4):440-56.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>380658</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.cgh.2009.11.018]]&gt;</url>
    <title>A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus</title>
    <publicationDate>2010-03-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,NON-ALCOHOLIC,HEPATOCELLULAR CARCINOMA,RECENT ADDITIONS,CANCER,CIRRHOSIS,CHRONIC HEPATITIS C,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Hepatitis C&amp;nbsp;virus (HCV)&amp;nbsp;patients with advanced fibrosis who do not undergo an&amp;nbsp;sustained viral respons (SVR)&amp;nbsp;have substantial liver-related morbidity and mortality. Achieving SVR is associated with substantially lower liver-related morbidity and mortality.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; The incidences of decompensated cirrhosis (defined by ascites, hepatic encephalopathy, or bleeding esophageal varices), hepatocellular carcinoma (HCC), and liver-related mortality among patients infected with HCV who achieve a SVR, compared with patients who fail treatment (treatment failure), are unclear. We performed a meta-analysis to quantify the incidences of these outcomes.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; This meta-analysis included observational cohort studies that followed HCV treatment failure patients; data were collected regarding the incidence of decompensated cirrhosis, HCC, or liver-related mortality and stratified by SVR status. Two investigators independently extracted data on patient populations, study methods, and results by using standardized forms. The agreement between investigators in data extraction was greater than 95%. Data analysis was performed separately for studies that enrolled only HCV patients with advanced fibrosis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; We identified 26 appropriate studies for meta-analysis. Among treatment failure patients with advanced fibrosis, rates of liver-related mortality (2.73%/year; 95% confidence interval [CI], 1.38-4.080), HCC (3.22%/year, 95% CI, 2.02-4.42), and hepatic decompensation (2.92%/year; 95% CI, 1.61-4.22) were substantial. Patients with SVR are significantly less likely than patients who experienced treatment failure to develop liver-related mortality (relative risk [RR], 0.23; 95% CI, 0.10-0.52), HCC (RR, 0.21; 95% CI, 0.16-0.27), or hepatic decompensation (RR, 0.16; 95% CI, 0.04-0.59).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. &lt;EM&gt;Clin Gastroenterol Hepatol&lt;/EM&gt; 2010;8(3):280-8.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345640</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://informahealthcare.com/doi/abs/10.3109/00365520903367254]]&gt;</url>
    <title>A systematic review and meta-analysis of anti-adhesion molecule therapy in patients with active Crohn's disease</title>
    <publicationDate>2009-12-01T00:00:00</publicationDate>
    <publisher>Informa</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Anti-adhesion molecule therapy, which could prevent leukocyte recruitment, was effective and safe for treating active Crohn's disease (CD). Because of the small number of studies included in this meta-analysis, the results should be interpreted with caution.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Due to the crucial role played by adhesion molecules in the pathogenesis of CD, targeting of these molecules has recently been proposed as a new direction for the development of anti-inflammatory strategies for CD. The aim of this study was to provide up-to-date evidence on the effectiveness and safety of anti-adhesion molecule therapy in treating active CD.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We studied articles retrieved by PubMed, EMBASE, the Cochrane Library and the Science Citation Index for randomized controlled trials (RCTs) relevant to CD and anti-adhesion molecule therapy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Seven RCTs comparing anti-adhesion molecule therapy with placebo were included in a meta-analysis to evaluate the efficacy and safety of anti-adhesion molecule strategies in active CD. On the basis of pooled results of the seven RCTs (n = 2228), we found a significant difference in clinical remission rates between groups [relative risk (RR) 1.31, 95% confidence interval (CI) 1.12–1.52, fixed-effect model]. Five RCTs (n = 2178) compared the response rates of anti-adhesion molecule therapy and placebo; in overall analysis, anti-adhesion molecule therapy was effective for active CD (RR 1.28, 95% CI 1.16–1.42, random-effect model). In five studies enrolling 1867 individuals, anti-adhesion molecule therapy did not increase adverse events (RR 1.03, 95% CI 0.98–1.08, fixed-effect model).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Li Y, Tian Y, Yu C, Zhu W, Li J. A systematic review and meta-analysis of anti-adhesion molecule therapy in patients with active Crohn's disease. &lt;EM&gt;Scand J Gastroenterol &lt;/EM&gt;2009;44(12):1435-42.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281291</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1572-0241.2007.01325.x]]&gt;</url>
    <title>A systematic review of patient inflammatory bowel disease information resources on the World Wide Web</title>
    <publicationDate>2008-03-10T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: &lt;/P&gt;
&lt;P&gt;Bernard, A. &lt;SPAN title="The American journal of gastroenterology."&gt;&lt;A href="#javascript:AL_get(this," Gastroenterol.?);? J ?Am ?jour?,&gt;Am J Gastroenterol.&lt;/A&gt;&lt;/SPAN&gt; 2007 Sep;102(9):2070-7. Epub 2007 May 19.&lt;/P&gt;
&lt;P class=abstract&gt;BACKGROUND AND AIMS: The Internet is a widely used information resource for patients with inflammatory bowel disease, but there is variation in the quality of Web sites that have patient information regarding Crohn's disease and ulcerative colitis. The purpose of the current study is to systematically evaluate the quality of these Web sites. METHODS: The top 50 Web sites appearing in Google using the terms "Crohn's disease" or "ulcerative colitis" were included in the study. Web sites were evaluated using a (a) Quality Evaluation Instrument (QEI) that awarded Web sites points (0-107) for specific information on various aspects of inflammatory bowel disease, (b) a five-point Global Quality Score (GQS), (c) two reading grade level scores, and (d) a six-point integrity score. RESULTS: Thirty-four Web sites met the inclusion criteria, 16 Web sites were excluded because they were portals or non-IBD oriented. The median QEI score was 57 with five Web sites scoring higher than 75 points. The median Global Quality Score was 2.0 with five Web sites achieving scores of 4 or 5. The average reading grade level score was 11.2. The median integrity score was 3.0. CONCLUSIONS: There is marked variation in the quality of the Web sites containing information on Crohn's disease and ulcerative colitis. Many Web sites suffered from poor quality but there were five high-scoring Web sites.&lt;/P&gt;
&lt;P&gt;The American Journal of Gastroenterology is the official journal of the American College of Gastroenterology and publishes a variety of material including editorials, clinical reviews, correspondance and research articles.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: This article is &lt;STRONG&gt;not&lt;/STRONG&gt; available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293825</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1586/14737167.7.6.577]]&gt;</url>
    <title>A systematic review of the cost-effectiveness of peginterferon alfa-2b in the treatment of chronic hepatitis C</title>
    <publicationDate>2007-12-01T00:00:00</publicationDate>
    <publisher>Ingenta</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,CHRONIC HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Shepherd, J et al Expert review of pharmacoeconomics and outcomes research Volume 7,&amp;nbsp;Number 6, December 2007 , pp. 577-595(19)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;DIV id=abstract&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract:&lt;/STRONG&gt;&lt;/P&gt;A systematic review was conducted of the full economic evaluations of the cost-effectiveness of peginterferon alfa-2b (PEG-IFN alfa-2b) plus ribavirin (RBV) in the treatment of chronic hepatitis C (CHC). A total of 439 references were screened and 11 studies were included. The studies employed decision analytic Markov models in which hypothetical cohorts of patients progressed through a series of health states characteristic of the natural history of CHC. The studies analyzed various regimens of PEG-IFN alfa-2b plus RBV including stopping rules for different genotypes, and fixed or weight-based dosing of RBV. In all studies, PEG-IFN alfa-2b plus RBV was associated with favorable incremental cost-effectiveness ratios (ICERs) when compared with IFN plus RBV. Tailored treatment according to bodyweight dosing and circumscribed treatment for different genotypes improves ICERs further. Further cost-effectiveness analyses should consider the impact of antiviral treatment in subgroups of patients including those co-infected with HIV, hemophiliacs and patients who are retreated following previous treatment failure, where data are available. &lt;/DIV&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>236045</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.nacc.org.uk/downloads/NACC_Systemeatic_Review_IBD_Nursing_Dec2006.pdf]]&gt;</url>
    <title>A systematic review of the effectiveness of Inflammatory Bowel Disease Specialist Nurses</title>
    <publicationDate>2006-08-01T00:00:00</publicationDate>
    <publisher>London South Bank University</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,INDETERMINATE COLITIS,ULCERATIVE COLITIS,MICROSCOPIC COLITIS,PROCTITIS &amp; DISTIL COLITIS,SEVERE COLITIS &amp; TOXIC MEGACOLON,DIVERSION COLITIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This review aimed to define the scope of specialist IBD nursing roles, and examine the evidence relating to their perceived value, benefits and effectiveness. Evidence from published literature and local audits indicates that specialist nurses are instrumental in developing new services to improve patient care.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims&lt;/STRONG&gt;:&amp;nbsp;This review aimed to define the scope of specialist IBD nursing roles, and examine the evidence relating to their percieved value, benefits and effectiveness.&lt;/P&gt;
&lt;P&gt;The review included literature searches of published and unpublished literature. Only studies that evaluted nurse-led IBD interventions, between January 1995 and February 2006 were included. Grey literature was also used to supplement published research found. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; The literature reflects considerable variation in the extent and scope of specialist nursing roles in gastroenterology. However, patient satisfaction with the standard of nursing was found to be generally high, and evidence from published literature and local audits indicates that specialist nurses are instrumental in developing new services to improve patient care.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text executive summary available freely online from National Association for Colitis and Crohn's Disease website.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314796</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.jhep.2009.01.024]]&gt;</url>
    <title>A systems biology perspective on cholangiocellular carcinoma development: focus on MAPK-signaling and the extracellular environment</title>
    <publicationDate>2009-06-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,BILIARY TREE &amp; GALLBLADDER,CHOLANGIOCARCINOMA,GALLBLADDER CANCER,CANCER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Our study suggests the liver microenvironment holds essential functions and structures key to CCC progression. Furthermore, we identified the MAPK signaling pathway consistently enriched, pointing towards a critical role in CCC development. These data may provide a rationale for treatment of CCC with sorafenib.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Multiple genes have been implicated in cholangiocellular carcinoma (CCC) development. However, the overall neoplastic risk is likely associated with a much lower number of critical physiological pathways. To investigate this hypothesis, we extracted all published genetic associations for the development of CCC from PubMed (genetic association studies, but also studies associating genes and CCC in general, i.e. functional studies in cell lines, genetic studies in humans, knockout mice etc.) and integrated CCC microarray data.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; We demonstrated the MAPK pathway was consistently enriched in CCC. Comparing our data to genetic associations in HCC often successfully treated by a multityrosine kinase inhibitor, sorafenib, we demonstrated a similar overrepresentation of MAPK. In contrast, most cancer-related genetic studies focusing on genes related to transcription and cell cycle control, we consistently found genes coding for products in the extracellular environment to be significantly enriched. Thus, CCC must be regarded as developing in the context of an altered extracellular environment.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Wang C, Maass T, Krupp M, Thieringer F, Strand S, Worns MA, Barreiros A, Galle PR, Teuful A. A systems biology perspective on cholangiocellular carcinoma development: Focus on MAPK-signaling. J Hepatol 2009;50(6):1122-31.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>328388</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.basl.org.uk/media/uploads/National_Liver_Plan_2009.pdf]]&gt;</url>
    <title>A time to act: improving liver health and outcomes in liver disease</title>
    <publicationDate>2009-10-20T00:00:00</publicationDate>
    <publisher>British Association for the Study of the Liver</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COMMON CLINICAL PRESENTATIONS,LIVER,HEPATITIS,HEPATITIS B,HEPATITIS C,ALCOHOLIC LIVER DISEASE,ALCOHOLIC CIRRHOSIS,NON-ALCOHOLIC,DISEASE PREVENTION,HEPATOCELLULAR CARCINOMA,TRANSPLANTATION,OBESITY,RECENT ADDITIONS,CANCER,CIRRHOSIS,ALCOHOLIC,FATTY LIVER,NOVEMBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The National Plan for Liver Services UK 2009</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt; The aim of this document is:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;To advise the DH on ways to improve outcomes of liver disease in the UK. 
&lt;LI&gt;To recommend a framework which ensures equal access to high quality and cost effective management of liver disease throughout the UK, and to outline ways to optimize the current configuration of Liver services, including paediatric hepatology. 
&lt;LI&gt;To recommend the setting of clinical standards, quality metrics and guidelines against which local services should be monitored and assessed. To demonstrate that high quality liver services lead to cost savings and improved health. 
&lt;LI&gt;To promote the concept that there should be a trained clinical hepatologist in every district general hospital, and establish a training framework for clinical hepatology with the goal of improving outcomes. 
&lt;LI&gt;To highlight the radical change in the profile of liver disease in the UK that is achievable through long term strategic planning in chronic viral hepatitis.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323577</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.hivandhepatitis.com/hep_b/news/2009/HBVTreatAlgorithm.pdf]]&gt;</url>
    <title>A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update</title>
    <publicationDate>2008-12-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,RECENT ADDITIONS,AUGUST 2009,CHRONIC HEPATITIS B]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt; Chronic HBV infection is an important public health problem worldwide and in the United States. A treatment algorithm for the management of this disease, published previously by a panel of U.S. hepatologists, has been revised on the basis of new developments in the understanding of the disorder, the availability of more sensitive molecular diagnostic tests, and the licensure of new therapies. In addition, a better understanding of the advantages and disadvantages of new treatments has led to the development of strategies for reducing the rate of resistance associated with oral agents and optimizing treatment outcomes. This updated algorithm was based primarily on available evidence by using a systematic review of the literature. Where data were lacking, the panel relied on clinical experience and consensus expert opinion. The primary aim of antiviral therapy is durable suppression of serum HBV DNA to low or undetectable levels. Assays can now detect serum HBV DNA at levels as low as 10 IU/mL and should be used to establish a baseline level, monitor response to antiviral therapy, and survey for the development of drug resistance. Interferon alfa-2b, lamivudine, adefovir, entecavir, peginterferon alfa-2a, telbivudine, and tenofovir are approved as initial therapy for chronic hepatitis B and have certain advantages and disadvantages. Although all of these agents can be used in selected patients, the preferred first-line treatment choices are entecavir, peginterferon alfa-2a, and tenofovir. Issues for consideration for therapy include efficacy, safety, rate of resistance, method of administration, and cost.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. &lt;EM&gt;Clin Gastroenterol Hepatol&lt;/EM&gt; 2008;6(12):1315-41.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>343575</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.aasld.org/practiceguidelines/Documents/Bookmarked%20Practice%20Guidelines/Chronic_Hep_B_Update_2009%208_24_2009.pdf]]&gt;</url>
    <title>AASLD practice guideline on chronic hepatitis B: update 2009</title>
    <publicationDate>2009-12-29T00:00:00</publicationDate>
    <publisher>American Association for the Study of Liver Diseases</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,NON-ALCOHOLIC,DISEASE PREVENTION,SCREENING,RECENT ADDITIONS,CIRRHOSIS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; These guidelines have been written to assist physicians and other health care providers in the recognition, diagnosis, and management of patients chronically infected with the hepatitis B virus (HBV). These recommendations provide a data-supported approach to patients with hepatitis B. They are based on the following: (1) formal review and analysis of published literature on the topic— Medline search up to December 2006 and data from selected papers published through December 2008 and meeting abstracts in 2003–2009 that impact the management of chronic HBV infection; (2) American College of Physicians Manual for Assessing Health Practices and Designing&amp;nbsp;Practice Guidelines; (3) guideline policies, including the AASLD Policy on the Development and Use of Practice Guidelines and the AGA Policy Statement on Guidelines; and (4) the experience of the authors in hepatitis B. In addition, the proceedings of the 2000 and 2006 National Institutes of Health (NIH) conferences on the “Management of Hepatitis B”, the EASL Clinical Practice Guidelines 2009 on Management of Chronic Hepatitis B, the Asian-Pacific Consensus Statement on the Management of Chronic Hepatitis B in 2008 and the NIH 2008 Consensus Conference on Management of Chronic Hepatitis B, were considered in the development of these guidelines. The recommendations suggest preferred approaches to the diagnostic, therapeutic, and preventive aspects of care. They are intended to be flexible. Specific recommendations are based on relevant published information. In an attempt to characterize the quality of evidence supporting recommendations, the Practice Guidelines Committee of the AASLD requires a category to be assigned and reported with each recommendation (Table 1). These guidelines may be updated periodically as new information becomes available.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience: &lt;/STRONG&gt;Hepatologists&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in 2009.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>343572</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://publish.aasld.org/practiceguidelines/Documents/Practice%20Guidelines/evalu_patient_livertransplantationpg.pdf]]&gt;</url>
    <title>AASLD practice guidelines: evaluation of the patient for liver transplantation</title>
    <publicationDate>2005-05-20T00:00:00</publicationDate>
    <publisher>American Association for the Study of Liver Diseases</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,BILIARY TREE &amp; GALLBLADDER,CHOLANGITIS,PRIMARY SCLEROSING CHOLANGITIS,CHOLANGIOCARCINOMA,LIVER,HEPATITIS,HEPATITIS B,HEPATITIS C,AUTOIMMUNE CHRONIC HEPATITIS,NON-ALCOHOLIC,ALCOHOLIC LIVER DISEASE,ALCOHOLIC CIRRHOSIS,HAEMOCHROMATOSIS,WILSON'S DISEASE,NUTRITIONAL &amp; METABOLIC DISEASE,GLYCOGEN STORAGE DISEASES,ALPHA-1-ANTITRYPSIN DEFICIENCY,CYSTIC FIBROSIS,NODULES &amp; BENIGN LESIONS,CYSTS,HEPATOCELLULAR CARCINOMA,TRANSPLANTATION,FULMINANT HEPATITIS,STEATOHEPATITIS,NON-ALCOHOLIC,NEUROENDOCRINE TUMOURS,BILIARY CIRRHOSIS,BILIARY ATRESIA,CANCER,RECENT ADDITIONS,CANCER,CIRRHOSIS,ALCOHOLIC,FEBRUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; Intended for use by physicians, these recommendations suggest preferred approaches to the diagnostic, therapeutic, and preventive aspects of care. They are intended to be flexible, in contrast to standards of care, which are inflexible policies to be followed in every case. Specific recommendations are based on relevant published information. In an attempt to characterize the quality of evidence supporting recommendations, the Practice Guidelines Committee of the AASLD requires a category to be assigned and reported with each recommendation.&amp;nbsp;These recommendations are fully endorsed by the AASLD and the American Society of Transplantation.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Physicians&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published May 2005; last reviewed 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>388025</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.bmj.com/content/341/bmj.c4372.abstract]]&gt;</url>
    <title>Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study</title>
    <publicationDate>2010-09-10T00:00:00</publicationDate>
    <publisher>British Medical Journal</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,OESOPHAGUS,DIAGNOSTIC PROCEDURES,DISEASE PREVENTION,BARRETT'S OESOPHAGUS,SCREENING,RECENT ADDITIONS,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;All the &lt;EM&gt;British Medical Journal&lt;/EM&gt;’s original research is published in full on bmj.com, with open access and no limits on word counts. The BMJ’s vision is to be the world’s most influential and widely read medical journal. Our mission is to lead the debate on health and to engage, inform, and stimulate doctors, researchers, and other health professionals in ways that will improve outcomes for patients. We aim to help doctors to make better decisions. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Kadri SR; Lao-Sirieix; O'Donovan M; Debiram I; Das M; Blazeby JM; Emery J; Boussioutas A; Morris H; Walter FM; Pharoah P; Hardwick RH; Fitzgerald RC. (2010) Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study. &lt;EM&gt;British Medical Journal&lt;/EM&gt; 341:c4372&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objectives:&lt;/STRONG&gt; To determine the accuracy and acceptability to patients of non-endoscopic screening for Barrett’s oesophagus, using an ingestible oesophageal sampling device (Cytosponge) coupled with immunocytochemisty for trefoil factor 3. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Design: &lt;/STRONG&gt;Prospective cohort study. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt; 12 UK general practices, with gastroscopies carried out in one hospital endoscopy unit. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Participants:&lt;/STRONG&gt; 504 of 2696 eligible patients (18.7%) aged 50 to 70 years with a previous prescription for an acid suppressant (H2 receptor antagonist or proton pump inhibitor) for more than three months in the past five years. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Main outcome measures:&lt;/STRONG&gt; Sensitivity and specificity estimates for detecting Barrett’s oesophagus compared with gastroscopy as the ideal method, and patient anxiety (short form Spielberger state trait anxiety inventory, impact of events scale) and acceptability (visual analogue scale) of the test. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; 501 of 504 (99%) participants (median age 62, male to female ratio 1:1.2) successfully swallowed the Cytosponge. No serious adverse events occurred. In total, 3.0% (15/501) had an endoscopic diagnosis of Barrett’s oesophagus (=1 cm circumferential length, median circumferential and maximal length of 2 cm and 5 cm, respectively) with intestinal metaplasia. Compared with gastroscopy the sensitivity and specificity of the test was 73.3% (95% confidence interval 44.9% to 92.2%) and 93.8% (91.3% to 95.8%) for 1 cm or more circumferential length and 90.0% (55.5% to 99.7%) and 93.5% (90.9% to 95.5%) for clinically relevant segments of 2 cm or more. Most participants (355/496, 82%, 95% confidence interval 78.9% to 85.1%) reported low levels of anxiety before the test, and scores remained within normal limits at follow-up. Less than 4.5% (2.8% to 6.1%) of participants reported psychological distress a week after the procedure. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; The performance of the Cytosponge test was promising and the procedure was well tolerated. These data bring screening for Barrett’s oesophagus into the realm of possibility. Further evaluation is recommended.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to NHS staff via Athens.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293619</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1572-0241.2008.01825.x]]&gt;</url>
    <title>Acute hepatitis C: a systematic review</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS C,HEPATITIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Kamal, SM American journal of gastroenterology 2008 May;103(5):1283-97; quiz 1298&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;INTRODUCTION: The annual incidence of acute hepatitis C virus (HCV) has fallen in recent years, primarily because of effective blood screening efforts and increased education on the dangers of needle sharing. However, hepatitis C infection is still relatively frequent in certain populations. Most patients infected with HCV are unaware of their exposure and remain asymptomatic during the initial stages of the infection, making early diagnosis during the acute phase (first 6 months after infection) unlikely. While some of those infections will have a spontaneous resolution, the majority will progress to chronic HCV. We scanned the literature for predictors of spontaneous resolution and treatment during the acute stage of HCV to identify factors that would assist in treatment decision making. METHODS: A medical literature search through MEDLINE was conducted using the keyword "acute hepatitis C" with a variety of keywords focused on (a) epidemiology, (b) natural history and outcome, (c) diagnosis, (d) mode of transmission, and (e) treatment. RESULTS: There are no reliable predictors for spontaneous resolution of HCV infection and a significant percentage of individuals exposed to HCV develop persistent infections that progress to chronic liver disease. An intriguing approach is to treat acute HCV and prevent the development of chronic hepatitis. Several clinical trials showed that treatment of hepatitis C infection during the acute phase is associated with high sustained virological response (SVR) rates ranging between 75% and 100%. Although there is a prevailing consensus that intervention during the acute phase is associated with improved viral eradication, relevant clinical questions have remained unanswered by clinical trials. Optimization of therapy for acute hepatitis C infection and identification of predictors of SVR represent a real challenge. CONCLUSION: With more than 170 million chronic hepatitis C patients worldwide and an increase in the related morbidity and mortality projected for the next decade, an improvement in our ability to diagnose and treat patients with acute hepatitis C would have a significant impact on the prevalence of chronic hepatitis and its associated complications particularly in countries with a high endemic background of the infection.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345586</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727899/]]&gt;</url>
    <title>Adalimumab for the treatment of Crohn's disease</title>
    <publicationDate>2008-12-01T00:00:00</publicationDate>
    <publisher>Dove Press</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Adalimumab (ADA) appears to be effective in inducing and maintain clinical remission in Crohn's disease (CD), including patients not manageable with infliximab (IFX). Successive clinical practice and further on going trials will confirm a positive role for ADA as a new anti-TNF treatment in CD. The impact on clinical management or on resources should be more studied.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; CD is a chronic inflammatory bowel disease characterized by a relapsing-remitting course with trans-mural inflammation of potentially any section of the digestive tract. ADA is a subcutaneously administered, recombinant, fully human, IgG1 monoclonal antibody that binds with high affinity and specificity to human TNF-alpha, thus modulating its biologic functions and its proinflammatory effects. The aims of this paper was to review the available data on ADA in CD for biological properties, efficacy, and safety.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Electronic searches were conducted using the Pubmed and SCOPUS databases from the earliest records to April 2008. The search terms used were "adalimumab", "anti-TNF", "TNF-alpha", "biologicals", "inflammatory bowel disease", and "Crohn's disease". Reference lists of all relevant articles were searched for further studies.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Available studies suggest that ADA has the potential to induce and maintain clinical response and remission in moderate-severe CD, both in anti-TNF-naïve patients and in subjects who lost their response and/or became intolerant to infliximab (IFX). ADA seems also effective in maintaining corticosteroid-free remission and obtaining complete fistula closure (although no specific randomized trials are available). No concomitant immunosuppressors seem to be necessary. Side effects appear similar to IFX, while site-injection reactions are frequent and specific. Data on immunogenicity and its clinical impact are uncertain. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Cassinotti A, Ardizzone S, Porro GB. Adalimumab for the treatment of Crohn's disease. &lt;EM&gt;Biologics &lt;/EM&gt;2008;2(4):763-77.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>346143</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1002/ibd.20956]]&gt;</url>
    <title>Adalimumab safety in global clinical trials of patients with Crohn's disease.</title>
    <publicationDate>2009-09-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The safety profile of adalimumab in patients with Crohn's disease (CD) was similar to that of other tumor necrosis factor&amp;nbsp;(TNF) antagonists in CD populations, and the rates of adverse events were comparable to other approved indications for adalimumab spanning &amp;gt;10 years of clinical observation. No new safety signals were identified.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Adalimumab, a fully human anti-TNF monoclonal antibody, is approved for the treatment of CD in adults. We evaluated the overall safety profile of adalimumab in global clinical trials in patients with CD. Patients who participated in these trials, which included randomized induction and maintenance trials, Phase IIIb trials, and open-label extension studies, had moderately to severely active CD and were evaluated for safety at regular intervals.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Rates of adverse events of interest were assessed per 100-patient-years of adalimumab exposure. Standardized mortality rates and standardized incidence rates (for malignancies) were calculated using population-matched data. As of April 15, 2008, 3160 patients with CD had been treated with adalimumab in clinical trials, representing 3401.9 patient-years of adalimumab exposure.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Serious infection was the most frequently reported serious adverse event of interest in the CD trials; abscess (intraabdominal and gastrointestinal related) was the most common serious infection. Low incidences of malignancies, lymphomas, opportunistic infections (including tuberculosis), demyelinating disorders, and lupus-like disorders were reported in the CD trials. The standardized mortality rate for adalimumab-treated patients with CD, 0.44 (95% confidence interval [CI], 0.12-1.12), is less than the rate of 1.52 (95% CI, 1.32-1.74) reported in a recent meta-analysis of patients with CD.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Colombel JF, Sandborn WJ, Panaccione R, Robinson AM, Lau W, Li J, Cardoso AT. Adalimumab safety in global clinical trials of patients with Crohn's disease. &lt;EM&gt;Inflamm Bowel Dis&lt;/EM&gt; 2009;15(9):1308-19.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>381419</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.hta.ac.uk/execsumm/summ1335.htm]]&gt;</url>
    <title>Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>National Institute for Health Research</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,RECENT ADDITIONS,CHRONIC HEPATITIS B,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Both adefovir dipivoxil (ADV)&amp;nbsp;and pegylated interferon alpha&amp;nbsp;(PEG-alpha) are beneficial for patients with&amp;nbsp;chronic hepatitis B&amp;nbsp;in terms of suppressing viral load, reducing liver damage-associated biochemical activity, inducing HBeAg seroconversion, and reducing liver fibrosis and necroinflammation. The effects of long-term treatment with ADV are generally durable, with relatively low rates of resistance. In most cases, cost-effectiveness estimates were within acceptable ranges. Further research should assess the clinical effectiveness and cost-effectiveness of newer antiviral agents in relation to existing drugs, including the role of initiating treatment with combination therapy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; To update and extend a 2006 report on the clinical effectiveness and cost-effectiveness of ADV and PEG-alpha for the treatment of CHB.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Thirteen bibliographic databases were searched including MEDLINE, EMBASE and the Cochrane Library. Searches were run from the beginning of 2005 to September 2007. For the clinical effectiveness review, randomised controlled trials (RCTs) comparing ADV, PEG-alpha-2a and PEG-alpha-2b with currently licensed treatments for CHB, including non-pegylated interferon alpha (IFN-alpha) and lamivudine (LAM), were included. Outcomes included biochemical, histological and virological response to treatment, drug resistance and adverse effects. A systematic review of economic evaluations of antiviral treatments for CHB was conducted. The economic Markov model used in the 2006 report was updated in terms of utility values, discount rates and costs.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Of the 82 papers retrieved for detailed screening, eight RCTs were included. Three evaluated ADV, four evaluated PEG-alpha-2b and one (from the original literature search) compared PEG-alpha-2b plus LAM with PEG-alpha-2b monotherapy. No RCTs of PEG-alpha-2a were identified. One ADV trial showed a statistically significant difference between ADV and placebo in terms of ALT response and HBV DNA levels, favouring ADV. Following withdrawal of ADV, levels were similar to those in placebo patients. In the ADV versus ADV plus LAM trial, there was a statistically significant difference in favour of the combination treatment. In the PEG-alpha trials, there were statistically significant differences favouring PEG-alpha-2b plus LAM compared with either one of the drugs given as monotherapy. For the comparison between PEG-alpha-2b and IFN-alpha and the comparison between different staggered regimens of the commencement of PEG-alpha-2b and LAM, there were no statistically significant differences between groups. Four full economic evaluations were identified, in addition to one identified in the original report. Two assessed PEG-alpha-2a; the remainder assessed ADV. PEG-alpha-2a was associated with increased treatment costs and gains in quality-adjusted life expectancy. In a UK study, the incremental cost-effectiveness ratio (ICER) for PEG-alpha-2a was 10,444 pounds per QALY gained compared with LAM. Evaluations of ADV found that LAM monotherapy was dominated; the ICER for ADV monotherapy compared with 'doing nothing' was $19,731. The results of the updated analysis were generally robust to changes in deterministic sensitivity analysis. In a probabilistic sensitivity analysis, the same sequence of treatments was identified as optimal. In a probabilistic sensitivity analysis, PEG-alpha-2b had a probability of being cost-effective of 79% at a willingness-to-pay threshold of 20,000 pounds per QALY, and 86% at a willingness-to-pay threshold of 30,000 pounds per QALY.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Jones J, Shepherd J, Baxter L, Gospodarevskaya E, Hartwell D, Harris P, Price A. Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation. &lt;EM&gt;Health Technol Assess&lt;/EM&gt; 2009;13(35):1-172, iii.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>376095</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.jhep.2009.12.041]]&gt;</url>
    <title>Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach</title>
    <publicationDate>2010-06-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>STRUCTURED ABSTRACT</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,HEPATITIS C,HEPATOCELLULAR CARCINOMA,RECENT ADDITIONS,CANCER,CHRONIC HEPATITIS B,CHRONIC HEPATITIS C,MAY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The meta-analysis suggests a potential efficacy of adjuvant &lt;SPAN class=nbApiHighlight&gt;interferon&lt;/SPAN&gt; after curative therapy for &lt;SPAN class=nbApiHighlight&gt;hepatocellular carcinoma (HCC)&lt;/SPAN&gt;.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Adjuvant anti-viral therapy after curative therapy for &lt;SPAN class=nbApiHighlight&gt;HCC&lt;/SPAN&gt; has been studied extensively but the true clinical benefit and the predictors of efficacy remain unclear.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; MEDLINE, PubMed, and the Cochrane library were searched until December 2008, plus the meeting abstracts of the American Association for the Study of &lt;SPAN class=nbApiHighlight&gt;Liver Disease&lt;/SPAN&gt; 2005–2008. Randomized trials and cohort studies were included if the studies (1) enrolled &lt;SPAN class=nbApiHighlight&gt;HCC&lt;/SPAN&gt; patients who had underlying &lt;SPAN class=nbApiHighlight&gt;chronic viral hepatitis B&lt;/SPAN&gt; or C and had undergone curative surgery or ablation therapy; (2) consisted of one or more treatment arms with &lt;SPAN class=nbApiHighlight&gt;interferon&lt;/SPAN&gt;-based therapy and a control arm of no anti-viral therapy; and (3) included recurrence-free survival of &lt;SPAN class=nbApiHighlight&gt;HCC&lt;/SPAN&gt; as an endpoint. Meta-analysis and meta-regression were done according to the Cochrane guidelines.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results: &lt;/STRONG&gt;Thirteen studies (9 randomized trials and 4 cohort studies, totally 1180 patients) were eligible for meta-analysis. Surgery and ablation therapy were used in 9 and 8 studies, respectively. All studies used conventional &lt;SPAN class=nbApiHighlight&gt;interferon&lt;/SPAN&gt; (natural or recombinant) as anti-viral therapy. Overall, &lt;SPAN class=nbApiHighlight&gt;interferon&lt;/SPAN&gt; improved the 1-year, 2-year, and 3-year recurrence-free survival by 7.8% (95% CI 3.7–11.8%), 35.4% (95% CI 30.7–40.0%), and 14.0% (95% CI 8.6–19.4%), respectively (all &lt;I&gt;p&amp;nbsp;&lt;/I&gt;&amp;lt;0.01). Lower percentage of patients with multiple tumors and use of ablation therapy were independent predictors for better treatment efficacy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Shen YC, Hsu C, Chen LT, Cheng CC, Hu FC, Cheng AL. Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach. &lt;EM&gt;J Hepatol &lt;/EM&gt;2010;52(6):889-94.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>251555</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.kcl.ac.uk/gsp09/programme/426]]&gt;</url>
    <title>Advanced Practice (Gastrointestinal Nursing) MSc/PG Dip/PG Cert</title>
    <publicationDate>2009-04-09T00:00:00</publicationDate>
    <publisher>Burdett Institute of Gastrointestinal Nursing</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COMMON CLINICAL PRESENTATIONS,OESOPHAGUS,STOMACH,BILIARY TREE &amp; GALLBLADDER,PANCREAS,LIVER,SMALL INTESTINE,COLON &amp; RECTUM,INFLAMMATORY BOWEL DISEASE,DIAGNOSTIC PROCEDURES,DISEASE PREVENTION,NEUROENDOCRINE TUMOURS,THERAPEUTIC NUTRITION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This MSc/Postgraduate Diploma/Certificate programme is designed for eaxperienced healthcare professionals who specialise in GI disorders. The programme may be completed part-time over a maximum of 6 years and a minimum of 2 years. Attendance is in either one day a week of study block format.</description>
    <body>&lt;![CDATA[ &lt;P&gt;The Advanced Practice programme, which comprises generic and specialist pathways,&amp;nbsp;is intended for experienced healthcare practitioners who are seeking to advance their clinical practice, enhance their knowledge of research and evidence based health care and develop their roles. It is suitable for practitioners, educators and managers from many health care disciplines who are developing autonomous practice, supporting educational and practice development or exercising clinical leadership. &lt;/P&gt;
&lt;P&gt;The Gastrointestinal Nursing pathway is designed for clinically based experienced healthcare professionals specialising in gastrointestinal disorders who are seeking to extend and expand their clinical practice and develop their professional role. Extensive previous clinical experience is assumed.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323700</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1185/03007990902779186]]&gt;</url>
    <title>Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis C</title>
    <publicationDate>2009-04-01T00:00:00</publicationDate>
    <publisher>Informa</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,RECENT ADDITIONS,AUGUST 2009,CHRONIC HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Albinterferon alfa-2b exhibits high antiviral activity, and appears to offer safety/tolerability comparable to the current standard of care, and health-related quality-of-life benefits in patients with chronic hepatitis C (CHC). Its ability to maintain drug concentrations above the 90% effective concentration over prolonged dosing intervals suggests that it may be an ideal partner for combination therapy with direct antiviral agents in CHC. The results of the phase 3 trials are eagerly anticipated as they should greatly clarify the future role of alb-IFN in the treatment of CHC.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; This review was based on all published data regarding alb-IFN to date. An unlimited PubMed database search was conducted using the keywords ‘albuferon,’ ‘albinterferon,’ and ‘albumin AND interferon.’&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Albinterferon alfa-2b has been developed for the treatment of CHC. This agent exhibits a prolonged half-life and duration of antiviral activity that indicate potential suitability for dosing intervals of 2–4 weeks. Phase 2 trials in prior IFN nonresponders and IFN-naïve patients with genotype 1 or 2/3 CHC have shown antiviral activity and acceptable safety/tolerability of alb-IFN 900–1500µg every 2 weeks and 1200–1500µg every 4 weeks. Based on the phase 2 data, alb-IFN 900µg and 1200µg every 2 weeks were selected for two ongoing phase 3 trials in IFN-naïve patients with genotype 1 and 2/3 CHC.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Rustgi VK. Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis C. &lt;EM&gt;Curr Med Res Opin&lt;/EM&gt; 2009 Apr;25(4):991-1002.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317189</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.acg.gi.org/physicians/pdfs/CCSJournalPublicationFebruary2009.pdf]]&gt;</url>
    <title>American College of Gastroenterology guidelines for colorectal cancer screening 2008</title>
    <publicationDate>2009-03-01T00:00:00</publicationDate>
    <publisher>American College of Gastroenterology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,CT / CAT SCAN,DISEASE PREVENTION,COLON &amp; RECTUM,DIAGNOSTIC PROCEDURES,GASTROINTESTINAL ENDOSCOPY,COLONOSCOPY,POLYPS,CANCER,SCREENING,RECENT ADDITIONS,OUTCOMES,CANCER,SCREENING,POPULATION BASED &amp; PREVENTATIVE SERVICES,PUBLIC HEALTH,SERVICES,NON-MALIGNANT NEOPLASMS,RADIOLOGY,MONTHLY ADDITIONS,MANAGEMENT &amp; INTERVENTIONS,2009 JULY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; This document is the first update of the American College of Gastroenterology (ACG) colorectal cancer (CRC) screening recommendations since 2000. The CRC screening tests are now grouped into cancer prevention tests and cancer detection tests.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience: &lt;/STRONG&gt;Gastroenterologists, endoscopists&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in March 2009.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317963</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.acg.gi.org/physicians/guidelines/CrohnsDiseaseinAdults2009.pdf]]&gt;</url>
    <title>American College of Gastroenterology practice guidelines: management of Crohn's disease in adults</title>
    <publicationDate>2009-02-01T00:00:00</publicationDate>
    <publisher>American College of Gastroenterology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,SURGERY,SURGERY,ABDOMEN,SMALL INTESTINE,COLON &amp; RECTUM,CROHN'S DISEASE,CROHN’S DISEASE,RECENT ADDITIONS,JUNE 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; Guidelines for clinical practice are intended to suggest preferable approaches to particular medical problems as established by interpretation and collation of scientifically valid research, derived from extensive review of published literature. When data that will withstand objective scrutiny are not available, a recommendation may be made based on a consensus of experts. Guidelines are intended to apply to the clinical situation for all physicians without regard to specialty. Guidelines are intended to be flexible, not necessarily indicating the only acceptable approach, and should be distinguished from standards of care that are inflexible and rarely violated. Given the wide range of choices in any health-care problem, the physician should select the course best suited to the individual patient and the clinical situation presented. These guidelines are developed under the auspices of the American College of Gastroenterology and its Practice Parameters Committee. Expert opinion is solicited from the outset for the document.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Gastroenterologists&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in&amp;nbsp;February 2009.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>125569</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://download.journals.elsevierhealth.com/pdfs/journals/0016-5085/PIIS0016508506000734.pdf]]&gt;</url>
    <title>American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease</title>
    <publicationDate>2006-03-01T00:00:00</publicationDate>
    <publisher>American Gastroenterological Association</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Recommendations developed to assist physicians in the appropriate use of medications to treat patients with inflammatory bowel disease.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aim:&lt;/STRONG&gt; recommendations developed to assist physicians in the appropriate use of medications to treat adult patients with inflammatory bowel disease (IBD). These recommendations represent the results of many years of research and many collaborative efforts but should not be construed as a standard of care. The medications reviewed include:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;corticosteroids, 
&lt;LI&gt;azathioprine (AZA), 
&lt;LI&gt;6-mercaptopurine (6-MP), 
&lt;LI&gt;methotrexate, 
&lt;LI&gt;mycophenolate mofetil, 
&lt;LI&gt;cyclosporine, and 
&lt;LI&gt;infliximab. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Article outine:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Corticosteroids &amp;gt; Recommendations for corticosteroid use, 
&lt;LI&gt;Mild to moderate IBD, 
&lt;LI&gt;Moderate to severe IBD, 
&lt;LI&gt;Severe to fulminant IBD, 
&lt;LI&gt;Maintenance therapy. 
&lt;LI&gt;Dosing and tapering for IBD, 
&lt;LI&gt;Monitoring for complications, 
&lt;LI&gt;AZA/6-MP &amp;gt; Recommendations for AZA/6-MP use, 
&lt;LI&gt;Methotrexate &amp;gt; Recommendations for methotrexate use, 
&lt;LI&gt;Mycophenoprine mofetil, 
&lt;LI&gt;Cyclosporine &amp;gt;&amp;nbsp; Recommendations or Cyclosporine use, 
&lt;LI&gt;Infliximab &amp;gt; Recommendations for Infliximab use, and 
&lt;LI&gt;Copyright&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;This position statement is derived from the AGAs Technical Review corticosterords, immunomodulators, and infliximab, see Related links below.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Healthcare providers of all specialties. This position statement&amp;nbsp;has been prepared by the American Gastroenterological Association Institute and is therefore primarily aimed at their membership. NHS professionals should check drug details with national and local medicines guidance.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Authority:&lt;/STRONG&gt; This document presents the official recommendations of the &lt;A href="http://www.gastro.org/" target="_blank"&gt;American Gastroenterological Association&lt;/A&gt; (AGA) on "Corticosteroids, Immunomodulators, and Infliximab in Inflammatory Bowel Disease." It was approved by the Clinical Practice and Economics Committee on November 22, 2005, and by the AGA Governing Board on&amp;nbsp;January 12, 2006.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Freely available article within a mostly restricted access journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>125577</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://download.journals.elsevierhealth.com/pdfs/journals/0016-5085/PIIS0016508506000746.pdf]]&gt;</url>
    <title>American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease</title>
    <publicationDate>2006-03-01T00:00:00</publicationDate>
    <publisher>American Gastroenterological Association</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A review of the evidence base and current practice patterns for the treatment IBD in adults with 3 classes of drugs: corticosteroids, immunomodulators , and infliximab.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details:&lt;/STRONG&gt; American Gastroenterological Association Institute 2006; Gastroenterology 130 pp. 940-987&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aim:&lt;/STRONG&gt; a review of the evidence base and current practice patterns for the treatement of Inflammatory Bowel Disease in adults with 3 classes of drugs: corticosteroids, immunomodulators, and infliximab. The medications reviewed include:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;corticosteroids, 
&lt;LI&gt;azathioprine (AZA), 
&lt;LI&gt;6-mercaptopurine (6-MP), 
&lt;LI&gt;methotrexate, 
&lt;LI&gt;mycophenolate mofetil, 
&lt;LI&gt;cyclosporine, and 
&lt;LI&gt;infliximab. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Introduction:&lt;/STRONG&gt; "The disorders collectively known as inflammatory bowel disease&amp;nbsp; include Crohn's Diseases and ulcerative colitis. Crohn's disease, initially credited as having been described in 1932 by Drs Burril Crohn, Gordon Oppenheimer, and Leon Ginzburg, is an idopathic transmural chronic infammatory disorder affecting the gastrintestinal tract. Ulcerative colitic, on the other hand, is credited to have been described by Drs Wilks and Moxon&amp;nbsp;in 1875.&lt;/P&gt;
&lt;P&gt;These disorders spare no socioeconomic class, age, sex, or country of origin. These disorders are relatively common in the United States, accounting for diease in approximately 1 million individulas, with similar numbers in Europe. These complex disorders may have varied presentations and compications that ensue during their course, as have been evidenced by wide variation in clinical practice. ... The intent of this position statement is to bring consistency to patient care, but this should not necessarily be viewed as the standard if care for all patients. Individual care of patients should be maanged on the basis of all clinical data available oflr taht particular case. Patient preferences should be sought in an effort to make decisions in a partnership between patients and health care professionals."&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This technical review is associted with a Position Statement on the use of corticosteroids, immunomodulators, and infliximab, see Related links below.&lt;/P&gt;
&lt;P&gt;This review has over 300 references, many of which are linked to their PubMed record.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Healthcare providers of all specialties. This position statement&amp;nbsp;has been prepared by the American Gastroenetrological Association Institute and is therefore primarily aimed at their membership. NHS professionals should check drug details with national and local medicines guidance.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Freely available article within a mostly restricted access journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317187</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://download.journals.elsevierhealth.com/pdfs/journals/0016-5085/PIIS0016508508016065.pdf]]&gt;</url>
    <title>American Gastroenterological Association medical position statement on the management of gastroesophageal reflux disease</title>
    <publicationDate>2008-10-01T00:00:00</publicationDate>
    <publisher>American Gastroenterological Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,OESOPHAGUS,DIAGNOSTIC PROCEDURES,GASTROINTESTINAL ENDOSCOPY,UPPER ENDOSCOPY,BIOPSY,GASTRO-OESOPHAGEAL REFLUX,RECENT ADDITIONS,JUNE 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims: &lt;/STRONG&gt;In the development of this medical position statement, 12 broad questions pertinent to diagnostic and management strategies for patients with gastroesophageal reflux disease (GERD) were developed by interaction among the authors of the AGA's recent &lt;A href="http://www.gastro.org/user-assets/Documents/02_Clinical_Practice/medical_position_statments/gerd_tr.pdf" target="_blank"&gt;technical review&lt;/A&gt;, representatives from the American Gastroenterological Association (AGA) Institute Council, and the AGA Institute Clinical Practice and Quality Management Committee. The questions were designed to encapsulate the major management issues encountered in patients with GERD in current clinical practice.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience: &lt;/STRONG&gt;Gastroenterologists, endoscopists&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in October 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>343356</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1200/JCO.2009.23.4450]]&gt;</url>
    <title>American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer</title>
    <publicationDate>2010-01-20T00:00:00</publicationDate>
    <publisher>American Society of Clinical Oncology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,COLON &amp; RECTUM,CANCER,RECENT ADDITIONS,CANCER,FEBRUARY 2010,SURGERY,LIVER RESECTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; There is a compelling need for more research to determine the efficacy and utility of radiofrequency ablation (RFA) to increase local recurrence-free, progression-free, and disease-free survival as well as&amp;nbsp;overall survival (OS)&amp;nbsp;for patients with hepatitc metastases from colorectal cancer (CRHM). Clinical trials have established that hepatic resection can improve OS for patients with resectable CRHM. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&amp;nbsp; &lt;/STRONG&gt;The aim of this review was to review the evidence about the efficacy and utility of RFA for&amp;nbsp;CRHM. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; The American Society of Clinical Oncology (ASCO) convened a panel to conduct and analyze a comprehensive systematic review of the RFA literature from Medline and the Cochrane Collaboration Library. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Because data were considered insufficient to form the basis of a practice guideline, ASCO has instead published a clinical evidence review. The evidence is from single-arm, retrospective, and prospective trials. No randomized controlled trials have been included. The following three clinical issues were considered by the panel: the efficacy of surgical hepatic resection versus RFA for resectable tumors; the utility of RFA for unresectable tumors; and RFA approaches (open, laparoscopic, or percutaneous). Evidence suggests that hepatic resection improves overall survival (OS), particularly for patients with resectable tumors without extrahepatic disease. Careful patient and tumor selection is discussed at length in the literature. RFA investigators report a wide variability in the 5-year survival rate (14% to 55%) and local tumor recurrence rate (3.6% to 60%). The reported mortality rate was low (0% to 2%), and the major complications rate was commonly reported to be between 6% and 9%. RFA is currently performed with all three approaches. &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Wong SL, Mangu PB, Choti MA, Crocenzi TS, Dodd GD 3rd, Dorfman GS, Eng C, Fong Y, Giusti AF, Lu D, Marsland TA, Michelson R, Poston GJ, Schrag D, Seidenfeld J, Benson AB 3rd. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. &lt;EM&gt;J Clin Oncol&lt;/EM&gt; 2010 Jan 20;28(3):493-508.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345571</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.crohns.2008.10.004]]&gt;</url>
    <title>An economic evaluation comparing once daily with twice daily mesalazine for maintaining remission based on results from a randomised controlled clinical trial</title>
    <publicationDate>2009-02-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Once daily 2g mesalazine for maintaining remission in&amp;nbsp;ulcerative colitis (UC)&amp;nbsp;is cost-saving compared with 1g twice daily. Cost-savings with 2g once daily were achieved by differences in ancillary care attributed to higher failure rates observed with 1g twice daily.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Standard practice to maintain remission in UCconsists of daily mesalazine therapy. However, frequent dosing is associated with poor adherence and increased failure rates. The PODIUM (Pentasa™ Once Daily In UC Maintenance) randomised control trial showed 2 g once daily (OD) to be superior to twice daily (BD) dosing for maintaining remission. We sought to determine whether this alternative dosing regimen is cost-effective.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; An economic evaluation was conducted to compare costs and outcomes of OD with twice daily (BD) dosing. The main outcome considered was quality-adjusted life years (QALYs) based on health state utilities derived from the primary outcome measure, remission without relapse at 12 months defined by a UCDAI score =1. The economic evaluation consisted of two health states: (1) remission and (2) active UC.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Annual average treatment costs for OD and BD dosing were £654 (95% CI: £536–£759) and £747 (£620–£860), respectively with an average per person savings of £93 per year. Average annual costs of ancillary care for relapse for OD and BD dosing were £307 (£241–£383) and £396 (£320–£483), respectively. Treatment with OD 2 g mesalazine resulted in an incremental QALY improvement of 0.004 units, indicating that it was the dominant treatment option (i.e. improved outcomes and cost-saving). Variations in parameter estimates in the sensitivity analysis indicated that mesalazine had &amp;gt;0.95 probability of being cost-effective compared to BD based on accepted willingness to pay thresholds applied by the UK National Health Service.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Connolly MP, Nielsen SK, Currie CJ, Poole CD, Travis SPL. An economic evaluation comparing once daily with twice daily mesalazine for maintaining remission based on results from a randomised controlled clinical trial.&lt;EM&gt; J Crohn's Colitis&lt;/EM&gt; 2009;3(1):32-7.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;See also:&amp;nbsp;&lt;/STRONG&gt;&lt;A href="nelh:327080:0" name=internalLink&gt;NHS EED&amp;nbsp;record&lt;/A&gt; for this article.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>322997</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.nature.com/ajg/journal/v104/n1s/pdf/ajg2008122a.pdf]]&gt;</url>
    <title>An evidence-based systematic review on the management of irritable bowel syndrome</title>
    <publicationDate>2009-01-01T00:00:00</publicationDate>
    <publisher>American College of Gastroenterology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,IRRITABLE BOWEL SYNDROME,RECENT ADDITIONS,AUGUST 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Includes "An evidence-based position statement on the management of irritable bowel syndrome"</description>
    <body>&lt;![CDATA[ &lt;DIV id=abstractSummary&gt;
&lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; This document consists of an ACG position statement on IBS followed by the systematic review that informed it. Irritable bowel syndrome (IBS) is a common disorder characterized by abdominal pain and altered bowel habit for at least 3 months.&amp;nbsp; As IBS is one of the most common disorders managed by gastroenterologists and primary care physicians, this monograph was developed to educate physicians about its epidemiology, diagnostic approach, and treatments.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; GPs, gastroenterologists.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published January 2009.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>346151</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1572-0241.2008.02158.x]]&gt;</url>
    <title>An update on the epidemiology of inflammatory bowel disease in Asia</title>
    <publicationDate>2008-12-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion: &lt;/STRONG&gt;There has been a trend of greater incidence and prevalance of inflammatory bowel disease (IBD) across Asia, particularly South Asia.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract:&lt;/STRONG&gt;&amp;nbsp;A rising trend in the incidence and prevalence of inflammatory bowel disease (IBD) in Asia has been recognized for the past two decades. It has been postulated that this phenomenon may be related to the westernization of lifestyles, including changes in dietary habits and environmental changes such as improved sanitation and industrialization. Previously we reported that the incidence and prevalence rates of IBD in Asia were low compared with the West, but there was a notably rising secular trend. In this review, we summarize the recent epidemiological data in Asia, characterize the clinical features, risk factors and genetic susceptibility of Asian IBD patients, and compare these to those of Western IBD patients. In the past decade, the incidence and prevalence of IBD reported across Asia, particularly in East Asia, has continued to increase. Familial clustering is generally uncommon in East Asia but appears to be higher in West Asia. The genetic susceptibilities in Asian IBD patients differ from those of White patients, as NOD2/CARD15 mutations are much less common. The clinical phenotypes and complication rates of Asian IBD resemble the White population in general, but with some differences, including lower surgical rates, higher prevalence of males, and higher prevalence of ileocolonic involvement among East Asian Crohn's disease patients, and a low frequency of primary sclerosing cholangitis among IBD patients in East and Southeast Asia.&lt;/P&gt;
&lt;P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Thia KT, Loftus EV Jr, Sandborn WJ, Yang SK. An update on the epidemiology of inflammatory bowel disease in Asia. &lt;EM&gt;Am J Gastroenterol&lt;/EM&gt; 2008;103(12):3167-82. 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>305630</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://learning.bmj.com/learning/search-result.html?moduleId=10011022&amp;searchTerm=]]&gt;</url>
    <title>Antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures</title>
    <publicationDate></publicationDate>
    <publisher>NICE/BMJ Learning</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,DIAGNOSTIC PROCEDURES,GASTROINTESTINAL ENDOSCOPY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;These online education tools have been developed by NICE in collaboration with BMJ Learning. BMJ Learning offers a wide range of learning resources, commissioned by the BMJ Group. The learning resources deal with everyday issues in primary care and hospital medicine. They are evidence based and peer reviewed. &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aims: &lt;/STRONG&gt;After completing this module you should know:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;The latest recommendations about prophylaxis against infective endocarditis 
&lt;LI&gt;What factors put people at increased risk of infective endocarditis 
&lt;LI&gt;How to communicate the latest guidelines to patients and their carers. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;You should be able to:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Challenge misconceptions about the guidance 
&lt;LI&gt;Apply this knowledge in your practice 
&lt;LI&gt;Reflect and compare your own practice against recommended audit criteria. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&amp;nbsp; Free registration with the site is required.&amp;nbsp; To register, click "Start module" and then "Register here".&amp;nbsp; Do not select the option to log in via Athens as access to BMJ Learning is not currently&amp;nbsp;part of NHS Athens accounts.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323587</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19124812]]&gt;</url>
    <title>Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health Consensus Development Conference</title>
    <publicationDate>2009-01-20T00:00:00</publicationDate>
    <publisher>American College of Physicians</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,RECENT ADDITIONS,AUGUST 2009,CHRONIC HEPATITIS B]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Evidence was insufficient to assess treatment effect on clinical outcomes or determine whether inconsistent improvements in selected intermediate measures are reliable surrogates. Future research is needed to provide evidence-based recommendations about optimal antiviral therapy in adults with chronic hepatitis B infection.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt;&amp;nbsp;&amp;nbsp;Data taken from all randomized, controlled trials (RCTs) of interferon (&amp;amp;alpha;2b and pegylated &amp;amp;alpha;2a), lamivudine, adefovir, entecavir, and telbivudine published from 1990 to 2008. Data extracted with standard protocols to calculate risk difference for clinical outcomes, viral load, HBeAg and HBsAg, ALT, histologic scores, and adverse events.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; In 16 RCTs (4431 patients), drug treatment did not improve clinical outcomes of chronic hepatitis B infection, but the trials were underpowered. In 60 RCTs that examined intermediate outcomes, no single treatment improved all intermediate outcomes. Low-quality evidence suggested HBsAg clearance after interferon-alpha2b (2 RCTs; 211 patients). Moderate-quality evidence suggested ALT normalization at follow-up after treatment with adefovir (2 RCTs; 600 patients) and HBeAg loss with lamivudine (2 RCTs; 318 patients). With interferon-alpha2b, moderate-quality evidence suggested HBeAg loss (3 RCTs; 351 patients), seroconversion (2 RCTs; 304 patients), and ALT normalization (2 RCTs; 131 patients). Pegylated interferon-alpha2a versus lamivudine improved HBeAg seroconversion (1 RCT; 814 patients) and ALT normalization (2 RCTs; 905 patients) off treatment. Pegylated interferon-alpha2a combined with lamivudine versus lamivudine improved HBeAg loss (1 RCT; 543 patients) and ALT normalization (2 RCTs; 905 patients). Adverse events during antiretroviral therapy occurred in more than 50% of patients but were not associated with increased treatment discontinuation. However, most studies excluded patients with hepatic or renal insufficiency or other serious comorbid conditions.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Shamliyan TA, MacDonald R, Shaukat A, Taylor BC, Yuan JM, Johnson JR, et al. Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health Consensus Development Conference. &lt;EM&gt;Ann Intern Med&lt;/EM&gt; 2009 Jan 20;150(2):111-24.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>380773</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.cgh.2009.10.026]]&gt;</url>
    <title>Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis</title>
    <publicationDate>2010-02-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,HEPATOCELLULAR CARCINOMA,RECENT ADDITIONS,CANCER,CHRONIC HEPATITIS C,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The risk of hepatocellular carcinoma (HCC) is reduced among patients with&amp;nbsp;hepatitis C virus (HCV)&amp;nbsp;who achieve a sustained virological response (SVR) with antiviral therapy. Maintenance therapy with&amp;nbsp;interferon (IFN)&amp;nbsp;does not reduce HCC risk among patients who do not respond to initial therapy. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; The effects of antiviral therapy on prevention of HCC in patients with HCV-related cirrhosis are unclear. We performed a systematic review and meta-analysis to assess HCC risk reduction in patients with HCV-related cirrhosis who have received antiviral therapy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Twenty studies (4700 patients) were analyzed that compared untreated patients with those given interferon (IFN) alone or ribavirin. Risk ratios (RRs) determined effect size using a random effects model.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Pooled data showed reduced HCC risk in the treatment group (RR, 0.43; 95% confidence interval [CI], 0.33-0.56), although the data were heterogenous (chi(2) = 59.10). Meta-regression analysis showed that studies with follow-up durations of more than 5 years contributed to heterogeneity. Analysis of 14 studies (n = 3310) reporting sustained virologic response (SVR) rates with antiviral treatment showed reduced HCC risk in patients with an SVR, compared with nonresponders (RR, 0.35; 95% CI, 0.26-0.46); the maximum benefits were observed in patients treated with ribavirin-based regimens (RR, 0.25; 95% CI, 0.14-0.46). Meta-analysis of 4 studies assessing the role of maintenance IFN in nonresponders did not show HCC risk reduction (RR, 0.58; 95% CI, 0.33-1.03). No publication bias was detected by the Egger test analysis (P &amp;gt; 0.1).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Singal AK, Singh A, Jaganmohan S, Guturu P, Mummadi R, Kuo YF, Sood GK. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. &lt;EM&gt;Clin Gastroenterol Hepatol&lt;/EM&gt; 2010;8(2):192-9.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>380775</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19578232]]&gt;</url>
    <title>Antiviral treatment for chronic hepatitis C in illicit drug users: a systematic review</title>
    <publicationDate>2009-06-01T00:00:00</publicationDate>
    <publisher>International Medical Press</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,RECENT ADDITIONS,CHRONIC HEPATITIS C,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Abstract:&lt;/STRONG&gt; According to recent World Health Organization data, approximately 170-200 million people worldwide are infected with hepatitis C virus (HCV). At present, illicit drug users (IDUs) constitute the largest group of individuals infected with HCV in industrial countries. Between 50% and 90% of IDUs are estimated to be positive for anti-HCV antibodies and most of the new infections occur in IDUs. The aim of our review is to focus on tertiary prevention of HCV infection among IDUs. We review strategies to prevent HCV infection and disease progression, attitude to antiviral treatment, access to specific HCV therapy and data of efficacy and safety of antiviral treatment among IDUs.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Zanini B, Lanzini A. Antiviral treatment for chronic hepatitis C in illicit drug users: a systematic review. &lt;EM&gt;Antivir Ther&lt;/EM&gt; 2009;14(4):467-79.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>330283</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18344107]]&gt;</url>
    <title>Are recommended doses of acetaminophen hepatotoxic for recently abstinent alcoholics? A randomized trial</title>
    <publicationDate>2008-03-01T00:00:00</publicationDate>
    <publisher>Informa</publisher>
    <publicationType>RANDOMISED CONTROLLED TRIAL</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,ALCOHOLIC LIVER DISEASE,RECENT ADDITIONS,NOVEMBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Therapeutic doses of sustained-release acetaminophen cause a measurable decrease in serum a-GST during the first days of abstinence from chronic alcohol use. While the mechanism is unclear, these observations do provide some reassurance that short courses of acetaminophen are unlikely to cause subclinical hepatocellular injury in recently abstinent alcoholics.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Although acetaminophen overdose is a leading cause of fulminant hepatic failure, it is controversial whether therapeutic doses of acetaminophen can cause hepatotoxicity in alcoholics, especially those rendered most vulnerable by recent abstinence.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We performed a randomized, triple-blind, parallel-group trial comparing sustained-release acetaminophen, 1300mg orally q8h for 11 doses, against placebo. We enrolled chronic alcohol abusers (defined as = 6 drinks daily for = 6 weeks) who had discontinued alcohol consumption 12 to 72 hours prior to enrolment. Individuals with self-reported viral hepatitis, HIV or intravenous drug use, baseline AST or ALT &amp;gt;120 IU/L, or INR &amp;gt;1.5 were excluded. Hepatic function tests were drawn daily for 5 days. The primary outcome was change in serum a-GST, a sensitive experimental biomarker of hepatocellular injury; secondary outcomes were changes in serum AST, ALT, INR, and study withdrawal for a doubling of aminotransferases to &amp;gt;120 IU/L.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Of 52 subjects randomized, 40 completed at least four days of intervention. Subjects receiving acetaminophen had 32% [95% CI 7%, 50%] and 29% [6%, 46%] &lt;I&gt;lower&lt;/I&gt; serum a-GST concentrations on days 2 and 3, respectively, compared to placebo, but these differences disappeared by day 4. No subjects were withdrawn for safety reasons.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Bartels S, Sivilotti M, Crosby D, Richard J. Are recommended doses of acetaminophen hepatotoxic for recently abstinent alcoholics? A randomized trial.&amp;nbsp;&lt;EM&gt;Clin Toxicol (Phila)&lt;/EM&gt; 2008 Mar;46(3):243-9.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>251157</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1053/j.gastro.2006.01.046]]&gt;</url>
    <title>Association of 6-Thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis</title>
    <publicationDate>2006-04-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>6-Thioguanine nucleotide (6-TGN) levels have been proposed to correlate with inflammatory bowel disease (IBD) activity among patients treated with azathioprine or 6-mercaptopurine (6-MP). Previous studies, most with small sample sizes, yielded conflicting conclusions. Our aim was to pool the available data to provide a more precise estimate of the association between 6-TGN levels and IBD activity.</description>
    <body>&lt;![CDATA[ &lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Osterman MT, Kundu R, Lichtenstein GR et al. 2006; Gastroenterology 130 (4) pp. 1047-1053 
&lt;H2&gt;Original article abstract:&lt;/H2&gt;
&lt;P&gt;BACKGROUND &amp;amp; AIMS: 6-Thioguanine nucleotide (6-TGN) levels have been proposed to correlate with inflammatory bowel disease (IBD) activity among patients treated with azathioprine or 6-mercaptopurine (6-MP). Previous studies, most with small sample sizes, yielded conflicting conclusions. Our aim was to pool the available data to provide a more precise estimate of the association between 6-TGN levels and IBD activity. METHODS: We searched Medline and PubMed (from 1966 to November 2004) and reviewed the reference lists of selected articles. Fixed and random-effects models were used to test whether mean/median 6-TGN levels differed among patients with active disease vs remission and whether 6-TGN levels above a threshold of 230-260 pmol/8 x 10(8) red blood cells were associated with clinical remission. When studies reported multiple 6-TGN threshold values, we used the data for the lower value. RESULTS: We identified 55 articles, 12 of which contained data sufficient for inclusion. The mean/median 6-TGN levels were higher among patients in remission than in those with active IBD (pooled difference, 66 pmol/8 x 10(8) red blood cells; 95% confidence interval, 18-113; P = .006), but with significant heterogeneity. Excluding the 1 outlier study eliminated this heterogeneity. Patients with 6-TGN levels above the threshold value were more likely to be in remission (62%) than those below the threshold value (36%) (pooled odds ratio, 3.3; 95% confidence interval, 1.7-6.3; P &amp;lt; .001), but with significant heterogeneity. Again, excluding the 1 outlier study eliminated this heterogeneity. CONCLUSIONS: Although prior studies yielded inconsistent conclusions, this analysis strongly supports that higher 6-TGN levels are associated with clinical remission.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is &lt;STRONG&gt;not &lt;/STRONG&gt;available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Other relevant articles&lt;/STRONG&gt;: You may also be interested in&amp;nbsp;the article&amp;nbsp;'&lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resID=251148&amp;amp;code=9105ac435d02084213ce41ca33acc235" target="_blank"&gt;Increased risk of lymphoma among IBD patients treated with azathioprine and 6-mercaptopurine&lt;/A&gt;' which&amp;nbsp;covers a similar topic.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345484</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1038/gene.2009.25]]&gt;</url>
    <title>Association of ATG16L1 and IRGM genes polymorphisms with inflammatory bowel disease: a meta-analysis approach</title>
    <publicationDate>2009-06-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion: &lt;/STRONG&gt;The ATG16L1 rs2241880 and IRGM rs13361189 and rs4958847 polymorphisms as important markers for Crohn's disease (CD) susceptibility and are also associated with ulcerative colitis (UC).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; The aim of this study was to determine the role of the ATG16L1 (rs2241880) and IRGM (rs13361189 and rs4958847) genes polymorphism in CD and UC.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Our study included 557 CD and 425 UC patients and 672 ethnically matched Spanish controls and a meta-analysis with the data published to date. The polymorphisms were genotyped using predesigned TaqMan single nucleotide polymorphism genotyping assays.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; There was a statistically significant difference in the distribution of the ATG16L1 rs2241880 G allele between CD patients and controls in the Spanish population: P=6.5 x 10(-9), odds ratio (OR)=1.62. Although no differences were observed between UC patients and controls in the Spanish cohort, a meta-analysis demonstrated that the ATG16L1 G allele increase significantly risk for UC (P=0.0003, pooled OR=1.08). In addition, our meta-analysis data showed that IRGM rs13361189 and rs4958847 polymorphisms were associated with CD (rs13361189 C allele P=1.07 x 10(-19), pooled OR=1.34; rs4958847 A allele P=2.78 x 10(-17), pooled OR=1.31) and UC (rs13361189 P=0.0069, pooled OR=1.16; rs4958847 P=0.014, pooled OR=1.13).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Palomino-Morales RJ, Oliver J, Gómez-García M, López-Nevot MA, Rodrigo L, Nieto A, Alizadeh BZ, Martín J. Association of ATG16L1 and IRGM genes polymorphisms with inflammatory bowel disease: a meta-analysis approach. &lt;EM&gt;Genes Immun&lt;/EM&gt; 2009 Jun;10(4):356-64.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>380695</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1093/jnci/djp180]]&gt;</url>
    <title>Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis</title>
    <publicationDate>2009-08-05T00:00:00</publicationDate>
    <publisher>Oxford Journals</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,HEPATOCELLULAR CARCINOMA,RECENT ADDITIONS,CANCER,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Hepatitis B virus (HBV)&amp;nbsp;PreS mutations, C1653T, T1753V, and A1762T/G1764A are associated with an increased risk of hepatocellular carcinoma (HCC). These mutations alone and in combination may be predictive for hepatocarcinogenesis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; The association between HBV mutations and hepatocarcinogenesis remains controversial because of conflicting data in the literature. We conducted a meta-analysis of case-control and cohort studies to examine HBV PreS, enhancer II (EnhII), basal core promoter (BCP), and precore mutations in relation to the risk of HCC.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We searched databases for studies of these associations that were published in English or Chinese up to August 31, 2008. HBV mutation-specific odds ratios and relative risks were pooled by use of a random-effects model and stratified by potential confounders. All statistical tests were two-sided.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Of the 43 studies included in this meta-analysis, 40 used a case-control design. The 43 studies evaluated a total of 11 582 HBV-infected participants, of whom 2801 had HCC. Statistically significant summary odds ratios of HCC were obtained for any PreS mutation (3.77, 95% confidence interval [CI] = 2.57 to 5.52), C1653T in EnhII (2.76, 95% CI = 2.09 to 3.64), T1753V (2.35, 95% CI = 1.63 to 3.40), and A1762T/G1764A in BCP (3.79, 95% CI = 2.71 to 5.29). PreS mutations were more strongly associated with an increased risk of HCC in subjects who were infected with HBV genotype C than in those who were infected with HBV genotype B, whereas the opposite was true for A1762T/G1764A. C1653T, T1753V, and A1762T/G1764A were more strongly associated with an increased risk of HCC in hepatitis B e antigen (HBeAg)-positive subjects than in HBeAg-negative subjects. PreS mutations, C1653T, T1753V, and A1762T/G1764A accumulated during the progression of chronic HBV infection from the asymptomatic carrier state to HCC (P(trend) &amp;lt; .001 for each mutation). PreS mutations, C1653T, C1653T + T1753V, and A1762T/G1764A-based combinations of mutations had specificities greater than 80% for the prediction of HCC. The precore mutations G1896A and C1858T were not associated with the risk of HCC, regardless of HBeAg status and HBV genotype.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Liu S, Zhang H, Gu C, Yin J, He Y, Xie J, Cao G. Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. &lt;EM&gt;J Natl Cancer Inst&lt;/EM&gt; 2009;101(15):1066-82.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345511</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1007/s00439-009-0660-7]]&gt;</url>
    <title>ATG16L1 T300A polymorphism and Crohn's disease susceptibility: evidence from 13,022 cases and 17,532 controls</title>
    <publicationDate>2009-06-01T00:00:00</publicationDate>
    <publisher>Springer</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The G allele of ATG16L1 T300A is a low-penetrant gene for developing Crohn's&amp;nbsp;disease (CD)&amp;nbsp;in Caucasians.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Many studies have reported the association between the autophagy-related 16-like 1 gene (ATG16L1) T300A polymorphism (rs2241880) and CD susceptibility, but the results were inconclusive. To derive a more precise estimation of the relationship, a meta-analysis was performed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A total of 24 studies including 13,022 cases and 17,532 controls were included in this meta-analysis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Logistic regression analysis indicated that the ATG16L1 T300A polymorphism was associated with CD risk in Caucasians (P &amp;lt; 0.01). The pooled estimations of OR1 (GG vs. AA) and OR2 (GA vs. AA) in Caucasian studies by Bayesian meta-analysis method was [1.87, 95% confidence interval (CI) 1.69–2.05] and (1.39, 95% CI 1.27–1.51), respectively. The mode of heritance of the G allele was most likely to be co-dominant in Caucasians. However, no significant association was found in Asians.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Zhang HF, Qiu LX, Chen Y, Zhu WL, Mao C, Zhu LG, Zheng MH, Wang Y, Lei L, Shi J. ATG16L1 T300A polymorphism and Crohn's disease susceptibility: evidence from 13,022 cases and 17,532 controls. &lt;EM&gt;Hum Genet&lt;/EM&gt; 2009;125(5-6):627-31. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>322935</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1038/ajg.2009.301]]&gt;</url>
    <title>Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis</title>
    <publicationDate>2009-08-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Purine analogs are more effective than placebo in preventing both clinical and endoscopic postoperative recurrence in Crohn's disease (CD), but they are associated with a higher rate of adverse events leading to drug withdrawal.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We searched MEDLINE, the Cochrane Library, and EMBASE. The primary end points, clinical and endoscopic recurrence of CD at 1 and 2 years, and safety were analyzed by the methods of Peto and Der Simonian and Laird.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Four controlled trials enrolled 433 patients and compared azathioprine (&lt;I&gt;n&lt;/I&gt;=3) or (6-MP) (&lt;I&gt;n&lt;/I&gt;=1) with control arms (placebo with or without antibiotic induction therapy or mesalamine). In the overall analysis, purine analogs were more effective than control arms in preventing clinical recurrence at 1 year (mean difference, 95% confidence interval (CI): 8, 1–15%, &lt;I&gt;P&lt;/I&gt;=0.021, number needed to treat (NNT)=13) and 2 years (mean difference, 95% CI: 13%, 2–24%, &lt;I&gt;P&lt;/I&gt;=0.018, NNT=8). In sensitivity analyses, the efficacy of purine analogs was superior to that of placebo for the prevention of clinical and endoscopic recurrence at 1 year (mean differences, 95% CI: 13, 1.8–25%, &lt;I&gt;P&lt;/I&gt;=0.025, NNT=7, and 23%, 9–37%, &lt;I&gt;P&lt;/I&gt;=0.0016, NNT=4, respectively). At 1 year, in the overall analysis, purine analogs were more effective than control arms were in preventing severe (i2–4) endoscopic recurrence (mean difference, CI 95%: 15, 1.8–29%, &lt;I&gt;P&lt;/I&gt;=0.026, NNT=7), but they were not effective in the prevention of very severe (i3–4) recurrence. The rate of adverse events leading to drug withdrawal was higher in thiopurine-treated patients than in control arms (17.2 vs. 9.8%, respectively, &lt;I&gt;P&lt;/I&gt;=0.021).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Peyrin-Biroulet L, Deltenre P, Ardizzone S, D'Haens G, Hanauer SB, Herfarth H, Lémann M, Colombel JF. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis.&amp;nbsp;&lt;EM&gt;Am J Gastroenterol&lt;/EM&gt; 2009;104(8):2089-96.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>295259</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.bsg.org.uk/images/stories/docs/patients/aza_ibd_pt.doc]]&gt;</url>
    <title>Azathioprine/6-mercaptopurine treatment for IBD patients</title>
    <publicationDate></publicationDate>
    <publisher>British Society of Gastroenterology</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE,RECENT ADDITIONS,SEPTEMBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The British Society of Gastroenterology is an organisation focused on the promotion of gastroenterology within the United Kingdom. It has over three thousand members drawn from the ranks of physicians, surgeons, pathologists, radiologists, scientists, nurses, dietitians, and others interested in the field. Founded in 1937 it has grown from a club to be a major force in British medicine, with representation within the British Royal Colleges and thus to the Department of Health and Government. Internationally it is represented at World and European level. The BSG is a registered charity.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt; This document is one of a series designed to provide information for gastroenterologists, primary care clinicians and patients with IBD regarding the use of disease modifying drugs, their indications, side effects and guidelines for safe monitoring. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>259833</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.endoscopylearning.org.uk/non-variceal-upper-gi-bleeding.html]]&gt;</url>
    <title>Basic therapeutic endoscopy course: pre-course online lecture: non-variceal upper GI bleeding</title>
    <publicationDate></publicationDate>
    <publisher>Wolfson Unit for Endoscopy</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,DIAGNOSTIC PROCEDURES,GASTROINTESTINAL ENDOSCOPY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>An online video of a lecture on non-variceal upper GI bleeding, given by Dr Chris Fraser MB, ChB, MD, MRCP. This lecture is freely available to view online, and is part of the theory content of a Basic Therapeutic Endoscopy course provided by the Wolfson Unit for Endoscopy.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Summary: &lt;/STRONG&gt;An online video of a lecture on the principles of diathermy, given by Dr Chris Fraser MB, ChB, MD, MRCP. This lecture is freely available to view online, and is part of the theory content of a Basic Therapeutic Endoscopy course provided by the Wolfson Unit for Endoscopy. This course also contains a practical element, details of which are available from the Wolfson Unit for Endoscopy Basic&amp;nbsp;Therapeutic Endoscopy Course&amp;nbsp;website (see &lt;STRONG&gt;Related links&lt;/STRONG&gt;).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&amp;nbsp; Sound output required.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>259831</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.endoscopylearning.org.uk/oesophageal-dilatation-stenting.html]]&gt;</url>
    <title>Basic therapeutic endoscopy course: pre-course online lecture: oesophageal dilatation and stenting</title>
    <publicationDate></publicationDate>
    <publisher>Wolfson Unit for Endoscopy</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,DIAGNOSTIC PROCEDURES,GASTROINTESTINAL ENDOSCOPY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>An online video of a lecture on oesophageal dilatation and stenting, given by Dr Andrew V. Thillainayagam MD, FRCP. This lecture is freely available to view online, and is part of the theory content of a Basic Therapeutic Endoscopy course provided by the Wolfson Unit for Endoscopy.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Summary: &lt;/STRONG&gt;An online video of a lecture on oesophageal dilatation and stenting, given by Dr&amp;nbsp;Andrew V. Thillainayagam&amp;nbsp;MD, FRCP. This lecture is freely available to view online, and is part of the theory content of a Basic Therapeutic Endoscopy course provided by the Wolfson Unit for Endoscopy. This course also contains a practical element, details of which are available from the Wolfson Unit for Endoscopy Basic&amp;nbsp;Therapeutic Endoscopy Course&amp;nbsp;website (see &lt;STRONG&gt;Related links&lt;/STRONG&gt;).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&amp;nbsp; Sound output required.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>259839</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.endoscopylearning.org.uk/peg-pegj.html]]&gt;</url>
    <title>Basic therapeutic endoscopy course: pre-course online lecture: PEG &amp; PEGJ: kill or cure</title>
    <publicationDate></publicationDate>
    <publisher>Wolfson Unit for Endoscopy</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,DIAGNOSTIC PROCEDURES,GASTROINTESTINAL ENDOSCOPY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>An online video of a lecture on PEG and PEGJ, given by Dr Simon Gabe MD, MSc, BSc, MBBS, MRCP. This lecture is freely available to view online, and is part of the theory content of a Basic Therapeutic Endoscopy course provided by the Wolfson Unit for Endoscopy.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Summary: &lt;/STRONG&gt;An online video of a lecture on PEG and PEGJ, given by Dr Simon Gabe MD MSc BSc MBBS MRCP. This lecture is freely available to view online, and is part of the theory content of a Basic Therapeutic Endoscopy course provided by the Wolfson Unit for Endoscopy. This course also contains a practical element, details of which are available from the Wolfson Unit for Endoscopy Basic&amp;nbsp;Therapeutic Endoscopy Course&amp;nbsp;website (see &lt;STRONG&gt;Related links&lt;/STRONG&gt;).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&amp;nbsp; Sound output required.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>259823</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.endoscopylearning.org.uk/principles-diathermy.html]]&gt;</url>
    <title>Basic therapeutic endoscopy course: pre-course online lecture: principles of diathermy</title>
    <publicationDate></publicationDate>
    <publisher>Wolfson Unit for Endoscopy</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,DIAGNOSTIC PROCEDURES,GASTROINTESTINAL ENDOSCOPY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>An online video of a lecture on the principles of diathermy, given by Dr Brain Saunders MD, FRCP. This lecture is freely available to view online, and is part of the theory content of a Basic Therapeutic Endoscopy course provided by the Wolfson Unit for Endoscopy.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Summary: &lt;/STRONG&gt;An online video of a lecture on the principles of diathermy, given by Dr Brain Saunders MD, FRCP. This lecture is freely available to view online, and is part of the theory content of a Basic Therapeutic Endoscopy course provided by the Wolfson Unit for Endoscopy. This course also contains a practical element, details of which are available from the Wolfson Unit for Endoscopy Basic&amp;nbsp;Therapeutic Endoscopy Course&amp;nbsp;website (see &lt;STRONG&gt;Related links&lt;/STRONG&gt;).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&amp;nbsp; Sound output required.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>339166</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/01January/Pages/Appendicitis-and-viral-infection.aspx]]&gt;</url>
    <title>Behind the headlines - Appendicitis cause still a mystery</title>
    <publicationDate>2010-01-19T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,INFECTIONS,RECENT ADDITIONS,APPENDICITIS,JANUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Appendicitis may be triggered by a viral infection,” reported the Daily Mail. The newspaper said that the same researchers who made this claim also suggested that non-perforated appendicitis (where the appendix has not burst) may not always warrant surgery.&lt;/P&gt;
&lt;P&gt;This news story is based on a study of hospital discharge records for patients with influenza, rotavirus and appendicitis over a 36-year period in the US. The number of viral infections and perforated and non-perforated cases of appendicitis were analysed to see if they had similar enough patterns of prevalence to suggest an association between the two.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This research found some evidence of a similar incidence pattern of flu and appendicitis over the last 36 years in the US, but this is not enough to suggest that a virus causes appendicitis. One finding that merits further research is the different incidence patterns between perforated appendicitis and non-perforating appendicitis.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/01January/Pages/Appendicitis-and-viral-infection.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Alder AC, Fomby TB, Woodward WA, et al. &lt;A href="http://dx.doi.org/10.1001/archsurg.2009.250" target="_blank"&gt;Association of Viral Infection and Appendicitis.&lt;/A&gt; &lt;EM&gt;Arch Surg&lt;/EM&gt; 2010;145:63-71.&lt;/P&gt;
&lt;P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>305162</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/01January/Pages/Aspirinandliverdamage.aspx]]&gt;</url>
    <title>Behind the headlines - 'Aspirin a day' for the liver</title>
    <publicationDate>2009-01-28T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,JANUARY 2009,RECENT ADDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Summary: &lt;/STRONG&gt;“An aspirin a day could help prevent liver damage caused by obesity, heavy drinking and drug use,” &lt;EM&gt;The Daily Telegraph&lt;/EM&gt; reports. The newspaper says that “millions of people susceptible to liver problems could have their lives prolonged by the painkiller”. It reports that a study in mice found that aspirin lessened the damage caused by paracetamol overdose. The researchers are reported to believe the drug could do the same for other types of liver damage.&lt;/P&gt;
&lt;P&gt;The newspaper has greatly over-inflated the implications of this study. Although the research gives a better understanding of the effects of paracetamol on the liver in mice, it is not yet clear whether these findings apply to humans.&lt;/P&gt;
&lt;P&gt;Liver disease and liver damage are broad terms and cover a large&amp;nbsp;array of conditions. For example, the damage caused by a paracetamol overdose is different to the fatty or fibrotic liver changes that are the result of alcohol abuse or obesity. Whether aspirin has any effect on other causes of liver disease or damage is unclear. This study’s findings do not support the suggestion that people should regularly take aspirin in the hope of warding off liver damage.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication information: &lt;/STRONG&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Citation of original study:&lt;/STRONG&gt; Imaeda AB, Watanabe A, Sohail MA et al. Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. J Clin Invest 2009; Published online January 26&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>313834</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/04April/Pages/Aspirincutscancerrisk.aspx]]&gt;</url>
    <title>Behind the headlines - Aspirin 'cuts' cancer risk</title>
    <publicationDate>2009-04-30T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,DISEASE PREVENTION,CANCER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Daily aspirin in your 40s 'can cut risk of cancer later in life' reported &lt;EM&gt;The Daily Telegraph&lt;/EM&gt;. The newspaper said that people who take the cheap painkiller for 10 years can reduce their risk of breast and bowel cancer. It said that experts say taking aspirin in your mid-40s could be the "best time to stop the disease progressing into full-blown cancer in your sixties”.&lt;/P&gt;
&lt;P&gt;The study underlying this report is a review of what is currently known about the benefits, risks and uncertainties of taking aspirin and similar drugs. It found that although research suggests that aspirin can cut the risk of some cancers, it is not currently recommended due to the risk of side effects such as internal bleeding. This risk is compounded by the fact that common cancers tend to develop after the age of 60, when the risk of aspirin causing internal bleeding is at its highest.&lt;/P&gt;
&lt;P&gt;The experts conclude that, “only treatment with aspirin combines the benefit of protection against cardiovascular disease with the potential to reduce the risk of some types of cancer, but that more randomised trials are essential.” This seems reasonable considering the current state of knowledge.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This paper does not claim to be a comprehensive review of the literature but may be interesting for those needing to decide whether to take aspirin or not. Aspirin is already known to benefit people with heart disease, so an additional benefit in preventing cancer would be a welcome bonus for people already taking on the small risk of bleeding. However, uncertainties remain, especially about the appropriate dose to take and at what age any preventive treatment should begin. Large, long-term studies would help to resolve these uncertainties.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/04April/Pages/Aspirincutscancerrisk.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, Jankowski J, La Vecchia C, Meyskens F, Senn HJ, Thun M. &lt;A href="http://dx.doi.org/10.1016/S1470-2045(09)70035-X" target="_blank"&gt;Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement.&lt;/A&gt;&lt;EM&gt; Lancet Oncol&lt;/EM&gt; 2009;10(5):501-7.&lt;/P&gt;
&lt;P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>306176</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/02February/Pages/Aspirincancer.aspx]]&gt;</url>
    <title>Behind the headlines - Aspirin 'cuts stomach cancer'</title>
    <publicationDate>2009-02-06T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,STOMACH,CANCER,DISEASE PREVENTION,RECENT ADDITIONS,FEBRUARY 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt; “Taking aspirin just once a year could lower the risk of stomach cancer by more than a third,” says the &lt;EM&gt;Daily Mail &lt;/EM&gt;in one of several media reports claiming that aspirin can cut the risk of developing the disease. &lt;/P&gt;
&lt;P&gt;The study behind these reports followed over 300,000 people aged over 50 for seven years, comparing their use of aspirin and other types of pain-relief drugs with rates of stomach and oesophagus cancer. The researchers found that the risk of a certain type of stomach cancer was 36% lower among people who had used aspirin at least once in the previous 12 months. &lt;/P&gt;
&lt;P&gt;While the researchers did find that stomach cancer risk was reduced 36% in those who took any aspirin, this result applied to the group overall, not necessarily to the group that used aspirin infrequently, as newspaper reports might imply. In fact, this was a dose-response benefit, meaning that more frequent use of aspirin had a more protective effect against cancer. &lt;/P&gt;
&lt;P&gt;Although taking aspirin can have benefits, high-frequency use can increase the risk of serious health problems. The researchers themselves caution against daily aspirin use, saying that “the expected benefits do not outweigh the risks” for the general population. Members of the public should consult their doctor before regularly taking aspirin on the basis of this study or subsequent media reports.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication information: &lt;/STRONG&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Citation of original study:&lt;/STRONG&gt; Abnet CC, Freedman ND, Kamangar F et al. &lt;A href="http://dx.doi.org/10.1038/sj.bjc.6604880" target="_blank"&gt;Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis&lt;/A&gt;. Br J Cancer 2009; 100, 551–557&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>372906</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/04April/Pages/new-bowel-cancer-screening-test.aspx]]&gt;</url>
    <title>Behind the headlines - Bowel test 'slashes cancer deaths'</title>
    <publicationDate>2010-04-28T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,DIAGNOSTIC PROCEDURES,GASTROINTESTINAL ENDOSCOPY,DISEASE PREVENTION,CANCER,SCREENING,RECENT ADDITIONS,APRIL 2010,COLON CANCER,RECTAL CANCER,FLEXIBLE SIGMOIDOSCOPY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;A new bowel cancer test “cuts deaths by 40 per cent”, according to &lt;EM&gt;The Daily Telegraph.&lt;/EM&gt; The newspaper estimates that offering the brief, one-off test to people aged 55 could save 3,000 lives a year and prevent a further 5,000 people from developing bowel cancer. &lt;/P&gt;
&lt;P&gt;Several other newspapers also reported the results of a well-conducted, landmark trial into the screening test, which involves inserting a flexible camera into the bowel to check for abnormal growths (polyps) that may become cancerous. Those who attended screening were 33% less likely to develop bowel cancer and 43% less likely to die from it than those not invited for screening. &lt;/P&gt;
&lt;P&gt;Several aspects of this test need consideration, such as the relatively low uptake rate (only 53% of those who were approached attended screening) and the invasive method used. However, bowel cancer is the third most common type of cancer in England, affecting around 31,000 people and causing around 13,000 deaths each year. Given this test’s potential to save thousands of lives through early treatment, its overall benefits seem clear.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This well-conducted, landmark trial investigated the effect of inviting healthy adults with an average age of 60 to attend a one-off lower-bowel examination, using flexible sigmoidoscopy, to screen for cancer.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/04April/Pages/new-bowel-cancer-screening-test.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Atkin WS, Edwards R, Kralj-Hans I, Woodrage K, Hart AR, Northover JMA, Parkin DM, Wardle J, Duffy SW, Cuzick J, UK Flexible Sigmoidoscopy Trial Investigators. &lt;A href="http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)60551-X/fulltext" target="_blank"&gt;Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial&lt;/A&gt;. &lt;EM&gt;Lancet&lt;/EM&gt; 28 April 2010 (early online publication).&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>311418</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/04April/Pages/Broccolisproutscutgutinfection.aspx]]&gt;</url>
    <title>Behind the headlines - Broccoli sprouts 'cut gut infection'</title>
    <publicationDate>2009-04-06T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,STOMACH,DISEASE PREVENTION,DIET,HELICOBACTER PYLORI,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Eating a daily portion of broccoli sprouts could help tame the &lt;EM&gt;H. pylori&lt;/EM&gt; bacteria, linked to stomach ulcers and even cancer,” BBC News reported. It said that research in 50 people in Japan found eating broccoli sprouts might give some protection. The news service continued that UK experts said while the vegetable may have an effect on levels of the bacteria, it probably made no difference to the risk of cancer.&lt;/P&gt;
&lt;P&gt;This research involved both mice and humans infected with Helicobacter pylori and fed a diet of broccoli sprouts, which contain high levels of the compound sulforaphane (SF). Previous research has demonstrated that SF kills the &lt;EM&gt;H. pylori&lt;/EM&gt; bacteria and enhances antioxidant and anti-inflammatory enzymes. This research found that mice fed broccoli sprouts had reduced stomach inflammation. In a trial in humans, a diet of SF-rich broccoli sprouts also reduced &lt;EM&gt;H. pylori&lt;/EM&gt; levels.&lt;/P&gt;
&lt;P&gt;The findings are promising but more research is needed to determine the possible implications for human illness, particularly cancer. At present, &lt;EM&gt;H. pylori&lt;/EM&gt; infection is effectively treated with a combination of antibiotics and stomach acid-reducing treatments.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;What does NHS Choices make of this study?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;This research involved both mice and humans that had been infected with &lt;EM&gt;H. pylori&lt;/EM&gt; and fed a diet of SF-rich broccoli sprouts. It demonstrated that SF appeared to reduced stomach inflammation and &lt;EM&gt;H. pylori&lt;/EM&gt; levels. It is not known whether this was due to SF-induced inhibition of &lt;EM&gt;H. pylori&lt;/EM&gt; colonisation (its bacteria-killing effects), or to increased Nrf2-dependent anti-inflammatory and antioxidant enzyme activity or by some combination of these two modes of protection.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/04April/Pages/Broccolisproutscutgutinfection.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Yanaka A, Fahey JW, Fukumoto A, Nakayama M, Inoue S, Zhang S, &lt;A href="http://dx.doi.org/10.1158/1940-6207.CAPR-08-0192" target="_blank"&gt;Tauchi M, Suzuki H, Hyodo I, Yamamoto M. Dietary sulforaphane-rich broccoli sprouts reduce colonization and attenuate gastritis in Helicobacter pylori-infected mice and humans.&lt;/A&gt; &lt;EM&gt;Cancer Prev Res&lt;/EM&gt; 2009;2(4):353-60.&lt;/P&gt;
&lt;P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>346823</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/03March/Pages/Can-curcumin-slow-liver-disease.aspx]]&gt;</url>
    <title>Behind the headlines - Can curcumin slow liver disease?</title>
    <publicationDate>2010-03-25T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,BILIARY TREE &amp; GALLBLADDER,CHOLANGITIS,PRIMARY SCLEROSING CHOLANGITIS,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Curry favour for your liver,” is the headline in the &lt;EM&gt;Daily Mirror.&lt;/EM&gt; The newspaper said that mice fed curcumin (the chemical in turmeric that gives curry a yellow colour) had less liver damage over time than those on a normal diet.&lt;/P&gt;
&lt;P&gt;The researchers in this animal study investigated how an extract of the spice protected mice that had been bred to have inflammation in their bile ducts from liver damage.&lt;/P&gt;
&lt;P&gt;The results suggest that liver damage, jaundice and scarring were all reduced by the curcumin and that the underlying cellular pathways affected might, in time, become promising targets for new drug development. However, there is no suggestion from this study that eating turmeric will have the same effect or be a useful treatment for humans.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;What does NHS Choices make of this study?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;This well-conducted animal and laboratory study has identified cellular targets for new drug development. The theories are at an early stage and it is too soon to say that any new treatments might be developed from the spice. However, researchers will welcome these findings as they give a clear direction for new study into treatments for these severe and hard-to-treat conditions.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/03March/Pages/Can-curcumin-slow-liver-disease.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Baghdasaryan A, Claudel T, Kosters A, Gumhold J, Silbert D, Thüringer A, Leski K, Fickert P, Karpen SJ, Trauner M. &lt;A href="http://dx.doi.org/10.1136/gut.2009.186528" target="_blank"&gt;Curcumin improves sclerosing cholangitis in Mdr2-/- mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation.&lt;/A&gt; &lt;EM&gt;Gut &lt;/EM&gt;2010;59(4):521-30.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>387986</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/09September/Pages/preventable-colon-cancer-set-to-rise.aspx]]&gt;</url>
    <title>Behind the headlines - Colon cancer predicted to rise</title>
    <publicationDate>2010-09-15T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,CANCER,RECENT ADDITIONS,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Colon cancer cases may rise 50%,” BBC News reported. The website said factors such as increasing levels of obesity and inactivity could drive cases up from 23,000 a year to 35,000 annual cases by the year 2040.&lt;/P&gt;
&lt;P&gt;This report was based on a study that made projections of future levels of colorectal cancer if obesity and physical activity remain at their current levels. It compared these projections to hypothetical situations where everyone had optimum weight and exercise levels. An optimum body mass index (BMI) was predicted to reduce cases of colorectal cancer by up to 18.2% in men and 4.6% in women.&amp;nbsp; Optimum physical activity levels could reduce the risk by 11.6% in men and 21.2% in women.&lt;/P&gt;
&lt;P&gt;This was a hypothetical model and these figures are only estimates that need further confirmation. However, in general, it is well established that maintaining a healthy weight, eating a balanced diet, getting enough exercise and avoiding smoking and excess alcohol are the best ways to remain healthy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;What does NHS Choices make of this study?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;This modelling study has made projections on how the future incidence of colorectal cancer could be affected by modifying obesity and physical activity levels in the population. It compared these optimum situations with current trends of obesity and inactivity and found that if everyone in the population had an optimum BMI, it would reduce incidence of colorectal cancer by up to 18.2% in men and 4.6% in women. If everyone did the recommended amount of physical activity, it could reduce colorectal cancer by up to 11.6% in men and 21.2% in women.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/09September/Pages/preventable-colon-cancer-set-to-rise.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;de Vries E, Soerjomataram I, Lemmens VE, Coebergh JW, Barendregt JJ, Oenema A, Møller H, Brenner H, Renehan AG. &lt;A href="http://dx.doi.org/10.1016/j.ejca.2010.07.040" target="_blank"&gt;Lifestyle changes and reduction of colon cancer incidence in Europe: A scenario study of physical activity promotion and weight reduction.&lt;/A&gt; &lt;EM&gt;Eur J Cancer&lt;/EM&gt; 2010;46(14):2605-2616.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>328289</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/10October/Pages/turmeric-curry-spice-cancer-treatment.aspx]]&gt;</url>
    <title>Behind the headlines - Curry spice kills cancer cells</title>
    <publicationDate>2009-10-28T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,CANCER,OESOPHAGUS,OCTOBER 2009,RECENT ADDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Extracts from the yellow curry spice turmeric can kill off cancer cells, according to BBC News. New research from the Cork Cancer Research Centre shows that the extract can destroy oesophagus cancer cells in a lab.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Extracts from the yellow curry spice turmeric can kill off cancer cells, according to BBC News. New research from the Cork Cancer Research Centre shows that the extract can destroy oesophagus cancer cells in a lab. &lt;/P&gt;
&lt;P&gt;Oesophageal cancer cells are often resistant to cell death (the aim of chemotherapy), so in this laboratory study the researchers investigated the effects of curcumin (the active extract from turmeric) on a range of different types of cancer cells from the gullet. Introducing the chemical induced a type of cell death, called mitotic catastrophe. &lt;/P&gt;
&lt;P&gt;While it is too soon to call this a cure for cancer, the findings pave the way for further investigations into the potential of plant-derived substances that are able to induce cell death in cancer cells. This could be particularly important for treating cancers that have so far proved resistant to chemotherapy.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This laboratory study exposed various different lines of oesophageal cancer to the chemical curcumin, which is an extract from the spice turmeric commonly used in Indian cooking.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/10October/Pages/turmeric-curry-spice-cancer-treatment.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;O'Sullivan-Coyne G, O'Sullivan G, O'Donovan TR et al. &lt;A href="http://dx.doi.org/10.1038/sj.bjc.6605308" target="_blank"&gt;Curcumin induces apoptosis-independent death in oesophageal cancer cells.&lt;/A&gt; British Journal of Cancer [advance online publication] October 6 2009&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>322919</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/07July/Pages/DietCausesUlcerativeColitis.aspx]]&gt;</url>
    <title>Behind the headlines - Diet 'causes bowel disease'</title>
    <publicationDate>2009-07-27T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,DISEASE PREVENTION,DIET,RECENT ADDITIONS,AUGUST 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A high intake of polyunsaturated fat “may lead to inflammatory bowel disease”, BBC News has reported. According to the website, experts believe that a high intake of linoleic acid, found in foods such as margarines may be implicated in a third of ulcerative colitis cases.</description>
    <body>&lt;![CDATA[ &lt;P&gt;A high intake of polyunsaturated fat “may lead to inflammatory bowel disease”, BBC News&amp;nbsp;has reported. According to the website, experts believe that a high intake of linoleic acid, found in foods such as margarines may be implicated in a third of ulcerative colitis cases.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;The study underlying this report looked at the diet and lifestyle of over 200,000 people and compared those who developed ulcerative colitis with a sample of those who remained healthy. It found that dietary linoleic acid may play a role in the development of ulcerative colitis. The findings need confirmation in studies of a more robust design as there are some shortcomings with this methodology. However, the results show a ‘dose-response’ relationship, with a higher dose of linoleic acid linked with an increased risk of disease. This supports the idea of a causal relationship.&lt;/P&gt;
&lt;P&gt;Even if a causal link between linoleic acid and ulcerative colitis is confirmed, the disease is complex and there are likely to be other factors playing a part too: even this study found that the highest intake levels when grouped were responsible for only 30% of the cases seen. It is important to note that ulcerative colitis is rare, affecting only 1 in 1600 subjects in this study.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This nested case-control study provides some evidence of a link between intake of linoleic acid and the risk of ulcerative colitis. Importantly, only a small number of people developed this disease over the follow-up period in this study showing that regardless of diet, the disease is a rare one. &lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/07July/Pages/DietCausesUlcerativeColitis.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Hart AR. &lt;A href="http://dx.doi.org/10.1136/gut.2008.169078" target="_blank"&gt;Linoleic Acid, a Dietary N-6 Polyunsaturated Fatty Acid, and the Aetiology of Ulcerative Colitis - A European Prospective Cohort Study&lt;/A&gt;. &lt;EM&gt;Gut &lt;/EM&gt;2009 Jul.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>374946</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/05May/Pages/probiotic-yogurt-and-child-infections.aspx]]&gt;</url>
    <title>Behind the headlines - Do probiotic yoghurts cut child illness?</title>
    <publicationDate>2010-05-19T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COMMON CLINICAL PRESENTATIONS,STOMACH,GASTRITIS,NAUSEA &amp; VOMITING,SMALL INTESTINE,DIARRHOEA,DISEASE PREVENTION,PROBIOTICS,INFECTIONS,DIETARY SUPPLEMENTS,RECENT ADDITIONS,INFECTIONS,ENTERITIS,MAY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“A daily probiotic drink can help protect young children against infections,” reported &lt;EM&gt;The Daily Telegraph.&lt;/EM&gt; It said that children who start the day with a probiotic drink are 20% less likely than their classmates to suffer from ear and sinus infections.&lt;/P&gt;
&lt;P&gt;This is a well-designed, randomised controlled trial, but the results are less significant than the headlines might imply. The study, sponsored by Danone, was in 638 healthy three to six year olds. The children were either given Actimel or an identical, inactive yoghurt drink every day for about three months. There was no change in the behaviour due to illness (as assessed by parents), but children in the probiotic group had slightly fewer common infections.&lt;/P&gt;
&lt;P&gt;The newspaper has correctly reported the findings of this research. However, the results are only of borderline significance, and symptoms of illness were reported by the children’s parents, then interpreted by the researchers. Although the relative difference in rates of disease between the groups sounds high (19%), the absolute effects are quite small. If one child took the yoghurt every day for&amp;nbsp;100 days, they would have two fewer incidences of common infectious disease compared to those who were taking the placebo.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This is a well-designed randomised controlled trial. The active and control groups were mostly similar, which indicates that the randomisation had been successful. There was a significant difference between the groups in compliance to the drink they had been given, with the control group not being as compliant. However, the researchers say this is unlikely to have been because the participants knew which group they had been assigned to.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/05May/Pages/probiotic-yogurt-and-child-infections.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Merenstein D, Murphy M, Fokar A, Hernandez RK, Park H, Nsouli H, Sanders ME, Davis BA, Niborski V, Tondu F, Shara NM.&amp;nbsp;&lt;A href="http://www.nature.com/ejcn/journal/vaop/ncurrent/full/ejcn201065a.html" target="_blank"&gt;Use of a fermented dairy probiotic drink containing Lactobacillus casei (DN-114 001) to decrease the rate of illness in kids: the DRINK study A patient-oriented, double-blind, cluster-randomized, placebo-controlled, clinical trial&lt;/A&gt;. &lt;EM&gt;European Journal of Clinical Nutrition&lt;/EM&gt; 2010; advance online publication May 19&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>386542</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/08August/Pages/Does-broccoli-aid-gut-problems.aspx]]&gt;</url>
    <title>Behind the headlines - Does broccoli aid gut problems?</title>
    <publicationDate>2010-08-27T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE,RECENT ADDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;"Eating broccoli and plantain could reduce bouts of Crohn’s disease,” reported The Daily Telegraph. It said researchers have found that certain types of soluble fibre from these plants can help to prevent bacteria from sticking to the gut's walls, thereby limiting the progress of the disease.&lt;/P&gt;
&lt;P&gt;This study looked at whether fibres from various edible plants affected the transport of E. coli bacteria across specialised cells found in the lining of the bowel. The researchers also looked at whether substances called emulsifiers (commonly found in processed foods) altered the transfer of bacteria across these cells.&lt;/P&gt;
&lt;P&gt;They found that fibres from broccoli and plantain reduced the transmission of bacteria across cells by between 45% and 82%, while leek and apple fibres had no effect. One emulsifier, called polysorbate 80, seemed to increase the transmission of bacteria across these cells.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This carefully conducted laboratory study indicates that soluble fibres from certain plant foods can reduce the transport of E coli strains associated with Crohn’s, and their transfer across specialised cells of the bowel lining. It also shows that one emulsifier used in food processing has the opposite effect, by increasing transport.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/08August/Pages/Does-broccoli-aid-gut-problems.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Roberts Cl, Keita AV, Duncan SH, et al. Translocation of Crohn’s disease Escherichia coli across M-cells: contrasting effects of soluble plant fibres and emulsifiers. Gut 2010; online first &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>378370</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/06June/Pages/stem-cells-grow-transplant-liver.aspx]]&gt;</url>
    <title>Behind the headlines - Early work on lab-grown liver tissue</title>
    <publicationDate>2010-06-14T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,LIVER TRANSPLANTATION,RECENT ADDITIONS,SURGERY,JUNE 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Grow-your-own organs” could soon be a reality, claims the &lt;EM&gt;Daily Mail,&lt;/EM&gt; which says that “scientists have grown a liver in a laboratory” using stem cells. The newspaper says the research could offer “fresh hope to hundreds of thousands of patients with diseased and damaged organs”.&lt;/P&gt;
&lt;P&gt;This was innovative research, albeit at a very early stage. However, many newspapers have overstated the significance of the findings at this time, and it is too soon to proclaim this as a solution to the shortage of suitable organs for transplants. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This laboratory study has developed a way of establishing a cellular scaffold that both retains the basic underlying structure of the liver and allows seeding with new cells to establish a potentially viable liver graft. This innovative research is a big initial step towards overcoming some of the problems that make the development of engineered tissue transplants such a challenge. It is likely that the methods that these researchers have developed will pave the way for further research in this area, and may one day lead to technologies that can be studied in humans.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/06June/Pages/stem-cells-grow-transplant-liver.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Uygun BE, Soto-Gutierrez A, Yagi H, Izamis ML, Guzzardi MA, Shulman C, Milwid J, Kobayashi N, Tilles A, Berthiaume F, Hertl M, Nahmias Y, Yarmush ML, Uygun K. &lt;A href="http://www.nature.com/nm/journal/vaop/ncurrent/full/nm.2170.html" target="_blank"&gt;Organ reengineering through development of a transplantable recellularized liver graft using decellularized liver matrix&lt;/A&gt;. &lt;EM&gt;Nat Med &lt;/EM&gt;2010 Jun 13. [Epub ahead of print]&lt;/P&gt;
&lt;P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>306353</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/02February/Pages/Coloncancerexercise.aspx]]&gt;</url>
    <title>Behind the headlines - Exercise cuts bowel cancer</title>
    <publicationDate>2009-02-12T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,DISEASE PREVENTION,CANCER,FEBRUARY 2009,RECENT ADDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Summary: &lt;/STRONG&gt;“Regular exercise can cut your risk of colon cancer by a quarter,” reported the &lt;EM&gt;Daily Mail &lt;/EM&gt;today.&amp;nbsp; The newspaper said that even walking reduces the likelihood of developing one of the most common cancers, which is diagnosed in more than 35,000 people the UK.&lt;/P&gt;
&lt;P&gt;The stories are based on a detailed analysis of 52 studies from the past 25 years. The review, which contained details from several thousand cases of colon cancer, showed that those people who were most active were 24% less likely to develop the disease than the least active individuals.&lt;/P&gt;
&lt;P&gt;This is a high-quality review, and looked at all sorts of activity from brisk walking to jogging and heavy manual labour. It has shown that activity was linked to a reduced risk of colon cancer, and that the benefits of exercise were similar for men and women. This protection remained even after the other risk factors measured in the study, such as diet, obesity and smoking, were taken into account.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication information: &lt;/STRONG&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Citation of original study:&lt;/STRONG&gt;&amp;nbsp;Wolin KY, Yan Y, Colditz GA and Lee I-M. &lt;A href="http://dx.doi.org/10.1038/sj.bjc.6604917" target="_blank"&gt;Physical activity and colon cancer prevention: a meta-analysis.&lt;/A&gt; &lt;EM&gt;Br J Cancer,&lt;/EM&gt; [advance online publication] 10 February 2009&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>332640</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/11November/Pages/diets-lose-weight-health-problems.aspx]]&gt;</url>
    <title>Behind the headlines - Fad diets 'make you gain weight'</title>
    <publicationDate>2009-11-23T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COMMON CLINICAL PRESENTATIONS,DISEASE PREVENTION,DIET,OBESITY,RECENT ADDITIONS,DECEMBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Fad diets make you fat,” according to the &lt;EM&gt;Daily Express&lt;/EM&gt;, which said that many quick fixes for obesity are “doomed to end in failure”.&lt;/P&gt;
&lt;P&gt;The claim was based on a conference presentation being given by Professor Chris Hawkey, president of the British Society of Gastroenterology. The newspaper quotes a press release on his talk, which says that people should avoid extreme food regimes based on “theory rather than evidence”. These include only eating grapefruit and&amp;nbsp; the Victorian practice of chewing each mouthful of food 32 times.&lt;/P&gt;
&lt;P&gt;While people may turn to extreme diets to lose weight, the most well-established way to maintain both good health and an ideal body weight is to adopt a balanced diet, take regular exercise, not smoke and limit alcohol consumption.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;There are numerous well-documented benefits associated with a healthy, balanced diet. These include preventing long-term illnesses, increasing lifespan and improving cardiovascular health. Consuming a healthy diet, doing regular exercise, not smoking and limiting alcohol are the most well-established ways of maintaining both good health and a healthy body weight. &lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/11November/Pages/diets-lose-weight-health-problems.aspx" target="_blank"&gt;NHS Choices commentary on&lt;/A&gt; this news item. &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>322917</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/08August/Pages/FizzyDrinksFattyLiver.aspx]]&gt;</url>
    <title>Behind the Headlines - fatty liver from fizzy drinks?</title>
    <publicationDate>2009-08-12T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,NON-ALCOHOLIC,DISEASE PREVENTION,DIET,RECENT ADDITIONS,FATTY LIVER,AUGUST 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>“Two soft drinks a day may lead to long term liver damage”, The Daily Telegraph has reported. The newspaper said that a new study has found that, like the known risks that alcohol poses to the liver, fizzy drinks with a high sugar content can increase a person’s risk of developing fatty liver disease.</description>
    <body>&lt;![CDATA[ &lt;P&gt;“Two soft drinks a day may lead to long term liver damage”, &lt;EM&gt;The Daily Telegraph&lt;/EM&gt; has reported. The newspaper said that a new study has found that, like the known risks that alcohol poses to the liver, fizzy drinks with a high sugar content can increase a person’s risk of developing fatty liver disease.&lt;/P&gt;
&lt;P&gt;This small study looked at 60 patients with non-alcoholic fatty liver disease (NAFLD), comparing their soft-drink habits, dietary intake, and blood markers of inflammation and insulin resistance to 18 controls without liver disease. The study found much higher levels of soft-drink consumption in those with NAFLD compared to those without.&lt;/P&gt;
&lt;P&gt;Obesity, high blood sugar, high blood pressure and high cholesterol are all features of metabolic syndrome, a condition associated with NAFLD. Therefore, it seems plausible that someone who consumes more sugary drinks may have other health behaviours and risk factors that contribute to NAFLD risk. Limitations in the study design and certain statistical adjustment methods mean that the work cannot prove that soft drinks alone are the cause of fatty liver. The full report of the research will be of interest when it is published later this year.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;What does NHS Choices make of this study?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;This small study looked at 60 patients with non-alcoholic fatty liver disease (NAFLD), with or without metabolic syndrome, and 18 controls without liver disease. It questioned their dietary intake and examined blood markers of inflammation and insulin resistance.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/08August/Pages/FizzyDrinksFattyLiver.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;Abed A, Nseir W, Ali T, Dabush S, Grosovski M, Assy N. &lt;A href="http://download.journals.elsevierhealth.com/pdfs/journals/0168-8278/PIIS0168827809609788.pdf" target="_blank"&gt;Soft drink consumption linked with fatty liver independently by metabolic syndrome&lt;/A&gt;.&amp;nbsp;&lt;EM&gt;J Hepatol&lt;/EM&gt;&amp;nbsp;2009 Apr;50(S1):S354.&amp;nbsp; 
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>313034</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/04April/Pages/FlatSoftDrinksStomachBugs.aspx]]&gt;</url>
    <title>Behind the headlines - Flat coke for tummy bugs 'myth'</title>
    <publicationDate>2009-04-22T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COMMON CLINICAL PRESENTATIONS,STOMACH,GASTRITIS,NAUSEA &amp; VOMITING,SMALL INTESTINE,DIARRHOEA,DISEASE PREVENTION,INFECTIONS,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Doctors have warned that ‘flat Coke or lemonade could be dangerous to children suffering stomach bugs’ the &lt;EM&gt;Daily Mail&lt;/EM&gt; has reported. It said new NHS guidance warns that the‘myth that sweet drinks can rehydrate sick children can actually make symptoms worse.&lt;/P&gt;
&lt;P&gt;This story is based on new guidelines issued by&amp;nbsp;National Institute of Health and Clinical Excellence (NICE) for the treatment of children under five with gastroenteritis. One of the recommendations is that children with mild diarrhoea and vomiting be given water or rehydrating salt solutions and not carbonated drinks or fruit juice. NICE believes some of the most serious cases could be avoided if parents and GPs followed the best advice early on.&lt;/P&gt;
&lt;P&gt;Most children with gastroenteritis can be safely managed at home. Parents and carers should follow the advice and keep children under five hydrated by encouraging fluid intake through water and milk, and to discourage fruit juices and carbonated drinks. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;There is a popular belief that carbonated drinks such as cola or lemonade that have gone ‘flat’ can help settle stomachs. These guidelines say that the evidence does not support the use of carbonated drinks, lemonade or fruit juice as alternatives to commercially produced oral rehydration solutions (ORS). These solutions were considered the appropriate fluid for oral rehydration.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/04April/Pages/FlatSoftDrinksStomachBugs.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.nice.org.uk/Guidance/CG84" target="_blank"&gt;Management of acute diarrhoea and vomiting due to gastoenteritis in children under 5.&lt;/A&gt;&amp;nbsp;NICE 2009&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>318492</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/06June/Pages/Antiobesitysurgerycancerrates.aspx]]&gt;</url>
    <title>Behind the headlines - Gastric bands and cancer rates</title>
    <publicationDate>2009-06-24T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COMMON CLINICAL PRESENTATIONS,STOMACH,OBESITY,RECENT ADDITIONS,JUNE 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;‘Gastric bands can cut cancer risk by one third,’ &lt;EM&gt;The Daily Telegraph&lt;/EM&gt; has said. The newspaper says that research following people for 11 years after anti-obesity surgery found that women’s risk of developing cancer fell even further, by 42%, which may be because the risk of breast cancer is reduced after surgery.&lt;/P&gt;
&lt;P&gt;The research behind this report followed 2010 obese people over 11 years following gastric surgery for weight loss. It compared their rates of cancer with the rates seen in 2037 obese people who received non-surgical weight management and found there were 117 cancer cases in the surgery group and 169 in the comparison group. Across men and women, this was a decrease in the risk of cancer in the surgery group of around a third, but separate analysis by gender found that the decreased risk only applied to women.&lt;/P&gt;
&lt;P&gt;There are important limitations to these findings, principally the small number of cancers observed, which makes it hard to draw firm conclusions from the associations seen. Also, the reasons why there may be a decreased risk were not explored and this will require further study. However, despite having limitations this study confirms the idea that reducing your weight if you are&amp;nbsp;obese does have health benefits.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This study has found that, over the course of an 11-year&amp;nbsp;follow-up, there were more cases of cancer among those who did not receive surgery. This equated to a decrease in risk of cancer of a third. Separate analysis of women and men found that the decreased risk occured in women but not in men.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/06June/Pages/Antiobesitysurgerycancerrates.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Sjöström L, Gummesson A, Sjöström CD, Narbro K, Peltonen M, Wedel H, Bengtsson C, Bouchard C, Carlsson B, Dahlgren S, Jacobson P, Karason K, Karlsson J, Larsson B, Lindroos AK, Lönroth H, Näslund I, Olbers T, Stenlöf K, Torgerson J, Carlsson LM; Swedish Obese Subjects Study. &lt;A href="http://dx.doi.org/10.1016/S1470-2045(09)70159-7" target="_blank"&gt;Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial.&lt;/A&gt; &lt;EM&gt;Lancet Oncol&lt;/EM&gt; 2009;10(7):653-62.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>386551</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/08August/Pages/genetic-effects-of-vitamin-D-studied.aspx]]&gt;</url>
    <title>Behind the headlines - Genetic effects of vitamin D studied</title>
    <publicationDate>2010-08-24T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,INFLAMMATORY BOWEL DISEASE,DISEASE PREVENTION,CANCER,CROHN'S DISEASE,DIETARY SUPPLEMENTS,RECENT ADDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Stocking up on vitamin D supplements and enjoying the summer sun could cut the risk of a host of diseases,” reported the &lt;EM&gt;Daily Mail&lt;/EM&gt;.&lt;/P&gt;
&lt;P&gt;This news story is based on a study that investigated how vitamin D might influence the risk of certain diseases by affecting the activity of genes. It found that vitamin D binds directly to genes associated with several common autoimmune diseases, including multiple sclerosis, type 1 diabetes, rheumatoid arthritis and colorectal cancer.&lt;/P&gt;
&lt;P&gt;Studies of this kind add to our knowledge of the function of vitamin D, and will be used to assess the guidelines for recommended vitamin D intake.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This is a valuable addition to our knowledge of the effects of vitamin D in the cells and how it might affect our risk of certain diseases.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/08August/Pages/genetic-effects-of-vitamin-D-studied.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Ramagopalan SV, Heger A, Berlanga AJ, Maugeri NJ, Lincoln MR, Burrell A, Handunnetthi L, Handel AE, Disanto G, Orton SM, Watson CT, Morahan JM, Giovannoni G, Ponting CP, Ebers GC, Knight JC. &lt;A href="http://genome.cshlp.org/content/early/2010/08/20/gr.107920.110.long" target="_blank"&gt;A ChIP-seq defined genome-wide map of vitamin D receptor binding: Associations with disease and evolution.&lt;/A&gt; &lt;EM&gt;Genome Res &lt;/EM&gt;2010 Aug 24.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>295561</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/10October/Pages/Geneticsusceptibilitytoulcerativecolitis.aspx]]&gt;</url>
    <title>Behind the headlines - Genetic susceptibility to ulcerative colitis</title>
    <publicationDate>2008-10-06T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Researchers have found an association between the inflammatory bowel condition ulcerative colitis and the “gene that encodes for interleukin 10 (IL10) – a compound which regulates inflammation”, BBC News website reports.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Researchers have found an association between the inflammatory bowel condition ulcerative colitis and the “gene that encodes for interleukin 10 (IL10)&amp;nbsp;– a compound which regulates inflammation”, BBC News website reports. Ulcerative colitis affects around 100,000 people in the UK, and symptoms include bloody diarrhoea, abdominal pain, losing weight and needing to go to the toilet frequently. The website reports that “the administration of interleukin 10 to individuals with colitis has been reported to have a positive effect in initial studies, although this potential therapy has not been assessed more thoroughly”.&lt;/P&gt;
&lt;P&gt;This study points researchers towards areas of the genome that warrant further study in people with ulcerative colitis, although the variant(s) that actually causes this increase has not yet been identified. However, further studies will be needed to investigate whether IL10 treatment would be helpful for people with ulcerative colitis.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This study provides evidence that variations within the region of the &lt;EM&gt;IL10 &lt;/EM&gt;gene are contributing to the risk of developing ulcerative colitis, although the variant(s) that actually causes this increase has not yet been identified. The findings were replicated in more than one group of people, and this increases the confidence in these results. As the authors suggest, further studies will be needed to investigate whether IL10 treatment would be helpful for people with ulcerative colitis. The previous use of this agent in human studies may make it easier for these trials to start, but it will still be a number of years until the results of such trials will be available. It is not known yet whether this treatment provides benefits to people with ulcerative colitis.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2008/10October/Pages/Geneticsusceptibilitytoulcerativecolitis.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Franke A, Balschun T, Karlsen TH, Sventoraityte J, Nikolaus S, Mayr G, Domingues FS, Albrecht M, Nothnagel M, Ellinghaus D, Sina C, Onnie CM, Weersma RK, Stokkers PC, Wijmenga C, Gazouli M, Strachan D, McArdle WL, Vermeire S, Rutgeerts P, Rosenstiel P, Krawczak M, Vatn MH; IBSEN study group, Mathew CG, Schreiber S. &lt;A href="http://dx.doi.org/10.1038/ng.221" target="_blank"&gt;Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility.&lt;/A&gt; Nat Genet. 2008 Nov;40(11):1319-23.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>295558</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/09September/Pages/Gutbacteria.aspx]]&gt;</url>
    <title>Behind the headlines - Gut bacteria and bowel cancer</title>
    <publicationDate>2008-09-22T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,SMALL INTESTINE,COLON &amp; RECTUM,INFECTIONS,CANCER,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>“How gut bugs could trigger cancer” is the headline of the BBC News article. It reports that scientists have uncovered a chain reaction that could link ‘Enterococcus faecalis’, a type of bacterium that lives in our intestines, to the development of colon cancer.</description>
    <body>&lt;![CDATA[ &lt;P&gt;“How gut bugs could trigger cancer” is the headline of the BBC News article. It reports that scientists have uncovered a chain reaction that could link ‘Enterococcus faecalis’, a type of bacterium that lives in our intestines, to the development of colon cancer. It continues that the bug is harmless in the vast majority of people, but that US scientists had found it could produce harmful chemicals, which can damage DNA. It quoted a UK expert as saying it was plausible that “bacteria could cause colon cancer” and that it is very unlikely that E. faecalis is the only bacterium that has such an effect.&lt;/P&gt;
&lt;P&gt;The science behind this story is very preliminary and should not cause undue alarm. Any chain reaction underlying colon cancer is likely to be complex, as illustrated by the 42 interrelated genes assessed in this study. As mentioned by BBC News, E. faecalis is only one of many bacteria that inhabit the gut, many of which the body needs to function and, in most cases, are harmless.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This is an extensive set of microbiological studies that require a full interpretation to be made by experts in the field. Some who were asked to comment by the BBC have said that the bug is a candidate for cancerous changes, but that there is unlikely to be only one culprit that causes colon cancer. There are also many other factors which are involved, such as an individual’s genetics and environment. Some commentators point out that most people have these bacteria in their gut, but most people do not get colon cancer, “so there must be other factors involved.”&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2008/09September/Pages/Gutbacteria.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Allen TD, Moore DR, Wang X, et al. &lt;A title="Dichotomous metabolism of Enterococcus faecalis induced by haematin starvation modulates colonic gene expression." href="http://dx.doi.org/10.1099/jmm.0.47798-0" target="_blank"&gt;Dichotomous metabolism of Enterococcus faecalis induced by haematin starvation modulates colonic gene expression.&lt;/A&gt; Med Microbiol 57; 2008: 1193-1204&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>310794</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/03March/Pages/Hotteaandcancer.aspx]]&gt;</url>
    <title>Behind the headlines - Hot tea and cancer</title>
    <publicationDate>2009-03-27T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,OESOPHAGUS,CANCER,DISEASE PREVENTION,DIET]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Very hot tea and coffee linked to raised oesophagus cancer,” reads the headline in The Times today. The newspaper reported on findings from a study in northern Iran, which found that drinking tea at 70ºC or more increased the risk of cancer eight-fold compared to drinking warm or lukewarm tea (65ºC or less). Drinking it at 65-69ºC doubled the risk.&lt;/P&gt;
&lt;P&gt;There are a number of points to consider when interpreting this study. It did not actually measure the temperature of tea drunk by the people with oesophageal cancer, rather it asked whether they drank their tea “very hot”, “hot”, or “warm or lukewarm”. These categories may mean different things to different people, and so it is difficult to identify the exact temperatures with which the risks are associated. Also, the researchers did not look at hot beverages other than tea, and so the results may not apply to these.&lt;/P&gt;
&lt;P&gt;As the researchers say, studies have shown that the preferred tea temperature in the UK is 56-60ºC.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This study suggests that it may be better to leave your tea to cool for a while rather than drinking it scalding hot. However, it is worth noting that the researchers say that studies have found that in the UK, a temperature of 56-60ºC is the average preferred tea temperature, while their study found that most people in the Golestan region drank their tea at above 60ºC.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/03March/Pages/Hotteaandcancer.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Islami F, Pourshams A, Nasrollahzadeh D, Kamangar F, Fahimi S, Shakeri R, Abedi-Ardekani B, Merat S, Vahedi H, Semnani S, Abnet CC, Brennan P, Møller H, Saidi F, Dawsey SM, Malekzadeh R, Boffetta P. &lt;A href="http://dx.doi.org/10.1136/bmj.b929" target="_blank"&gt;Tea drinking habits and oesophageal cancer in a high risk area in northern Iran: population based case-control study.&lt;/A&gt; &lt;EM&gt;BMJ&lt;/EM&gt; 2009 Mar 26;338:b929.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>323114</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/08August/Pages/Livercancerontherise.aspx]]&gt;</url>
    <title>Behind the headlines - Liver cancer on the rise</title>
    <publicationDate>2009-08-20T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,HEPATITIS C,NON-ALCOHOLIC,HEPATOCELLULAR CARCINOMA,RECENT ADDITIONS,CANCER,CIRRHOSIS,ALCOHOLIC,AUGUST 2009,CHRONIC HEPATITIS B,CHRONIC HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Several newspapers reported today that cases of liver cancer have tripled. The Mirror said that alcohol is to blame, as well as obesity and the blood infection hepatitis C. It reports that all three cause cirrhosis (scarring) of the liver, a condition that can develop into liver cancer. It said the “startling” figures from Cancer Research UK show that the number of cases of liver cancer has risen to 3,108 in 2006 from 865 in 1975.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Several newspapers reported today that cases of liver cancer have tripled.&amp;nbsp;&lt;EM&gt;The Mirror&lt;/EM&gt;&amp;nbsp;said that alcohol is to blame, as well as obesity and the blood infection hepatitis C. It reports that all three cause cirrhosis (scarring) of the liver, a condition that can develop into liver cancer. It said the “startling” figures from Cancer Research UK show that the number of cases of liver cancer has risen to 3,108 in 2006 from 865 in 1975.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What is the news based on?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;These stories are based on the&amp;nbsp;&lt;A href="http://info.cancerresearchuk.org/cancerstats/types/liver/incidence/" target="_blank"&gt;latest statistics&lt;/A&gt; published by Cancer Research UK about cancers starting in the liver (primary liver cancers) in 2006. The statistics look at how common the cancer is, how it has changed over time and how figures in the UK compare with those from other parts of the world. These statistics do not cover cancers that have spread to the liver from other parts of the body.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/08August/Pages/Livercancerontherise.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://info.cancerresearchuk.org/cancerstats/types/liver/incidence/" target="_blank"&gt;Cancer Research UK liver cancer statistics.&lt;/A&gt; Cancer Research website.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>306670</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/02February/Pages/LivertargetforAlzheimers.aspx]]&gt;</url>
    <title>Behind the headlines - Liver target for Alzheimer's</title>
    <publicationDate>2009-02-17T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,RECENT ADDITIONS,FEBRUARY 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Summary: &lt;/STRONG&gt;“Alzheimer’s could be tackled by treating a sufferer’s liver”, the Daily Mail said. The newspaper reported that researchers have found a link between levels of a toxic protein in the blood and Alzheimer’s disease. It said a study in rats suggests that helping the liver to clear the protein amyloid beta from the blood could fight the disease.&lt;/P&gt;
&lt;P&gt;This is preliminary research and does not have any immediate, direct implications for patients with Alzheimer’s disease. The rats did not have conditions that are similar to Alzheimer’s disease, but underwent surgical procedures before being injected with amyloid beta to affect levels of the protein in the body. These conditions do not reflect what would be seen in a human with Alzheimer’s.&lt;/P&gt;
&lt;P&gt;More research using animal models of Alzheimer’s disease would be needed to determine whether it is possible to accelerate amyloid beta breakdown in the liver. Whether this has any effect on brain clearance of amyloid beta, or the progression of the disease, will also need to be investigated.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication information: &lt;/STRONG&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Citation of original study:&lt;/STRONG&gt; Marques MA, Kulstad JJ, Savard CE, et al. &lt;A href="http://dx.doi.org/10.3233/JAD-2009-0964" target="_blank"&gt;Peripheral Amyloid-ß Levels Regulate Amyloid-ß Clearance from the Central Nervous System&lt;/A&gt;. Journal of Alzheimer's Disease 2009; 16: 1387-2877&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>295560</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/10October/Pages/Obesityswitch.aspx]]&gt;</url>
    <title>Behind the headlines - Obesity 'switch'</title>
    <publicationDate>2008-10-03T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COMMON CLINICAL PRESENTATIONS,OBESITY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>“‘Switch’ in brain linked to weight gain” is the headline in The Daily Telegraph. If this switch is faulty, the newspaper says, then the body will not recognise that it is full, and “the brain sends out signals to eat more and to store more sugars as fat”.</description>
    <body>&lt;![CDATA[ &lt;P&gt;“‘Switch’ in brain linked to weight gain” is the headline in &lt;EM&gt;The Daily Telegraph&lt;/EM&gt;. If this switch is faulty, the newspaper says, then the body will not recognise that it is full, and “the brain sends out signals to eat more and to store more sugars as fat”. The newspaper suggests “drugs could be used to suppress this switch and help people get back to a healthy weight”.&lt;/P&gt;
&lt;P&gt;The news report is based on a complex study in mice. The findings suggest that there is a chemical in the brains of the mice that may be key in regulating the response to overnutrition, which ultimately leads to obesity and associated problems. However, mice and humans have very different metabolisms, so the results will need to be confirmed in humans, and research will need to go into developing safe drugs for humans and safe methods of delivering drugs to a very specific site in the brain. These developments are undoubtedly a long way off.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This complex animal study has profiled the activity of a chemical called IKKß/NF-?B, which in normal physiology is inactive, but overnutrition causes it to be activated, and this leads to an inflammatory response. This finding will be of interest to the scientific community, which will seek to replicate the findings. &lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2008/10October/Pages/Obesityswitch.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Zhang X, Zhang G, Zhang H, et al. &lt;A href="http://dx.doi.org/10.1016/j.cell.2008.07.043" target="_blank"&gt;Hypothalamic IKKß/NF-?B and ER Stress Link Overnutrition to Energy Imbalance and Obesity.&lt;/A&gt; Cell 2008; 135:61–73 &lt;/P&gt;
&lt;P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>298774</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/11November/Pages/Peppermintsoothesirritablebowel.aspx]]&gt;</url>
    <title>Behind the headlines - Peppermint does sooth IBS</title>
    <publicationDate>2008-11-14T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,IRRITABLE BOWEL SYNDROME,COLON &amp; RECTUM]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Peppermint oil is the most effective treatment for irritable bowel syndrome, according to news reports today. The non-prescription supplement has been shown to be better at easing symptoms than prescribed muscle relaxants or fibre.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Peppermint oil is the most effective treatment for irritable bowel syndrome, according to news reports today. The non-prescription supplement has been shown to be better at easing symptoms than prescribed muscle relaxants or fibre. The results are reported to have been so convincing that an update to national and international treatment guidelines is recommended by researchers. Between five and 20% of the population are believed&amp;nbsp; to suffer from irritable bowel syndrome (IBS).&lt;/P&gt;
&lt;P&gt;This news report is based on a high quality, systematic review that provides good evidence that peppermint oil can be an effective treatment for irritable bowel syndrome. It examined all available studies of peppermint oil, muscle relaxants (or antispasmodics) and fibre used in the treatment of IBS. All three treatments significantly reduced the risk of persistent symptoms (such as abdominal pain and bloating) compared to placebo. &lt;/P&gt;
&lt;P&gt;As the studies compared the treatments with placebo and not against each other, it is not possible to conclude which treatment was most effective. However, compared to placebo, peppermint oil had the greatest effect.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This is a high quality systematic review that looked into all published research of peppermint oil, muscle relaxants (or antispasmodics) and fibre used in the treatment of IBS. The three treatments were all found to reduce the risk of having persistent symptoms (such as abdominal pain and bloating) compared to placebo.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2008/11November/Pages/Peppermintsoothesirritablebowel.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt;&amp;nbsp;on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Ford AC, Talley NJ, Spiegel BMR, et al. &lt;A href="http://dx.doi.org/10.1136/bmj.a2313" target="_blank"&gt;Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis.&lt;/A&gt; BMJ 2008; 337:a2313&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>386537</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/08August/Pages/grow-new-liver-cells-stem-cell-technology.aspx]]&gt;</url>
    <title>Behind the headlines - Stem cells converted to liver cells</title>
    <publicationDate>2010-08-27T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,LIVER TRANSPLANTATION,RECENT ADDITIONS,SURGERY,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;You will be able to “grow your own transplant liver in a lab within just five years”, says the &lt;EM&gt;Daily Mail&lt;/EM&gt;.&lt;/P&gt;
&lt;P&gt;This news story is based on research that demonstrated a method to develop skin cells into stem cells, which were then matured into liver cells. The researchers used this technique to develop lab-grown liver cells from patients with various inherited liver diseases, which they hope might aid future research into diseases. They found that the new liver cells shared a number of characteristics with the liver cells of the patients.&lt;/P&gt;
&lt;P&gt;The method developed in this research looks likely to be an invaluable technique for creating cell cultures that could be experimented on in the lab. However, this research did not aim to investigate how a fully-functional liver or transplantable cells could be grown in a lab, both of which are probably many years away.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;What does NHS Choices make of this study?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;This laboratory study has developed a method to produce liver cells from skin cells by producing inducible stem cells. The study showed the potential of this technique to produce cell culture models of inherited liver diseases. As the researchers point out, this is likely to be a useful tool to learn more about these diseases and screen for useful drugs.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/08August/Pages/grow-new-liver-cells-stem-cell-technology.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Rashid ST, Corbineau S, Hannan N, Marciniak SJ, Miranda E, Alexander G, Huang-Doran I, Griffin J, Ahrlund-Richter L, Skepper J, Semple R, Weber A, Lomas DA, Vallier L. &lt;A href="http://dx.doi.org/10.1172/JCI43122" target="_blank"&gt;Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells.&lt;/A&gt; &lt;EM&gt;J Clin Invest&lt;/EM&gt; 2010 Aug 25.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>307512</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/03March/Pages/ChildGastricBands.aspx]]&gt;</url>
    <title>Behind the headlines - 'Surgery for obese children'</title>
    <publicationDate>2009-03-02T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COMMON CLINICAL PRESENTATIONS,STOMACH,OBESITY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;An expert has said that “fat children should be given gastric bands to tackle diabetes” according to &lt;EM&gt;The Daily Telegraph&lt;/EM&gt;. The newspaper says paediatrician Professor Julian Shield believes that the NHS needs to take more radical measures to prevent serious damage to the health of obese children with ‘weight-related diabetes’.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;This and other newspaper stories were based on a study looking at a group of 73 medical cases of adolescent type 2 diabetes. These individuals were followed-up for a year after their diagnosis and were managed in a variety of ways by their doctors. Some were taking medication and others were treated with diet and exercise regimes to manage their weight and diabetes. However, many gained weight rather than losing it, and on balance, this group of cases seemed to be ineffectively treated. &lt;/P&gt;
&lt;P&gt;Gastric banding was not the subject of this research, and only one morbidly obese child who had failed medical treatment was awaiting weight-loss surgery. The lead researcher has been quoted as saying that it should be considered in the more serious cases. This study was not set up to compare one treatment with another.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This case series study has followed-up children diagnosed with type 2 diabetes in the UK, and reports on the characteristics of the patients one year after diagnosis. According to the researchers, the study highlights shortcomings in the way that paediatric diabetes clinics in the UK managed the participating children’s diabetes.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/03March/Pages/ChildGastricBands.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Shield JPH, Lynn R, Wan KC, et al. &lt;A href="http://dx.doi.org/10.1136/adc.2008.143313" target="_blank"&gt;Management and 1 year outcome for UK children with type 2 diabetes.&lt;/A&gt; Arch. Dis. Child. 2009;94;206-209,&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>384946</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/July07/Pages/Triggers-for-coeliac-disease-found.aspx]]&gt;</url>
    <title>Behind the headlines - Triggers for coeliac disease 'found'</title>
    <publicationDate>2010-07-22T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,SMALL INTESTINE,COELIAC DISEASE,RECENT ADDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“The precise cause of the immune reaction that leads to coeliac disease has been discovered,” BBC News reported. It said that three key substances in gluten have been found to trigger the condition, and researchers believe them to be a potential new target for developing treatments and possibly a vaccine.&lt;/P&gt;
&lt;P&gt;These researchers asked 200 volunteers with coeliac disease to eat bread, rye muffins or boiled barley, all of which contained gluten. They then measured the volunteers’ immune response to thousands of different peptides (gluten fragments) six days later. Among 90 possible peptides, three were found to be particularly toxic.&lt;/P&gt;
&lt;P&gt;This research appears to have been carefully carried out and is well reported. These are important findings and show some promise in the search for a treatment for coeliac disease. Early clinical trials are reportedly already underway, testing whether a compound containing these three peptides can stimulate an immune reaction. The full implications will not be known until after these trials are complete.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This research appears to have been carefully carried out and is well reported. These are important findings and show some promise in the search for a treatment for coeliac disease. Early clinical trials are reportedly already underway, testing whether a compound containing these three peptides can stimulate an immune reaction. The full implications will not be known until after these trials are complete.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/July07/Pages/Triggers-for-coeliac-disease-found.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Tye-Din JA, Stewart JA, Dromey JA, Beissbarth T, van Heel DA, Tatham A, Henderson K, Mannering SI, Gianfrani C, Jewell DP, Hill AV, McCluskey J, Rossjohn J, Anderson RP. &lt;A href="http://dx.doi.org/10.1126/scitranslmed.3001012" target="_blank"&gt;Comprehensive, quantitative mapping of T cell epitopes in gluten in celiac disease.&lt;/A&gt;&lt;EM&gt; Sci Transl Med&lt;/EM&gt; 2010;2(41):41ra51.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>374947</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/05May/Pages/ppi-stomach-drugs-harm-vs-good.aspx]]&gt;</url>
    <title>Behind the headlines - Use of stomach drugs debated</title>
    <publicationDate>2010-05-11T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,OESOPHAGUS,STOMACH,ULCERS,DUODENAL ULCERS,GASTRIC ULCERS,SMALL INTESTINE,GASTRO-OESOPHAGEAL REFLUX,DYSPEPSIA,RECENT ADDITIONS,MAY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;There is a risk of side-effects for “millions who take unnecessary stomach drugs”, reported the Daily Mail. It said that proton pump inhibitors (PPIs), used for treating symptoms of ulcers and heartburn (dyspepsia) by reducing stomach acid, are wrongly prescribed in up to two-thirds of cases.&lt;/P&gt;
&lt;P&gt;The news is based on an editorial by a US Doctor, on the potential side-effects, over-prescription, and problems associated with these drugs. This article is the opinion of the author, in which he references several scientific studies researching the issue. As such, the accuracy of the estimates of over prescription would need further investigation.&lt;/P&gt;
&lt;P&gt;Importantly, this editorial is based on the situation in the US, and may not necessarily reflect what is happening in the UK. However, the newspaper report is correct in saying that UK Doctors have recently expressed their concerns about the over-prescription of these drugs here. There is&amp;nbsp;&lt;A href="http://www.nice.org.uk/nicemedia/pdf/proton.pdf" target="_blank"&gt;NICE guidance on treatment of ulcers and heart burn&lt;/A&gt; which includes how to prescribe PPIs. PPIs can be used for non-ulcer dyspepsia but prolonged use of high doses should be avoided.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This was an editorial that described papers contained within the journal relating to the use of PPIs, and discussed the effect of a high prescription prevalence of PPIs in the US. While it raises interesting points of discussion, it should be remembered that it is intended as a narrative review by a single author, drawing on a small number of selected studies for illustrative purposes. This type of opinion-based article can be informative, but cannot take the place of a systematic review of all studies relevant to a particular health issue. &lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/05May/Pages/ppi-stomach-drugs-harm-vs-good.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Katz MH. &lt;A href="http://archinte.ama-assn.org/cgi/content/extract/170/9/747?maxtoshow=&amp;amp;hits=10&amp;amp;RESULTFORMAT=&amp;amp;fulltext=katz&amp;amp;searchid=" target="_blank"date&amp;amp;resourcetype=HWCIT&amp;quot;'"&gt;Failing the Acid Test: Benefits of Proton Pump Inhibitors May Not Justify the Risks for Many Users&lt;/A&gt;. &lt;EM&gt;Arch Intern Med&lt;/EM&gt; 2010;170(9):747-748.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>329954</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/11November/Pages/Obesity-and-gut-bacteria.aspx]]&gt;</url>
    <title>Behind the headlines - Yoghurt story 'hard to swallow'</title>
    <publicationDate>2009-11-12T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COMMON CLINICAL PRESENTATIONS,DISEASE PREVENTION,PROBIOTICS,OBESITY,DIETARY SUPPLEMENTS,RECENT ADDITIONS,NOVEMBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A headline in today’s Daily Mail stated: “Yoghurt drinks could beat bugs that pile the weight on.” It said scientists have shown that “bugs that live in our stomachs could be causing us to get fat.”</description>
    <body>&lt;![CDATA[ &lt;P&gt;A headline in today’s Daily Mail stated: “Yoghurt drinks could beat bugs that pile the weight on.” It said scientists have shown that “bugs that live in our stomachs could be causing us to get fat.” The newspaper said the research could lead to probiotic yoghurts that can combat weight gain.&lt;/P&gt;
&lt;P&gt;The newspaper’s claim about probiotic yoghurts is misleading. In fact, the study examined the effect of a change in diet on gut flora (micro organisms found in the gut) and weight in mice. The research was well conducted and should help advance investigations into gut flora. However, probiotic drinks such as Yakult, as specifically mentioned in the Daily Mail, did not feature in the study. While it is easy to see how the newspaper made its interpretation, it is too great a leap, and the relevance of this study to human diet needs to be better researched.&lt;/P&gt;
&lt;P&gt;While Yakult has had some more publicity because of this study, the research had nothing to do with probiotic yoghurts.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This animal study was well conducted. The purpose of the experiment, which is well described, was to establish an animal model for further studies of human diet and of the complex ecosystems that exist in the digestive system.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/11November/Pages/Obesity-and-gut-bacteria.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Turnbaugh PJ, Ridaura VK, Faith JJ, et al. &lt;A href="http://dx.doi.org/10.1126/scitranslmed.3000322" target="_blank"&gt;The Effect of Diet on the Human Gut Microbiome: A Metagenomic Analysis in Humanized Gnotobiotic Mice.&lt;/A&gt; Sci Transl Med 11 November 2009: 1; 6ra14&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>281356</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.jpeds.2007.04.004]]&gt;</url>
    <title>Body mass index in children with newly diagnosed inflammatory bowel disease: observations from two multicenter North American inception cohorts</title>
    <publicationDate>2008-03-10T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,RECENT ADDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Kugathasan, S. &lt;SPAN title="The Journal of pediatrics."&gt;&lt;A href="#javascript:AL_get(this," ?jour?, ?J Pediatr.?);?&gt;J Pediatr.&lt;/A&gt;&lt;/SPAN&gt; 2007 Nov;151(5):523-7. Epub 2007 Aug 24&lt;/P&gt;
&lt;P class=abstract&gt;OBJECTIVE: To conduct a systematic review of children with newly diagnosed inflammatory bowel disease (IBD) from 2 prospective inception cohorts to examine body mass index (BMI) status at presentation. STUDY DESIGN: Clinical, demographic, and BMI data were obtained from 783 patients with newly diagnosed IBD. National Health and Nutrition Examination Survey data for 2748 healthy children were used as a control. RESULTS: Most children with Crohn's disease and ulcerative colitis had a BMI in the normative range (5%-84%). Low BMI (&amp;lt;5%) was seen in 22% to 24% of children with Crohn's disease and 7% to 9% of children with ulcerative colitis. Ten percent of children with Crohn's disease and 20% to 30% of children with ulcerative colitis had a BMI at diagnosis consistent with overweight or risk for overweight. CONCLUSION: Children with IBD are affected by current population trends toward overweight. A significant subgroup of children with newly diagnosed IBD has a BMI categorized as overweight or at risk for overweight. Clinicians should be aware of possible IBD diagnosis in the presence increased BMI.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>262132</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.bsg.org.uk/pdf_word_docs/postgrad05.pdf]]&gt;</url>
    <title>British Society of Gastroenterology post graduate teaching day: inflammatory bowel disease</title>
    <publicationDate>2005-03-14T00:00:00</publicationDate>
    <publisher>British Society of Gastroenterology</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,SURGERY,SURGERY,ABDOMEN,SMALL INTESTINE,CROHN'S DISEASE,CROHN’S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This brochure provides an outline of the course content of the BSG Post Graduate Teaching Day on Inflammatory Bowel Disease that was held in March 2005. The brochure contains notes on a series of lectures given by experts in IBD.</description>
    <body>&lt;![CDATA[ &lt;P&gt;This brochure provides an outline of the course content of the BSG Post Graduate Teaching Day on Inflammatory Bowel Disease that was held in March 2005. The brochure contains notes on a series of lectures given by experts in IBD. &lt;/P&gt;
&lt;P&gt;The brochure contains the following sections:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Prevalence and pattern of IBD, including...Is Crohn's disease increasing? (Professor RFA Logan) 
&lt;LI&gt;Bridging the gap: from genes to function, including...What does Nod2 do? (Professor DP Jewell) 
&lt;LI&gt;Breaking down barriers: bacterial : epithelial crosstalk, including...Is this the basis of inflammation? (Professor IR Sanderson) 
&lt;LI&gt;Growing pains: IBD in adolescence (Professor IW Booth) 
&lt;LI&gt;Timing of colectomy in severe ulcerative colitis (Dr SP Travis) 
&lt;LI&gt;PSC - What treatment and when to transplant? (Dr RW Chapman) 
&lt;LI&gt;Getting the most from your pathologist, including...Reducing reports of non-specific colitis and...Does low grade dysplasia matter? (Professor M Novelli) 
&lt;LI&gt;Imaging for Crohn's disease today and tomorrow, including...The places of wireless Endoscopy and MRI (Dr S Jackson) 
&lt;LI&gt;Surgery and postoperative prophylaxis for Crohn's disease, including...Does the operation matter? (Professor R MacLeod) 
&lt;LI&gt;Probiotics, first or last (Professor F Shanahan) 
&lt;LI&gt;Crohn's disease treatment: infliximab and beyond (Professor S Ghosh)&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This brochure&amp;nbsp;is available for&amp;nbsp;download free from the BSG website&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>251556</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.kcl.ac.uk/teares/nmvc/external/prospectus/prog_info.php?pcourse_id=13]]&gt;</url>
    <title>BSc (Hons) in Gastrointestinal Nursing</title>
    <publicationDate>2009-02-20T00:00:00</publicationDate>
    <publisher>Burdett Institute of Gastrointestinal Nursing</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COMMON CLINICAL PRESENTATIONS,OESOPHAGUS,STOMACH,BILIARY TREE &amp; GALLBLADDER,PANCREAS,LIVER,SMALL INTESTINE,COLON &amp; RECTUM,INFLAMMATORY BOWEL DISEASE,DIAGNOSTIC PROCEDURES,DISEASE PREVENTION,NEUROENDOCRINE TUMOURS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The Gastrointestinal Nursing programme offers a unique combination of modules which can be taken as part of the degree or as free-standing modules. It has been designed for practitioners wishing to specialise in the field of gastrointestinal nursing.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Summary: &lt;/STRONG&gt;The Gastrointestinal Nursing programme offers a unique combination of modules which can be taken as part of the degree or as free-standing modules. It has been designed for practitioners wishing to specialise in the field of gastrointestinal nursing.&lt;/P&gt;
&lt;P&gt;Entry requirements:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;effective NMC registration 
&lt;LI&gt;working within a relevant area of clinical practice 
&lt;LI&gt;support from your employer 
&lt;LI&gt;DipHE or equivalent of 120 credits at level 5&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>344518</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.pasa.nhs.uk/pasa/Doc.aspx?Path=%5bMN%5d%5bSP%5d/NHSprocurement/CEP/Infusionpumps/CEP08021.pdf]]&gt;</url>
    <title>Buyers' guide: portal pumps for home parenteral nutrition</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>NHS Purchasing and Supply Agency</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,PARENTERAL,RECENT ADDITIONS,THERAPEUTIC NUTRITION,FEBRUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=abstractSummary&gt;
&lt;P&gt;The Centre for Evidence-based Purchasing (CEP) provides impartial and objective information about medical technology to help the NHS make better purchasing decisions.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt; This document provides recommendations for the purchasing of pumps for home parenteral&amp;nbsp;nutrition, including technical, operational and economic considerations.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in May 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>325165</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1038/ajg.2009.269]]&gt;</url>
    <title>Can a wire-guided cannulation technique increase bile duct cannulation rate and prevent post-ERCP pancreatitis?: A meta-analysis of randomized controlled trials</title>
    <publicationDate>2009-09-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,PANCREAS,DIAGNOSTIC PROCEDURES,GASTROINTESTINAL ENDOSCOPY,ERCP,PANCREATITIS,RECENT ADDITIONS,SEPTEMBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt;&amp;nbsp;The wire-guided technique for primary deep biliary cannulation increases the success rate of the procedure and reduces the risk of post-endoscopic retrograde cholangiopancreatography (post-ERCP) pancreatitis compared with the standard contrast-injection method. Further large, well-performed, randomized controlled studies are needed to confirm these findings.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Literature searches of electronic databases and online clinical trial registers up to March 2009 were conducted to identify RCTs comparing primary cannulation and post-ERCP pancreatitis rates with the wire-guided method and the standard cannulation technique. A meta-analysis of these clinical trials was performed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Five RCTs were included. Overall, the primary cannulation rates reported with the wire-guided cannulation technique and the standard method were 85.3 and 74.9%, respectively. The pooled analysis of all the selected studies comparing the wire-guided cannulation technique with the standard method yielded an odds ratio (OR) of 2.05 (95% confidence interval (CI): 1.27–3.31). The pooled analysis comparing the post-ERCP pancreatitis rates for the wire-guided-cannulation groups with those for the standard-method groups yielded an OR of 0.23 (95% CI: 0.13–0.41).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;See also: &lt;/STRONG&gt;&lt;A href="nelh:360490:0" name=internalLink&gt;DARE record&lt;/A&gt; for this article.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Cennamo V, Fuccio L, Zagari RM, Eusebi LH, Ceroni L, Laterza L, Fabbri C, Bazzoli F. Can a wire-guided cannulation technique increase bile duct cannulation rate and prevent post-ERCP pancreatitis?: A meta-analysis of randomized controlled trials. &lt;EM&gt;Am J Gastroenterol&lt;/EM&gt; 2009;104(9):2343-50. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317960</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.cag-acg.org/uploads/cag_cpg_crohnsmar2009.pdf]]&gt;</url>
    <title>Canadian Association of Gastroenterology clinical practice guidelines: the use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease</title>
    <publicationDate>2009-03-01T00:00:00</publicationDate>
    <publisher>Canadian Association of Gastroenterology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE,RECENT ADDITIONS,JUNE 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims: &lt;/STRONG&gt;Guidelines regarding the use of infliximab in Crohn's disease were previously published by the CAG/ACG in 2004.&amp;nbsp; Recent clinical findings and drug developments warrant a review and update of these guidelines.&amp;nbsp; This document aims to review and update Canadian guidelines regarding the use of tumour necrosis factor-alpha antibody therapy in both luminal and fistulizing Crohn's disease.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience: &lt;/STRONG&gt;Gastroenterologists&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in March 2009.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>105552</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/15685294]]&gt;</url>
    <title>Canadian consensus conference on the management of gastroesophageal reflux diseases in adults-update 2004</title>
    <publicationDate>2005-01-01T00:00:00</publicationDate>
    <publisher>Canadian Association of Gastroenterology</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,OESOPHAGUS,GASTRO-OESOPHAGEAL REFLUX]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;STRONG&gt;Aims&lt;/STRONG&gt;:&amp;nbsp; To develop evidence based recommendations relevant&amp;nbsp;to the management of the oesophageal manifestations of GORD (GERD).&amp;nbsp; The guideline is aimed specifically at the needs of Canadian health care providers.&amp;nbsp; The document is published in sections immediately translated into French before going on to the following section.&amp;nbsp; The guideline layout follows the format of individual statements followed by a summary and the quality of supporting evidence for the individual statement. 
&lt;H2&gt;&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience&lt;/STRONG&gt;:&amp;nbsp;&amp;nbsp; Aimed specifically at Canadian health care providers but more generally at those involved in the management of the oesophageal manifestations of GORD (GERD).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;Full text open access via the &lt;A href="http://www.cag-acg.org/" target="_blank"&gt;CAG&lt;/A&gt; website.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>377687</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1038/ajg.2009.713]]&gt;</url>
    <title>Capsule endoscopy has a significantly higher diagnostic yield in patients with suspected and established small-bowel Crohn's disease: a meta-analysis</title>
    <publicationDate>2010-06-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,DIAGNOSTIC PROCEDURES,GASTROINTESTINAL ENDOSCOPY,COLONOSCOPY,ENTEROSCOPY,MRI,CT / CAT SCAN,CAPSULE ENDOSCOPY,VIRTUAL ENDOSCOPY,CROHN'S DISEASE,RECENT ADDITIONS,RADIOLOGY,JUNE 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Our meta-analysis demonstrates that capsule endoscopy (CE) is superior to&amp;nbsp;small-bowel radiography (SBR), computed tomography enterography (CTE), and colonoscopy with ileoscopy (C+IL) in the evaluation of suspected Crohn's disease (CD) patients. CE is also a more effective diagnostic tool in established CD patients compared with SBR, CTE, and push enteroscopy (PE).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; CE has demonstrated superior performance compared with other modalities in its ability to detect early small-bowel (SB) CD, especially when ileoscopy is negative or unsuccessful. The aim of this study was to evaluate the diagnostic yield of CE compared with other modalities in patients with suspected and established CD using a meta-analysis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A thorough literature search for prospective studies comparing the diagnostic yield of CE with other modalities in patients with CD was undertaken. Other modalities included PE, C+IL, SBR, CTE, and magnetic resonance enterography (MRE). Data on diagnostic yield among various modalities were extracted, pooled, and analyzed. Data on patients with suspected and established CD were analyzed separately. Weighted incremental yield (IY(W)) (diagnostic yield of CE-diagnostic yield of comparative modality) and 95% confidence intervals (CIs) of CE over comparative modalities were calculated.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; A total of 12 trials (n=428) compared the yield of CE with SBR in patients with CD. Eight trials (n=236) compared CE with C+IL, four trials (n=119) compared CE with CTE, two trials (n=102) compared CE with PE, and four trials (n=123) compared CE with MRE. For the suspected CD subgroup, several comparisons met statistical significance. Yields in this subgroup were CE vs. SBR: 52 vs. 16% (IY(w)=32%, P&amp;lt;0.0001, 95% CI=16-48%), CE vs. CTE: 68 vs. 21% (IY(w)=47%, P&amp;lt;0.00001, 95% CI=31-63%), and CE vs. C+IL: 47 vs. 25% (IY(w)=22%, P=0.009, 95% CI=5-39%). Statistically significant yields for CE vs. an alternate diagnostic modality in established CD patients were seen in CE vs. PE: 66 vs. 9% (IY(w)=57%, P&amp;lt;0.00001, 95% CI=43-71%), CE vs. SBR: 71 vs. 36% (IY(w)=38%, P&amp;lt;0.00001, 95% CI=22-54%), and in CE vs. CTE: 71 vs. 39% (IY(w)=32%, P=&amp;lt;0.0001, 95% CI=16-47%).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Dionisio PM, Gurudu SR, Leighton JA, Leontiadis GI, Fleischer DE, Hara AK, Heigh RI, Shiff AD, Sharma VK. Capsule endoscopy has a significantly higher diagnostic yield in patients with suspected and established small-bowel Crohn's disease: a meta-analysis. &lt;EM&gt;Am J Gastroenterol&lt;/EM&gt; 2010;105(6):1240-8. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>332746</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.npci.org.uk/blog/?p=891]]&gt;</url>
    <title>Cardiovascular outcomes and mortality in patients using clopidogrel with a PPI: more data</title>
    <publicationDate>2009-12-10T00:00:00</publicationDate>
    <publisher>National Prescribing Centre</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,OESOPHAGUS,STOMACH,ULCERS,DUODENAL ULCERS,GASTRIC ULCERS,SMALL INTESTINE,GASTRO-OESOPHAGEAL REFLUX,DYSPEPSIA,RECENT ADDITIONS,DECEMBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The National Prescribing Centre is a health service organisation, formed in April 1996 by the Department of Health. Its aim is to ‘promote and support high quality, cost-effective prescribing and medicines management across the NHS, to help improve patient care and service delivery’.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt; A large observational study finds no conclusive evidence for a clinically relevant drug interaction between clopidogrel and PPIs in elderly patients after percutaneous coronary intervention or hospitalisation for acute coronary syndrome. &lt;/P&gt;
&lt;P&gt;See the &lt;A href="http://www.npci.org.uk/blog/?p=891" target="_blank"&gt;full article on the NPC website&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345599</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.clinthera.2009.06.015]]&gt;</url>
    <title>Certolizumab pegol for the management of Crohn's disease in adults</title>
    <publicationDate>2009-06-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Based on the findings from the present review, certolizumab pegol had moderate efficacy in the treatment of moderate to severe, active Crohn's disease (CD). In well-designed Phase III clinical trials, certolizumab pegol was associated with significantly greater response rates compared with placebo at weeks 6 and 26 of induction treatment. In patients who responded to the 6-week induction, certolizumab pegol administered as a monthly subcutaneous injection was effective in maintaining CD response and remission. Findings from studies of certolizumab pegol in refractory CD are awaited.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; CD is an inflammatory disorder that can affect any portion of the gastrointestinal tract, from the mouth to the rectum. The American Gastroenterological Association recommends that treatment with anti-tumor necrosis factor (TNF)-alpha be considered in patients with moderate to severe CD refractory to concomitant aminosalicylates, corticosteroids, or immunosuppressive treatment, or who have contraindications to or poor tolerance of these agents. Anti-TNF-alpha agents available in the United States for the management of CD are infliximab, adalimumab, and certolizumab pegol. The latter is a recombinant humanized antibody Fab' fragment against TNF-alpha. It is conjugated with a 40-kDa polyethylene glycol molecule to increase the t(1/2) of the treatment to approximately 2 weeks. The objective of this review was to extract and assess all relevant available data on the efficacy and tolerability of certolizumab pegol in the treatment of CD.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Searches of MEDLINE and International Pharmaceutical Abstracts from 1985 to March 3, 2009, were conducted using the key terms certolizumab pegol, CDP870, and Crohn's disease. Data from all available clinical trials published in English and ongoing trials were included in this review. The reference lists of the identified articles were searched for additional references. Data from abstracts presented at the annual meetings of the American College of Gastroenterology and Digestive Disease Week from 2004 to 2008 were reviewed and included if relevant.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; A total of 8 studies were included in this review (1474 patients). In Phase II trials, there were no significant differences between certolizumab pegol and inactive vehicle (placebo) in week-4 or week-12 clinical response or remission rates. In the first of 2 Phase III clinical trials, certolizumab pegol was associated with significantly greater rates of response compared with placebo at weeks 6 (37% vs 26%; P = 0.04) and 26 (22% vs 12%; P = 0.05) of induction treatment (data from patients with baseline CRP concentrations &amp;gt; or =10 mg/L). Response was defined as a decrease from baseline in CD activity index &amp;gt; or =100 at week 6 and at both weeks 6 and 26 in patients with baseline C-reactive protein &amp;gt; or =10 mg/L. Remission rates were not significantly different between the 2 groups. In the second Phase III trial, the proportion of patients in whom response was sustained up to 26 weeks was significantly greater with certolizumab pegol compared with placebo (63% vs 36%; P &amp;lt; 0.001). The tolerability profile of certolizumab pegol was similar to those of other anti-TNF-alpha agents and included an increased risk for infections (including opportunistic infections [eg, tuberculosis]) compared with placebo. Infusion and injection-site reactions were infrequent (3%) with certolizumab pegol treatment. The most common adverse events reported with certolizumab pegol treatment included upper respiratory infection (20%), immunogenicity (8%), and urinary tract infection (7%). No new unanticipated adverse events emerged during the 30-month tolerability follow-up. Certolizumab pegol is being assessed in patients with CD refractory to other medications, including other biologic agents.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Rivkin A. Certolizumab pegol for the management of Crohn's disease in adults. &lt;EM&gt;Clin Ther&lt;/EM&gt; 2009;31(6):1158-76.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314802</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1200/JCO.2008.19.7921]]&gt;</url>
    <title>Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review</title>
    <publicationDate>2009-03-23T00:00:00</publicationDate>
    <publisher>HighWire Press</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,PANCREAS,CANCER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; No standard treatment exists, but there are two options for treatment of locally advanced pancreatic carcinoma (LAPC); these are gemcitabine-based chemotherapy and chemoradiotherapy. Induction chemotherapy followed by a chemoradiotherapy is a promising strategy for selection of patients without early metastatic/progressing disease.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A search to identify eligible studies was undertaken using the MEDLINE database. All phase III randomized trials and systematic reviews evaluating the role of radiotherapy in LAPC were included, together with some noncontrolled studies if no phase III trials were retrieved. The quality and clinical relevance of the studies were evaluated using validated checklists, which allowed associating each result with a level of evidence.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Twenty-one studies were included, as follows: two meta-analyses, 13 randomized trials, and six nonrandomized trials. Chemoradiotherapy increases overall survival when compared with best supportive care (level of evidence C) or with exclusive radiotherapy (level B1), but is more toxic (level B1). Chemoradiotherapy is not superior to chemotherapy in terms of survival (level B1) and increases toxicity (level A). Recent data favor limited irradiation to the tumor volume (level C). Fluorouracil is still the reference chemotherapy in association with radiotherapy (level B1). Induction chemotherapy before chemoradiotherapy improves survival (level C).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Hugert F, Girard N, Guerche S-E, Hennequin C, Mornex F, Azria D. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review.&amp;nbsp;J Clin Oncol 2009;27(13):2269-77.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not currently available freely or via NHS Athens username and password. The journal publishes articles in open access with a one year embargo; as a result the full text will be freely available in May 2010.&amp;nbsp; In the meantime, NHS professionals are advised to check their local library to access the fulltext of this journal.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>325953</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.bsg.org.uk/images/stories/docs/patients/ciclo_ibd_pt.doc]]&gt;</url>
    <title>Ciclosporin treatment for patients with IBD</title>
    <publicationDate></publicationDate>
    <publisher>British Society of Gastroenterology</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,RECENT ADDITIONS,SEPTEMBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The British Society of Gastroenterology is an organisation focused on the promotion of gastroenterology within the United Kingdom. It has over three thousand members drawn from the ranks of physicians, surgeons, pathologists, radiologists, scientists, nurses, dietitians, and others interested in the field. Founded in 1937 it has grown from a club to be a major force in British medicine, with representation within the British Royal Colleges and thus to the Department of Health and Government. Internationally it is represented at World and European level. The BSG is a registered charity.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt; This document is one of a series designed to provide information for gastroenterologists, primary care clinicians and patients with IBD regarding the use of disease modifying drugs, their indications, side effects and guidelines for safe monitoring. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>380656</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19485429]]&gt;</url>
    <title>Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines</title>
    <publicationDate>2009-04-01T00:00:00</publicationDate>
    <publisher>Adis Data Information</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,RECENT ADDITIONS,CHRONIC HEPATITIS C,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt;&amp;nbsp;Administering&amp;nbsp;the German guidelines&amp;nbsp;should allow tailoring treatment efficiently to genotype, bodyweight and early viral response in patients with chronic hepatitis C, and appears cost effective compared with other well accepted medical interventions.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Recently developed German guidelines for antiviral treatment in patients with chronic hepatitis C recommend basing drug dosage, intended treatment duration and early stopping rules on the genotype of the hepatitis C virus and early viral responses to treatment. The objective of of this study was to evaluate effectiveness and cost effectiveness of different antiviral treatment strategies including the German guidelines, for chronic hepatitis C.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A validated lifetime Markov model was used to project life expectancy, QALYs and lifetime costs for the following strategies: (i) no antiviral therapy (NoAVT); (ii) interferon-a-2b plus ribavirin for 48 weeks (IFN?+?R); (iii) peginterferon-a-2b plus weight-based ribavirin for 48 weeks (PEG?+?R); (iv) peginterferon-a-2b plus ribavirin according to German guidelines with genotype-dependent treatment duration, dosage and 12-week viral response evaluation (GUIDE). Clinical and resource utilization data were derived from a clinical trial, the published literature and a survey of German hepatologists. Incremental cost-effectiveness ratios (ICERs) were calculated adopting the German societal perspective. Costs (in €, year 2005 values) and health outcomes were discounted at 3% annually. Uncertainty was assessed using deterministic and probabilistic sensitivity analyses.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Compared with NoAVT, PEG?+?R increased undiscounted life expectancy by 5.0 life-years (5.2 QALYs) and GUIDE increased undiscounted life expectancy by 4.9 years (5.1 QALYs). Compared with PEG?+?R, GUIDE saved 13% of hepatitis C virus-related lifetime costs per patient. GUIDE dominated IFN?+?R. Compared with NoAVT, discounted ICERs were €1500 per QALY for GUIDE and €3200 per QALY for PEG?+?R.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Siebert U, Sroczynski G, Aidelsburger P, Rossol S, Wasem J, Manns MP, McHutchison JG, Wong JB. Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines. &lt;EM&gt;Pharmacoeconomics&lt;/EM&gt; 2009;27(4):341-54.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>329677</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1038/ajg.2009.494]]&gt;</url>
    <title>Clinical effects of colonic cleansing for general health promotion: a systematic review</title>
    <publicationDate>2009-11-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,RECENT ADDITIONS,NOVEMBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The practice of colonic cleansing to improve or promote general health is not supported in the published literature and cannot be recommended at this time.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background:&lt;/STRONG&gt; The practice of colonic cleansing to promote general health and well-being continues to generate interest among the lay population. These practices are widely touted as adjuncts to improve vitality and as therapeutic modalities to minimize the symptoms, or prevent the actual development, of a variety of chronic disease states. The data supporting colonic cleansing and body "detoxification" have not been studied well in a systematic manner.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt;&amp;nbsp;A systematic review of the published literature of both the traditional and complementary and alternative medicine arenas was performed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; There are no methodologically rigorous controlled trials of colonic cleansing to support the practice for general health promotion. Conversely, there are multiple case reports and case series that describe the adverse effects of colonic cleansing.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Acosta RD, Cash BD. Clinical effects of colonic cleansing for general health promotion: a systematic review. &lt;EM&gt;Am J Gastroenterol&lt;/EM&gt; 2009 Nov;104(11):2830-6.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>187098</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1097/01.mib.0000231496.92013.85]]&gt;</url>
    <title>Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: summary statement</title>
    <publicationDate>2006-10-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,PROCTITIS &amp; DISTIL COLITIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>There are few published guidelines for inflammatory bowel disease. In this article the author's summarise their own set of guidelines, which are based on evidence collected through literature searching and a critical evaluation of existing treatments. Recommendations for the most effective treatments for left-sided ulcerative colitis and ulcerative procititis are given.</description>
    <body>&lt;![CDATA[ &lt;STRONG&gt;Bibliographic details:&lt;/STRONG&gt; Inflammatory Bowel Disease 2006; 12: p.979-994. 
&lt;H2&gt;Description&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;Aims&lt;/STRONG&gt;: This article provides treatment guidelines for the induction and maintenance of ulcerative proctitis and left-sided colitis and the management of disease refractory to 5-aminosalicylic acid (5-ASA) compounds and corticosteroids. The guidelines are derived from evidence-based data and, when lacking, expert opinion or the authors' experience. The comprehensive review of the literature is presented in the accompanying article, "The Medical Management of Left-Sided Ulcerative Colitis and Ulcerative Proctitis: Critical Evaluation of Therapeutic Trials". The authors recommend rectally administered 5-ASA and corticosteroid suppositories as an&amp;nbsp;effective treatment for most ulcerative proctitis patients, and corticosteroid and 5-ASA enemas, for patients with left-sided ulcerative colitis. Those who have ongoing signs and symptoms of these conditions despite maximal medical therapy require a proctocolectomy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience&lt;/STRONG&gt;: Healthcare professionals.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext this journal.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publisher's review date&lt;/STRONG&gt;:&amp;nbsp;none given&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>381392</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20133223]]&gt;</url>
    <title>Clinical management of hepatitis B virus infection correlated with liver transplantation</title>
    <publicationDate>2010-02-01T00:00:00</publicationDate>
    <publisher>First Affiliated Hospital</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,DISEASE PREVENTION,LIVER TRANSPLANTATION,VACCINATION,RECENT ADDITIONS,SURGERY,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Hepatitis B vaccine needs further large-scale and rigorous randomized controlled trials to confirm its effective dose and injection frequency. Monoclonal antibody is still experimental, and the next step is to carry out the relevant animal and human studies. A consensus standard regimen for the treatment of hepatitis B should be developed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; As a radical cure for post-hepatitis B virus (HBV)-related liver cirrhosis and hepatocellular carcinoma, liver transplantation has been applied in many medical centers. Before the use of effective measures, hepatitis B recurrence and the existence of HBsAg(+) donors, patients with hepatitis B-related diseases are contraindicated for liver transplantation. Application of interferon, hepatitis B immunoglobulin (HBIG), and nucleotide analogues (e.g., lamivudine) has made great progress in the clinical care of HBV. However, there are still many shortcomings such as low viral suppression rate, rising expense, and the induction of HBV tyrosine-methionine-aspartate-aspartate (YMDD) mutation. This article systematically reviews the current evidence that immunotherapy, conventional drug combinations, and some special fields of HBV infection correlate with liver transplantation.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Studies were identified by searching MEDLINE and PubMed for articles using the keywords "hepatitis B virus", "hepatitis B vaccination", "lamivudine", "adefovir", "entecavir", "tenofovir", "HBV genotype", and "liver transplantation" up to October 2009. Additional papers were identified by a manual search of the references from the key articles.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Hepatitis B vaccine and human monoclonal antibody have very good clinical prospects. Compared with traditional therapies, the new medical regimens have many benefits such as boosting viral suppression rate and decreasing medical expenses. The triple therapy for YMDD mutation also has an excellent therapeutic effect and a low barrier to resistance. New nucleos(t)ide analogues (entecavir and tenofovir) eliminate virus more effectively with few adverse reactions, and may replace lamivudine or HBIG in future.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Zhang J, Zhou L, Zheng SS. Clinical management of hepatitis B virus infection correlated with liver transplantation. &lt;EM&gt;Hepatobiliary Pancreat Dis Int&lt;/EM&gt; 2010;9(1):15-21.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323523</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1002/hep.22929]]&gt;</url>
    <title>Clinical outcomes in adults with chronic hepatitis B in association with patient and viral characteristics: a systematic review of evidence</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,CHRONIC HEPATITIS B]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Adults with chronic hepatitis B had increased risk for poorer health outcomes compared to the general population; however, the magnitude of risk varied greatly depending on baseline patient and disease characteristics, and typically clinical outcomes required many years to become manifest. Many adults with chronic hepatitis B had low absolute risks of clinical outcomes and likely would not benefit from immediate treatment. Baseline patient and disease characteristics provide important information about the risk of clinical outcomes and should be incorporated into monitoring or treatment decisions.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We systematically reviewed the literature on the extent to which population characteristics or clinical features predict groups of individuals likely to develop advanced liver disease or die from chronic infection with hepatitis B virus (HBV). We searched Medline to include studies with reported cirrhosis, liver failure, liver cancer, or death outcomes after at least 1 year of follow-up from the measurement of predictive factors (age, age at infection, geographic location, race/ethnicity, sex, positive family history, presence of coinfections, HBV viral level, change in hepatitis B e antigen [HBeAg] status, genotype, HBV mutations, nonalcoholic fatty liver disease, alcohol consumption, liver enzymes, and liver biopsy finding).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Evidence from 41 included articles suggested that cirrhosis, higher HBV viral level, and male sex were consistently associated with significantly increased risk of death and liver cancer. Evidence about the role of HBV genotype, HBeAg status, age and duration of infection, coinfections with hepatitis C virus, human immunodeficiency virus, hepatitis delta virus, and alanine aminotransferase levels were limited and inconsistent, but were deemed promising to identify patients at higher risk of clinical outcomes.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Taylor BC, Yuan J-M, Shamliyan TA, Shaukat A, Kane RL, Wilt TJ. Clinical outcomes in adults with chronic hepatitis B in association with patient and viral characteristics: a systematic review of evidence. &lt;EM&gt;Hepatology&lt;/EM&gt; 2009;49:S85-S95.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>346884</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.jhep.2009.12.004]]&gt;</url>
    <title>Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis</title>
    <publicationDate>2010-03-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATOCELLULAR CARCINOMA,RECENT ADDITIONS,CANCER,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Radiofrequency ablation (RFA) seems to be a superior ablative therapy than percutaneous ethanol injection (PEI) for hepatocellular carcinoma (HCC), particularly for tumours &amp;gt;2 cm. PAI did not differ significantly from PEI for all the outcomes evaluated. RFA and Percutaneous acetic acid injection (PAI) have similar survival rates. For tumours &amp;lt;=2 cm outcome benefits comparing RFA and PEI are similar. PAI needs re-evaluation versus both PEI and RFA for tumours &amp;lt;=2 cm.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; RFA is often the preferred local ablation therapy for HCC. PEI is less frequently used, and&amp;nbsp;PAI has been mostly abandoned. Robust evidence showing benefit of one therapy versus another is lacking. Our aim was to evaluate the evidence comparing RFA, PEI and PAI using meta-analytical techniques.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Literature search was undertaken until December 2008 to identify comparative studies evaluating survival, recurrence, complete necrosis of tumour and complications. Only randomized clinical trials and quasi-randomized studies were included. Adjusted indirect comparisons were made when direct comparative studies were insufficient.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Eight studies were identified: RFA vs. PEI (n=5), PAI vs. PEI (n=2) and RFA vs. PAI vs. PEI (n=1) including 1035 patients with nine comparisons. RFA was superior to PEI for survival (OR 0.52; 95% CI 0.35-0.78; p=0.001), complete necrosis of tumour and local recurrence. For tumours 2 cm RFA was not significantly better than PEI. PAI did not differ significantly from PEI for survival (OR 0.55; 95% CI 0.23-1.33; p=0.18), and local recurrence but required less sessions. PAI had similar outcomes, except local recurrence, to RFA in the direct and indirect comparison.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Germani G, Pleguezuelo M, Gurusamy K, Meyer T, Isgrò G, Burroughs AK. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis. &lt;EM&gt;J Hepatol&lt;/EM&gt; 2010;52(3):380-8.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345643</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1007/s11605-008-0792-4]]&gt;</url>
    <title>Colectomy in patients with acute colitis: a systematic review</title>
    <publicationDate>2009-01-01T00:00:00</publicationDate>
    <publisher>Springer</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE,COLON,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Colectomy for acute colitis is complicated by considerable morbidity. The incidence of adverse outcome has substantially decreased over the last three decades, but further improvements are still required. The retrospective nature of the included studies allows for a considerable degree of selection bias that limits robust and clinically sound conclusions about both conventional and laparoscopic surgery.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; For patients with acute colitis, the decision when and how to operate is difficult in most cases. It was the aim of this systematic review to analyze early mortality and morbidity of colectomy for severe acute colitis in order to identify opportunities to improve perioperative treatment and outcome.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A systematic review of the available literature in the Medline and PubMed databases from 1975 to 2007 was performed. All articles were assessed methodologically; the articles of poor methodological quality were excluded. Articles on laparoscopic colectomy for acute colitis were analyzed separately.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; In total, 29 studies met the criteria for the systematic review, describing a total of 2,714 patients, 1,257 of whom were operated on in an acute setting, i.e., urgent or emergency colectomy. Reported in-hospital mortality was 8.0%; the 30-day mortality was 5.2%. Morbidity was 50.8%. The majority of complications were of infectious and thromboembolic nature. Over the last three decades, there was a shift in indications from toxic megacolon, from 71.1% in 1975-1984 to 21.6% in 1995-2005, to severe acute colitis not responding to conservative treatment, from 16.5% in 1975-1984 to 58.1% in 1995-2007. Mortality decreased from 10.0% to 1.8%. Morbidity remained high, exceeding 40% in the last decade. Mortality after laparoscopic surgery was 0.6%. Complication rate varies from 16-37%.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Teeuwen PH, Stommel MW, Bremers AJ, van der Wilt GJ, de Jong DJ, Bleichrodt RP. Colectomy in patients with acute colitis: a systematic review.&lt;EM&gt; J Gastrointest Surg&lt;/EM&gt; 2009;13(4):676-86.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293822</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1440-1746.2007.05068.x]]&gt;</url>
    <title>Comparative cost-effectiveness of antiviral therapies in patients with chronic hepatitis B: a systematic review of economic evidence</title>
    <publicationDate>2007-09-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,CHRONIC HEPATITIS B]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Sun, X et al Journal of Gastroenterology and Hepatology 2007 Sep;22(9):1369-77&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract: &lt;/STRONG&gt;BACKGROUND AND AIM: Economic efficiency of the alternative antiviral therapies for chronic hepatitis B has not been systematically investigated and their quality remains unknown. The aim of the present study was to systematically overview economic evidence of antiviral therapies for chronic hepatitis B. METHODS: We searched six databases and eight major journals supplemented with screening references of eligible studies. Full economic evaluations comparing alternative antiviral therapies in patients with chronic hepatitis B virus infection were included. Two investigators assessed the study quality and transferability, independently. Data were analyzed qualitatively with adjustment when appropriate. RESULTS: Fourteen studies (six modeling vs eight trials and database analyses) were included. Quality was high in five studies, moderate in one US and five Chinese studies, and low in three Chinese studies. The major problems of quality are costing methods and analysis and the presentation of results. In Australia and Poland, lamivudine-preferred strategies dominated interferon (IFN)-alpha and its related strategy from the health-care sector perspective. In the US, adefovir salvage produced US$8446 per additional quality-adjusted life years (QALY) compared with IFN-alpha. In Spain, the cost of adefovir was US$34,840 for additional virological response. In Taiwan, the use of pegylated IFN-alpha (pegIFN-alpha) produced US$11,711.4 per additional QALY, compared with lamivudine. In China, the incremental cost-effectiveness ratios of combination therapy lamivudine ranged from US$2860 to US$22,160 per additional loss of hepatitis B e antigen (HBeAg), and IFN-alpha versus lamivudine ranged from US$2490 to US$8890 per additional loss of HBeAg. CONCLUSION: The cost-effectiveness frontiers of treatment alternatives vary and are influenced by the comparators and socioeconomic conditions of countries. Lamivudine-containing therapy is cost-effective when newer antiviral agents (e.g. adefovir/pegIFN-alpha) were not available. Economic methods should be further improved in studies, particularly in China.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>346754</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1002/lt.21998]]&gt;</url>
    <title>Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody-positive donors: a systematic review</title>
    <publicationDate>2010-03-03T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,LIVER TRANSPLANTATION,RECENT ADDITIONS,MARCH 2010,CHRONIC HEPATITIS B,SURGERY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Published studies have not shown hepatitis B immunoglobulin and lamivudine (HBIG+LAM) combination therapy to be more effective than LAM-only treatment in treating hepatitis B (HBV)&amp;nbsp;negative&amp;nbsp;patients who have received liver allografts from hepatitis B core antigen-positive&amp;nbsp;[HBcAb(+)] donors. Nucleoside analogue monotherapy should therefore be considered when treating these patients.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Orthotopic liver transplantation (OLT) recipients without HBV infection who receive liver grafts from antibody to HBcAb(+), hepatitis B surface antigen-negative [HBsAg(-)] donors have an increased risk of developing de novo hepatitis B infection. We compared the 2 most commonly employed prophylactic regimens-LAM monotherapy and HBIG+LAM combination therapy-to determine the relative efficacies of these 2 protocols in preventing de novo hepatitis B infection.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method: &lt;/STRONG&gt;A comprehensive search of the Cochrane Database of Systematic Reviews, MEDLINE (1966 to June 2009), and bibliographies of retrieved trials was conducted. Eligible studies included OLT recipients who received HBcAb(+) liver grafts and were treated prophylactically with either LAM monotherapy or HBIG+LAM combination therapy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt;&amp;nbsp;13 studies were identified as meeting the eligibility criteria. The rates of de novo hepatitis B infection, mortality, and mortality due to de novo hepatitis B infection were assessed. The incidence of de novo hepatitis B infection was 2.7% (n = 73) in patients receiving LAM-only prophylaxis versus 3.6% (n = 110) in patients receiving HBIG+LAM combination therapy. In the HBIG+LAM group, the dose and duration of HBIG therapy were highly variable. The median follow-up time for the LAM monotherapy group was 25.4 months with a range of 14.78 to 27.6 months, whereas the median follow-up time for the LAM+HBIG group was 31.1 months with a range of 15.3 to 38.5 months. The risk of developing de novo hepatitis B infection based on the pretransplant recipient HBV serology in each treatment group could not be calculated because of incomplete data and the limited number of de novo hepatitis B infection cases in the series reviewed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Saab S, Waterman B, Chi AC, Tong MJ. Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody-positive donors: a systematic review. &lt;EM&gt;Liver Transpl&lt;/EM&gt; 2010;16(3):300-7.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>346754</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1002/lt.21998]]&gt;</url>
    <title>Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody-positive donors: a systematic review</title>
    <publicationDate>2010-03-03T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,LIVER TRANSPLANTATION,RECENT ADDITIONS,MARCH 2010,CHRONIC HEPATITIS B,SURGERY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Published studies have not shown hepatitis B immunoglobulin and lamivudine (HBIG+LAM) combination therapy to be more effective than LAM-only treatment in treating hepatitis B (HBV)&amp;nbsp;negative&amp;nbsp;patients who have received liver allografts from hepatitis B core antigen-positive&amp;nbsp;[HBcAb(+)] donors. Nucleoside analogue monotherapy should therefore be considered when treating these patients.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Orthotopic liver transplantation (OLT) recipients without HBV infection who receive liver grafts from antibody to HBcAb(+), hepatitis B surface antigen-negative [HBsAg(-)] donors have an increased risk of developing de novo hepatitis B infection. We compared the 2 most commonly employed prophylactic regimens-LAM monotherapy and HBIG+LAM combination therapy-to determine the relative efficacies of these 2 protocols in preventing de novo hepatitis B infection.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method: &lt;/STRONG&gt;A comprehensive search of the Cochrane Database of Systematic Reviews, MEDLINE (1966 to June 2009), and bibliographies of retrieved trials was conducted. Eligible studies included OLT recipients who received HBcAb(+) liver grafts and were treated prophylactically with either LAM monotherapy or HBIG+LAM combination therapy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt;&amp;nbsp;13 studies were identified as meeting the eligibility criteria. The rates of de novo hepatitis B infection, mortality, and mortality due to de novo hepatitis B infection were assessed. The incidence of de novo hepatitis B infection was 2.7% (n = 73) in patients receiving LAM-only prophylaxis versus 3.6% (n = 110) in patients receiving HBIG+LAM combination therapy. In the HBIG+LAM group, the dose and duration of HBIG therapy were highly variable. The median follow-up time for the LAM monotherapy group was 25.4 months with a range of 14.78 to 27.6 months, whereas the median follow-up time for the LAM+HBIG group was 31.1 months with a range of 15.3 to 38.5 months. The risk of developing de novo hepatitis B infection based on the pretransplant recipient HBV serology in each treatment group could not be calculated because of incomplete data and the limited number of de novo hepatitis B infection cases in the series reviewed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Saab S, Waterman B, Chi AC, Tong MJ. Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody-positive donors: a systematic review. &lt;EM&gt;Liver Transpl&lt;/EM&gt; 2010;16(3):300-7.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>380728</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1002/lt.21998]]&gt;</url>
    <title>Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody-positive donors: a systematic review</title>
    <publicationDate>2010-03-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,LIVER TRANSPLANTATION,RECENT ADDITIONS,SURGERY,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Published studies have not shown hepatitis B immunoglobulin (HBIG) + lamivudine (LAM)&amp;nbsp;combination therapy to be more effective than LAM-only treatment. Nucleoside analogue monotherapy should therefore be considered when one is treating&amp;nbsp;hepatitis B virus (HBV) negative&amp;nbsp;patients who have received liver allografts from HBcAb(+) donors.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Orthotopic liver transplantation (OLT) recipients without HBV infection who receive liver grafts from antibody to hepatitis B core antigen-positive [HBcAb(+)], hepatitis B surface antigen-negative [HBsAg(-)] donors have an increased risk of developing de novo hepatitis B infection.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We compared the 2 most commonly employed prophylactic regimens-LAM monotherapy and hepatitis HBIG+LAM combination therapy-to determine the relative efficacies of these 2 protocols in preventing de novo hepatitis B infection. A comprehensive search of the Cochrane Database of Systematic Reviews, MEDLINE (1966 to June 2009), and bibliographies of retrieved trials was conducted. Eligible studies included OLT recipients who received HBcAb(+) liver grafts and were treated prophylactically with either LAM monotherapy or HBIG+LAM combination therapy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; 13 studies were identified as meeting the eligibility criteria. The rates of de novo hepatitis B infection, mortality, and mortality due to de novo hepatitis B infection were assessed. The incidence of de novo hepatitis B infection was 2.7% (n = 73) in patients receiving LAM-only prophylaxis versus 3.6% (n = 110) in patients receiving HBIG+LAM combination therapy. In the HBIG+LAM group, the dose and duration of HBIG therapy were highly variable. The median follow-up time for the LAM monotherapy group was 25.4 months with a range of 14.78 to 27.6 months, whereas the median follow-up time for the LAM+HBIG group was 31.1 months with a range of 15.3 to 38.5 months. The risk of developing de novo hepatitis B infection based on the pretransplant recipient HBV serology in each treatment group could not be calculated because of incomplete data and the limited number of de novo hepatitis B infection cases in the series reviewed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Saab S, Waterman B, Chi AC, Tong MJ. Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody-positive donors: a systematic review. &lt;EM&gt;Liver Transpl&lt;/EM&gt; 2010;16(3):300-7.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>380728</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1002/lt.21998]]&gt;</url>
    <title>Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody-positive donors: a systematic review</title>
    <publicationDate>2010-03-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,LIVER TRANSPLANTATION,RECENT ADDITIONS,SURGERY,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Published studies have not shown hepatitis B immunoglobulin (HBIG) + lamivudine (LAM)&amp;nbsp;combination therapy to be more effective than LAM-only treatment. Nucleoside analogue monotherapy should therefore be considered when one is treating&amp;nbsp;hepatitis B virus (HBV) negative&amp;nbsp;patients who have received liver allografts from HBcAb(+) donors.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Orthotopic liver transplantation (OLT) recipients without HBV infection who receive liver grafts from antibody to hepatitis B core antigen-positive [HBcAb(+)], hepatitis B surface antigen-negative [HBsAg(-)] donors have an increased risk of developing de novo hepatitis B infection.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We compared the 2 most commonly employed prophylactic regimens-LAM monotherapy and hepatitis HBIG+LAM combination therapy-to determine the relative efficacies of these 2 protocols in preventing de novo hepatitis B infection. A comprehensive search of the Cochrane Database of Systematic Reviews, MEDLINE (1966 to June 2009), and bibliographies of retrieved trials was conducted. Eligible studies included OLT recipients who received HBcAb(+) liver grafts and were treated prophylactically with either LAM monotherapy or HBIG+LAM combination therapy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; 13 studies were identified as meeting the eligibility criteria. The rates of de novo hepatitis B infection, mortality, and mortality due to de novo hepatitis B infection were assessed. The incidence of de novo hepatitis B infection was 2.7% (n = 73) in patients receiving LAM-only prophylaxis versus 3.6% (n = 110) in patients receiving HBIG+LAM combination therapy. In the HBIG+LAM group, the dose and duration of HBIG therapy were highly variable. The median follow-up time for the LAM monotherapy group was 25.4 months with a range of 14.78 to 27.6 months, whereas the median follow-up time for the LAM+HBIG group was 31.1 months with a range of 15.3 to 38.5 months. The risk of developing de novo hepatitis B infection based on the pretransplant recipient HBV serology in each treatment group could not be calculated because of incomplete data and the limited number of de novo hepatitis B infection cases in the series reviewed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Saab S, Waterman B, Chi AC, Tong MJ. Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody-positive donors: a systematic review. &lt;EM&gt;Liver Transpl&lt;/EM&gt; 2010;16(3):300-7.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>251170</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1007/s00464-005-0500-3]]&gt;</url>
    <title>Comparison of laparoscopic and open ileocecal resection for Crohn's disease: a metaanalysis</title>
    <publicationDate>2006-07-01T00:00:00</publicationDate>
    <publisher>Springer</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The role of laparoscopic surgery for patients with ileocecal Crohn's disease is a contentious issue. This metaanalysis aimed to compare open resection with laparoscopically assisted resection for ileocecal Crohn's disease.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Tilney HS, Constantinides VA, Heriot, AG et al. 2006; Surgical Endoscopy 20 (7) pp. 1036-1044 &lt;/P&gt;&lt;BR&gt;
&lt;H2&gt;Laparoscopic and open resection for Crohn's Disease&lt;/H2&gt;&lt;BR&gt;
&lt;H3&gt;Topic summary by Dr Stephen Grainger, Consultant Gastroenterologist, King George Hospital Essex. &lt;/H3&gt;&lt;BR&gt;&lt;BR&gt;
&lt;P&gt;A shorter scar, fewer days in hospital and a better body image seem attractive reasons for patients to ask their surgeon to perform their ileocaecal resection laparoscopically. Rosman et al (2005) and Tilney et al (2006) report in Surgical Endoscopy meta-analyses of open versus laparoscopic surgery for Crohn's Disease. The later paper confines itself to ileocaecal resections but in nearly 800 patients. The studies are not homogeneous but do include a randomised controlled trial and the meta-analysis seeks to maximise the validity of the comparisons of the two approaches.&lt;/P&gt;
&lt;P&gt;On average laparoscopic resection took 30 minutes longer but time to first liquid and solid diets and discharge from hospital were 1-3 days shorter. Posr-operative complications were no greater with laparoscopy and other authors have suggested fewer late complications such as adhesions and ventral hernias.&lt;/P&gt;
&lt;P&gt;The downside doesn't seem too great. On average 6.8% of operations had to be converted to open resections: large fixed masses; multiple fistulae and abscesses often being present in such patients. Smoking, per-op steroids, malnutrition and extra-colonic disease have been found by others to be associated with the need to abandon the laparoscopic approach.&amp;nbsp; Examining the whole intestine laparoscopically can be difficult, but with good pre-operative assessment it should now be possible to select suitable patients for laparoscopic resection and please the patient and the bed manager.&lt;/P&gt;&lt;BR&gt;
&lt;H2&gt;Original article abstract:&lt;/H2&gt;
&lt;P&gt;BACKGROUND: The role of laparoscopic surgery for patients with ileocecal Crohn's disease is a contentious issue. This metaanalysis aimed to compare open resection with laparoscopically assisted resection for ileocecal Crohn's disease. METHODS: A literature search of the Medline, Ovid, Embase, and Cochrane databases was performed to identify comparative studies reporting outcomes for both laparoscopic and open ileocecal resection. Metaanalytical techniques were applied to identify differences in outcomes between the two groups. Sensitivity analysis was undertaken to evaluate the heterogeneity of the study. RESULTS: Of 20 studies identified by literature review, 15 satisfied the criteria for inclusion in the study. These included outcomes for 783 patients, 338 (43.2%) of whom had undergone laparoscopic resection, with an overall conversion rate to open surgery of 6.8%. The operative time was significantly longer in the laparoscopic group, by 29.6 min (p = 0.002), although the blood loss and complications in the two groups were similar. In terms of postoperative recovery, the laparoscopic patients had a significantly shorter time for recovery of their enteric function and a shorter hospital stay, by 2.7 days (p &amp;lt; 0.001). CONCLUSIONS: For selected patients with noncomplicated ileocecal Crohn's disease, laparoscopic resection offered substantial advantages in terms of more rapid resolution of postoperative ileus and shortened hospital stay. There was no increase in complications, as compared with open surgery. The contraindications to laparoscopic approaches for Crohn's disease remain undefined.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is &lt;STRONG&gt;not&lt;/STRONG&gt; available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345527</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1007/s10620-008-0428-2]]&gt;</url>
    <title>Comparison of mesalazine and balsalazide in induction and maintenance of remission in patients with ulcerative colitis: a meta-analysis</title>
    <publicationDate>2009-04-01T00:00:00</publicationDate>
    <publisher>Springer</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt;&amp;nbsp;Balsalazide is more effective than mesalazine in induction of remission in ulcerative colitis, but balsalazide has no benefit compared with mesalazine in preventing relapse in the population selected. The number of patients with any adverse events and withdrawals because of severe adverse events is similar for mesalazine and balsalazide.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; 5-Aminosalicylates are the standard treatment for induction and maintenance of remission in mild-to-moderate ulcerative colitis. In recent years, the 5-aminosalicylic acid-containing pro-drug balsalazide has been the focus of attention. The aim of this review was to compare the efficacy and tolerance of balsalazide and mesalazine by meta-analysis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Pubmed, Embase, Scopus, Web of Science, and the Cochrane Central Register of Controlled Trials were searched for studies comparing the efficacy and/or tolerance of balsalazide with mesalazine in the management of UC. The search terms were: "mesalazine" or "5-aminosalicylic acid" and "balsalazide" and "ulcerative colitis." Data were collected from 1966 to 2007 (up to February). There was no language restriction. "Symptomatic remission," "complete remission," "relapse rate," "total adverse events," and "withdrawals because of adverse events" were the key outcomes of interest.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Six randomized placebo-controlled clinical trials met our criteria and were included in the meta-analysis. In these "symptomatic remission," "complete remission," "relapse rate," "total adverse events," and "withdrawals because of adverse events" were evaluated in three, three, two, five, and six of the trials, respectively. They included 653 patients consisting of 55.4% men and 44.6% women randomized to receive either balsalazide or mesalazine. Pooling of three trials for symptomatic remission yielded a significant relative risk (RR) of 1.23 (95% confidence interval of 1.03-1.47, P = 0.02). The summary RR for complete remission in three trials was 1.3 (95% CI of 1.002-1.68, P = 0.048). Pooling of two trials for the outcome of relapse yielded a non-significant RR of 0.77 (95% CI of 0.56-1.07, P = 0.12). Pooling five studies from which data for any adverse events were extracted, yielded a non-significant RR of 0.87 (95% CI of 0.75-1.001, P = 0.53). The summary RR for withdrawals because of adverse events in six trials was 0.69, a non-significant RR (95% CI of 0.37-1.29, P = 0.24). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Comparison of mesalazine and balsalazide in induction and maintenance of remission in patients with ulcerative colitis: a meta-analysis. &lt;EM&gt;Dig Dis Sci &lt;/EM&gt;2009;54(4):712-21.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>346855</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1200/JCO.2009.24.2099]]&gt;</url>
    <title>Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients</title>
    <publicationDate>2010-03-01T00:00:00</publicationDate>
    <publisher>American Society of Clinical Oncology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,STOMACH,CANCER,SMALL INTESTINE,CANCER,RECENT ADDITIONS,MARCH 2010,STROMAL TUMORS,STROMAL TUMORS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; A daily 800g dose of imatinib does not offer any advantage over a 400g dose for most patients with unresectable or metastatic gastrointestinal stromal tumors. The exception may be patients who harbor&lt;SUP&gt; &lt;/SUP&gt;&lt;I&gt;KIT&lt;/I&gt; exon 9 mutations, but even then there is no difference in overall survival (OS).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; The Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST) project aims to additionally explore the data of the two large, randomized, cooperative-group studies comparing two doses of imatinib (400 mg daily v twice daily) in 1,640 patients with advanced GIST.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; End points were progression-free survival (PFS) and OS. Investigated cofactors included age, sex, performance status (PS), primary tumor site, time from diagnosis, prior therapies, baseline biology, and KIT/PDGFRalpha mutations for a subset of 772 patients. Univariate and multivariate models were used for the analysis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; At a median follow-up of 45 months, a small but significant PFS advantage was documented for the high-dose arm. OS was identical in the two arms. The multivariate prognostic models included the following adverse factors: male sex, poor PS, and high baseline neutrophils counts (PFS and OS); low hemoglobin and GIST from small bowel origin (PFS); and advanced age, large tumor size, low albumin level, and prior chemotherapy (OS). In patients analyzed for mutations, patients with wild type, patients with KIT exon 9 mutations, and patients with other mutations had worse prognoses than patients with KIT exon 11 mutations for both end points. The mutation status was the only predictive factor for the PFS benefit attributed to high-dose treatment that resulted in significantly longer PFS (and higher objective response rate) for patients with KIT exon 9 mutations.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. &lt;EM&gt;J Clin Oncol&lt;/EM&gt; 2010;28(7):1247-53.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>324074</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.neuroendocrine.net/guidelines_tnm_classifications.html&amp;OPEN=menue,14]]&gt;</url>
    <title>Consensus guidelines for the standard of care for patients with digestive neuroendocrine tumors</title>
    <publicationDate>2009-08-01T00:00:00</publicationDate>
    <publisher>European Neuroendocrine Tumor Society</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,DIAGNOSTIC PROCEDURES,NEUROENDOCRINE TUMOURS,RECENT ADDITIONS,CARCINOIDS,PANCREATIC ENDOCRINE TUMOURS,SEPTEMBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; These guidelines are intended as recommendations for the techical and practical details necessary for implementing the previous ENETS consensus guidelines on the clinical management of neuroendocrine tumors (NET) of the digestive tract.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience: &lt;/STRONG&gt;Gastroenterologists&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in August 2009 in &lt;EM&gt;Neuroendocrinology &lt;/EM&gt;90(2):155:234.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>381275</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1002/hep.23384]]&gt;</url>
    <title>Contemporary clinical research of traditional Chinese medicines for chronic hepatitis B in China: an analytical review</title>
    <publicationDate>2010-02-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,RECENT ADDITIONS,CHRONIC HEPATITIS B,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Some traditional Chinese medicines (TCMs) seem effective as alternative remedies for patients with chronic hepatitis B (CHB), suggesting that further study of TCMs in the treatment of CHB is warranted, both in preclinical models of hepatitis B virus (HBV) infection and in higher quality randomised controlled trials (RCTs) worldwide.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims: &lt;/STRONG&gt;CHB is major global health problem. In China, where about 120,000,000 persons are chronically infected, CHB has been treated for centuries with TCMs. This review summarizes and meta-analyzes the results of RCTs of TCM formulations reported in China in 1998-2008 for treatment of CHB.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; RCTs comparing either TCM formulations alone or in combination with interferon (IFN) or lamivudine (LAM) versus IFN or LAM were included. Chinese electronic databases were searched. The methodological quality of RCTs was assessed using the Jadad scale.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; TCMs had a greater beneficial effect (P = 0.0003) than IFN and a slightly better effect (P = 0.01) than LAM on the normalization of serum alanine aminotransferase. TCMs had a similar beneficial effect when compared with IFN or LAM for CHB on antiviral activity as evidenced by the loss of serum hepatitis B e antigen and hepatitis B virus (HBV) DNA. TCMs enhanced IFN and LAM antiviral activities and improvements of liver function. The quality of many studies was poor; reports often lacked information regarding methods of randomization or blinding and adverse events.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Zhang L, Wang G, Hou W, Li P, Dulin A, Bonkovsky HL. Contemporary clinical research of traditional Chinese medicines for chronic hepatitis B in China: an analytical review. &lt;EM&gt;Hepatology &lt;/EM&gt;2010;51(2):690-8.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323564</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1093/eurpub/ckm123]]&gt;</url>
    <title>Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation</title>
    <publicationDate>2008-06-01T00:00:00</publicationDate>
    <publisher>Oxford Journals</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,DISEASE PREVENTION,VACCINATION,RECENT ADDITIONS,AUGUST 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt;&amp;nbsp;At a cost of 29 euros&amp;nbsp;per dose of the six-component vaccine, universal infant hepatitis B vaccination is cost effective at 37018 euros/LYG. This compares favourably with other preventive programmes in Ireland. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A cost effectiveness analysis was conducted using a Markov model. The perspective of the analysis was the Irish Health Service Executive. Unit cost and resource utilization data were derived from expert clinical opinion, published sources, diagnosis-related group costs for hospital admissions and local cost estimates for medical fees and laboratory investigations. A full probabilistic sensitivity analysis was undertaken. Both costs and outcomes were modelled over a period of 80 years and discounted at 3.5%. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Assuming an incidence of acute hepatitis B virus (HBV) infection in Ireland of 8.4 per 100 000 population, the incremental cost effectiveness ratio ranged from 10 992/life years gained (LYG) to 67 200/LYG, at the lowest and highest price estimates for the six-component vaccine, respectively. The cost effectiveness of universal versus selective hepatitis B vaccination was sensitive to the risk of acute HBV infection, the cost of the universal infant vaccination programme and the discount rate.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;See also: &lt;/STRONG&gt;&lt;A href="nelh:331906:0" name=internalLink&gt;NHS EED record&lt;/A&gt; for this article.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Tilson L, Thornton L, O'Flanagan D, Johnson H, Barry M. Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation. &lt;EM&gt;Eur J Public Health&lt;/EM&gt; 2008 Jun;18(3):275-82. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>325169</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1038/ajg.2009.264]]&gt;</url>
    <title>Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates</title>
    <publicationDate>2009-09-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,DISEASE PREVENTION,CANCER,SCREENING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; If 5-Aminosalicylates (5-ASA)&amp;nbsp;are efficacious chemoprevention for ulcerative colitis (UC)-associated colorectal cancer (CRC), endoscopic surveillance might be safely performed every 2 years or less often. Such practice could decrease burdens to patients and on endoscopic resources with a minimal decrease in quality-adjusted length of life, because 5-ASA with annual surveillance may cost nearly $1 million per additional quality-adjusted life-year (QALY) gained.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We performed systematic reviews of the literature, and created a Markov computer model simulating a cohort of 35-year-old men with chronic UC, followed until the age of 90 years. Twenty-two strategies were modeled: natural history (no 5-ASA or surveillance), surveillance without 5-ASA at intervals of 1–10 years, 5-ASA plus surveillance every 1–10 years, and 5-ASA alone. The primary outcome was the ideal interval of surveillance in the setting of 5-ASA maintenance, assuming a third-party payer was willing to pay $100,000 for each QALY gained.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; In the natural history strategy, the CRC incidence was 30%. Without 5-ASA, annual surveillance was the ideal strategy, preventing 89% of CRC and costing $69,100 per QALY gained compared with surveillance every 2 years. 5-ASA alone prevented 49% of CRC. In the setting of 5-ASA, surveillance every 3 years was ideal, preventing 87% of CRC. 5-ASA with surveillance every 2 years cost an additional $147,500 per QALY gained, and 5-ASA with annual surveillance cost nearly $1 million additional per QALY gained compared with every 2 years. In Monte Carlo simulations, surveillance every 2 years or less often was ideal in 95% of simulations.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Rubenstein JH, Waljee AK, Jeter JM, Velayos FS, Ladabaum U, Higgins PD. Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates. &lt;EM&gt;Am J Gastroenterol &lt;/EM&gt;2009;104(9):2222-32.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345583</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1572-0241.2008.02130.x]]&gt;</url>
    <title>Cost-effectiveness of 5-aminosalicylic acid therapy for maintenance of remission in ulcerative colitis</title>
    <publicationDate>2008-12-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion: &lt;/STRONG&gt;Maintenance 5-aminosalicylic acid (5-ASA) therapy decreases&amp;nbsp;ulcerative colitis (UC)&amp;nbsp;flares, but its cost may be substantial, depending on society's willingness to pay. If sulfasalazine can be tolerated and yields comparable benefits, sulfasalazine maintenance therapy is likely to be cost-effective. The cost per quality-adjusted life-year (QALY) gained by 5-ASA maintenance is highly dependent on the quality of life while taking versus not taking maintenance 5-ASA, highlighting the importance of patients' preferences.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Oral 5-ASA is effective in inducing and maintaining remission in UC. The relative benefits and costs of maintenance 5-ASA therapy are uncertain. Our aims were to evaluate this strategy's potential cost-effectiveness.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt;&amp;nbsp;We constructed a Markov model to compare two strategies over 2 yr: (a) no maintenance 5-ASA, with 5-ASA 4.8 g/day given for flares, (b) maintenance 5-ASA 2.4 g/day, escalated and maintained at 4.8 g/day after the first flare. In both arms, the failure to induce remission led to other treatments, as needed: prednisone, parenteral corticosteroids, cyclosporine, 6-mercaptopurine, infliximab, and colectomy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Without maintenance 5-ASA, the mean flares per person were 1.92, and the mean cost per person was $3,402. With maintenance 5-ASA providing a relative risk of flare of 0.7 at 5-ASA cost of $198/month, flares per person decreased to 1.38 at a cost of $8,810/flare prevented. Maintenance 5-ASA increased discounted&amp;nbsp;QALYs per person from 1.75 to 1.77 at a discounted cost of $224,000/QALY gained. The results were most sensitive to the flare risk reduction and cost of 5-ASA, the utilities of being in remission without or with 5-ASA, and the colectomy rates. At $15/month (the cost of sulfasalazine), maintenance 5-ASA cost $640/flare prevented and $16,300/QALY gained.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Yen EF, Kane SV, Ladabaum U. Cost-effectiveness of 5-aminosalicylic acid therapy for maintenance of remission in ulcerative colitis. &lt;EM&gt;Am J Gastroenterol&lt;/EM&gt; 2008;103(12):3094-105.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345566</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2009.04033.x]]&gt;</url>
    <title>Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data</title>
    <publicationDate>2009-08-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The model suggests acceptable incremental cost-effectiveness ratios (ICERs) for biological agents in Crohn's disease (CD)&amp;nbsp;when considering a lifetime horizon with periods of up to 4 years continuous therapy. As with all economic evaluations, the results may not be generalizable beyond the perspective of analysis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Anti-TNF-alpha agents for CD have good clinical efficacy but high acquisition cost compared to rival drugs.&amp;nbsp; The aim of this paper is to assess the cost-effectiveness of infliximab and adalimumab for Crohn's disease from the perspective of the UK NHS, incorporating recent trial and observational data.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Lifetime Markov analyses constructed to simulate quality-adjusted life-years (QALYs) and costs. CD was represented by four health-states representing: Full response, partial response, nonresponse, surgery and death. The course of CD under standard care was based on the Olmsted county cohort. Systematic review identified ACCENT I (infliximab) and CHARM (adalimumab) as sources for efficacy data. We modelled an intention-to-treat strategy for biologics including surgical rates based on observational data, cost estimates from our UK dataset and utilities from an algorithm converting CDAI to EQ-5D utilities.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The ICERs compared to standard care for 1-year of treatment with infliximab or adalimumab were £19 050 and £7190 per QALY gained, respectively. Lifetime therapy was dominated by standard care. Analyses over shorter time horizons, matched to treatment duration, resulted in unfavourable ICERs.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Bodger K, Kikuchi T, Hughes D. Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2009;30(3):265-74.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293820</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1097/MEG.0b013e3281108079]]&gt;</url>
    <title>Cost-effectiveness of peginterferon alpha-2a compared with lamivudine treatment in patients with HBe-antigen-positive chronic hepatitis B in the United Kingdom</title>
    <publicationDate>2007-08-01T00:00:00</publicationDate>
    <publisher>Lippincott Williams &amp; Wilkins</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,CHRONIC HEPATITIS B]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Veenstra, DL et al European Journal of Gastroenterology and Hepatology 2007 Aug;19(8):631-8&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract: &lt;/STRONG&gt;BACKGROUND: Peginterferon alpha-2a (40 kDa), a new treatment for chronic hepatitis B, produces seroconversion within 48 weeks in approximately 32% of HBeAg-positive patients. Over a defined treatment duration it offers improved efficacy over lamivudine, but at higher cost. We assessed the clinical outcomes and costs, from the perspective of the UK National Health Service, of 48 weeks of peginterferon alpha-2a (40 kDa) vs. 4 years of lamivudine. METHODS: Cost-effectiveness was analysed using a state-transition Markov model simulating HBeAg-positive chronic hepatitis B natural history. Efficacy data were obtained from a large randomized trial comparing peginterferon alpha-2a (40 kDa) with lamivudine over 48 weeks. Use of adefovir salvage treatment for lamivudine-resistant patients was also evaluated. Long-term lamivudine efficacy, treatment durability, disease progression, cost, and quality-of-life estimates were derived from the literature. One-way and probabilistic sensitivity analyses evaluated uncertainty. RESULTS: Treatment with peginterferon alpha-2a (40 kDa) for 48 weeks resulted in higher discounted total healthcare costs ( pound 3100), but an increase of 0.3 discounted quality-adjusted life years compared with long-term lamivudine, giving an incremental cost-effectiveness ratio of pound 10,400 per quality-adjusted life year gained ( pound 8300- pound 15,400 in one-way sensitivity analyses). The cost-effectiveness acceptability curve showed intervention was below the pound 30,000/QALY threshold in over 95% of the simulations. When adefovir was included for patients with lamivudine resistance, peginterferon alpha-2a (40 kDa) had an incremental cost of pound 6100/QALY gained. CONCLUSIONS: Treatment with peginterferon alpha-2a (40 kDa) for a defined duration of 48 weeks, although more expensive than lamivudine therapy, provides improvement in health outcomes, with a cost-effectiveness ratio well below the current UK cost-effectiveness threshold.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;See also:&lt;/STRONG&gt;&amp;nbsp;&lt;A href="nelh:295948:0" name=internalLink&gt;NHS EED&lt;/A&gt; for this article&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>380685</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1017/S0266462309090229]]&gt;</url>
    <title>Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice</title>
    <publicationDate>2009-04-01T00:00:00</publicationDate>
    <publisher>Cambridge University Press</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,RECENT ADDITIONS,CHRONIC HEPATITIS C,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The study concludes that, based on cost and effectiveness data collected from routine clinical practice, treatment with pegylated interferon and ribavirin is generally cost-effective. The study shows that there are variations according to patient subgroup and for older (aged 50 or over) genotype 1 patients with cirrhosis, antiviral treatment appears less cost-effective.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; This study assesses whether pegylated interferon and ribavirin is cost-effective compared with no antiviral treatment provided in routine clinical practice, for different patient subgroups.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; The cost-effectiveness analysis (CEA) uses a Markov decision model to estimate the lifetime cost per quality-adjusted life-year (QALY) of antiviral treatment compared with no treatment. The model is populated with data on sustained virological responses, costs, and transition probabilities all taken from a large representative sample of UK cases and centers (Trent HCV database).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The CEA found that pegylated interferon and ribavirin was cost-effective for most patient subgroups. The CEA found that for patients with genotype non-1, the intervention led to cost reductions and gains of at least 0.5 QALYs. For genotype 1 cases with mild or moderate disease, and younger cirrhotic patients (aged 40 or less), costs per QALY remained below 20,000 pound sterling ($40,000 or 29,000 euro). For genotype 1 cases with cirrhosis aged 50, the mean cost per QALY rose to over 60,000 pound sterling ($120,000 or 87,000 euro).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Grishchenko M, Grieve RD, Sweeting MJ, De Angelis D, Thomson BJ, Ryder SD, Irving WL, Trent HCV Study Group. Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice. &lt;EM&gt;Int J Technol Assess Health Care&lt;/EM&gt; 2009;25(2):171-80.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293607</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17635373]]&gt;</url>
    <title>Cost-effectiveness of suppressing hepatitis B virus DNA in immune tolerant patients to prevent hepatocellular carcinoma and cirrhosis</title>
    <publicationDate>2007-08-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HEPATITIS B,HEPATITIS,LIVER,GASTROENTEROLOGY &amp; LIVER DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Enriquez, AD et al Alimentary Pharmacology and Therapeutics 2007 Aug 1;26(3):383-91&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract: &lt;/STRONG&gt;BACKGROUND: For patients with hepatitis B virus (HBV) infection in the immune tolerant phase, the current standard of care is to not offer treatment. However, the recent Risk Evaluation of the Viral Load Elevation and Associated Liver Disease/Cancer-In study results show a striking relationship between high HBV DNA levels and risk for hepatocellular carcinoma and cirrhosis. AIM: In a cost effectiveness analysis, to assess whether immune tolerant patients with high HBV DNA levels should undergo treatment. METHODS: We created a lifetime Markov model to evaluate the cost-effectiveness of two strategies for immune tolerant hepatitis B: (i) HBV DNA suppression with lamivudine, (ii) no treatment. Patients cycled between the following health states: viral suppression, ongoing viremia, seroconversion, hepatocellular carcinoma, cirrhosis and death. RESULTS: Compared with the no treatment strategy, lamivudine therapy was more expensive but more cost-effective with an additional cost of $5784 and $12 584 per quality adjusted life year gained in males and females, respectively. Treatment resulted in a gain in life expectancy and a decrease in lifetime risk of hepatocellular carcinoma and cirrhosis. CONCLUSIONS: Suppressing HBV DNA to prevent hepatocellular carcinoma and cirrhosis in immune tolerant patients is very cost-effective, and treatment of these patients may be considered. Future prospective clinical trials will need to be undertaken to confirm our findings.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;See also: &lt;/STRONG&gt;&lt;A href="nelh:293007:0" name=internalLink&gt;NHS EED record&lt;/A&gt; for this article.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293605</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&amp;pubmedid=17349451]]&gt;</url>
    <title>Cost-effectiveness of treatment for hepatitis C in an urban cohort co-infected with HIV</title>
    <publicationDate>2007-03-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,CHRONIC HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Campos, NG et al American Journal of Medicine 2007 Mar;120(3):272-9&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract: &lt;/STRONG&gt;PURPOSE: Recent clinical trials have evaluated treatment strategies for chronic infection with hepatitis C virus (HCV) in patients co-infected with human immunodeficiency virus (HIV). Our objective was to use these data to examine the cost-effectiveness of treating HCV in an urban cohort of co-infected patients. METHODS: A computer-based model, together with available published data, was used to estimate lifetime costs (2004 US dollars), life expectancy, and incremental cost per year of life saved (YLS) associated with 3 treatment strategies: (1) interferon-alfa and ribavirin; (2) pegylated interferon-alfa; and (3) pegylated interferon-alfa and ribavirin. The target population included treatment-eligible patients, based on an actual urban cohort of HIV-HCV co-infected subjects, with a mean age of 44 years, of whom 66% had genotype 1 HCV, 16% had cirrhosis, and 98% had CD4 cell counts &amp;gt;200 cells/mm3. RESULTS: Pegylated interferon-alfa and ribavirin was consistently more effective and cost-effective than other treatment strategies, particularly in patients with non-genotype 1 HCV. For patients with CD4 counts between 200 and 500 cells/mm3, survival benefits ranged from 5 to 11 months, and incremental cost-effectiveness ratios were consistently less than $75,000 per YLS for men and women of both genotypes. Due to better treatment efficacy in non-genotype 1 HCV patients, this group experienced greater life expectancy gains and lower incremental cost-effectiveness ratios. CONCLUSIONS: Combination therapy with pegylated interferon-alfa and ribavirin for HCV in eligible co-infected patients with stable HIV disease provides substantial life-expectancy benefits and appears to be cost-effective. Overcoming barriers to HCV treatment eligibility among urban co-infected patients remains a critical priority.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>380684</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/gut.2007.145516]]&gt;</url>
    <title>Costs and cost-effectiveness of different follow-up schedules for detection of occupational hepatitis C virus infection</title>
    <publicationDate>2009-01-01T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,DIAGNOSTIC PROCEDURES,BLOOD TESTS,RECENT ADDITIONS,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; In health care workers (HCWs) exposed to hepatitis C virus (HCV), a strategy based on early HCV RNA testing shortens the period during which the HCW's wait for his HCV status, leads to lower risk of progression to&amp;nbsp;chronic hepatitis C (CHC)&amp;nbsp;and is reasonably cost-effective.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; The purpose of this study was to compare the costs and cost-effectiveness (C/E) of early HCV RNA testing (alternative-US recommendations) after occupational exposure to HCV with existing follow-up strategies: (1) French, anti-HCV antibodies and alanine transaminase (ALT) activity at months 1, 3 and 6; (2) European, monthly ALT activity for 4 months and anti-HCV antibodies at month 6; (3) and baseline-US, anti-HCV antibodies and ALT activity at month 6.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A decision tree simulated each strategy for 7300 HCWs exposed to HCV each year in France, taking into account the impact of early diagnosis on the response to antiviral treatment and the deterioration of HCW quality of life after exposure.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; For a HCV transmission risk of 0.5% after exposure, the French strategy led to the highest costs/person (181.40 euros) and the baseline-US strategy to the lowest (126.60 euros) (178.50 euros) for alternative-US). The shortest mean time to HCV infection diagnosis (1 month) and the lowest number of chronic hepatitis C (CHC) patients (1.9/7300 HCWs exposed) was obtained with the alternative-US strategy (vs 6 months and 7.9 CHC, respectively with baseline-US). Compared with the alternative-US, the French strategy was associated with higher costs and lower utilities, and the European with a higher incremental C/E ratio. Compared with the baseline-US strategy, the alternative-US strategy C/E ratio was 2020 euros per quality-adjusted life year saved.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Deuffic-Burban S, Abiteboul D, Lot F, Branger M, Bouvet E, Yazdanpanah Y. Costs and cost-effectiveness of different follow-up schedules for detection of occupational hepatitis C virus infection. &lt;EM&gt;Gut &lt;/EM&gt;2009;58(1):105-10.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281259</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17509051]]&gt;</url>
    <title>Crohn's disease: systematic review of assessment of disease severity and its relevance to surgery</title>
    <publicationDate>2008-03-10T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;SPAN title="Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland."&gt;Rao, P.K. &lt;A href="#javascript:AL_get(this," ?jour?, ?Colorectal Dis.?);?&gt;Colorectal Dis.&lt;/A&gt;&lt;/SPAN&gt; 2007 Oct;9(8):678-85. Epub 2007 May 17.&lt;/P&gt;
&lt;P class=abstract&gt;BACKGROUND: The aims of treatments for Crohn's disease are symptom control by medical or surgical means and improvement in health-related quality of life (HRQOL). A wide number of classification systems, instruments of disease activity measurement (DAM) and HRQOL are available, but few are used in routine surgical practice. OBJECTIVE: To review the validity of DAM and HRQOL instruments and their applicability to surgically treated patients. METHOD: A systematic literature search was undertaken to identify these instruments. Qualifying articles were used to determine the construct, content and criterion validity of the instruments identified with respect to surgically treated patients. RESULTS: Thirteen disease activity indices and 11 HRQOL assessment tools were identified. Construct validity was demonstrated throughout but concerns of content and criterion validity were noted. CONCLUSION: None of the current disease activity or HRQOL tools can be used without potential bias in a trial of surgical vs medical therapy as the items included favour the outcomes experienced following medical therapy. A more balanced assessment tool in the setting of a multidisciplinary trial is needed.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>105351</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.helicobacter.org/download/consensus_report.pdf]]&gt;</url>
    <title>Current concepts in the management of Helicobacter pylori infection - The Maastricht 2-2000 consensus report</title>
    <publicationDate>2002-02-01T00:00:00</publicationDate>
    <publisher>European Helicobacter Study Group</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,STOMACH,DIAGNOSTIC PROCEDURES,HELICOBACTER PYLORI,STOOL TESTS,BREATH TESTS,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims&lt;/STRONG&gt;:&amp;nbsp;&amp;nbsp; This consensus is an update&amp;nbsp;of the 1997 Maastricht Consensus report.&amp;nbsp; Although created by a European group the specialists involved included international experts.&amp;nbsp; The intent of the consensus is to update the original considering all the additional information that has been published since 1997. The three main areas of the consensus are with who and how to treat, the public health care issues of h.pylori, and infection in children.&amp;nbsp; The text includes a summary of&amp;nbsp;the key management strategies in table format.&amp;nbsp; Published in &lt;EM&gt;Alimentary Pharmacology and Therapeutics&lt;/EM&gt; 2002;16(2):167-180.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience&lt;/STRONG&gt;:&amp;nbsp;Primary and secondary clinical practice irrespective of specialty.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;Full-text open access via the &lt;A href="http://www.helicobacter.org/" target="_blank"&gt;European Helicobacter pylori study group&lt;/A&gt; or from the ATP journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309254</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.clinicaladvances.com/index.php/our_publications/gastro_hep-article/1148/]]&gt;</url>
    <title>Current controversies in Crohn's disease: a roundtable discussion of the BRIDGe group</title>
    <publicationDate>2008-10-01T00:00:00</publicationDate>
    <publisher>Millennium Medical Publishing</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt; In March 2008, a roundtable discussion was convened by the inflammatory bowel disease (IBD) specialist panel the BRIDGe (Building Resources and Research in IBD Globally) group, which consists of junior faculty gastroenterologists who have undergone advanced fellowship training at IBD referral centers in the United States, Canada, the United Kingdom, and Australia. An agenda was formulated to discuss three current controversies in Crohn’s disease management: the role of 5-aminosalicylates, the use of biologic combination therapy versus monotherapy, and the use of step-up therapy versus top-down therapy for Crohn’s disease. The aim of the meeting was three-fold: to review the data pertaining to each topic; to collect opinions from the participants as to their analysis of the literature and their current practice; and, where possible, to formulate recommendations of current best practice given the available evidence. This manuscript summarizes the discussions on these three areas of controversy in the current management of Crohn’s disease.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Sparrow, M. P., Irving, P. M., Baidoo, L., Bressler, B., Cheifetz, A. S., Devlin, S. M., Harrell, L. E., Jones, J., Kozuch, P. L., Melmed, G. Y., Velayos, F. S., &amp;amp; Siegel, C. A. (2008) Current controversies in CD: A roundtable discussion of the BRIDGe group. &lt;I&gt;Gastroenterology and Hepatology&lt;/I&gt;, 4(10):713-720.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in October 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>381413</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1478-3231.2009.02085.x]]&gt;</url>
    <title>Current management of hepatitis B virus infection before and after liver transplantation</title>
    <publicationDate>2009-10-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,LIVER TRANSPLANTATION,RECENT ADDITIONS,SURGERY,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The newer anti-hepatitis&amp;nbsp;B virus (HBV)&amp;nbsp;agents improve the treatment of HBV both pretransplant and post-transplant. HBV immunoglobulin is still used in combination with an anti-HBV agent for post-transplant prophylaxis. Monoprophylaxis with one of the new anti-HBV agents might be possible, particularly in patients preselected as having a low risk of HBV recurrence, but further data are needed and strategies to ensure compliance must be used.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; The progress in treatment against HBV has substantially improved the outcome of all HBV-infected patients. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We systematically reviewed the existing data in the management of HBV transplant patients in order to assess the optimal regimen in the pretransplant setting, for post-transplant prophylaxis and for therapy of HBV recurrent infection.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; All data suggest that an effective pretransplant anti-HBV therapy prevents post-transplant HBV recurrence. Pretransplant therapy has been based on lamivudine with addition of adefovir upon lamivudine resistance, but the use of newer, potent high-genetic barrier agents is expected to improve long-term efficacy. Moreover, it may lead to improvement of liver function, which sometimes removes the need for transplantation, although more objective criteria for removal from waiting lists are required. After liver transplantation, the combination of HBV immunoglobulin and one nucleos(t)ide analogue, mostly lamivudine, is currently the best approach, almost eliminating the probability of HBV recurrence. Treatment of post-transplant HBV recurrence has been mainly studied with lamivudine, but it will be most effective with entecavir and tenofovir, which have a low risk of resistance.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Papatheodoridis GV, Cholongitas E, Archimandritis AJ, Burroughs AK. Current management of hepatitis B virus infection before and after liver transplantation. &lt;EM&gt;Liver Int &lt;/EM&gt;2009;29(9):1294-305. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;&amp;nbsp;This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>251160</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1345/aph.1G374]]&gt;</url>
    <title>Cyclosporine for severe ulcerative colitis</title>
    <publicationDate>2006-01-01T00:00:00</publicationDate>
    <publisher>Harvey Whitney Books Co.</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This article evaluates evidence for the use of cyclosporine in treating patients with severe ulcerative colitis.</description>
    <body>&lt;![CDATA[ &lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Pham CQ, Efros CB and Berardi, RR 2006; Annals of Pharmacotherapy 40 (1) pp. 96-101 
&lt;H2&gt;Original article abstract:&lt;/H2&gt;
&lt;P&gt;OBJECTIVE: To evaluate evidence for the use of cyclosporine in treating patients with severe ulcerative colitis. DATA SOURCES: A literature search was performed using MEDLINE, EMBASE, Cochrane Database, and ISI Web of Knowledge (1966-November 2005) with the search terms cyclosporine, cyclosporin A, CsA, ulcerative colitis, UC, inflammatory bowel disease, IBD, steroid-refractory, and immunosuppression. Additional papers were located by hand-searching relevant references. Only human studies in adults and literature published in English were included. DATA SYNTHESIS: Intravenous cyclosporine has been evaluated for the treatment of severe ulcerative colitis in 4 randomized, controlled trials, as well as in many open-label and retrospective studies. Studies that evaluated cyclosporine for severe ulcerative colitis were reviewed. All 4 controlled trials showed an initial positive clinical response as defined by the Crohn's Activity Index when intravenous cyclosporine 4 mg/kg/day was administered as monotherapy or combined with intravenous corticosteroids. One of the 4 trials indicated that high-dose cyclosporine (4 mg/kg/day) has no additional clinical benefit over the low-dose (2 mg/kg/day) and that the lower dose may improve safety related to dose-dependent adverse effects. CONCLUSIONS: There is evidence to support the use of intravenous cyclosporine for patients with severe ulcerative colitis who are refractory to corticosteroid therapy. Because most of the adverse effects associated with cyclosporine are dose dependent, therapy should be initiated with the lower 2 mg/kg/day dose. Subsequent doses should be adjusted based on cyclosporine blood concentrations of 150-250 ng/mL. Cyclosporine should be used only to induce remission and serve as a "bridge" to azathioprine or 6-mercaptopurine maintenance therapy. At this time, there are insufficient data to support the long-term use of cyclosporine monotherapy for avoidance of surgery or maintenance of remission.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;This article is &lt;STRONG&gt;not &lt;/STRONG&gt;available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>380687</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1002/lt.21712]]&gt;</url>
    <title>Decision analysis model for hepatitis B prophylaxis one year after liver transplantation</title>
    <publicationDate>2009-04-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,DISEASE PREVENTION,LIVER TRANSPLANTATION,RECENT ADDITIONS,SURGERY,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract:&lt;/STRONG&gt; In patients receiving orthotopic liver transplantation, hepatitis B recurrence rates have decreased significantly with the use of various methods for prophylaxis. At present, a combination of hepatitis B immunoglobulin (HBIG) and lamivudine is the standard of care, resulting in recurrence rates of 0% to 11%. Recent data suggest that the addition of adefovir to lamivudine is successful in treating patients with recurrent hepatitis B infection. A Markov model was used to compare costs and outcomes of 2 strategies for hepatitis B prophylaxis 1 year after transplantation. The first consisted of prophylaxis with lamivudine and adefovir (strategy 1), whereas the second consisted of intramuscular HBIG and lamivudine (strategy 2) with the addition of adefovir in patients who subsequently developed hepatitis B recurrence. Patients who failed with adefovir and lamivudine were then treated with tenofovir and entecavir. 16.8% of liver transplant recipients had hepatitis B recurrence after 10 years of treatment with lamivudine and HBIG. The medical costs for strategy 1 and strategy 2 after 10 years of therapy were $151,819 and $166,246, respectively, and this resulted in cost savings of $14,427. The decision analysis model began 1 year after liver transplantation. A 1-way sensitivity analysis demonstrated that the model was most sensitive to cost changes of adefovir and HBIG injections as well as variations in the hepatitis B virus recurrence rate. The model was robust to costs of lamivudine, laboratory costs, administrative fees, and office visit fees. Our decision analysis model resulted in marked savings in costs with strategy 1 (lamivudine and adefovir), providing pharmacoeconomic support for the use of this strategy as first-line therapy in hepatitis B prophylaxis in liver transplant recipients 1 year after liver transplantation. Copyright 2009 AASLD.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Saab S, Ham MY, Stone MA, Holt C, Tong M. Decision analysis model for hepatitis B prophylaxis one year after liver transplantation. &lt;EM&gt;Liver Transpl &lt;/EM&gt;2009;15(4):413-20.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>380745</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1440-1746.2009.05874.x]]&gt;</url>
    <title>Development of thyroid diseases in the treatment of chronic hepatitis C with alpha-interferon may be a good prognosticator in achieving a sustained virological response: a meta-analysis</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,RECENT ADDITIONS,CHRONIC HEPATITIS C,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Despite lacking supportive evidence from the meta-analysis, it is important that this&amp;nbsp;hypothesis is confirmed (or refuted) in future studies.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Thyroid dysfunction is the most common endocrinopathy associated with hepatitis C and its interferon-based treatment. When undergoing treatment, interferon and ribavirin synergize to potently stimulate the immune system in order to eradicate the virus. One of the innocent bystanders in this accentuated response is the thyroid. The present study investigated whether thyroid dysfunction while undergoing combination treatment for hepatitis C is a favorable prognostic maker for a sustained virological response.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We carried out a prospective clinical audit in 201 patients treated with combination ribavirin and alpha-interferon and determined the prevalence of sustained virological response in patients in association with thyroid disease. A meta-analysis was also carried out pooling 741 patients from four previous studies on this topic.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; There was positive and significant association between thyroid disease and viral clearance. This was not supported by the meta-analysis, however, and some plausible explanations are proffered for this inconsistency.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Tran HA, Malcolm Reeves GE, Gibson R, Attia JR. Development of thyroid diseases in the treatment of chronic hepatitis C with alpha-interferon may be a good prognosticator in achieving a sustained virological response: a meta-analysis. &lt;EM&gt;J Gastroenterol Hepatol&lt;/EM&gt; 2009;24(7):1163-8.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>343595</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.aasld.org/practiceguidelines/Documents/Bookmarked%20Practice%20Guidelines/Diagnosis_of_HEP_C_Update.Aug%20_09pdf.pdf]]&gt;</url>
    <title>Diagnosis, management, and treatment of hepatitis C: an update</title>
    <publicationDate>2009-03-25T00:00:00</publicationDate>
    <publisher>American Association for the Study of Liver Diseases</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,NON-ALCOHOLIC,DIAGNOSTIC PROCEDURES,BIOPSY,LIVER,RECENT ADDITIONS,CIRRHOSIS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aim:&lt;/STRONG&gt; These recommendations provide a data-supported approach to establishing guidelines. They are based on the following: (1) a formal review and analysis of the recently published world literature on the topic (Medline search up to September 2008); (2) the American College of Physicians’ Manual for Assessing Health Practices and Designing Practice Guidelines; (3) guideline policies, including the American Association for the Study of Liver Diseases’ (AASLD) Policy on the Development and Use of Practice Guidelines and the American Gastroenterological Association’s Policy Statement on the Use ofMedical Practice Guidelines;&amp;nbsp;and (4) the experience of the authors in regard to hepatitis C. Intended for use by physicians, these recommendations suggest preferred approaches to the diagnostic, therapeutic and preventive aspects of care. They are intended to be flexible, in contrast to standards of care, which are inflexible policies to be followed in every case. Specific recommendations are based on relevant published information.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended&amp;nbsp;audience: &lt;/STRONG&gt;Hepatologists&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in March 2009&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323831</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.clinbiochem.2008.06.020]]&gt;</url>
    <title>Diagnostic accuracy, reproducibility and robustness of fibrosis blood tests in chronic hepatitis C: a meta-analysis with individual data</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,DIAGNOSTIC PROCEDURES,BLOOD TESTS,RECENT ADDITIONS,SEPTEMBER 2009,CHRONIC HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; This study on clinical applicability shows significant differences in diagnostic accuracy, inter-center reproducibility, and robustness of biomarkers to changes in population characteristics between blood tests.&amp;nbsp;The&amp;nbsp;meta-analysis validates the global diagnostic accuracy of FibroMeter, Fibrotest, and APRI, but not Hepascore, and shows significant differences in terms of performance.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Four independent centers provided four blood tests and Metavir staging from 825 patients with chronic hepatitis C.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; FibroMeter area under the receiver operating characteristic&amp;nbsp;(AUROC) (0.840) for significant fibrosis was superior to those of Fibrotest (0.803, &lt;I&gt;p&lt;/I&gt;&amp;nbsp;=&amp;nbsp;0.049), APRI (0.789, &lt;I&gt;p&lt;/I&gt;&amp;nbsp;=&amp;nbsp;0.001) and Hepascore (0.781, &lt;I&gt;p&lt;/I&gt;&amp;nbsp;&amp;lt;&amp;nbsp;0.001). The misclassification rate was lower for FibroMeter (23%) than for Fibrotest and Hepascore (both 28%, &lt;I&gt;p&lt;/I&gt;&amp;nbsp;&amp;lt;&amp;nbsp;0.001). The variation in the diagnostic cut-offs of tests among centers, reflecting the overall reproducibility, was: FibroMeter: 4.2%, APRI: 24.0%, Fibrotest: 24.2%, Hepascore: 35.0%. Accordingly, the proportion of patients diagnosed with significant fibrosis changed: FibroMeter: 0.8%, Hepascore: 2.4% (&lt;I&gt;p&lt;/I&gt;&amp;nbsp;=&amp;nbsp;0.02 vs FibroMeter), Fibrotest: 5.8% (&lt;I&gt;p&lt;/I&gt;&amp;nbsp;&amp;lt;&amp;nbsp;10&lt;SUP&gt;-&amp;nbsp;3&lt;/SUP&gt;), APRI: 18.2% (&lt;I&gt;p&lt;/I&gt;&amp;nbsp;&amp;lt;&amp;nbsp;10&lt;SUP&gt;-&amp;nbsp;3&lt;/SUP&gt;).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Leroy V, Halfon P, Bacq Y, Boursier J, Rousselet MC, Bourliere M, et al. Diagnostic accuracy, reproducibility and robustness of fibrosis blood tests in chronic hepatitis C: a meta-analysis with individual data. &lt;EM&gt;Clin Biochem&lt;/EM&gt; 2008 Nov;41(16-17):1368-76.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281279</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17324124]]&gt;</url>
    <title>Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy</title>
    <publicationDate>2008-03-10T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: &lt;/P&gt; &lt;P&gt;&lt;SPAN title="The American journal of gastroenterology."&gt;Von Roon, A.C. &lt;A href="#javascript:AL_get(this," ?jour?, ?Am J Gastroenterol.?);?&gt;Am J Gastroenterol.&lt;/A&gt;&lt;/SPAN&gt; 2007 Apr;102(4):803-13. Epub 2007 Feb 23.&lt;/P&gt; &lt;P class=abstract&gt;OBJECTIVES: Fecal calprotectin (FC) is a relatively new marker of intraluminal intestinal inflammation. Using meta-analytical techniques, the study aimed to evaluate the diagnostic precision of FC for inflammatory bowel disease (IBD) and colorectal cancer (CRC) in adults and children. METHODS: Quantitative meta-analysis was performed on prospective studies, comparing FC levels against the histological diagnosis. Sensitivity, specificity, and diagnostic odds ratio (DOR) were calculated for each study. Summary receiver-operating characteristic (sROC) curves and subgroup analysis were undertaken. Study quality and heterogeneity were evaluated. RESULTS: Thirty studies of 5,983 patients were included. FC levels in patients with IBD were higher by 219.2 micrograms per gram (microg/g) compared with normal patients (P &lt; 0.001). sROC curve analysis showed a sensitivity of 0.95 (95% CI 0.93-0.97), specificity of 0.91 (95% CI 0.86-0.91), and an area under the curve (AUC) of 0.95 for the diagnosis of IBD. Patients with colorectal neoplasia had nonsignificantly higher FC levels by 132.2 microg/g compared with noncancer controls (P= 0.18). Sensitivity and specificity of FC for the diagnosis of CRC were 0.36 and 0.71, respectively, with an AUC of 0.66. The diagnostic precision of FC for IBD was higher in children than adults with better accuracy at a cutoff level of 100 microg/g versus 50 microg/g. Sensitivity analysis and metaregression analysis did not significantly alter the results. CONCLUSIONS: FC cannot be recommended as a screening test for CRC in the general population. FC appeared to offer a good diagnostic precision in distinguishing IBD from non-IBD diagnoses, with higher precision at a cutoff of 100 microg/g.&lt;/P&gt; &lt;P class=abstract&gt;See also the &lt;A href="nelh:283811:0" name=internalLink&gt;DARE record&lt;/A&gt; for this article.&lt;/P&gt; &lt;P&gt;&lt;EM&gt;The American Journal of Gastroenterology is the official journal of the American College of Gastroenterology and publishes a variety of material including editorials, clinical reviews, correspondance and research articles.&lt;/EM&gt;&lt;/P&gt; &lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: This article is &lt;STRONG&gt;not&lt;/STRONG&gt; available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>346150</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1038/ajg.2009.190]]&gt;</url>
    <title>Distribution and manifestations of inflammatory bowel disease in Asians, Hispanics, and African Americans: a systematic review</title>
    <publicationDate>2009-08-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Prevalence and incidence rates of inflammatory bowel disease (IBD) in Hispanics and Asians have recently increased. There are many similarities and differences in disease location and behavior among racial/ethnic groups. There is a paucity of literature on all aspects of the disease in Hispanics, in the incidence and prevalence of IBD in African Americans, and in Asians with IBD outside Asia.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Although IBD has been reported worldwide, most studies have focused on Caucasian populations. Our aim was to summarize the existing epidemiological literature, identify temporal trends, and highlight areas for future research.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We carried out a systematic review following standard guidelines to evaluate the incidence, prevalence, temporal trends, disease characteristics, and extra-intestinal manifestations (EIMs) of IBD in African American, Hispanic, and Asian adult patients. Two investigators independently identified eligible studies through 2008 using structured keyword searches in PubMed, applied several inclusion and exclusion criteria, and abstracted the data.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Twenty-eight publications were included, encompassing 1,272 Hispanic, 547 African American, and 35,844 Asian patients with IBD. Greater proportions of Hispanic (36.7-84.3%) and Asian (30.6-74.7%) patients were diagnosed with ulcerative colitis (UC) than with Crohn's disease (CD) compared with African Americans (27.6-40.6%). The prevalence rates of IBD in Hispanics in Puerto Rico varied between 5 (rural) and 62 (urban) per 100,000. Crude prevalence rates in Asia varied between 6 (Singapore) and 136 (South Asians in UK) per 100,000 for UC, and between 3 (Singapore) and 33 (South Asians in UK) per 100,000 for CD. Three studies reported a rising annual incidence rate among Hispanics (from 2.6 to 7.5 per 100,000) and Asians (from 0.22 to 3.62 per 100,000). Fistulizing CD was reported in nearly one-third of Hispanic patients, up to one-quarter of African-American patients, and up to one-half of Asian patients. Ileocolonic disease was the most common site of CD among the three racial/ethnic groups, with skin and joint manifestations noted as the most common EIMs.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Hou JK, El-Serag H, Thirumurthi S. Distribution and manifestations of inflammatory bowel disease in Asians, Hispanics, and African Americans: a systematic review. &lt;EM&gt;Am J Gastroenterol&lt;/EM&gt; 2009;104(8):2100-9.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345634</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1038/ajg.2009.15]]&gt;</url>
    <title>Do NSAIDs, antibiotics, infections, or stress trigger flares in IBD?</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract:&lt;/STRONG&gt; Non-steroidal anti-inflammatory drugs (NSAIDs), antibiotics, enteric or other systemic infections, and stress have all been reported to be potential triggers of inflammatory bowel disease (IBD). Although a mechanism of triggering a flare of IBD can be hypothesized for each factor, the associations of these factors with flares of IBD remains confusing. In this review, we analyze the literature that explores these associations. There is some evidence to support an association between NSAID use and flares but little data to associate antibiotic use directly with flares. An important connection between antibiotic use and an exacerbation of symptoms is through the development of Clostridium difficile infections. However, for all enteric infections, including C. difficile, it is unclear whether these infections simply trigger symptoms in patients with IBD that resolve on resolution of the infection, or whether they truly trigger a flare of intestinal inflammation that outlasts the infection. There is a paucity of evidence that other systemic infections trigger flares of IBD. Although there is strong evidence for an association between perceived stress levels and flares, there is a weaker association between a simple accounting of stressful life events and flares. Much of the literature is limited by a lack of adequate control groups and failure to report on base rates in the population under study (i.e., NSAIDs and antibiotic use, occurrence of infections, and stress levels). More large population-based matched cohort or case crossover studies and a continued emphasis on prospective designs are needed to better explore these potential associations. Clinical implications given the current state of knowledge are discussed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Singh S, Graff LA, Bernstein CN. Do NSAIDs, antibiotics, infections, or stress trigger flares in IBD? &lt;EM&gt;Am J Gastroenterol&lt;/EM&gt; 2009;104(5):1298-313.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309211</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18076738]]&gt;</url>
    <title>Drug interactions in inflammatory bowel disease</title>
    <publicationDate>2008-01-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Abstract: &lt;/STRONG&gt;Patients with inflammatory bowel disease (IBD) often require a combination of drugs, some of which are taken for many years, to control their disease. Some of these drugs have potentially serious side effects, which may be initiated or exacerbated by interaction with other agents used to treat IBD. Furthermore, patients with IBD may take treatment for other, unrelated conditions. It is important for doctors who manage patients with IBD to be aware of, and thereby minimize, the dangers presented by such drug interactions. In this review, we summarize the common and important interactions of drugs used in patients with IBD, including some that may be of therapeutic benefit. Particular attention is paid to interactions that occur where both drugs are used to treat IBD.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Irving, P. M., Shanahan, F., &amp;amp; Rampton, D. S. (2008) Drug interactions in inflammatory bowel disease. &lt;I&gt;American Journal of Gastroenterology&lt;/I&gt;, 103(1):207-219.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in January 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>325958</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.bsg.org.uk/images/stories/docs/patients/5asa_ibd_pt.doc]]&gt;</url>
    <title>Drugs for inflammatory bowel disease: the aminosalicylates (5-ASA)</title>
    <publicationDate></publicationDate>
    <publisher>British Society of Gastroenterology</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE,RECENT ADDITIONS,SEPTEMBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The British Society of Gastroenterology is an organisation focused on the promotion of gastroenterology within the United Kingdom. It has over three thousand members drawn from the ranks of physicians, surgeons, pathologists, radiologists, scientists, nurses, dietitians, and others interested in the field. Founded in 1937 it has grown from a club to be a major force in British medicine, with representation within the British Royal Colleges and thus to the Department of Health and Government. Internationally it is represented at World and European level. The BSG is a registered charity.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt; This document is one of a series designed to provide information for gastroenterologists, primary care clinicians and patients with IBD regarding the use of disease modifying drugs, their indications, side effects and guidelines for safe monitoring. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>156900</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.cgh.2006.03.001]]&gt;</url>
    <title>Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus</title>
    <publicationDate>2006-05-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,OESOPHAGUS,BARRETT'S OESOPHAGUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;H2&gt;Description&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;Background &amp;amp; Aims&lt;/STRONG&gt;:&amp;nbsp;The exact incidence of adenocarcinoma in patients with Barrett's esophagus (BE) is not known and is reported to vary from 0.2%-2% per year. Published series of patients with BE have included &lt;BR&gt;relatively small numbers of patients with limited duration of follow-up. The goal of this study was to define the prevalence and incidence of dysplasia and cancer and evaluate the paths of progression in a large multicenter cohort of BE patients. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods&lt;/STRONG&gt;: The BE study is a multicenter clinical and endoscopic outcomes project involving a single large database of patients with BE. Data from each of the participating centers were merged into the main study database. Cancers and HGD occurring within 12 months of the index endoscopy were regarded as prevalent cases. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt;&amp;nbsp;Preliminary results from this trial define the prevalence and incidence of dysplasia and cancer in a multicenter cohort of patients with BE. At least half the patients who developed HGD and/or cancer had 2 consecutive initial endoscopies with biopsies revealing nondysplastic mucosa. The majority of patients with LGD regressed and had a cancer incidence similar to all BE patients.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Topic lead's review:&lt;/STRONG&gt; This study is further evidence that the annual incidence of esophageal adenocarcinoma is 0.5% in the USA, consisitent with previous studies, although this may very well underestimate the incidence in higher risk regions such as the UK.&lt;/P&gt;
&lt;P&gt;This article is also consistent with the rate of high grade dysplasia and low grade dysplasia that is found in Barrett's patients. This study gives the incidence of surrogate end points such as dysplasia, which could be used in translational studies.&lt;/P&gt;
&lt;P&gt;Review by Professor Janusz Jankowski for Gastroenterology and Liver Diseases Specialist Library (GLDSL) - August 2006.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Audience&lt;/STRONG&gt;: Health care professionals&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;This article is &lt;STRONG&gt;not &lt;/STRONG&gt;available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>396512</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20573925]]&gt;</url>
    <title>Early use of TIPS in patients with cirrhosis and variceal bleeding</title>
    <publicationDate>2010-06-24T00:00:00</publicationDate>
    <publisher>New England Journal of Medicine</publisher>
    <publicationType>RANDOMISED CONTROLLED TRIAL</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,ALCOHOLIC LIVER DISEASE,ALCOHOLIC CIRRHOSIS,CIRRHOSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; In patients with cirrhosis who were hospitalized for acute variceal bleeding and at high risk for treatment failure, the early use of TIPS was associated with significant reductions in treatment failure and in mortality. (Current Controlled Trials number, ISRCTN58150114.)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Patients with cirrhosis in Child-Pugh class C or those in class B who have persistent bleeding at endoscopy are at high risk for treatment failure and a poor prognosis, even if they have undergone rescue treatment with a transjugular intrahepatic portosystemic shunt (TIPS). This study evaluated the earlier use of TIPS in such patients.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We randomly assigned, within 24 hours after admission, a total of 63 patients with cirrhosis and acute variceal bleeding who had been treated with vasoactive drugs plus endoscopic therapy to treatment with a polytetrafluoroethylene-covered stent within 72 hours after randomization (early-TIPS group, 32 patients) or continuation of vasoactive-drug therapy, followed after 3 to 5 days by treatment with propranolol or nadolol and long-term endoscopic band ligation (EBL), with insertion of a TIPS if needed as rescue therapy (pharmacotherapy-EBL group, 31 patients).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; During a median follow-up of 16 months, rebleeding or failure to control bleeding occurred in 14 patients in the pharmacotherapy-EBL group as compared with 1 patient in the early-TIPS group (P=0.001). The 1-year actuarial probability of remaining free of this composite end point was 50% in the pharmacotherapy-EBL group versus 97% in the early-TIPS group (P&amp;lt;0.001). Sixteen patients died (12 in the pharmacotherapy-EBL group and 4 in the early-TIPS group, P=0.01). The 1-year actuarial survival was 61% in the pharmacotherapy-EBL group versus 86% in the early-TIPS group (P&amp;lt;0.001). Seven patients in the pharmacotherapy-EBL group received TIPS as rescue therapy, but four died. The number of days in the intensive care unit and the percentage of time in the hospital during follow-up were significantly higher in the pharmacotherapy-EBL group than in the early-TIPS group. No significant differences were observed between the two treatment groups with respect to serious adverse events.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; García-Pagán JC, Caca K, Bureau C, Laleman W, Appenrodt B, Luca A, Abraldes JG, Nevens F, Vinel JP, Mössner J, Bosch J; Early TIPS (Transjugular Intrahepatic Portosystemic Shunt) Cooperative Study Group. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med. 2010 Jun 24;362(25):2370-9.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344519</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.pasa.nhs.uk/pasa/Doc.aspx?Path=[MN][SP]/NHSprocurement/CEP/CEP08053.pdf]]&gt;</url>
    <title>Economic report: cost-effectiveness of ultrasound elastography in the assessment of liver fibrosis</title>
    <publicationDate>2009-02-19T00:00:00</publicationDate>
    <publisher>NHS Purchasing and Supply Agency</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,DIAGNOSTIC PROCEDURES,BIOPSY,ULTRASOUND,BLOOD TESTS,RECENT ADDITIONS,CIRRHOSIS,RADIOLOGY,FEBRUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=abstractSummary&gt;
&lt;P&gt;The Centre for Evidence-based Purchasing (CEP) provides impartial and objective information about medical technology to help the NHS make better purchasing decisions.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt; Ultrasound elastography is a medical diagnostic test which makes non-invasive measurements of the stiffness of tissue.&amp;nbsp; The non-invasive nature of the technique, its accuracy and the quick acquisition of screening results provide a good basis for the technique being promising for wider usage within the NHS, especially for screening for liver fibrosis.&amp;nbsp; This report presents findings on the potential cost-effectiveness of UE in the investigation of liber fibrosis compared with FibroTest and biopsy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in September 2009.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>346723</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.pasa.nhs.uk/pasa/Doc.aspx?Path=[MN][SP]/NHSprocurement/CEP/CEP09041.pdf]]&gt;</url>
    <title>Economic report: value of calprotectin in screening out irritable bowel syndrome</title>
    <publicationDate>2010-02-01T00:00:00</publicationDate>
    <publisher>NHS Purchasing and Supply Agency</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,IRRITABLE BOWEL SYNDROME,INFLAMMATORY BOWEL DISEASE,DIAGNOSTIC PROCEDURES,DISEASE PREVENTION,STOOL TESTING,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=abstractSummary&gt;
&lt;P&gt;The Centre for Evidence-based Purchasing (CEP) provides impartial and objective information about medical technology to help the NHS make better purchasing decisions.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt; Calprotectin is a protein originating from neutrophils which can be used ans an indicator of inflammation of the bowel, and may have diagnostic value in patients presenting with gastrointestinal symproms, in particularly to distinguish irritable bowel syndrome (IBS) from inflammatory bowel disease (IBD).&amp;nbsp; This document examines the costs and effectiveness associated with the use of calprotectin for screening out IBS in primary care.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in&amp;nbsp;February 2010&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>251174</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1572-0241.2005.41442.x]]&gt;</url>
    <title>Effect of 5-Aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies</title>
    <publicationDate>2005-06-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CANCER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A systematic review with metaanalysis of observational studies evaluating the association between 5-ASA use and colorectal cancer (CRC) or dysplasia among patients with ulcerative colitis.</description>
    <body>&lt;![CDATA[ &lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Velayos FS, Terdiman JP and Walsh JM 2005; American Journal of Gastroenterology 100 (6) pp. 1345-53 
&lt;H2&gt;Original article abstract&lt;/H2&gt;
&lt;P&gt;OBJECTIVES: We performed a systematic review with metaanalysis of observational studies evaluating the association between 5-ASA use and colorectal cancer (CRC) or dysplasia among patients with ulcerative colitis. METHODS: We conducted a search of Medline Embase Biosis, Web of Science, Cochrane Collaboration, manually reviewed the literature, and consulted with experts. Studies were included if they 1) evaluated and clearly defined exposure to 5-aminosalicylates in patients with ulcerative colitis, 2) reported CRC or dysplasia outcomes, 3) reported relative risks or odds ratio or provided data for their calculations. Quantitative analysis using a random-effects model is presented. RESULTS: Nine studies (3 cohort, 6 case-control) containing 334 cases of CRC, 140 cases of dysplasia, and a total of 1,932 subjects satisfied all inclusion criteria. Five studies reported CRC outcomes alone, two studies reported separate cancer and dysplasia outcomes, and two studies reported a combined outcome of CRC or dysplasia. All primary estimates are homogenous. Pooled analysis showed a protective association between use of 5-aminosalicylates and CRC (OR=0.51; 95% confidence interval (CI): 0.37-0.69) or a combined endpoint of CRC/dysplasia (OR 0.51; 95% CI: 0.38-0.69). 5-ASA use was not associated with a lower risk of dysplasia, although only two studies evaluated this outcome (OR=1.18; 95% CI: 0.41-3.43). CONCLUSION: Pooled results of observational studies support a protective association between 5-aminosalicylates and CRC or a combined endpoint of CRC/dysplasia in patients with ulcerative colitis. Additional studies analyzing the effect of 5-ASA on risk of dysplasia are needed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;This article is &lt;STRONG&gt;not&lt;/STRONG&gt; available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293622</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.cgh.2007.08.006]]&gt;</url>
    <title>Effect of human immunodeficiency virus and antiretrovirals on outcomes of hepatitis C: a systematic review from an epidemiologic perspective</title>
    <publicationDate>2007-11-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,HIV / AIDS,CHRONIC HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Kramer, JR et al Clinical Gastroenterology and Hepatology 2007 Nov;5(11):1321-1328.e7.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract: &lt;/STRONG&gt;BACKGROUND &amp;amp; AIMS: We systematically reviewed the literature examining the association of human immunodeficiency virus (HIV) and antiretroviral therapy (ART) with liver disease in patients with hepatitis C virus (HCV) infection. METHODS: PubMed was searched for studies examining hepatic fibrosis, cirrhosis, decompensated liver disease, hepatocellular carcinoma, and liver-related death. Thirty-nine reports (describing 34 unique studies) met inclusion criteria. Information was abstracted on study design, sampling frame, inclusion/exclusion criteria, sample size, results, and covariates used for adjustment. Because of the heterogeneity among study designs, a meta-analysis was not conducted. RESULTS: Nine of the 12 cross-sectional studies showed a statistically significant association between HIV co-infection and fibrosis or cirrhosis, whereas 7 retrospective cohort studies were inconsistent. Six studies examined decompensated liver disease as the outcome: 5 of these found a significantly increased risk in patients with HIV co-infection. The 7 studies examining liver-related death showed a trend toward an association with HIV co-infection, although only 4 were statistically significant. Four studies examined the effect of HIV on hepatocellular carcinoma, 2 of which found no association. Of 10 studies that investigated the effect of ART on the risk of liver disease, half reported a significant protective association. CONCLUSIONS: HIV co-infection is associated with an increased risk of advanced liver disease in hepatitis C virus-infected patients. Data on hepatocellular carcinoma are sparse, but an association is plausible given the increased risk of advanced liver disease. In contrast, data for an effect of ART are plentiful, but findings are inconsistent. More robust studies are needed on this topic.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>381386</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2704311/]]&gt;</url>
    <title>Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>Ferrata Storti Foundation</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,DISEASE PREVENTION,RECENT ADDITIONS,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; If 1,000 HBsAg-positive lymphoma patients receive prophylaxis, one will die from hepatitis B virus reactivation versus 25/1,000 if no prophylaxis is administered. This effect is probably mediated through a reduction of hepatitis B virus reactivation and hepatitis B virus (HBV)-related mortality. The ideal antiviral agent needs to be determined.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Lamivudine prophylaxis is an effective strategy in HbSAg-positive patients receiving cancer chemotherapy. Recent data indicate that a lamividune-prophylaxis strategy results in a decrease of HBV reactivation rates, though its effect on HBV-mortality remains equivocal. This report evaluates the benefits from this strategy among lymphoma patients and develops a management approach for patients with prolonged immunosuppression.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A Medline search was conducted to retrieve published trials on HBsAg-positive lymphoma patients receiving prophylactic lamivudine during chemotherapy. Basic inclusion criterion was to report HBV-reactivation rates with and without lamivudine prophylaxis. A meta-analysis of the risk of HBV-reactivation and HBV-related mortality was conducted, and the pooled effect was calculated as risk ratio (RR).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; We found that lamivudine prophylaxis is associated with a significant reduction in hepatitis B virus reactivation (RR 0.21, 95%CI 0.13-0.35) and a trend in reducing HBV-related mortality (RR 0.68, 95%CI 0.19-2.49). In order to study the long-term effects of anti-HBV prophylaxis when prolonged immunosuppression is needed, we used our findings to model a decision tree. Overall survival was the main outcome used in the analysis. Rituximab maintenance in B-cell lymphomas was used as a paradigm of prolonged immunosuppression. We found that extended anti-HBV prophylaxis can improve survival rates by 2.4% in HBsAg-positive patients.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Ziakas PD, Karsaliakos P, Mylonakis E. Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. &lt;EM&gt;Haematologica&lt;/EM&gt; 2009;94(7):998-1005.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>330597</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1186/cc4985]]&gt;</url>
    <title>Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure</title>
    <publicationDate>2006-07-19T00:00:00</publicationDate>
    <publisher>BioMed Central</publisher>
    <publicationType>RANDOMISED CONTROLLED TRIAL</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,ALCOHOLIC LIVER DISEASE,ALCOHOLIC HEPATITIS,ALCOHOLIC CIRRHOSIS,STEATOHEPATITIS,ALCOHOLIC,ACUTE LIVER FAILURE,LIVER FAILURE,CHRONIC LIVER FAILURE,RECENT ADDITIONS,CIRRHOSIS,ALCOHOLIC,NOVEMBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The molecular adsorbent recirculating system (MARS) device, and not the Prometheus device, significantly attenuates the hyperdynamic circulation in acute-on-chronic liver failure, presumably by a difference in removal rate of certain vasoactive substances. These findings suggest conspicuous conceptual differences among the albumin dialysis devices.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Patients with acute-on-chronic liver failure show an aggravated hyperdynamic circulation. We evaluated, in a controlled manner, potential changes in systemic haemodynamics induced by the&amp;nbsp;MARS and Prometheus system liver detoxification devices in a group of patients with acute-on-chronic liver failure.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Eighteen patients (51.2 ± 2.3 years old; Child–Pugh score, 12.5 ± 0.2; Maddrey score, 63.1 ± 5.0; hepatic venous pressure gradient, 17.6 ± 0.9 mmHg) with biopsy-proven alcoholic cirrhosis and superimposed alcoholic hepatitis were either treated with standard medical therapy (SMT) combined with MARS (&lt;EM&gt;n &lt;/EM&gt;= 6) or Prometheus (&lt;EM&gt;n &lt;/EM&gt;= 6) or were treated with SMT alone (&lt;EM&gt;n &lt;/EM&gt;= 6) on three consecutive days (6 hours/session). Liver tests, systemic haemodynamics and vasoactive substances were determined before and after each session.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Groups were comparable for baseline haemodynamics and levels of vasoactive substances. Both MARS and Prometheus decreased serum bilirubin levels (&lt;EM&gt;P &lt;/EM&gt;&amp;lt; 0.005 versus SMT), the Prometheus device being more effective than MARS (&lt;EM&gt;P &lt;/EM&gt;= 0.002). Only MARS showed significant improvement in the mean arterial pressure (&lt;SPAN class=entity&gt;?&lt;/SPAN&gt;change, +9 ± 2.4 mmHg versus -0.3 ± 2.4 mmHg with Prometheus and -5.2 ± 2.1 mmHg with SMT, &lt;EM&gt;P &lt;/EM&gt;&amp;lt; 0.05) and in the systemic vascular resistance index (&lt;SPAN class=entity&gt;?&lt;/SPAN&gt;change, +131.5 ± 46.2 dyne.s/cm&lt;SUP&gt;5&lt;/SUP&gt;/m&lt;SUP&gt;2 &lt;/SUP&gt;versus -92.8 ± 85.2 dyne.s/cm&lt;SUP&gt;5&lt;/SUP&gt;/m&lt;SUP&gt;2&lt;/SUP&gt;with Prometheus and -30.7 ± 32.5 dyne.s/cm&lt;SUP&gt;5&lt;/SUP&gt;/m&lt;SUP&gt;2 &lt;/SUP&gt;with SMT; &lt;EM&gt;P &lt;/EM&gt;&amp;lt; 0.05), while the cardiac index and central filling remained constant. This circulatory improvement in the MARS group was paralleled by a decrease in plasma renin activity (&lt;EM&gt;P &lt;/EM&gt;&amp;lt; 0.05), aldosterone (&lt;EM&gt;P &lt;/EM&gt;&amp;lt; 0.03), norepinephrine (&lt;EM&gt;P &lt;/EM&gt;&amp;lt; 0.05), vasopressin (&lt;EM&gt;P &lt;/EM&gt;= 0.005) and nitrate/nitrite levels (&lt;EM&gt;P &lt;/EM&gt;&amp;lt; 0.02).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Laleman W, Wilmer A, Evenepoel P, Elst IV, Zeegers M, Zaman Z, Verslype C, Fevery J, Nevens F. Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. &lt;EM&gt;Crit Care&lt;/EM&gt; 2006;10(4):R108.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309078</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18277887]]&gt;</url>
    <title>Effectiveness and safety of capsule endoscopy in the diagnosis of small bowel diseases</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Lippincott Williams &amp; Wilkins</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,DIAGNOSTIC PROCEDURES,GASTROINTESTINAL ENDOSCOPY,CAPSULE ENDOSCOPY,CROHN'S DISEASE,SMALL INTESTINE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Although CE occupies a preferential place in the diagnosis of gastrointestinal bleeding and CD; there is insufficient evidence to establish whether it could be used as a first line diagnostic test. The evidence is insufficient to ascertain this technique's usefulness in small bowel disorders other than obscure bleeding or CD.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Systematic review carried out in the main electronic databases, including MEDLINE, EMBASE, and COCHRANE. Papers were selected independently by the 2 researchers and the quality was determined using a purpose-designed scale.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; A total of 9 systematic reviews and 28 original papers were included [11 assessed obscure gastrointestinal bleeding, 9 Crohn's disease (CD), and 4 hereditary polyposis syndromes]. The diagnostic yield of CE for the diagnosis of obscure gastrointestinal bleeding ranged from 39% to 77%. The diagnostic yield of push enteroscopy was lower than 40% in all but 1 study. CE detected suggestive findings in 19% to 71% of patients with suspected CD, whereas radiologic techniques did so in only 0% to 37% of the cases. In patients with suspected recurrence, detection with these techniques was 58% to 81% and 19% to 67%, respectively. Endoscopic capsule detected a greater number of polyps in patients with polyposis syndromes but other techniques allowed for better localization.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Varela Lema, L. &amp;amp; Ruano-Ravina, A. (2008) Effectiveness and safety of capsule endoscopy in the diagnosis of small bowel diseases. &lt;I&gt;Journal of Clinical Gastroenterology&lt;/I&gt;, 42(5):466-470.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in May 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>380715</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.clinthera.2010.01.005]]&gt;</url>
    <title>Effects of oral levamisole as an adjuvant to hepatitis B vaccine in adults with end-stage renal disease: a meta-analysis of controlled clinical trials</title>
    <publicationDate>2010-01-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,DISEASE PREVENTION,VACCINATION,RECENT ADDITIONS,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The results from this meta-analysis suggest significant benefit in the administration of levamisole as an adjuvant to hepatitis B&amp;nbsp;virus (HBV)&amp;nbsp;vaccine to increase seroprotection in patients with end-stage renal disease (ESRD).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Many patients receiving long-term dialysis do not produce protective antibodies to HBV surface antigen (HBsAg) after HBV vaccination. The results from several studies have suggested benefit of oral levamisole as an adjuvant to HBV vaccination in patients with ESRD. However, reliable information is still lacking.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; This meta-analysis included prospective controlled clinical trials identified using literature searches of MEDLINE, SCOPUS, Institute for Scientific Information bibliographic database, and Cochrane Collaboration's Central Register of Controlled Clinical Trials for controlled clinical trials that weighted the seroprotection rate in patients with ESRD who received oral levamisole + HBV vaccine versus those who received the HBV vaccine alone (control). The fixed-effects Mantel-Haenszel model was applied with the heterogeneity and sensitivity analyses. The response rate, defined as the proportion of patients with seroprotective concentrations of antibodies to HBsAg (&amp;gt;10 mIU/mL) at completion and 6 to 10 months after completion of the HBV vaccine schedule, was the end point of interest and was also analyzed separately. For the tolerability assessment, studies that reported dose reduction, levamisole discontinuation, and their adverse effects including laboratory abnormalities were included.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The literature search identified 4 studies that fulfilled the inclusion criteria (328 patients). The mean ages of the patients in these studies ranged from 41 to 53 years, and sex distribution ranged from 52.6% to 68.0% male. Twenty-two patients received oral levamisole 100 mg/d for 12 days (from 6 days before to 6 days after each vaccination). A total of 106 patients received oral levamisole 80 to 120 mg for 4 to 6 months. Aggregation of study results suggested a significant increase in response rate in the group that received levamisole + HBV vaccine compared with the control group (pooled odds ratio [OR] = 2.77 [95% CI, 1.56-4.94]) after completion and 6 to 10 months after the vaccination period (pooled OR = 3.96 [95% CI, 1.71-9.18]). The test of heterogeneity was not statistically significant in either group. Five patients underwent dose reduction due to mild adverse events. In one trial, 3 patients died, 1 of whom was receiving levamisole; however, the authors did not provide the causes of death. No other serious adverse events were reported with levamisole administration.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Alavian SM, Tabatabaei SV. Effects of oral levamisole as an adjuvant to hepatitis B vaccine in adults with end-stage renal disease: a meta-analysis of controlled clinical trials. &lt;EM&gt;Clin Ther&lt;/EM&gt; 2010;32(1):1-10.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>383355</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1007/s10620-009-1076-x]]&gt;</url>
    <title>Effects of proton pump inhibitors on gastric emptying: a systematic review</title>
    <publicationDate>2010-09-01T00:00:00</publicationDate>
    <publisher>Springer</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,OESOPHAGUS,STOMACH,ULCERS,DUODENAL ULCERS,GASTRIC ULCERS,SMALL INTESTINE,GASTRO-OESOPHAGEAL REFLUX,DYSPEPSIA,RECENT ADDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract:&lt;/STRONG&gt; The proton pump inhibitor (PPI) is widely used for the treatment of gastroesophageal reflux disease, peptic ulcer diseases, and functional dyspepsia. The pathogenesis of these acid-related and/or functional upper gastrointestinal disorders is potentially associated with abnormal gastric emptying. To date, variable effects of PPIs on gastric emptying have been reported. Therefore, it is relevant to gather and analyze published information on this topic. A systematic literature search has been performed, showing that the delaying effect of PPIs on gastric emptying of solid meals is consistent, whereas the effect of PPIs on the emptying of liquids is inconsistent. The underlying mechanisms whereby PPIs may affect gastric emptying have been discussed, most of which still remain hypothetic. Gastric emptying of solids involves a process of peptic hydrolysis. PPIs impair the hydrolytic digestion by inhibiting acid-dependent peptic activity, thereby delaying the solid emptying. Gastric emptying of liquids largely depends on volume and energy density of intragastric contents. PPIs variably modify the volume and the energy density by reducing gastric fluid secretion, thereby modifying the liquid emptying in an unpredictable manner. Hypergastrinemia has been considered to delay gastric emptying, but it seems of minor importance in the regulation of gastric emptying during PPI use. The delayed emptying of solids due to PPI therapy may have clinical implications in the management of gastroesophageal reflux disease, functional dyspepsia, as well as diabetes.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Sanaka M, Yamamoto T, Kuyama Y. Effects of proton pump inhibitors on gastric emptying: a systematic review. &lt;EM&gt;Dig Dis Sci&lt;/EM&gt; 2010;55(9):2431-40.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>330578</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1186/1471-230X-7-1]]&gt;</url>
    <title>Effects of urodilatin on natriuresis in cirrhosis patients with sodium retention</title>
    <publicationDate>2007-01-26T00:00:00</publicationDate>
    <publisher>BioMed Central</publisher>
    <publicationType>RANDOMISED CONTROLLED TRIAL</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,ALCOHOLIC LIVER DISEASE,ALCOHOLIC CIRRHOSIS,RECENT ADDITIONS,CIRRHOSIS,ALCOHOLIC,NOVEMBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; A short-term low-dose urodilatin (URO) infusion increased the sodium excretion of cirrhotic patients. The increase was small but systematic and potentially clinically important for such patients. The small response contrasts the preserved responsiveness of the URO receptors. The markedly activated systemic pressor hormones in cirrhosis evidently antagonized the local tubular effects of URO.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims: &lt;/STRONG&gt;Sodium retention and ascites are serious clinical problems in cirrhosis. URO is a peptide with paracrine effects in decreasing sodium reabsorption in the distal nephron. Our aim was to investigate the renal potency of synthetic URO on urine sodium excretion in cirrhosis patients with sodium retention and ascites.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt;&amp;nbsp;Seven cirrhosis patients with diuretics-resistant sodium retention received a short-term (90 min) infusion of URO in a single-blind, placebo-controlled cross-over study. In the basal state after rehydration the patients had urine sodium excretion &amp;lt; 50 mmol/24 h.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; URO transiently increased urine sodium excretion from 22 ± 16 µmol/min (mean ± SD) to 78 ± 41 µmol/min (P &amp;lt; 0.05) and there was no effect of placebo (29 ± 14 to 44 ± 32). The increase of URO's second messenger after the receptor, cGMP, was normal. URO had no effect on urine flow or on blood pressure. Most of the patients had highly elevated plasma levels of renin, angiotensin II and aldosterone and URO did not change these.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Carstens J, Grønbaek H, Larsen HK, Pedersen EB, Vilstrup H.&amp;nbsp;Effects of urodilatin on natriuresis in cirrhosis patients with sodium retention. &lt;EM&gt;BMC Gastroenterol&lt;/EM&gt; 2007 Jan 26;7:1.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309191</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.cgh.2008.03.014]]&gt;</url>
    <title>Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials</title>
    <publicationDate>2008-06-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Infliximab, adalimumab, and certolizumab are effective in luminal Crohn's disease. Efficacy of anti-TNF agents other than infliximab in treating fistulizing Crohn's disease requires additional investigations. A longer duration of follow-up and a larger number of patients are required to better assess the safety profile of TNF antagonists in Crohn's disease.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We searched MEDLINE, Cochrane Library, and EMBASE. The primary end points were clinical remission for luminal Crohn's disease and fistula closure at =2 consecutive visits. Deaths, serious infections, and malignancies were also analyzed by the methods of Peto and Der Simonian and Laird.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Fourteen luminal Crohn's disease trials enrolled 3995 patients. In overall analysis, anti-TNF therapy was effective for induction of remission at week 4 (mean difference, 11%; 95% confidence interval [CI], 6%–16%; &lt;I&gt;P&lt;/I&gt; &amp;lt; .001) and maintenance of remission at weeks 20–30 in patients who responded to induction therapy and in patients randomized before induction (mean difference, 23%; 95% CI, 18%–28% and mean difference, 8%; 95% CI, 3%–12%, respectively; &lt;I&gt;P&lt;/I&gt; &amp;lt; .001 for all comparisons). Ten studies evaluated anti-TNF for treatment of fistulizing Crohn's disease, involving 776 patients. In overall analysis, anti-TNF therapy was effective for fistula closure only in maintenance trials after open-label induction (mean difference, 16%; 95% CI, 8%–25%; &lt;I&gt;P&lt;/I&gt; &amp;lt; .001). In 21 studies enrolling 5356 individuals, anti-TNF therapy did not increase the risk of death, malignancy, or serious infection.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Peyrin-Biroulet, L., Deltenre, P., de, S. N., Branche, J., Sandborn, W. J., &amp;amp; Colombel, J. F. (2008) Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. &lt;I&gt;Clinical Gastroenterology &amp;amp; Hepatology&lt;/I&gt;. 6(6):644-653.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;See also: &lt;/STRONG&gt;&lt;A href="nelh:342835:0" name=internalLink&gt;DARE record&lt;/A&gt; for this article.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in June 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>320159</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1038/ajg.2009.223]]&gt;</url>
    <title>Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,IRRITABLE BOWEL SYNDROME,RECENT ADDITIONS,JULY 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The 5-HT agents alosetron, cilansetron, and tegaserod are all effective in the treatment of irritable bowel syndrome (IBS). Serious adverse events were rare in the eligible&amp;nbsp;randomised&amp;nbsp;controlled trials (RCTs)&amp;nbsp;included in this systematic review.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; MEDLINE, EMBASE, and the Cochrane Controlled Trials Register were searched (up to June 2008). Trials recruiting adults with IBS in primary, secondary, or tertiary care comparing 5-HT&lt;SUB&gt;3&lt;/SUB&gt;antagonists or 5-HT4 5-HT&lt;SUB&gt;4&lt;/SUB&gt; agonists with placebo were eligible. Dichotomous symptom data were pooled to obtain a relative risk (RR) of remaining symptomatic after therapy, with a 95% confidence interval (CI). The number needed to treat (NNT) was calculated from the reciprocal of the risk difference.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The strategic search identified 1,593 citations. A total of 29 RCTs were eligible for inclusion; placebo was compared with 5-HT&lt;SUB&gt;3&lt;/SUB&gt; antagonists in 11 RCTs, with tegaserod in 11, and with mixed 5-HT&lt;SUB&gt;3&lt;/SUB&gt; antagonists/5-HT&lt;SUB&gt;4&lt;/SUB&gt; agonists in 7. The study quality was generally high. The RR of IBS symptoms persisting with 5-HT&lt;SUB&gt;3&lt;/SUB&gt; antagonists vs. placebo was 0.78 (95% CI: 0.71–0.86), with a similar benefit for both alosetron and cilansetron. Tegaserod was also superior to placebo (RR=0.85; 95% CI: 0.80–0.90). Renzapride and cisapride had no benefit in IBS.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Ford AC, Brandt LJ, Young C, Chey WD, Foxx-Orenstein AE, Moayyedi P. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis.&amp;nbsp;&lt;EM&gt;Am J Gastroenterol&lt;/EM&gt; 2009;104(7):1831-43.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>311423</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/gut.2008.163162]]&gt;</url>
    <title>Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis</title>
    <publicationDate>2008-11-10T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,IRRITABLE BOWEL SYNDROME]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Antidepressants are effective in the treatment of IBS. There is less high-quality evidence for routine use of psychological therapies in IBS, but available data suggest these may be of comparable efficacy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Systematic review and meta-analysis of randomised controlled trials (RCTs). MEDLINE, EMBASE and the Cochrane Controlled Trials Register were searched (up to May 2008).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The search strategy identified 571 citations. Thirty-two RCTs were eligible for inclusion: 19 compared psychological therapies with control therapy or "usual management", 12 compared antidepressants with placebo, and one compared both psychological therapy and antidepressants with placebo. Study quality was generally good for antidepressant but poor for psychological therapy trials. The RR of IBS symptoms persisting with antidepressants versus placebo was 0.66 (95% CI, 0.57 to 0.78), with similar treatment effects for both tricyclic antidepressants and selective serotonin reuptake inhibitors. The RR of symptoms persisting with psychological therapies was 0.67 (95% CI, 0.57 to 0.79). The NNT was 4 for both interventions.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Ford AC, Talley NJ, Schoenfeld PS, Quigley EMM, Moayyedi P.&amp;nbsp; Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis.&amp;nbsp;&lt;EM&gt;Gut&lt;/EM&gt;&amp;nbsp;2009;58(3):367-8.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>339129</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1038/ajg.2009.508]]&gt;</url>
    <title>Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: systematic review and meta-analysis of efficacy and tolerability</title>
    <publicationDate>2010-01-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,STOMACH,HELICOBACTER PYLORI,RECENT ADDITIONS,INFECTIONS,JANUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Quadruple and triple therapies yielded similar eradication rates as primary therapy for &lt;EM&gt;Helicobacter pylori&lt;/EM&gt; infection. Both therapies yielded suboptimal eradication rates. Patient compliance and side effects are similar for quadruple and triple therapies.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Recent treatment guidelines recommend two first-line therapies for &lt;I&gt;H. pylori&lt;/I&gt; infection: proton pump inhibitor (PPI), bismuth, tetracycline, and metronidazole (quadruple therapy) or PPI, clarithromycin, and amoxicillin (triple therapy). We performed a systematic review and meta-analysis to compare the efficacy and tolerability of these regimens as first-line treatment of &lt;I&gt;H. pylori&lt;/I&gt;.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A search of MEDLINE, EMBASE, Google Scholar, the Cochrane Central Register of Controlled Trials, &lt;I&gt;ACP Journal Club&lt;/I&gt;, the Database of Abstracts of Reviews of Effectiveness, Cochrane Methodology Register, Health Technology Assessment Database, and abstracts from prominent gastrointestinal scientific meetings was carried out. Randomized controlled trials (RCTs) comparing bismuth quadruple therapy to clarithromycin triple therapy were selected for meta-analysis. Two independent reviewers extracted data, using standardized data forms. Meta-analysis was carried out with the metan command in Stata 10.1. Funnel plots and subgroup analyses were carried out.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Nine RCTs (&lt;I&gt;N&lt;/I&gt;&lt;SPAN class=mb&gt;=&lt;/SPAN&gt;1,679) were included. Although dosing regimens of clarithromycin triple therapy were quite consistent between trials, dosing regimens varied considerably for bismuth quadruple therapy. Bismuth quadruple therapy achieved eradication in 78.3&lt;SPAN class=mb&gt;%&lt;/SPAN&gt; of patients, whereas clarithromycin triple therapy achieved an eradication rate of 77.0&lt;SPAN class=mb&gt;%&lt;/SPAN&gt; (risk ratio (RR)&lt;SPAN class=mb&gt;=&lt;/SPAN&gt;1.002, 95&lt;SPAN class=mb&gt;%&lt;/SPAN&gt; confidence interval (CI): 0.936–1.073). There was moderate heterogeneity and no evidence for significant publication bias. Subgroup analyses by study location, treatment duration, and study population did not account for the heterogeneity. There were no statistically significant differences in side effects yielded by quadruple vs. clarithromycin triple therapy (RR&lt;SPAN class=mb&gt;=&lt;/SPAN&gt;1.04, 95&lt;SPAN class=mb&gt;%&lt;/SPAN&gt; CI: 1.04–1.14).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Luther J, Higgins PD, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD.&amp;nbsp;Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. &lt;EM&gt;Am J Gastroenterol&lt;/EM&gt; 2010;105(1):65-73.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>395055</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://jcem.endojournals.org/cgi/content/abstract/95/11/4823]]&gt;</url>
    <title>Endocrine and nutritional management of the post-bariatric surgery patient: an endocrine society clinical practice guideline</title>
    <publicationDate>2010-11-01T00:00:00</publicationDate>
    <publisher>The Endocrine Society</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COMMON CLINICAL PRESENTATIONS,STOMACH,OBESITY,RECENT ADDITIONS,NOVEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Bibliography: Heber D, Greenway FL, Kaplan LM, Livingston E, Salvador J, Still C. (2010) Endocrine and nutritional management of the post-bariatric surgery patient: an endocrine society clinical practice guideline. &lt;EM&gt;The Journal of Clinical Endocrinology and Metabolism&lt;/EM&gt; 95(11): 4823-4843&lt;BR&gt;
&lt;P&gt;&lt;STRONG&gt;Objective:&lt;/STRONG&gt; We sought to provide guidelines for the nutritional and endocrine management of adults after bariatric surgery, including those with diabetes mellitus. The focus is on the immediate postoperative period and long-term management to prevent complications, weight regain, and progression of obesity-associated comorbidities. The treatment of specific disorders is only summarized. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Participants:&lt;/STRONG&gt; The Task Force was composed of a chair, five additional experts, a methodologist, and a medical writer. It received no corporate funding or remuneration. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; Bariatric surgery is not a guarantee of successful weight loss and maintenance. Increasingly, patients regain weight, especially those undergoing restrictive surgeries such as laparoscopic banding rather than malabsorptive surgeries such as Roux-en-Y bypass. &lt;/P&gt;
&lt;P&gt;Active nutritional patient education and clinical management to prevent and detect nutritional deficiencies are recommended for all patients undergoing bariatric surgery. Management of potential nutritional deficiencies is particularly important for patients undergoing malabsorptive procedures, and strategies should be employed to compensate for food intolerance in patients who have had a malabsorptive procedure to reduce the risk for clinically important nutritional deficiencies. &lt;/P&gt;
&lt;P&gt;To enhance the transition to life after bariatric surgery and to prevent weight regain and nutritional complications, all patients should receive care from a multidisciplinary team including an experienced primary care physician, endocrinologist, or gastroenterologist and consider enrolling postoperatively in a comprehensive program for nutrition and lifestyle management. &lt;/P&gt;
&lt;P&gt;Future research should address the effectiveness of intensive postoperative nutritional and endocrine care in reducing morbidity and mortality from obesity-associated chronic diseases. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>105807</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.pcsg.org.uk/storage/documents/EndoscopyInPrimaryCare2001.pdf]]&gt;</url>
    <title>Endoscopy in primary care</title>
    <publicationDate>2001-05-01T00:00:00</publicationDate>
    <publisher>Primary Care Society for Gastroenterology</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,DIAGNOSTIC PROCEDURES,GASTROINTESTINAL ENDOSCOPY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;STRONG&gt;Summary:&lt;/STRONG&gt;&amp;nbsp;A report by the PCSG initiated as a result of the increase in community based endoscopy clinics.&amp;nbsp; The report provides the results of a series questionnaires given to both clinicians and patients attending a&amp;nbsp;community based endoscopy clinic.&amp;nbsp; As a result of the information attained and other existing informaiton, minimum standards&amp;nbsp;of equipment, staffing levels, and practising endoscopists competence levels are suggested. 
&lt;P&gt;&lt;STRONG&gt;Intended audience&lt;/STRONG&gt;:&amp;nbsp;All medical personnel involved in providing community based endoscopies.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;Available to the general public&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>387885</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1159/000287255]]&gt;</url>
    <title>ENETS consensus guidelines for the management of bone and lung metastases from neuroendocrine tumors</title>
    <publicationDate>2010-05-19T00:00:00</publicationDate>
    <publisher>European Neuroendocrine Tumor Society</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,NEUROENDOCRINE TUMOURS,RECENT ADDITIONS,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; Gastroenteropancreatic (GEP) neuroendocrine tumors (NET) are rare tumors with a low incidence of at least 3–5/100,000 but a considerably higher prevalence of 35/100,000. The majority of patients at the time of diagnosis&lt;BR&gt;are found to have an advanced stage of the disease. Bone metastasis is not an infrequent complication in most neoplasms and has been found in 70–85% of cancer patients at autopsy. GEP-NET bone metastases frequently remain undetected. They are often accompanied by widespread extraosseous metastases and are found to occur predominantly in patients with liver metastases. It is thought that lung metastases occur with a similar frequency to bone metastases. These guidelines deal with epidemiology, diagnosis, treatment and follow-up of these tumours.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience: &lt;/STRONG&gt;Gastroenterologists, oncologists&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in May 2010 in &lt;EM&gt;Neuroendocrinology &lt;/EM&gt;91(4):326-332.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; These guidelines are not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>387883</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1159/000287277]]&gt;</url>
    <title>ENETS consensus guidelines for the management of brain, cardiac and ovarian metastases from neuroendocrine tumors</title>
    <publicationDate>2010-05-19T00:00:00</publicationDate>
    <publisher>European Neuroendocrine Tumor Society</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,NEUROENDOCRINE TUMOURS,RECENT ADDITIONS,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=abstractSummary&gt;
&lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; Metastatic disease is a critical issue in the management of neuroendocrine tumors (NETs) and forms a key component in the management of such patients. In general, the majority of metastases occur in the liver, lungs and bone; other sites are much rarer. Nevertheless, when present, they pose substantial management issues and therefore require serious consideration. Rare metastatic sites include the brain, heart, ovaries, breast, thyroid, pancreas, skin, adrenal glands, kidney, spleen, orbit, retroperitoneum, testis and pituitary gland. This overview will focus primarily on metastatic lesions of the brain, heart and ovary.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience: &lt;/STRONG&gt;Gastroenterologists, oncologists&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in May 2010 in &lt;EM&gt;Neuroendocrinology &lt;/EM&gt;91(4):326-332.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; These guidelines are not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>387886</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1159/000286700]]&gt;</url>
    <title>ENETS consensus guidelines for the management of peritoneal carcinomatosis from neuroendocrine tumors</title>
    <publicationDate>2010-05-19T00:00:00</publicationDate>
    <publisher>European Neuroendocrine Tumor Society</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,NEUROENDOCRINE TUMOURS,RECENT ADDITIONS,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; Peritoneal carcinomatosis (PC) from gastroenteropancreatic (GEP) neuroendocrine tumors (NET) is a rare event and there are insufficient data regarding its exact prevalence and treatment. Therefore, these guidelines regarding diagnosis and treatment of PC from GEP-NET are based on level 2–3 published articles.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience: &lt;/STRONG&gt;Gastroenterologists, oncologists&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in May 2010 in &lt;EM&gt;Neuroendocrinology &lt;/EM&gt;91(4):333-340.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; These guidelines are not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>268415</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.clinthera.2006.02.012]]&gt;</url>
    <title>Entecavir for the treatment of chronic hepatitis B virus infection</title>
    <publicationDate>2006-02-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,CHRONIC HEPATITIS B]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Matthews SJ 2006; Clinical Therapeutics 28 (2) pp. 184-203&lt;/P&gt;
&lt;H2&gt;Orignal article abstract&lt;/H2&gt;
&lt;P class=abstract&gt;OBJECTIVE: This article reviews the pharmacology/pharmacokinetics and therapeutic efficacy of entecavir, which was approved on March 29, 2005, for the management of adult patients with chronic hepatitis B virus (HBV) infection who have active viral replication and/or elevations in liver transaminases or signs of active liver disease on histologic examination. Potential drug interactions and adverse events associated with the use of entecavir are also reviewed. METHODS: Relevant literature was identified through searches of MEDLINE (1996-July 2005) and BIOSIS (1993-July 2005). Search terms included, but were not limited to, entecavir, BMS-200475, hepatitis B, pharmacology, pharmacokinetics, adverse events, and therapeutic use. Further publications were identified from the reference lists of the identified articles and through correspondence with the manufacturer of entecavir. RESULTS: Entecavir is highly selective for the HBV and inhibits all 3 steps of viral replication. Results of early studies indicated a 6% resistance potential after 48 weeks of therapy, although the potential may be higher in patients who harbor lamivudine-resistant mutants. The approved dosage in treatment-naive patients is 0.5 mg/d p.o., administered on an empty stomach; in patients who have failed lamivudine therapy or are known to harbor lamivudine-resistant mutants, the approved dosage is 1.0 mg/d p.o.. The oral tablet and solution can be used interchangeably. Entecavir is well absorbed orally, achieving a dose-related Cmax between 0.6 and 1.5 hours after administration. It is metabolized to a small extent and is not a substrate for the cytochrome P450 enzyme system. The mean elimination t(1/2) ranges from 77 to 149 hours in patients with normal kidney function. Entecavir is eliminated primarily in the urine via glomerular filtration and tubular secretion (62%-73%). No dose adjustment appears to be necessary in patients with moderate to severe liver disease alone. The potential for drug interactions with entecavir appears to be minimal, although medications that inhibit tubular secretion of drugs (eg, probenecid) may be expected to prolong serum concentrations of entecavir. One of the Phase III studies of entecavir found statistically significant benefits compared with lamivudine in terms of improvements in liver histology after 48 weeks of therapy (72% vs 62%, respectively; P&amp;lt;0.009), the proportions of patients with undetectable HBV DNA titers on branched DNA signal amplification assay after 48 weeks of therapy (91% vs 65%; P&amp;lt;0.001), and the proportion with undetectable HBV DNA on polymerase chain reaction (PCR) assay after 48 weeks of therapy (69% vs 38%; P&amp;lt;0.001). In another Phase III study, patients who had failed to respond to lamivudine therapy responded to entecavir: after 48 weeks of therapy, significant differences between entecavir and lamivudine were seen in histologic improvement (55% vs 28%; P&amp;lt;0.001) and the proportion of patients with undetectable HBV DNA on PCR assay (21% vs 1%; P&amp;lt;0.001). Adverse events associated with entecavir therapy were similar in character, severity, and incidence to those associated with placebo or lamivudine therapy. The most common adverse events in clinical trials of entecavir were headache (17%-23% of patients), upper respiratory tract infection (18%-20%), cough (12%-15%), nasopharyngitis (9%-14%), fatigue (10%-13%), dizziness (9%), upper abdominal pain (9%-10%), and nausea (6%-8%). CONCLUSIONS: Entecavir is a new antiviral agent for the management of chronic HBV infection. Questions concerning the ideal length of therapy, long-term efficacy, and resistance rates over time await the results of ongoing clinical trials.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>380694</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.canlet.2008.10.046]]&gt;</url>
    <title>Epidemiology and prevention of hepatocellular carcinoma</title>
    <publicationDate>2009-12-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,HEPATITIS C,DISEASE PREVENTION,HEPATOCELLULAR CARCINOMA,VACCINATION,RECENT ADDITIONS,CANCER,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract:&lt;/STRONG&gt; A meta-analysis on the seroprevalence of hepatitis B surface antigen (HBsAg) and antibodies against hepatitis C virus (anti-HCV) in 27881 hepatocellular carcinomas from 90 studies confirmed wide international variations. A predominance of HBsAg was found in hepatocellular carcinomas from most Asian, African and Latin American countries, but anti-HCV predominated in Europe, North America, Japan, Pakistan, Mongolia, and Egypt. Anti-HCV was found more often than HBsAg in Europe and the United States. Twenty-five years after having been licensed, HBV vaccination programmes are now carried out in 158 countries, but they have yet to reach many high-risk populations in sub-Saharan Africa and Asia. In the absence of a vaccine, the prevention of HCV infection requires an integrated strategy (i.e., screening of blood donations, safe injection practices, and avoidance of unnecessary injections).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Franceschi S, Raza SA. Epidemiology and prevention of hepatocellular carcinoma. &lt;EM&gt;Cancer Lett &lt;/EM&gt;2009;286(1):5-8.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>322937</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1038/ajg.2009.314]]&gt;</url>
    <title>Eradication therapy for Helicobacter pylori in patients with gastric MALT lymphoma: a pooled data analysis</title>
    <publicationDate>2009-08-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,STOMACH,HELICOBACTER PYLORI,RECENT ADDITIONS,INFECTIONS,AUGUST 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; This was the first comprehensive (approximately 1,300 patients) analysis of the therapeutic management of H. pylori in gastric lymphoma patients. Data suggest that this infection is easily managed in these patients, being cured in nearly all cases.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Pooled data analysis of systematic review of the literature was performed in this study.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Data from 34 studies with 1,271 treated patients were used. After first-line therapy, the infection was cured in 91% (95% confidence interval (CI)=89.4-92.5) of cases, the eradication rate being higher after dual therapy compared with the 7- or 14-day triple therapies (P=0.0525). After second-line therapy, the eradication rate was 80.8% (95% CI=82.7-95.1), being higher after triple rather than quadruple therapy. Further therapies (from three to five attempts) cured the infection in 75% of patients. H. pylori infection was ultimately cured in 1,250 patients, resulting in eradication rates of 98.3% (95% CI=97.6-99) and 99.8% (95% CI=99.6-100) at intention-to-treat and per-protocol analysis levels, respectively. Bacterial reinfection occurred in 18 (2.7%; 95% CI=1.4-3.9) of 676 patients who were followed-up (0.7% yearly). Overall, gastric lymphoma remission was achieved in 973 (77.8%) of 1,250 patients successfully cured of H. pylori infection.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Zullo A, Hassan C, Andriani A, Cristofari F, De Francesco V, Ierardi E, Tomao S, Morini S, Vaira D. Eradication therapy for Helicobacter pylori in patients with gastric MALT lymphoma: a pooled data analysis. Am J Gastroenterol. 2009 Aug;104(8):1932-7.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102401</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.esge.com/assets/downloads/pdfs/guidelines/2001_quality_control_in_gastroint_endosc.pdf]]&gt;</url>
    <title>ESGE recommendations for quality control in gastrointestinal endoscopy: guidelines for image documentation in upper and lower GI endoscopy</title>
    <publicationDate>2001-10-01T00:00:00</publicationDate>
    <publisher>European Society of Gastrointestinal Endoscopy</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,DIAGNOSTIC PROCEDURES,GASTROINTESTINAL ENDOSCOPY,UPPER ENDOSCOPY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims&lt;/STRONG&gt;: Originally published in, &lt;EM&gt;Endoscopy&lt;/EM&gt;, this three page guideline aims to encourage the implementation of a systematic protocol of recording endoscopic images in European countries.&amp;nbsp; An explanantion/diagram of each of the 8 suggested images is shown as well as a rationale for producing the guideline. The evidence base for determination of the protocol is however not stated.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; The protocol was written for health professionals performing endoscopies.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>103210</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.esge.com/assets/downloads/pdfs/guidelines/2008_cleaning_and_disifnection.pdf]]&gt;</url>
    <title>ESGE ESGENA guideline: cleaning and disinfection in gastrointestinal endoscopy</title>
    <publicationDate>2008-09-23T00:00:00</publicationDate>
    <publisher>European Society of Gastrointestinal Endoscopy</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,DIAGNOSTIC PROCEDURES,GASTROINTESTINAL ENDOSCOPY,RECENT ADDITIONS,JANUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims&lt;/STRONG&gt;:&amp;nbsp;ESGE/ESGENA have created a guideline to set standards for the reprocessing of endoscopic equipment.&amp;nbsp; The standards require reprocessing to take place between each patient and each procedure with an emphasis on avoiding infections.&amp;nbsp; This document is an update of previous recommendations published in 2000.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience&lt;/STRONG&gt;:&amp;nbsp;All health professionals using endoscopes or endoscopic equipment.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323795</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1002/hep.22375]]&gt;</url>
    <title>Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,NON-ALCOHOLIC,DIAGNOSTIC PROCEDURES,RECENT ADDITIONS,CIRRHOSIS,AUGUST 2009,CHRONIC HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion: &lt;/STRONG&gt;Fibrosis progression in chronic hepatitis C virus (HCV) infection appears to be nonlinear and estimates of disease progression are significantly influenced by duration of infection. Cirrhosis risk is&amp;nbsp;particularly high in the third decade of HCV infection. The review provides increased precision in estimating fibrosis progression in chronic HCV infection.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A systematic review of published prognostic studies was undertaken. Study inclusion criteria were as follows: (1) presence of HCV infection determined by serological assays; (2) available information about age at assessment of liver disease or HCV acquisition; (3) duration of HCV infection; and (4) histological and/or clinical diagnosis of cirrhosis. Annual stage-specific transition probabilities (F0-&amp;gt;F1, &lt;IMG src="https://rmsadmin.library.nhs.uk/libraryImages/gastroliver/contentID323795/nelhImp_0000_hellip.gif" border=0&gt; , F3-&amp;gt;F4) were derived using the Markov maximum likelihood estimation method and a meta-analysis was performed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Based on the random effects model, the estimated annual mean (95% confidence interval) stage-specific transition probabilities were: F0-&amp;gt;F1 0.117 (0.104-0.130); F1-&amp;gt;F2 0.085 (0.075-0.096); F2-&amp;gt;F3 0.120 (0.109-0.133); and F3-&amp;gt;F4 0.116 (0.104-0.129). The estimated prevalence of cirrhosis at 20 years after the infection was 16% (14%-19%) for all studies, 18% (15%-21%) for cross-sectional/retrospective studies, 7% (4%-14%) for retrospective-prospective studies, 18% (16%-21%) for studies conducted in clinical settings, and 7% (4%-12%) for studies conducted in nonclinical settings. Duration of infection was the most consistent factor significantly associated with progression of fibrosis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. &lt;EM&gt;Hepatology&lt;/EM&gt; 2008 Aug;48(2):418-31.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317965</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[https://www.ecco-ibd.eu/documents/UC_definitions_diagnosis.pdf]]&gt;</url>
    <title>European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis</title>
    <publicationDate>2008-02-01T00:00:00</publicationDate>
    <publisher>European Crohn's &amp; Colitis Organisation</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,DIAGNOSTIC PROCEDURES,GASTROINTESTINAL ENDOSCOPY,COLONOSCOPY,STOOL TESTS,RECENT ADDITIONS,JUNE 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; This document sets out the current European Consensus on the diagnosis and management of UC, reached by the European Crohn's and Colitis Organisation (ECCO) at a meeting held in Berlin on 20th October 2006. ECCO is a forum for specialists in inflammatory bowel disease from 23 European countries. Like the initial Consensus on the management of Crohn's disease, the current Consensus is grouped into three parts: definitions and diagnosis; current management; and management of special situations. This first section concerns aims, methods and definitions of the Consensus, as well as classification, diagnosis, imaging and pathology of UC.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience: &lt;/STRONG&gt;Gastroenterologists&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in February 2008&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317968</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[https://www.ecco-ibd.eu/documents/UC_current_management.pdf]]&gt;</url>
    <title>European evidence-based consensus on the management of ulcerative colitis: current management</title>
    <publicationDate>2008-02-01T00:00:00</publicationDate>
    <publisher>European Crohn's &amp; Colitis Organisation</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,SURGERY,SURGERY,ABDOMEN,COLON &amp; RECTUM,ULCERATIVE COLITIS,RECENT ADDITIONS,JUNE 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=abstractSummary&gt;
&lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; This document sets out the current European Consensus on the diagnosis and management of UC, reached by the European Crohn's and Colitis Organisation (ECCO) at a meeting held in Berlin on 20th October 2006. ECCO is a forum for specialists in inflammatory bowel disease from 23 European countries. Like the initial Consensus on the management of Crohn's disease, the current Consensus is grouped into three parts: definitions and diagnosis; current management; and management of special situations. This second section is on current management, including treatment of active disease, maintenance of medically-induced remission and surgery of UC.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience: &lt;/STRONG&gt;Gastroenterologists &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in February 2008&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public&lt;/P&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>317969</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[https://www.ecco-ibd.eu/documents/UC_special_situations.pdf]]&gt;</url>
    <title>European evidence-based consensus on the management of ulcerative colitis: special situations</title>
    <publicationDate>2008-02-01T00:00:00</publicationDate>
    <publisher>European Crohn's &amp; Colitis Organisation</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,DISEASE PREVENTION,SURGERY,SURGERY,ABDOMEN,CANCER,SCREENING,COLON &amp; RECTUM,ULCERATIVE COLITIS,RECENT ADDITIONS,JUNE 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; This document sets out the current European Consensus on the diagnosis and management of UC, reached by the European Crohn's and Colitis Organisation (ECCO) at a meeting held in Berlin on 20th October 2006. ECCO is a forum for specialists in inflammatory bowel disease from 23 European countries. Like the initial Consensus on the management of Crohn's disease, the current Consensus is grouped into three parts: definitions and diagnosis; current management; and management of special situations. This third section is on special situations including pouch disorders, cancer surveillance, pregnancy, paediatrics, psychosomatics, extra-intestinal manifestations and alternative therapy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience: &lt;/STRONG&gt;Gastroenterologists &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in February 2008&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public&lt;/P&gt;
&lt;DIV&gt;&lt;/DIV&gt;
&lt;DIV&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>333809</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.esge.com/assets/downloads/pdfs/guidelines/2009_recommendations_video_capsule.pdf]]&gt;</url>
    <title>European Society of Gastrointestinal Endoscopy (ESGE): recommendations (2009) on clinical use of video capsule endoscopy to investigate small-bowel, esophageal and colonic diseases</title>
    <publicationDate>2010-03-01T00:00:00</publicationDate>
    <publisher>European Society of Gastrointestinal Endoscopy</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COMMON CLINICAL PRESENTATIONS,ANAEMIA,OESOPHAGUS,OESOPHAGEAL VARICES,SMALL INTESTINE,CANCER,COELIAC DISEASE,COLON &amp; RECTUM,INFLAMMATORY BOWEL DISEASE,DIAGNOSTIC PROCEDURES,GASTROINTESTINAL ENDOSCOPY,BARRETT'S OESOPHAGUS,CAPSULE ENDOSCOPY,POLYPS,CROHN'S DISEASE,RECENT ADDITIONS,NON-MALIGNANT NEOPLASMS,GI BLEEDING,JUNE 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; Video capsule endoscopy (VCE) for diseases of the small intestine was introduced into clinical practice in 2001. Over the past 8 years, an annually increasing number of publications have shown that VCE is a reliable, noninvasive method for endoscopic examination of the entire small-bowel mucosa. &lt;/P&gt;
&lt;P&gt;An esophageal and a colon capsule have also been launched on the market and are under intensive clinical investigation. The aim is to update the previous document published over 3 years ago, in 2006. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Health professionals who are involved in the use of the capsule and/or who require guidance on the implications for use.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323573</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2008.03691.x]]&gt;</url>
    <title>Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis</title>
    <publicationDate>2008-06-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,RECENT ADDITIONS,AUGUST 2009,CHRONIC HEPATITIS B]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;SPAN class=h5-inline&gt;&lt;STRONG&gt;Background:&lt;/STRONG&gt;&amp;nbsp;&lt;/SPAN&gt;Several anti-viral treatments are now available for HBeAg-negative chronic hepatitis B (CHB), but the clinical and economic outcomes of potential treatment strategies and durations are unclear.&lt;/P&gt;
&lt;P class=para&gt;&lt;SPAN class=h5-inline&gt;&lt;STRONG&gt;Aim:&lt;/STRONG&gt;&amp;nbsp;&lt;/SPAN&gt;To examine the clinical and economic outcomes of potential treatment strategies and durations for HBeAg-negative CHB.&lt;/P&gt;
&lt;P class=para&gt;&lt;SPAN class=h5-inline&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt;&amp;nbsp;&lt;/SPAN&gt;We conducted a cost-utility analysis from a payer perspective over a lifetime time horizon. Disease progression probabilities, costs and quality of life data were derived from the literature. We evaluated 5-year, 10-year, lifetime and 5 on–1 off treatment durations. For each of these treatment durations, we evaluated initial therapy with entecavir, lamivudine or adefovir, with addition of adefovir or entecavir for patients who developed virological breakthrough because of resistance (12 strategies total).&lt;/P&gt;
&lt;P class=para&gt;&lt;SPAN class=h5-inline&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt;&amp;nbsp;&lt;/SPAN&gt;Increasing treatment duration improved quality-adjusted life-years (QALYs) and was generally cost-effective for all three drugs. However, a 5 on–1 off strategy was the most cost-effective: lifetime vs. 5 on–1 off entecavir had an ICER of $148&amp;nbsp;200/QALY. In probabilistic sensitivity analyses, entecavir 5 on–1 off was the preferred strategy over the range of commonly reimbursed cost-effectiveness thresholds. Lifetime treatment was preferred to a 5 on–1 off strategy, if treatment durability was &amp;lt;10%.&lt;/P&gt;
&lt;P&gt;&lt;SPAN class=h5-inline&gt;&lt;STRONG&gt;Conclusion:&lt;/STRONG&gt;&amp;nbsp;&lt;/SPAN&gt;The results of our analysis suggest that in HBeAg-negative CHB infection, a 5 on–1 off treatment strategy with entecavir improves health outcomes in a cost-effective manner compared to alternative strategies.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;See also:&lt;/STRONG&gt; &lt;A href="nelh:324090:0" name=internalLink&gt;NHS EED record&lt;/A&gt; for this article.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Veenstra DL, Spackman DE, Bisceglie A, Kowdley K, V, Gish RG. Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2008;27(12):1240-52.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344516</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.pasa.nhs.uk/pasa/Doc.aspx?Path=[MN][SP]/NHSprocurement/CEP/CEP08054.pdf]]&gt;</url>
    <title>Evaluation report: clostridium difficile toxin detection assays</title>
    <publicationDate>2009-02-23T00:00:00</publicationDate>
    <publisher>NHS Purchasing and Supply Agency</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,DIAGNOSTIC PROCEDURES,INFECTIONS,STOOL TESTING,PSEUDOMEMBRANOUS COLITIS,RECENT ADDITIONS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=abstractSummary&gt;
&lt;P&gt;The Centre for Evidence-based Purchasing (CEP) provides impartial and objective information about medical technology to help the NHS make better purchasing decisions.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt; The &lt;EM&gt;Clostridium difficile &lt;/EM&gt;toxin A &amp;amp; B detection assay is a test for the presence of the toxins that are present in &lt;EM&gt;C. difficile &lt;/EM&gt;infection (CDI).&amp;nbsp; This report tested faecal samples for the presence of &lt;EM&gt;C. difficile &lt;/EM&gt;toxin using nine commercial toxin detection assays and the gold standard cytotoxin assay.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in February 2009.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>344512</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.pasa.nhs.uk/pasa/Doc.aspx?Path=[MN][SP]/NHSprocurement/CEP/CEP09042.pdf]]&gt;</url>
    <title>Evaluation report: immunochemical faecal occult blood tests</title>
    <publicationDate>2009-11-17T00:00:00</publicationDate>
    <publisher>NHS Purchasing and Supply Agency</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,DIAGNOSTIC PROCEDURES,DISEASE PREVENTION,CANCER,STOOL TESTING,FAECAL BLOOD,SCREENING,RECENT ADDITIONS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=abstractSummary&gt;
&lt;P&gt;The Centre for Evidence-based Purchasing (CEP) provides impartial and objective information about medical technology to help the NHS make better purchasing decisions.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary: &lt;/STRONG&gt;Immunological faecal occult blood tests (iFOBT) use antibodies rasied against human haemoglobin (Hb) to detect human blood present in faeces.&amp;nbsp; The presence of blood in a faecal sample can be used as a marker to detect significant neoplasia in otherwise asymptomatic people.&amp;nbsp; They have the potentially to be used in bowel cancer screening programmes. This document is an assessment of the perfomance of three automated analytical iFOB methods.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in November 2009.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>344509</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.pasa.nhs.uk/pasa/Doc.aspx?Path=%5bMN%5d%5bSP%5d/NHSprocurement/CEP/Critical/CEP08012.pdf]]&gt;</url>
    <title>Evidence review: oesophageal Doppler monitoring in patients undergoing high-risk surgery and in critically ill patients</title>
    <publicationDate>2008-04-10T00:00:00</publicationDate>
    <publisher>NHS Purchasing and Supply Agency</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,OESOPHAGUS,DIAGNOSTIC PROCEDURES,RECENT ADDITIONS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=abstractSummary&gt;
&lt;P&gt;The Centre for Evidence-based Purchasing (CEP) provides impartial and objective information about medical technology to help the NHS make better purchasing decisions.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt; Oesophageal Doppler monitoring (ODM) measures blood flow velocity in the descending thoracic aorta using a flexible ultrasonic probe inserted into the patient's oesophagus.&amp;nbsp; This information allows continuous monitoring of cardiac output and haemodynamic status.&amp;nbsp; It can be used in patients undergoing high-risk surgery and critically ill patients to guide fluid replacement and drug treatment.&amp;nbsp; This report summarises the evidence for the use of ODM in these groups.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in April 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>344506</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.pasa.nhs.uk/pasa/Doc.aspx?Path=[MN][SP]/NHSprocurement/CEP/CEP08052.pdf]]&gt;</url>
    <title>Evidence review: ultrasound elastography</title>
    <publicationDate>2009-02-19T00:00:00</publicationDate>
    <publisher>NHS Purchasing and Supply Agency</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,DIAGNOSTIC PROCEDURES,ULTRASOUND,RECENT ADDITIONS,CIRRHOSIS,RADIOLOGY,FEBRUARY 2010,CHRONIC HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The Centre for Evidence-based Purchasing (CEP) provides impartial and objective information about medical technology to help the NHS make better purchasing decisions.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary: &lt;/STRONG&gt;Ultrasound elastography is the use of ultrasound to produce measurements of images of tissue stiffness.&amp;nbsp; Several different approaches are used, but all rely on creating some form of displacement in the tissue and measuring the response.&amp;nbsp; This document reviews the evidence for the use of elastrography in assessing liver fibrosis and breast imaging, also presenting a brief summary of prostate, endoscopic and vascular applications.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in February 2009.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>346147</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1007/s00228-009-0719-3]]&gt;</url>
    <title>Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality?</title>
    <publicationDate>2009-10-01T00:00:00</publicationDate>
    <publisher>Springer</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Further randomized, double-blind, controlled trials should be performed to address this issue, and more in vitro studies to identify the pathways involved are required.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Nonsteroidal anti-inflammatory drugs (NSAIDs), conventional and selective cyclooxygenase-2 (COX-2) inhibitors, are among the most widely used medications for the treatment of various inflammatory conditions. There is strong evidence of a possible association between the use of these drugs and the relapse of inflammatory bowel diseases (IBD). Our objective was to examine the literature regarding the exacerbation of IBD associated with the use of conventional NSAIDs and selective COX-2 inhibitors and the underlying pathogenetic mechanisms.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We reviewed articles, including original papers, controlled trials, case reports, reviews, and editorials published in English at the PubMed, Scopus Database, and Science Direct database, searching with the following keywords: nonsteroidal anti-inflammatory drugs (NSAIDs), COX-2 inhibitors, Coxibs, inflammatory bowel diseases (IBD), ulcerative colitis (UC), Crohn's disease (CD).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; There is substantial evidence that exacerbation of IBD happens after treatment with NSAIDs, but the available data remain conflicting, and it is not clear whether selective COX-2 inhibitors are safer than traditional NSAIDs. However, there is some evidence that selective COX-2 inhibition and COX-1 inhibition (with low-dose aspirin) appear to be well-tolerated in the short term. Regarding the mechanisms of relapse, the reduction of prostaglandins appears to be the hallmark of the NSAIDs adverse effects.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Kefalakes H, Stylianides TJ, Amanakis G, Kolios G. Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality? &lt;EM&gt;Eur J Clin Pharmacol&lt;/EM&gt; 2009;65(10):963-70.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281248</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1007/s10620-007-0036-6]]&gt;</url>
    <title>Exposing the weaknesses: a systematic review of azathioprine efficacy in ulcerative colitis</title>
    <publicationDate>2008-06-01T00:00:00</publicationDate>
    <publisher>Springer</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Pooled results demonstrated a modest efficacy of AZA for the treatment of ulcerative colitis. However, the use of AZA for the management of UC is not based on high-quality evidence. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A comprehensive search of online databases was conducted. Only randomized controlled trials with 6-thioguanine anti-metabolites within a minimum duration of follow-up of 6&amp;nbsp;months were selected.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Five trials were included in the meta-analysis. The pooled relative risk estimate for “success of treatment” with azathioprine (AZA) compared to 5-aminosalicylic acid or placebo was 1.42 [95% confidence interval (CI): 0.93–2.17, &lt;I&gt;p&lt;/I&gt;&amp;nbsp;=&amp;nbsp;0.109]; when only trials of a higher quality were used, a pooled relative risk estimate of 2.05 (95% CI: 1.30–3.23, &lt;I&gt;p&lt;/I&gt;&amp;nbsp;=&amp;nbsp;0.002) was obtained.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Leung, Y., Panaccione, R., Hemmelgarn, B., &amp;amp; Jones, J. (2008) Exposing the weaknesses: a systematic review of azathioprine efficacy in ulcerative colitis. &lt;I&gt;Digestive Diseases &amp;amp; Sciences&lt;/I&gt;, 53(6):1455-1461.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;See also: &lt;/STRONG&gt;&lt;A href="nelh:314260:0" name=internalLink&gt;DARE record&lt;/A&gt; for this article.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>346886</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1038/ajg.2009.685]]&gt;</url>
    <title>Factors associated with non-adherence to oral medication for inflammatory bowel disease: a systematic review</title>
    <publicationDate>2010-03-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,IRRITABLE BOWEL SYNDROME,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Demographic, clinical, and treatment variables were not consistently associated with non-adherence. Psychological distress, patients' beliefs about medications, and doctor-patient discordance were associated with non-adherence. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Adherence is generally associated with improved treatment outcomes. Risk factors for non-adherence must be understood to improve adherence. A systematic review was undertaken to determine which variables were consistently associated with non-adherence to oral medication in inflammatory bowel disease (IBD).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; The databases EMBASE, Medline, and PsycINFO were searched for titles relating to adherence, medication, and IBD (1980-2008). Primary, quantitative studies were included if they concerned adult patients with IBD, measured adherence to oral medication, and measured characteristics associated with adherence. The resulting 17 papers were independently reviewed by two researchers who also assessed their quality according to pre-defined criteria. The main outcome was the frequency with which demographic, clinical, treatment, and psychosocial variables were found to be statistically significantly associated with non-adherence.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Non-adherence rates ranged from 7 to 72%, with most studies reporting that 30-45% of patients were non-adherent. No demographic, clinical, or treatment variables were consistently associated with non-adherence. Psychological distress and patients' beliefs about medications were both related to non-adherence in four out of five studies, and doctor-patient discordance was associated with non-adherence in two out of three studies.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Jackson CA, Clatworthy J, Robinson A, Horne R. Factors associated with non-adherence to oral medication for inflammatory bowel disease: a systematic review.&lt;EM&gt; Am J Gastroenterol &lt;/EM&gt;2010;105(3):525-39.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>305534</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/ebm.14.1.15]]&gt;</url>
    <title>Faecal occult blood test screening reduces risk of colorectal cancer mortality</title>
    <publicationDate>2009-02-01T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,DIAGNOSTIC PROCEDURES,DISEASE PREVENTION,STOOL TESTING,FAECAL BLOOD,CANCER,SCREENING,RECENT ADDITIONS,FEBRUARY 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Hewitson P.&amp;nbsp; Review: faecal occult blood test screening reduces risk of colorectal cancer mortality.&amp;nbsp; Evid Based Med 2009 Feb;14(1):15.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary: &lt;/STRONG&gt;A review of the original article: Glasziou P, Watson E, et al. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 2008;103:1541–9.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bibliographic details:&lt;/STRONG&gt; Evidence-Based Medicine is a secondary evidence journal, containing informative abstracts and expert commentaries about the best quality research from primary care medicine.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to NHS staff via Athens.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345608</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19182729]]&gt;</url>
    <title>FDG-PET in inflammatory bowel disease</title>
    <publicationDate>2009-02-01T00:00:00</publicationDate>
    <publisher>Minerva Medical</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,DIAGNOSTIC PROCEDURES,NUCLEAR MEDICINE,CROHN'S DISEASE,RECENT ADDITIONS,PET,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Current clinical applications for positron emission tomography (PET) in inflammatory bowel disease (IBD) include its use in the early evaluation of IBD, especially in children who may not tolerate an invasive test such as colonoscopy; and its use in differentiating between a flare of IBD versus the onset of a non-inflammatory process causing similar symptoms in patients with known IBD. Many unanswered questions remain, but PET appears to be a promising tool in the non-invasive evaluation of IBD.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Accurate, inexpensive, non-invasive studies in evaluation of IBD would represent a significant advancement in identifying and measuring disease activity. There is new evidence that PET scanning can fulfill many of these criteria. The aim of this review is to report the studies pertaining to the use of PET in IBD and provide an evidence-based approach on how to use PET clinically in IBD.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Searching Medline and the Cochrane Database of Clinical Trails on July 18, 2008 identified 12 relevant manuscripts for review.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Types of studies of PET in IBD include the incidental identification of IBD during studies performed for other indications, the evaluation of suspected IBD and the assessment of known IBD. PET has been studied in both children and adults and has shown excellent sensitivity for detecting active bowel inflammation, but with poor specificity in some studies. PET alone appears sufficient for the evaluation of ulcerative colitis, but PET/computed tomography provides considerably more information over PET alone in the evaluation of Crohn's disease.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Spier BJ, Perlman SB, Reichelderfer M. FDG-PET in inflammatory bowel disease. &lt;EM&gt;Q J Nucl Med Mol Imaging&lt;/EM&gt; 2009;53(1):64-71.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293832</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1572-0241.2007.01466.x]]&gt;</url>
    <title>FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy</title>
    <publicationDate>2007-11-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,DIAGNOSTIC PROCEDURES,BIOPSY,BLOOD TESTS,CHRONIC HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Shaheen AA et al American Journal of Gastroenterology 2007 Nov;102(11):2589-600. Epub 2007 Sep 10&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract: &lt;/STRONG&gt;BACKGROUND: The accurate diagnosis of hepatitis C virus (HCV)-related fibrosis is crucial for prognostication and treatment decisions. Due to the limitations of biopsy, noninvasive alternatives including FibroTest and FibroScan have been developed. Our objective was to systematically review studies describing the accuracy of these tests for predicting HCV-related fibrosis. METHODS: Studies comparing FibroTest or FibroScan versus biopsy in HCV patients were identified via an electronic search. Random effects meta-analyses and areas under summary receiver operating characteristics curves (AUC) were examined to characterize test accuracy for significant fibrosis (F2-4) and cirrhosis. Heterogeneity was explored using meta-regression. RESULTS: Twelve studies were identified, 9 for FibroTest (N = 1,679) and 4 for FibroScan (N = 546). In heterogeneous analyses for significant fibrosis, the AUCs for FibroTest and FibroScan were 0.81 (95% CI 0.78-84) and 0.83 (0.03-1.00), respectively. At a threshold of approximately 0.60, the sensitivity and specificity of the FibroTest were 47% (35-59%) and 90% (87-92%). For FibroScan (threshold approximately 8 kPa), corresponding values were 64% (50-76%) and 87% (80-91%), respectively. Methodological quality, the length of liver biopsy specimens, and inclusion of special populations did not explain the observed heterogeneity. However, the diagnostic accuracy of both measures was associated with the prevalence of significant fibrosis and cirrhosis in the study populations. For cirrhosis, the summary AUCs for FibroTest and FibroScan were 0.90 (95% CI not calculable) and 0.95 (0.87-0.99), respectively. CONCLUSIONS: FibroTest and FibroScan have excellent utility for the identification of HCV-related cirrhosis, but lesser accuracy for earlier stages. Refinements are necessary before these tests can replace liver biopsy.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323814</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.em-consulte.com/showarticlefile/187168/main.pdf]]&gt;</url>
    <title>FibroTest-ActiTest as a non-invasive marker of liver fibrosis</title>
    <publicationDate>2008-09-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,HEPATITIS C,ALCOHOLIC LIVER DISEASE,NON-ALCOHOLIC,DIAGNOSTIC PROCEDURES,BLOOD TESTS,RECENT ADDITIONS,FATTY LIVER,LIVER FUNCTION TESTS,SEPTEMBER 2009,CHRONIC HEPATITIS B,CHRONIC HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; &lt;SPAN class=textenormal&gt;FibroTest (FT)&amp;nbsp;is an effective alternative to biopsy in patients with chronic hepatitis C (CHC) or B (CHB), alcoholic liver disease (ALD) or non-alcoholic fatty liver disease (NAFLD). Indeed, the prognostic performance of FibroTest was at least as accurate as that of biopsy in patients with chronic hepatitis C or B, or ALD.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; &lt;SPAN class=textenormal&gt;The primary aim of the present study was to update a previous meta-analysis of FT diagnostic value, and to summarize its advantages and limitations. &lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;SPAN class=textenormal&gt;A total of 38 diagnostic studies were included, which pooled 7985 subjects who had undergone both FT and biopsy (4600 HCV, 1580 HBV, 267 NAFLD, 524 ALD and 1014 mixed). The mean standardized AUROC was 0.84 (95% CI, 0.83-0.86), with no differences in terms of causes of liver disease: HCV 0.84 (0.82-0.87); HBV 0.81 (0.78-0.83); NAFLD 0.84 (0.76-0.92); ALD 0.87 (0.82-0.92); and mixed 0.85 (0.81-0.89). Three prognostic studies were also included. FT was found to have higher or similar prognostic value compared with biopsy in patients with CHC, CHB or ALD.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Halfon P, Munteanu M, Poynard T. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. &lt;EM&gt;Gastroenterol Clin Biol&lt;/EM&gt; 2008 Sep;32(6:Suppl 1):Suppl-39.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>106002</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.cancercare.on.ca/pdf/pebc2-9f.pdf]]&gt;</url>
    <title>Follow-up of patients with curatively resected colorectal cancer</title>
    <publicationDate>2004-01-01T00:00:00</publicationDate>
    <publisher>Cancer Care Ontario</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,CANCER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; Guidelines focusing on whether follow-up of patients after curative resection of colorectal cancer improves survival. These guidelines were originally published in 2002, but were up-dated with new evidence in January 2004.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Specialists&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>268551</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.jhin.2005.10.014]]&gt;</url>
    <title>Gastrointestinal endoscopy decontamination failure and the risk of transmission of blood-borne viruses: a review</title>
    <publicationDate>2006-05-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,DIAGNOSTIC PROCEDURES,GASTROINTESTINAL ENDOSCOPY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=abstract&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Morris J., Duckworth G.J., Ridgway G.L. 2006; Journal of Hospital Infection 63 (1) pp. 1-13&lt;/P&gt;
&lt;H2 class=abstract&gt;Original article abstract&lt;/H2&gt;
&lt;P class=abstract&gt;The risk of blood-borne virus transmission with an inadequately decontaminated endoscope during gastrointestinal endoscopy remains unclear, although it is likely to be low. A systematic review of the literature was undertaken to determine previous episodes of blood-borne virus transmission in these circumstances. In total, 31 articles were included in this review. No articles relating to possible transmission of human immunodeficiency virus were identified. The articles included were generally case series or case reports and were written prior to the comprehensive endoscope decontamination guidelines in use today. The results suggest that hepatitis B and hepatitis C transmission are low during endoscopy with an inadequately decontaminated endoscope.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345508</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1373/clinchem.2009.127126]]&gt;</url>
    <title>Genotyping for NOD2 genetic variants and Crohn disease: a metaanalysis</title>
    <publicationDate>2009-11-01T00:00:00</publicationDate>
    <publisher>HighWire Press</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion: &lt;/STRONG&gt;The per-allele risk of Crohn disease was markedly higher for Leu1007fsinsC than for Arg702Trp and Gly908Arg. Combining all genotypes revealed the risks of Crohn disease for compound heterozygotes and homozygotes to be similar and markedly higher than for simple heterozygotes&lt;STRONG&gt;.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Arg702Trp, Gly908Arg, and Leu1007fsinsC variants of the NOD2 gene (nucleotide-binding oligomerization domain containing 2; alias, CARD15) influence the risk of Crohn disease.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We conducted a systematic review to examine whether Arg702Trp, Gly908Arg, and Leu1007fsinsC are equally important risk factors for Crohn disease. In addition, we used studies for which combined information from all genotypes was available to compare risks in simple heterozygotes, compound heterozygotes, and homozygotes. PubMed, EMBASE, and Web of Science were searched. Seventy-five articles (18 727 cases and 17 102 controls) met the inclusion criteria and contributed data to the metaanalyses.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The odds ratios per allele for Crohn disease were 2.2 (95% CI, 2.0-2.5) for Arg702Trp, 2.6 (2.2-2.9) for Gly908Arg, and 3.8 (3.4-4.3) for Leu1007fsinsC (z-test results: Arg702Trp vs Gly908Arg, P = 0.03; Arg702Trp vs Leu1007fsinsC, P &amp;lt; 0.001; Gly908Arg vs Leu1007fsinsC, P &amp;lt; 0.001). When all 3 genotypes were combined, odds ratios for Crohn disease were 2.4 (95% CI, 2.0-2.8) for simple heterozygotes, 9.0 (6.0-13.5) for compound heterozygotes, and 6.7 (4.1-10.9) for homozygotes, compared with noncarriers (z-test results: simple heterozygotes vs compound heterozygotes, P &amp;lt; 0.001; simple heterozygotes vs homozygotes, P &amp;lt; 0.001; compound heterozygotes vs homozygotes, P = 0.18).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Yazdanyar S, Weischer M, Nordestgaard BG. Genotyping for NOD2 genetic variants and Crohn disease: a metaanalysis. &lt;EM&gt;Clin Chem&lt;/EM&gt; 2009;55(11):1950-7. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;Available to NHS staff via Athens; will be available to the general public from November 2010.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>103346</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/assetRoot/04/05/75/29/04057529.pdf]]&gt;</url>
    <title>Good practice in continence services</title>
    <publicationDate>2000-04-19T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,FAECAL INCONTINENCE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims&lt;/STRONG&gt;:&amp;nbsp;This update of the 1991 continence services guidance aims to determine the extent of the problem and set clear achievable service targets.&amp;nbsp; The targets consider both&amp;nbsp;clinical and managerial elements and include implementation and monitoring methods.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience&lt;/STRONG&gt;:&amp;nbsp;Medical practitioners and administrators.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>298571</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=298571]]&gt;</url>
    <title>Guest Editorial: Autoimmune Pancreatitis</title>
    <publicationDate>2008-11-14T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,PANCREAS,PANCREATITIS,RECENT ADDITIONS,NOVEMBER 2008,AUTOIMMUNE PANCREATITIS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Guest Editorial: Autoimmune Pancreatitis&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;
&lt;H1 style="FONT-WEIGHT: bold; FONT-SIZE: x-large; COLOR: #ffffff; BACKGROUND-COLOR: #33cccc"&gt;Autoimmune Pancreatitis&lt;/H1&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;
&lt;H3 style="FONT-WEIGHT: normal; FONT-SIZE: small; FONT-STYLE: italic"&gt;Dr George Webster BSc MD FRCP, Consultant Gastroenterologist and Hepatologist, University College London Hospitals, London, UK&lt;/H3&gt;
&lt;P&gt;&lt;/P&gt;&lt;BR&gt;&lt;BR&gt;
&lt;P&gt;
&lt;H2 style="FONT-WEIGHT: bold; FONT-SIZE: medium"&gt;Background&lt;/H2&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Autoimmune pancreatitis (AIP) is a recently described, and probably rare, fibroinflammatory disease of unknown aetiology, which is characterised histologically by an IgG4-positive lymphoplasmacytic infiltrate&lt;STRONG style="FONT-WEIGHT: normal; FONT-SIZE: xx-small; VERTICAL-ALIGN: 50%"&gt;&lt;A href="#ref1"&gt;1&lt;/A&gt;&lt;/STRONG&gt;. Although the disease was initially described more than 10 years ago, most reports have originated from Japan&lt;STRONG style="FONT-WEIGHT: normal; FONT-SIZE: xx-small; VERTICAL-ALIGN: 50%"&gt;&lt;A href="#ref2"&gt;2&lt;/A&gt;&lt;/STRONG&gt;. Only in the last few years has it become accepted that this is a Worldwide disease, and case series from USA&lt;STRONG style="FONT-WEIGHT: normal; FONT-SIZE: xx-small; VERTICAL-ALIGN: 50%"&gt;&lt;A href="#ref3"&gt;3&lt;/A&gt;&lt;/STRONG&gt; and UK&lt;STRONG style="FONT-WEIGHT: normal; FONT-SIZE: xx-small; VERTICAL-ALIGN: 50%"&gt;&lt;A href="#ref4"&gt;4&lt;/A&gt;&lt;/STRONG&gt; have recently been reported. In all series the disease occurs most usually in middle-age and elderly males.&lt;/P&gt;
&lt;P&gt;An understanding of the disease has been hampered by the wide range of nomenclature used for the disease, and the heterogenous nature of the condition. It is increasingly recognised that AIP is part of a multi-system disease, with similar histological lesions in all affected organs (the alternative term IgG4-sclerosing disease has been suggested&lt;STRONG style="FONT-WEIGHT: normal; FONT-SIZE: xx-small; VERTICAL-ALIGN: 50%"&gt;&lt;A href="#ref5"&gt;5&lt;/A&gt;&lt;/STRONG&gt;).&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;
&lt;H2 style="FONT-WEIGHT: bold; FONT-SIZE: medium"&gt;Clinical Features&lt;/H2&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;AIP is frequently misdiagnosed as pancreaticobiliary malignancy, in view of the common presentation of obstructive jaundice with non-specific abdominal pain and weight loss, and findings of a low bile duct stricture, and a pancreatic mass. Presentation with classical acute pancreatitis is rare. The disease may progress to atrophic chronic pancreatitis with exocrine insufficiency.&lt;/P&gt;
&lt;P&gt;Extrapancreatic disease is increasingly reported with AIP, particularly sclerosing cholangitis, which has recently been termed IgG-associated cholangitis&lt;STRONG style="FONT-WEIGHT: normal; FONT-SIZE: xx-small; VERTICAL-ALIGN: 50%"&gt;&lt;A href="#ref6"&gt;6&lt;/A&gt;&lt;/STRONG&gt;. Parenchymal liver disease (“IgG4-hepatopathy”), retroperitoneal fibrosis; renal disease (tubulo-interstitial nephritis), lung, mediastinal and peritoneal lymphadenopathy, and even neurological involvement has been reported. &lt;/P&gt;
&lt;P&gt;Pre-existing autoimmune-type diseases include Sjogren’s syndrome, inflammatory bowel disease, thyroid disease, and diabetes mellitus. &lt;/P&gt;&lt;BR&gt;
&lt;P&gt;
&lt;H2 style="FONT-WEIGHT: bold; FONT-SIZE: medium"&gt;Investigations&lt;/H2&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;There are characteristic, but not pathognomonic, features on imaging. CT scanning may show a focal pancreatic mass or diffuse pancreatic enlargement (“sausage pancreas”). Diffuse pancreatic duct stricturing is common. Hilar and intrahepatic biliary stricturing can be difficult to differentiate from primary sclerosing cholangitis (PSC). &lt;/P&gt;
&lt;P&gt;Elevated levels of serum IgG4 were initially reported to be &amp;gt; 95% sensitive and specific for AIP&lt;STRONG style="FONT-WEIGHT: normal; FONT-SIZE: xx-small; VERTICAL-ALIGN: 50%"&gt;&lt;A href="#ref7"&gt;7&lt;/A&gt;&lt;/STRONG&gt;, but more recent data suggests positive rates in 70% of AIP patients&lt;STRONG style="FONT-WEIGHT: normal; FONT-SIZE: xx-small; VERTICAL-ALIGN: 50%"&gt;&lt;A href="#ref4"&gt;4&lt;/A&gt;&lt;/STRONG&gt;, and elevated levels may also be seen in 9% of patients with PSC&lt;STRONG style="FONT-WEIGHT: normal; FONT-SIZE: xx-small; VERTICAL-ALIGN: 50%"&gt;&lt;A href="#ref8"&gt;8&lt;/A&gt;&lt;/STRONG&gt;, and rarely in pancreatic adenocarcinoma. Positive autoantibodies appear to be present in a minority of patients (including anti-nuclear antibodies, anti-carbonic anhydrase, anti-lactoferrin antibodies), and no specific antibody tests has been identified to date.&lt;/P&gt;
&lt;P&gt;The classical histological feature is that of a chronic lymphoplasmacytic infiltrate, with varying degrees of fibrosis. Immunostaining showing &amp;gt; 10 IgG4 + plasma cells per high power film strongly supports the diagnosis&lt;STRONG style="FONT-WEIGHT: normal; FONT-SIZE: xx-small; VERTICAL-ALIGN: 50%"&gt;&lt;A href="#ref9"&gt;9&lt;/A&gt;&lt;/STRONG&gt;, and can be made on both pancreatic and non-pancreatic specimens (eg duodenal papilla, gallbladder, liver biopsies)&lt;STRONG style="FONT-WEIGHT: normal; FONT-SIZE: xx-small; VERTICAL-ALIGN: 50%"&gt;&lt;A href="#ref10"&gt;10&lt;/A&gt;&lt;/STRONG&gt;. Elevated tissue IgG4 may occur independently of serum IgG4. There is no clear evidence that IgG4 is pathogenic, and may represent an epiphenomenon. &lt;/P&gt;&lt;BR&gt;
&lt;P&gt;
&lt;H2 style="FONT-WEIGHT: bold; FONT-SIZE: medium"&gt;Treatment&lt;/H2&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;There is no randomized placebo controlled data to support steroid therapy in AIP. Nevertheless, a clinical, radiological and biochemical response within weeks of starting oral steroids is characteristic, and steroids appear to reduce subsequent complications&lt;STRONG style="FONT-WEIGHT: normal; FONT-SIZE: xx-small; VERTICAL-ALIGN: 50%"&gt;&lt;A href="#ref11"&gt;11&lt;/A&gt;&lt;/STRONG&gt;. Dramatic improvement in inflammatory mass lesions and pancreatic and biliary stricturing may be seen. There is no standardized steroid regimen, but prednisolone 30-40mg OD, reducing by 5mg every 2 weeks, appears to be effective. Disease relapse after stopping steroids may occur in &amp;gt; 30% of patients, necessitating longer term immunosuppression (eg with azathioprine)&lt;STRONG style="FONT-WEIGHT: normal; FONT-SIZE: xx-small; VERTICAL-ALIGN: 50%"&gt;&lt;A href="#ref12"&gt;12&lt;/A&gt;,&lt;A href="#ref13"&gt;13&lt;/A&gt;&lt;/STRONG&gt;.&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;
&lt;H2 style="FONT-WEIGHT: bold; FONT-SIZE: medium"&gt;Further questions:&lt;/H2&gt;
&lt;P&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Nomenclature needs to be defined and agreed upon.&lt;/LI&gt;
&lt;LI&gt;The aetiopathogenesis of AIP, including the pathological relevance of IgG4+ plasma cells, requires further study.&lt;/LI&gt;
&lt;LI&gt;A better understanding is needed of the epidemiology of AIP, including its role in idiopathic chronic pancreatitis, and possible overlap with PSC.&lt;/LI&gt;
&lt;LI&gt;Optimal treatment for initial disease, and relapse, needs to be clarified.&lt;/LI&gt;&lt;/UL&gt;&lt;BR&gt;
&lt;P&gt;
&lt;H2 style="FONT-WEIGHT: bold; FONT-SIZE: medium"&gt;References&lt;/H2&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=ref1&gt;1.&lt;/A&gt; Finkelberg DL, Sahani D, Deshpande V, Brugge WR. &lt;A href="http://dx.doi.org/10.1056/NEJMra061200" target="_blank"&gt;Autoimmune pancreatitis.&lt;/A&gt; N Engl J Med 2006;355:2670-6.&lt;/P&gt;
&lt;P&gt;&lt;A name=ref2&gt;2.&lt;/A&gt; Yoshida K, Toki F, Takeuchi T, Watanabe S, Shiratori K, Hayashi N. &lt;A href="http://dx.doi.org/10.1007/BF02285209" target="_blank"&gt;Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis.&lt;/A&gt; Dig Dis Sci 1995;40:1561-8.&lt;/P&gt;
&lt;P&gt;&lt;A name=ref3&gt;3.&lt;/A&gt; Chari ST, Smyrk TC, Levy MJ, Topazian MD, Takahashi N, Zhang L, Clain JE, Pearson RK, Petersen BT, Vege SS, Farnell MB. &lt;A href="http://dx.doi.org/10.1016/j.cgh.2006.05.017" target="_blank"&gt;Diagnosis of autoimmune pancreatitis: the Mayo Clinic experience.&lt;/A&gt; Clin Gastroenterol Hepatol 2006;4:1010-6.&lt;/P&gt;
&lt;P&gt;&lt;A name=ref4&gt;4.&lt;/A&gt; Church NI, Pereira SP, Deheragoda MG, Sandanayake N, Amin Z, Lees WR, Gillams A, Rodriguez-Justo M, Novelli M, Seward EW, Hatfield AR, Webster GJ. &lt;A href="http://dx.doi.org/10.1111/j.1572-0241.2007.01531.x" target="_blank"&gt;Autoimmune Pancreatitis: Clinical and Radiological Features and Objective Response to Steroid Therapy in a UK Series.&lt;/A&gt; Am J Gastroenterol 2007;102:2417-25.&lt;/P&gt;
&lt;P&gt;&lt;A name=ref5&gt;5.&lt;/A&gt; Kamisawa T. &lt;A href="http://dx.doi.org/10.3748/wjg.14.3948" target="_blank"&gt;IgG4-related sclerosing disease.&lt;/A&gt; Intern Med 2006;45:125-6.&lt;/P&gt;
&lt;P&gt;&lt;A name=ref6&gt;6.&lt;/A&gt; Bjornsson E, Chari ST, Smyrk TC, Lindor K. &lt;A href="http://dx.doi.org/10.1002/hep.21685" target="_blank"&gt;Immunoglobulin G4 associated cholangitis: description of an emerging clinical entity based on review of the literature.&lt;/A&gt; Hepatology 2007;45:1547-54.&lt;/P&gt;
&lt;P&gt;&lt;A name=ref7&gt;7.&lt;/A&gt; Hamano H, Kawa S, Horiuchi A, Unno H, Furuya N, Akamatsu T, Fukushima M, Nikaido T, Nakayama K, Usuda N, Kiyosawa K. &lt;A href="http://dx.doi.org/10.1056/NEJM200103083441005" target="_blank"&gt;High serum IgG4 concentrations in patients with sclerosing pancreatitis.&lt;/A&gt; N Engl J Med 2001;344:732-8.&lt;/P&gt;
&lt;P&gt;&lt;A name=ref8&gt;8.&lt;/A&gt; Mendes FD, Jorgensen R, Keach J, Katzmann JA, Smyrk T, Donlinger J, Chari S, Lindor KD. &lt;A href="http://dx.doi.org/10.1111/j.1572-0241.2006.00772.x" target="_blank"&gt;Elevated Serum IgG4 Concentration in Patients with Primary Sclerosing Cholangitis.&lt;/A&gt; Am J Gastroenterol 2006;101:2070-5.&lt;/P&gt;
&lt;P&gt;&lt;A name=ref9&gt;9.&lt;/A&gt; Kamisawa T, Funata N, Hayashi Y, Eishi Y, Koike M, Tsuruta K, Okamoto A, Egawa N, Nakajima H. &lt;A href="http://dx.doi.org/10.1007/s00535-003-1175-y" target="_blank"&gt;A new clinicopathological entity of IgG4-related autoimmune disease.&lt;/A&gt; J Gastroenterol 2003;38:982-4.&lt;/P&gt;
&lt;P&gt;&lt;A name=ref10&gt;10.&lt;/A&gt; Deheragoda MG, Church NI, Rodriguez-Justo M, Munson P, Sandanayake N, Seward EW, Miller K, Novelli M, Hatfield AR, Pereira SP, Webster GJ. &lt;A href="http://dx.doi.org/10.1016/j.cgh.2007.04.023" target="_blank"&gt;The use of immunoglobulin g4 immunostaining in diagnosing pancreatic and extrapancreatic involvement in autoimmune pancreatitis.&lt;/A&gt; Clin Gastroenterol Hepatol 2007;5:1229-34.&lt;/P&gt;
&lt;P&gt;&lt;A name=ref11&gt;11.&lt;/A&gt; Hirano K, Tada M, Isayama H, Yagioka H, Sasaki T, Kogure H, Nakai Y, Sasahira N, Tsujino T, Yoshida H, Kawabe T, Omata M. &lt;A href="http://dx.doi.org/10.1136/gut.2006.115246" target="_blank"&gt;Long-term Prognosis of Autoimmune Pancreatitis without and with Corticosteroid Treatment.&lt;/A&gt; Gut 2007;56:1719-24.&lt;/P&gt;
&lt;P&gt;&lt;A name=ref12&gt;12.&lt;/A&gt; Sandanayake N, Church NI, Chapman MH, Johnson GJ, Dhar DK, Amin Z, Deheragoda M, Novelli M, Winstanley A, Rodriguez-Justo M, Hatfield AR, Pereira SP, Webster GJM. Presentation and management of post-treatment relapse in Autoimmune Pancreatitis/IgG4-Associated Cholangitis. Gastroenterology 2008.&lt;/P&gt;
&lt;P&gt;&lt;A name=ref13&gt;13.&lt;/A&gt; Chari ST, Murray JA. &lt;A href="http://dx.doi.org/doi:10.1053/j.gastro.2007.12.014" target="_blank"&gt;Autoimmune pancreatitis, Part II: the relapse.&lt;/A&gt; Gastroenterology 2008;134:625-8.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>332193</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1751-2980.2008.00332.x]]&gt;</url>
    <title>Guidelines for the diagnosis and treatment of alcoholic liver disease</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,ALCOHOLIC LIVER DISEASE,ALCOHOLIC FATTY LIVER DISEASE,ALCOHOLIC HEPATITIS,ALCOHOLIC CIRRHOSIS,DIAGNOSTIC PROCEDURES,STEATOHEPATITIS,ALCOHOLIC,RECENT ADDITIONS,CIRRHOSIS,ALCOHOLIC,FATTY LIVER,ALCOHOLIC,DECEMBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; Alcoholic liver disease (ALD) is caused by long-term heavy drinking of alcohol and usually manifests initially as a fatty liver, then develops progressively to alcoholic hepatitis, alcoholic liver fibrosis and alcoholic liver cirrhosis. Excessive drinking of alcohol may induce widespread hepatocellular necrosis and even liver failure. ALD is a common liver disease in our country, causing severe harm. For standardizing the diagnosis and treatment of ALD, the Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Society of Hepatology organized experts to work out guidelines for the diagnosis and treatment of alcoholic liver disease with reference to the latest worldwide research data and in accordance with the principles of evidence-based medicine.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309206</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1002/ibd.20378]]&gt;</url>
    <title>Guidelines for the management of growth failure in childhood inflammatory bowel disease</title>
    <publicationDate>2008-06-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We carried out a systematic review of publications to identify the best available evidence for managing growth failure in children with IBD.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt;&amp;nbsp;Despite the paucity of high-quality publications, sufficient data were available in the literature to allow practical, evidence-based where possible, management guidelines to be formulated. Although there is clear evidence that exclusive enteral nutrition achieves mucosal healing, its effect on growth has only been assessed at 6 months. In contrast to corticosteroids, EEN has no negative effect on growth. Corticosteroids remain the key therapy responsible for medication-induced growth impairment, although the use of budesonide in selected patients may minimize the steroid effect on dividing growth plates. Immunosuppressants have become a mainstay of treatment in children with IBD, and are being used earlier in the disease course than ever before. However, there are currently no long-term data reporting better growth outcome if these agents are introduced very soon after diagnosis. In comparison, recent data from a large prospective trial of infliximab in children with moderate to severe CD suggested significant catch-up growth during the first year of regular infusions. The only other intervention that has documented clear catch-up growth has been surgical resection. Resection of localized CD, in otherwise treatment-resistant children, early in the disease process achieves clear catch-up growth within the next 6 months. There are no data available that growth hormone improves final adult height in children with CD. In conjunction with expert endocrinological support, pubertal delay, more common in boys, may be treated with parenteral testosterone if causing significant psychological problems. The optimal management of children and adolescents requires a multidisciplinary approach frequently available within the pediatric healthcare setting. Dedicated dietetic support, along with nurse-specialist, child psychologist, and with closely linked medical and surgical care will likely achieve the best possible start for children facing a lifetime of chronic gut disease.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Heuschkel, R., Salvestrini, C., Beattie, R. M., Hildebrand, H., Walters, T., &amp;amp; Griffiths, A. (2008) Guidelines for the management of growth failure in childhood inflammatory bowel disease. &lt;I&gt;Inflammatory Bowel Diseases&lt;/I&gt; 14(6):839-849.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>177032</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.helicobacter.org/download/summary_guidelines_hp_infection%20_business_briefing.pdf]]&gt;</url>
    <title>Guidelines for the management of Helicobacter pylori infection</title>
    <publicationDate>2005-01-01T00:00:00</publicationDate>
    <publisher>European Helicobacter Study Group</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,STOMACH,CANCER,DISEASE PREVENTION,HELICOBACTER PYLORI,DYSPEPSIA,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims&lt;/STRONG&gt;:&amp;nbsp;This consensus report&amp;nbsp;is a summary of guidelines for the management of&amp;nbsp; Helicobacter Pylori infection.&amp;nbsp;This consensus meeting focussed on who to treat, how to diagnose and treat H. pylori and the prevention of gastric cancer by H. pylori eradication. The link between H. pylori and reflux oesophagitis is also discussed in the report.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience&lt;/STRONG&gt;:&amp;nbsp;&amp;nbsp;Healthcare professionals.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>389995</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://ebm.bmj.com/content/15/5/153.short?rss=1]]&gt;</url>
    <title>H pylori infection associated with unspecified abdominal pain in referred children but not with (UAP) in primary care or with recurrent abdominal pain</title>
    <publicationDate>2010-10-01T00:00:00</publicationDate>
    <publisher>BMJ Journals</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,STOMACH,HELICOBACTER PYLORI,RECENT ADDITIONS,INFECTIONS,OCTOBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Chong SKF (2010) H pylori infection associated with unspecified abdominal pain in referred children but not with (UAP) in primary care or with recurrent abdominal pain. &lt;EM&gt;Evidence Based Medicine&lt;/EM&gt; 15(5):153-154&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Context:&lt;/STRONG&gt; Ever since its correlation with gastritis was discovered by Warren and Marshall in 1983,1 clinicians have been intrigued by the possible association of symptomatology with Helicobacter pylori infection of the stomach. Epidemiologic studies have shown that the disease starts in early childhood, and as such, may be causative of abdominal pain, gassiness and satiety. As the number of patients infected, particularly in developing countries is vast, many without symptoms or are silent, inputting a causative role for gastrointestinal (GI) symptoms is difficult to prove in adults, and even harder in children. &lt;/P&gt;
&lt;DIV id=sec-1 class=section&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Spee and colleagues have performed a systematic literature review of the current published evidence for a relationship between GI symptoms and H pylori infection in children. It is a comprehensive search of both English and non-English publications from 1966 to mid 2009. The search is non-biased and has strict selection criteria for inclusions to ensure that the children with relevant comorbidities are excluded. The data sources and search was thorough, and rigorous criteria were used to select … &lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Evidence-Based Medicine&lt;/EM&gt; is a secondary evidence journal, containing informative abstracts and expert commentaries about the best quality research from primary care medicine.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to NHS staff via Athens.&lt;/P&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>293616</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.drugpo.2007.01.016]]&gt;</url>
    <title>HCV synthesis project: preliminary analyses of HCV prevalence in relation to age and duration of injection</title>
    <publicationDate>2007-10-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Hagan, H et al International Journal of Drug Policy 2007 Oct;18(5):341-51. Epub 2007 May 2&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract: &lt;/STRONG&gt;Early acquisition of hepatitis C virus (HCV) infection appears to affect a substantial proportion of injection drug users (IDUs)--between 20 percent and 90 percent. Analysing the range of HCV prevalence estimates in new injectors may help identify factors that can be modified to reduce HCV transmission. The HCV Synthesis Project is a meta-analysis of studies of HCV epidemiology and prevention in drug users worldwide. In this preliminary analysis, we examined data from 127 studies of IDUs that reported HCV prevalence in relation to age or year since onset of drug injection, analysing heterogeneity and calculating summary statistics where appropriate. Six studies reported gender-specific HCV prevalence rates among young or new injectors; the group mean prevalence was 47 percent for men and 44 percent for women (NS). Group mean age for HCV-negatives was 24.7 years (range 24-28) and 26.1 years (range 21-31) for HCV-positives (n=8 studies). Data were examined from 13 studies that compared HCV prevalence among young injectors to older injectors using 5-year age categories; substantial variation was present within these categories such that measures of central tendency were not calculated. Similarly, among studies reporting HCV prevalence among IDUs in relation to 1-year intervals of duration of injection (&amp;lt;1 year, &amp;lt;2 years, and &amp;lt;3 years), considerable variability was observed. Notably, there were studies in each category that reported prevalence of 70 percent or higher among recent-onset drug injectors. Our findings confirm previous studies reporting high risk of acquiring HCV shortly after onset of injection; thus, HCV prevention programmes must emphasize methods to reach new injectors. Future research should (1) report data on time to infection in depth, (2) provide detailed information on study methodology, and (3) characterize the research setting with respect to underlying factors that affect injection practices and networks. This will permit synthesis of a greater number of studies and may lead to the identification of factors that impede HCV transmission.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345578</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2008.03709.x]]&gt;</url>
    <title>Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease--modelling outcomes in active luminal and fistulizing disease in adults</title>
    <publicationDate>2008-07-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Eight-week scheduled maintenance treatment with infliximab is a cost-effective treatment for adult patients suffering from active luminal or fistulizing Crohn's disease (CD)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Infliximab has been shown to be efficacious in moderate-to-severe CD. The aim of this study was to evaluate the cost-effectiveness of scheduled maintenance treatment with infliximab in luminal and fistulizing CD patients.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Markov models were constructed to simulate the progression of adult CD patients with and without fistulae during treatment with infliximab (5 mg/kg). Transitions were estimated from published clinical trials of infliximab. Standard care, comprising immunomodulators and/or corticosteroids was used as a comparator. An average weight of 60 kg was used to estimate the dose of infliximab. The costs and outcomes were discounted at 3.5% over 5 years. The primary effectiveness measurement was quality-adjusted life years (QALYs) estimated using EQ-5D. One-way and probabilistic sensitivity analyses were performed by varying the infliximab efficacy estimates, costs and utilities.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The incremental cost per QALY gained was £26 128 in luminal CD and £29 752 in fistulizing CD at 5 years. Results were robust and remained in the range of £23 752–£38 848 for luminal CD and £27 047–£44 206 for fistulizing CD. Patient body weight was the most important factor affecting cost-effectiveness.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Lindsay J, Punekar YS, Morris J, Chung-Faye G. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease--modelling outcomes in active luminal and fistulizing disease in adults. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2008;28(1):76-87.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;See also: &lt;/STRONG&gt;&lt;A href="nelh:308043:0" name=internalLink&gt;NHS EED record&lt;/A&gt; for this article.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>381427</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19844890]]&gt;</url>
    <title>Health-related quality of life in dialysis patients with HCV infection</title>
    <publicationDate>2009-10-21T00:00:00</publicationDate>
    <publisher>Wichtig Editore</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,RECENT ADDITIONS,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract:&lt;/STRONG&gt; Measuring the impact of chronic kidney disease (CKD) treatment on patient quality of life has become increasingly recognized as an important outcome measure. Despite improvements in the treatment of chronic kidney disease, health-related quality of life (HRQOL) is lower than in the general population. HRQOL measures, particularly the Physical Component Summary (PCS), have predictive validity for risk of both mortality and hospitalization in dialysis populations. For every 10-point lower PCS score, the relative risk (RR) of death increases by 29% (RR=1.29; 95% CI=1.23 to 1.35; p&amp;lt;0.001) and the risk of hospitalization increases by 15% (RR=1.15; 95% CI=1.11 to 1.19, p&amp;lt;0.001), according to the Dialysis Outcomes and Practice Patterns Study (DOPPS). Hepatitis C virus (HCV) infection remains prevalent among dialysis patients with a recent meta-analysis showing that anti-HCV seropositive status was an independent and significant risk factor for death in patients on maintenance dialysis. Seven studies with 11,589 unique patients on maintenance dialysis were identified; the summary estimate for adjusted relative risk (aRR) (all-cause mortality) was 1.34 with a 95% confidence interval (CI) of 1.13-1.59. In non-uremic populations HCV diminishes HRQOL, and individuals with HCV scored lower than controls across all scales of the short form 36 (SF-36). Patients achieving sustained virological responses (SVR) scored higher across all scales versus patients without SVR, especially in the physical health domains. Whether the adverse influence of HCV on survival in dialysis population is related to the negative impact of HCV on HRQOL requires further research. Information on HRQOL indices in patients with HCV on maintenance dialysis is extremely limited but the available evidence shows that HCV infection impairs HRQOL, especially in mental aspects, among patients on maintenance hemodialysis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Fabrizi F, Messa P, Martin P. Health-related quality of life in dialysis patients with HCV infection. &lt;EM&gt;Int J Artif Organs &lt;/EM&gt;2009;32(8):473-481.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323557</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1177/0272989X08315240]]&gt;</url>
    <title>Health-state utilities in liver disease: a systematic review</title>
    <publicationDate>2008-07-01T00:00:00</publicationDate>
    <publisher>Sage Publications</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS A,HEPATITIS B,HEPATITIS C,LIVER TRANSPLANTATION,RECENT ADDITIONS,CIRRHOSIS,AUGUST 2009,SURGERY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The authors have created a valuable liver disease- based utility resource from which researchers and policy makers can easily view all available utility estimates from the literature. They have also estimated health-state utilities for major states of hepatitis C.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A search of MED-LINE, EMBASE, and CINAHL from 1966 to September 2006 was conducted including key words related to liver disease and utility measuring tools. Articles were included if health-state utility tools or expert opinion were used. Variance-weighted mean utility estimates were pooled using metaregression adjusting for disease state and utility assessment method.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Thirty studies measured utilities of liver diseases/disease states. Half of these estimated utilities for hepatitis viruses: hepatitis A (n = 1), hepatitis B (n = 4), and hepatitis C (n = 10). Others included liver transplant (n= 6) and chronic liver disease (n= 5) populations. Twelve utility methods were used throughout. The EQ-5D (n = 10) was most popular method, followed by visual analogue scale (n = 9), time tradeoff (n = 6), and standard gamble (n = 4). Respondents were patients (n= 16), an expert panel (n = 10), non-liver diseases adults ( n=2), patient and expert (n = 1), and patient and healthy adult (n = 1). Type of perspective included community (n=21), patient (n=4), and both (n = 5). The pooled mean estimates in hepatitis C with moderate disease, compensated cirrhosis, decompensated cirrhosis, and post-liver transplant using the EQ-5D were 0.75, 0.75, 0.67, and 0.71, respectively. The change in these utilities using different methods were -0.07 (visual analogue scale), -0.01 (health utilities index version 3), +0.04 (standard gamble), + 0.08 (health utilities index version 2), + 0.12 (time tradeoff), and + 0.15 (standard gamble-transformed visual analogue scale).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; McLernon DJ, Dillon J, Donnan PT. Health-state utilities in liver disease: a systematic review. &lt;EM&gt;Med Decis Making&lt;/EM&gt; 2008 Jul;28(4):582-92.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>103430</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.acg.gi.org/physicians/guidelines/HepaticEncephalopathy.pdf]]&gt;</url>
    <title>Hepatic encephalopathy</title>
    <publicationDate>2001-07-01T00:00:00</publicationDate>
    <publisher>American College of Gastroenterology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATIC ENCEPHALOPATHY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims&lt;/STRONG&gt;:&amp;nbsp;&amp;nbsp;&amp;nbsp;To provide a&amp;nbsp;guideline based on the critical appraisal of &amp;nbsp;all available evidence and expert opinion on the diagnosis and treatment options of hepatic encepalopathy.&amp;nbsp; The controlled vocabulary used to determine the clinical subtypes are those set out by the &lt;A href="http://www.omge.org/" target="_blank"&gt;World Congress of Gastorenterology&lt;/A&gt;.&amp;nbsp;Of the four subtypes used, only one is considered&amp;nbsp;to&amp;nbsp;have controversial therapeutic imperatives; minimal or subclinical encephalopathy&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience&lt;/STRONG&gt;:&amp;nbsp;Clinicians regardless of specialty&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;Availble to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>330289</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1530-0277.2007.00593.x]]&gt;</url>
    <title>Hepatic safety of once-monthly injectable extended-release naltrexone administered to actively drinking alcoholics</title>
    <publicationDate>2008-03-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>RANDOMISED CONTROLLED TRIAL</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,ALCOHOLIC LIVER DISEASE,RECENT ADDITIONS,NOVEMBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Extended-release formulation of naltrexone does not appear to be hepatotoxic when taken at the recommended clinical doses in actively drinking alcohol-dependent patients.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Hepatoxicity has been reported with oral naltrexone. Hepatic safety data were examined from a 6-month study evaluating the efficacy and safety of a now available extended-release formulation of naltrexone (XR-NTX) in patients with alcohol dependence.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; In all, 624 patients (68% male; median age of 44 years) were randomly assigned to XR-NTX 380 mg (n = 205), XR-NTX 190 mg (n = 210), or placebo (n = 209).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; There were no significant differences in alanine aminotrasferase, aspartate aminotransferase, or bilirubin levels between the study groups at study initiation or at subsequent assessments. Gamma-glutamyltransferase in the XR-NTX 380 mg group was lower compared with placebo at weeks 4, 8, 12, and 20. Both high (&amp;gt;3 times the upper limit of normal) liver chemistry tests (LCTs) and hepatic-related adverse events were infrequent in all study groups. In patients who were drinking heavily throughout the study, obese subjects, or those taking nonsteroidal anti-inflammatory drugs, there was no increase in frequency of high LCTs or hepatic-related adverse events in patients receiving XR-NTX (either dose) compared with placebo.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Lucey MR, Silverman BL, Illeperuma A, O'Brien CP. Hepatic safety of once-monthly injectable extended-release naltrexone administered to actively drinking alcoholics. &lt;EM&gt;Alcohol Clin Exp Res&lt;/EM&gt; 2008 Mar;32(3):498-504.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>384943</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1002/hep.23619]]&gt;</url>
    <title>Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: a meta-analysis of the risk factors</title>
    <publicationDate>2010-07-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,NON-ALCOHOLIC,HIV / AIDS,STEATOHEPATITIS,NON-ALCOHOLIC,RECENT ADDITIONS,FATTY LIVER,CHRONIC HEPATITIS C,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; In patients coinfected with hepatitic C virus (HCV) and human immunodeficiency virus (HIV), hepatic steatosis (HS) does not seem to be more frequent than in HCV monoinfected patients and is mostly associated with metabolic factors, such as increased weight, diabetes mellitus, and more severe liver disease. The fact that no associations with HCV factors were found may be due to the small percentage of genotype 3-infected patients.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; HS is frequent in patients with HCV infection, occurring in 40%-80%, associating with metabolic and virus-related factors, namely, genotype 3 and viral load. HIV infection and antiretroviral treatment seem to be risk factors for HS. Several studies addressed this issue in coinfected patients, with discrepant results.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A meta-analysis was performed on the HS risk factors in coinfected patients. Eligible studies were identified through structured keywords including coinfection, HCV, HIV, and steatosis in relevant databases including PubMed. Pooled odds ratios (ORs) and confidence limits (CIs) were obtained with the random-effects model and the DerSimonian-Laird method.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Twelve studies, including 1,989 coinfected patients, were selected. Twenty percent were infected with HCV genotype 3. The overall prevalence of HS was 50.8% (23%-72%). Four studies also included 1,540 HCV monoinfected patients, not showing an increased risk for HS in coinfected patients (OR 1.61, 95% CI 0.84-3.10, P = 0.151). In coinfected patients, HS was associated with higher body mass index (OR 1.13, 95% CI 1.07-1.19, P &amp;lt; 0.001), diabetes mellitus (OR 2.32, 95% CI 1.32-4.07, P = 0.003), elevated alanine aminotransferase levels (OR 1.28, 95% CI 1.02-1.61, P = 0.035), necroinflammatory activity (OR 1.72, 95% CI 1.11-2.67, P = 0.016), and fibrosis (OR 1.67, 95% CI 1.20-2.34, P = 0.003). No associations were found between HS and gender, other metabolic factors (dyslipidemia, glucose, metabolic syndrome), HCV-related factors (genotype, viral load), or HIV-related factors (viral load, CD4 count, antiretroviral therapy, and class of medication).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: a meta-analysis of the risk factors. &lt;EM&gt;Hepatology&lt;/EM&gt; 2010;52(1):71-8.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323555</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2516.2008.01954.x]]&gt;</url>
    <title>Hepatitis A and B immunization for individuals with inherited bleeding disorders</title>
    <publicationDate>2009-03-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS A,HEPATITIS B,DISEASE PREVENTION,VACCINATION,RECENT ADDITIONS,AUGUST 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt; Hepatitis A and B vaccines are highly effective tools that can greatly reduce infection risk in the bleeding disorder population. Although hepatitis A and B immunization for individuals with bleeding disorders is universally recommended, various advisory bodies often differ with respect to many practical aspects of vaccination. To review the published literature and guidelines and form a practical, comprehensive and consistent approach to hepatitis A and B immunization for individuals with bleeding disorders. We reviewed published immunization guidelines from North American immunization advisory bodies and published statements from North American and international haemophilia advisory bodies. A search of the MEDLINE database was performed to find original published literature pertaining to hepatitis A or B immunization of patients with haemophilia or bleeding disorder patients that provided supporting or refuting evidence for advisory body guidelines. Various advisory bodies' immunization guidelines regarding individuals with bleeding disorders have contradictory statements and often did not clarify issues (e.g. post vaccination surveillance). Published literature addressing immunization in bleeding disorder patients is sparse and mostly examines route of vaccine administration, complications and corresponding antibody response. Although the risk of hepatitis A and B infection is low, the use of simple measures such as vaccination is reasonable and advocated by haemophilia advisory bodies. Following our review of the available literature and North American guidelines, we have developed comprehensive and practical recommendations addressing hepatitis A and B immunization for the bleeding disorder population that may be applicable in Bleeding Disorder clinics.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Steele M, Cochrane A, Wakefield C, Stain A-M, Ling S, Blanchette V, et al. Hepatitis A and B immunization for individuals with inherited bleeding disorders. &lt;EM&gt;Haemophilia&lt;/EM&gt; 2009;15(2):437-47.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>268543</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/sti.2006.023218]]&gt;</url>
    <title>Hepatitis A, B, and C</title>
    <publicationDate>2006-12-01T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS A,HEPATITIS B,HEPATITIS C,ACUTE HEPATITIS B,CHRONIC HEPATITIS B,ACUTE HEPATITIS C,CHRONIC HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation&lt;/STRONG&gt;: Gilson R., Brook M.G. 2006; Sexually Transmitted Infections 82 Suppl 4 iv35-9&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;There is no abstract available online for this article&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>380733</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.3109/15569520903427717]]&gt;</url>
    <title>Hepatitis B vaccine and uveitis: an emerging hypothesis suggested by review of 32 case reports</title>
    <publicationDate>2010-03-01T00:00:00</publicationDate>
    <publisher>Informa</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,DISEASE PREVENTION,VACCINATION,RECENT ADDITIONS,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Hepatitis B vaccine may have a possible association with the development of uveitis in some patients. Immune complex deposition and adjuvant effects are potential pathogenic mechanisms.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; To report a possible association between hepatitis B vaccine and uveitis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Spontaneous reports from the National Registry of Drug-Induced Ocular Side Effects, the World Health Organization, and the Food and Drug Administration were collected on hepatitis B vaccine associated with uveitis between 1982 and 2009. In addition, we performed a Medline literature search using the keywords of uveitis, iritis, or vitritis, in combination with vaccines and hepatitis B vaccine. Data garnered from the spontaneous reports included age, gender, adverse drug reaction, temporal association of uveitis with vaccine doses, concomitant drugs, other systemic disease, recovery, and recurrence after repeat dosage.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Thirty-two case reports of uveitis occurring after hepatitis B vaccine were reported to the spontaneous reporting databases. The mean age of the patients was 29 years (1-57 years), with 8 male and 24 female patients. The mean number of days until uveitis was reported after vaccination was 3 days (1-15 days). The uveitis was reported to occur after the first vaccination in 15 patients, after the second vaccination in 3 patients, and after the third vaccination in 3 patients; the duration of time to occurrence of uveitis was not reported for 9 patients. One patient had recurrent uveitis after both the second and third doses of vaccine. One patient had recurrent uveitis after the first and second doses of vaccine.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Fraunfelder FW, Suhler EB, Fraunfelder FT. Hepatitis B vaccine and uveitis: an emerging hypothesis suggested by review of 32 case reports. &lt;EM&gt;Cutan Ocul Toxicol&lt;/EM&gt; 2010;29(1):26-9.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>328533</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.britishlivertrust.org.uk/content/retrieve.aspx?id=423&amp;name=ae9cdf31e9890dd8d1622eeecdd0e6b1&amp;type=docs]]&gt;</url>
    <title>Hepatitis B: out of the shadows</title>
    <publicationDate>2004-10-13T00:00:00</publicationDate>
    <publisher>Foundation for Liver Research</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,DIAGNOSTIC PROCEDURES,DISEASE PREVENTION,HIV / AIDS,PREGNANCY,BLOOD TESTS,VACCINATION,RECENT ADDITIONS,LIVER FUNCTION TESTS,NOVEMBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Chronic hepatitis B is not seen as a public health priority. In spite of the substantial clinical and economic burden, chronic hepatitis B currently
lurks in the shadows, missing out on the publicity, awareness and financial support given to other diseases.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Summary: &lt;/STRONG&gt;A report from the Foundation for Liver Research on chronic hepatitis B infection.&amp;nbsp; It covers basic facts about the disease, the clinical and economic burden of hepatitis B in the UK, transmission and prevention, diagnosis, treatment, and considerations for pregnant patients and those coinfected with HIV. It concludes by assessing the adequacy&amp;nbsp;of current provision and makes recommendations for future development.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>126589</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/assetRoot/04/08/47/13/04084713.pdf]]&gt;</url>
    <title>Hepatitis C action plan for England</title>
    <publicationDate>2004-07-01T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,CHRONIC HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The Hepatitis C Action Plan for England implements the Hepatitis C Strategy for England which was published for consultation in 2002.</description>
    <body>&lt;![CDATA[ &lt;P&gt;The Action Plan implements the&lt;STRONG&gt; &lt;/STRONG&gt;Departement for Health&lt;STRONG&gt; &lt;A href="nelh:126588:0" name=internalLink&gt;&lt;A href="http://www.dh.gov.uk/assetRoot/04/05/95/10/04059510.pdf" target="_blank"&gt;Hepatitis C Strategy for England&lt;/A&gt;&lt;/A&gt;&lt;/STRONG&gt;.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Chapters:&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Introduction&lt;/LI&gt;
&lt;LI&gt;National outlook: where we are now&lt;/LI&gt;
&lt;LI&gt;International outlook: how do we compare?&lt;/LI&gt;
&lt;LI&gt;The future&lt;/LI&gt;
&lt;LI&gt;The actions:&lt;/LI&gt;&lt;/OL&gt;
&lt;UL&gt;
&lt;LI&gt;Action 1: Surveillence and research&lt;/LI&gt;
&lt;LI&gt;Action 2: Increasing awareness and reducing undiagnosed infections&lt;/LI&gt;
&lt;LI&gt;Action 3: High-quality health and social care services&lt;/LI&gt;
&lt;LI&gt;Action 4: Prevention&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Audience:&lt;/STRONG&gt; All those affected by hepatitis C care within the NHS, especially healthcare professionals and managers&lt;FONT face="Times New Roman,Times New Roman"&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Related links:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:126588:0" name=internalLink&gt;&lt;A href="http://www.dh.gov.uk/assetRoot/04/05/95/10/04059510.pdf" target="_blank"&gt;Hepatitis C Strategy for England&lt;/A&gt;&lt;A href="http://www.dh.gov.uk/assetRoot/04/05/95/10/04059510.pdf" target="_blank"&gt;&lt;/A&gt;&lt;/A&gt;, Department&amp;nbsp;of&amp;nbsp;Health.&lt;/P&gt;
&lt;P&gt;Full report &lt;A href="nelh:126678:0" name=internalLink&gt;&lt;A href="nelh:126678:0" name=internalLink&gt;&lt;A href="http://www.hepcuk.info/data/news/213_The%20UK%20vs.%20Europe.pdf" target="_blank"&gt;The UK vs. Europe: ready to fight back?&lt;/A&gt;&lt;/A&gt;&lt;/A&gt; The Hepatitis C Trust and University of Southampton.&lt;/P&gt;
&lt;P&gt;Interim report &lt;A href="nelh:126590:0" name=internalLink&gt;&lt;A href="http://www.hepcuk.info/data/news/213_The%20UK%20vs.%20Europe.pdf" target="_blank"&gt;The UK vs. Europe: losing the fight against Hepatitis C&lt;/A&gt;&lt;/A&gt;. The Hepatitis C Trust and University of Southampton.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;A href="nelh:126587:0" name=internalLink&gt;&lt;A href="http://www.hepcuk.info/data/usercontentroot/home/" target="_blank"&gt;&lt;EM&gt;The Hepatitis C Trust&lt;/EM&gt;&lt;/A&gt;&lt;A href="http://www.hepcuk.info/data/usercontentroot/home/" target="_blank"&gt;&lt;/A&gt;&lt;/EM&gt;&lt;/A&gt; website.&lt;/FONT&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293535</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.cgh.2008.02.011]]&gt;</url>
    <title>Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium</title>
    <publicationDate>2008-04-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;de Sanjose, S et al Clinical gastroenterology and hepatology 2008 Apr;6(4):451-8.&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;Abstract: &lt;/STRONG&gt;BACKGROUND &amp;amp; AIMS: Increasing evidence points towards a role of hepatitis C virus (HCV) infection in causing malignant lymphomas. We pooled case-control study data to provide robust estimates of the risk of non-Hodgkin's lymphoma (NHL) subtypes after HCV infection. METHODS: The analysis included 7 member studies from the International Lymphoma Epidemiology Consortium (InterLymph) based in Europe, North America, and Australia. Adult cases of NHL (n = 4784) were diagnosed between 1988 and 2004 and controls (n = 6269) were matched by age, sex, and study center. All studies used third-generation enzyme-linked immunosorbent assays to test for antibodies against HCV in serum samples. Participants who were human immunodeficiency virus positive or were organ-transplant recipients were excluded. RESULTS: HCV infection was detected in 172 NHL cases (3.60%) and in 169 (2.70%) controls (odds ratio [OR], 1.78; 95% confidence interval [CI], 1.40-2.25). In subtype-specific analyses, HCV prevalence was associated with marginal zone lymphoma (OR, 2.47; 95% CI, 1.44-4.23), diffuse large B-cell lymphoma (OR, 2.24; 95% CI, 1.68-2.99), and lymphoplasmacytic lymphoma (OR, 2.57; 95% CI, 1.14-5.79). Notably, risk estimates were not increased for follicular lymphoma (OR, 1.02; 95% CI, 0.65-1.60). CONCLUSIONS: These results confirm the association between HCV infection and NHL and specific B-NHL subtypes (diffuse large B-cell lymphoma, marginal zone lymphoma, and lymphoplasmacytic lymphoma).&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>333344</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1259152221464]]&gt;</url>
    <title>Hepatitis C in the UK</title>
    <publicationDate>2009-12-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,RECENT ADDITIONS,DECEMBER 2009,CHRONIC HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;STRONG&gt;Summary: &lt;/STRONG&gt;Overall, it is estimated that around 185,000 individuals in the UK are chronically infected with hepatitis C (HCV). Much of the prevalent infection is concentrated in marginalised populations – with injecting drug users (IDUs) at greatest risk of acquiring infection. More recent evidence suggests that some minority ethnic populations are also at high risk of infection. National Action Plans are in place in all UK countries to help tackle HCV infection. This annual report documents the progress of these UK hepatitis C action plans. In all of the plans, public health action is focussed on: 
&lt;UL&gt;
&lt;LI&gt;preventing new infections 
&lt;LI&gt;increasing awareness of the infection among the public and healthcare professionals 
&lt;LI&gt;increasing diagnosis 
&lt;LI&gt;getting diagnosed individuals into treatment and care&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323540</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.jhep.2008.08.006]]&gt;</url>
    <title>Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,HEPATITIS C,RECENT ADDITIONS,AUGUST 2009,CHRONIC HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&amp;nbsp;&lt;/STRONG&gt;There is a significant excess risk of diabetes mellitus (DM)&amp;nbsp;with&amp;nbsp;hepatitis C virus (HCV)&amp;nbsp;infection in comparison to non-infected controls.&amp;nbsp; This find&amp;nbsp;is strengthened by consistency of results from both prospective and retrospective studies. The excess risk observed in comparison to hepatitis B virus-infected controls suggests a potential direct viral role in promoting DM risk, but this needs to be further examined.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We followed standard guidelines for performance of meta-analyses. Two independent investigators identified eligible studies through structured keyword searches in relevant databases including PubMed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; We identified 34 eligible studies. Pooled estimators indicated significant DM risk in HCV-infected cases in comparison to non-infected controls in both retrospective (OR_adjusted = 1.68, 95% CI 1.15–2.20) and prospective studies (HR_adjusted = 1.67, 95% CI 1.28–2.06). Excess risk was also observed in comparison to HBV-infected controls (OR_adjusted = 1.80, 95% CI 1.20–1.40) with suggestive excess observed in HCV+/HIV+ cases in comparison to HIV+ controls (OR_unadjusted = 1.82, 95% CI 1.27–2.38).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. &lt;EM&gt;J Hepatol&lt;/EM&gt; 2008 Nov;49(5):831-44.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293829</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18286451]]&gt;</url>
    <title>Hepatitis C infection in patients with chronic kidney disease</title>
    <publicationDate>2008-01-01T00:00:00</publicationDate>
    <publisher>Wichtig Editore</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,COMPLICATIONS OF KIDNEY DISEASE,OTHER,KIDNEY DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Mangia A, Burra P, Ciancio A, Fagiuoli S, Guido M, Picciotto A, Fabrizi F; Italian Association for The Study of The Liver (A.I.S.F). International Journal of Artificial Organs, 2008 Jan;31(1):15-33. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract: &lt;/STRONG&gt;The management of hepatitis C virus (HCV)-infected patients with chronic kidney disease (CKD) is complex and represents a particular concern since numerous issues, such as antiviral therapy in dialysis patients and post renal transplant, and prevention of HCV spread within dialysis units, remain unresolved. An enormous body of literature has been published on HCV in the CKD population; however, clinical evidence on important issues is mostly based on uncontrolled clinical trials or retrospective surveys. The aim of this paper is to provide a systematic review of the literature. Responses to the critical issues have been developed by a consensus of experts, endorsed by the Italian Association for the Study of the Liver (AISF) and some clinical recommendations have been added.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>126588</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/assetRoot/04/05/95/10/04059510.pdf]]&gt;</url>
    <title>Hepatitis C strategy for England</title>
    <publicationDate>2002-08-14T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,CHRONIC HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The Department of Health developed this strategy  in recognition of its public health importance.</description>
    <body>&lt;![CDATA[ &lt;P&gt;The Department of Health developed this strategy with experts and key stakeholders. It sets out proposals to improve the effectiveness of prevention, diagnosis and treatment services for hepatitis C. It is designed as a framework to assist loacl commissioners and service providers, working in partnership with local communities. It is supported by the more recent &lt;A href="nelh:126589:0" name=internalLink&gt;Action Plan&lt;/A&gt; and other documents, links below.&lt;/FONT&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Chapters:&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Context and relationship to other programes and strategies&lt;/FONT&gt;&lt;/FONT&gt;&lt;/LI&gt;
&lt;LI&gt;Hepatitis C - a cause for concern&lt;/FONT&gt;&lt;/FONT&gt;&lt;/LI&gt;
&lt;LI&gt;Improving prevention&lt;/FONT&gt;&lt;/FONT&gt;&lt;/LI&gt;
&lt;LI&gt;Improving services for people with hepatitis C&lt;/FONT&gt;&lt;/FONT&gt;&lt;/LI&gt;
&lt;LI&gt;Actions to support change&lt;/FONT&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Audience:&lt;/STRONG&gt;&amp;nbsp;All those effected by the delivery of hepatitis C care&amp;nbsp;within the NHS,&amp;nbsp;especially&amp;nbsp;healthcare professionals and&amp;nbsp;managers.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Related links:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:126586:0" name=internalLink&gt;&lt;A href="nelh:126586:0" name=internalLink&gt;A matter of chance: an audit of the Department of Health 2005 Hepatitis C Action Plan for England&lt;/A&gt;&lt;A href="nelh:126586:0" name=internalLink&gt;&lt;/A&gt;.&lt;/A&gt;&amp;nbsp;Department of Health.&lt;/P&gt;
&lt;P&gt;Full report &lt;A href="nelh:126678:0" name=internalLink&gt;&lt;A href="nelh:126678:0" name=internalLink&gt;&lt;A href="http://www.hepcuk.info/data/news/213_The%20UK%20vs.%20Europe.pdf" target="_blank"&gt;The UK vs. Europe: ready to fight back?&lt;/A&gt;&lt;/A&gt;&lt;/A&gt; The Hepatitis C Trust and University of Southampton.&lt;/P&gt;
&lt;P&gt;Interim report &lt;A href="nelh:126590:0" name=internalLink&gt;&lt;A href="http://www.hepcuk.info/data/news/213_The%20UK%20vs.%20Europe.pdf" target="_blank"&gt;The UK vs. Europe: losing the fight against Hepatitis C&lt;/A&gt;&lt;/A&gt;. The Hepatitis C Trust and University of Southampton.&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:126587:0" name=internalLink&gt;&lt;A href="http://www.hepcuk.info/data/usercontentroot/home/" target="_blank"&gt;The Hepatitis C Trust&lt;/A&gt;&lt;A href="http://www.hepcuk.info/data/usercontentroot/home/" target="_blank"&gt;&lt;/A&gt;&lt;/A&gt; website.&lt;/FONT&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>380770</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1086/600304]]&gt;</url>
    <title>Hepatitis C treatment for injection drug users: a review of the available evidence</title>
    <publicationDate>2009-08-01T00:00:00</publicationDate>
    <publisher>The University of Chicago Press</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,RECENT ADDITIONS,CHRONIC HEPATITIS C,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract:&lt;/STRONG&gt; Globally, approximately 90% of new hepatitis C infections are attributed to injection drug use, but there is a continuing reluctance to treat injection drug users (IDUs). There is evidence that a sizeable proportion of IDUs who begin hepatitis C treatment achieve a sustained virological response (SVR). In chronic hepatitis C treatment trials, the SVR rate among IDUs appears to be comparable to rates among non-IDUs; in trials prescribing pegylated interferon plus ribavirin, the median rate of SVR among IDUs was 54.3% (range, 18.1%-94.1%), compared with 54%-63% in the large treatment trials. Few trials of acute hepatitis C treatment report on outcomes in IDUs; however, among these trials, the SVR among IDUs was 68.5% (n=89), compared with 81.5% among non-IDUs (n=65). Additional studies are required to determine the optimal circumstances for treatment (e.g., enrollment in drug treatment, the requirement of a period of abstinence from injection drug use, or the establishment of multidisciplinary treatment programs).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. &lt;EM&gt;Clin Infect Dis&lt;/EM&gt; 2009;49(4):561-73.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>268413</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1176/appi.psy.47.2.93]]&gt;</url>
    <title>Hepatitis C treatment for people with severe mental illness</title>
    <publicationDate>2006-03-01T00:00:00</publicationDate>
    <publisher>American Psychiatric Press</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,CHRONIC HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Mistler LA, Brunette MF, Marsh BJ et al. Psychosomatics 2006; 47 (2) pp. 93-107&lt;/P&gt;&lt;STRONG&gt;Abstract: &lt;/STRONG&gt;Over 4 million people in the United States are chronically infected with hepatitis C virus (HCV), and, if untreated, over 20% of these will progress to more serious disease. Persons with severe mental illness (SMI) have markedly elevated rates of HCV infection, but treatment of persons with SMI and HCV has been controversial. Effective antiviral treatment is available, but side effects include depression and other neuropsychiatric symptoms. This article reviews the available data on neuropsychiatric side effects of interferon (IFN) treatment, discusses the limitations of the current research, and makes recommendations regarding HCV treatment in persons with SMI.]]&gt;</body>
  </document>
  <document>
    <id>268505</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1158/1055-9965.EPI-06-0308]]&gt;</url>
    <title>Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies</title>
    <publicationDate>2006-11-01T00:00:00</publicationDate>
    <publisher>American Association for Cancer Research</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=abstract&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Del Maso L. and&amp;nbsp;Franceschi S. 2006; Cancer epidemiology, biomarkers and prevention 15 (11) pp. 2078-85&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;Abstract:&lt;/STRONG&gt; The present meta-analysis was conducted to evaluate the strength and the consistency of the association between hepatitis C virus (HCV) infection and non-Hodgkin lymphoma (NHL) and other lymphoid neoplasms. Only studies with &amp;gt;or=100 cases which were also adjusted for sex and age were included. Fifteen case-control studies and three prospective studies contributed to present analysis, nine of which had not been included in previous meta-analyses. We calculated the pooled relative risks (RR) with corresponding 95% confidence intervals (95% CI), as a weighted average of the estimated RRs by random-effect models. The pooled RR of all NHL among HCV-positive individuals was 2.5 (95% CI, 2.1-3.0), but substantial heterogeneity was found between studies and by study design. Pooled RRs were 2.5 (95% CI, 2.1-3.1) in case-control studies and 2.0 (95% CI, 1.8-2.2) in cohort ones. The strongest source of heterogeneity seemed to be the prevalence of HCV among NHL-free study subjects (RR for NHL among HCV-positive individuals 3.0 and 1.9, respectively, for &amp;gt;or=5% and &amp;lt;5% HCV prevalence). RRs were consistently increased for all major B-NHL subtypes, T-NHL, and primary sites of NHL presentation. Thus, previous suggestions that the RRs for HCV differed by NHL subtype were not confirmed in our meta-analysis. Associations weaker than with NHL were found between HCV infection and Hodgkin's lymphoma (RR, 1.5; 95% CI, 1.0-2.1) and multiple myeloma (RR, 1.6; 95% CI, 0.7-3.6), but they were based on much fewer studies than NHL. The etiologic fraction of NHL attributable to HCV varies greatly by country, and may be upward of 10% in areas where HCV prevalence is high.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323800</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.jhep.2009.01.019]]&gt;</url>
    <title>Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis</title>
    <publicationDate>2009-06-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,HEPATOCELLULAR CARCINOMA,CANCER,CHRONIC HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt;&amp;nbsp;This meta-analysis suggests that HCV genotype 1b plays an important role in HCC development, especially in patients with early stage liver disease.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We identified 57 relevant papers through a literature search to December 2007 but, since age could represent a major confounder, we focused the meta-analysis on the 21 studies presenting age-adjusted risk estimates for HCV genotype 1b vs. other genotypes. We used random-effects models with the DerSimonian–Laird method and assessed heterogeneity between studies and publication bias.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Patients infected with HCV genotype 1b have almost double the risk to develop HCC than those infected with other genotypes (Relative Risk (95% Confidence Intervals)&amp;nbsp;=&amp;nbsp;1.78(1.36–2.32)). The pooled risk estimate was somewhat lower when we restricted the analysis to the eight studies conducted in patients with liver cirrhosis (1.60;1.07–2.39) or considering the 36 studies presenting only crude data (1.63;1.30–2.06). In seven studies excluding patients with liver cirrhosis, the RR (95% CI) increased to 2.46(1.69–3.59).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Raimondi S, Bruno S, Mondelli MU, Maisonneuve P. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. &lt;EM&gt;J Hepatol&lt;/EM&gt; 2009 Jun;50(6):1142-54.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323531</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18825640]]&gt;</url>
    <title>Hepatitis C virus infection and post-transplant diabetes mellitus among renal transplant patients: a meta-analysis</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>Wichtig Editore</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,RECENT ADDITIONS,AUGUST 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt;&amp;nbsp;Our study shows a marked increase of the risk of post-transplant diabetes mellitus in anti-hepatitis C virus-positive renal transplant recipients. The excess risk of death in hepatitis C virus-positive renal transplant recipients may be at least partially attributed to post-transplant diabetes mellitus with its attendant complications.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We retrieved studies published in any language by systematically searching Medline, and Embase and by manually examining the references of the original articles, reviews, and monographs retrieved. We included cohort and case-control studies reporting relative risk estimates and 95% confidence intervals (CIs) for PTDM occurrence with HCV after renal transplantation. Thirteen studies providing information on a total of 30,099 unique patients were included in our meta-analysis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Study-specific relative risks were weighted by the inverse of their variance to obtain fixed and a 95% confidence interval (CI) of 1.94; 3.83 (10 studies). In a stratified analysis including only large studies (2 studies), the pooled RR was 1.36 (95% CI, 1.21; 1.54). Egger's regression test showed some evidence of publication bias (p=0.0001), but our sensitivity analysis showed that this issue did not meaningfully change the results.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Fabrizi F, Messa P, Martin P, Takkouche B. Hepatitis C virus infection and post-transplant diabetes mellitus among renal transplant patients: a meta-analysis. &lt;EM&gt;Int J Artif Organs&lt;/EM&gt; 2008 Aug;31(8):675-82.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>305632</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_093851]]&gt;</url>
    <title>Hepatitis C: quick reference guide for primary care</title>
    <publicationDate>2009-01-28T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt; Concise information and good practice advice about hepatitis C testing and diagnosis for use by doctors and nurses in primary care, including a testing and diagnosis flowchart.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bibliographic details: &lt;/STRONG&gt;A guidance document from the Department of Health.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>377689</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1038/ajg.2009.725]]&gt;</url>
    <title>High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations</title>
    <publicationDate>2010-06-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,STOMACH,CANCER,PANCREAS,CANCER,SMALL INTESTINE,CANCER,COLON &amp; RECTUM,DISEASE PREVENTION,CANCER,SCREENING,RECENT ADDITIONS,COLON CANCER,RECTAL CANCER,JUNE 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt;&amp;nbsp;Peutz-Jeghers syndrome (PJS)&amp;nbsp;patients are markedly at risk for several malignancies, in particular gastrointestinal cancers and breast cancer. On the basis of these elevated risks, a surveillance recommendation is developed to detect malignancies in an early phase and to remove polyps that may be premalignant and may cause complications, so as to improve the outcome.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; PJS is an autosomal dominant inherited disorder associated with increased cancer risk. Surveillance and patient management are, however, hampered by a wide range in cancer risk estimates. We therefore performed a systematic review to assess cancer risks in PJS patients and used these data to develop a surveillance recommendation.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A systematic PubMed search was performed up to February 2009, and all original articles dealing with PJS patients with confirmed cancer diagnoses were included. Data involving cancer frequencies, mean ages at cancer diagnosis, relative risks (RRs), and cumulative risks were collected.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Twenty-one original articles, 20 cohort studies, and one meta-analysis fulfilled the inclusion criteria. The cohort studies showed some overlap in the patient population and included a total of 1,644 patients; 349 of them developed 384 malignancies at an average age of 42 years. The most common malignancy was colorectal cancer, followed by breast, small bowel, gastric, and pancreatic cancers. The reported lifetime risk for any cancer varied between 37 and 93%, with RRs ranging from 9.9 to 18 in comparison with the general population. Age-related cumulative risks were given for any cancer and gastrointestinal, gynecological, colorectal, pancreatic, and lung cancers.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; van Lier MG, Wagner A, Mathus-Vliegen EM, Kuipers EJ, Steyerberg EW, van Leerdam ME. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. &lt;EM&gt;Am J Gastroenterol&lt;/EM&gt; 2010;105(6):1258-64.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309241</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/gut.2007.143453]]&gt;</url>
    <title>High frequency of early colorectal cancer in inflammatory bowel disease</title>
    <publicationDate>2008-09-01T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CANCER,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The diagnosis of colorectal cancer is delayed or missed in a substantial number of patients (17–28%) when conducting surveillance strictly according to formal guidelines.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A nationwide automated pathology database (PALGA) was consulted to identify patients with IBD-associated colorectal carcinoma in seven university medical centres in The Netherlands between January 1990 and June 2006. Data were collected retrospectively from patient charts. Time intervals between onset of disease and cancer diagnosis were calculated in months.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; 149 patients were identified with confirmed diagnoses of IBD and CRC (ulcerative colitis n = 89/Crohn’s disease n = 59/indeterminate colitis n = 1). Taking date of diagnosis as the entry point, 22% of patients developed cancer before the 8 or 15 year starting points of surveillance, and 28% if surveillance was commenced 10 or 20 years after diagnosis for extensive or left-sided disease, respectively. Using onset of symptoms to calculate the time interval, 17–22% of patients would present with cancer prior to the surveillance starting points.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Lutgens, M. W. M. D., Vleggaar, F. P., Schipper, M. E. I., Stokkers, P. C. F., van der Woude, C. J., Hommes, D. W., de Jong, D. J., Dijkstra, G., van Bodegraven, A. A., Oldenburg, B., &amp;amp; Samsom, M. (2008) High frequency of early colorectal cancer in inflammatory bowel disease. &lt;I&gt;Gut&lt;/I&gt;, 57(9):1246-1251.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to NHS users via Athens.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>380607</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1038/ajg.2010.137]]&gt;</url>
    <title>High quantity and variable quality of guidelines for acute pancreatitis: a systematic review</title>
    <publicationDate>2010-07-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,PANCREAS,ACUTE PANCREATITIS,PANCREATITIS,RECENT ADDITIONS,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The many clinical guidelines for acute pancreatitis range widely in quality. Guidelines developed by professional bodies, and those with tables, a recommendations summary, evidence grading, and audit goals, are of higher quality. Further research is required to determine whether guideline quality alters clinical outcomes.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Several clinical guidelines exist for acute pancreatitis, with varying recommendations. The aim of this study was to determine the quality of guidelines for acute pancreatitis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A literature search identified relevant guidelines, which were then reviewed to determine their document format and scope and the presence of endorsement by a professional body. The quality of guidelines was determined using the validated Grilli, Shaneyfelt, and AGREE instruments.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Twenty-one of the 30 guidelines analyzed were endorsed by professional bodies. Median quality scores were as follows: Grilli, 2; Shaneyfelt, 13; and AGREE, 50. Guideline quality did not improve over time. Guidelines endorsed by a professional body had higher scores than those without official endorsement. Guidelines with tables, a recommendations summary, evidence grading, and audit goals had significantly higher scores than guidelines lacking those features.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Loveday BP, Srinivasa S, Vather R, Mittal A, Petrov MS, Phillips AR, Windsor JA. High quantity and variable quality of guidelines for acute pancreatitis: a systematic review. &lt;EM&gt;Am J Gastroenterol&lt;/EM&gt; 2010;105(7):1466-76.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>374931</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20458081]]&gt;</url>
    <title>High-dose vs non-high-dose proton pump inhibitors after endoscopic treatment in patients with bleeding peptic ulcer: a systematic review and meta-analysis of randomized controlled trials</title>
    <publicationDate>2010-05-10T00:00:00</publicationDate>
    <publisher>HighWire Press</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COMMON CLINICAL PRESENTATIONS,STOMACH,ULCERS,DUODENAL ULCERS,GASTRIC ULCERS,SMALL INTESTINE,DIAGNOSTIC PROCEDURES,GASTROINTESTINAL ENDOSCOPY,UPPER ENDOSCOPY,UPPER,RECENT ADDITIONS,GI BLEEDING,MAY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Compared with non–high-dose proton pump inhibitors (PPIs), high-dose PPIs do not further reduce the rates of rebleeding, surgical intervention, or mortality after endoscopic treatment in patients with bleeding peptic ulcer. &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; High-dose PPIs (80-mg bolus, followed by 8-mg/h continuous infusion for 72 hours) have been widely studied and used. However, to date no concrete evidence has shown that high-dose PPIs are more effective than non–high-dose PPIs. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We performed a literature search for randomized controlled trials that compared the use of high-dose PPIs vs non–high-dose PPIs in patients with bleeding peptic ulcer and determined their effects on rebleeding, surgical intervention, and mortality. Outcomes data were combined in a meta-analysis and were reported as odds ratios (ORs) with 95% confidence intervals (CIs). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; A total of 1157 patients from 7 high-quality randomized studies were included in this meta-analysis. High-dose PPIs and non–high-dose PPIs did not differ in their effects on the rates of rebleeding (7 studies and 1157 patients; OR, 1.30; 95% CI, 0.88-1.91), surgical intervention (6 studies and 1052 patients; 1.49; 0.66-3.37), or mortality (6 studies and 1052 patients; 0.89; 0.37-2.13). Post hoc subgroup analyses revealed that summary outcomes measures were unaffected by severity of signs of recent hemorrhage at initial endoscopy, route of PPI administration, or PPI dose.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Wang CH, Ma MH, Chou HC, Yen ZS, Yang CW, Fang CC, Chen SC. High-dose vs non-high-dose proton pump inhibitors after endoscopic treatment in patients with bleeding peptic ulcer: a systematic review and meta-analysis of randomized controlled trials. &lt;EM&gt;Arch Intern Med&lt;/EM&gt; 2010;170(9):751-8.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;Available to NHS staff via Athens.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>268547</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1432-2277.2006.00412.x]]&gt;</url>
    <title>Hilar lymph nodes sampling at time of liver transplantation for hepatocellular carcinoma: to do or not to do?</title>
    <publicationDate>2007-02-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS C,HEPATITIS,TRANSPLANTATION,HEPATOCELLULAR CARCINOMA,CANCER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=abstract&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt;&amp;nbsp;Sotiropoulos G.C., Malago M., Molmenti E.P. 2007; Transplant International 20 (2) pp. 141-6&lt;/P&gt;&lt;STRONG&gt;Abstract:&lt;/STRONG&gt; The purpose of this study was to evaluate the impact of tumor-positive hilar lymph nodes (LN) on tumor recurrence and survival in patients with hepatocellular carcinoma (HCC) undergoing liver transplantation (LT). A computer search of the Medline database was carried out. The outcome of patients with positive hilar LN (study group) was compared with that of patients with negative LN (reference group). Five clinical studies evaluating tumor recurrence after LT for HCC according to hilar LN status were identified. Five further clinical studies evaluated patients' survival in reference to LN metastases. The test of heterogeneity for each comparison revealed no significant differences (exact P=0.4638). A significant correlation between tumor-positive LN and tumor recurrence was shown (exact estimation of common odds ratio by 10.44, 95% confidence interval of 3.431-38.59). Furthermore, data analyses using the Fisher-combination test regarding patient survival in the two groups showed a statistical difference (P&amp;lt;0.0001). The negative prognostic value of hilar LN metastasis for both tumor recurrence and survival was confirmed by this analysis. Given the ever-present diagnostic dilemma associated with enlarged hilar LN, especially in hepatitis C-positive patients, hilar LN sampling during LT for HCC could better define patients at risk.]]&gt;</body>
  </document>
  <document>
    <id>266348</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1080/17449200600743420]]&gt;</url>
    <title>HIV/AIDS and HCV in prisons: A select annotated bibliography (part 1)</title>
    <publicationDate>2006-03-01T00:00:00</publicationDate>
    <publisher>Informa</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,HIV / AIDS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The aim of this three part bibliography is to promote effective responses based on scientific evidence and respect for human rights, to the issues raised by HIV/AIDS and HCV in prison.</description>
    <body>&lt;![CDATA[ &lt;STRONG&gt;Aims&lt;/STRONG&gt;:&amp;nbsp;The aim of this&amp;nbsp;three part bibliography is to promote effective responses based on scientific evidence and respect for human rights, to the issues raised by HIV/AIDS and HCV in prison. 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Part one contains overview documents, policies and guidelines, documents on legal, eithical and human rights issues associated with HIV/AIDS in prison and relevant websites and periodicals.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is &lt;STRONG&gt;not&lt;/STRONG&gt; available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>266349</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1080/17449200600935786]]&gt;</url>
    <title>HIV/AIDS and HCV in prisons: A select annotated bibliography (part 2)</title>
    <publicationDate>2006-06-01T00:00:00</publicationDate>
    <publisher>Informa</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,HIV / AIDS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The aim of this three part bibliography is to promote effective responses based on scientific evidence and respect for human rights, to the issues raised by HIV/AIDS and HCV in prison.</description>
    <body>&lt;![CDATA[ &lt;STRONG&gt;Aims&lt;/STRONG&gt;: The aim of this&amp;nbsp;three part bibliography is to promote effective responses based on scientific evidence and respect for human rights, to the issues raised by HIV/AIDS and HCV in prison. 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Part two contains selected "essential" articles and reports that provide information about (1) prevalence of HIV, HCV and risk behaviours in prisons; (2) transmission of HIV and HCV in prisons; and (3) measures aimed at preventing HIV and HCV infection in prisons. Each section also contains a brief review of the evidence, based on recent work undertaken by the WHO.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;This article is &lt;STRONG&gt;not&lt;/STRONG&gt; available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>266350</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1080/17449200601043689]]&gt;</url>
    <title>HIV/AIDS and HCV in prisons: A select annotated bibliography (part 3)</title>
    <publicationDate>2006-09-01T00:00:00</publicationDate>
    <publisher>Informa</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,HIV / AIDS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The aim of this three part bibliography is to promote effective responses based on scientific evidence and respect for human rights, to the issues raised by HIV/AIDS and HCV in prison.</description>
    <body>&lt;![CDATA[ &lt;STRONG&gt;Aims&lt;/STRONG&gt;: The aim of this&amp;nbsp;three part bibliography is to promote effective responses based on scientific evidence and respect for human rights, to the issues raised by HIV/AIDS and HCV in prison. 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Part three contains selected "essential" articles and reports that provide information about (1) substitution treatment and other forms of drug-dependence treatment; (2) other drug demand and drug supply reduction measures; and (3) care, treatment and support for prisoners living with HIV/AIDS and/or HCV. Each section contains a brief review of the evidence based on recent work undertaken by the WHO.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;This article is &lt;STRONG&gt;not&lt;/STRONG&gt; available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309039</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.wjgnet.com/downpdf.asp?url=/1007-9327/14/165]]&gt;</url>
    <title>Hygiene hypothesis in inflammatory bowel disease: A critical review of the literature</title>
    <publicationDate>2008-01-14T00:00:00</publicationDate>
    <publisher>WJG Press and Beijing Baishideng BioMed Scientific Co.</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The 'hygiene hypothesis' in IBD is an important area of research that may give clues to the aetiology of this disease. Directions for future research are recommended. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Publications identified from a broad based MEDLINE and Current Contents search between 1966 and 2007 on key terms relevant to the 'hygiene hypothesis' and IBD including H pylori exposure, helminths, cold chain hypothesis, measles infection and vaccination, antibiotic use, breastfeeding, family size, sibship, urban upbringing, day care attendance and domestic hygiene were reviewed. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The literature suggests that the hygiene hypothesis and its association with decreased microbial exposure in childhood probably plays an important role in the development of IBD, although the strength of the supporting data for each of the factors varies considerably. The most promising factors that may potentially be associated with development of IBD include H pylori exposure, helminths, breastfeeding and sibship. However, the vast majority of studies in this area are plagued by serious methodological shortcomings, particularly the reliance on retrospective recall of information making it difficult to truly ascertain the importance of a 'hygiene hypothesis' in IBD.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Koloski, N. A., Bret, L., &amp;amp; Radford-Smith, G. (2008) Hygiene hypothesis in inflammatory bowel disease: A critical review of the literature. &lt;I&gt;World Journal of Gastroenterology&lt;/I&gt;, 14(2):165-173.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309251</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.crohns.2008.02.001]]&gt;</url>
    <title>IBD patients need in health quality of care: ECCO consensus</title>
    <publicationDate>2008-06-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Evidence-based medicine in QoHC is limited. It is concluded that optimizing QoHC by “information”; “education”, “benchmarking” and “psychological analysis” helps the patient to understand the disease and comply with its therapy, increasing QoL, reducing depression and anxiety. Future aspects regarding more evidence-based science and optimization of QoHC in IBD throughout Europe have been proposed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; To define IBD patient needs in Quality of Health Care (QoHC) in Europe based on up- to date available evidence. The working group consisted of doctors, nurses and patient organizations from 12 European countries and Israel. Pub Med searching was performed as defined in the Delta Method. Each recommendation was graded (RG) in accordance with level of evidence (EL) based on Evidence Based Medicine, Oxford Centre. During UEGW 2007 the group reconvened to agree on the final version for each chapter of guideline statement.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; PubMed search led to 6 RCT, 7 reviews, 63 original articles, but no meta-analysis regarding “Information”; “Education”; “Primary Care”, “Quality of life”, “Psychological help” and “Benchmarking of Health Care systems” in IBD. Seven ECCO statements have been worked out.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Elkjaer, M., Moser, G., Reinisch, W., Durovicova, D., Lukas, M., Vucelic, B., Wewer, V., Frederic, C. J., Shuhaibar, M., O'Morain, C., Politi, P., Odes, S., Bernklev, T., Oresland, T., Nikulina, I., Belousova, E., Van, d. E., I, &amp;amp; Munkholm, P. (2008) IBD patients need in health quality of care: ECCO consensus. &lt;I&gt;Journal of Crohn's and Colitis&lt;/I&gt;, 2(2):181-188.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in June 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>346960</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.nacc.org.uk/downloads/factsheets/GeneralNurses.pdf]]&gt;</url>
    <title>IBD: a guide for general nurses</title>
    <publicationDate>2006-03-01T00:00:00</publicationDate>
    <publisher>National Association for Colitis and Crohn's Disease</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,DISEASE PREVENTION,DIET,CROHN'S DISEASE,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The National Association for Colitis and Crohn's Disease (NACC) brings together people of all ages who have Crohn's Disease or Ulcerative Colitis, which includes Proctitis, their families and the health professionals involved in their care. These two illnesses are both forms of Inflammatory Bowel Disease (IBD) and they affect about 1 in 250 people in the United Kingdom.&lt;/P&gt;
&lt;P&gt;NACC provides a range of information sheets and booklets for patients and their families, to help them to manage their IBD and to live their lives as effectively as possible within the constraints of their illness.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary: &lt;/STRONG&gt;This is a general introduction to IBD for nurses.&amp;nbsp; It covers characteristics of the disease (including extraintestinal manifestations), diagnostics, treatment, nutrition and diet, surgery, and patient concerns.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345637</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1053/j.scrs.2009.05.008]]&gt;</url>
    <title>Ileal pouch anal anastomosis: meta-analysis and comparison of outcomes between techniques</title>
    <publicationDate>2009-06-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The optimal anastomosis technique for ulcerative colitis&amp;nbsp;depends on the balance between impairment of bowel function and the risk of development of dysplasia or inflammation in the residual rectal mucosa.&amp;nbsp; Rectal cancer or high-grade dyplasia would be an indication for mucosestomy and hand-sewn pouch anal anastomosis; stapled anastomosis would be preferable in other circumstances.&amp;nbsp;J-pouch reconstruction is simpler and easier than S- or W-pouches.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract:&lt;/STRONG&gt; Ileal pouch anal anastomosis is the procedure of choice for most patients undergoing proctocolectomy for ulcerative colitis and a proportion of patients with familial adenomatous polyposis. Since its first description in 1978, there has been evolution and refinement in the technical aspects of ileoanal pouch construction. This has been facilitated by advancements in stapler technology, and an increased focus on functional outcome.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Heriot AG, Lynch AC. Ileal pouch anal anastomosis: meta-analysis and comparison of outcomes between techniques. &lt;EM&gt;Semin Col Rect Surg&lt;/EM&gt; 2009;20(2):88-92.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281250</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17571291]]&gt;</url>
    <title>Ileal pouch-anal anastomosis</title>
    <publicationDate>2008-03-10T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;SPAN title="The British journal of surgery."&gt;McGuire, B.B. &lt;A href="#javascript:AL_get(this," ?jour?, ?Br J Surg.?);?&gt;Br J Surg.&lt;/A&gt;&lt;/SPAN&gt; 2007 Jul;94(7):812-23&lt;/P&gt;
&lt;P class=abstract&gt;BACKGROUND: Since 1977, restorative proctocolectomy with ileoanal anastomosis (IAA) has evolved into the surgical treatment of choice for most patients with intractable ulcerative colitis. Construction of an ileal pouch reservoir is now standard, usually in the form of J pouch (IPAA). The aim of this report is to review selection criteria for, and functional outcomes, follow-up and management of complications of IPAA after 30 years of widespread clinical application. METHODS AND RESULTS: Literature published in English on the clinical indications, surgical technique, morbidity, complications and outcome following IAA and IPAA was sourced by electronic search, performed independently by two reviewers who selected potentially relevant papers based on title and abstract. Additional articles were identified by cross-referencing from papers retrieved in the initial search. CONCLUSION: The functional results of IPAA are good. Pouchitis, irritable pouch syndrome and cuffitis are specific long-term complications but rarely result in failure. Pouch salvage is possible in selected patients with poor functional outcomes. One-stage operations are increasingly performed. Copyright (c) 2007 British Journal of Surgery Society Ltd. Published by John Wiley &amp;amp; Sons, Ltd.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>330580</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.annals.org/content/150/3/153.long]]&gt;</url>
    <title>Immediate listing for liver transplantation versus standard care for Child-Pugh stage B alcoholic cirrhosis: a randomized trial</title>
    <publicationDate>2009-02-03T00:00:00</publicationDate>
    <publisher>American College of Physicians</publisher>
    <publicationType>RANDOMISED CONTROLLED TRIAL</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,ALCOHOLIC LIVER DISEASE,ALCOHOLIC CIRRHOSIS,TRANSPLANTATION,RECENT ADDITIONS,CIRRHOSIS,ALCOHOLIC,NOVEMBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion: &lt;/STRONG&gt;Immediate listing for liver transplantation did not show a survival benefit compared with standard care for Child–Pugh stage B alcoholic cirrhosis. In addition, immediate listing for transplantation increased the risk for extrahepatic cancer. Patients with continued alcohol consumption had poorer outcome regardless of treatment received, and a Child-Pugh score greater than 7 was the cutoff value for predicting poor survival, whereas recovery from Child–Pugh stage C disease was associated with better survival. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Liver transplantation improves survival of patients with end-stage (Child–Pugh stage C) alcoholic cirrhosis, but its benefit for patients with stage B disease is uncertain.&amp;nbsp;To compare the outcomes of patients with Child–Pugh stage B alcoholic cirrhosis who are immediately listed for liver transplantation with those of patients assigned to standard treatment with delay of transplantation until progression to stage C disease. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; 120 patients with Child–Pugh stage B alcoholic cirrhosis and no viral hepatitis, cancer, or contraindication to transplantation were randomly assigned to immediate listing for liver transplantation (60 patients) or standard care (60 patients). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Sixty-eight percent of patients assigned to immediate listing for liver transplantation and 25% of those assigned to standard care received a liver transplant. All-cause death and cirrhosis-related death did not statistically differ between the 2 groups: 5-year survival was 58% (95% CI, 43% to 70%) for those assigned to immediate listing versus 69% (CI, 54% to 80%) for those assigned to standard care. In multivariate analysis, independent predictors of long-term survival were absence of ongoing alcohol consumption (hazard ratio, 7.604 [CI, 2.395 to 24.154]), recovery from Child–Pugh stage C (hazard ratio, 7.633 [CI, 2.392 to 24.390]), and baseline Child–Pugh score less than 8 (hazard ratio, 2.664 [CI, 1.052 to 6.746]). Immediate listing for transplantation was associated with an increased risk for extrahepatic cancer: The 5-year cancer-free survival rate was 63% (CI, 43% to 77%) for patients who were immediately listed and 94% (CI, 81% to 98%) for those who received standard care. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Vanlemmens C, Di Martino V, Milan C, Messner M, Minello A, Duvoux C, Poynard T, Perarnau JM, Piquet MA, Pageaux GP, Dharancy S, Silvain C, Hillaire S, Thiefin G, Vinel JP, Hillon P, Collin E, Mantion G, Miguet JP; TRANSCIAL Study Group.&amp;nbsp; Immediate listing for liver transplantation versus standard care for Child-Pugh stage B alcoholic cirrhosis: a randomized trial. &lt;EM&gt;Ann Intern Med&lt;/EM&gt; 2009 Feb 3;150(3):153-61.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>268550</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1002/lt.21035]]&gt;</url>
    <title>Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis</title>
    <publicationDate>2007-01-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,LIVER TRANSPLANTATION,SURGERY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=abstract&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Berenguer M., Royuela A., Zamora J. 2007; Liver Transplantation 13 (1) pp. 21-9&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;A controversy exists over whether the outcome of a hepatitis C virus (HCV)-infection-related liver transplant differs based on the calcineurin inhibitor (CNI) used. We have performed a systematic review and a subsequent meta-analysis evaluating tacrolimus (Tac)-based vs. cyclosporine A-based immunosuppression in HCV-infected liver transplant recipients. Searches were conducted to locate randomized controlled trials comparing Tac vs. cyclosporine A. Data on HCV liver transplant recipients were obtained, independently of whether the study was specifically designed for patients with this disease or not. A fixed effects model was used for statistical pooling of the relative risks (RR) for the different outcomes. A total of 5 articles (366 patients) fulfilled the inclusion criteria. Statistically significant differences between Tac-based vs. cyclosporine A-based therapies were not found for mortality (P = 0.11; RR = 0.72; 95% confidence interval [CI], 0.49-1.08), graft survival (P = 0.37; RR = 0.86; 95% CI, 0.61-1.21), biopsy-proven acute rejection (P = 0.65; RR = 0.91; 95% CI, 0.61-1.36), corticoresistant acute rejection (P = 0.26; RR = 2.25; 95% CI, 0.55-9.29), and fibrosing cholestatic hepatitis (P = 0.92; RR = 0.96; 95% CI, 0.41-2.26). In 1 study, no differences were detected regarding severe fibrosis at 1 yr. In conclusion, patient and graft survivals in HCV-positive liver transplant patients are similar independently of the CNI selected as basic immunosuppressant. Unfortunately, data on the severity of recurrence and effect on viremia are scarce. Well-designed randomized prospective studies are needed to determine whether there are differences between the 2 CNIs regarding these specific variables. (c) 2006 AASLD.&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;See also: &lt;/STRONG&gt;&lt;A href="nelh:284750:0" name=internalLink&gt;DARE record&lt;/A&gt; for this article.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>268515</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.idc.2006.09.001]]&gt;</url>
    <title>Impact of biologic agents on infectious diseases</title>
    <publicationDate>2006-12-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation&lt;/STRONG&gt;: Saketkoo L.A., Espinoza L.R. et al. 2006; Infectious Disease Clinics of North America 20 (4) pp. 931-61&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract: &lt;/STRONG&gt;Until recently, inflammatory diseases, collagen vascular diseases, inflammatory bowel diseases, and multiple sclerosis were met with a limited offering for treatment. The introduction of biologic agents has revolutionized the approach to these diseases, offering many patients freedom from disease activity staving off resultant destruction to organs and joints with marked improvement in quality of life and disability. This article focuses on the development of serious infections associated with the use of biologic agents. Presented is a synthesis of case series, reports, and systematic reviews to elucidate implicated pathogens and clinical presentations in patients being treated with biologic agents and to form a cursory backbone for prevention and treatment strategies to which clinicians prescribing these agents or encountering patients already on these agents can readily refer. Maintenance of a high index of suspicion is imperative for the prevention and appropriate treatment of serious life-threatening infections in these patients.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323527</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.3748/wjg.15.996]]&gt;</url>
    <title>Impact of human immunodeficiency virus infection on the course of hepatitis C virus infection: A meta-analysis</title>
    <publicationDate>2009-02-28T00:00:00</publicationDate>
    <publisher>WJG Press and Beijing Baishideng BioMed Scientific Co.</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,HIV / AIDS,RECENT ADDITIONS,AUGUST 2009,CHRONIC HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Without highly active antiretroviral therapies (HAART), HIV accelerates HCV disease progression, including death, histological fibrosis/cirrhosis and decompensated liver disease. However, the rate of hepatocellular carcinoma is similar in persons who had HCV infection and were positive for HIV or negative for HIV.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We performed a meta-analysis to quantify the effect of HIV co-infection on progressive liver disease in patients with HCV infection. Published studies in the English or Chinese-language medical literature involving cohorts of HIV-negative and -positive patients coinfected with HCV were obtained by searching the PUBMED, EMBASE and CBM. Data were extracted independently from relevant studies by 2 investigators and used in a fixed-effect meta analysis to determine the difference in the course of HCV infection in the 2 groups. &lt;/P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt;&amp;nbsp;&amp;nbsp;Twenty-nine trials involving 16,750 patients were identified including the outcome of histological fibrosis or cirrhosis or de-compensated liver disease or hepatocellular carcinoma or death. These studies yielded a combined adjusted odds ratio (OR) of 3.40 [95% confidence interval (CI) = 2.45 and 4.73]. Of note, studies that examined histological fibrosis/cirrhosis, decompensated liver disease, hepatocellular carcinoma or death had a pooled OR of 1.47 (95% CI = 1.27 and 1.70), 5.45 (95% CI = 2.54 and 11.71), 0.76 (95% CI = 0.50 and 1.14), and 3.60 (95% CI = 3.12 and 4.15), respectively. 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Deng LP, Gui XE, Zhang YX, Gao SC, Yang RR. Impact of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. &lt;EM&gt;World J Gastroenterol&lt;/EM&gt; 2009 Feb 28;15(8):996-1003.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>381274</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.gcb.2009.06.006]]&gt;</url>
    <title>Impact of interferon-alpha treatment on liver fibrosis in patients with chronic hepatitis B: an overview of published trials</title>
    <publicationDate>2009-10-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,NON-ALCOHOLIC,RECENT ADDITIONS,CIRRHOSIS,CHRONIC HEPATITIS B,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; According to these findings, the benefit of interferon treatment on fibrosis progression is clinically significant in patients with advanced fibrosis by the reduction of fibrosis progression to cirrhosis. Pegylated interferon now needs to be compared, in terms of benefit-risk factors, with the new generation of&amp;nbsp;hepatitis B virus (HBV)&amp;nbsp;treatments (such as entecavir and tenofovir), using non-invasive biomarkers.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; The impact of interferon treatment in patients with hepatitis B virus (HBV) infection on fibrosis progression in comparison with its natural history has yet to be assessed in any large-scale randomized studies. The present report is a review of the evidence-based data published so far.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Studies were included if they had at least two repeated estimates of liver fibrosis per patient treated with interferon-alpha (whether pegylated or not). Meta-analysis was performed using a random-effects model.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Altogether, 13 studies were included in the review, involving a total of 707 HBV patients treated with interferon-alpha-2a or -2b for 12-83 months. Only one study included pegylated interferon as monotherapy. A total of 787 untreated patients were also followed. Only one study used a non-invasive biomarker. There was a significant reduction in the fibrosis progression rate, with a risk reduction of 0.49 (95% CI: -0.64--0.34; chi(2)=119; degrees of freedom [DF]=6; P&amp;lt;0.0001), and significant heterogeneity (Cochran Q=81; P&amp;lt;0.0001). This significant impact was similar for both randomized (reduction of risk: -0.45; 95% CI: -0.64--0.26; P&amp;lt;0.0001) and not-randomized (controlled) studies (reduction of risk: -0.53; 95% CI: -0.79--0.28; P&amp;lt;0.0001).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Poynard T, Massard J, Rudler M, Varaud A, Lebray P, Moussalli J, Munteanu M, Ngo Y, Thabut D, Benhamou Y, Ratziu V. Impact of interferon-alpha treatment on liver fibrosis in patients with chronic hepatitis B: an overview of published trials. &lt;EM&gt;Gastroenterol Clin Biol&lt;/EM&gt; 2009;33(10-11):916-22.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>268511</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1086/512815]]&gt;</url>
    <title>Impact of maternal HIV coinfection on the vertical transmission of hepatitis C virus: a meta-analysis</title>
    <publicationDate>2007-04-15T00:00:00</publicationDate>
    <publisher>The University of Chicago Press</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation&lt;/STRONG&gt;: Polis C.B., Shah S.N., Johnson K.E. et al. 2007; Clinical Infectious Diseases 44 (8) pp. 1123-31&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract: &lt;/STRONG&gt;BACKGROUND: Observational studies suggest that maternal human immunodeficiency virus (HIV)-hepatitis C virus (HCV) coinfection is associated with increased odds of vertical HCV transmission. We performed a meta-analysis to summarize current evidence. METHODS: We systematically searched for relevant articles published during the period from January 1992 through July 2006 and independently abstracted articles that met our inclusion criteria. Under a random effects model, we calculated the pooled odds ratio for vertical HCV transmission according to maternal HIV-HCV coinfection status and performed sensitivity analyses. RESULTS: Ten articles met our inclusion criteria. Study quality varied widely, and study estimates displayed high statistical heterogeneity. Restriction of the analysis to studies that included &amp;gt;50 HIV-HCV-coinfected women provided our most reliable estimate: maternal HIV-HCV coinfection increases the odds of vertical HCV transmission by approximately 90% (odds ratio, 1.9; 95% confidence interval, 1.36-2.67), compared with maternal HCV infection alone. When we restricted analyses to HIV-infected mothers with HCV viremia, the odds of vertical HCV transmission were 2.82-fold (95% confidence interval, 1.17-fold to 6.81-fold) greater than the odds for HIV-infected mothers without HCV viremia. CONCLUSIONS: HIV-HCV-coinfected women have significantly higher odds of transmitting HCV to their infants than do women who are infected with HCV alone.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345589</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1002/ibd.20899]]&gt;</url>
    <title>Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review</title>
    <publicationDate>2009-08-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; There is no clear evidence that anti-infliximab antibodies (ATIs) have an impact on efficacy or safety, nor a need to measure or prevent them in clinical practice. Circulating drug concentration may be a more relevant measure of immunogenicity.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Infliximab (IFX) is a chimeric (mouse/human) anti-TNF-alpha monoclonal antibody approved for the treatment of refractory luminal and fistulizing Crohn's disease (CD). It is a source of potential immunogenicity for humans, with the occurrence of anti-infliximab antibodies (ATIs), which are thought to interfere with the pharmacodynamics and/or pharmacokinetics of the compound. It remains unclear whether ATIs have any clinical importance for drug efficacy or safety. We review studies specifically evaluating the incidence of ATIs in CD and their impact on the efficacy and safety of IFX.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A systematic review was undertaken by electronic searches of the PubMed and SCOPUS databases from earliest records to October 2008, as well as reference lists of all relevant articles and relevant abstracts from meetings.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The biological and clinical mechanisms of ATI development are poorly understood. The incidence of ATIs in vivo depends on multiple analytical and clinical factors, both patient- and treatment-related. The presence of ATIs is weakly and variably associated with clinical response or infusion reactions, but not with reactions relevant to clinical decision-making. Enormous variation in the methods of reporting ATIs and immunogenicity of IFX make almost any interpretation possible from different studies, but few have clinical relevance.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Cassinotti A, Travis S. Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review. &lt;EM&gt;Inflamm Bowel Dis&lt;/EM&gt; 2009;15(8):1264-75.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>385068</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.jhep.2010.02.035]]&gt;</url>
    <title>Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review</title>
    <publicationDate>2010-08-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,HEPATOCELLULAR CARCINOMA,RECENT ADDITIONS,CANCER,CHRONIC HEPATITIS B,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; C&lt;SPAN&gt;hronic hepatitis B patients receiving medium-term nucleos(t)ide analogue therapy had a significantly lower incidence of hepatocellular carcinoma (HCC) compared to untreated patients but treatment does not completely eliminate the risk of HCC. Among the treated patients, cirrhosis, HBeAg negative at baseline and failure to remain in virological remission were associated with an increased risk of HCC.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; &lt;SPAN&gt;Chronic hepatitis B patients are at increased risk for HCC. The effect of medium-term nucleos(t)ide analogue therapy on HCC incidence is unclear; therefore, we systematically reviewed all the data on HCC incidence from studies in chronic hepatitis B patients treated with nucleos(t)ide analogues.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; &lt;SPAN&gt;We performed a literature search to identify studies with chronic hepatitis B patients treated with nucleos(t)ide analogues for&amp;gt; or = 24 months.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;SPAN&gt;&lt;SPAN&gt;Twenty-one studies including 3881 treated and 534 untreated patients met our inclusion criteria. HCC was diagnosed in 2.8% and 6.4% of treated and untreated patients, respectively, during a 46 (32-108) month period (p=0.003), in 10.8% and 0.5% of nucleos(t)ide naive patients with and without cirrhosis (p&amp;lt;0.001) and in 17.6% and 0% of lamivudine resistance patients with and without cirrhosis (p&amp;lt;0.001). HCC developed less frequently in nucleos(t)ide naive patients compared to those without virological remission (2.3% vs 7.5%, p&amp;lt;0.001), but there was no difference between lamivudine resistance patients with or without virological response to rescue therapy (5.9% vs 8.8%, p=0.466).&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review.&lt;EM&gt; J Hepatol&lt;/EM&gt; 2010;53(2):348-56.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>385079</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/ebn1043]]&gt;</url>
    <title>Inconclusive evidence regarding the volume of gastric aspirate that can be safely reintroduced following residual volume measurements</title>
    <publicationDate>2010-07-01T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,ENTERAL,RECENT ADDITIONS,THERAPEUTIC NUTRITION,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Evidence-Based&amp;nbsp;Nursing is a secondary evidence journal, containing informative abstracts and expert commentaries about the best quality research from primary care medicine.&amp;nbsp;Evidence-Based Nursing surveys a wide range of international medical journals applying strict criteria for the quality and validity of research. Practising clinicians assess the clinical relevance of the best studies. The key details of these essential studies are presented in a succinct, informative abstract with an expert commentary on its clinical application.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Metheny NA. Inconclusive evidence regarding the volume of gastric aspirate that can be safely reintroduced following residual volume measurements. &lt;EM&gt;Evid Based Nurs&lt;/EM&gt; 2010;13(3):71.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt; A review of the original article: &lt;SPAN class=cit-auth&gt;&lt;SPAN class=cit-name-surname&gt;Juvé-Udina ME, Valls-Miró C, Carreño-Granero A, et al. To return or to discard? Randomised trial on gastric residual volume management. &lt;EM&gt;Intensive Crit Care Nurs&lt;/EM&gt; 2009;25:258–67.&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;CITE&gt;&lt;/CITE&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to NHS staff via Athens.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>251146</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1572-0241.2005.00287.x]]&gt;</url>
    <title>Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies</title>
    <publicationDate>2005-12-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,SMALL INTESTINE,CANCER,COLON &amp; RECTUM,CROHN'S DISEASE,CANCER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The risk of intestinal malignancy in Crohn's disease (CD) remains uncertain since risk estimates vary worldwide. The global CD population is growing and there is a demand for better knowledge of prognosis of this disease. Hence, the aim of the present study was to conduct a meta-analysis of population-based data on intestinal cancer risk in CD.</description>
    <body>&lt;![CDATA[ &lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Jess T, Gamborg M, Matzen P 2005; American Journal of Gastroenterology 100 (12) pp. 2724-2729 
&lt;H2&gt;Original article abstract&lt;/H2&gt;
&lt;P class=abstract&gt;OBJECTIVES: The risk of intestinal malignancy in Crohn's disease (CD) remains uncertain since risk estimates vary worldwide. The global CD population is growing and there is a demand for better knowledge of prognosis of this disease. Hence, the aim of the present study was to conduct a meta-analysis of population-based data on intestinal cancer risk in CD. METHODS: The MEDLINE search engine and abstracts from international conferences were searched for the relevant literature by use of explicit search criteria. All papers fulfilling the strict inclusion criteria were scrutinized for data on population size, time of follow-up, and observed to expected cancer rates. STATA meta-analysis software was used to perform overall pooled risk estimates (standardized incidence ratio (SIR), observed/expected) and meta-regression analyses of the influence of specific variables on SIR. RESULTS: Six papers fulfilled the inclusion criteria and reported SIRs of colorectal cancer (CRC) in CD varying from 0.9 to 2.2. The pooled SIR for CRC was significantly increased (SIR, 1.9; 95% CI 1.4-2.5), as was the risk for colon cancer separately (SIR, 2.5; 95% CI 1.7-3.5). Regarding small bowel cancer, five studies reported SIRs ranging from 3.4 to 66.7, and the overall pooled estimate was 27.1 (95% CI 14.9-49.2). CONCLUSIONS: The present meta-analysis of intestinal cancer risk in CD, based on population-based studies only, revealed an overall increased risk of both CRC and small bowel cancer among patients with CD. However, some of the available data were several decades old, and future studies taking new treatment strategies into account are required.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is &lt;STRONG&gt;not &lt;/STRONG&gt;available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>251148</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/gut.2004.049460]]&gt;</url>
    <title>Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine</title>
    <publicationDate>2005-08-01T00:00:00</publicationDate>
    <publisher>British Medical Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Inflammatory bowel disease (IBD) is commonly treated with immunomodulators such as azathioprine and 6-mercaptopurine (6-MP). Studies examining lymphoma risk in IBD patients treated with these medications have been underpowered and have yielded conflicting conclusions.</description>
    <body>&lt;![CDATA[ &lt;STRONG&gt;Citation&lt;/STRONG&gt;: Kandiel A, Fraser AG, Korelitz BI et al. 2005; Gut 54 pp. 1121-1125 
&lt;P class=abstract&gt;&lt;STRONG&gt;Abstract: &lt;/STRONG&gt;BACKGROUND: Inflammatory bowel disease (IBD) is commonly treated with immunomodulators such as azathioprine and 6-mercaptopurine (6-MP). Studies examining lymphoma risk in IBD patients treated with these medications have been underpowered and have yielded conflicting conclusions. AIMS: The purpose of this meta-analysis was to provide a more precise estimate of the relative risk of lymphoma among IBD patients treated with azathioprine or 6-MP. METHODS: Studies were included if they were English language, full article, cohort studies specifically designed to evaluate cancer as an adverse outcome of treatment with azathioprine or 6-MP. Pooled standardised incidence ratios were calculated to estimate the relative risk of lymphoma associated with therapy. Heterogeneity was assessed using Poisson regression. Sensitivity analyses examined the influence of individual studies on risk estimate and heterogeneity statistics. RESULTS: Six studies were identified that met our inclusion criteria. When the data were combined across all studies, the pooled relative risk was 4.18 (95% confidence interval 2.07-7.51; 11 observed cases, 2.63 expected). Sensitivity analysis showed that exclusion of any one study had a relatively small effect on the pooled relative risk estimate (range 3.49-5.21) but excluding either the study with the highest or lowest estimated relative risk eliminated the statistically significant heterogeneity. CONCLUSIONS: Our data suggest an approximate fourfold increased risk of lymphoma in IBD patients treated with azathioprine/6-MP. The increased risk of lymphoma could be a result of the medications, the severity of the underlying disease, or a combination of the two.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;Full text available freely online to NHS Athens account holders&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Other relevant articles&lt;/STRONG&gt;: You may also be interested in these articles '&lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resID=251141&amp;amp;code=6409a5dddc9e6c20c6499d8ee1ec8029" target="_blank"&gt;Review article: thiopurines in IBD&lt;/A&gt;' and '&lt;A href="http://www.library.nhs.uk/gastroliver/viewResource.aspx?resID=251157&amp;amp;code=46e227c6087eb52da89c1999abe65841" target="_blank"&gt;Association of 6-Thioguanine nucleotide levels and IBD activity: a meta-analysis&lt;/A&gt;' which cover the same topic. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>389208</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.gastrojournal.org/article/PIIS0016508510008784/abstract]]&gt;</url>
    <title>Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis</title>
    <publicationDate>2010-06-16T00:00:00</publicationDate>
    <publisher>Gastroenterology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,RECENT ADDITIONS,CIRRHOSIS,OCTOBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Arvaniti V, D'Amico G, Fede G, Manousou P, Tsochatzis E, Plequezuelo M, Burroughs AK. (2010) Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. &lt;EM&gt;Gastroenterology&lt;/EM&gt; 139(4): 1246-1256 e5&lt;/P&gt;
&lt;P&gt;Gastroenterology is the official journal of the American Gastroenterological Association Institute. It publishes reports on the latest treatments for diseases, and has an exculusive correspondence section.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background &amp;amp; Aims:&lt;/STRONG&gt; A staged prognostic model of cirrhosis based on varices, ascites, and bleeding has been proposed. We analyzed data on infections in patients with cirrhosis to determine whether it is also a prognostic factor.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Studies were identified by MEDLINE, EMBASE, COCHRANE, and ISI Web of Science searches (1978–2009); search terms included sepsis, infection, mortality, and cirrhosis. Studies (n = 178) reporting more than 10 patients and mortality data were evaluated (225 cohorts, 11,987 patients). Mortality after 1, 3, and 12 months was compared with severity, site, microbial cause of infection, etiology of cirrhosis, and publication year. Pooled odds ratio of death was compared for infected versus noninfected groups (18 cohorts, 2317 patients).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Overall median mortality of infected patients was 38%: 30.3% at 1 month and 63% at 12 months. Pooled odds ratio for death of infected versus noninfected patients was 3.75 (95% confidence interval, 2.12–4.23). In 101 studies that reported spontaneous bacterial peritonitis (7062 patients), the median mortality was 43.7%: 31.5% at 1 month and 66.2% at 12 months. In 30 studies that reported bacteremia (1437 patients), the median mortality rate was 42.2%. Mortality before 2000 was 47.7% and after 2000 was 32.3% (P = .023); mortality was reduced only at 30 days after spontaneous bacterial peritonitis (49% vs 31.5%; P = .005).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; In patients with cirrhosis, infections increase mortality 4-fold; 30% of patients die within 1 month after infection and another 30% die by 1 year. Prospective studies with prolonged follow-up evaluation and to evaluate preventative strategies are needed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309048</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1053/j.gastro.2008.05.081]]&gt;</url>
    <title>Infectious gastroenteritis and risk of developing inflammatory bowel disease</title>
    <publicationDate>2008-06-09T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,STOMACH,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; These data support theories that the initiation of IBD is a multifactorial process that might include the disruption of normal gut homeostatic mechanisms. Further studies are warranted to evaluate the pathogen-specific risks, identify susceptible populations, and better understand the pathophysiologic relationship between IGE and IBD.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; By using a medical encounter data repository of active duty military personnel, a study was conducted to assess IBD risk in subjects with an antecedent case of IGE.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Between 1999 and 2006, there were 3019 incident IBD cases and 11,646 matched controls who were evaluated in a conditional logistic regression model. To control for potential misclassification, IGE episodes within 6 months of IBD diagnosis were excluded as exposures. After adjusting for potential confounders, an episode of IGE increased the risk of IBD (odds ratio, 1.40; 95% confidence interval, 1.19–1.66). The risk was slightly higher for Crohn's disease compared with ulcerative colitis. In addition, there was an approximate 5-fold increase in IBD risk for persons with a previous irritable bowel syndrome diagnosis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Porter, C. K., Tribble, D. R., Aliaga, P. A., Halvorson, H. A., &amp;amp; Riddle, M. S. (2008) Infectious gastroenteritis and risk of developing inflammatory bowel disease. &lt;I&gt;Gastroenterology&lt;/I&gt;, 135(3):781-786.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>125562</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.gloshospitals.nhs.uk/pdf/requirements.pdf]]&gt;</url>
    <title>Inflammatory bowel disease - do once and share</title>
    <publicationDate>2006-04-03T00:00:00</publicationDate>
    <publisher>IBD Do Once &amp; Share Action Team</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>IBD Do Once and Share project reported on the information needed to run a high quality IBD service to inform electronic patient record systems developed for the NHS by 2010.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aim:&lt;/STRONG&gt; to set out requirements for a Inflammatory Bowel Disease Care Record&amp;nbsp;(IBDCR)&amp;nbsp;that will be used to inform system developed&amp;nbsp;by&amp;nbsp;the&amp;nbsp;NHS National Programme for IT by 2010.&lt;/P&gt;
&lt;P&gt;IBD was chosen as one of 43 disease areas for the Do Once and Share (DOAS) Programme. DOAS is a national programme set up by Connecting for Health, the agency responcible for implementing the National Programme for IT (NPfIT). The IBD DOAS team was based at Gloucester Hospitals NHS Foundation Trust.&lt;/P&gt;
&lt;P&gt;The IBD DOAS project team also produced:&lt;/P&gt;
&lt;UL style="MARGIN-RIGHT: 0px" dir=ltr&gt;
&lt;LI&gt;&lt;A href="http://www.gloshospitals.org.uk/pdf/risksIBD.pdf" target="_blank"&gt;Risks Inherent in an IBD Patient Journey&lt;/A&gt;&amp;nbsp;(PDF), and 
&lt;LI&gt;&lt;A href="http://www.gloshospitals.org.uk/pdf/kmsystem.pdf" target="_blank"&gt;The Benefits of Integrating a Knowledge Management System into the IBDCR&lt;/A&gt;&amp;nbsp;(PDF).&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Alll NHS IBD service stakeholders eg healthcare professionals, professional, charitable and societal organisations, patients and their carers.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; After a 6 month stakeholder engagement and consultation process the project team reported to Connecting for Health in April 2006.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309073</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1148/radiol.2471070611]]&gt;</url>
    <title>Inflammatory bowel disease diagnosed with US, MR, scintigraphy, and CT: meta-analysis of prospective studies</title>
    <publicationDate>2008-04-01T00:00:00</publicationDate>
    <publisher>Radiological Society of North America</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,DIAGNOSTIC PROCEDURES,NUCLEAR MEDICINE,ULTRASOUND,MRI,CT / CAT SCAN,CROHN'S DISEASE,RADIOLOGY,PET,SCINTIGRAPHY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; No significant differences in diagnostic accuracy among the imaging techniques were observed. Because patients with IBD often need frequent reevaluation of disease status, use of a diagnostic modality that does not involve the use of ionizing radiation is preferable.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method: &lt;/STRONG&gt;MEDLINE, EMBASE, CINAHL, and Cochrane databases were searched for studies on the accuracy of US, MR imaging, scintigraphy, CT, and PET, as compared with a predefined reference standard, in the diagnosis of IBD. Sensitivity and specificity estimates were calculated on per-patient and per-bowel-segment bases by using a bivariate random-effects model.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Thirty-three studies, from a search that yielded 1406 articles, were included in the final analysis. Mean sensitivity estimates for the diagnosis of IBD on a per-patient basis were high and not significantly different among the imaging modalities (89.7%, 93.0%, 87.8%, and 84.3% for US, MR imaging, scintigraphy, and CT, respectively). Mean per-patient specificity estimates were 95.6% for US, 92.8% for MR imaging, 84.5% for scintigraphy, and 95.1% for CT; the only significant difference in values was that between scintigraphy and US (P = .009). Mean per-bowel-segment sensitivity estimates were lower: 73.5% for US, 70.4% for MR imaging, 77.3% for scintigraphy, and 67.4% for CT. Mean per-bowel-segment specificity estimates were 92.9% for US, 94.0% for MR imaging, 90.3% for scintigraphy, and 90.2% for CT. CT proved to be significantly less sensitive and specific compared with scintigraphy (P = .006) and MR imaging (P = .037)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;See also: &lt;/STRONG&gt;&lt;A href="nelh:331740:0" name=internalLink&gt;DARE record&lt;/A&gt; for this article.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Horsthuis, K., Bipat, S., Bennink, R. J., &amp;amp; Stoker, J. (2008) Inflammatory bowel disease diagnosed with US, MR, scintigraphy, and CT: meta-analysis of prospective studies. &lt;I&gt;Radiology&lt;/I&gt;, 247(1):64-79.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in April 2008&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public as of April 2009.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344774</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.worldgastroenterology.org/assets/downloads/en/pdf/guidelines/21_inflammatory_bowel_disease.pdf]]&gt;</url>
    <title>Inflammatory bowel disease: a global perspective</title>
    <publicationDate>2009-06-01T00:00:00</publicationDate>
    <publisher>World Gastroenterology Organisation</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; Inflammatory bowel disease (IBD) represents a group of idiopathic chronic inflammatory intestinal conditions. The two main disease categories the term covers are Crohn’s disease (CD) and ulcerative colitis (UC), with both overlapping and distinct clinical and pathological features.&amp;nbsp; These guidelines cover diagnosis and management of both CD and UC, and describe the differences in IBD and its&amp;nbsp;incidence in different parts of the world. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience: &lt;/STRONG&gt;Gastroenterologists&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in June 2009&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281242</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17499606]]&gt;</url>
    <title>Inflammatory bowel disease: clinical aspects and established and evolving therapies</title>
    <publicationDate>2008-03-10T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: &lt;/P&gt;
&lt;P&gt;Baumgart, D.&amp;nbsp; &lt;SPAN title=Lancet.&gt;&lt;A href="#javascript:AL_get(this," ?Lancet.?);? ?jour?,&gt;Lancet.&lt;/A&gt;&lt;/SPAN&gt; 2007 May 12;369(9573):1641-57.&lt;/P&gt;
&lt;P class=abstract&gt;Crohn's disease and ulcerative colitis are two idiopathic inflammatory bowel disorders. In this paper we discuss the current diagnostic approach, their pathology, natural course, and common complications, the assessment of disease activity, extraintestinal manifestations, and medical and surgical management, and provide diagnostic and therapeutic algorithms. We critically review the evidence for established (5-aminosalicylic acid compounds, corticosteroids, immunomodulators, calcineurin inhibitors) and emerging novel therapies--including biological therapies--directed at cytokines (eg, infliximab, adalimumab, certolizumab pegol) and receptors (eg, visilizumab, abatacept) involved in T-cell activation, selective adhesion molecule blockers (eg, natalizumab, MLN-02, alicaforsen), anti-inflammatory cytokines (eg, interleukin 10), modulation of the intestinal flora (eg, antibiotics, prebiotics, probiotics), leucocyte apheresis and many more monoclonal antibodies, small molecules, recombinant growth factors, and MAP kinase inhibitors targeting various inflammatory cells and pathways. Finally, we summarise the practical aspects of standard therapies including dosing, precautions, and side-effects.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;The Lancet was established in 1823 and is an independent journal without affiliation to any medical or scientific organisation. The journal publishes high quality clinical trials, as well as editorials and comment and correspondance.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293843</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=2156150&amp;blobtype=pdf]]&gt;</url>
    <title>Interferon and lamivudine vs. interferon for hepatitis B e antigen-positive hepatitis B treatment: meta-analysis of randomized controlled trials</title>
    <publicationDate>2007-11-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,CHRONIC HEPATITIS B]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Rudin D, Shah SM, Kiss A, Wetz RV, Sottile VM.&amp;nbsp;&amp;nbsp;Liver International, 2007 Nov;27(9):1185-93.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract: &lt;/STRONG&gt;AIMS: To compare interferon monotherapy with its combination with lamivudine for hepatitis B e antigen (HBeAg)-positive hepatitis B treatment. METHODS: Two independent researchers identified pertinent randomized controlled trials. The trials were evaluated for methodological quality and heterogeneity. Rates of sustained virological and biochemical responses, and HBeAg clearance and seroconversion were used as primary efficacy measures. Quantitative meta-analyses were conducted to assess differences between groups for conventional and pegylated interferon, and overall. RESULTS: Greater sustained virological, biochemical and seroconversion rates were observed with addition of lamivudine to conventional [odds ratio (OR)=3.1, 95% confidence intervals (CI) (1.7-5.5), P&amp;lt;0.0001, OR=1.8, 95% CI (1.2-2.7), P=0.007 and OR=1.8, 95% CI (1.1-2.8), P=0.01 respectively], although not pegylated [OR=1.1, 95% CI (0.5-2.3), P=0.8, OR=1.0, 95% CI (0.7-1.3), P=0.94, and OR=0.9, 95% CI (0.6-1.2), P=0.34 respectively] interferon-alpha, with no significant affect on HBeAg clearance rates [OR=1.6, 95% CI (0.9-2.7), P=0.09, and OR=0.8, 95% CI (0.6-1.1), P=0.26 respectively]. Excluding virological response (P&amp;lt;0.001), pegylated interferon monotherapy and conventional interferon and lamivudine combination therapy were similarly efficacious (P&amp;gt;0.05), with the former studied in harder to treat patients, as evidenced by the superior virological response observed with conventional as compared with pegylated interferon monotherapy (P&amp;lt;0.0001). CONCLUSION: In comparable populations, pegylated interferon monotherapy is likely to be equally or more efficacious than conventional interferon and lamivudine combination therapy, thus constituting the treatment of choice, with no added benefit with lamivudine addition. However, when conventional interferon is used, its combination with lamivudine should be considered.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>380764</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.2215/CJN.01850309]]&gt;</url>
    <title>Interferon for hepatitis C virus in hemodialysis--an individual patient meta-analysis of factors associated with sustained virological response</title>
    <publicationDate>2009-09-01T00:00:00</publicationDate>
    <publisher>American Society of Nephrology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,RECENT ADDITIONS,CHRONIC HEPATITIS C,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Sustained virological response (SVR) is more likely with larger&amp;nbsp;interferon (IFN)&amp;nbsp;dose, longer treatment duration, treatment completion, female gender, lower&amp;nbsp;hepatitis C virus (HCV)&amp;nbsp;RNA and early virological negativity. For appropriate treatment candidates, regimens should consist of three million units of IFN three times weekly for at least 6 mo, with patients encouraged to complete the full course.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; HCV infection is prevalent in hemodialysis patients and causes excess mortality. IFN treatment of chronic HCV infection in hemodialysis patients results in high SVR rates 6 mo after treatment. The authors aimed to identify factors associated with SVR in hemodialysis patients through analysis of individual patient data obtained from systematic review of published literature.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Medline was searched from 1966 through February 2009, and prospective studies describing IFN treatment of hemodialysis patients with chronic HCV infection with published individual patient data were included. To identify factors associated with SVR, logistic regression was applied with adjustment for study.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Twenty studies of IFN treatment provided data on 428 patients. Overall SVR was 45% and in univariate analyses was higher with: 1) three million units or higher three times weekly of IFN; 2) treatment for at least 6 mo; 3) treatment completion; 4) lower baseline HCV RNA; 5) female gender; and 6) early virological negativity. Although limited by missing data, these relationships persisted in multivariate regression.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Gordon CE, Uhlig K, Lau J, Schmid CH, Levey AS, Wong JB. Interferon for hepatitis C virus in hemodialysis--an individual patient meta-analysis of factors associated with sustained virological response. &lt;EM&gt;Clin J Am Soc Nephrol&lt;/EM&gt; 2009;4(9):1449-58.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293613</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2893.2007.00907.x]]&gt;</url>
    <title>Interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials</title>
    <publicationDate>2008-02-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,CHRONIC HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Fabrizi, F et al. Journal of Viral Hepatitis 2008 Feb;15(2):79-88&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract: &lt;/STRONG&gt;The efficacy of monotherapy with interferon (IFN) (conventional or pegylated IFN) in dialysis patients with chronic hepatitis C remains unclear, although a number of clinical trials have been published addressing this issue. The aim of the study was to evaluate the efficacy and safety of monotherapy by conventional or pegylated IFN in dialysis patients with chronic hepatitis C by performing a systematic review of the literature with a meta-analysis of clinical trials. The primary outcome was sustained virological response (SVR; as a measure of efficacy), and the secondary outcome was drop-out rate (as a measure of tolerability). We used the random-effects model of Der Simonian and Laird, with heterogeneity and sensitivity analyses. We identified 28 clinical trials (645 unique patients), of which six (21.4%) had a controlled design. In the group of trials based on conventional IFN, the summary estimate for SVR and drop-out rate was 39% [95% confidence interval (CI) 32-46] and 19% (95% CI 13-26) respectively. The summary estimate for SVR rate in patients with the hepatitis C virus genotype 1 was 33% (95% CI 19-47). In the subset of trials using pegylated IFN, the summary estimate for SVR and drop-out rate was 31% (95% CI 7-55) and 27% (95% CI 1-52) respectively. The most frequent side-effects requiring interruption of treatment were flu-like symptoms, and gastrointestinal and haematological changes. A relationship between age and drop-out rate was found, even if no statistical significance was reached (P = 0.064). The studies were heterogeneous with regard to SVR and drop-out rate. No publication bias was observed. One-third of dialysis patients with chronic hepatitis C were successfully treated with conventional or pegylated IFN monotherapy. Preliminary evidence does not support additional benefit due to monotherapy with pegylated IFN on the viral response in the chronic kidney disease (CKD) population. Tolerance to IFN monotherapy was unsatisfactory, particularly to pegylated IFN. The optimal antiviral treatment of chronic hepatitis C in dialysis populations is currently under active investigation.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293610</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17417760?ordinalpos=15&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Interferon therapy for HCV-associated glomerulonephritis: meta-analysis of controlled trials</title>
    <publicationDate>2007-03-01T00:00:00</publicationDate>
    <publisher>Wichtig Editore</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Fabrizi, F et al International journal of artificial organs 2007 Mar;30(3):212-9.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract: &lt;/STRONG&gt;BACKGROUND: A relationship between hepatitis C virus (HCV) infection and chronic glomerulonephritis (GN) has been asserted on the grounds of epidemiological and experimental data. Although this suggests a role for an antiviral approach to HCV-associated GN instead of the more conventional immunosuppressive (or supportive) therapy, the optimal management of HCV related glomerulonephritis remains controversial. OBJECTIVE: To compare antiviral with immunosuppressive therapy for HCV-associated GN. DESIGN: Meta-analysis of controlled clinical trials (CCTs) of the two treatments (antiviral versus immunosuppressive) of HCV-associated GN. METHODS: We used the fixed or random effects model of DerSimonian and Laird, with heterogeneity and sensitivity analyses. The rate of proteinuria and serum creatinine decrease after therapy for HCV-associated GN were regarded as the most reliable outcome end-points. RESULTS: We identified six studies involving 145 unique patients with HCV-associated GN. Pooling of study results demonstrated that proteinuria decreased more commonly after IFN than corticosteroid therapy (OR 1.92 (95% CI, 0.39; 9.57), NS), P-test for heterogeneity, 0.06 (I2=52.9%). In a sensitivity analysis including only CCTs using standard IFN-doses, OR was 3.86 (95% CI, 1.44; 10.33, (P=0.007)), P-test for heterogeneity, 0.18 (I2=35.9%). No improvement of serum creatinine after IFN compared to immunosuppressive therapy was noted (OR, 0.59 (95% CI, 0.21; 1.65), NS), P-test for heterogeneity, 0.76 (I2=0%). Only three CCTs gave information on the rate of proteinuria decrease over follow-up (OR, 5.08 (95% CI, 0.69; 37.31), NS). A few major side effects were noted after IFN administration. CONCLUSIONS: Our meta-analysis indicates that standard IFN-doses were more effective than immunosuppressive therapy in lowering proteinuria of patients with HCV-related glomerulonephritis. However, no significant improvement in serum creatinine was seen by IFN or steroid therapy across the studies. Also, information on proteinuria recurrence after the completion of antiviral therapy was not sufficient. Prospective, randomized trials based on combined antiviral therapy (pegylated IFN plus ribavirin) with adequate dose and follow-up are required to assess the efficacy and safety of antiviral treatment of HCV-associated glomerulonephritis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;See also: &lt;/STRONG&gt;&lt;A href="nelh:303916:0" name=internalLink&gt;DARE record&lt;/A&gt; for this article&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323641</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2893.2009.01070.x]]&gt;</url>
    <title>Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis</title>
    <publicationDate>2009-04-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,NON-ALCOHOLIC,HEPATOCELLULAR CARCINOMA,RECENT ADDITIONS,CANCER,CIRRHOSIS,AUGUST 2009,CHRONIC HEPATITIS B]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Interferon (INF)&amp;nbsp;prevents or delays the development of liver cirrhosis and&amp;nbsp;hepatocellular carcinoma (HCC)&amp;nbsp;in patients with chronic hepatitis B.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Meta-analysis of available literature.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Twelve clinical controlled trials, including 2082 patients and comparing IFN with no treatment, were selected. Data on the incidence of liver cirrhosis and HCC in IFN treated and untreated patients were extracted from each study. The evaluation of preventive effectiveness was performed with an intention-to-treat method. The relative risk (RR) and 95% confidence interval (CI) of the main outcomes as a measure of efficacy were used. Meta-analysis was performed using fixed-effect or random-effect methods, depending on absence or presence of significant heterogeneity. Analyses were performed with &lt;SPAN class=smallcapitals&gt;stata&lt;/SPAN&gt; version 9.0 and Review Manager Version 4.2. Five studies including the data on development of liver cirrhosis, and eleven studies including the data on development of HCC were analyzed. There was no evidence for publication bias on the funnel plot or by Egger's test, and the heterogeneity test indicated that the variation of trial-specific RR was not statistically significant. A different incidence of liver cirrhosis and HCC was observed between treated and untreated patients. The RR of liver cirrhosis and HCC was 0.65 (95% CI: 0.47, 0.91) and 0.59 (95% CI: 0.43, 0.81), respectively.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Yang YF, Zhao W, Zhong YD, Xia HM, Shen L, Zhang N. Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. &lt;EM&gt;J Viral Hepat&lt;/EM&gt; 2009 Apr;16(4):265-71.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293615</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1053/j.ajkd.2007.11.003]]&gt;</url>
    <title>Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms</title>
    <publicationDate>2008-02-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,CHRONIC HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Gordon, CE et al. American Journal of Kidney Disease 2008 Feb;51(2):263-77&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract: &lt;/STRONG&gt;BACKGROUND: Hepatitis C virus (HCV) infection is prevalent in patients undergoing hemodialysis and is associated with greater mortality. We determined the efficacy and harms of interferon (IFN) and pegylated IFN (PEG-IFN) treatment of hemodialysis patients with chronic HCV infection and identified factors associated with these outcomes. STUDY DESIGN: Meta-analysis and meta-regression of randomized controlled trials, uncontrolled trials, and prospective observational studies. SETTING &amp;amp; POPULATION: Hemodialysis patients with chronic HCV infection. SELECTION CRITERIA FOR STUDIES: MEDLINE indexed studies since 1966, sample size greater than 10. INTERVENTION: IFN-based treatment, including PEG-IFN with and without ribavirin. OUTCOMES: Sustained virological response (SVR) 6 months after treatment, rate of treatment discontinuation caused by adverse events, and factors associated with these outcomes. RESULTS: 20 studies of 459 IFN-treated patients, 3 studies of 38 PEG-IFN-treated patients, and 2 studies of 49 PEG-IFN and ribavirin-treated patients met inclusion criteria. The overall SVR rate was 41% (95% confidence interval [CI], 33 to 49) for IFN and 37% (95% CI, 9 to 77) for PEG-IFN. Treatment discontinuation rates were 26% (95% CI, 20 to 34) for IFN and 28% (95% CI, 12 to 53) for PEG-IFN. SVR was higher with 3 million units (MU) or higher of IFN 3 times weekly, with lower mean HCV RNA, and with lower rates of cirrhosis, HCV genotype 1 or elevated transaminase, but these findings were not statistically significant. Treatment discontinuation rates were greater in studies using larger doses. LIMITATIONS: Publication bias, few randomized controlled trials, and limitations in generalizability to all hemodialysis patients. CONCLUSION: IFN treatment of hemodialysis patients results in an SVR rate of 41%. Higher dose, lower mean HCV RNA level, and lower rates of cirrhosis, transaminase level increase, and HCV genotype 1 may be associated with greater SVR rates, but additional studies using individual patient data are needed.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>268530</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1600-6143.2006.01362.x]]&gt;</url>
    <title>Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis</title>
    <publicationDate>2006-07-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,LIVER TRANSPLANTATION,SURGERY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt;&amp;nbsp;Wang C.S., Ko H.H. Yoshida E.M. et al. 2006; American Journal of Transplantation 6 (7) pp. 1586-99&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;Abstract: &lt;/STRONG&gt;Recurrence of hepatitis C virus (HCV) infection after liver transplantation (LT) is universal. However, the efficacy, tolerability and safety of combination interferon and ribavirin (IFN-RIB) or peginterferon and ribavirin (PEG-RIB) anti-viral therapies post-LT are uncertain. We performed a comprehensive search of major medical databases (1980-2005) and conference proceedings (1996-2005). The main outcome measure was sustained virological response (SVR, undetectable HCV RNA) at 6 months. Summary estimates were calculated using random-effects models. Twenty-seven IFN-RIB and 21 PEG-RIB studies were included. IFN-RIB was associated with a pooled SVR rate of 24% (95% CI, 20-27%), while PEG-RIB was associated with an SVR rate of 27% (23-31%). Pooled discontinuation rates were 24% (21-27%) with IFN-RIB and 26% (20-32%) with PEG-RIB. The pooled rate of acute graft rejection was 2% (1-3%) with IFN-RIB and 5% (3-7%) with PEG-RIB. IFN-RIB and PEG-RIB therapies in HCV infection post-LT were associated with similar but overall low SVR and were poorly tolerated. The rate of acute rejection was small. The therapeutic advantage of PEG-RIB therapy observed in non-transplant chronic HCV infection appears to be attenuated post-LT. Clinical trials are needed to evaluate reasons for this post-transplant therapeutic disadvantage and to find strategies to ameliorate them.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>310848</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1038/ajg.2008.16]]&gt;</url>
    <title>Interventions for treating microscopic colitis: a Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Review Group systematic review of randomized trials</title>
    <publicationDate>2009-01-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,MICROSCOPIC COLITIS,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Budesonide is effective and well tolerated for inducing and maintaining clinical and histological responses in patients with collagenous colitis, and for inducing clinical and histological responses in patients with lymphocytic colitis. Determining the magnitude of benefit is limited by the small sample sizes of the studies. The evidence for other agents, including bismuth subsalicylate, prednisolone, B. serrata extract, probiotics, and mesalamine with or without cholestyramine is weaker. It is not clear that any of these agents induce or maintain actual remission of collagenous or lymphocytic colitis, as opposed to clinical or histological response.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Relevant papers were identified via the MEDLINE, PUBMED, and Cochrane Collaboration databases, manual searches of the references of identified papers and review papers on microscopic colitis, as well as searches of abstracts from major gastroenterological meetings.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; All studies assessing treatment of microscopic colitis had relatively small sample sizes. A total of 10 randomized trials included patients with collagenous colitis. Budesonide was studied for induction of response in three trials and for maintenance of response in two trials. The pooled odds ratio for inducing clinical response with budesonide was 12.32 (95% confidence interval, CI 5.53–27.46), and for maintaining clinical response was 8.82 (95% CI 3.19–24.37), with a number needed to treat (NNT) of 2 patients for each outcome. Budesonide also induced and maintained histological response and was well tolerated. Bismuth subsalicylate, prednisolone, and mesalamine with or without cholestyramine may be effective, whereas Boswellia serrata extract and probiotics were ineffective for treating collagenous colitis. Three randomized trials included patients with lymphocytic colitis. Budesonide was shown in one study to be effective for inducing clinical response (OR 9.00; 95% CI 1.98–40.93), with an NNT of three patients. Budesonide also induced histological response and was well tolerated. Bismuth subsalicylate and mesalamine with or without cholestyramine may be effective for treating lymphocytic colitis. No trials assessed maintenance of response in patients with lymphocytic colitis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Chande N, MacDonald JK, McDonald JW. Interventions for treating microscopic colitis: a Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Review Group systematic review of randomized trials. &lt;EM&gt;Am J Gastroenterol&lt;/EM&gt; 2009;104(1):235-41.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>346145</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19279432]]&gt;</url>
    <title>Intra-abdominal venous and arterial thromboembolism in inflammatory bowel disease</title>
    <publicationDate>2009-02-01T00:00:00</publicationDate>
    <publisher>Lippincott Williams &amp; Wilkins</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Venous and arterial thromboembolism associated with inflammatory bowel disease (IBD) is a serious event that requires a high degree of vigilance by clinicians and surgeons.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract:&lt;/STRONG&gt; Venous and arterial thromboembolism constitutes a significant cause of morbidity and mortality in patients with inflammatory bowel disease. The most common thrombotic manifestations are lower extremity deep vein thromboses with or without pulmonary embolism. Occasionally, thromboembolic events occur in the main abdominal vessels, such as the portal and superior mesenteric veins, vena cava and hepatic vein, aorta, splanchnic and iliac arteries, or in the limb arteries. The decision-making process for the treatment of these uncommon thromboembolic complications in inflammatory bowel disease may be very challenging for several reasons: 1) no standardized therapies are available; 2) the decision of starting anticoagulant therapy implies the potential risk of intestinal bleeding; 3) thromboembolic events may recur and be life-threatening if inadequately treated. The literature was searched by using MEDLINE, Embase, and the Cochrane library database. Studies published between 1970 and 2007 were reviewed. We discuss the medical and surgical therapeutic options that should be considered to optimize the outcome and reduce the risk of complications in abdominal thromboembolisms associated with inflammatory bowel disease.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Di Fabio F, Obrand D, Satin R, Gordon PH. Intra-abdominal venous and arterial thromboembolism in inflammatory bowel disease. &lt;EM&gt;Dis Colon Rectum&lt;/EM&gt; 2009;52(2):336-42.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323553</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.vaccine.2009.01.043]]&gt;</url>
    <title>Intradermal hepatitis B vaccination: A systematic review and meta-analysis</title>
    <publicationDate>2009-03-13T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,DISEASE PREVENTION,VACCINATION,RECENT ADDITIONS,AUGUST 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Slightly lower seroprotection is associated with intradermal vaccination for hepatitis B virus relative to intramuscular vaccination.&amp;nbsp; Seroprotection from intradermal vaccination was higher among females and children, suggesting that these populations may be most appropriate for future intradermal vaccine development efforts.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Systematic review of observational studies and a meta-analysis of randomized trials. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Meta-analysis of data from 757 adults demonstrated that intradermal hepatitis B vaccination was slightly (14%) less likely to achieve seroprotection than intramuscular vaccination (risk ratio&lt;SUB&gt;pooled&lt;/SUB&gt; 0.86; 95% confidence interval: 0.77–0.95). Diverse study methodologies detracted from our ability to synthesize data from these studies; standardized approaches would enhance comparability of future studies. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Sangare L, Manhart L, Zehrung D, Wang CC. Intradermal hepatitis B vaccination: a systematic review and meta-analysis. Vaccine 2009 Mar 13;27(12):1777-86.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>305625</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://learning.bmj.com/learning/search-result.html?moduleId=10010951&amp;searchTerm=]]&gt;</url>
    <title>Irritable bowel syndrome in adults: diagnosis and management</title>
    <publicationDate></publicationDate>
    <publisher>NICE/BMJ Learning</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,IRRITABLE BOWEL SYNDROME]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;These online education tools have been developed by NICE in collaboration with BMJ Learning. BMJ Learning offers a wide range of learning resources, commissioned by the BMJ Group. The learning resources deal with everyday issues in primary care and hospital medicine. They are evidence based and peer reviewed. &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; After completing this module you should know: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;How to diagnose irritable bowel syndrome 
&lt;LI&gt;The red flags that should prompt you to refer your patient to secondary care 
&lt;LI&gt;What lifestyle advice is appropriate 
&lt;LI&gt;What drug and psychological interventions are appropriate. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;You should be able to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Challenge misconceptions about the guidelines on diagnosing and managing irritable bowel syndrome 
&lt;LI&gt;Apply this knowledge in your practice 
&lt;LI&gt;Reflect and compare your own practice against recommended audit criteria. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&amp;nbsp; Free registration with the site is required.&amp;nbsp; To register, click "Start module" and then "Register here".&amp;nbsp; Do not select the option to log in via Athens as access to BMJ Learning is not currently&amp;nbsp;part of NHS Athens accounts.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>374948</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1038/ajg.2009.734]]&gt;</url>
    <title>Is there an increased risk of GERD after Helicobacter pylori eradication?: a meta-analysis</title>
    <publicationDate>2010-05-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,OESOPHAGUS,STOMACH,ULCERS,DUODENAL ULCERS,GASTRIC ULCERS,SMALL INTESTINE,GASTRO-OESOPHAGEAL REFLUX,HELICOBACTER PYLORI,RECENT ADDITIONS,INFECTIONS,MAY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt;&amp;nbsp;There is no association between &lt;EM&gt;Helicobacter pylori&lt;/EM&gt; (&lt;EM&gt;Hp&lt;/EM&gt;)&lt;EM&gt; &lt;/EM&gt;eradication and development of new cases of gastro-oesophageal reflux disease (GORD) in the population of dyspeptic patients. However, in cohort studies, there seems to be a twofold higher risk of development of erosive GORD in patients with peptic ulcer disease (PUD) in patients where &lt;EM&gt;Hp &lt;/EM&gt;was eradicated compared to those in which it persisted. The effect in randomised controlled trials (RCTs) of patients with PUD did not show a significant difference.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Some studies suggest that eradication of &lt;EM&gt;Hp &lt;/EM&gt;might increase the risk of GORD in a portion of patients. We aimed to conduct a meta-analysis to investigate this.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A comprehensive, English, multiple-source literature search was performed from 1983 to February 2007. Only RCTs and cohort studies comparing the prevalence of GERD in patients free from GERD at baseline with Hp eradication vs. those with persistent Hp were included. Quality of RCTs and cohorts was assessed by Jadad and New Castle-Ottawa scores, respectively. Meta-analysis of pooled odds ratios (ORs) was performed using Review Manager 4.2.10. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Twelve (7 RCTs and 5 cohorts) of 271 articles were included. In six RCTs using erosive GERD as outcome, the OR for the frequency of GERD in Hp eradicated group vs. persistent Hp group was 1.11 (0.81-1.53, P=0.52). In five RCTs using symptomatic outcome, the OR for the frequency of GERD in Hp eradicated group vs. persistent Hp was 1.22 (0.89-1.69, P=0.22). In cohort studies, the OR for the frequency of GERD in Hp eradicated group vs. persistent Hp was 1.37 (0.89-2.12; P=0.15). Test of heterogeneity was not significant for any analyses. The results were consistent in subgroup and sensitivity analyses, including cohort studies vs. RCTs, high-quality studies vs. low-quality studies, and use of endoscopic vs. symptomatic outcomes except for the subgroup of patients with peptic ulcer disease (PUD) in cohort studies (OR: 2.04 (1.08-3.85); P=0.03).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Yaghoobi M, Farrokhyar F, Yuan Y, Hunt RH. Is there an increased risk of GERD after Helicobacter pylori eradication?: a meta-analysis. &lt;EM&gt;Am J Gastroenterol&lt;/EM&gt; 2010;105(5):1007-13.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>316176</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.attract.wales.nhs.uk/answer.aspx?&amp;qid=6070]]&gt;</url>
    <title>Is there any evidence that misoprostol 400 mcg/day (Arthrotec) is  better/worse than a PPIs for preventing GI bleeds/ulcers when used with a NSAID?</title>
    <publicationDate>2009-05-22T00:00:00</publicationDate>
    <publisher>ATTRACT</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ SMALL INTESTINE,DUODENAL ULCERS,GASTRIC ULCERS,ULCERS,STOMACH,COMMON CLINICAL PRESENTATIONS,GASTROENTEROLOGY &amp; LIVER DISEASES,UPPER,JUNE 2009,GI BLEEDING,RECENT ADDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=abstractSummary&gt;
&lt;P&gt;The ATTRACT service is based in Wales, and performs pragmatic reviews of the evidence-base for questions suggested by clinicians within the UK.&amp;nbsp; The following answer is given to this question:&lt;/P&gt;
&lt;P&gt;&lt;U&gt;Answer:&lt;/U&gt; We found relatively little evidence that directly compares misoprostol with PPIs in patients on NSAIDs. A meta-analysis to be found in the Cochrane Library on the prevention of NSAID-induced gastroduodenal ulcers examined head to head comparisons of various interventions. The CKS guideline on NSAIDs - prescribing issues contains a summary of outcome data from two systematic reviews comparing gastroprotective strategies.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>313874</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.attract.wales.nhs.uk/answer.aspx?&amp;qid=6110]]&gt;</url>
    <title>Is there any evidence/concern about long term use of PPIs?</title>
    <publicationDate>2009-04-29T00:00:00</publicationDate>
    <publisher>ATTRACT</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ SMALL INTESTINE,DUODENAL ULCERS,GASTRIC ULCERS,ULCERS,STOMACH,OESOPHAGUS,GASTROENTEROLOGY &amp; LIVER DISEASES,GASTRO-OESOPHAGEAL REFLUX,MAY 2009,RECENT ADDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=abstractSummary&gt;
&lt;P&gt;The ATTRACT service is based in Wales, and performs pragmatic reviews of the evidence-base for questions suggested by clinicians within the UK.&amp;nbsp; The following answer is given to this question:&lt;/P&gt;
&lt;P&gt;&lt;U&gt;Answer:&lt;/U&gt; ATTRACT found a number of two review articles, case reports and two previously answered queries in relation to long term PPI use and harm.&amp;nbsp;(Full details &lt;A href="http://www.attract.wales.nhs.uk/question_answers.cfm?question_id=2752" target="_blank"&gt;here&lt;/A&gt;)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>305874</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.attract.wales.nhs.uk/answer.aspx?&amp;qid=6165]]&gt;</url>
    <title>Is there any likely interaction between GTN ointment (for treatment of anal fissure) and sildenafil administration?</title>
    <publicationDate>2009-01-28T00:00:00</publicationDate>
    <publisher>ATTRACT</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ COLON &amp; RECTUM,GASTROENTEROLOGY &amp; LIVER DISEASES,FEBRUARY 2009,RECENT ADDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The ATTRACT service is based in Wales, and performs pragmatic reviews of the evidence-base for questions suggested by clinicians within the UK.&amp;nbsp; The following answer is given to this question:&lt;/P&gt;
&lt;P&gt;&lt;U&gt;Answer:&lt;/U&gt;&lt;STRONG&gt; &lt;/STRONG&gt;The summary of product characteristics (SPC) for Rectogesic (1) the glyceryl trinitrate ointment for treatment of anal fissure found in the BNF notes under contraindications:&lt;/P&gt;
&lt;P&gt;“Concomitant treatment with sildenafil citrate, tadalafil, vardenafil and with nitric oxide (NO) donors, such as other long-acting GTN products, isosorbide dinitrate and amyl or butyl-nitrite.”&lt;/P&gt;
&lt;P&gt;&amp;nbsp;Further in the SPC they note under interactions with other medicines:&lt;/P&gt;
&lt;P&gt;&amp;nbsp;“The hypotensive effect of nitrates are potentiated by concurrent administration of phosphodiesterase inhibitors, e.g. sildenafil, tadalafil and vardenafil.”&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in January 2009.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>347308</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ahrq.gov/downloads/pub/evidence/pdf/lactoseint/lactint.pdf]]&gt;</url>
    <title>Lactose intolerance and health</title>
    <publicationDate>2010-02-01T00:00:00</publicationDate>
    <publisher>Agency for Healthcare Research and Quality</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,SMALL INTESTINE,LACTOSE INTOLERANCE,RECENT ADDITIONS,APRIL 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=centerContent&gt;
&lt;P&gt;&lt;STRONG&gt;Objectives:&lt;/STRONG&gt; We systematically reviewed evidence to determine lactose intolerance (LI) prevalence, bone health after dairy-exclusion diets, tolerable dose of lactose in subjects with diagnosed LI, and management.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data Sources:&lt;/STRONG&gt; We searched multiple electronic databases for original studies published in English from 1967-November 2009.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Review Methods:&lt;/STRONG&gt; We extracted patient and study characteristics using author's definitions of LI and lactose malabsorption (LM). We assessed the prevalence of LI according to the diagnostic test used, such as lactose challenge, intestinal biopsies of lactase enzyme levels, genetic tests, and symptoms. Fractures, bone mineral content (BMC) and bone mineral density (BMD) were compared in categories of self reported dairy intake and diagnosis of lactose intolerance, malabsorption, or lactase deficiency. Reported symptoms, lactose dose and formulation, and co-ingested food were analyzed in association with tolerability of lactose. Symptoms were compared after administration of probiotics, enzyme replacements, lactose-reduced milk, and increasing lactose load.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Prevalence was reported in 54 primarily nonpopulation based studies (15 from the United States). Studies did not directly assess LI and subjects were highly selected. LI magnitude was very low in children and remained low into adulthood among individuals of Northern European descent. For African American, Hispanic, Asian, and American Indian populations LI rates may be 50 percent higher in late childhood and adulthood. Small doses of lactose were well tolerated in most populations. &lt;/P&gt;
&lt;P&gt;Low level evidence from 55 observational studies indicated that low milk consumers may have increased fracture risk, although there was inconsistency in strength and significance depending on exposure definitions. Dietary dairy supplementation in those with low baseline lactose intake did not consistently improve long-term bone health outcomes in children (seven RCTs) or adult women (two RCTs) compared to those not receiving dairy supplementation. Small feeding studies (28 studies) generally demonstrated that a 12 gram dose of lactose (1 cup of milk) produces no or minor symptoms. Symptoms became more prominent at doses above 12 grams and appreciable after 24 grams of lactose; 50 grams induced symptoms in the vast majority. A daily divided dose of 24 grams was generally tolerated. We found moderate level evidence that lactase or lactose hydrolyzed milk (28 RCTs) was effective in reducing LI symptoms. &lt;/P&gt;
&lt;P&gt;Evidence was insufficient for probiotics (eight RCTs), colonic adaptation (two RCTs) or varying lactose doses (three RCTs) or other agents (one RCT). Inclusion criteria, interventions, and outcomes were variable. Yogurt and probiotic types studied were variable and results either showed no difference in symptom scores or small differences in symptoms that may be of low clinical relevance.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; There are race and age differences in LI prevalence. Evidence is insufficient to accurately assess U.S. population prevalence of LI. Children with low lactose intake have worse bone outcomes compared to children assigned to receive supplemental diary interventions. Many individuals with LI can tolerate up to 24 grams of lactose daily if ingested throughout the day. Lactose reduced milk may be an effective strategy to reduce some LI symptoms. Research is needed to evaluate LI prevalence, bone outcomes in adults in association with lactose intake, genetic predisposition, lactose malabsorption, and intolerance. Studies are needed to determine LI treatment effectiveness. &lt;/P&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>293620</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2893.2007.00902.x]]&gt;</url>
    <title>Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis</title>
    <publicationDate>2008-02-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Katz, LH et al. Journal of Viral Hepatitis 2008 Feb;15(2):89-102&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract: &lt;/STRONG&gt;To assess the effects of prophylactic lamivudine on reactivation and mortality following immunosuppressive therapy in hepatitis B surface antigen (HBsAg)-positive patients, we performed a meta-analysis. Systematic review and meta-analysis of randomized and nonrandomized prospective controlled trials and retrospective comparative case series were identified through The Cochrane Hepato-Biliary Group Controlled Trials Register, The Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE and LILACS. The primary outcomes were virological reactivation, clinical reactivation and mortality. Secondary outcomes included hepatitis B virus (HBV)-related mortality, liver histology, discontinuation or disruption of immunosuppressive therapy, lamivudine-resistant HBV strains and adverse events. A total of 21 studies were included, two of which were randomized controlled trials. Clinical and virological reactivation were significantly reduced in the lamivudine group [odds ratio (OR) 0.09; 95% confidence interval (CI) 0.05-0.15 and OR 0.04; 95% CI 0.01-0.14 respectively]. All-cause mortality was significantly reduced in the lamivudine group (OR 0.36; 95% CI 0.23-0.56) which translates to only 11 patients who need to be treated to prevent one death. Lamivudine significantly reduced HBV-related mortality, and discontinuations or disruptions of the immunosuppressive treatment. No adverse effects of lamivudine were recorded, and resistance to lamivudine occurred in low rates. We demonstrated a clear benefit of lamivudine in terms of clinical and virological HBV reactivation, overall mortality, HBV-related mortality and interruptions or discontinuations in the immunosuppressive treatment. Lamivudine should be administered prophylactically to HBsAg-positive patients who are about to receive immunosuppressive therapy.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293833</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1478-3231.2007.01618.x]]&gt;</url>
    <title>Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: a meta-analysis</title>
    <publicationDate>2008-01-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Martyak LA, Taqavi E, Saab S.&amp;nbsp; Liver International, 2008 Jan;28(1):28-38. Epub 2007 Nov 1.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract: &lt;/STRONG&gt;BACKGROUND: Hepatitis B viral (HBV) reactivation in patients undergoing chemotherapy is associated with significant morbidity and mortality. Lamivudine has been suggested to be useful as a prophylaxis for HBV reactivation; however, its impact on overall survival and HBV reactivation-related liver disease survival is unclear. OBJECTIVE: To determine the effect of lamivudine prophylaxis on the rate of HBV reactivation, overall survival and HBV reactivation-related survival in patients with HBV undergoing chemotherapy. METHODS: A comprehensive search of MEDLINE, Cochrane Collaboration Database, reference lists and abstracts from national meetings. Statistical analysis was performed using revman. RESULTS: Eleven studies met the defined inclusion criteria and were included in the analysis. Two-hundred and twenty patients received lamivudine prophylaxis and 400 did not receive prophylaxis. Patients given lamivudine prophylaxis had an 87% decrease in HBV reactivation [risk ratio (RR) 0.13, 95% confidence interval (CI), 0.07-0.24] than patients not given prophylaxis [absolute risk reduction (ARR) -0.46, 95% CI, -0.61 to -0.31]. The number needed to treat to prevent one reactivation was 3. The Lamivudine prophylaxis group was also associated with a 70% reduction in reactivation-related mortality (RR 0.30, 95% CI, 0.1-0.94) compared with controls (ARR -0.03, 95% CI, 0.07-0.00). There was a reduction in treatment delays and premature termination of chemotherapy in the lamivudine prophylaxis arm (RR 0.41, 95% CI, 0.27-0.63; ARR -0.33, 95% CI, -0.33 to -0.15). There was no significant heterogeneity in the comparisons. CONCLUSION: Lamivudine prophylaxis during chemotherapy is effective in reducing the rate of HBV reactivation, and reactivation-related liver mortality. Patients with lamivudine prophylaxis had less chemotherapy treatment delays and premature termination of their chemotherapy. Few patients need to be treated to prevent reactivation. Patients with HBV undergoing chemotherapy should be started on lamivudine prophylaxis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;See also: &lt;/STRONG&gt;&lt;A href="nelh:303944:0" name=internalLink&gt;DARE record&lt;/A&gt; for this article&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281273</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17380366]]&gt;</url>
    <title>Laparoscopic surgery for Crohn's disease: a meta-analysis</title>
    <publicationDate>2008-03-10T00:00:00</publicationDate>
    <publisher>Springer</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;SPAN title="Diseases of the colon and rectum."&gt;Tan, J.J. &lt;A href="#javascript:AL_get(this," ?jour?, ?Dis Colon Rectum.?);?&gt;Dis Colon Rectum.&lt;/A&gt;&lt;/SPAN&gt; 2007 May;50(5):576-85.&lt;/P&gt; &lt;P class=abstract&gt;PURPOSE: This study was designed to determine the safety and feasibility of laparoscopic surgery in Crohn's disease. METHODS: A search of published studies in English between January 1990 and February 2006 was performed by using the MEDLINE and PubMed databases and the Cochrane Central Register of Controlled Trials. The studies were reviewed by two independent assessors. Meta-analysis with the Forest plot was performed when raw data, means, and standard deviations were available. RESULTS: The rate of conversion from laparoscopic to open surgery was 11.2 percent. Laparoscopic procedures took longer to perform compared with open procedures, with a weighted mean difference of 25.54 minutes (P = 0.03). Patients who underwent laparoscopic surgery had a more rapid recovery of bowel function, with a weighted mean difference of 0.75 days (P = 0.02) and were able to tolerate oral intake earlier, with a weighted mean difference of 1.43 days (P = 0.0008). The duration of hospitalization was shorter, with a weighted mean difference of 1.82 days (P = 0.02). Morbidity was lower for laparoscopic procedures compared with open procedures (odds ratio, 0.57; 95 percent confidence interval, 0.37-0.87; P = 0.01). The rate of disease recurrence was similar for both laparoscopic and open surgery. CONCLUSIONS: Laparoscopic surgery for Crohn's disease takes longer to perform, but there are significant short-term benefits to the patient. The morbidity also is lower, and the rate of disease recurrence is similar. Therefore, laparoscopic surgery for Crohn's disease is both safe and feasible.&lt;/P&gt; &lt;P class=abstract&gt;See also the &lt;A href="nelh:292919:0" name=internalLink&gt;DARE record&lt;/A&gt; for this article.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>251164</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1463-1318.2006.00971.x]]&gt;</url>
    <title>Laparoscopic surgery for ulcerative colitis - a meta-analysis</title>
    <publicationDate>2006-10-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This article aimed to assess the safety and feasibility of laparoscopic surgery for patients with ulcerative colitis.</description>
    <body>&lt;![CDATA[ &lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Tan JJ and Tjandra JJ 2006; Colorectal Diseases 8 (8) pp. 626-636 
&lt;H2&gt;Original article abstract&lt;/H2&gt;
&lt;P&gt;OBJECTIVE: To assess the safety and feasibility of laparoscopic surgery for patients with ulcerative colitis. METHODS: A search of published studies in English between January 1992 and September 2005 was obtained, using the MEDLINE and PubMed databases and the Cochrane Central Register of Controlled Trials. Two independent assessors reviewed the studies using a standardized protocol. Where raw data, means and standard deviations were available, meta-analysis was performed using the Forest plot review. Studies where medians and ranges were presented were separately analysed. RESULTS: The duration of surgery for laparoscopic and open procedures were similar (weighted mean difference 62.92 min, P = 0.19). Patients were able to tolerate oral intake significantly earlier, with a weighted mean difference of 1.39 days (P = 0.002), but recovery of bowel function was similar (weighted mean difference 0.73 days, P = 0.36). The length of hospital stay was shorter for patients who had undergone laparoscopic surgery, with a weighted mean difference of 2.64 days (P = 0.003). The complication rate was higher in open colectomy, compared to laparoscopic colectomy (67.6%vs 39.7%, P = 0.005). For restorative proctocolectomy, complication rates were comparable between the laparoscopic and open groups (P = 0.25). CONCLUSIONS: The time taken to perform laparoscopic surgery is similar to open surgery. Patients are able to tolerate oral intake earlier, and have a shorter hospitalization. Laparoscopic colectomy was safer compared to the open procedure, but both were equally safe for patients who had restorative proctocolectomy. Thus, laparoscopic surgery for ulcerative colitis is both safe and feasible.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;See also: &lt;/STRONG&gt;&lt;A href="nelh:284774:0" name=internalLink&gt;DARE record&lt;/A&gt; for this article.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is &lt;STRONG&gt;not &lt;/STRONG&gt;available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>310799</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://ebm.bmj.com/cgi/content/short/14/2/54]]&gt;</url>
    <title>Laparoscopic surgery was more effective than medical management for GORD disease</title>
    <publicationDate>2009-04-01T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,OESOPHAGUS,GASTRO-OESOPHAGEAL REFLUX,RECENT ADDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Jani K. Therapeutics: Laparoscopic surgery was more effective than medical management for GORD disease.&amp;nbsp; Evid Based Med 2009 Apr;14(2):54.&lt;/P&gt;&lt;/FONT&gt;
&lt;P&gt;&lt;STRONG&gt;Summary: &lt;/STRONG&gt;A review of the original article: Grant A, Wileman S, Ramsay C, et al. The effectiveness and cost-effectiveness of minimal access surgery amongst people with gastro-oesophageal reflux disease—a UK collaborative study. The REFLUX trial. Health Technol Assess 2008;12:1–181.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bibliographic details:&lt;/STRONG&gt; Evidence-Based Medicine is a secondary evidence journal, containing informative abstracts and expert commentaries about the best quality research from primary care medicine.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in April 2009.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to NHS staff via Athens.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>332718</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//gastroliver/ViewResource.aspx?resID=332718]]&gt;</url>
    <title>Launch of the GLDSC Nurses' Area</title>
    <publicationDate>2009-12-10T00:00:00</publicationDate>
    <publisher>NHS Evidence - gastroenterology and liver diseases</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,RECENT ADDITIONS,JANUARY 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Launch of the GLDSC Nurses' Area&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Welcome to the first editorial for the NHS Evidence – gastroenterology and liver diseases nurses’ section (available free online at &lt;A href="http://www.library.nhs.uk/gastroliver" target="_blank"&gt;www.library.nhs.uk/gastroliver&lt;/A&gt;),&amp;nbsp; to introduce ourselves we are Lynda Greenslade, Clinical Nurse Specialist in Hepatology and Isobel Mason, Consultant Nurse in Gastroenterology and we both work at the Royal Free Hospital NHS Trust, in London. We are representing you as the nursing editors for the specialist collection. Articles and information included the nurses section have reviewed by the editorial board as the best available.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;Why bother using the collection?&lt;/STRONG&gt; The NHS Evidence specialist collections are free and should be available via your trust-wide computer in your hospital. They provide you with a wealth of information and resources. Are you writing some patient information? Or a new guideline and protocol? Or are studying in your speciality or do you just want somewhere to go to update yourself? Then this is the site for you.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;What does the collection contain? &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Up to date evidence in gastroenterology and liver diseases.&lt;/LI&gt;
&lt;LI&gt;Secondary sources of evidence such as Cochrane reviews, and&amp;nbsp;national and international guidelines.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;These can provide a great starting point for a literature review&lt;/LI&gt;
&lt;LI&gt;In the nurses' section we aim to provide links to seminal articles relating to GI and liver nursing practice.&lt;BR&gt;&amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;There will be monthly guest editorials from expert nurses within the speciality updating us on current innovation and practice. The site has a section on forthcoming events including study days, conferences and relevant meetings across the country. There are links to other professional organisations including NACC, BSG, RCN, BASL, and others. You will also find links to patients’ organisations.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Another important set of resources&amp;nbsp;are the annual evidence updates,&amp;nbsp;which highlight and review all the relevant papers published in the last year and present the best evidence in each speciality with thoughts and opinions from our editorial board.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Please enjoy looking through the whole site and we would welcome any suggestions for additions.&amp;nbsp;&amp;nbsp;If you have any suggestions&amp;nbsp;for articles, comments, courses and patient information that you would like included, please &lt;A href="http://www.library.nhs.uk/Gastroliver/ContactUs.aspx" target="_blank"&gt;contact us&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>293604</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1423-0410.2007.00941.x]]&gt;</url>
    <title>Legal, financial, and public health consequences of transfusion-transmitted hepatitis C virus in persons with haemophilia</title>
    <publicationDate>2007-08-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Angelotta, C et al Vox Sanguinis 2007 Aug;93(2):159-65&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract: &lt;/STRONG&gt;BACKGROUND: Since the first cases of acquired immunodeficiency syndrome in persons with haemophilia were reported in 1982, much has been written about the consequences of human immunodeficiency virus (HIV) contamination of the blood supply. Relatively little attention has been paid to similar hepatitis C virus (HCV) concerns since the first cases of HCV-infected persons with haemophilia were identified in 1989. METHODS: We review the history, public health, policy, and financial consequences of blood supply policy decisions made for persons with haemophilia who received HCV-contaminated blood products in eight countries that were severely impacted by viral contamination of the blood supply during the 1980s, contrasting these findings with those reported previously for HIV contamination of the blood supply during the same time-period. A Medline search and a hand search of retrieved bibliographies of English-language articles on HCV concerns in haemophilia patients published from 1989 to 2006 were performed. RESULTS: Our review identified that two- to eightfold more persons with haemophilia in the eight countries contracted HCV vs. HIV from contaminated blood products during the 1980s. Opportunistic infections and immunosuppression-related complications among persons with haemophilia developed shortly after these patients received HIV-infected blood products whereas hepatic complications among HCV-infected persons with haemophilia are just now being diagnosed two decades after these individuals received HCV-contaminated blood products. Policy makers in four countries conducted official public inquiries into blood safety decisions related to HIV- and/or HCV-contamination of the blood supply. More than 20 countries allocated compensation funds for HIV-infected persons with haemophilia (mean award ranging from $37 000 to 400 000) whereas only the UK, Canada, and Ireland allocated compensation funds for HCV-infected persons with haemophilia (mean award ranging from $37 000 to 50 000). CONCLUSION: While the clinical impact among persons with haemophilia of HCV contamination of the blood supply in the 1980s was larger than the impact of HIV contamination of the blood supply during this time-period, the policy response was smaller. Consideration should be given to adopting support programmes for HCV-infected persons with haemophilia in countries that do not have these programs.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>103432</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.acg.gi.org/physicians/guidelines/LiverDiseaseinPregnantPatient.pdf]]&gt;</url>
    <title>Liver disease in the pregnant patient</title>
    <publicationDate>1999-07-01T00:00:00</publicationDate>
    <publisher>American College of Gastroenterology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,PREGNANCY,CANCER,FATTY LIVER,OBSTETRIC CHOLESTASIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims&lt;/STRONG&gt;:&amp;nbsp;&amp;nbsp; Concise guideline intended to assist practioners in recognising liver disease and their warning signs in the often unfamiliar territory of pregnancy physiology.&amp;nbsp; Focus is on commonly occuring illnessses that may be altered by pregnancy as well as those unique to pregnancy.&amp;nbsp; The affects of liver disease on both mother and foetus are considered.&lt;/P&gt;
&lt;P&gt;Note: Also approved by the American Gastroenterological Association, the American Society for Gastrointestinal Endoscopy, and the American Association for the study of Liver Disease.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience&lt;/STRONG&gt;:&amp;nbsp;All physicians in a clinical setting regardless of specialty.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;Available to the general public&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>378384</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.jhep.2009.11.009]]&gt;</url>
    <title>Liver grafts from anti-hepatitis B core positive donors: a systematic review</title>
    <publicationDate>2010-02-10T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,LIVER TRANSPLANTATION,RECENT ADDITIONS,CHRONIC HEPATITIS B,SURGERY,JUNE 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Liver grafts from anti-HBc positive donors can be safely used, preferentially in HBsAg-positive or anti-HBc/anti-HBs positive recipients. HBsAg-negative recipients should receive prophylaxis with lamivudine, while both anti-HBc and anti-HBs positive recipients may need no prophylaxis at all.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt;&amp;nbsp;Although hepatitis B virus (HBV) transmission after liver transplantation of grafts from HBsAg-negative, anti-HBc positive donors is well established, the growing organ shortage favours the use of such marginal grafts. We systematically evaluated the risk of HBV infection after liver transplantation with such grafts and the effect of anti-HBV prophylaxis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We performed a literature review over the last 15 years identifying 39 studies including 903 recipients of anti-HBc positive liver grafts. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Recurrent HBV infection developed in 11% of HBsAg-positive liver transplant recipients of anti-HBc positive grafts, while survival was similar (67-100%) to HBsAg-positive recipients of anti-HBc negative grafts. De novo HBV infection developed in 19% of HBsAg-negative recipients being less frequent in anti-HBc/anti-HBs positive than HBV naive cases without prophylaxis (15% vs 48%, p&amp;lt;0.001). Anti-HBV prophylaxis reduced de novo infection rates in both anti-HBc/anti-HBs positive (3%) and HBV naive recipients (12%). De novo infection rates were 19%, 2.6% and 2.8% in HBsAg-negative recipients under hepatitis B immunoglobulin, lamivudine and their combination, respectively.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Cholongitas E, Papatheodoridis GV, Burroughs AK. Liver grafts from anti-hepatitis B core positive donors: a systematic review. &lt;EM&gt;J Hepatol&lt;/EM&gt; 2010;52(2):272-9.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>380661</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2893.2009.01147.x]]&gt;</url>
    <title>Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C</title>
    <publicationDate>2010-01-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,RECENT ADDITIONS,CHRONIC HEPATITIS C,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Antiviral therapy may prolong life, improve long-term health-related quality-of-life and be reasonably cost-effective in treatment-naïve patients with chronic hepatitis C as well as in former relapsers/nonresponders. Further research is needed in patients with specific co-morbidities or risk profiles.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; We aimed to systematically review the evidence for long-term effectiveness and cost-effectiveness of antiviral treatment in patients with chronic hepatitis C.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We performed a systematic literature search on the long-term effectiveness and cost-effectiveness of AVT in hepatitis C (1990-March 2007), and included health technology assessment (HTA) reports, systematic reviews, long-term clinical trials, economic studies conducted alongside clinical trials and decision-analytic modelling studies. All costs were converted to 2005euro.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Antiviral therapy with peginterferon plus ribavirin in treatment-naïve patients with chronic hepatitis C was the most effective (3.6-4.7 life years gained [LYG]) treatment and was reasonably cost-effective (cost-saving to 84 700euro/quality adjusted life years [QALY]) when compared to interferon plus ribavirin. Some results also suggest cost-effectiveness (below 8400euro/(QALY) of re-treatment in nonresponders/relapsers. Results for patients with persistently normal alanine aminotransferase (ALT) levels or with special co-morbidities (e.g. HIV) or risk profiles were rare.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Sroczynski G, Esteban E, Conrads-Frank A, Schwarzer R, Mühlberger N, Wright D, Zeuzem S, Siebert U.&amp;nbsp;Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C. &lt;EM&gt;J Viral Hepat&lt;/EM&gt; 2010;17(1):34-50.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>380707</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1093/eurpub/ckp001]]&gt;</url>
    <title>Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection</title>
    <publicationDate>2009-06-01T00:00:00</publicationDate>
    <publisher>Oxford Journals</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,DISEASE PREVENTION,SCREENING,RECENT ADDITIONS,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Hepatitis C virus (HCV) screening and early treatment have the potential to improve average life-expectancy, but should focus on populations with elevated HCV prevalence to be cost-effective. Further research on the long-term health-economic impact of HCV screening when combined with appropriate monitoring strategies in different European health care systems is needed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; HCV infection is an emerging problem in public health. In most countries, the majority of HCV infected people are yet undiagnosed. Early detection and treatment may result in better health outcomes and save costs by preventing future advanced liver disease. The evidence for long-term effectiveness and cost-effectiveness of HCV screening was systematically reviewed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We performed a systematic literature search on long-term health-economic effects of HCV screening and included Health Technology Assessment (HTA) reports, systematic reviews, long-term clinical trials, full health economic and decision-analytic modelling studies with a sufficiently long time horizon and patient-relevant long-term outcomes such as life-years gained (LYG) or quality-adjusted life years (QALY) gained. Economic results were converted to 2005 Euros.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Seven studies were included. Target population, HCV prevalence, study perspective, discount rate, screening and antiviral treatment mode varied. The incremental effectiveness of HCV screening and early treatment compared to no screening and standard care varied from 0.0004 to 0.066 LYG, and from 0.0001 to 0.072 QALY. Incremental cost-effectiveness and cost-utility ratios of HCV screening vs. no screening were 3900-243,700 euro/LYG and 18,300-1,151,000 euro/QALY. HCV screening seems to be cost-effective in populations with high HCV prevalence, but not in low HCV prevalence populations.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Sroczynski G, Esteban E, Conrads-Frank A, Schwarzer R, Mühlberger N, Wright D, Zeuzem S, Siebert U. Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection. &lt;EM&gt;Eur J Public Health&lt;/EM&gt; 2009;19(3):245-53.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>381273</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.antiviral.2009.10.023]]&gt;</url>
    <title>Long-term efficacy of interferon alpha therapy on hepatitis B viral replication in patients with chronic hepatitis B: a meta-analysis</title>
    <publicationDate>2010-02-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,RECENT ADDITIONS,CHRONIC HEPATITIS B,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The results of this meta-analysis indicate that interferon (IFN) increases the incidence of hepatitis B e antigen (HBeAg) seroclearance and hepatitis B&amp;nbsp;surface antigen (HBsAg) seroclearance after long-term follow-up of three to seven years. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; IFN alpha has been used in the treatment of chronic hepatitis B for decades. Beneficial effects including HBeAg/HBV DNA seroclearance have been documented. However, it remains unclear whether interferon has long-term efficacy on inhibiting hepatitis B viral replication. So we conducted a meta-analysis of available literature to assess the evidence obtained on the efficacy of IFN treatment in chronic hepatitis B virus (HBV) infection.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Seven clinical controlled trials, including 1550 patients and comparing IFN to no treatment, were selected. Data on the incidence of HBV DNA seroclearance, HBeAg seroclearance, and HBsAg seroclearance in IFN treated and untreated patients were extracted from each study. The evaluation of effectiveness was performed with an intention-to-treat (ITT) method. We used the relative risk (RR) and 95% confidence interval (CI) of the main outcomes as the measure of efficacy. Meta-analysis was performed using fixed-effect or random-effect methods, depending on absence or presence of significant heterogeneity. Analyses were performed with STATA version 9.0 and Review Manager Version 4.2.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Four studies including the data of HBeAg seroclearance with significant heterogeneity were analyzed by random-effect method; six studies including the data of HBsAg seroclearance without significant heterogeneity were analyzed by fixed-effect method. A different incidence of HBeAg seroclearance and HBsAg seroclearance was observed between treated and untreated patients. The RR of HBeAg seroclearance and HBsAg seroclearance was 0.66 (95% CI: 0.44, 0.99) and 0.28 (95% CI: 0.17, 0.46), respectively.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Yang YF, Zhao W, Xia HM, Zhong YD, Huang P, Wen J. Long-term efficacy of interferon alpha therapy on hepatitis B viral replication in patients with chronic hepatitis B: a meta-analysis. &lt;EM&gt;Antiviral Res&lt;/EM&gt; 2010;85(2):361-5.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>380718</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.vaccine.2009.10.068]]&gt;</url>
    <title>Long-term protection provided by hepatitis B vaccine and need for booster dose: a meta-analysis</title>
    <publicationDate>2010-01-08T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,DISEASE PREVENTION,VACCINATION,RECENT ADDITIONS,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The protection provided by three or four doses of monovalent hepatitis B (HB) vaccine persists for at least two decades in the great majority of immunocompetent individuals. Additional studies are needed for assessing vaccine efficacy for longer periods of time and the need of booster doses in different subgroups of population.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; The duration of protection provided by&amp;nbsp;HB vaccine is still unknown but can be estimated through long-term follow-up studies.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Electronic databases and conference databases to December 2008 were searched. Reference lists of articles were screened and the studies authors and manufacturers were contacted for additional unpublished references. Randomized clinical trials and prospective cohort studies addressing the long-term protective effect of hepatitis B vaccine were included in this meta-analysis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Randomized clinical trials and prospective cohort studies addressing the long-term protective effect of hepatitis B vaccine were included in this meta-analysis. We assessed 42 separate cohorts involving overall 11,090 subjects; 34 cohorts involving 9356 subjects were included in the final meta-analysis. Results indicate that the overall cumulative incidence of HBV breakthrough infection 5-20 years post-primary vaccination was 0.007 [95% CI: 0.005 to 0.010] with a variation among studies from 0 to 0.094. Available data do not allow us to exclude an increased risk for infection with time since vaccination.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Poorolajal J, Mahmoodi M, Majdzadeh R, Nasseri-Moghaddam S, Haghdoost A, Fotouhi A. Long-term protection provided by hepatitis B vaccine and need for booster dose: a meta-analysis. &lt;EM&gt;Vaccine&lt;/EM&gt; 2010;28(3):623-31.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345593</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1038/ajg.2008.88]]&gt;</url>
    <title>Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review</title>
    <publicationDate>2009-03-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; A variable but relevant proportion of Crohn's disease patients on long-term infliximab treatment lose response. This may be interpreted in two different but compatible ways: a positive view, highlighting that infliximab therapy is relatively durable, with the majority of patients predicted to continue infliximab treatment at least during the first year; or a negative view, interpreting that a significant proportion of Crohn's disease patients-more than 10% per patient-year of infliximab treatment-on long term will lose response and will require an increase in dose and/or decrease in infusion interval.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; To review the frequency with which infliximabloses its effect and dose "intensification" is required for Crohn's disease treatment. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Bibliographical searches were performed in MEDLINE, and European (ECCO) and American (DDW) Congresses. Studies evaluating loss of efficacy and requirement of infliximab dose intensification-defined either as an increase of the infliximab dose (generally from 5 mg/kg to 10 mg/kg) or as a decrease in the frequency of infusion (to as often as every 4 weeks)-in Crohn's disease patients were included.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Sixteen studies evaluating the incidence of loss of response to infliximab in Crohn's disease patients were found. A total of 2,236 patients were included (the majority of them receiving a three-dose induction regimen at weeks 0, 2, and 6, followed by maintenance therapy every 8 weeks), providing 6,284 patient-years of follow-up. The mean percentage of patients with loss of infliximab response was 37%. However, as the follow-up time varied markedly among studies, the risk of losing response to infliximab is better expressed as the incidence of this complication per patient-year of follow-up. Therefore, the annual risk for loss of infliximab response was calculated to be 13% per patient-year.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Gisbert JP, Panés J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. &lt;EM&gt;Am J Gastroenterol&lt;/EM&gt; 2009;104(3):760-7. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345606</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1007/s00330-008-1287-0]]&gt;</url>
    <title>Magnetic resonance imaging for evaluation of disease activity in Crohn's disease: a systematic review</title>
    <publicationDate>2009-06-01T00:00:00</publicationDate>
    <publisher>Springer</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,DIAGNOSTIC PROCEDURES,MRI,CROHN'S DISEASE,RECENT ADDITIONS,RADIOLOGY,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt;&amp;nbsp;MRI correctly grades disease activity in a large proportion of Crohn's disease (CD) patients with frank disease. For patients in remission or with mild disease, MRI correctly stages disease activity in many patients (62%).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; To systematically review the evidence on the accuracy of MRI for grading disease activity in CD.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; The MEDLINE, EMBASE, CINAHL and Cochrane databases were searched for studies on the accuracy of MRI in grading CD compared to a predefined reference standard. Two independent observers scored all relevant data. Three disease stages were defined: remission, mild and frank disease. The accuracy rates of MRI per disease stage were calculated by means of a random-effects model.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Seven studies were included from a search resulting in 253 articles. In total 140 patients (16 patients in remission, 29 with mild disease and 95 with frank disease) were used for data analysis. MRI correctly graded 91% (95% CI: 84-96%) of patients with frank disease, 62% (95% CI: 44-79) of patients with mild disease and 62% (95% CI: 38-84) of patients in remission. MRI more often overstaged than understaged disease activity; MRI overstaged disease activity in 38% of patients in remission, mostly as mild disease. Overstaging of mild disease was observed in 21%, understaging in 17%.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Horsthuis K, Bipat S, Stokkers PC, Stoker J. Magnetic resonance imaging for evaluation of disease activity in Crohn's disease: a systematic review. &lt;EM&gt;Eur Radiol&lt;/EM&gt; 2009;19(6):1450-60.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>177016</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.bapen.org.uk/pdfs/must/must_full.pdf]]&gt;</url>
    <title>Malnutrition universal screening tool (MUST)</title>
    <publicationDate></publicationDate>
    <publisher>British Association for Parenteral &amp; Enteral Nutrition</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COMMON CLINICAL PRESENTATIONS,DIAGNOSTIC PROCEDURES,DISEASE PREVENTION,SCREENING,NUTRITION ASSESSMENT,MALNUTRITION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A five step screening tool published by The British Association for Parenteral and Enteral Nutrition (BAPEN), designed to help identify adults who are at risk of malnutrition or obesity.</description>
    <body>&lt;![CDATA[ &lt;P&gt;The British Association for Parenteral and Enteral Nutrition (BAPEN) aims to improve the nutritional treatment of all suffers from illness who have become, or are likely to become, malnourished and who are unable to consume or absorb normal food in sufficent quantities to promote recovery.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary: &lt;/STRONG&gt;MUST&amp;nbsp;is a five step screening tool to identify adults&amp;nbsp;who are at risk of malnutrition, or are obese. It includes a BMI chart and guidance on management of cases of malnutrition.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>343596</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.aasld.org/practiceguidelines/Documents/Bookmarked%20Practice%20Guidelines/Ascites%20Update6-2009.pdf]]&gt;</url>
    <title>Management of adult patients with ascites due to cirrhosis: an update</title>
    <publicationDate>2009-05-25T00:00:00</publicationDate>
    <publisher>American Association for the Study of Liver Diseases</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,ASCITES,CIRRHOTIC ASCITES,HEPATO-RENAL SYNDROME,NON-ALCOHOLIC,ALCOHOLIC LIVER DISEASE,ALCOHOLIC CIRRHOSIS,DISEASE PREVENTION,BACTERIAL INFECTIONS,SPONTANEOUS BACTERIAL PERITONITIS,RECENT ADDITIONS,CIRRHOSIS,ALCOHOLIC,FEBRUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; This guideline has been approved by the AASLD and represents the position of the Association. These recommendations provide a data-supported approach. They are based on the following: (1) formal review and analysis of the recently-published world literature on the topic (Medline search); (2) American College of Physicians Manual for Assessing Health Practices and Designing Practice Guidelines; (3) guideline policies, including the AASLD Policy on the Development and Use of Practice Guidelines and the American Gastroenterological Association Policy Statement on Guidelines; and (4) the author’s decades of experience caring for patients with cirrhosis and ascites.&lt;/P&gt;
&lt;P&gt;Intended for use by physicians, these recommendations suggest preferred approaches to the diagnostic, therapeutic, and preventive aspects of care. They are intended to be flexible, in contrast to standards of care, which are inflexible policies to be followed in every case. Specific recommendations are based on relevant published information. To more fully characterize the quality of evidence supporting recommendations, the Practice Guidelines Committee of the AASLD requires a Class (reflecting benefit versus risk) and Level (assessing strength or certainty) of Evidence to be assigned and reported with each recommendation.&lt;/P&gt;
&lt;P&gt;These guidelines were developed for the care of adult patients with clinically detectable ascites. Although the general approach may be applicable to children, the pediatric database is much smaller and there may be unanticipated differences between adults and children. Patients&lt;BR&gt;with ascites detected only by imaging modalities but not yet clinically evident are excluded because of the lack of published information regarding the natural history of this entity.&lt;/P&gt;
&lt;P&gt;A Medline search from 1966 through 2007 was performed; search terms included ascites, hepatorenal syndrome, diet therapy, drug therapy, radiotherapy, surgery, and therapy. The search involved only articles published in English and involving humans. A manual search of the author’s files and recent abstracts was also performed. The search yielded 2115 articles including 153 published since a similar search was performed in 2002 in ppreparation for writing the previous guideline on ascites.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience: &lt;/STRONG&gt;Hepatologists&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published May 2009&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323582</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ahrq.gov/downloads/pub/evidence/pdf/hepb/hepb.pdf]]&gt;</url>
    <title>Management of chronic hepatitis B</title>
    <publicationDate>2008-10-01T00:00:00</publicationDate>
    <publisher>Agency for Healthcare Research and Quality</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,HEPATOCELLULAR CARCINOMA,LIVER FAILURE,RECENT ADDITIONS,CANCER,AUGUST 2009,CHRONIC HEPATITIS B]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Objectives:&lt;/STRONG&gt; Synthesize evidence of the natural history of chronic hepatitis B (CHB) and effects and harms of antiviral drugs on clinical, virological, histological, and biochemical outcomes.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data Sources:&lt;/STRONG&gt; MEDLINE®, electronic databases, and manual searches of systematic reviews.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Review Methods:&lt;/STRONG&gt; We included original observational studies to assess natural history and randomized controlled trials (RCTs) of adults with CHB published in English to assess treatment effects and harms if they reported mortality, incidence of hepato-cellular carcinoma (HCC), cirrhosis or failure, HBeAg or HBsAg, viral load (HBV DNA), alanine aminotransferase (ALT) levels, histological necroinflammatory and fibrosis scores, and adverse events after interferon alfa-2b, pegylated interferon alfa 2-a, lamivudine, adefovir, entecavir, tenovir or telbivudine. We excluded pregnant women, transplant patients, and individuals undergoing cancer chemotherapy. We calculated relative risk or absolute risk differences at end of treatment and post-treatment.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Observational studies (41 publications) suggested that male gender, coinfection with hepatitis C, D, or HIV, increased HBV DNA, and cirrhosis were associated with increased risk of HCC and death. Drugs did not reduce death, liver failure, or HCC in 16 RCTs not designed to test long-term clinical outcomes. Evidence from 93 publications of 60 RCTs suggested drug effects on viral load or replication, liver enzymes, and histology at end of treatment and lasting from &amp;lt;3 to &amp;gt;6 months off treatment. No one treatment improved all outcomes and there was limited evidence on comparative effects. Two RCTs suggested interferon alfa-2b increased CHB resolution versus placebo. Interferon alfa-2b or lamivudine improved off treatment HBV DNA and HBeAg clearance and seroconversion and ALT normalization. Adefovir improved off treatment ALT normalization and HBV DNA clearance. Pegylated interferon alfa 2-a versus lamivudine improved off-treatment HBV DNA and HBeAg clearance and seroconversion, ALT normalization and liver histology. Lamivudine combined with interferon alfa-2b versus lamivudine improved off treatment HBV DNA clearance and HBeAg seroconversion and reduced HBV DNA mutations. Pegylated interferon alfa 2-a plus lamivudine improved off treatment HBV DNA and HBeAg clearance and seroconversion and ALT normalization compared to lamivudine but not pegylated interferon alfa 2-a monotherapy. Adverse events were common but generally mild and did not result in increased treatment discontinuation. Longer hepatitis duration, male gender, baseline viral load and genotype, HBeAg, and histological status may modify treatment effect on intermediate outcomes. Adefovir and pegylated interferon alfa 2-a with lamivudine improved off treatment viral clearance in HBeAg negative patients. There was insufficient evidence to determine if biochemical, viral, or histological measures are valid surrogates of treatment effect on mortality, liver failure, or cancer.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusion:&lt;/STRONG&gt; Adults with CHB have an increased risk of death, hepatic decompensation, and HCC. Mono or combined drug therapy improves selected virological, biochemical, and histological markers with no consistent effects on all examined outcomes. Patient and disease characteristics may modify treatment-induced intermediate outcomes. Evidence was insufficient to assess treatment effect on clinical outcomes, predict individualized patient response, or determine if intermediate measures are reliable surrogates. Future research should assess longterm drug effects on clinical outcomes and among patient subpopulations.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Wilt TJ, Shamliyan T, Shaukat A, Taylor BC, MacDonald R, Yuan JM, et al. Management of chronic hepatitis B. &lt;EM&gt;Evid Rep Technol Assess (Full Rep)&lt;/EM&gt; 2008 Oct;(174):1-671.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102395</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.nzgg.org.nz/guidelines/0077/Dyspepsia_Guideline_(web).pdf]]&gt;</url>
    <title>Management of dyspepsia and heartburn</title>
    <publicationDate>2004-06-01T00:00:00</publicationDate>
    <publisher>New Zealand Guidelines Group</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,STOMACH,DYSPEPSIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims&lt;/STRONG&gt;: The guideline was initiated to update the existing 1995 GORD guidelines as it was felt that considerable changes in evidence had occurred since publication.&amp;nbsp; Literature reviews were done by four groups and then a consensus formed between them.&amp;nbsp; Three areas regarding the management of dyspepsia and heartburn are covered: clinincal (e.g. symptons), resources/equity, and public health.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience&lt;/STRONG&gt;: Predominantly aimed at primary care practitioners, but also considered for medical and surgical specialists as well as pharmacists and nurse paractioners.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>123240</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.aasld.org/practiceguidelines/Documents/Bookmarked%20Practice%20Guidelines/HCCUpdate2010.pdf]]&gt;</url>
    <title>Management of hepatocellular carcinoma: an update</title>
    <publicationDate>2010-07-01T00:00:00</publicationDate>
    <publisher>American Association for the Study of Liver Diseases</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATOCELLULAR CARCINOMA,SURGERY,SURGERY,ABDOMEN,LIVER &amp; SPLEEN,LIVER TUMOURS,RECENT ADDITIONS,CANCER,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims&lt;/STRONG&gt;:&amp;nbsp;The recommendations provided in this document provide a data-supported approach to the diagnosis, staging and treatment of patients diagnosed with hepatocellular carcinoma (HCC). They are based on the following: (a) formal review and analysis of the recently-published world literature on the topic (Medline search through early 2010); (b) American College of Physicians Manual for Assessing Health Practices and Designing Practice Guidelines; (c) guideline policies, including the AASLD Policy on the Development and Use of Practice Guidelines and the American Gastroenterology Association Policy Statement on Guidelines; (d) the experience of the authors. These recommendations suggest preferred approaches to the diagnostic, therapeutic, and preventive aspects of care. In an attempt to characterize the quality of evidence supporting recommendations, the Practice Guidelines Committee of the American Association for Study of Liver Disease (AASLD) requires a category to be assigned and reported with each recommendation (Table 1). These recommendations are fully endorsed by the American Association for the Study of Liver Diseases.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience&lt;/STRONG&gt;:&amp;nbsp;Physicians &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>330629</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17700425]]&gt;</url>
    <title>Mechanisms of synergy between alcohol and hepatitis C virus</title>
    <publicationDate>2007-09-01T00:00:00</publicationDate>
    <publisher>Lippincott Williams &amp; Wilkins</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,ALCOHOLIC LIVER DISEASE,RECENT ADDITIONS,NOVEMBER 2009,CHRONIC HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Alcoholics with&amp;nbsp;hepatitis C virus (HCV)&amp;nbsp;infection have more severe liver disease compared with nondrinkers. Patients should be encouraged to enroll in rehabilitation programs so as to improve treatment adherence and response.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Since the discovery of the HCV, extensive literature has emerged on alcohol and HCV interaction. The goal of this study is to understand the impact of alcohol and HCV infection on the severity of liver disease and the mechanisms of interaction between the two.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method: &lt;/STRONG&gt;Of 1269 articles (1991 to 2006) searched through MEDLINE and cited cross references, 133 were thoroughly reviewed to assess: (a) prevalence of combined alcohol use and HCV, (b) severity of liver disease (c) treatment response, and (d) mechanisms of interaction between HCV and alcohol. Data on study design, patient demographics, diagnostic tests used, and study outcomes were extracted for critical analysis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt;&amp;nbsp;Prevalence of HCV is 3-fold to 30-fold higher in alcoholics compared with the general population. Patients with HCV infection and alcohol abuse develop more severe fibrosis with higher rate of cirrhosis and hepatocellular cancer compared with nondrinkers. Increased oxidative stress seems to be the dominant mechanism for this synergism between alcohol and the HCV. Abstinence is the key to the management of liver disease due to HCV and alcohol. Data have shown that lower response rates to interferon in alcoholics with HCV infection are likely due to noncompliance.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Singal AK, Anand BS. Mechanisms of synergy between alcohol and hepatitis C virus. &lt;EM&gt;J Clin Gastroenterol&lt;/EM&gt; 2007 Sep;41(8):761-72.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309202</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/bmj.39547.603218.AE]]&gt;</url>
    <title>Medical management of Crohn's disease</title>
    <publicationDate>2008-05-10T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt; Biological therapies have radically changed the management of Crohn’s disease but must be used judiciously with great awareness of possible adverse events. Treatment strategies for the disease are rapidly evolving, with immunomodulator and biological therapy being considered in patients who have indicators for developing early severe disease. Clinical indicators of a poor prognosis (at diagnosis) include perianal or stricturing disease, weight loss &amp;gt;5 kg, or the need for steroids. Treatment of active disease with mesalazine is little better than placebo; mesalazine is used mainly to reduce the risk of relapse after small intestinal resection.&lt;BR&gt;Access to specialist services, parallel medical and surgical clinics, nurse specialists, dietitians, pharmacists, and other allied professionals is as important as the medication. Publication of standards of care should drive improvement in the care and provision of resources for patients with Crohn’s disease.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Cummings, J., Keshav, S., &amp;amp; Travis, S. (2008) Medical management of Crohn's disease. &lt;I&gt;BMJ&lt;/I&gt;, 336(7652):1062-1066.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to NHS users via Athens.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>187046</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1097/01.mib.0000231495.92013.5e]]&gt;</url>
    <title>Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials</title>
    <publicationDate>2006-10-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,PROCTITIS &amp; DISTIL COLITIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A critical evaluation of published studies on the treatment of ulcerative proctitis and left-sided ulcerative colitis. All English language articles published between 1995 and 2005 were identified via a comprehensive search. This evaluation has produced a set of guidelines on the medications available for treatment of ulcerative proctitis and left-sided ulcerative colitis.
</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims&lt;/STRONG&gt;:&amp;nbsp;The goal of this work was to critically evaluate the published studies on the treatment of ulcerative proctitis (UP) and left-sided ulcerative colitis (L-UC). The results of this review provided the content for the accompanying treatment guidelines, Clinical Guidelines for the Medical Management of Left-sided Ulcerative Colitis and Ulcerative Proctitis: Summary Statement. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; All English language articles published between 1995 and September 2005 were identified through a comprehensive literature &lt;BR&gt;search using OVID and PubMed. The quality of the data supporting or rejecting the use of specific therapies was categorized by a data quality grading scale. The therapeutic efficacy of a treatment was defined by its success in treating UP and L-UC compared with placebo. Quality and efficacy scores were agreed on by author consensus.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; This critical evaluation of treatment provides a "report card" on medications available for the management of patients with UP and L-UC. The guidelines should provide a useful reference and supplement for physicians treating UC patients.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bibliographic details:&lt;/STRONG&gt; Lippincott Williams &amp;amp; Wilkins Inflammatory Bowel Disease 2006; 12: p.979-994&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience&lt;/STRONG&gt;:&amp;nbsp;Healthcare professionals&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;This article is &lt;STRONG&gt;not &lt;/STRONG&gt;available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281263</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17877506]]&gt;</url>
    <title>Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission</title>
    <publicationDate>2008-03-10T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic information:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;Sandborn, W.J.&amp;nbsp;&lt;SPAN title="Alimentary pharmacology &amp;amp; therapeutics."&gt;&lt;A href="#javascript:AL_get(this," ?jour?, ?Aliment Pharmacol Ther.?);?&gt;Aliment Pharmacol Ther.&lt;/A&gt;&lt;/SPAN&gt; 2007 Oct 1;26(7):987-1003.&lt;/P&gt;
&lt;P class=abstract&gt;BACKGROUND: Patients with Crohn's disease alternate between periods of active, symptomatic disease and periods of remission. The treatment goal for Crohn's disease is to induce and then maintain remission of symptoms. AIM: To review evidence from randomized, controlled, clinical trials on medical therapies for inducing and maintaining remission in patients with mild-to-moderate Crohn's disease, and to suggest the best evidence-based approaches for induction and maintenance therapies. METHODS: PubMed search using the following terms: sulfasalazine or salicylazosulfapyridine or aminosalicylate or aminosalicylic acid or mesalamine or mesalazine or corticosteroid or prednisone or prednisolone or methylprednisolone or budesonide or antibiotic or metronidazole or ciprofloxacin or immunosuppressive or azathioprine or mercaptopurine or thiopurine or methotrexate and Crohn's disease. RESULTS: Randomized, controlled trials demonstrated that sulfasalazine, budesonide, and conventional corticosteroids are effective for inducing remission of mild-to-moderate Crohn's disease when administered for a period of 8-16 weeks. An ideal maintenance therapy does not currently exist. CONCLUSIONS: Selection of maintenance therapy is based on a combination of evidence from controlled trials and patient features including disease severity and location, co-morbidities, previous response to treatment, and previous surgical resection. The options for maintenance therapy include therapy cessation and patient observation following successful induction, budesonide, or immunosuppressive therapy.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Alimentary Pharmacology and Therapeutics is an international journal concerned with the effects of drugs on the human gastrointestinal and hepato-biliary systems. The journal publishes original research on all aspects of pharmacology, pharmacokinetics and therapeutic use of drugs in the alimentary tract.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is &lt;STRONG&gt;not&lt;/STRONG&gt; available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293837</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.biomedcentral.com/content/pdf/1471-230X-7-40.pdf]]&gt;</url>
    <title>Meta-analyses of FibroTest diagnostic value in chronic liver disease</title>
    <publicationDate>2007-10-01T00:00:00</publicationDate>
    <publisher>BioMed Central</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,HEPATITIS C,ALCOHOLIC LIVER DISEASE,DIAGNOSTIC PROCEDURES,BLOOD TESTS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt;&amp;nbsp;FibroTest (FT)&amp;nbsp;is an effective alternative to biopsy in patients with chronic hepatitis C (CHC) and B (CHB),&amp;nbsp;alcoholic liver disease (ALD)&amp;nbsp;and non-alcoholic fatty liver disease (NAFLD). The FT diagnostic value is similar for the diagnosis of intermediate and extreme fibrosis stages.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; FibroTest is a biomarker of liver fibrosis initially validated in patients with&amp;nbsp;CHC. The aim was to test two hypotheses, one, that the FT diagnostic value was similar in the three other frequent fibrotic diseases: CHB, ALD and NAFLD; and the other, that the FT diagnostic value was similar for intermediate and extreme fibrosis stages.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; The main end points were the FT area under the ROC curves (AUROCs) for the diagnosis of bridging fibrosis (F2F3F4 vs. F0F1), standardized for the spectrum of fibrosis stages, and the comparison of FT AUROCs between adjacent stages. Two meta-analyses were performed: one combining all the published studies (random model), and one of an integrated data base combining individual data. Sensitivity analysis integrated the independency of authors, lenght of biopsy, prospective design, respect of procedures, comorbidities, and duration between biopsy and serum sampling.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; A total of 30 studies were included which pooled 6,378 subjects with both FT and biopsy (3,501 HCV, 1,457 HBV, 267 NAFLD, 429 ALD, and 724 mixed). Individual data were analyzed in 3,282 patients. The mean standardized AUROC was 0.84 (95% CI, 0.83-0.86), without differences between causes of liver disease: HCV 0.85 (0.82-0.87), HBV 0.80 (0.77-0.84), NAFLD 0.84 (0.76-0.92), ALD 0.86 (0.80-0.92), mixed 0.85 (0.80-0.93). The AUROC for the diagnosis of the intermediate adjacent stages F2 vs. F1 (0.66; 0.63-0.68, n = 2,055) did not differ from that of the extreme stages F3 vs. F4 (0.69; 0.65-0.72, n = 817) or F1 vs. F0 (0.62; 0.59-0.65, n = 1788).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Poynard T, Morra R, Halfon P, Castera L, Ratziu V, Imbert-Bismut F, Naveau S, Thabut D, Lebrec D, Zoulim F, Bourliere M, Cacoub P, Messous D, Munteanu M, de Ledinghen V.&amp;nbsp; Meta-analyses of FibroTest diagnostic value in chronic liver disease. &lt;EM&gt;BMC Gastroenterol &lt;/EM&gt;2007 Oct 15;7:40.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>384541</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1038/ajg.2010.194]]&gt;</url>
    <title>Meta-analyses of the effect of symptoms of gastroesophageal reflux on the risk of Barrett's esophagus</title>
    <publicationDate>2010-08-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,OESOPHAGUS,CANCER,BARRETT'S OESOPHAGUS,GASTRO-OESOPHAGEAL REFLUX,RECENT ADDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; In the highest-quality studies, gastroesophageal reflux disease (GERD) symptoms are not associated with short-segment Barrett's esophagus (SSBE), but increased the odds of long-segment BE (LSBE) by fivefold. GERD symptoms can serve as a reliable predictor of LSBE, but not SSBE. If SSBE is considered worthy of identification, then current screening practices do not select patients at risk for endoscopy, and alternative methods of selection for screening need to be developed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Esophageal adenocarcinoma (EAC) is a devastating disease that has risen in incidence over the past several decades. BE is an associated premalignant lesion. Current preventative efforts rely on endoscopic screening of individuals with GERD symptoms and surveillance endoscopy for those with BE. However, some recent studies have found a high prevalence of BE in patients without GERD, and others have found little or no association with GERD. We hypothesized that studies of higher-quality design show weaker associations of GERD with BE, and that GERD is only weakly associated with SSBE.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We performed a systematic literature search in multiple online electronic databases regardless of language. Eligible studies required visualization of columnar mucosa and histological confirmation of intestinal metaplasia, and GERD symptoms ascertained by questionnaire or interview. The highest-quality sampling design was defined a priori by both cases and controls identified among unselected research volunteers ("research design") rather than by patients selected for endoscopy for clinical indications ("clinical design"), which introduces selection and ascertainment bias. A priori, heterogeneity was defined by Cochrane's Q P&amp;lt;0.20 and the inconsistency index (I(2); 25% low, 50% moderate, and 75% high). Heterogeneity of results can reflect significant differences in study design or effect modification by strata of outcomes.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Systematic review identified 13,392 citations. Evaluation identified 108 potentially relevant journal articles, of which 26 met eligibility. Of these, 14 studies identified cases of BE and controls based on clinical indication ("clinical design"), and 6 used the "research design." The remaining six studies identified cases of BE from patients undergoing endoscopy for clinical indication and controls among patients without known BE ("cases clinical/controls research"). The summary odds ratio (OR) for the association of GERD with BE from all studies was 2.90 (95% confidence interval (CI), 1.86-4.54), but the results were very heterogeneous (P=0.0001; I(2)=89%). When stratified by BE length and sampling design, the studies with clinical design showed substantial, but heterogeneous, associations with SSBE (OR, 2.38; 95% CI, 1.21-4.70; P=0.02; I(2)=62%), and stronger and homogeneous association with long-segment BE (LSBE; fixed effects OR, 2.96; 95% CI, 1.69-5.19; P=0.25; I(2)=25%). In the research study design, stratifying by length of BE resolved the heterogeneity and showed a strong association between GERD and LSBE (fixed effects OR, 4.92; 95% CI, 2.01-12.0; P=0.30; I(2)=19%) and no association with SSBE (fixed effects OR, 1.15; 95% CI, 0.763-1.73; P=0.84; I(2)=0%). Funnel plots showed potential evidence for bias against dissemination of small negative studies.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Taylor JB, Rubenstein JH. Meta-analyses of the effect of symptoms of gastroesophageal reflux on the risk of Barrett's esophagus. &lt;EM&gt;Am J Gastroenterol&lt;/EM&gt; 2010;105(8):1729, 1730-7.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>387997</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1053/j.gastro.2010.05.077]]&gt;</url>
    <title>Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins</title>
    <publicationDate>2010-09-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,DISEASE PREVENTION,VACCINATION,RECENT ADDITIONS,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; &lt;SPAN&gt;The inclusion of nonstructural proteins in hepatitis C virus (HCV) vaccines might be detrimental to protective immune responses, and/or structural proteins might activate T-cell responses that mediate viral clearance.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; &lt;SPAN&gt;Studies in patients and chimpanzees that spontaneously cleared HCV infections demonstrated that natural immunity to the virus is induced during primary infections and that this immunity can be cross protective. These discoveries led to optimism about prophylactic HCV vaccines, and several studies were performed in chimpanzees, although most included fewer than 6 animals. To draw meaningful conclusions about the efficacy of HCV vaccines in chimpanzees, we performed statistical analyses of data from previously published studies from different groups.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; &lt;SPAN&gt;We performed a meta-analysis that compared parameters among naïve (n = 63), vaccinated (n = 53), and rechallenged (n = 36) animals, including peak RNA titer postchallenge, time points of peak RNA titer, duration of viremia, and proportion of persistent infections.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;SPAN&gt;Each vaccination study induced immune responses that were effective in rapidly controlling HCV replication. Levels of induced T-cell responses did not indicate vaccine success. There was no reduction in the rate of HCV persistence in vaccinated animals, compared with naïve animals, when nonstructural proteins were included in the vaccine. Vaccines that contained only structural proteins had clearance rates that were significantly higher than vaccines that contained nonstructural components (P = .015).&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Dahari H, Feinstone SM, Major ME. Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins. &lt;EM&gt;Gastroenterology &lt;/EM&gt;2010;139(3):965-74.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>387174</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.jhep.2010.03.023]]&gt;</url>
    <title>Meta-analysis of performance of Kings's College Hospital Criteria in prediction of outcome in non-paracetamol-induced acute liver failure</title>
    <publicationDate>2010-09-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATIC ENCEPHALOPATHY,LIVER TRANSPLANTATION,ACUTE LIVER FAILURE,LIVER FAILURE,RECENT ADDITIONS,SURGERY,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; &lt;SPAN&gt;The Kings College Criteria&lt;/SPAN&gt; (&lt;SPAN&gt;KCC) for outcome in &lt;SPAN&gt;non-paracetamol-induced acute liver failure (&lt;/SPAN&gt;non-POD ALF) have good specificity and more limited sensitivity. There is significant heterogeneity in the published data partially related to methodological quality. KCC perform best in groups with high grade encephalopathy and in historically earlier studies suggesting modern medical management of ALF may modify performance of KCC.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; &lt;SPAN&gt;Current techniques for predicting outcome and requirement for emergency liver transplantation (ELT) in ALF are imperfect, though KCC are the most commonly applied tools for this purpose. Their performance in identification of patients with non-POD ALF, who would not survive without ELT, has recently been questioned. Using quantitative techniques, we therefore performed a meta-analysis of outcome data of the KCC for prediction of survival in non-POD ALF.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt;&amp;nbsp;&lt;SPAN&gt;A systematic database search was performed and retrieved articles graded according to a pre-agreed pro-forma of methodological quality. Collated data was meta-analysed for summary sensitivity, specificity, diagnostic odds ratio (DOR) and ROC curve analysis. Pre-specified sub-group analysis was performed on the basis of methodological quality, the severity of hepatic encephalopathy (HE) of reported patients, timing of KCC application and exclusion of those who underwent ELT.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;SPAN&gt;Eighteen studies with data on 1105 patients were available for production of 2x2 tables. Summary sensitivity was 68 (95% CI 59-77)%, specificity 82 (75-88)% and DOR 12.6 (6.5-26.1). Heterogeneity was detected in the DOR and related to methodological quality (I(2)=64% for all studies versus 47% for 'good' quality studies) and was lower in studies considering high grade HE or dynamic application of KCC (I(2)=0%). For data where ELT were excluded (13 studies) summary sensitivity was 68 (57-79)%, specificity 81 (72-90)% and DOR 12.2 (4.9-30.1) and a symmetric summary ROC curve was produced. Specificity was highest in studies of patients with high grade HE (93 (80-100)%) and where KCC were applied dynamically through the clinical course (88 (78-97)%). Sensitivity was reduced in studies published post 2005 compared with studies pre 1995 (58 (46-71)% versus 85 (76-82)%).&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; McPhail MJ, Wendon JA, Bernal W. Meta-analysis of performance of Kings's College Hospital Criteria in prediction of outcome in non-paracetamol-induced acute liver failure. &lt;EM&gt;J Hepatol&lt;/EM&gt; 2010;53(3):492-9.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317084</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1038/ajg.2009.176]]&gt;</url>
    <title>Meta-analysis of randomized clinical trials comparing open and laparoscopic anti-reflux surgery</title>
    <publicationDate>2009-06-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,OESOPHAGUS,GASTRO-OESOPHAGEAL REFLUX,RECENT ADDITIONS,JUNE 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; On the basis of this meta-analysis, the authors conclude that laparoscopic anti-reflux surgery (LARS) is an effective and safe alternative to&amp;nbsp;open &amp;nbsp;anti-reflux surgery (OARS) for the treatment of proven gastroesophagal reflux disease&amp;nbsp;(GERD). LARS enables a faster convalescence and return to productive activity, with a reduced risk of complications and a similar treatment outcome, than an open approach. However, there is a significantly higher rate of re-operation (79%) in the LARS group.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A search of the Medline, Embase, Science Citation Index, Current Contents, and PubMed databases identified all randomized clinical trials that compared LARS and OARS and that were published in the English language between 1990 and 2007. A meta-analysis was carried out in accordance with the QUOROM (Quality of Reporting of Meta-Analyses) statement. The six outcome variables analyzed were operating time, hospital stay, return to normal activity, perioperative complications, treatment failure, and requirement for further surgery. Random-effects meta-analyses were carried out using odds ratios (ORs) and weighted mean differences (WMDs).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Twelve trials were considered suitable for the meta-analysis. A total of 503 patients underwent OARS and 533 had LARS. For three of the six outcomes, the summary point estimates favored LARS over OARS. There was a significant reduction of 2.68 days in the duration of hospital stay for the LARS group compared with that for the OARS group (WMD: -2.68, 95% confidence interval (CI): -3.54 to -1.81; &lt;I&gt;P&lt;/I&gt;&amp;lt;0.0001), a significant reduction of 7.75 days in return to normal activity for the LARS group compared with that for the OARS group (WMD: -7.75, 95% CI: -14.37 to -1.14; &lt;I&gt;P&lt;/I&gt;=0.0216), and finally, there was a statistically significant reduction of 65% in the relative odds of complication rates for the LARS group compared with that for the OARS group (OR: 0.35, 95% CI: 0.16–0.75; &lt;I&gt;P&lt;/I&gt;=0.0072). The duration of operating time was significantly longer (39.02&amp;nbsp;min) in the LARS group (WMD: 39.02, 95% CI: 17.99–60.05; &lt;I&gt;P=&lt;/I&gt;0.0003). Treatment failure rates were comparable between the two groups (OR: 1.39, 95% CI: 0.71–2.72; &lt;I&gt;P=&lt;/I&gt;0.3423). Despite this, the requirement for further surgery was significantly higher in the LARS group (OR: 1.79, 95% CI: 1.00–3.22; &lt;I&gt;P=&lt;/I&gt;0.05).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Peters MJ, Mukhtar A, Yunus RM, Khan S, Pappalardo J, Memon B, Memon MA. Meta-analysis of randomized clinical trials comparing open and laparoscopic anti-reflux surgery. Am J Gastroenterol. 2009 Jun;104(6):1548-61.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;See also:&lt;/STRONG&gt; &lt;A href="nelh:359668:0" name=internalLink&gt;DARE record&lt;/A&gt; for this article&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>330614</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1002/lt.21278]]&gt;</url>
    <title>Meta-analysis of risk for relapse to substance use after transplantation of the liver or other solid organs</title>
    <publicationDate>2008-02-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,ALCOHOLIC LIVER DISEASE,TRANSPLANTATION,RECENT ADDITIONS,NOVEMBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; In a given year, relapse to alcohol use will occur in 6% of transplant patients with histories of usage, and relapse to illicit drug abuse in 4%. Relapse to any alcohol use after liver transplantation&amp;nbsp;was twice as common as relapse to heavy alcohol use. Relapse&amp;nbsp;to alcohol use was significantly but modestly associated with poor social&amp;nbsp;support, family history of alcohol abuse or dependence, and pretransplantation abstinence lasting less than six months.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; For patients receiving liver or other organ transplants for diseases associated with substance use, risk for relapse posttransplantation is a prominent clinical concern. However, there is little consensus regarding either the prevalence or risk factors for relapse to alcohol or illicit drug use in these patients. Moreover, the evidence is inconsistent as to whether patients with pretransplantation substance use histories show poorer posttransplantation medical adherence. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We conducted a meta-analysis of studies published between 1983 and 2005 to estimate relapse rates, rates of nonadherence to the medical regimen, and the association of potential risk factors with these rates.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The analysis included 54 studies (50 liver, 3 kidney, and 1 heart). Average alcohol relapse rates (examined only in liver studies) were 5.6 cases per 100 patients per year (PPY) for relapse to any alcohol use and 2.5 cases per 100 PPY for relapse with heavy alcohol use. Illicit drug relapse averaged 3.7 cases per 100 PPY, with a significantly lower rate in liver vs. other recipients (1.9 vs. 6.1 cases). Average rates in other areas (tobacco use, immunosuppressant and clinic appointment nonadherence) were 2 to 10 cases per 100 PPY. Risk factors could be examined only for relapse to any alcohol use. Demographics and most pretransplantation characteristics showed little correlation with relapse. Poorer social support, family alcohol history, and pretransplantation abstinence of &amp;lt; or =6 months showed small but significant associations with relapse (r = 0.17-0.21). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Dew MA, DiMartini AF, Steel J, De Vito Dabbs A, Myaskovsky L, Unruh M, Greenhouse J. Meta-analysis of risk for relapse to substance use after transplantation of the liver or other solid organs.&amp;nbsp;&lt;EM&gt;Liver Transpl&lt;/EM&gt; 2008 Feb;14(2):159-72.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281249</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17200426]]&gt;</url>
    <title>Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease</title>
    <publicationDate>2008-03-10T00:00:00</publicationDate>
    <publisher>Harvey Whitney Books Co.</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;SPAN title="The Annals of pharmacotherapy."&gt;Masanaga, Y. &lt;A href="#javascript:AL_get(this," ?jour?, ?Ann Pharmacother.?);?&gt;Ann Pharmacother.&lt;/A&gt;&lt;/SPAN&gt; 2007 Jan;41(1):21-8. Epub 2007 Jan 2&lt;/P&gt; &lt;P class=abstract&gt;BACKGROUND: There is a concern as to whether long-term administration of immunosuppressants in patients with inflammatory bowel disease (IBD) would increase the risk of malignancy. OBJECTIVE: To compare the risks of developing malignancy between patients with IBD treated with immunosuppressive agents and patients with IBD not receiving these agents. METHODS: A systematic literature review was conducted, and a meta-analysis was performed on data retrieved from cohort studies that followed patients with IBD who received immunosuppressive agents for more than a year and documented the incidence of newly developed malignancy. An electronic search was conducted using MEDLINE (1966-September 2006), the Cochrane Library (issue 3, 2006), and Japana Centra Revuo Medicina (1981-September 2006). Medical subject headings used in the searches were azathioprine, 6-mercaptopurine, cyclosporine, methotrexate, tacrolimus, inflammatory bowel disease, and neoplasms. We imposed no language limitation in the searches. Additionally, a manual search of reference listings from all articles retrieved from the electronic databases was performed. Using data obtained from control groups or population-based studies, the incidence of newly developed malignancy in patients with IBD treated with immunosuppressive agents was compared with that of patients with IBD who were not receiving immunosuppressive agents. Statistical analysis for the change in risk of developing malignancy was performed using the weighted mean difference (WMD) normalized to per person-year and its 95% confidence interval. RESULTS: Nine cohort studies met the inclusion criteria for this meta-analysis. Analysis of these studies showed no discernible difference (WMD -0.3 x 10(-3)/person-year; 95% CI -1.2 x 10(-3) to 0.7 x 10(-3)) in the incidence of any kind of malignancy in patients with IBD who received immunosuppressants compared with those who did not receive immunosuppressants. No significant difference in WMD was observed when the data from patients with either Crohn's disease (CD) or ulcerative colitis (UC) were analyzed separately. CONCLUSIONS: Our findings suggest that the administration of immunosuppressive agents in patients with either CD or UC probably does not confer a significantly increased risk of malignancy compared with patients with IBD who are not receiving these agents.&lt;/P&gt; &lt;P class=abstract&gt;See also the &lt;A href="nelh:297298:0" name=internalLink&gt;DARE record&lt;/A&gt; for this article.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309199</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1053/j.gastro.2008.07.066]]&gt;</url>
    <title>Meta-analysis of the placebo rates of clinical relapse and severe endoscopic recurrence in postoperative Crohn's disease</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; There is significant heterogeneity among placebo rates in postoperative CD. No single design variable was identified that explained the heterogeneity in placebo outcomes for clinical or endoscopic recurrence.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We performed a meta-analysis of placebo-controlled, randomized clinical trials, evaluating therapies for postoperative maintenance of CD identified on MEDLINE from 1990 to 2006. Primary outcomes were clinical relapse and severe endoscopic recurrence.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The pooled estimate of the placebo relapse rate was 23.7% (95% confidence interval [CI], 13–35; range 0–78). There was a statistically significant heterogeneity among studies (&lt;I&gt;P&lt;/I&gt; &amp;lt; .0001). Heterogeneity in clinical relapse was present even if the trials were stratified according to the time of outcome. The pooled estimate of the severe endoscopic recurrence rate was 50.2% (95% CI, 28–73; range, 30–79). There was significant heterogeneity among the studies (&lt;I&gt;P&lt;/I&gt; = .00038). This heterogeneity was less apparent in studies carried out within 12 months. The logistic analysis identified only duration of follow-up as a variable associated with different placebo relapse rates. No variable was identified as a predictor of a placebo endoscopic recurrence rate.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Renna, S., Camma, C., Modesto, I., Cabibbo, G., Scimeca, D., Civitavecchia, G., Mocciaro, F., Orlando, A., Enea, M., &amp;amp; Cottone, M. (2008) Meta-analysis of the placebo rates of clinical relapse and severe endoscopic recurrence in postoperative Crohn's disease. &lt;I&gt;Gastroenterology&lt;/I&gt;, 135(5):1500-1509.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in November 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281300</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1007/s10620-007-9954-6]]&gt;</url>
    <title>Meta-analysis of the placebo response in ulcerative colitis</title>
    <publicationDate>2008-04-01T00:00:00</publicationDate>
    <publisher>Springer</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Placebo remission and response rates in RCTs of UC are highly variable and are significantly influenced by the country in which the RCT is performed. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We performed a meta-analysis of 110 RCTs carried out between 1955 and 2005 and published in English. Regression analysis was used to identify factors significantly modifying placebo response.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The pooled placebo remission rate was 23% (95%CI: 18.4–28%) and the pooled placebo improvement rate was 32.1% (95%CI: 28.1–36.3%). Multivariate analysis showed that the country where the study was performed (&lt;I&gt;P&lt;/I&gt;&amp;nbsp;=&amp;nbsp;0.025 for placebo remission and &lt;I&gt;P&lt;/I&gt;&amp;nbsp;=&amp;nbsp;0.0083 for placebo response rates) significantly influenced the placebo remission and response rates.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Garud, S., Brown, A., Cheifetz, A., Levitan, E. B., &amp;amp; Kelly, C. P. (2008) Meta-analysis of the placebo response in ulcerative colitis. &lt;I&gt;Digestive Diseases &amp;amp; Sciences&lt;/I&gt;, 53(4):875-891.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>251162</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1007/s00464-005-0114-9]]&gt;</url>
    <title>Metaanalysis of trials comparing laparoscopic and open surgery for Crohn's disease</title>
    <publicationDate>2005-12-01T00:00:00</publicationDate>
    <publisher>Springer</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Several studies in the literature have suggested that laparoscopic surgery for Crohn's disease is associated with faster postoperative recovery and a morbidity and recurrence rate similar to that for open surgery. Most of these studies have been limited by a small sample size and a short follow-up period.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Abstract:&lt;/STRONG&gt;&amp;nbsp;Rosman AS, Melis M and Fichera A 2005; Surgical Endoscopy 19 pp. 1549-1555&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Topic summary by Dr Stephen Grainger, Consultant Gastroenterologist, King George Hospital Essex: &lt;/STRONG&gt;A shorter scar, fewer days in hospital and a better body image seem attractive reasons for patients to ask their surgeon to perform their ileocaecal resection laparoscopically. Rosman et al (2005) and Tilney et al (2006) report in Surgical Endoscopy meta-analyses of open versus laparoscopic surgery for Crohn's Disease. The later paper confines itself to ileocaecal resections but in nearly 800 patients. The studies are not homogeneous but do include a randomised controlled trial and the meta-analysis seeks to maximise the validity of the comparisons of the two approaches.&lt;/P&gt;
&lt;P&gt;On average laparoscopic resection took 30 minutes longer but time to first liquid and solid diets and discharge from hospital were 1-3 days shorter. Posr-operative complications were no greater with laparoscopy and other authors have suggested fewer late complications such as adhesions and ventral hernias.&lt;/P&gt;
&lt;P&gt;The downside doesn't seem too great. On average 6.8% of operations had to be converted to open resections: large fixed masses; multiple fistulae and abscesses often being present in such patients. Smoking, per-op steroids, malnutrition and extra-colonic disease have been found by others to be associated with the need to abandon the laparoscopic approach.&amp;nbsp; Examining the whole intestine laparoscopically can be difficult, but with good pre-operative assessment it should now be possible to select suitable patients for laparoscopic resection and please the patient and the bed manager.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract: &lt;/STRONG&gt;BACKGROUND: Several studies in the literature have suggested that laparoscopic surgery for Crohn's disease is associated with faster postoperative recovery and a morbidity and recurrence rate similar to that for open surgery. Most of these studies have been limited by a small sample size and a short follow-up period. METHODS: To clarify whether open or laparoscopic resection results in a better outcome, a metaanalysis of studies was performed comparing the two procedures for Crohn's disease. Pooled effects were estimated using a random-effects model. RESULTS: Laparoscopic surgery required more operative time than open surgery (26.8 min; 95% confidence interval [CI], 6.4-47.2 min), but resulted in a shorter duration of ileus and a decreased hospital stay (-2.62 days; 95% CI, -3.62 to -1.62). Laparoscopic surgery also was associated with a decreased rate for postoperative bowel obstruction and surgical recurrences. CONCLUSIONS: Laparoscopic surgery for Crohn's disease is feasible, safe, and associated with shorter duration of ileus and a shorter hospital stay.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;See also: &lt;/STRONG&gt;&lt;A href="nelh:268855:0" name=internalLink&gt;DARE record&lt;/A&gt; for this article&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Full text available online to NHS Athens account holders&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>325164</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1053/j.gastro.2009.05.001]]&gt;</url>
    <title>Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location</title>
    <publicationDate>2009-09-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,STOMACH,CANCER,RECENT ADDITIONS,INFECTIONS,SEPTEMBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Epstein-Barr Virus (EBV)-positive gastric cancers greatly differ from other gastric carcinomas based on sex, anatomic subsite, and surgically disrupted anatomy, indicating that it is a distinct etiologic entity. Epidemiologic studies comparing EBV-positive and -negative gastric cancers are warranted to investigate EBV's role in gastric carcinogenesis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We conducted a meta-analysis of 70 studies including 15,952 cases of gastric cancer assessed by in situ hybridization for EBV-encoded small RNA.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The pooled prevalence estimate of EBV positivity was 8.7% (95% confidence interval [CI]: 7.5%–10.0%) overall, with a 2-fold difference by sex: 11.1% (95% CI: 8.7%–14.1%) of gastric cancer cases in males vs 5.2% (95% CI: 3.6%–7.4%) of cases in females. Tumors arising in the gastric cardia (13.6%) or corpus (13.1%) were more than twice as likely to be EBV-positive as those in the antrum (5.2%; &lt;I&gt;P&lt;/I&gt; &amp;lt; .01 for both comparisons). EBV prevalence was 4 times higher (35.1%) for tumors in postsurgical gastric stump/remnants. Over 90% of lymphoepithelioma-like carcinomas were EBV positive, but only 15 studies reported any cases of this type; prevalence did not significantly differ between the more common diffuse (7.6%) and intestinal (9.5%) histologies. EBV prevalence was similar in cases from Asia (8.3%), Europe (9.2%), and the Americas (9.9%).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Murphy G, Pfeiffer R, Camargo MC, Rabkin CS. Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location.&amp;nbsp;&lt;EM&gt;Gastroenterology&lt;/EM&gt; 2009;137(3):824-33.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281255</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17599035]]&gt;</url>
    <title>Meta-analysis technique confirms the effectiveness of anti-TNF-alpha in the management of active ulcerative colitis when administered in combination with corticosteroids</title>
    <publicationDate>2008-03-10T00:00:00</publicationDate>
    <publisher>Medical Science International</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;SPAN title="Medical science monitor : international medical journal of experimental and clinical research."&gt;Rahimi, R. &lt;A href="#javascript:AL_get(this," ?jour?, ?Med Sci Monit.?);?&gt;Med Sci Monit.&lt;/A&gt;&lt;/SPAN&gt; 2007 Jul;13(7):PI13-8.&lt;/P&gt; &lt;P class=abstract&gt;BACKGROUND: TNF-alpha has an important role in the pathogenesis of ulcerative colitis (UC). It therefore seems that infliximab, the antibody against TNF-alpha, is beneficial in the treatment of UC. The aim was to determine whether infliximab induces clinical response and remission in patients with UC using the meta-analysis technique. MATERIAL/METHODS: The Pubmed and Embase databases were searched for studies investigating the efficacy of infliximab on UC. Data from 1966 to 2006 were collected. The keywords used to search were "ulcerative colitis" with "infliximab", "anti tumor necrosis factor", or "anti tumor necrosis factors". The reference lists from the retrieved articles were also reviewed for additional applicable studies. RESULTS: The summary odds ratio (OR) for clinical remission in four studies was 3.24 with a 95%CI of 1.6-6.57 and a significant OR. The summary OR for clinical response in three studies was 3.93 with a 95%CI of 2.84-5.45 and a significant OR. CONCLUSIONS: Infliximab is effective in inducing response and remission in patients with ulcerative colitis when administered in combination with corticosteroids.&lt;/P&gt; &lt;P class=abstract&gt;See also the &lt;A href="nelh:295874:0" name=internalLink&gt;DARE record&lt;/A&gt; for this article.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>381381</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://virologyj.com/content/6/1/163]]&gt;</url>
    <title>Meta-analysis: adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus</title>
    <publicationDate>2009-10-09T00:00:00</publicationDate>
    <publisher>BioMed Central</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,RECENT ADDITIONS,CHRONIC HEPATITIS B,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The combination of adefovir dipivoxil (ADV) with lamivudine (LAM) was superior in inhibiting hepatitis B virus (HBV) replication and preventing drug resistance as compared to ADV alone for LAM-resistant chronic hepatitis B (CHB) patients.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Currently, there are no conclusive results on the efficacy of ADV plus LAM in LAM-resistant patients with CHB. The aim of study was to evaluate the efficacy of rescue therapy with ADV plus LAM compared to ADV monotherapy in LAM-resistant CHB patients.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We searched PUBMED, EMBASE, Web of Science, CNKI (National Knowledge Infrastructure), VIP database, the Cochrane Central Register of Controlled Trials and the Cochrane Database of Systematic Reviews.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Six eligible trials (442 patients in total) were included and evaluated for methodologic quality and heterogeneity. Greater virological response and lower emergence rate of ADV-associated mutants was observed in ADV plus LAM compared to ADV monotherapy (both P &amp;lt; 0.05). On the contrary, the rate of ALT normalization, HBeAg clearance and seroconversion were all similar between ADV plus LAM and ADV (all P &amp;gt; 0.05). Additionally, adding-on or switch-to ADV was both well tolerated.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Chen EQ, Wang LC, Lei J, Xu L, Tang H. Meta-analysis: adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus. &lt;EM&gt;Virol J&lt;/EM&gt; 2009;6:163.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>384927</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2010.04371.x]]&gt;</url>
    <title>Meta-analysis: antioxidant supplements for liver diseases - the Cochrane Hepato-Biliary Group</title>
    <publicationDate>2010-08-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS A,HEPATITIS B,HEPATITIS C,AUTOIMMUNE CHRONIC HEPATITIS,ALCOHOLIC LIVER DISEASE,RECENT ADDITIONS,CIRRHOSIS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; &lt;SPAN class=sub_abstract_label&gt;&lt;/SPAN&gt;&lt;SPAN&gt;We found no evidence to support or refute antioxidant supplements in patients with liver disease. Antioxidant supplements may increase liver enzymes.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; &lt;SPAN class=sub_abstract_label&gt;&lt;/SPAN&gt;&lt;SPAN&gt;Several liver diseases have been associated with oxidative stress. Accordingly, antioxidants have been suggested as potential therapeutics for various liver diseases. The evidence supporting these suggestions is equivocal. The aim of this study was t&lt;SPAN&gt;o assess the benefits and harms of antioxidant supplements for patients with liver diseases.&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; &lt;SPAN&gt;We identified trials through electronic and manual searches until August 2009. We included randomized trials comparing antioxidant supplements (beta-carotene, vitamin A, C, E and selenium) vs. placebo or no intervention for autoimmune liver diseases, viral hepatitis, alcoholic liver disease and cirrhosis (any aetiology). Random-effects and fixed-effect meta-analyses were conducted. Results were presented as relative risks (RR), or mean difference (MD), both with 95% confidence intervals (CI).&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;SPAN&gt;Twenty randomized trials with 1225 participants were included. The trials assessed beta-carotene (3 trials), vitamin A (2 trials), vitamin C (9 trials), vitamin E (15 trials) and selenium (8 trials). The majority of the trials had high risk of bias and showed heterogeneity. Overall, the assessed antioxidant supplements had no significant effect on all-cause mortality [relative risk (RR) 0.84, 95% confidence interval (CI) 0.60-1.19, I(2) = 0%] or liver-related mortality (RR 0.89, 95% CI 0.39-2.05, I(2) = 37%). Stratification according to the type of liver disease assessed did not affect the conclusions. Antioxidant supplements significantly increased the activity of gamma glutamyl transpeptidase (MD 24.21 IU/L, 95% CI 6.67-41.75, I(2) = 0%).&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Bjelakovic G, Gluud LL, Nikolova D, Bjelakovic M, Nagorni A, Gluud C. Meta-analysis: antioxidant supplements for liver diseases - the Cochrane Hepato-Biliary Group. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2010;32(3):356-67.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>268532</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2006.03041.x]]&gt;</url>
    <title>Meta-analysis: anti-viral therapy of hepatitis B virus-associated glomerulonephritis</title>
    <publicationDate>2006-09-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,KIDNEY DISEASES AND MALE UROGENITAL DISORDERS,GLOMERULONEPHRITIS,KIDNEY DISEASES,CHRONIC HEPATITIS B]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation&lt;/STRONG&gt;: Fabrizi F., Dixit V., and Martin P. 2006; Alimentary Pharmacology and Therapeutics 24 (5) pp. 781-8&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;Abstract: &lt;/STRONG&gt;BACKGROUND: Hepatitis B virus-associated glomerulonephritis is an infrequent complication of chronic hepatitis B virus (HBV) with significant morbidity. A causal association between hepatitis B virus infection and the development of glomerulonephritis remains controversial. Also, the optimal therapy is undefined although several approaches have been made. AIM: To evaluate the efficacy and safety of anti-viral therapy (interferon or lamivudine) in HBV-associated glomerulonephritis by a systematic review and meta-analysis of clinical trials. METHODS: The primary outcome was clinical response (as a measure of efficacy); the secondary outcomes were drop-out rate (as a measure of tolerability), and virological response. We used the random effects model of DerSimonian and Laird, with heterogeneity, sensitivity and meta-regression analyses. RESULTS: We identified six clinical trials (84 unique patients); three had controlled design. The overall estimate for proteinuria remission was 65.2% (95% confidence intervals: 52.7-75.9%), Q-test for heterogeneity = 7.731, P = 0.172, I(2) = 35.327. The overall estimate for hepatitis B e antigen clearance was 62.0% (95% confidence intervals: 50.5-72.2%). The overall estimate for drop-out rate was 12.7% (95% confidence intervals: 6.4-23.6%). Meta-regression analysis showed a significant link between hepatitis B e antigen clearance and logit rate of proteinuria remission after interferon therapy [coefficient -2.585 (S.E. 1.089), P = 0.017]. CONCLUSION: Remission of the nephrotic syndrome is accompanied by clearance of HBV replication, supporting the role of the virus in the pathogenesis of the disease.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;See also: &lt;/STRONG&gt;&lt;A href="nelh:267005:0" name=internalLink&gt;DARE record&lt;/A&gt; for this article&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>251156</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2005.02625.x]]&gt;</url>
    <title>Meta-analysis: capsule enteroscopy vs. conventional modalities in diagnosis of small bowel diseases</title>
    <publicationDate>2005-10-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE,DIAGNOSTIC PROCEDURES,GASTROINTESTINAL ENDOSCOPY,CAPSULE ENDOSCOPY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Prospective trials support the role of capsule enteroscopy as an improvement in diagnosing mucosal lesions in the small bowel. This article aimed to determine the diagnostic yield and safety of capsule enteroscopy vs. alternative diagnostic modalities (such as push enteroscopy, small bowel follow-through or enteroclysis) in patients with small bowel diseases.</description>
    <body>&lt;![CDATA[ &lt;STRONG&gt;Bibliographic details:&lt;/STRONG&gt; Marmo R,&amp;nbsp;Rotondano G, Piscopo R et al. 2005; Alimentary Pharmacology and Therapeutics 22 (7) pp. 595-604 
&lt;H2&gt;Original article abstract&lt;/H2&gt;
&lt;P&gt;BACKGROUND: Prospective trials support the role of capsule enteroscopy as an improvement in diagnosing mucosal lesions in the small bowel. AIM: To determine the diagnostic yield and safety of capsule enteroscopy vs. alternative diagnostic modalities (such as push enteroscopy, small bowel follow-through or enteroclysis) in patients with small bowel diseases. METHODS: A search for prospective studies comparing capsule enteroscopy vs. other diagnostic tests in adults was performed between 1966 and 2005. Selected articles were included in a meta-analysis. Three analyses were run separately, all included studies and studies having occult gastrointestinal bleeding or Crohn's disease as main outcome. RESULTS: Seventeen studies (526 patients) met inclusion criteria. The rate difference (i.e. the absolute pooled difference in the rate of positive findings) between capsule enteroscopy and alternative modalities for small bowel disease was 41% (95% CI 35.6-45.9); 37% (95% CI 29.6-44.1) for occult gastrointestinal bleeding; and 45% (95% CI 30.9-58.0) for Crohn's disease. Failure to visualize the caecum occurred in 13%, significantly more often in occult bleeders (17%) than in patients with Crohn's disease (8%) (P &amp;lt; 0.006). Adverse events were recorded in 29 patients (6%). Capsule retention was more frequent in patients with Crohn's disease (3% vs. 1%, OR 4.37). CONCLUSIONS: Capsule enteroscopy proved significantly superior to push enteroscopy and small bowel radiology in the diagnosis of ileal diseases. Capsule enteroscopy is safe, though prior radiology is still necessary to rule out small bowel strictures in patients with known or suspected Crohn's disease.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;See also: &lt;/STRONG&gt;&lt;A href="nelh:268865:0" name=internalLink&gt;DARE record&lt;/A&gt; for this article&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;This article is &lt;STRONG&gt;not&lt;/STRONG&gt; available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>326237</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2009.04069.x]]&gt;</url>
    <title>Meta-analysis: clinicopathological and prognostic significance of cyclooxygenase-2 expression on oesophageal squamous cell carinoma</title>
    <publicationDate>2009-09-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,OESOPHAGUS,CANCER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; &lt;SPAN class=h5-inline&gt;&lt;/SPAN&gt;Cyclooxygenase-2 (&lt;SPAN class=h5-inline&gt;&lt;/SPAN&gt;COX-2) might play an important role in the progress of oesophageal squamous cell carcinoma (ESCC).&amp;nbsp;Overexpression of COX-2 correlates with not only the depth of invasion and TNM stage but also reduced overall survival. COX-2 might be a potential therapy target for ESCC and work as a prognostic factor for ESCC patients, yet the clinicopathological and prognostic role of COX-2 in ESCC still needs further confirmation by well-designed prospective studies.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Studies assessing clinical or prognostic significance of COX-2 expression in ESCC published until December 2008 were selected. A meta-analysis was performed to clarify the impact of COX-2 expression on clinicopathological parameters or overall survival (OS) in ESCC.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;SPAN class=h5-inline&gt;&lt;/SPAN&gt;A total of 19 studies met the inclusion criteria, among which 17 studies were about the clinicopathological significance of COX-2 expression in ESCC, 12 studies were dealing with prognostic role of COX-2 expression in ESCC and 10 studies evaluated both of them. Overexpression of COX-2 was significantly correlated with not only the depth of invasion and TNM stage, with a combined odds ratio (OR) of 0.55 (95%CI: 0.34–0.90, &lt;SPAN class=i&gt;Z&lt;/SPAN&gt;&amp;nbsp;=&amp;nbsp;2.41, &lt;SPAN class=i&gt;P&lt;/SPAN&gt;&amp;nbsp;=&amp;nbsp;0.02) and 0.55 (95%CI: 0.32–0.95, &lt;SPAN class=i&gt;Z&lt;/SPAN&gt;&amp;nbsp;=&amp;nbsp;2.13, &lt;SPAN class=i&gt;P&lt;/SPAN&gt;&amp;nbsp;=&amp;nbsp;0.03) respectively but also the reduced OS with relative risk (RR) 1.42, 95% CI: 1.07–1.90, &lt;SPAN class=i&gt;Z&lt;/SPAN&gt;&amp;nbsp;=&amp;nbsp;2.43, &lt;SPAN class=i&gt;P&lt;/SPAN&gt;&amp;nbsp;=&amp;nbsp;0.02).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Li L, Zhao J, Wu Z, Wang G, Chen G. Meta-analysis: clinicopathological and prognostic significance of cyclooxygenase-2 expression on oesophageal squamous cell carcinoma. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2009;30(6):589-96.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>251140</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2006.02854.x]]&gt;</url>
    <title>Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease</title>
    <publicationDate>2006-04-15T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,COLON &amp; RECTUM,CANCER,SMALL INTESTINE,CROHN'S DISEASE,CANCER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Crohn's disease is associated with small bowel cancer whilst risk of colorectal cancer is less clear. This article aimed to ascertain the combined estimates of relative risk of these cancers in Crohn's disease.</description>
    <body>&lt;![CDATA[ &lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Canavan C, Abrams KR and Mayberry J 2006; Alimentary Pharmacology and Therapeutics 23 (8) pp. 1097-1104 
&lt;H2&gt;Original article abstract&lt;/H2&gt;
&lt;P&gt;BACKGROUND: Crohn's disease is associated with small bowel cancer whilst risk of colorectal cancer is less clear. AIM: To ascertain the combined estimates of relative risk of these cancers in Crohn's disease. METHODS: MEDLINE was searched to identify relevant papers. Exploding references identified additional publications. When two papers reviewed the same cohort, the later study was used. RESULTS: Meta-analysis showed overall colorectal cancer relative risk in Crohn's disease as 2.5 (1.3-4.7), 4.5 (1.3-14.9) for patients with colonic disease and 1.1 (0.8-1.5) in ileal disease. Meta-regression showed reduction in relative risk over the past 30 years. Subgroup analysis showed Scandinavia had significantly lower colorectal cancer relative risk than the UK and North America. Cumulative risk analysis showed 10 years following diagnosis of Crohn's disease relative risk of colorectal cancer is 2.9% (1.5%-5.3%). Meta-analysis showed small bowel cancer relative risk in Crohn's disease is 33.2 (15.9-60.9). Small bowel cancer relative risk has not significantly reduced over the last 30 years. CONCLUSION: Relative risk of colorectal and small bowel cancers are significantly raised in Crohn's disease. Cumulative risk of colorectal cancer of 2.9% at 10 years suggests a potential benefit from routine screening. However, the value of screening requires rigorous appraisal.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;This article is &lt;STRONG&gt;not&lt;/STRONG&gt; available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>385107</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2009.04110.x]]&gt;</url>
    <title>Meta-analysis: deamidated gliadin peptide antibody and tissue transglutaminase antibody compared as screening tests for coeliac disease</title>
    <publicationDate>2010-01-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,SMALL INTESTINE,COELIAC DISEASE,DIAGNOSTIC PROCEDURES,DISEASE PREVENTION,BLOOD TESTS,SCREENING,RECENT ADDITIONS,SEROLOGIC TESTS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; &lt;SPAN class=sub_abstract_label&gt;&lt;/SPAN&gt;&lt;SPAN&gt;Although both tests perform well, the tissue transglutaminase antibody test outperforms the deamidated gliadin peptides antibody test and remains the preferred serological test for the diagnosis and/or exclusion of coeliac disease.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims: &lt;/STRONG&gt;&lt;SPAN&gt;Following the appreciation of the importance of gliadin deamidation in the immunopathogenesis of coeliac disease, diagnostic tests based on antibodies to deamidated gliadin peptides have been developed and shown to have high sensitivity and specificity.&lt;/SPAN&gt; The aim of this study was to &lt;SPAN&gt;compare the performance of the deamidated gliadin peptides antibody test with the current standard, the tissue transglutaminase antibody test, through a meta-analysis of published studies.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; &lt;SPAN&gt;Databases from 1998 to 2008 were searched for relevant studies. These were assessed for methodological quality and standard statistical tests were applied to compare particularly the sensitivity and specificity of the two tests for the diagnosis of coeliac disease.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;SPAN&gt;Most studies had methodological flaws, especially ascertainment bias. The pooled sensitivities for the deamidated gliadin peptides antibody and tissue transglutaminase antibody tests were 87.8% (95% CI, 85.6-89.9) and 93.0% (95% CI, 91.2-94.5) respectively and the pooled specificities were 94.1% (95% CI, 92.5-95.5) and 96.5% (95% CI, 95.2-97.5) respectively.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Lewis NR, Scott BB. Meta-analysis: deamidated gliadin peptide antibody and tissue transglutaminase antibody compared as screening tests for coeliac disease. Aliment Pharmacol Ther 2010;31(1):73-81.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>388004</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2010.04409.x]]&gt;</url>
    <title>Meta-analysis: do irritable bowel syndrome symptoms vary between men and women?</title>
    <publicationDate>2010-09-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,IRRITABLE BOWEL SYNDROME,RECENT ADDITIONS,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion: &lt;SPAN class=sub_abstract_label&gt;&lt;/SPAN&gt;&lt;/STRONG&gt;&lt;SPAN&gt;In the general and irritable bowel syndrome (IBS) populations, gender differences in IBS symptoms exist, although these differences are modest. Studies suggest that female sex hormones influence the severity of IBS symptoms, but more studies are needed.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; &lt;SPAN&gt;Studies suggest that sex and gender-related differences exist in irritable bowel syndrome (IBS), but data is often conflicting.&lt;/SPAN&gt; The aim of this study was t&lt;SPAN&gt;o evaluate gender differences and the effect of menstrual cycle and menopausal status on IBS symptoms.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; &lt;SPAN&gt;We performed a systematic review of MEDLINE to search for studies comparing IBS symptoms between gender, menstrual cycle phases and menopausal states in IBS and/or healthy individuals. We performed meta-analyses to compare the relative risk (RR) of individual IBS symptoms between men and women.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;SPAN&gt;Twenty-two studies measured gender differences in IBS symptoms. Women were more likely to report abdominal pain (RR = 1.12, 95% CI: 1.02, 1.22) and constipation-related symptoms (RR = 1.12, 95% CI: 1.02, 1.23) than men (all P &amp;lt; 0.05). However, men with IBS were more likely to report diarrhoea-related symptoms than women with IBS (RR = 0.84, 95% CI: 0.75, 0.94, P &amp;lt; 0.05). A systematic review of 13 studies demonstrated that both IBS and healthy women reported increased IBS symptoms during menses vs. other phases. There were insufficient data to determine the effect of menopause and hormone supplementation on IBS symptoms.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Adeyemo MA, Spiegel BM, Chang L. Meta-analysis: do irritable bowel syndrome symptoms vary between men and women? &lt;EM&gt;Aliment Pharmacol Ther &lt;/EM&gt;2010;32(6):738-55.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281298</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17767463]]&gt;</url>
    <title>Meta-analysis: enteral nutrition in active Crohn's disease in children</title>
    <publicationDate>2008-03-10T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE,ENTERAL,THERAPEUTIC NUTRITION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic information:&lt;/STRONG&gt; &lt;/P&gt; &lt;P&gt;Dziechciarz, P. &lt;SPAN title="Alimentary pharmacology &amp;amp; therapeutics."&gt;&lt;A href="#javascript:AL_get(this," ?jour?, ?Aliment Pharmacol Ther.?);?&gt;Aliment Pharmacol Ther.&lt;/A&gt;&lt;/SPAN&gt; 2007 Sep 15;26(6):795-806&lt;/P&gt; &lt;P class=abstract&gt;BACKGROUND: Controversy exists surrounding the optimal treatment for inducing remission in active Crohn's disease. AIM: To review and update evidence on the effectiveness of enteral nutrition (EN) in treating active Crohn's disease in children. METHODS: MEDLINE, EMBASE and The Cochrane Library (up to February 2007) were searched for randomized controlled trials (RCTs) relevant to Crohn's disease and EN in children. RESULTS: We included 11 RCTs (n = 394). Seven RCTs (n = 204) compared EN with corticosteroid therapy. On the basis of pooled results of four RCTs (n = 144), we found no significant difference in the remission rates between groups (relative risk, RR 0.97, 95% CI 0.7-1.4, random effect model). Four RCTs (n = 190) compared two EN regimens. One of the four RCTs (n = 50) revealed a significant increase in the percentage of patients achieving remission in the total EN group compared with the partial EN group (RR 2.7, 95% CI 1-7.4). Because of lack of data, formal pooling of results was not possible for many outcomes (e.g., time until remission, duration of remission, growth data). CONCLUSIONS: Limited data suggest similar efficacy for EN and corticosteroids. As the number of patients needed to provide a definite answer is too large, future studies should focus on detailed outcome measurements including growth and quality of life.&lt;/P&gt; &lt;P class=abstract&gt;See also the &lt;A href="nelh:297329:0" name=internalLink&gt;DARE record&lt;/A&gt; for this article.&lt;/P&gt; &lt;P&gt;&lt;EM&gt;Alimentary Pharmacology and Therapeutics is an international journal concerned with the effects of drugs on the human gastrointestinal and hepato-biliary systems. The journal publishes original research on all aspects of pharmacology, pharmacokinetics and therapeutic use of drugs in the alimentary tract.&lt;/EM&gt;&lt;/P&gt; &lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is &lt;STRONG&gt;not&lt;/STRONG&gt; available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>384672</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2010.04328.x]]&gt;</url>
    <title>Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome</title>
    <publicationDate>2010-07-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,IRRITABLE BOWEL SYNDROME,RECENT ADDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; &lt;SPAN&gt;Placebo response rates across &lt;SPAN&gt;randomised controlled trials&lt;/SPAN&gt; (RCTs) of pharmacological therapies in i&lt;SPAN&gt;rritable bowel syndrome (&lt;/SPAN&gt;IBS) were high. Future research should identify patient characteristics predicting placebo response.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; &lt;SPAN&gt;IBS is a functional disorder of the gastrointestinal tract with a significant placebo response. The aim of this study was to &lt;SPAN&gt;conduct a systematic review and meta-analysis examining the magnitude of placebo response rate in treatment trials for IBS.&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; &lt;SPAN&gt;MEDLINE, EMBASE and the Cochrane central register of controlled trials were searched to identify RCTs comparing pharmacological therapies with placebo in adult IBS patients. Studies reported either global assessment of IBS symptom cure or improvement or abdominal pain cure or improvement. Data were extracted as intention-to-treat analyses with drop-outs assumed to be treatment failures and pooled using a random-effects model. Proportion of placebo patients experiencing symptom improvement or resolution was reported with a 95% confidence interval (CI). Effect of trial characteristics on magnitude of placebo response was examined.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;SPAN&gt;In all, 73 RCTs were eligible, including 8364 patients with IBS allocated to placebo. Pooled placebo response rate across all RCTs was 37.5% (95% CI 34.4-40.6%). Rates were higher in European RCTs, RCTs that used physician-reported outcomes and RCTs using shorter duration of therapy.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Ford AC, Moayyedi P. Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2010;32(2):144-58.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309196</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2008.03774.x]]&gt;</url>
    <title>Meta-analysis: factors predicting post-operative recurrence with placebo therapy in patients with Crohn's disease</title>
    <publicationDate>2008-09-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Placebo rates in PC-RCTs evaluating post-operative clinical and endoscopic recurrence demonstrate significant variability, which is influenced by specific study characteristics.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We performed a systematic review and meta-analysis of PC-RCTs evaluating post-operative maintenance therapies for CD identified from MEDLINE from 1966 to 2005.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Twelve studies met our inclusion criteria. The pooled placebo rate of maintaining clinical remission was 56% (95% CI 47–64%; range 34–89%) during a median follow-up of 52&amp;nbsp;weeks (range 12–156&amp;nbsp;weeks), but significant heterogeneity existed among the studies (&lt;SPAN class=i&gt;P&amp;nbsp;&lt;/SPAN&gt;&amp;lt;&amp;nbsp;0.001). Prior steroid therapy was the only factor found to be associated with maintaining remission (&lt;SPAN class=i&gt;P&amp;nbsp;&lt;/SPAN&gt;=&amp;nbsp;0.04). The pooled placebo endoscopic recurrence rate was 58% (95% CI 51–65%; range 36–80%) during a median follow-up of 52&amp;nbsp;weeks (range 12–156&amp;nbsp;weeks), with significant heterogeneity noted (&lt;SPAN class=i&gt;P&amp;nbsp;&lt;/SPAN&gt;=&amp;nbsp;0.0003). Prior surgery, concomitant small bowel and colonic disease, fistulizing phenotype, or prior immunomodulator therapy influenced endoscopic recurrence (&lt;SPAN class=i&gt;P&amp;nbsp;&lt;/SPAN&gt;&amp;lt;&amp;nbsp;0.05).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Pascua, M., Su, C., Lewis, J. D., Brensinger, C., &amp;amp; Lichtenstein, G. R. (2008) Meta-analysis: factors predicting post-operative recurrence with placebo therapy in patients with Crohn's disease. &lt;I&gt;Alimentary Pharmacology &amp;amp; Therapeutics&lt;/I&gt;, 28(5):545-556.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>385098</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2010.04238.x]]&gt;</url>
    <title>Meta-analysis: folic acid in the chemoprevention of colorectal adenomas and colorectal cancer</title>
    <publicationDate>2010-04-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,DISEASE PREVENTION,POLYPS,CANCER,RECENT ADDITIONS,NON-MALIGNANT NEOPLASMS,COLON CANCER,RECTAL CANCER,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; &lt;SPAN&gt;There is no evidence that folic acid is effective in the chemoprevention of colorectal adenomas or colorectal cancer for any population.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; &lt;SPAN&gt;Folic acid has been identified as a possible agent for the chemoprevention of colorectal cancer.&lt;/SPAN&gt; The aim of this study was t&lt;SPAN&gt;o assess the effectiveness of folic acid in reducing the recurrence of adenomas (precursors of colorectal cancer) among populations with a history of adenomas and the incidence of colorectal cancer within average-risk populations.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; &lt;SPAN&gt;Systematic review of randomized controlled trials comparing folic acid alone, or with other agents, vs. placebo. Eight databases were searched for relevant trials. Meta-analysis was performed.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;SPAN&gt;&lt;/SPAN&gt;Results:&lt;/STRONG&gt; &lt;SPAN&gt;The literature search retrieved 3785 citations. Six studies met the inclusion criteria. Meta-analysis of three studies in individuals with a history of adenomas showed no statistically significant difference in the relative risk of adenoma recurrence (RR 0.93, P = 0.27). A sensitivity analysis of the two higher quality trials changed the direction of effect (RR 1.16, P = 0.11). Meta-analysis of three trials in general populations demonstrated no statistically significant effect on the relative risk of colorectal cancer (RR 1.13, P = 0.54). In all three analyses, outcome event rates were higher in individuals receiving folic acid.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Carroll C, Cooper K, Papaioannou D, Hind D, Tappenden P, Pilgrim H, Booth A. Meta-analysis: folic acid in the chemoprevention of colorectal adenomas and colorectal cancer. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2010;31(7):708-18.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>380699</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1086/644771]]&gt;</url>
    <title>Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression</title>
    <publicationDate>2009-11-15T00:00:00</publicationDate>
    <publisher>The University of Chicago Press</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,HIV / AIDS,RECENT ADDITIONS,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Hepatitis C virus&amp;nbsp;(HCV)&amp;nbsp;coinfection did not increase mortality among patients with&amp;nbsp;human immunodeficiency virus (HIV)&amp;nbsp;infection before the introduction of highly active antiretroviral therapy (HAART). In contrast, in the HAART era, HCV coinfection, compared with HIV infection alone, increases the risk of mortality, but not the risk of AIDS-defining events. Future studies should determine whether successful treatment of HCV infection could reduce this excess risk of mortality in coinfected patients.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; It is unclear whether coinfection with HCV increases mortality in patients with HIV infection during the era of HAART. With use of a meta-analysis, we estimated the effect of HCV infection on HIV disease progression and overall mortality in the pre-HAART and HAART eras.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; The PubMed and EMBASE databases were searched for studies published through 30 April 2008. Additional studies were identified from cited references. Studies reporting disease progression or mortality among HCV-HIV coinfected patients were selected. Cross-sectional studies, studies without HCV-negative control subjects, and studies involving children and/or patients who had undergone liver transplantation were excluded. Two authors reviewed articles and extracted data on the demographic characteristics of study populations and risk estimates. Meta-regression was used to explore heterogeneity.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Ten studies from the pre-HAART era and 27 studies from the HAART era were selected. In the pre-HAART era, the risk ratio for overall mortality among patients with HCV-HIV coinfection, compared with that among patients with HIV infection alone, was 0.68 (95% confidence interval [CI], 0.53-0.87). In the HAART era, the risk ratio was 1.12 (95% CI, 0.82-1.51) for AIDS-defining events and 1.35 (95% CI, 1.11-1.63) for overall mortality among coinfected patients, compared with that among patients with HIV monoinfection.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Chen TY, Ding EL, Seage Iii GR, Kim AY. Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. &lt;EM&gt;Clin Infect Dis&lt;/EM&gt; 2009;49(10):1605-15.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>388866</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2036.2010.04467.x/abstract]]&gt;</url>
    <title>Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis</title>
    <publicationDate>2010-09-23T00:00:00</publicationDate>
    <publisher>Alimentary Pharmacology and Therapeutics</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,STEATOHEPATITIS,NON-ALCOHOLIC,RECENT ADDITIONS,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Rakoski MO, Singal AG, Rogers AM, Conjeevaram H. (2010) Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis. &lt;EM&gt;Alimentary Pharmacology and Therapeutics&lt;/EM&gt; 23rd September early view&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Alimentary pharmacology and therapeutics&lt;/EM&gt; is an international journal concerned with the effects of drugs on the human gastrointestinal and hepato-biliary systems. The journal publishes original research on all aspects of pharmacology, pharmacokinetics and therapeutic use of drugs in the alimentary tract.&lt;STRONG&gt;Background: &lt;/STRONG&gt;Non-alcoholic fatty liver disease generally has a benign course; however, patients with non-alcoholic steatohepatitis (NASH) may progress to cirrhosis and hepatocellular carcinoma. Currently, there is a lack of consensus about optimal NASH treatment.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aim:&lt;/STRONG&gt; To assess the efficacy of insulin-sensitizing agents on histological and biochemical outcomes in randomized control trials of biopsy-proven NASH.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Multiple online databases and conference abstracts were searched. Random effects meta-analyses were performed, with assessment for heterogeneity and publication bias.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Nine trials were included; five trials using thiazolidinediones (glitazones), three using metformin and one trial using both drugs. There was no publication bias. Compared with controls, glitazones resulted in improved steatosis (WMD = 0.57, 95% CI 0.36–0.77, P = &amp;lt;0.001), hepatocyte ballooning (WMD = 0.36, 95% CI 0.24–0.49, P &amp;lt; 0.001) and ALT (WMD = 16.4, 95% CI 7.7–25.0, P &amp;lt; 0.001), but not inflammation (P = 0.09) or fibrosis (P = 0.11). In patients without diabetes, glitazones significantly improved all histological and biochemical outcomes, most importantly including fibrosis (WMD = 0.29, 95% CI 0.078–0.51, P = 0.008). Metformin failed to improve any pooled outcome.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; Treatment of NASH with glitazones, but not metformin, demonstrates a significant histological and biochemical benefit, especially in patients without diabetes. Additional studies are needed to investigate long-term outcomes of glitazone therapy in patients without diabetes.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is &lt;STRONG&gt;not&lt;/STRONG&gt; available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>387732</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2010.04414.x]]&gt;</url>
    <title>Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma</title>
    <publicationDate>2010-10-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,NON-ALCOHOLIC,HEPATOCELLULAR CARCINOMA,RECENT ADDITIONS,CANCER,CIRRHOSIS,CHRONIC HEPATITIS C,SURGERY,LIVER RESECTION,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion: &lt;/STRONG&gt;Interferon treatment after curative resection or ablation of hepatocellular carcinoma (HCC) in hepatitis C virus (HCV)-related cirrhotics prevents HCC recurrence and improves survival.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; HCC is third most common cause of tumour-related death in the US with HCV the most common aetiology. Surgical resection and tumour ablation are curative in patients who cannot be transplanted. With native liver having cirrhosis, HCC recurrence is a potential problem. The aim of this study was to perform a systematic review and meta-analysis of studies evaluating efficacy of IFN to prevent HCC recurrence after its curative treatment in HCV-related cirrhosis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Ten studies (&lt;EM&gt;n&lt;/EM&gt;&amp;nbsp;=&amp;nbsp;645, 301 treated with IFN) on the use of IFN after resection or ablation of HCV-associated HCC were analysed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Pooled data showed benefit of IFN for HCC prevention with OR (95% CI) of 0.26 (0.15–0.45); &lt;EM&gt;P&lt;/EM&gt;&amp;nbsp;&amp;lt;&amp;nbsp;0.00001. The proportion of patients surviving at 5&amp;nbsp;years (&lt;EM&gt;n&lt;/EM&gt;&amp;nbsp;=&amp;nbsp;505 in 6 studies) was in favour of IFN with OR of 0.31 [(95% CI 0.21–0.46); &lt;EM&gt;P&lt;/EM&gt;&amp;nbsp;&amp;lt;&amp;nbsp;0.00001]. Data were homogeneous for HCC recurrence (?&lt;SUP&gt;2&lt;/SUP&gt; 12.05, &lt;EM&gt;P&lt;/EM&gt;&amp;nbsp;=&amp;nbsp;0.21) and survival (?&lt;SUP&gt;2&lt;/SUP&gt; 6.93, &lt;EM&gt;P&lt;/EM&gt;&amp;nbsp;=&amp;nbsp;0.44). The benefit of IFN was stronger with sustained virological response compared with nonresponders for HCC recurrence [0.19 (0.06–0.60); &lt;EM&gt;P&lt;/EM&gt;&amp;nbsp;=&amp;nbsp;0.005] and survival [0.31 (0.11–0.90); &lt;EM&gt;P&lt;/EM&gt;&amp;nbsp;=&amp;nbsp;0.03].&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Singal AK, Freeman DH Jr, Anand BS. Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther 2010;32(7):851-8.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>387980</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2010.04418.x]]&gt;</url>
    <title>Meta-analysis: isosorbide-mononitrate alone or with either beta-blockers or endoscopic therapy for the management of oesophageal varices</title>
    <publicationDate>2010-10-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,OESOPHAGUS,OESOPHAGEAL VARICES,DIAGNOSTIC PROCEDURES,GASTROINTESTINAL ENDOSCOPY,RECENT ADDITIONS,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; &lt;SPAN class=sub_abstract_label&gt;&lt;/SPAN&gt;&lt;SPAN&gt;Isosorbide-mononitrate used alone or in combination with beta blockers does not seem to offer any reduction in bleeding in the primary or secondary prevention of oesophageal varices. Compared with endoscopic therapy, there may be a survival advantage in using &lt;SPAN&gt;isosorbide-mononitrate&lt;/SPAN&gt; (IsMn) and beta-blockers, but additional large multicentre trials are needed to verify this finding.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; &lt;SPAN&gt;The evidence concerning the use of IsMn for oesophageal varices is equivocal. The aim of this study was to &lt;SPAN&gt;assess the effects of IsMn for patients with oesophageal varices and no previous bleeding (primary prevention) or previous variceal bleeding (secondary prevention).&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; &lt;SPAN class=sub_abstract_label&gt;&lt;/SPAN&gt;&lt;SPAN&gt;Systematic review with meta-analyses of randomized trials on IsMn alone or with beta-blockers or endoscopic therapy for oesophageal varices. Electronic and manual searches were combined. Randomized trials on primary and secondary prevention were included. The primary outcome measure was mortality. Intention-to-treat random effects meta-analyses were performed. The robustness of the results was assessed in trial sequential analyses.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt;&lt;SPAN class=sub_abstract_label&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;SPAN&gt;Ten randomized trials on primary and 17 on secondary prevention were included. Evidence of bias was identified. No apparent effect of IsMn on mortality compared with placebo or beta-blockers or IsMn plus beta-blockers vs. beta-blockers was identified. Compared with endoscopic therapy, IsMn plus beta-blockers had no apparent effect on bleeding, but did seem to reduce mortality in secondary prevention (RR 0.73, 95% CI 0.59-0.89), but not in primary prevention. The effect of IsMn plus beta-blockers on mortality in secondary prevention was not confirmed in trial sequential analysis.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Gluud LL, Langholz E, Krag A. Meta-analysis: isosorbide-mononitrate alone or with either beta-blockers or endoscopic therapy for the management of oesophageal varices. &lt;EM&gt;Aliment Pharmacol Ther &lt;/EM&gt;2010;32(7):859-71.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>388002</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2010.04410.x]]&gt;</url>
    <title>Meta-analysis: levamisole improves the immune response to hepatitis B vaccine in dialysis patients</title>
    <publicationDate>2010-09-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,DISEASE PREVENTION,VACCINATION,RECENT ADDITIONS,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; &lt;SPAN&gt;Our meta-analysis showed that levamisole significantly improves immune response to hepatitis B vaccine in dialysis population. The limited number of patients precluded more conclusions.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt;&amp;nbsp;&lt;SPAN&gt;Patients undergoing maintenance dialysis often fail to mount protective antibodies to hepatitis B virus surface antigen (HBsAg) following vaccination against hepatitis B virus (HBV). Some authors have suggested that levamisole improves immune response to HBV vaccine in dialysis population. However, consistent information on this issue does not exist. The aim of this study was t&lt;SPAN&gt;o evaluate efficacy and safety of levamisole as adjuvant to hepatitis B virus (HBV) vaccine in dialysis patients by performing a systematic review of the literature with a meta-analysis of clinical trials.&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN&gt;&lt;SPAN&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; &lt;SPAN&gt;We used the random-effects model of DerSimonian and Laird, with heterogeneity and sensitivity analyses. Only trials comparing the seroresponse rate in study subjects (levamisole plus HBV vaccine) vs. controls (HBV vaccine alone) were included. The end point of interest was the rate of patients showing seroprotective anti-hepatitis B titres at completion of HBV vaccine schedule in study vs. control groups.&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt;&amp;nbsp;&lt;SPAN&gt;We identified four studies involving 328 unique patients on regular dialysis. Only prospective, randomized clinical trials (RCTs) were included. Pooling of study results showed a significant increase in response rates among study (levamisole plus HBV vaccine) vs. control (HBV vaccine alone) patients; the pooled Odds Ratio was 2.432 (95% Confidence Intervals, 1.34; 4.403), P = 0.002. No study heterogeneity was found. These results did not change in various subgroups of interest.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Fabrizi F, Dixit V, Messa P, Martin P. Meta-analysis: levamisole improves the immune response to hepatitis B vaccine in dialysis patients. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2010;32(6):756-62.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>326241</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2009.04022.x]]&gt;</url>
    <title>Meta-analysis: longitudinal studies of serum vitamin D and colorectal cancer risk</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,CANCER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The results&amp;nbsp;of the meta-analysis support suggestions that serum 25 hydroxyvitamin D (25(OH)D) is inversely related to colorectal cancer (CRC) risk.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; &lt;SPAN class=h5-inline&gt;&lt;/SPAN&gt;Relevant studies published until September 2008 were identified by systematically searching Ovid Medline, EMBASE, and ISI Web of Knowledge databases and by cross-referencing. Due to the heterogeneity of studies in categorizing serum vitamin D levels, all results were recalculated for an increase of serum 25(OH)D by 20&amp;nbsp;ng/mL. Summary odds ratios (ORs) were calculated using meta-analysis methods.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Overall, eight original articles reporting on the association between serum 25(OH) D and CRC risk were included. In meta-analyses, summary ORs (95% confidence intervals) for the incidence of CRC, colon cancer and rectal cancer associated with an increase of 25(OH)D by 20&amp;nbsp;ng/mL were 0.57 (0.43–0.76), 0.78 (0.54–1.13) and 0.41 (0.11–1.49). No indication for publication bias was found.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H. Meta-analysis: longitudinal studies of serum vitamin D and colorectal cancer risk.&amp;nbsp;&lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2009 Jul 1;30(2):113-25.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281292</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17402989]]&gt;</url>
    <title>Meta-analysis: mortality in Crohn's disease</title>
    <publicationDate>2008-03-10T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic information:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;Canavan, C.&amp;nbsp; &lt;SPAN title="Alimentary pharmacology &amp;amp; therapeutics."&gt;&lt;A href="#javascript:AL_get(this," ?jour?, ?Aliment Pharmacol Ther.?);?&gt;Aliment Pharmacol Ther.&lt;/A&gt;&lt;/SPAN&gt; 2007 Apr 15;25(8):861-70&lt;/P&gt;
&lt;P class=abstract&gt;AIM: To perform a meta-analysis is of published literature reporting standardized mortality ratios (SMR) for Crohn's patients from 1970 to date. METHODS: Medline search identified relevant papers. Exploding references identified additional papers. When two papers reviewed mortality of one patient group at different times, the later publication was used. RESULTS: Of 13 papers identified, three studies reported SMR below 1.0, two others had confidence intervals including 1.0. All other studies reported mortality higher than the general population. Meta-analysis using a random effects model shows the pooled estimate for SMR in Crohn's disease is 1.52 (95% CI: 1.32 to 1.74 [P &amp;lt; 0.0001]). Meta-regression shows the SMR for these patients has decreased slightly over the past 30 years, but this decrease is not statistically significant (P = 0.08). CONCLUSION: Assessing evidence from original studies and conducting a meta-analysis shows age-adjusted mortality risk from Crohn's disease is over 50% greater than the general population. Whilst mortality has improved since the condition was first recognized, further evaluation of the patients studied in the cohorts included here is necessary to assess more recent changes in clinical practice.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Alimentary Pharmacology and Therapeutics is an international journal concerned with the effects of drugs on the human gastrointestinal and hepato-biliary systems. The journal publishes original research on all aspects of pharmacology, pharmacokinetics and therapeutic use of drugs in the alimentary tract.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is &lt;STRONG&gt;not&lt;/STRONG&gt; available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>316441</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2009.03991.x]]&gt;</url>
    <title>Meta-analysis: octreotide prevents post-ERCP pancreatitis, but only at sufficient doses</title>
    <publicationDate>2009-03-03T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,PANCREAS,ACUTE PANCREATITIS,GASTROINTESTINAL ENDOSCOPY,ERCP,DIAGNOSTIC PROCEDURES,RECENT ADDITIONS,PANCREATITIS,JUNE 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion: &lt;/STRONG&gt;The aim of the review was to examine effects of octreotide at different doses on post-ERCP pancreatitis. It found that&amp;nbsp;it is effective in preventing PEP, but only at sufficient doses (=0.5&amp;nbsp;mg).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A comprehensive search of relevant databases, including MEDLINE, EMBASE, the Cochrane Controlled Trials Register, the Cochrane Library and Science Citation Index yielded 18 randomized controlled trials (RCTs). Trials were divided into two groups according to the total dosage of octreotide: &amp;lt;0.5&amp;nbsp;mg (OCT1), =0.5&amp;nbsp;mg (OCT2). The rate of PEP was analysed using a fixed effect model.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; At doses of =0.5&amp;nbsp;mg, octreotide reduced the rate of PEP. In the OCT2 group, analysis revealed a statistically significant difference on PEP between the octreotide group and the controls (3.4% vs. 7.5%, pooled OR&amp;nbsp;=&amp;nbsp;0.45; 95% CI: 0.28–0.73; &lt;SPAN class=i&gt;P&lt;/SPAN&gt;&amp;nbsp;=&amp;nbsp;0.001, NNT&amp;nbsp;=&amp;nbsp;25). In the OCT1 group, the rate of PEP was similar between patients receiving octreotide and the controls (7.2% vs. 6.0%, pooled OR&amp;nbsp;=&amp;nbsp;1.23; 95% CI: 0.80–1.91; &lt;SPAN class=i&gt;P&lt;/SPAN&gt;&amp;nbsp;=&amp;nbsp;0.35).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Zhang Y, Chen QB, Gao ZY, Xie WF. Meta-analysis: octreotide prevents post-ERCP pancreatitis, but only at sufficient doses. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2009 Jun 1;29(11):1155-64.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>384674</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2010.04340.x]]&gt;</url>
    <title>Meta-analysis: polymorphisms in TNF-alpha gene promoter and Crohn's disease</title>
    <publicationDate>2010-07-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE,RECENT ADDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; &lt;SPAN&gt;Tumour necrosis factor alpha &lt;/SPAN&gt;(&lt;SPAN&gt;TNF-alpha) polymorphisms in the promoter region might be used as a biomarker for Crohn's disease (CD) risk prediction. Larger studies with mixed ethnicity subjects and stratified by clinical and sub clinical characteristics are needed to validate our findings.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; &lt;SPAN&gt;TNF-alpha is involved in the pathogenesis of CD. However, results on the association between the polymorphisms in TNF-alpha promoter and the risk of CD are inconsistent.&amp;nbsp;The aim of this study was to &lt;SPAN&gt;perform a quantitative synthesis for the genetic polymorphisms in TNF-alpha promoter and CD risk.&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; &lt;SPAN&gt;Databases were searched (up to 2009) and 31 studies were included. Risks of CD associated with the polymorphisms in TNF-alpha promoter were assessed.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results: &lt;/STRONG&gt;&lt;SPAN&gt;Overall, individuals with -1031 TC+CC genotype had a slightly increased risk to develop CD compared with individuals with -1031 TT genotype (OR, 1.32; 95% CI, 1.03-1.70). In the further stratified analysis, we found Asians with the -1031T&amp;gt;C, -863 C&amp;gt;A and -857 C&amp;gt;T variant polymorphisms have almost one and a half CD risk compared with other genotypes (OR, 1.58; 95% CI, 1.16-2.15; OR, 1.55; 95% CI, 1.18-2.02; OR, 1.54; 95% CI, 1.19-1.99 respectively). We did not find -308 G&amp;gt;A variant associated with CD location and disease behaviours in stratified analysis.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Han Z, Li C, Han S, Han Y, Qiu J, Shi Y, Wang J, Sun A, Ding J, Wu K, Fan D. Meta-analysis: polymorphisms in TNF-alpha gene promoter and Crohn's disease. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2010;32(2):159-70.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>385075</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2009.04204.x]]&gt;</url>
    <title>Meta-analysis: pre-operative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis</title>
    <publicationDate>2010-02-15T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,RECENT ADDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; &lt;SPAN&gt;Pre-operative infliximab use increased the risk of short-term post-operative complications in patients with ulcerative colitis. Subgroup analysis is underpowered to assess the nature of these complications but shows a trend towards increased post-operative infection.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; &lt;SPAN&gt;Infliximab was approved for use in ulcerative colitis in recent years. It has been debated if infliximab increases the risk of post-operative complications in patients with ulcerative colitis.&amp;nbsp; The aim of this study was t&lt;SPAN&gt;o perform a meta-analysis that examines the relationship between preoperative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis.&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; &lt;SPAN class=sub_abstract_label&gt;&lt;/SPAN&gt;&lt;SPAN&gt;We searched the PubMed and MEDLINE databases to identify observational studies on the impact of pre-operative infliximab use on short-term post-operative complications in ulcerative colitis. Infectious complications mainly included wound infection, sepsis and abscess, whereas non-infectious complications included intestinal obstruction, thromboembolism and gastrointestinal haemorrhage. Pooled odds ratios (ORs) were calculated for each relationship.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;SPAN class=sub_abstract_label&gt;&lt;/SPAN&gt;&lt;SPAN&gt;A total of 5 studies and 706 patients were included in our meta-analysis. Overall, we did not find a strong association between pre-operative treatment of infliximab and short-term infectious [OR 2.24, 95% confidence interval (CI) 0.63-7.95] or non-infectious (OR 0.85, 95% CI 0.50-1.45) post-operative complications in ulcerative colitis patients. On the contrary, we discovered that pre-operative infliximab use increased short-term total post-operative complications (OR 1.80, 95% CI 1.12-2.87).&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN&gt;&lt;STRONG&gt;See also: &lt;/STRONG&gt;&lt;A href="nelh:374719:0" name=internalLink&gt;DARE record&lt;/A&gt; for this article.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Yang Z, Wu Q, Wu K, Fan D. Meta-analysis: pre-operative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2010;31(4):486-92.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Note: This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>385087</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2010.04284.x]]&gt;</url>
    <title>Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia</title>
    <publicationDate>2010-06-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,OESOPHAGUS,STOMACH,RECENT ADDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; &lt;SPAN&gt;Exploratory analysis revealed that duration of proton pump inhibitor (PPI) use may impact the risk of community-acquired pneumonia, a finding that should be explored in future studies.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; &lt;SPAN class=sub_abstract_label&gt;&lt;/SPAN&gt;&lt;SPAN&gt;Observational studies examining the association between&amp;nbsp;PPI use and risk of community-acquired pneumonia are conflicting. The aim of this study was to &lt;SPAN&gt;assess systematically the association between risk of community-acquired pneumonia and PPI use in adults.&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; &lt;SPAN class=sub_abstract_label&gt;&lt;/SPAN&gt;&lt;SPAN&gt;We searched MEDLINE, EMBASE and CINAHL databases between 1988 and January 2010. Two reviewers independently selected studies based on eligibility criteria and extracted data. Included studies evaluated adults (&amp;gt; or =18 years) who took PPIs as an out-patient. The primary outcome was community-acquired pneumonia. Only observational studies with a comparison arm were included.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;SPAN&gt;Over 2600 citations were reviewed. Six studies were included. All were nested case-control studies. Meta-analysis found an increased risk of community-acquired pneumonia associated with PPI use [OR 1.36 (95% CI 1.12-1.65)]; significant heterogeneity remained (I(2) 92%, P &amp;lt; 0.001). In exploratory subgroup analysis, short duration of use was associated with an increased odds of community-acquired pneumonia [OR 1.92 (95% CI 1.40-2.63), I(2) 75%, P = 0.003], whereas chronic use was not [OR 1.11 (95% CI 0.90-1.38), I(2) 91%, P &amp;lt; 0.001], a significant interaction (P &amp;lt; 0.005).&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Johnstone J, Nerenberg K, Loeb M. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2010;31(11):1165-77.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>384545</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2010.04326.x]]&gt;</url>
    <title>Meta-analysis: randomized controlled trials of 4-L polyethylene glycol and sodium phosphate solution as bowel preparation for colonoscopy</title>
    <publicationDate>2010-07-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,DIAGNOSTIC PROCEDURES,GASTROINTESTINAL ENDOSCOPY,COLONOSCOPY,RECENT ADDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Among 18 head-to-head randomized controlled trials (RCTs) of sodium phosphate (NaP) vs. 4-L polyethylene glycol (PEG), NaP was more likely to be completed and to result in an excellent or good quality preparation.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; RCTs comparing PEG with NaP are inconsistent.&amp;nbsp; The aim&amp;nbsp;of&amp;nbsp;this study was to compare the efficacy of and tolerance to PEG vs. NaP for bowel preparation.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We used MEDLINE and EMBASE to identify English-language RCTs published between 1990 and 2008 comparing 4-L PEG with two 45 mL doses of NaP in adults undergoing elective colonoscopy. We calculated the pooled odds ratios (ORs) for preparation quality and proportion of subjects completing the preparation.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; From 18 trials (n = 2792), subjects receiving NaP were more likely to have an excellent or good quality preparation than those receiving PEG (82% vs. 77%; OR = 1.43; 95% CI, 1.01-2.00). Among a subgroup of 10 trials in which prep quality was reported in greater detail, there were no differences in the proportions of excellent, good, fair or poor preparation quality. Among nine trials that assessed preparation completion rates, patients receiving NaP were more likely to complete the preparation than patients receiving 4-L PEG (3.9% vs. 9.8% respectively did not complete the preparation; OR = 0.40; CI, 0.17-0.88).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Juluri R, Eckert G, Imperiale TF. Meta-analysis: randomized controlled trials of 4-L polyethylene glycol and sodium phosphate solution as bowel preparation for colonoscopy. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2010;32(2):171-81.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309201</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18346185]]&gt;</url>
    <title>Meta-analysis: remission and response from control arms of randomized trials of biological therapies for active luminal Crohn's disease</title>
    <publicationDate>2008-06-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Populations used as 'add-on' treatment comparator in trials of biological therapies for active luminal CD are poorly characterized and outcomes are heterogeneous. Planning of future trials will require better description of patients and concomitant therapies, blinding of outcome assessors and homogeneous criteria of outcome definition.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We studied control patients from trials of biological therapies through articles retrieved by MEDLINE search (from 1997 to 2007) and by bibliography review. Thousand nine hundred and thirteen control patients from 28 trials were identified; data were extracted by three independent observers and pooled by DerSimonian and Laird random effect model; factors influencing remission and clinical response were explored by metaregression for aggregated data.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The pooled control rates of remission and response were 17% and 33%, respectively, both with significant heterogeneity among studies (&lt;SPAN class=i&gt;P&lt;/SPAN&gt;&amp;nbsp;&amp;lt;&amp;nbsp;0.0001). At metaregression, the time of primary outcome evaluation was associated with remission, whereas the trial's criteria for defining response and publication year were predictors of response. CDAI score, CRP levels or other clinical variables related with disease activity or concomitant medications were not significant factors.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Tine, F., Rossi, F., Sferrazza, A., Orlando, A., Mocciaro, F., Scimeca, D., Olivo, M., &amp;amp; Cottone, M. (2008) Meta-analysis: remission and response from control arms of randomized trials of biological therapies for active luminal Crohn's disease. &lt;I&gt;Alimentary Pharmacology &amp;amp; Therapeutics&lt;/I&gt;, 27(12):1210-1223.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>387730</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2010.04423.x]]&gt;</url>
    <title>Meta-analysis: ribavirin plus interferon vs. interferon monotherapy for chronic hepatitic C – an updated Cochrane review</title>
    <publicationDate>2010-10-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,RECENT ADDITIONS,CHRONIC HEPATITIS C,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The rationale behind several recent trials on adding ribavirin to interferon for chronic hepatitis C is debatable as the effect on virological response is established. More evidence is needed to assess if adding ribavirin to interferon improves clinical outcomes.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Multiple randomized trials have been published on antiviral treatment for chronic hepatitis C. The aim of this study was to meta-analyse the effect of adding ribavirin to interferon for chronic hepatitis C.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; The results of randomized trials were combined in cumulative meta-analyses. Trial sequential analyses were used to adjust for spurious results because of random errors and multiplicity. The outcome measures were undetectable hepatitis C virus RNA in serum (sustained virological response) and liver-related morbidity plus all-cause mortality.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; We included 82 randomized trials with 12&amp;nbsp;615 patients. Trial sequential analysis established clear beneficial effect of interferon plus ribavirin vs. interferon on the sustained virological response in 1998 after nine trials (RR: 0.74; 95% CI: 0.64–0.85, &lt;EM&gt;P&amp;nbsp;&lt;/EM&gt;&amp;lt;&lt;EM&gt;&amp;nbsp;&lt;/EM&gt;0.0001, 1734 patients). Subsequently, additional 73 trials were published just narrowing the confidence interval and decreasing the &lt;EM&gt;P&lt;/EM&gt;-value. By contrast, trial sequential analysis found that additional evidence is needed to convincingly detect a beneficial effect of interferon plus ribavirin vs. interferon monotherapy on clinical outcomes.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Brok J, Gluud L-L, Gluud C. Meta-analysis: ribavirin plus interferon vs. interferon monotherapy for chronic hepatitic C – an updated Cochrane review. Aliment Pharmacol Ther 2010;32(7):840-50.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>385102</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2010.04231.x]]&gt;</url>
    <title>Meta-analysis: targeting the intestinal microbiota in prophylaxis for post-operative Crohn's disease</title>
    <publicationDate>2010-04-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,DISEASE PREVENTION,PROBIOTICS,CROHN'S DISEASE,DIETARY SUPPLEMENTS,RECENT ADDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt;&amp;nbsp;&lt;SPAN&gt;Nitroimidazole antibiotics are effective in the prevention of post-operative Crohn's disease recurrence, but their side-effects limit acceptability. Probiotics have failed to show efficacy for post-operative prophylaxis, but may merit further study.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; &lt;SPAN class=sub_abstract_label&gt;&lt;/SPAN&gt;&lt;SPAN&gt;Enteric bacteria play an important early role in the pathogenesis of Crohn's disease.&lt;/SPAN&gt; The aim of this study was t&lt;SPAN&gt;o perform a meta-analysis of trials testing antibiotics or probiotics for prevention of post-operative recurrence of Crohn's disease.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; &lt;SPAN&gt;Review of all randomized controlled trials comparing antibiotics or probiotics with placebo in prevention of endoscopic or clinical recurrence of Crohn's disease after surgical resection. Fixed-effect meta-analysis was performed with dichotomous data summarized using relative risk with 95% confidence intervals, where appropriate.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;SPAN&gt;Seven studies were identified as suitable for inclusion (two comparing antibiotics with placebo, five comparing probiotics with placebo). The use of nitroimidazole antibiotics (metronidazole, ornidazole) reduced the risk of clinical (RR 0.23; 95% CI 0.09-0.57, NNT = 4) and endoscopic (RR 0.44; 95% CI 0.26-0.74, NNT = 4) recurrence relative to placebo. However, these agents were associated with higher risk of adverse events (RR 2.39, 95% CI 1.5-3.7) and patient withdrawal. Probiotic administration was not associated with any significant difference in risk of recurrence compared with placebo.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Doherty GA, Bennett GC, Cheifetz AS, Moss AC. Meta-analysis: targeting the intestinal microbiota in prophylaxis for post-operative Crohn's disease. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2010;31(8):802-9. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>388867</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2036.2010.04471.x/abstract]]&gt;</url>
    <title>Meta-analysis: the association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal reflux</title>
    <publicationDate>2010-09-23T00:00:00</publicationDate>
    <publisher>Alimentary Pharmacology and Therapeutics</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,OESOPHAGUS,CANCER,GASTRO-OESOPHAGEAL REFLUX,RECENT ADDITIONS,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Rubenstein JH, Taylor JB (2010) Meta-analysis: the association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal reflux. &lt;EM&gt;Alimentary Pharmacology and Therapeutics&lt;/EM&gt; 23rd September early view&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Alimentary pharmacology and therapeutics&lt;/EM&gt; is an international journal concerned with the effects of drugs on the human gastrointestinal and hepato-biliary systems. The journal publishes original research on all aspects of pharmacology, pharmacokinetics and therapeutic use of drugs in the alimentary tract.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background:&lt;/STRONG&gt; Endoscopic screening has been proposed for patients with symptoms of gastro-oesophageal reflux disease (GERD) in the hope of reducing mortality from oesophageal adenocarcinoma. Assessing the net benefits of such a strategy requires a precise understanding of the cancer risk in the screened population.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aim:&lt;/STRONG&gt; To estimate precisely the association between symptoms of GERD and oesophageal adenocarcinoma.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Systematic review and meta-analysis of population-based studies with strict ascertainment of exposure and outcomes.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Five eligible studies were identified. At least weekly symptoms of GERD increased the odds of oesophageal adenocarcinoma fivefold (odds ratio = 4.92; 95% confidence interval = 3.90, 6.22), and daily symptoms increased the odds sevenfold (random effects summary odds ratio = 7.40, 95% confidence interval = 4.94, 11.1), each compared with individuals without symptoms or less frequent symptoms. Duration of symptoms was also associated with oesophageal adenocarcinoma, but with very heterogeneous results, and unclear thresholds.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; Frequent GERD symptoms are strongly associated with oesophageal adenocarcinoma. These results should be useful in developing epidemiological models of the development of oesophageal adenocarcinoma, and in models of interventions aimed at reducing mortality from this cancer.&lt;/P&gt;&lt;STRONG&gt;
&lt;DIV class=para&gt;&lt;/STRONG&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is &lt;STRONG&gt;not&lt;/STRONG&gt; available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>268513</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2006.02877.x]]&gt;</url>
    <title>Meta-analysis: the dialysis mode and immunological repsonse to hepatitis B virus vaccine in dialysis population</title>
    <publicationDate>2006-04-15T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation&lt;/STRONG&gt;: Fabrizi F, Dixit V, Bunnapradist S et al. 2006; Alimentary Pharmacology and Therapeutics 23 (8) pp. 1105-12&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract:&lt;/STRONG&gt; BACKGROUND: Patients on maintenance dialysis typically show a suboptimal immune response to hepatitis B virus vaccine compared with the non-uraemic population. Some authors have claimed that dialysis mode has an impact on the immune response to hepatitis B virus vaccine but consistent information is lacking on this issue. AIM: To evaluate the relationship between dialysis mode and immune response to hepatitis B vaccine in dialysis population by performing a systematic review with a meta-analysis of clinical trials. METHOD: We used the random effects model of DerSimonian and Laird; sources of heterogeneity in effect estimates were explored by performing sensitivity analyses. RESULTS: The relative risk of failure to respond to hepatitis B vaccine among patients who underwent maintenance haemodialysis vs. peritoneal dialysis was the end point of interest. We identified 14 clinical trials involving 1211 unique patients on maintenance dialysis. Pooling of study results did not show a significant decreased risk of response to hepatitis B vaccine among haemodialysis patients (overall risk ratio: 1.0, 95% confidence intervals: 0.92-1.1). The P-value was 0.13 for our test of study heterogeneity. CONCLUSION: There is no significant link between dialysis mode and seroresponse to hepatitis B virus vaccine in dialysis population. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;See also: &lt;/STRONG&gt;&lt;A href="nelh:267021:0" name=internalLink&gt;DARE record&lt;/A&gt; for this article&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345641</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1445-5994.2008.01791.x]]&gt;</url>
    <title>Meta-analysis: the effect and adverse events of Lactobacilli versus placebo in maintenance therapy for Crohn disease</title>
    <publicationDate>2009-02-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ COMPLEMENTARY AND ALTERNATIVE MEDICINE,DIETARY AND NUTRITIONAL THERAPIES,INFLAMMATORY BOWEL DISEASE,GASTROENTEROLOGY &amp; LIVER DISEASES,DISEASE PREVENTION,PROBIOTICS,CROHN'S DISEASE,DIETARY SUPPLEMENTS,CONDITIONS A-Z,RECENT ADDITIONS,CONDITIONS I-L,MARCH 2010,MARCH 2010,FOOD AND BEVERAGES,PROBIOTICS,INFLAMMATORY BOWEL DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Our meta-analysis suggests that compared with placebo, administration of L. rhamnosus strain GG as maintenance therapy may increase the relapse rates of Crohn disease. L. johnsonii is inefficacious in reducing the incidence of relapse.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Lactobacilli are used in an attempt to maintain remission for Crohn disease. The aim of this study was to evaluate the efficacy and adverse events of Lactobacilli compared with placebo in maintenance therapy for Crohn disease.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We searched MEDLINE, EMBASE, the Cochrane Controlled Trials Register, OVID and BIOSIS. All randomized trials comparing Lactobacilli with placebo in maintenance therapy for Crohn disease were included.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Six randomized controlled trials with a total of 359 participants met the inclusion criteria. From the meta-analyses, the relative risk (RR) of clinical relapse rate was 1.15 (95% confidence interval (CI) 0.90-1.48) comparing Lactobacilli with placebo and RR of endoscopic relapse rate was 1.31 (95%CI 0.57-3.00). Subgroup analyses showed RR for clinical relapse rates of Lactobacilli versus placebo was 0.99 (95%CI 0.76-1.29) in adults, 1.85 (95%CI 1.00-3.41) in children, 1.68 (95%CI 1.07-2.64) in Lactobacillus rhamnosus strain GG and 0.91 (95%CI 0.68-1.23) in Lactobacillus johnsonii respectively. The pooled RR of adverse events was 0.83 (95%CI 0.61-1.12).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Shen J, Ran HZ, Yin MH, Zhou TX, Xiao DS. Meta-analysis: the effect and adverse events of Lactobacilli versus placebo in maintenance therapy for Crohn disease. &lt;EM&gt;Intern Med J&lt;/EM&gt; 2009;39(2):103-9.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323627</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1007/s00535-009-0024-z]]&gt;</url>
    <title>Meta-analysis: the effect of interferon on development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>Springer</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,DISEASE PREVENTION,HEPATOCELLULAR CARCINOMA,RECENT ADDITIONS,CANCER,AUGUST 2009,CHRONIC HEPATITIS B]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Interferon treatment is considered to restrain&amp;nbsp;hepatocellular carcinoma (HCC)&amp;nbsp;development in patients with chronic hepatitis B virus infection, especially in HBeAg-positive patients,&amp;nbsp;Asians, and groups whose risks of HCC when untreated is greater than 10%&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We conducted a meta-analysis of published studies. Eight studies were retrieved (1,303 patients), including two randomized controlled trials (RCTs) and six non-RCTs (553 patients received interferon treatment). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The pooled estimate of the preventive effect of treatment was significantly in favor of interferon (risk difference -5.0%; 95% CI -9.4 to -0.5, &lt;I&gt;P&lt;/I&gt;&amp;nbsp;=&amp;nbsp;0.028). By subgroup analyses, the preventive effect of interferon treatment was shown in the Asian population (risk difference -8.5%; 95%CI -13.6 to -3.6, &lt;I&gt;P&lt;/I&gt;&amp;nbsp;=&amp;nbsp;0.0012), the population with the incidental rate of HCC =10% if untreted with interferon (risk difference -9.4%; 95%CI -14.2 to -4.6, &lt;I&gt;P&lt;/I&gt;&amp;nbsp;=&amp;nbsp;0.0001), and the population with the proportion of HBeAg-positive patients to the study population =70% (RD -6.0%; 95%CI -11.8 to -0.2, &lt;I&gt;P&lt;/I&gt;&amp;nbsp;=&amp;nbsp;0.043). However, the preventive effect of interferon was not shown in the European population, the population with a lower incidental rate of HCC if untreated with interferon, and the population with the lower proportion of hepatitis B e antigen-positive patients to the study population. An evaluation using the Begg method indicated no evidence of publication bias.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Miyake Y, Kobashi H, Yamamoto K. Meta-analysis: the effect of interferon on development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. &lt;EM&gt;J Gastroenterol&lt;/EM&gt; 2009;44(5):470-5.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>377773</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20353496]]&gt;</url>
    <title>Meta-analysis: the effects of placebo treatment on gastro-oesophageal reflux disease</title>
    <publicationDate>2010-07-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,OESOPHAGUS,GASTRO-OESOPHAGEAL REFLUX,RECENT ADDITIONS,JUNE 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The placebo response rate in randomized controlled trials for gastro-oesophageal reflux disease (GORD) is substantial, although lower than that reported in other disorders of gastrointestinal function. A lower placebo response was associated with the testing of proton pump inhibitors, but not with the underlying presence of erosive oesophagitis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims: &lt;/STRONG&gt;GORD is a common chronic condition effectively treated in most patients with proton pump inhibitors (PPI) or H(2)-receptor antagonists (H2RA). There appears to be a significant placebo response rate in clinical trials for GORD. Despite this, little is known about the determinants and the circumstances associated with placebo response in the treatment of GORD. The purpose of this study is to estimate the magnitude of the placebo response rate in randomized controlled trials (RCTs) for GERD and to identify factors that influence this response.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We performed a meta-analysis of published, English language, randomized, double-blind, placebo-controlled trials that included 20 or more patients with GORD who were treated with either a proton-pump inhibitor or H(2)-receptor antagonist for at least 2 weeks. Medline, Cochrane and EMBASE databases were searched. We considered only studies that reported a global response for 'heartburn'. Eligible studies were synthesized using meta-analysis methods, including cumulative meta-analysis. Heterogeneity and study quality issues were explored.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; 24 studies were included with 9,989 total patients with GORD. The pooled odds ratio (OR) for response to active treatment versus placebo was 3.71 [95% CI: 2.78-4.96]. The pooled estimate of the overall placebo response was 18.85% [range 2.94% - 47.06%]. Patients with erosive esophagitis had a non-significantly lower placebo response rate than patients without it (11.87% and 18.31%, respectively; p = 0.246). Placebo response was significantly lower in studies of PPI therapy versus studies of H(2)-receptor antagonists (14.51% vs. 24.69%, respectively; p=0.05). Conclusion: The placebo response rate in randomized controlled trials for GORD is substantial, although lower than that reported in other disorders of gastrointestinal function. A lower placebo response was associated with the testing of proton pump inhibitors, but not with the underlying presence of erosive esophagitis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Cremonini F, Ziogas D, Chang HY, Kokkotou E, Kelly J, Conboy L, Kaptchuk TJ, Lembo AJ. Meta-analysis: the effects of placebo treatment on gastro-oesophageal reflux disease. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2010;32(1):29-42.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>385105</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2010.04247.x]]&gt;</url>
    <title>Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel</title>
    <publicationDate>2010-04-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,OESOPHAGUS,STOMACH,RECENT ADDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; &lt;SPAN&gt;As there are conflicting and inconsistent data regarding the adverse clopidogrel-&lt;SPAN&gt;proton pump inhibitor&lt;/SPAN&gt; (PPI) interaction, clinicians should focus on potential harm from ulcers/haemorrhage before deciding to omit PPIs in patients taking clopidogrel.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; &lt;SPAN&gt;Recent studies have suggested an adverse interaction between PPIs and clopidogrel. The aim of this study was to &lt;SPAN&gt;perform a meta-analysis of cardiovascular outcomes and mortality in patients taking clopidogrel, with and without concomitant PPI.&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; &lt;SPAN&gt;We searched MEDLINE, EMBASE, Cochrane Controlled Trials Register in October 2009, and checked conference abstracts for randomized and nonrandomized studies that reported the risk of cardiovascular events and mortality with PPI exposure in patients taking clopidogrel. We performed random effects meta-analysis, stratified by study design and assessed heterogeneity using the I2 statistic.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;SPAN&gt;Our review included 23 studies covering 93,278 patients. There was substantial heterogeneity in the meta-analyses of major cardiovascular events (19 studies, I2 = 79%) or myocardial infarction (12 studies, I2 = 77%). Analysis of propensity-matched or randomized trial participants showed no associated cardiovascular risk with PPIs, whereas other observational studies generally showed a significant association. Meta-analysis of 13 studies showed no significant association between PPI use and overall mortality (RR 1.09, 95% CI: 0.94-1.26, P = 0.23, I2 = 60%).&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Kwok CS, Loke YK. Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2010;31(8):810-23.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>388863</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2036.2010.04457.x/abstract]]&gt;</url>
    <title>Meta-analysis: the effects of Saccharyomyces boulardii supplementation on Heliobacter pylori eradication rates and side effects during treatment</title>
    <publicationDate>2010-09-16T00:00:00</publicationDate>
    <publisher>Alimentary Pharmacology and Therapeutics</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,STOMACH,DISEASE PREVENTION,PROBIOTICS,HELICOBACTER PYLORI,DIETARY SUPPLEMENTS,RECENT ADDITIONS,INFECTIONS,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Szajewska H, Horvath A, Piwowarczyk A. (2010) Meta-analysis: the effects of Saccharomyces&amp;nbsp; boulardii supplementation on Heliobacter pylori eradication rates and side effects during treatment. &lt;EM&gt;Alimentary Pharmacology and Therapeutics&lt;/EM&gt; early view 16th September&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Alimentary pharmacology and therapeutics&lt;/EM&gt; is an international journal concerned with the effects of drugs on the human gastrointestinal and hepato-biliary systems. The journal publishes original research on all aspects of pharmacology, pharmacokinetics and therapeutic use of drugs in the alimentary tract.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background:&lt;/STRONG&gt; Problems with currently recommended Helicobacter pylori eradication therapies include unsatisfactory eradication rates and/or therapy-associated side effects.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aim:&lt;/STRONG&gt; To investigate the effects of Saccharomyces boulardii as supplementation to standard triple therapy on H. pylori eradication rates and therapy-associated side effects.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; The Cochrane Library, MEDLINE and EMBASE databases were searched in July 2010, with no language restrictions, for randomized controlled trials (RCTs); additional references were obtained from reviewed articles.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt;&amp;nbsp;Five RCTs involving a total of 1307 participants (among them only 90 children) met the inclusion criteria. Compared with placebo or no intervention, S. boulardii given along with triple therapy significantly increased the eradication rate [four RCTs, n = 915, relative risk (RR) 1.13, 95% confidence interval (CI) 1.05–1.21] and reduced the risk of overall H. pylori therapy-related adverse effects (five RCTs, n = 1305, RR 0.46, 95% CI 0.3–0.7), particularly of diarrhoea (four RCTs, n = 1215, RR 0.47, 95% CI 0.32–0.69). There were no significant differences between groups in the risk of other adverse effects.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusion:&lt;/STRONG&gt; In patients with H. pylori infection, there is evidence to recommend the use of S. boulardii along with standard triple therapy as an option for increasing the eradication rates and decreasing overall therapy-related side effects, particularly diarrhoea.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is &lt;STRONG&gt;not&lt;/STRONG&gt; available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345601</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2009.03929.x]]&gt;</url>
    <title>Meta-analysis: the efficacy and safety of certolizumab pegol in Crohn's disease</title>
    <publicationDate>2009-03-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Certolizumab pegol is effective and safe in treating Crohn's disease. Further studies are still required to assess its full safety profile.&lt;/P&gt; &lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Certolizumab pegol is the third anti-TNF-alpha agent approved by the Food and Drug Administration of the United States.&amp;nbsp;The aim of this paper was&amp;nbsp;to provide a comprehensive up-to-date review of the efficacy and safety of certolizumab in Crohn's disease (CD).&lt;/P&gt; &lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Electronic databases, including PubMed, EMBASE, the Cochrane library and the Science Citation Index, were searched to retrieve relevant trials. In addition, meeting abstracts and the reference lists of retrieved articles were reviewed for further relevant studies.&lt;/P&gt; &lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Three trials, enrolling a total of 1040 patients, are included in the meta-analysis to evaluate the short-term efficacy of certolizumab, which is effective for rapid induction and long-term maintenance of clinical response or remission and can improve quality of life in patients with Crohn's disease. Certolizumab is also effective for patients who have lost response to infliximab. However, its efficacy in infliximab-exposed patients is probably less than in infliximab-naive patients. Re-induction with certolizumab in patients who have flared on maintenance therapy can rescue a significant proportion of patients. There is no significant association between the efficacy of certolizumab and the baseline C-reactive protein level. In comparison with placebo, certolizumab does not increase the risk of serious adverse events.&lt;/P&gt; &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Shao LM, Chen MY, Cai JT. Meta-analysis: the efficacy and safety of certolizumab pegol in Crohn's disease. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2009 Mar 15;29(6):605-14.&lt;/P&gt; &lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>324068</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2009.04023.x]]&gt;</url>
    <title>Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt;&amp;nbsp;Azathioprine (AZA)&amp;nbsp;is more effective than placebo for the prevention of relapse in ulcerative colitis, with an&amp;nbsp;number needed to&amp;nbsp;treat&amp;nbsp;of 5 and an absolute risk reduction of 23%. AZA and mercaptopurine (MP) map be effective for the induction of remission, but this meta-analysis could not find a statistically significant benefit.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Selection of studies: Evaluating AZA/MP for induction and/ or maintenance of clinical remission of UC. Randomized-controlled-trials comparing AZA/MP with placebo/ 5-aminosalicylates were included in the meta-analysis. Search strategy: Electronic and manual. Study quality: Independently assessed by two reviewers. Data synthesis: By ‘intention-to-treat’.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Thirty noncontrolled studies (1632 patients) were included in the systematic review. Mean efficacy of AZA/MP was 65% for induction and 76% for maintenance of the remission. Seven controlled studies were included in the meta-analysis. (i) Induction of remission: four studies (89 AZA/ MP-treated patients) showed mean efficacy of 73% vs. 64% in controls (OR = 1.59; 95% CI = 0.59–4.29). (ii) Maintenance of remission: six studies (124 AZA/ MP-treated patients) showed mean efficacy of 60% vs. 37% in controls (OR = 2.56; 95% CI = 1.51–4.34). When only studies comparing AZA/MP vs. placebo were considered, OR was 2.59 (95% CI = 1.26–5.3), absolute risk reduction was 23% and number needed-to-treat (NNT) to prevent one recurrence was 5.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;See also: &lt;/STRONG&gt;&lt;A href="nelh:379038:0" name=internalLink&gt;DARE record&lt;/A&gt; for this article.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Gisbert JP, Linares PM, McNicholl AG, Maté J, Gomollón F.&amp;nbsp;Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2009 Jul 1;30(2):126-37.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323646</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2008.03763.x]]&gt;</url>
    <title>Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,RECENT ADDITIONS,AUGUST 2009,CHRONIC HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; &lt;SPAN class=h5-inline&gt;&lt;/SPAN&gt;Twenty-four weeks of therapy should remain standard duration for HCV-2 and low viraemic HCV-3 patients. In patients with a rapid virological response (RVR), HCV-3 patients respond to short-treatment as well as HCV-2 patients, irrespective of basal viraemia. Patients without RVR may need longer treatment than the recommended 24&amp;nbsp;weeks.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Meta-analyses were carried out on&amp;nbsp;sustained&amp;nbsp;virological response (SVR)&amp;nbsp;data on 2275 patients treated for 24&amp;nbsp;weeks in eight individual trials and on 968 patients with RVR treated for 12–16&amp;nbsp;weeks or 24&amp;nbsp;weeks in four studies.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; After 24&amp;nbsp;weeks of therapy, SVR rates were 74% and 68%, respectively, for HCV-2 and HCV-3 genotype patients. Among high viraemics, SVR rate in HCV-2 infection (75%) differed from the 58% value in HCV-3 infection. Among low viraemic patients, respective rates were 79% and 75%. In RVR patients treated for 12–16 or 24&amp;nbsp;weeks, SVR rates in HCV-2 infection were 83% and 84%, respectively, and in HCV-3 infection 84% and 86%. In patients without RVR treated for 24&amp;nbsp;weeks, SVR was higher in HCV-2, with a 17.8% weighted difference.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Andriulli A, Mangia A, Iacobellis A, Ippolito A, Leandro G, Zeuzem S. Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2008 Aug 15;28(4):397-404.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281267</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17697199]]&gt;</url>
    <title>Meta-analysis: the utility and safety of heparin in the treatment of active ulcerative colitis</title>
    <publicationDate>2008-03-10T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic information:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;Shen, J.&amp;nbsp;&lt;SPAN title="Alimentary pharmacology &amp;amp; therapeutics."&gt;&lt;A href="#javascript:AL_get(this," ?jour?, ?Aliment Pharmacol Ther.?);?&gt;Aliment Pharmacol Ther.&lt;/A&gt;&lt;/SPAN&gt; 2007 Sep 1;26(5):653-63&lt;/P&gt;
&lt;P class=abstract&gt;BACKGROUND: The use of heparin for the treatment of ulcerative colitis has been evaluated in several open and controlled trials, with varying outcomes. AIM: To evaluate the efficacy and safety of heparin as supplemental therapy compared with conventional therapy in patients with ulcerative colitis. METHODS: All randomized trials comparing heparin supplementation to conventional therapy were included from electronic databases. Statistical analysis was performed with review manager 4.2.8 (The Cochrane Collaboration, Oxford, UK). Sub-analysis and sensitivity analysis were also performed. RESULTS: Eight randomized-controlled trials, investigating a total of 454 participants, met the inclusion criteria. The odds ratio (OR) for the efficacy of heparin supplementation vs. conventional therapy was 0.78 (95% CI = 0.50-1.21). Few serious adverse events were observed. The OR for the efficacy of unfractionated heparin and low-molecular-weight heparin vs. conventional therapy was 0.26 (95% CI = 0.07-0.93) and 0.92 (95% CI = 0.57-1.47), respectively. The OR for the efficacy of heparin vs. conventional therapy with placebo was 0.87 (95% CI = 0.53-1.44). CONCLUSIONS: Our meta-analysis suggests that administration of heparin in patients with ulcerative colitis is safe, but no additive benefit over conventional therapy is indicated.&lt;/P&gt;
&lt;P class=abstract&gt;See also the &lt;A href="nelh:295885:0" name=internalLink&gt;DARE record&lt;/A&gt; for this article.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Alimentary Pharmacology and Therapeutics is an international journal concerned with the effects of drugs on the human gastrointestinal and hepato-biliary systems. The journal publishes original research on all aspects of pharmacology, pharmacokinetics and therapeutic use of drugs in the alimentary tract.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is &lt;STRONG&gt;not&lt;/STRONG&gt; available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323808</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2008.03816.x]]&gt;</url>
    <title>Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,NON-ALCOHOLIC,HEPATOCELLULAR CARCINOMA,RECENT ADDITIONS,CANCER,CIRRHOSIS,SEPTEMBER 2009,CHRONIC HEPATITIS B]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Interferon (IFN) or nucleoside/tide analogue (NA) treatment significantly reduces risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). While IFN benefited patients with cirrhosis, NA benefited patients with no cirrhosis and HBeAg-positive CHB infection.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt;&amp;nbsp;Randomized trials, case–control and cohort studies were retrieved from five electronic databases and international conferences over the past 10&amp;nbsp;years. Relative risks (RRs) of HCC with or without treatment were studied.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;SPAN class=h5-inline&gt;&lt;/SPAN&gt;Twelve studies (&lt;SPAN class=i&gt;n&lt;/SPAN&gt;&amp;nbsp;=&amp;nbsp;2742) enrolling patients treated by IFN vs. control showed that the risk of HCC after treatment was reduced by 34% (RR: 0.66, 95% CI: 0.48–0.89). Benefit is more significant among patients with early cirrhosis than among those without cirrhosis. Five studies (&lt;SPAN class=i&gt;n&lt;/SPAN&gt;&amp;nbsp;=&amp;nbsp;2289) compared patients treated by NA with control. The risk of HCC after treatment was reduced by 78% (RR: 0.22, 95% CI: 0.10–0.50). HBeAg-positive patients showed more significantly reduced HCC risk with treatment. Patients without cirrhosis benefited more from NA than those with cirrhosis. Resistance to NA has obviated the benefit of the treatment.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;See also: &lt;/STRONG&gt;&lt;A href="nelh:375512:0" name=internalLink&gt;DARE record&lt;/A&gt; for this article.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Sung JJ, Tsoi KK, Wong VW, Li KC, Chan HL. Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2008 Nov 1;28(9):1067-77.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>318718</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2009.04008.x]]&gt;</url>
    <title>Meta-analysis: yield of diagnostic tests for coeliac disease in dyspepsia</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,STOMACH,SMALL INTESTINE,COELIAC DISEASE,DIAGNOSTIC PROCEDURES,BIOPSY,INTESTINAL,BLOOD TESTS,DYSPEPSIA,RECENT ADDITIONS,JUNE 2009,SEROLOGIC TESTS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The prevalence of biopsy-proven&amp;nbsp;coeliac disease (CD)&amp;nbsp;in subjects with dyspepsia was 1% and was higher than in controls, although this difference was not statistically significant.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; MEDLINE, EMBASE, and CINAHL were searched up to February 2009. Case series and case-control studies applying serological tests and/or distal duodenal biopsy for CD to unselected adults with dyspepsia were eligible. Prevalence of positive coeliac serology and biopsy-proven CD were pooled for all studies and compared between cases and controls using an odds ratio (OR) and 95% confidence interval (CI).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;SPAN class=h5-inline&gt;&lt;/SPAN&gt;Fifteen studies were identified. Prevalence of positive coeliac serology was higher in cases with dyspepsia (7.9%) compared with controls (3.9%), but not significantly so (OR for positive endomysial antibodies or tissue transglutaminase 1.89; 95% CI 0.90–3.99). Prevalence of biopsy-proven CD following positive serology was also higher (3.2% in cases vs. 1.3% in controls), but again this was not statistically significant (OR 2.85; 95% CI 0.60–13.38). Prevalence of biopsy-proven CD was 1% in ten studies performing duodenal biopsy first-line.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Ford AC, Ching E, Moayyedi P. Meta-analysis: Yield of Diagnostic Tests for Coeliac Disease in Dyspepsia. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2009;30(1):28-36.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323508</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1093/aje/kwn237]]&gt;</url>
    <title>Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place</title>
    <publicationDate>2008-11-15T00:00:00</publicationDate>
    <publisher>Oxford Journals</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,RECENT ADDITIONS,AUGUST 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The time from onset of illicit drug injection (IDU)&amp;nbsp;to&amp;nbsp;hepatitis C virus&amp;nbsp;(HCV)&amp;nbsp;infection in developed countries has lengthened. The date of onset&amp;nbsp;of IDU should not be used to estimate the&amp;nbsp;date of HCV infection.&amp;nbsp;More rapid onset of HCV infection in drug injectors in developing/transitional countries resembles an earlier era of the HCV epidemic in other regions.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; The authors examined the relation between time since onset of&amp;nbsp;IDU (time at risk) and rates of HCV infection by using meta-regression.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; In 72 prevalence studies, median time since onset of injection was 7.24 years and median prevalence was 66.02%. The model showed statistically significant linear and quadratic effects of time at risk on HCV prevalence and significantly higher prevalence in developing and transitional countries and in earlier samples (1985–1995). In developed countries post-1995, mean fitted prevalence was 32.02% (95% confidence interval: 25.31, 39.58) at 1 year of injection and 53.01% (95% confidence interval: 40.69, 65.09) at 5 years. In developing/transitional countries post-1995, mean fitted HCV prevalence was 59.13% (95% confidence interval: 30.39, 82.74) at 1 year of injection. In 10 incidence studies, median time at risk was 5.29 years and median cumulative HCV incidence was 20.69%. Mean fitted cumulative incidence was 27.63% (95% confidence interval: 16.92, 41.70) at 1 year of drug injection.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Hagan H, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger C. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. &lt;EM&gt;Am J Epidemiol&lt;/EM&gt; 2008;168:1099-1109.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>312632</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2009.03951.x]]&gt;</url>
    <title>Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome Consensus Conference</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,SMALL INTESTINE,LACTOSE INTOLERANCE,COLON &amp; RECTUM,IRRITABLE BOWEL SYNDROME,DIAGNOSTIC PROCEDURES,BACTERIAL OVERGROWTH,BREATH TESTS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; The Rome Consensus Conference was convened to offer recommendations for clinical practice about the indications and methods of H2-breath testing in gastrointestinal diseases.Experts were selected on the basis of a proven knowledge / expertise in H2-breath testing and divided into Working Groups (methodology; sugar malabsorption; small intestine bacterial overgrowth; oro-coecal transit time and other gas-related syndromes). They performed a systematic review of the literature, and then formulated statements on the basis of the scientific evidence, which were debated and voted by a multidisciplinary Jury. Recommendations were then modified on the basis of the decisions of the Jury by the members of the Expert Group.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The final statements, graded according to the level of evidence and strength of recommendation, are presented in this document; they identify the indications for the use of H2-breath testing in the clinical practice and methods to be used for performing the tests.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Gasbarrini A, Corazza GR, Gasbarrini G, Montalto M, Di Stefano M, Basilisco G, Parodi A, Satta PU, Vernia P, Anania C, Astegiano M, Barbara G, Benini L, Bonazzi P, Capurso G, Certo M, Colecchia A, Cuoco L, Di Sario A, Festi D, Lauritano C, Miceli E, Nardone G, Perri F, Portincasa P, Risicato R, Sorge M, Tursi A; 1st Rome H2-Breath Testing Consensus Conference Working Group. Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome Consensus Conference.&amp;nbsp;&lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2009;29 Suppl 1:1-49.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>325957</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.bsg.org.uk/images/stories/docs/patients/meth_ibd_pt.doc]]&gt;</url>
    <title>Methotrexate treatment for patients with IBD</title>
    <publicationDate></publicationDate>
    <publisher>British Society of Gastroenterology</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The British Society of Gastroenterology is an organisation focused on the promotion of gastroenterology within the United Kingdom. It has over three thousand members drawn from the ranks of physicians, surgeons, pathologists, radiologists, scientists, nurses, dietitians, and others interested in the field. Founded in 1937 it has grown from a club to be a major force in British medicine, with representation within the British Royal Colleges and thus to the Department of Health and Government. Internationally it is represented at World and European level. The BSG is a registered charity.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt; This document is one of a series designed to provide information for gastroenterologists, primary care clinicians and patients with IBD regarding the use of disease modifying drugs, their indications, side effects and guidelines for safe monitoring. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309081</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1517/14656566.9.6.1049]]&gt;</url>
    <title>MMX mesalamine: a novel high-dose, once-daily 5-aminosalicylate formulation for the treatment of ulcerative colitis</title>
    <publicationDate>2008-04-01T00:00:00</publicationDate>
    <publisher>Informa</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; MMX mesalamine is the first and only approved once-daily 5-ASA treatment option for patients with UC. It is efficacious for the induction of remission in mild to moderate UC and has a favorable safety profile. With the advantage of low pill burden and easy dosing schedule, it may potentially improve patient compliance and treatment success.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A systematic review of published literature was performed on PubMed using the search terms ‘MMX mesalamine’ and ‘Lialda™’. Abstracts presented at US gastroenterology conferences between 2006 and 2007, were also reviewed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; MMX mesalamine uses a novel multi-matrix delivery system to achieve a sustained release of 5-ASA throughout the colon. Clinical trials have demonstrated MMX mesalamine 2.4 g/day or 4.8 g/day to be superior to placebo in inducing remission in active mild to moderate UC. The drug is well tolerated with a safety profile comparable to other oral 5-ASA agents. With a high-dose formulation of 1.2 g 5-ASA per tablet, MMX mesalamine can be administered conveniently at two to four pills once a day.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Hu, M. Y. &amp;amp; Peppercorn, M. A. (2008) MMX mesalamine: a novel high-dose, once-daily 5-aminosalicylate formulation for the treatment of ulcerative colitis. &lt;I&gt;Expert Opinion on Pharmacotherapy&lt;/I&gt;, 9(6):1049-1058.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in April 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>380668</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.jhep.2009.04.013]]&gt;</url>
    <title>Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B</title>
    <publicationDate>2009-10-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,RECENT ADDITIONS,CHRONIC HEPATITIS B,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion: &lt;/STRONG&gt;In chronic&amp;nbsp;hepatitis B virus (HBV)&amp;nbsp;infected patients, tenofovir is a cost-effective or even cost-saving strategy compared with other available treatment options.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Chronic hepatitis B (CHB) is a common disease associated with high morbidity, mortality and impact on healthcare costs. Several oral antiviral therapies can lead to complete virologic response, which is associated with prevention of disease progression. The aim of this study was to estimate the cost-effectiveness of the oral antiviral treatments lamivudine, adefovir, telbivudine, entecavir and tenofovir, in patients with CHB.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A Markov model was used to project the lifetime complications and costs in cohorts of both HBeAg-positive and HBeAg-negative CHB patients treated with one of the above drugs or no treatment. Rescue therapy with two different combination therapies (adefovir plus lamivudine or tenofovir plus entecavir) with their corresponding costs and efficacy rates was also considered. The probabilities of disease progression were based on serum HBV DNA levels. Disease and complication costs were assessed using the perspective of the Spanish National Health System.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The highest rate of virologic response was obtained with tenofovir, and this translated to its higher life years saved (LYS) and quality adjusted life years (QALY) compared with the rest of the alternatives in HBeAg-positive and HBeAg-negative patients. Tenofovir is associated with lower costs and higher efficacy over entecavir, telbivudine and adefovir in HBeAg-positive patients, and telbivudine and entecavir in HBeAg-negative patients. The incremental cost-effectiveness ratios with respect to the rest of the alternatives are below the common reference efficiency threshold of 30,000 euro per LYS/QALY.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Buti M, Brosa M, Casado MA, Rueda M, Esteban R. Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. &lt;EM&gt;J Hepatol&lt;/EM&gt; 2009;51(4):640-6.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>268541</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1001/jama.297.7.724]]&gt;</url>
    <title>Molecular diagnostics of hepatitis C virus infection: a systematic review</title>
    <publicationDate>2007-02-21T00:00:00</publicationDate>
    <publisher>American Medical Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,ACUTE HEPATITIS C,CHRONIC HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation&lt;/STRONG&gt;: Scott J.D., Gretch D.R. 2007; JAMA 297 (7) pp. 724-32&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract: &lt;/STRONG&gt;CONTEXT: Hepatitis C virus (HCV) is a common blood-borne pathogen that relies heavily on nucleic acid testing for confirmation of infection. Nucleic acid tests are invaluable for the diagnosis of HCV infection and provide critical prognostic information for guiding treatment and measuring the response to antiviral therapy. OBJECTIVE: To review the currently available molecular diagnostic tests for HCV, their clinical applications, and how these tests shed light on the natural history of HCV. EVIDENCE ACQUISITION: Search of MEDLINE (1966 to July 2006), article reference lists, and national meeting abstracts for the diagnosis and applications of molecular diagnostic tests for HCV. Studies were selected on the basis of clinical relevance. EVIDENCE SYNTHESIS: Qualitative nucleic acid tests have low limits of detection (&amp;lt;50 IU HCV RNA/mL) and are used for confirmation of HCV infection and for screening blood donations. Hepatitis C virus genotype test results provide important prognostic information related to therapeutic response and are routinely used for selecting treatment regimens. Quantitative HCV RNA testing provides prognostic information regarding likelihood of treatment response and plays an important role in monitoring the antiviral response to treatment. Sustained virological response is defined as testing negative for HCV RNA 6 months after cessation of therapy. Recent studies suggest that the rate of response to therapy is also important. For example, conversion to an HCV RNA negative test result after 4 weeks of therapy constitutes a rapid virological response and is a strong predictor of treatment success. Patients who have not had an early virological response, defined as at least a 2-log decline in HCV RNA after 12 weeks of therapy, are unlikely to respond with an additional 36 weeks of therapy, and should stop therapy. CONCLUSIONS: A sensitive nucleic acid test should be used to confirm all cases of acute or chronic HCV infection. A genotype test and quantitative HCV RNA test should be performed on all patients prior to therapy to best assess probability of response and to aid in selection of appropriate therapeutic regimen. Monitoring HCV RNA during treatment provides important information on likelihood of sustained virological response. The same type of quantitative HCV RNA test should be used throughout a patient's treatment course.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>330579</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18242076]]&gt;</url>
    <title>Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients</title>
    <publicationDate>2008-03-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>RANDOMISED CONTROLLED TRIAL</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,ALCOHOLIC LIVER DISEASE,ALCOHOLIC CIRRHOSIS,HEPATOCELLULAR CARCINOMA,RECENT ADDITIONS,CANCER,CIRRHOSIS,ALCOHOLIC,NOVEMBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; This study suggests that transarterial lipiodol chemoembolisation&amp;nbsp;(TACE) improves neither the survival nor the quality of life in patients with&amp;nbsp;hepatocellular carcinoma (HCC)&amp;nbsp;and cirrhosis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; The FFCD 9402 multicentre phase III trial was designed to compare the effects of the combination of Transarterial Lipiodol Chemoembolisation (TACE) and tamoxifen with tamoxifen alone on overall survival and quality of life in the palliative treatment of&amp;nbsp;HCC with cirrhosis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; From 1995 to 2002, 138 patients were randomised between the two groups. One hundred and twenty three patients were eligible including 61 in the Tamoxifen group and 62 in the TACE group.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Baseline characteristics were similar: Child-Pugh class A: 70%, alcoholic cirrhosis: 76%, Okuda stage I: 71%, multinodular tumour: 70% and segmental portal vein thrombosis: 10%. At 2years, the overall survival was 22% and 25% in the Tamoxifen and TACE groups (P=.68), respectively. Multivariate analysis identified four independent prognostic factors for survival: alpha-fetoprotein (AFP)&amp;gt;400ng/mL (P=.008), abdominal pain (P=.011), hepatomegaly (P=.023) and Child-Pugh score (P=.032). The Spitzer Index level assessing the quality of life during follow-up did not differ between the two groups (P=.70). Amongst patients with stage Okuda I, the 2-year overall survival was 28% in the Tamoxifen group and 32% in the TACE group (P=.58). In this subgroup, two prognostic factors were statistically significant for survival: AFP&amp;gt;400ng/mL (P=.004) and Spitzer Index (P=.013) as shown by multivariable analysis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Doffoël M, Bonnetain F, Bouché O, Vetter D, Abergel A, Fratté S, Grangé JD, Stremsdoerfer N, Blanchi A, Bronowicki JP, Caroli-Bosc FX, Causse X, Masskouri F, Rougier P, Bedenne L; Fédération Francophone de Cancérologie Digestive. Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402). &lt;EM&gt;Eur J Cancer&lt;/EM&gt; 2008 Mar;44(4):528-38.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309083</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1345/aph.1K469]]&gt;</url>
    <title>Multi-matrix system mesalamine: to use or not to use.</title>
    <publicationDate>2009-01-08T00:00:00</publicationDate>
    <publisher>Harvey Whitney Books Co.</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Current evidence supports the use of MMX mesalamine for treatment of mild-to-moderate UC by demonstrating that MMX mesalamine 2.4-4.8 g daily induces remission. It has the advantage of once-daily dosing regimens with lower pill burden than comparable products and, as an oral agent, may have better patient acceptability compared with topical mesalamine formulations. Therefore, MMX mesalamine is an option in patients with UC. The cost of MMX mesalamine is comparable to that of oral and rectal formulations of mesalamine. Further pharmacoeconomic studies are warranted to examine the cost impact of MMX mesalamine.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Literature was obtained through searches of MEDLINE (1966-October 2007) and a bibliographic review of published articles. Key terms used in the searches included ulcerative colitis, mesalamine, MMX, SPD476, and Lialda. All English-language articles that were identified through the search were evaluated. All primary literature was included in the review.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The standard treatment for the induction and maintenance of remission in patients with mild-to-moderate UC is aminosalicylate products (mesalamine, sulfasalazine, balasalazide, olsalazine). Current mesalamine formulations are not ideal for long-term treatment due to issues with patient adherence secondary to complex dosing regimens and high pill burden. Clinical studies show that MMX mesalamine achieves clinical and endoscopic remission more frequently compared with placebo or mesalamine enema. Patients receiving MMX mesalamine achieved statistically significant clinical and endoscopic remission when compared with those taking placebo (34.1% vs 12.9%; p &amp;lt; 0.001 with 2.4 g/day vs placebo, and 29.2% vs 12.9%; p = 0.009 with 4.8 g/day vs placebo). Similarly, in another study, significantly more patients achieved remission in the MMX mesalamine groups compared with patients in the placebo group (40.5% vs 22.1% with 2.4 g/day vs placebo; p = 0.01, and 41.2% vs 22.1% with 4.8 g/day vs placebo; p = 0.007). MMX mesalamine is well tolerated, with headache, flatulence, and abdominal pain being the most frequently reported adverse events.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Kale-Pradhan, P. B., Pradhan, R. S., &amp;amp; Wilhelm, S. M. (2008) Multi-matrix system mesalamine: to use or not to use. &lt;I&gt;Annals of Pharmacotherapy&lt;/I&gt;, 42(2):265-269.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281299</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17714674]]&gt;</url>
    <title>Mycobacterium avium subspecies paratuberculosis and Crohn's disease: a systematic review and meta-analysis</title>
    <publicationDate>2008-03-10T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ CROHN'S DISEASE,GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,TUBERCULOSIS,INFECTIOUS DISEASES,INFECTIONS,TUBERCULOSIS,VACCINE PREVENTABLE DISEASES,JAN 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: &lt;/P&gt;
&lt;P&gt;Feller, M. &lt;SPAN title="The Lancet infectious diseases."&gt;&lt;A href="#javascript:AL_get(this," ?jour?, ?Lancet Infect Dis.?);?&gt;Lancet Infect Dis.&lt;/A&gt;&lt;/SPAN&gt; 2007 Sep;7(9):607-13&lt;/P&gt;
&lt;P&gt;This systematic review assesses the evidence for an association between Mycobacterium avium subspecies paratuberculosis (MAP) and Crohn's disease. We analysed 28 case-control studies comparing MAP in patients with Crohn's disease with individuals free of inflammatory bowel disease (IBD) or patients with ulcerative colitis. Compared with individuals free of IBD, the pooled odds ratio (OR) from studies using PCR in tissue samples was 7.01 (95% CI 3.95-12.4) and was 1.72 (1.02-2.90) in studies using ELISA in serum. ORs were similar for comparisons with ulcerative colitis patients (PCR, 4.13 [1.57-10.9]; ELISA, 1.88 [1.26-2.81]). The association of MAP with Crohn's disease seems to be specific, but its role in the aetiology of Crohn's disease remains to be defined.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;The Lancet was established in 1823 and is an independent journal without affiliation to any medical or scientific organisation. The journal publishes high quality clinical trials, as well as editorials and comment and correspondence.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323579</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.annals.org/cgi/reprint/150/2/104]]&gt;</url>
    <title>National Institutes of Health consensus development conference statement: management of hepatitis B</title>
    <publicationDate>2009-01-05T00:00:00</publicationDate>
    <publisher>American College of Physicians</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,RECENT ADDITIONS,AUGUST 2009,ACUTE HEPATITIS B,CHRONIC HEPATITIS B]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary: &lt;/STRONG&gt;Hepatitis B is a major cause of liver disease worldwide, ranking as a substantial cause of cirrhosis and hepatocellular carcinoma. The development and use of a vaccine for hepatitis B virus (HBV) has resulted in a substantial decline in the number of new cases of acute hepatitis B among children, adolescents, and adults in the United States. However, this success has not yet been duplicated worldwide, and both acute and chronic HBV infection continue to represent important global health problems.&lt;/P&gt;
&lt;P&gt;Seven treatments are currently approved for adult patients with chronic HBV infection in the United States: interferon-{alpha}, pegylated interferon-{alpha}, lamivudine, adefovir dipivoxil, entecavir, telbivudine, and tenofovir disoproxil fumarate. Interferon-{alpha} and lamivudine have been approved for children with HBV infection. Although available randomized, controlled trials (RCTs) show encouraging short-term results—demonstrating the favorable effect of these agents on such intermediate markers of disease as HBV DNA level, liver enzyme tests, and liver histology—limited rigorous evidence exists demonstrating the effect of these therapies on important long-term clinical outcomes, such as the development of hepatocellular carcinoma or a reduction in deaths. Questions therefore remain about which groups of patients benefit from therapy and at which point in the course of disease this therapy should be initiated.&lt;/P&gt;
&lt;P&gt;We were charged with answering the following critical questions about the management of hepatitis B:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;What is the current burden of hepatitis B? 
&lt;LI&gt;What is the natural history of hepatitis B? 
&lt;LI&gt;What are the benefits and risks of the current therapeutic options for hepatitis B? 
&lt;LI&gt;Which persons with hepatitis B should be treated? 
&lt;LI&gt;What measures are appropriate to monitor therapy and assess outcomes? 
&lt;LI&gt;What are the greatest needs and opportunities for future research on hepatitis B?&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;At the conference, invited experts presented information relevant to these questions and a systematic literature review, prepared under contract with the AHRQ, was summarized. The evidence report, available at &lt;A href="http://www.ahrq.gov/clinic/tp/hepbtp.htm" target="_blank"&gt;http://www.ahrq.gov/clinic/tp/hepbtp.htm&lt;/A&gt;, emphasizes RCTs with health outcomes as their end points. Conference attendees also provided oral and written comments in response to the conference questions, and we considered all of this evidence when preparing the consensus statement.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Sorrell MF, Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM, et al. National Institutes of Health consensus development conference statement: Management of hepatitis B. &lt;EM&gt;Ann Intern Med&lt;/EM&gt; 2009;150(2):104-10.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345575</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1007/s11605-009-0853-3]]&gt;</url>
    <title>National trends and outcomes for the surgical therapy of ileocolonic Crohn's disease: a population-based analysis of laparoscopic vs. open approaches</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>Springer</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; A variety of patient- and system-related factors influence the utilization of laparoscopy in Crohn’s disease. Laparoscopic resection is associated with excellent short-term outcomes compared to open surgery. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; The laparoscopic approach to Crohn’s disease has demonstrated benefits in several small series. We sought to examine its use and outcomes on a national level. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; All admissions with a diagnosis of Crohn’s disease requiring bowel resection were selected from the 2000–2004 Nationwide Inpatient Sample. Regression analyses were used to compare outcome measures and identify independent predictors of undergoing laparoscopy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Of 396,911 patients admitted for Crohn’s disease, 49,609 (12%) required surgical treatment. They were predominately Caucasian (64%), female (54%), and with ileocolic disease (72%). Most had private insurance (71%) and had surgery in urban hospitals (91%). Laparoscopic resection was performed in 2,826 cases (6%) and was associated with lower complications (8% vs. 16%), shorter length of stay (6 vs. 9 days), lower charges ($27,575 vs. $38,713), and mortality (0.2% vs. 0.9%, all P? &lt;?0.01). Open surgery was used more often for fistulas (8% vs. 1%) and when ostomies were required (12% vs. 7%). Independent predictors of laparoscopic resection were age &lt;35 [odds ratio (OR)?=?2.4], female gender (OR?=?1.4), admission to a teaching hospital (OR?=?1.2), ileocecal location (OR?=?1.5), and lower disease stage (OR?=?1.1, all P? &lt;?0.05). Ethnic category, insurance status, and type of admission (elective vs. non-elective) were not associated with operative method (P?&gt;?0.05). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Lesperance K, Martin MJ, Lehmann R, Brounts L, Steele SR. National trends and outcomes for the surgical therapy of ileocolonic Crohn's disease: a population-based analysis of laparoscopic vs. open approaches. &lt;EM&gt;J Gastrointest Surg&lt;/EM&gt; 2009;13(7):1251-9.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323538</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1097/QAD.0b013e32830e6d51]]&gt;</url>
    <title>Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis</title>
    <publicationDate>2008-10-01T00:00:00</publicationDate>
    <publisher>Lippincott Williams &amp; Wilkins</publisher>
    <publicationType>STRUCTURED ABSTRACT</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,NON-ALCOHOLIC,HIV / AIDS,RECENT ADDITIONS,CIRRHOSIS,AUGUST 2009,CHRONIC HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The rate of fibrosis progression among individuals coinfected with HIV and hepatitis C virus (HCV) appears constant. Our results confirm that chronic hepatitis C outcomes are worse among coinfected individuals. Over the period studied, highly active antiretroviral therapy (HAART) did not appear to fully correct the adverse effect of HIV infection on HCV prognosis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Systematic review of natural history studies among HCV-infected individuals.&amp;nbsp;Markov maximum likelihood estimation method was used to estimate stage-specific transition probabilities. A meta-analysis was performed to obtain pooled transition probabilities, and a meta-regression to investigate the impact of covariates on these rates. Risk of cirrhosis between individuals monoinfected with HCV and coinfected with HIV/HCV were compared by HAART status.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The estimated mean (95% confidence intervals) annual transition probabilities of 3567 individuals coinfected with HIV/HCV (n = 17 studies) were as follows: fibrosis stage (F) F0 -&amp;gt; F1 0.122 (0.098–0.153); F1 -&amp;gt; F2 0.115 (0.095–0.140); F2 -&amp;gt; F3 0.124 (0.097–0.159); and F3 -&amp;gt; F4 0.115 (0.098–0.135) units/year. The prevalence of cirrhosis after 20 and 30 years of HCV infection was 21% (16–28%) and 49% (40–59%), respectively. Longer duration of HCV infection was significantly associated with slower rate of fibrosis progression. The overall rate ratio of cirrhosis between individuals coinfected with HIV/HCV and monoinfected with HCV (n = 27 studies) was 2.1 (1.5–3.0), 2.5 (1.8–3.4) in the non-HAART group, and 1.7 (1.1–2.8) in the HAART group.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. &lt;EM&gt;AIDS&lt;/EM&gt; 2008 Oct 1;22(15):1979-91.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor generally via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323525</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1432-2277.2008.00804.x]]&gt;</url>
    <title>New onset diabetes mellitus after liver transplantation and hepatitis C virus infection: meta-analysis of clinical studies</title>
    <publicationDate>2009-04-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,LIVER TRANSPLANTATION,RECENT ADDITIONS,AUGUST 2009,SURGERY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The present meta-analysis based on retrospective studies suggested a significant relationship between&amp;nbsp;hepatitis C&amp;nbsp;virus (HCV)&amp;nbsp;and new onset diabetes mellitus (NODM) after&amp;nbsp;liver transplantation (LT), and it seems that HCV infection might also increase the prevalence of persistent-NODM (P-NODM).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We electronically searched databases of MEDLINE, EMBASE and the Cochrane Library from January 1980 to January 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Only retrospective studies could be identified. Seven of them were subjected to the meta-analysis. Analysis was performed by using &lt;SPAN class=smallcapitals&gt;revman&lt;/SPAN&gt; 4.2 software. We found that HCV increased the prevalence of NODM [OR 2.46; 95%CI (1.44, 4.19)]. Then, we further analyzed the association between HCV and persistent-NODM (P-NODM) after LT. The result showed that prevalence of P-NODM was higher in HCV-positive group than in HCV-negative group with marginally statistical significance [OR&amp;nbsp;=&amp;nbsp;1.39; 95%CI (1.06, 1.83)].&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Chen T, Jia H, Li J, Chen X, Zhou H, Tian H. New onset diabetes mellitus after liver transplantation and hepatitis C virus infection: meta-analysis of clinical studies. &lt;EM&gt;Transpl Int&lt;/EM&gt; 2009 Apr;22(4):408-15.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293847</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1892753/pdf/nihms-22741.pdf]]&gt;</url>
    <title>Non-injection drug use and hepatitis C Virus: a systematic review</title>
    <publicationDate>2007-06-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Scheinmann R, Hagan H, Lelutiu-Weinberger C, Stern R, Des Jarlais DC, Flom PL, Strauss S.&amp;nbsp; Drug and Alcohol Dependency, 2007 Jun 15;89(1):1-12. Epub 2006 Dec 15.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract: &lt;/STRONG&gt;This systematic review examined the evidence on the prevalence of the Hepatitis C Virus (HCV) in non-injecting drug users (NIDUs) who sniff, smoke or snort drugs such as heroin, cocaine, crack or methamphetamine. The search included studies published from January 1989 to January 2006. Twenty-eight eligible studies were identified and the prevalence of HCV in these NIDU populations ranged from 2.3 to 35.3%. There was substantial variation in study focus and in the quality of the NIDU data presented in the studies. The results of our systematic review suggested that there are important gaps in the research of HCV in NIDUs. We identified a problem of study focus; much of the research did not aim to study HCV in users of non-injection drugs. Instead, NIDUs were typically included as a secondary research concern, with a principal focus on the problem of transmission of HCV in IDU populations. Despite methodological issues, HCV prevalence in this population is much higher than in a non-drug using population, even though some IDUs might have inadvertently been included in the NIDU samples. These studies point to a real problem of HCV in NIDU populations, but the causal pathway to infection remains unclear.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>295240</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.bsg.org.uk/pdf_word_docs/endo_%20nonmed.pdf]]&gt;</url>
    <title>Non-medical endoscopists</title>
    <publicationDate>2005-08-01T00:00:00</publicationDate>
    <publisher>British Society of Gastroenterology</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,DIAGNOSTIC PROCEDURES,GASTROINTESTINAL ENDOSCOPY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A Report of the Working Party of the British Society of Gastroenterology</description>
    <body>&lt;![CDATA[ &lt;P&gt;The British Society of Gastroenterology is an organisation focused on the promotion of gastroenterology within the United Kingdom. It has over three thousand members drawn from the ranks of physicians, surgeons, pathologists, radiologists, scientists, nurses, dietitians, and others interested in the field. Founded in 1937 it has grown from a club to be a major force in British medicine, with representation within the British Royal Colleges and thus to the Department of Health and Government. Internationally it is represented at World and European level. The BSG is a registered charity.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary: &lt;/STRONG&gt;This is a report of the British Society for Gastroenterology on non-medical endoscopists, particularly nurse endoscopists.&amp;nbsp; Key points are:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Non-medical endoscopists, particularly nurses are already an integral part of the national gastrointestinal service and contribute significantly. 
&lt;LI&gt;Such practitioners are safe, competent, effective and thorough. There is strong patient approval for their role. 
&lt;LI&gt;The practical and legal risks have been addressed by the development of robust training pathways and clinical governance. The Training Programme developed by JAG is a requirement for all endoscopists. 
&lt;LI&gt;The role of non-medical endoscopists is developing and expanding to include therapeutic endoscopy and training. 
&lt;LI&gt;The development of non-medical endoscopists from non-health care backgrounds is in progress. 
&lt;LI&gt;Nurses, like doctors, register with their professional council. Non-medical endoscopists from other disciplines will probably be regulated by the Health Profession Council. 
&lt;LI&gt;Endoscopists in training must have a&amp;nbsp;recognised supervisor and a process of mentoring is strongly advised for all independent non-medical endoscopists. 
&lt;LI&gt;It is essential that aspiring endoscopists, their medical colleagues, trainers and employing trusts recognise the benefits, risks, medicolegal implications and training requirements.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>387180</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.jhep.2010.03.026]]&gt;</url>
    <title>Null genotypes of GSTM1 and GSTT1 contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis</title>
    <publicationDate>2010-09-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATOCELLULAR CARCINOMA,RECENT ADDITIONS,CANCER,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt;&amp;nbsp;&lt;SPAN&gt;This meta-analysis suggests null genotypes of GSTM1 and GSTT1 are both associated with increased &lt;SPAN&gt;&lt;SPAN&gt;hepatocellular carcinoma&lt;/SPAN&gt;&lt;/SPAN&gt; (HCC) risk in Asians, and individuals with the dual null genotype of GSTM1/GSTT1 are particularly susceptible to developing HCC.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; &lt;SPAN&gt;Studies investigating the associations between glutathione S-transferase (GST) genetic polymorphisms and HCC risk have reported controversial results. Thus, a meta-analysis was performed to clarify the effects of GSTM1 and GSTT1 polymorphisms on HCC risk.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; &lt;SPAN&gt;We identified 132 relevant records through a literature search up to November 22, 2009, and 24 individual case-control studies from 23 publications were finally included, involving a total of 3349 HCC cases and 5609 controls. Subgroup analyses were performed by ethnicity, or by area according to the incidence rate and hepatitis virus status.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;SPAN&gt;Analyses of total relevant studies showed an increased HCC risk was significantly associated with null genotypes of GSTM1 (OR=1.26, 95% CI 1.03-1.54, p(OR)=0.027) and GSTT1 (OR=1.28, 95% CI 1.09-1.51, p(OR)=0.002). In addition, the GSTM1-GSTT1 interaction analysis showed that the dual null genotype of GSTM1/GSTT1 was significantly associated with increased HCC risk (OR=1.89, 95% CI 1.38-2.60, p(OR)&amp;lt;0.001). Subgroup analyses showed that the associations above were still statistically significant in Asians (p(GSTM1)=0.017, p(GSTT1)=0.001, p(Dual null genotype)&amp;lt;0.001), high-rate areas (p(GSTM1)=0.012, p(GSTT1)=0.006, p(Dual null genotype)&amp;lt;0.001), and HBV-dominant areas (p(GSTM1)=0.003, p(GSTT 1)=0.003, p(Dual null genotype)&amp;lt;0.001).&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Wang B, Huang G, Wang D, Li A, Xu Z, Dong R, Zhang D, Zhou W. Null genotypes of GSTM1 and GSTT1 contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis. &lt;EM&gt;J Hepatol&lt;/EM&gt; 2010;53(3):508-18.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>126636</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/15536866]]&gt;</url>
    <title>Nutrition in acute care</title>
    <publicationDate>2004-09-01T00:00:00</publicationDate>
    <publisher>Royal College of Physicians of London</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COMMON CLINICAL PRESENTATIONS,DIAGNOSTIC PROCEDURES,NUTRITION ASSESSMENT,ENTERAL,MALNUTRITION,PARENTERAL,THERAPEUTIC NUTRITION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A guide and professional education to hospital clinicians to aid better recognition and treatment of malnutrition.</description>
    <body>&lt;![CDATA[ &lt;P&gt;A guide and professional education to hospital clinicians to aid better recognition&amp;nbsp;and treatment of malnutrition.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Key points:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Malnutrition is common in hospitalised patients but is underrecognised and undertreated. It increases mortaity and comlications, and delays recovery from illness during and after hospital stay.&lt;/P&gt;
&lt;P&gt;Nutritional screening shoudl be carried out routinely in patients admitted to hospital using a relaiable and valid tool e.g. &lt;A href="nelh:126632:0" name=internalLink&gt;Screening tool for adults at risk of malnutrition&lt;/A&gt;&lt;STRONG&gt; &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The doctor has overall responsibility for the nutritional care of the patient; this may begin in hopspital and continue in the community.&lt;/P&gt;
&lt;P&gt;Nutritional support teams can improve the clinical outcome of patients requiring specialist nutritional support.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal. Members of the Royal College of Physicians of London receive a print copy with their membership.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>333544</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.obesitylearningcentre-nhf.org.uk/]]&gt;</url>
    <title>Obesity Learning Centre</title>
    <publicationDate></publicationDate>
    <publisher>National Heart Forum</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COMMON CLINICAL PRESENTATIONS,OBESITY,RECENT ADDITIONS,OBESITY,EDUCATION,EDUCATION,BIOLOGICAL COMPOSITION,NATIONAL ORGANISATIONS,PUBLIC HEALTH,DETERMINANTS,ORGANISATIONS,POPULATIONS,DECEMBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This portal aims to share best practice, provide links to information, training and data available on obesity. This website has been developed to support those people who work, either directly or indirectly, on promoting a healthy weight and tackling obesity.</description>
    <body>&lt;![CDATA[ &lt;STRONG&gt;Summary:&amp;nbsp;&lt;/STRONG&gt;The Obesity Learning Centre (OLC) aims to share best practice, provide links to information, training and data available on obesity. This website has been developed to support those people who work, either directly or indirectly, on promoting a healthy weight and tackling obesity. 
&lt;P&gt;The OLC has been developed by the National Heart Forum, with the support of the Department of Health and Department for Children, Schools and Families.&lt;/P&gt;
&lt;P&gt;The Obesity Improvement Programme aims provide information, tools, training and innovation to strengthen local capabilities to prevent and treat overweight and obesity via the Obesity Learning Centre (OLC).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>305626</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://learning.bmj.com/learning/search-result.html?moduleId=5004431&amp;searchTerm=?obesity?&amp;page=0]]&gt;</url>
    <title>Obesity: a guide to prevention and management</title>
    <publicationDate></publicationDate>
    <publisher>NICE/BMJ Learning</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COMMON CLINICAL PRESENTATIONS,DISEASE PREVENTION,OBESITY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;These online education tools have been developed by NICE in collaboration with BMJ Learning. BMJ Learning offers a wide range of learning resources, commissioned by the BMJ Group. The learning resources deal with everyday issues in primary care and hospital medicine. They are evidence based and peer reviewed. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aims: &lt;/STRONG&gt;After completing this module you should know:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;How best to assess patients with overweight and obesity 
&lt;LI&gt;How best to manage patients who need to lose weight 
&lt;LI&gt;How best to communicate with patients with obesity so they can help to manage their condition 
&lt;LI&gt;When you should refer patients to a specialist. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&amp;nbsp; Free registration with the site is required.&amp;nbsp; To register, click "Start module" and then "Register here".&amp;nbsp; Do not select the option to log in via Athens as access to BMJ Learning is not currently&amp;nbsp;part of NHS Athens accounts.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309222</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.crohns.2008.04.001]]&gt;</url>
    <title>Occurrence of demyelinating diseases after anti-TNFalpha treatment of inflammatory bowel disease: A Danish Crohn Colitis Database</title>
    <publicationDate>2008-12-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MULTIPLE SCLEROSIS,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,GASTROENTEROLOGY &amp; LIVER DISEASES,CROHN'S DISEASE,CONDITIONS,FEBRUARY 2010,ISOLATED DEMYELINATING SYNDROMES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The literature review revealed an up to four-fold increased risk of demyelinating diseases, in particular MS, in IBD patients in general. The risk of developing MS in the anti-TNFa treated Danish cohort did apparently not exceed this risk.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; The aim was to conduct a systematic review of literature on occurrence of demyelinating diseases in IBD patients, to assess a national Danish anti-TNFa treated IBD cohort in order to search for and describe the IBD cases with coexisting demyelinating diseases, and finally to compare the occurrence of MS in the anti-TNFa cohort to the occurrence in the general Danish population.&lt;/P&gt;
&lt;P&gt;A systematic MEDLINE literature search was conducted, medical files were scrutinized for identification and description of cohort patients with demyelinating disease, and risk of MS was calculated as a standardized morbidity ratio (SMR) using general population data for comparison.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Four studies on the risk of demyelinating diseases in IBD were identified. One study revealed an observed prevalence of MS at onset of IBD at 3.7 times the expected (95% CI, 0.8–10.8). In the Danish anti-TNFa IBD cohort, 4 out of 651 patients developed demyelinating disorders after anti-TNFa treatment. The SMR for developing MS among Danish IBD patients treated with anti-TNFa was 4.2 (95% CI, 0.1–23.0).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Andersen, N. N., Caspersen, S., Jess, T., &amp;amp; Munkholm, P. (2008) Occurrence of demyelinating diseases after anti-TNFalpha treatment of inflammatory bowel disease: A Danish Crohn Colitis Database study. &lt;I&gt;Journal of Crohn's and Colitis&lt;/I&gt;, 2(4), 304-309.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in December 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>310840</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2702.2008.02577.x]]&gt;</url>
    <title>Older people and inflammatory bowel disease: a systematic review</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Generally speaking, the clinical features of inflammatory bowel disease are similar in younger and older people, as are indications for surgery, survival and the usual wide spectrum of severity of disease. Corticosteroid treatment carries additional risk for older people. The studies used both retrospective and prospective designs, with the former using patient records, and the latter using follow-up of patients with inflammatory bowel disease. Sample sizes were adequate for statistical analyses but there was no reference to reliability or validity of data collection methods. None of the studies considered psychosocial aspects, or the role of nurses in caring for people with inflammatory bowel disease. A specific gerontological perspective was lacking from the papers reviewed. While the clinical features of inflammatory bowel disease are similar in younger and older people, with the bimodal distribution of age of onset of inflammatory bowel disease, the possibility exists that quality of life and adjustment in older people depend on age of onset. This has not been investigated. Future lines of enquiry taking psychosocial aspects of inflammatory bowel disease into account in older people are explored.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; &lt;SPAN class=h5-inline&gt;&lt;/SPAN&gt;A systematic review of literature related to inflammatory bowel disease and older people was carried out using the MEDLINE, CINAHL EMBASE and Cochrane databases between 1990–2006.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Smith, G.D., Watson, R., &amp;amp; Thompson, D.R. (2008) Older people and inflammatory bowel disease: a systematic review. &lt;EM&gt;Journal of Clinical Nursing&lt;/EM&gt;, 17(11c):400-406.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309181</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1007/s10620-007-0006-z]]&gt;</url>
    <title>On the benefit of probiotics in the management of pouchitis in patients underwent ileal pouch anal anastomosis: a meta-analysis of controlled clinical trials</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Springer</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,DISEASE PREVENTION,POLYPS,PROBIOTICS,DIETARY SUPPLEMENTS,NON-MALIGNANT NEOPLASMS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The benefit of probiotics in the management of pouchitis after IPAA operation was confirmed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; The Pubmed, Medline, EMbase, CINAHL, Web of Science, and Scopus bibliographic, and Google Scholar databases were searched between 1966 and May 2007, and relevant controlled clinical trials were extracted, reviewed, and validated according to the study protocol. The outcome of interest was for pouchitis defined by a pouchitis disease activity index (PDAI) =7.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Five randomized, placebo-controlled clinical trials were included in the meta-analysis. Pooling of the results from these trials yielded an odds ratio (OR) of 0.04 with a 95% CI of 0.01–0.14 (&lt;I&gt;P&lt;/I&gt;&amp;nbsp;&amp;lt;&amp;nbsp;0.0001) in the treatment group in comparison with the placebo group.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Elahi, B., Nikfar, S., Derakhshani, S., Vafaie, M., &amp;amp; Abdollahi, M. (2008) On the benefit of probiotics in the management of pouchitis in patients underwent ileal pouch anal anastomosis: a meta-analysis of controlled clinical trials. &lt;I&gt;Digestive Diseases &amp;amp; Sciences&lt;/I&gt;, 53(5):1278-1284.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;See also: &lt;/STRONG&gt;&lt;A href="nelh:342863:0" name=internalLink&gt;DARE record&lt;/A&gt; for this article.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in May 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309168</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.phrs.2008.08.003]]&gt;</url>
    <title>Once daily 5-aminosalicylic acid for the treatment of ulcerative colitis: are we there yet?</title>
    <publicationDate>2008-09-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Abstract:&lt;/STRONG&gt; 5-Aminosalicylate (5-ASA) agents remain the mainstay treatment in ulcerative colitis (UC). A number of oral 5-ASA agents are commercially available, including azo-bond pro-drugs such as sulfasalazine, olsalazine and balsalazide, and delayed- and controlled-release forms of mesalazine. In addition, the effectiveness of oral therapy relies on good compliance, which may be adversely affected by frequent daily dosing and a large number of tablets. Furthermore, poor adherence has been shown to be an important barrier to successful management of patients with UC. Recently, new, once daily formulations of mesalazine including the unique multi-matrix delivery system and mesalazine granules were proven to be efficacious in inducing and maintaining remission in mild-to-moderate UC, with a good safety profile comparable to that of other oral mesalazine formulations. In addition, they offer the advantage of low pill burden and may contribute to increased long-term compliance and treatment success in clinical practice and might potentially further contribute to a decline in the risk for UC-associated colon cancers. In this systematic review, the authors summarize the available literature on the short- and medium-term efficacy and safety of the new once daily mesalazine formulations.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Lakatos, P. L. &amp;amp; Lakatos, L. (2008) Once daily 5-aminosalicylic acid for the treatment of ulcerative colitis: are we there yet? &lt;I&gt;Pharmacological Research&lt;/I&gt;, 58(3-4):190-195.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in September 2008&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>390002</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://ebm.bmj.com/content/15/5/155.short?rss=1]]&gt;</url>
    <title>Once-only flexible sigmoidoscopy screening for adults aged 55–64 years old reduces the incidence of colorectal cancer and colorectal cancer deaths</title>
    <publicationDate>2010-10-01T00:00:00</publicationDate>
    <publisher>BMJ Journals</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,DIAGNOSTIC PROCEDURES,GASTROINTESTINAL ENDOSCOPY,CANCER,RECENT ADDITIONS,COLON CANCER,RECTAL CANCER,FLEXIBLE SIGMOIDOSCOPY,OCTOBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Blom J. (2010) Once-only flexible sigmoidoscopy screening for adults aged 55–64 years old reduces the incidence of colorectal cancer and colorectal cancer deaths. &lt;EM&gt;Evidence-Based Medicine&lt;/EM&gt; 15(5):155-156&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Context:&lt;/STRONG&gt; Colorectal cancer is an important health problem due to high morbidity and mortality but curable at an early stage and therefore ideal for screening. The faecal occult blood test (Hemoccult) has been demonstrated to reduce colorectal cancer mortality in population-based screening1 and is used in several European screening programmes. In addition, screening programmes with flexible sigmoidoscopy also have the potential of reducing the incidence of colorectal cancer by the removal of precursor stage – the adenomatous polyp. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Atkin and colleagues have performed a randomised controlled trial (RCT) to evaluate the effect of once-only flexible sigmoidoscopy screening on incidence and mortality of colorectal cancer in the 55 to 64-year-old UK population. At 14 centres, approximately 170 000 people who had indicated in a questionnaire an interest to comply if they were offered screening were randomly allocated to the … &lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Evidence-Based Medicine&lt;/EM&gt; is a secondary evidence journal, containing informative abstracts and expert commentaries about the best quality research from primary care medicine.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to NHS staff via Athens.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>332632</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/ebm.14.6.171]]&gt;</url>
    <title>Once-only flexible sigmoidoscopy screening for colorectal cancer may not reduce colorectal cancer incidence or mortality</title>
    <publicationDate>2009-12-01T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ SCREENING,ADULT,COLORECTAL (BOWEL) CANCER,GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,DIAGNOSTIC PROCEDURES,GASTROINTESTINAL ENDOSCOPY,DISEASE PREVENTION,CANCER,SCREENING,RECENT ADDITIONS,DECEMBER 2009,FLEXIBLE SIGMOIDOSCOPY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Evidence-Based Medicine is a secondary evidence journal, containing informative abstracts and expert commentaries about the best quality research from primary care medicine.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Koretz RL. Once-only flexible sigmoidoscopy screening for colorectal cancer may not reduce colorectal cancer incidence or mortality. &lt;EM&gt;Evid Based Med &lt;/EM&gt;2009;14(6):171.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt; A review of the original article: Hoff G, Grotmol T, Skovlund E, et al. Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: randomised controlled trial. &lt;EM&gt;BMJ&lt;/EM&gt; 2009;338:b1846.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to NHS staff via Athens.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>310801</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://ebm.bmj.com/cgi/content/short/14/2/44]]&gt;</url>
    <title>Ondansetron reduced the need for intravenous hydration in children with acute gastritis/gastroenteritis and dehydration</title>
    <publicationDate>2009-04-01T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,STOMACH,GASTRITIS,SMALL INTESTINE,INFECTIONS,INFECTIONS,ENTERITIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Edmonds M. Therapeutics: Ondansetron reduced the need for intravenous hydration in children with acute gastritis/gastroenteritis and dehydration.&amp;nbsp; Evid Based Med 2009 Apr;14(2):44.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary: &lt;/STRONG&gt;A review of the original article: Roslund G, Hepps TS, McQuillen KK. The role of oral ondansetron in children with vomiting as a result of acute&lt;BR&gt;gastritis/gastroenteritis who have failed oral rehydration therapy: a randomized controlled trial. Ann Emerg Med 2008;52:22–9.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bibliographic details:&lt;/STRONG&gt; Evidence-Based Medicine is a secondary evidence journal, containing informative abstracts and expert commentaries about the best quality research from primary care medicine.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in April 2009.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to NHS staff via Athens.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>380659</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.3851/IMP1464]]&gt;</url>
    <title>Optimal length of antiviral therapy in patients with hepatitis C virus genotypes 2 and 3: a meta-analysis</title>
    <publicationDate>2009-12-01T00:00:00</publicationDate>
    <publisher>International Medical Press</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,RECENT ADDITIONS,CHRONIC HEPATITIS B,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; A shorter course (12-16 weeks) of combination therapy does not impair efficacy compared with a 24-week course in&amp;nbsp;hepatitis C virus (HCV)&amp;nbsp;genotypes 2 and 3 patients who achieve an rapid virological response (RVR). HCV patients without RVR should consider 24 weeks of treatment.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Current guidelines recommend a duration of 24 weeks of treatment with pegylated interferon and ribavirin for patients infected with chronic HCV genotypes 2 and 3. Several trials investigated whether shorter treatment duration is equally effective in achieving sustained virological response (SVR). Our aim was to determine the optimal length of treatment in patients with HCV genotypes 2 and 3.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Systematic literature identified eight randomized controlled trials (RCTs). Meta-analyses were carried out on SVR data from three studies randomized at baseline and five studies randomized at RVR to either 12-16 weeks or a 24-week course.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Pooled SVR data were higher in standard treatment in RCTs that randomized at baseline, with a relative risk (RR) of 0.88 (95% confidence interval [CI] 0.76-1.01). The pooled proportion of SVR rates of RCTs that randomized at RVR were similar in the short treatment group (82%) as in the standard treatment (83%), with the pooled effect given by a RR of 1.00 (95% CI 0.92-1.09).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Slavenburg S, Weggelaar I, van Oijen MG, Drenth JP. Optimal length of antiviral therapy in patients with hepatitis C virus genotypes 2 and 3: a meta-analysis. &lt;EM&gt;Antivir Ther&lt;/EM&gt; 2009;14(8):1139-48.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>311562</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1038/ajg.2009.3]]&gt;</url>
    <title>Oral antibiotic prophylaxis reduces spontaneous bacterial peritonitis occurrence and improves short-term survival in cirrhosis: a meta-analysis</title>
    <publicationDate>2009-04-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COMMON CLINICAL PRESENTATIONS,LIVER,ASCITES,CIRRHOTIC ASCITES,NON-ALCOHOLIC,ALCOHOLIC LIVER DISEASE,ALCOHOLIC CIRRHOSIS,PERITONITIS,CIRRHOSIS,ALCOHOLIC]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Antibiotic prophylaxis improved short-term survival in treated patients when compared with untreated control groups and reduced the overall risk of infections, including SBP, during follow-up. In summary, antibiotic prophylaxis should be considered for high-risk cirrhotic patients with ascites.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We conducted a comprehensive search of the Cochrane Database of Systematic Reviews, MEDLINE (1966 to May 2008), bibliographies of retrieved trials, and reports presented at major scientific meetings. Eligible studies included prospective, randomized controlled trials comparing high-risk cirrhotic patients receiving oral antibiotic prophylaxis for SBP with groups receiving placebo or no intervention. Dichotomous outcomes were reported as relative risk (RR) with 95% confidence intervals (CIs).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Eight studies with a total of 647 patients were identified and included in this analysis. The combined analysis showed an overall mortality benefit (RR=0.65; 95% CI, 0.48–0.88) for treatment groups. The overall mortality rate was 16% (52/324) for treated patients and 25% (81/323) for the control group. Groups treated with prophylactic antibiotics also demonstrated a lower incidence of all infections (including SBP) of 6.2% as compared with the control groups with a rate of 22.2% (RR=0.32; &lt;I&gt;P&lt;/I&gt;&amp;lt;0.00001; 95% CI, 0.20–0.51). Subgroup analysis showed a survival benefit at 3 months (RR=0.28; &lt;I&gt;P&lt;/I&gt;=0.005; 95% CI, 0.12–0.68).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Saab S, Hernandez JC, Chi AC, Tong MJ.&amp;nbsp;Oral antibiotic prophylaxis reduces spontaneous bacterial peritonitis occurrence and improves short-term survival in cirrhosis: a meta-analysis.&lt;EM&gt; Am J Gastroenterol&lt;/EM&gt; 2009;104(4):993-1001.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;See also: &lt;/STRONG&gt;&lt;A href="nelh:342960:0" name=internalLink&gt;DARE record&lt;/A&gt; for this article.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>387996</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1053/j.gastro.2010.06.010]]&gt;</url>
    <title>Organ failure and infection of pancreatic necrosis as determinants of mortality in patients with acute pancreatitis</title>
    <publicationDate>2010-09-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,PANCREAS,ACUTE PANCREATITIS,PANCREATITIS,RECENT ADDITIONS,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; &lt;SPAN&gt;In patients with acute pancreatitis, the absolute influence of &lt;SPAN&gt;organ failure&lt;/SPAN&gt; (OF) and &lt;SPAN&gt;infected pancreatic necrosis&lt;/SPAN&gt; (IPN) on mortality is comparable and thus the presence of either indicates severe disease. The relative risk of mortality doubles when OF and IPN are both present and indicates extremely severe disease or critical acute pancreatitis.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; &lt;SPAN&gt;There is no consistency between the individual studies in the literature on whether OF or IPN is the main determinant of severity in acute pancreatitis. We aimed to statistically aggregate the available data and determine the pooled influence of OF and IPN on mortality in patients with acute pancreatitis.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; &lt;SPAN class=sub_abstract_label&gt;&lt;/SPAN&gt;&lt;SPAN&gt;The search for relevant observational studies was undertaken in the MEDLINE, EMBASE, and Scopus electronic databases, as well as in the proceedings of major gastroenterology meetings. The summary estimates are presented as relative risk (RR) and 95% confidence interval (CI).&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;SPAN&gt;Fourteen studies comprising 1478 patients with acute pancreatitis were meta-analyzed. A total of 600 patients developed OF and 179 of them died (mortality, 30%); 314 patients developed IPN and 102 of them died (mortality, 32%). In a stratified analysis, patients with OF and IPN had a significantly higher risk of death in comparison with patients with OF and no IPN (RR = 1.94; 95% CI: 1.32-2.85; P = .0007) and in comparison with patients with IPN and no OF (RR = 2.65; 95% CI: 1.30-5.40; P = .0007).&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Petrov MS, Shanbhag S, Chakraborty M, Phillips AR, Windsor JA. Organ failure and infection of pancreatic necrosis as determinants of mortality in patients with acute pancreatitis. &lt;EM&gt;Gastroenterology &lt;/EM&gt;2010;139(3):813-20.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317683</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19502959]]&gt;</url>
    <title>Orthotopic liver transplantation: T-tube or not T-tube? Systematic review and meta-analysis of results</title>
    <publicationDate>2009-06-15T00:00:00</publicationDate>
    <publisher>Lippincott Williams &amp; Wilkins</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,LIVER TRANSPLANTATION,RECENT ADDITIONS,JUNE 2009,SURGERY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt;&amp;nbsp;The systematic review and meta analysis favor the abandonment of T-tubes in orthotopic liver transplantation.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We pooled the outcomes of 1027 patients undergoing choledocho-choledochostomy with or without T-tube in 9 of 46 screened trials by means of fixed or random effects models.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The “without T-tube” and “with T-tube” groups had equivalent outcomes for: anastomotic bile leaks or fistulas, choledocho-jejunostomy revisions, dilatation and stenting, hepatic artery thromboses, retransplantation, and mortality due to biliary complications. The “without T-tube” group had better outcomes when considering “fewer episodes of cholangitis,” “fewer episodes of peritonitis,” and showed a favorable trend for “overall biliary complications.” Although the “with T-tube” group showed superior result for “anastomotic and nonanastomotic strictures,” the incidence of interventions was not diminished.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Sotiropoulos GC, Sgourakis G, Radtke A, Molmenti EP, Goumas K, Mylona S, Fouzas I, Karaliotas C, Lang H. Orthotopic liver transplantation: T-tube or not T-tube? Systematic review and meta-analysis of results. Transplantation. 2009 Jun 15;87(11):1672-80.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to NHS staff via Athens.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>295249</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.bsg.org.uk/pdf_word_docs/out_of_hours_07.doc]]&gt;</url>
    <title>Out of hours gastroenterology - a position paper</title>
    <publicationDate>2007-07-01T00:00:00</publicationDate>
    <publisher>British Society of Gastroenterology</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,DIAGNOSTIC PROCEDURES,GASTROINTESTINAL ENDOSCOPY,SURGERY,THEATRE MANAGEMENT,ETHICS AND PROFESSIONAL STANDARDS,EFFICIENCY,SURGERY,STAFFING &amp; SKILL MIX]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The British Society of Gastroenterology is an organisation focused on the promotion of gastroenterology within the United Kingdom. It has over three thousand members drawn from the ranks of physicians, surgeons, pathologists, radiologists, scientists, nurses, dietitians, and others interested in the field. Founded in 1937 it has grown from a club to be a major force in British medicine, with representation within the British Royal Colleges and thus to the Department of Health and Government. Internationally it is represented at World and European level. The BSG is a registered charity.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary:&amp;nbsp; &lt;/STRONG&gt;There has been a decline in the amount of out-of-hours (OOH)&amp;nbsp;access available for patients requiring gastrointestinal endoscopy.&amp;nbsp; The BSG recommends that all acute hospitals should have&amp;nbsp;procedures for OOH endoscopy, but&amp;nbsp;current arrangements are unsustainable and bad for patients.&amp;nbsp; This document makes a number of recommendations to support efforts to improve the situation.&amp;nbsp; It suggest the future configuration of services, and provides a "toolkit" for service provision in institutions where it does not currently exist.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281310</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17156150?ordinalpos=6&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Overall and cause-specific mortality in ulcerative colitis: meta- analysis of population-based inception cohort studies</title>
    <publicationDate>2008-03-10T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: &lt;/P&gt;
&lt;P&gt;Jess, T. &lt;SPAN title="The American journal of gastroenterology."&gt;&lt;A href="#javascript:AL_get(this," ?jour?, ?Am J Gastroenterol.?);?&gt;Am J Gastroenterol.&lt;/A&gt;&lt;/SPAN&gt; 2007 Mar;102(3):609-17.&lt;/P&gt;
&lt;P class=abstract&gt;OBJECTIVES: It remains debated whether patients with ulcerative colitis (UC) are at greater risk of dying and whether a possible alteration in mortality can be attributed to specific causes of death. We aimed to clarify this issue by conducting a meta-analysis of population-based inception cohort studies on overall and cause-specific mortality in patients with UC. METHODS: The MEDLINE search engine and abstracts from international conferences were searched for relevant literature by use of explicit search criteria. STATA meta-analysis software was used to calculate pooled risk estimates (SMR, standardized mortality ratio, observed/expected deaths) of overall mortality and specific causes of death and to conduct metaregression analyses of the influence of specific variables on SMR. RESULTS: Ten papers fulfilled the inclusion criteria, reporting SMRs varying from 0.7 to 1.4. The overall pooled estimate was 1.1 (95% confidence interval [CI] 0.9-1.2, P= 0.42). However, greater risk of dying was observed during the first years of follow-up, in patients with extensive colitis, and in patients from Scandinavia. Metaregression analysis showed an increase in SMR by increasing cohort size. UC-related mortality accounted for 17% of all deaths. Mortality from gastrointestinal diseases, nonalcoholic liver diseases, pulmonary embolisms, and respiratory diseases was increased whereas mortality from pulmonary cancer was reduced. CONCLUSIONS: The overall risk of dying in patients with UC did not differ from that of the background population, although subgroups of patients were at greater risk of dying. The cause-of-death distribution seemed to differ from that of the background population.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;The American Journal of Gastroenterology is the official journal of the American College of Gastroenterology and publishes a variety of material including editorials, clinical reviews, correspondence and research articles.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: This article is &lt;STRONG&gt;not&lt;/STRONG&gt; available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>122803</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://clinicalevidence.bmj.com/ceweb/conditions/dsd/0409/0409_background.jsp]]&gt;</url>
    <title>Pancreatic cancer</title>
    <publicationDate>2007-11-20T00:00:00</publicationDate>
    <publisher>BMJ Clinical Evidence</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,PANCREAS,CANCER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;NOTE&lt;/STRONG&gt;: The links provided for Clinical Evidence pertain to the "about the condition" page.&amp;nbsp; Should you require additional information such as interventions please link from options in the left hand column from the "about the condition" page.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;What is Clinical Evidence?&lt;/STRONG&gt; Clinical Evidence summarises the current state of knowledge and uncertainty about the prevention and treatment of clinical conditions, based on thorough searches and appraisal of the literature.&amp;nbsp; &lt;A href="http://www.clinicalevidence.com/ceweb/about/index.jsp" target="_blank"&gt;Link here&lt;/A&gt; for additional information on the Clinical Evidence methodology, team, and text.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Availability&lt;/STRONG&gt;: Clinical Evidence is available without a password or subscription within England and Wales.&amp;nbsp; For other areas, availability is dependent on local/institutional agreements and/or with a subscription.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344536</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://ebn.bmj.com/content/13/1/14.full]]&gt;</url>
    <title>Partner-assisted emotional disclosure intervention may improve relationship quality in couples where one partner has gastrointestinal cancer and has difficulty discussing cancer-related concerns</title>
    <publicationDate>2010-01-01T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,CANCER,RECENT ADDITIONS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Evidence-Based&amp;nbsp;Nursing is a secondary evidence journal, containing informative abstracts and expert commentaries about the best quality research from primary care medicine.&amp;nbsp;Evidence-Based Nursing surveys a wide range of international medical journals applying strict criteria for the quality and validity of research. Practising clinicians assess the clinical relevance of the best studies. The key details of these essential studies are presented in a succinct, informative abstract with an expert commentary on its clinical application.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Kelly D. Partner-assisted emotional disclosure intervention may improve relationship quality in couples where one partner has gastrointestinal cancer and has difficulty discussing cancer-related concerns. &lt;EM&gt;Evid Based Nurs&lt;/EM&gt; 2010;13(1):14-5.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt; A review of the original article: Porter LS, Keefe FJ, Baucom DH, et al. Partner-assisted emotional disclosure for patients with gastrointestinal cancer: results from a randomized controlled trial. &lt;EM&gt;Cancer &lt;/EM&gt;2009;115:4326–38.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309031</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1572-0241.2008.01999.x]]&gt;</url>
    <title>Passive smoking and inflammatory bowel disease: a meta-analysis</title>
    <publicationDate>2008-09-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Our meta-analysis suggests that there is not a strong association between childhood passive smoke exposure and the development of CD. We found no evidence that childhood passive smoke exposure exerts a protective effect against UC, as is the case in active smoke exposure. The heterogeneity among the small number of studies limited the ability to draw conclusions about prenatal smoke exposure.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We searched the MEDLINE and EMBASE databases to identify observational studies regarding the relationship between prenatal and/or childhood passive smoke exposure and the development of Crohn's disease (CD) and/or ulcerative colitis (UC). Pooled odds ratios (OR) were calculated for each relationship.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; We searched the MEDLINE and EMBASE databases to identify observational studies regarding the relationship between prenatal and/or childhood passive smoke exposure and the development of Crohn's disease (CD) and/or ulcerative colitis (UC). Pooled odds ratios (OR) were calculated for each relationship.A total of 534 and 699 potential studies were identified from the MEDLINE and EMBASE databases, respectively, of which 13 met all of our inclusion criteria. Overall, we did not observe a positive relationship between childhood passive smoke exposure and CD (OR 1.10, 95% confidence interval [CI] 0.92–1.30) or UC (OR 1.01, 95% CI 0.85–1.20). Likewise, we did not observe an association between prenatal smoke exposure and CD (OR 1.10, 95% CI 0.67–1.80), or prenatal smoke exposure and UC (OR 1.11, 95% CI 0.63–1.97).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Jones DT, Osterman MT, Bewtra M, Lewis JD. Passive smoking and inflammatory bowel disease: a meta-analysis. &lt;BR&gt;&lt;EM&gt;Am J Gastroenterol&lt;/EM&gt; 2008;103(9):2382-93.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323517</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1186/1741-7015-7-15]]&gt;</url>
    <title>Patient to patient transmission of hepatitis B virus: a systematic review of reports on outbreaks between 1992 and 2007</title>
    <publicationDate>2009-04-08T00:00:00</publicationDate>
    <publisher>BioMed Central</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,RECENT ADDITIONS,AUGUST 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The analysis of transmission pathways showed that some breaches in infection control measures, such as administration of drugs using multi-vial compounds and capillary blood sampling, are the most frequent routes for patient-to-patient transmission of hepatitis B virus. Moreover some outbreak reports underlined that heart-transplant recipients are at risk of contracting hepatitis B virus infection during the transvenous endomyocardial biopsy procedure through indirect contact with infected blood as a result of environmental contamination. To prevent transmission, healthcare workers must adhere to standard precautions and follow fundamental infection control principles, such as the use of sterile, single-use, disposable needles and avoiding the use of multi-vial compounds in all healthcare settings including outpatient settings.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; The research was performed using two different databases: the PubMed Database and the Outbreak Database, the worldwide database for nosocomial outbreaks. Selection of papers was carried out using the Quorom algorithm, and to avoid selection biases, the inclusion criteria were established before the articles were identified.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Overall, 30 papers were analyzed, reporting on 33 hepatitis B virus outbreaks that involved 471 patients, with 16 fatal cases. Dialysis units accounted for 30.3% of outbreaks followed by medical wards (21.2%), nursing homes (21.2%), surgery wards (15.2), and outpatient clinics (12.1%). The transmission pathways were: multi-vial drugs (30.3%), non-disposable multi-patient capillary blood sampling devices (27.2%), transvenous endomyocardial biopsy procedures (9.1%), and multiple deficiencies in applying standard precautions (9.1%).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Lanini S, Puro V, Lauria FN, Fusco FM, Nisii C, Ippolito G. Patient to patient transmission of hepatitis B virus: a systematic review of reports on outbreaks between 1992 and 2007. &lt;EM&gt;BMC Med&lt;/EM&gt; 2009:7:15.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>371934</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1002/hep.23504]]&gt;</url>
    <title>Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials</title>
    <publicationDate>2010-04-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,RECENT ADDITIONS,APRIL 2010,CHRONIC HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt;&amp;nbsp; Current evidence suggests that pegylated interferon (peginterferon) alpha-2a is associated with higher&amp;nbsp;sustained virological&amp;nbsp;response (SVR)&amp;nbsp;than peginterferon alfa-2b. However, the paucity of evidence on adverse events curbs the decision to definitively recommend one peginterferon over the other, because any potential benefit must outweigh the risk of harm. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; A combination of weekly peginterferon alpha and daily ribavirin represents the standard of care for the treatment of chronic hepatitis C according to current guidelines. It is not established which of the two licensed products (peginterferon alpha-2a or peginterferon alfa-2b) is most effective.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We searched the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, and LILACS through July 2009. Using standardized forms, two reviewers independently extracted data from each eligible trial report. We statistically combined data using a random effects meta-analysis according to the intention-to-treat principle.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; We identified 12 randomized clinical trials, including 5,008 patients, that compared peginterferon alpha-2a plus ribavirin versus peginterferon alfa-2b plus ribavirin. Overall, peginterferon alpha-2a significantly increased the number of patients who achieved a SVR versus peginterferon alfa-2b (47% versus 41%; risk ratio 1.11, 95% confidence interval 1.04-1.19; P = 0.004 [eight trials]). Subgroup analyses of risk of bias, viral genotype, and treatment history yielded similar results. The meta-analysis of adverse events leading to treatment discontinuation included 11 trials and revealed no significant differences between the two peginterferons.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Awad T, Thorlund K, Hauser G, Stimac D, Mabrouk M, Gluud C. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. &lt;EM&gt;Hepatology&lt;/EM&gt; 2010;51(4):1176-84.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>325168</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1038/ajg.2009.311]]&gt;</url>
    <title>Peginterferon plus ribavirin for chronic hepatitis C in patients with human immunodeficiency virus</title>
    <publicationDate>2009-09-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,HIV / AIDS,RECENT ADDITIONS,SEPTEMBER 2009,CHRONIC HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Peginterferon plus ribavirin may be considered for treatment-naive patients with human immunodeficiency virus (HIV) and chronic hepatitis C. Adverse events should be monitored carefully.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; The aim of this study was to assess the effects of peginterferon plus ribavirin for chronic hepatitis C in patients with HIV.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method: &lt;/STRONG&gt;Trials were identified through manual and electronic searches. Randomized trials comparing peginterferon plus ribavirin with other antiviral treatments for patients with chronic hepatitis C and HIV were included. The primary outcome measure was virological response at the end of treatment and after greater than or equal to6 months (sustained). Intention-to-treat meta-analyses including data on all patients who were randomized were carried out.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Seven randomized trials were eligible for inclusion. The patients included had chronic hepatitis C and stable HIV and were not previously treated with interferon or ribavirin (treatment naive). The mean dosages were 180 or 1.5 mug/kg once weekly for peginterferon and 800 mg daily for ribavirin. The treatment duration ranged from 24 to 48 weeks. Peginterferon plus ribavirin increased the proportion of patients with an end-of-treatment or sustained virological response compared with interferon plus ribavirin or peginterferon alone. In subgroup analyses of trials comparing peginterferon plus ribavirin with interferon plus ribavirin, the proportion with a sustained virological response was 26% (109 of 423) for patients with genotype 1 or 4 and 57% (130 of 230) for genotype 2 or 3. Several adverse events occurred, including fatal lactic acidosis and liver failure, but there were no significant differences in mortality rates between treatment groups.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Gluud LL, Marchesini E, Iorio A. Peginterferon plus ribavirin for chronic hepatitis C in patients with human immunodeficiency virus. &lt;EM&gt;Am J Gastroenterol&lt;/EM&gt; 2009;104(9):2335-41.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323701</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1007/s10096-008-0557-8]]&gt;</url>
    <title>Peginterferon vs. interferon in the treatment of different HCV genotype infections in HIV patients</title>
    <publicationDate>2008-12-01T00:00:00</publicationDate>
    <publisher>Springer</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,HIV / AIDS,RECENT ADDITIONS,AUGUST 2009,CHRONIC HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; For genotypes 1 or 4 hepatitic C virus (HCV) and HIV-coinfected patients, both types of peginterferon, a-2a and a-2b, achieved higher SVRs compared with the respective types of interferon.&amp;nbsp; The SVRs achieved in patients infected with HCV genotypes 1 or 4 treated with peginterferon and ribavirin was not satisfactory in comparison with those of patients infected with HCV genotypes 2 or 3, but it is superior when compared with other antivirus therapies.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A Medline literature search was conducted to identify RCTs evaluating SVRs to peginterferon and interferon in HCV/HIV-coinfected patients.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results: &lt;/STRONG&gt;Six studies matched the selection criteria, and the HCV genotype of 1,717 coinfected patients was reported. For genotypes 1 or 4 HCV and HIV-coinfected patients, both types of peginterferon, a-2a and a-2b, achieved higher SVRs compared with the respective types of interferon. The SVRs achieved in patients infected with HCV genotypes 1 or 4 treated with peginterferon and ribavirin was not satisfactory in comparison with those of patients infected with HCV genotypes 2 or 3 (26% vs. 55%). The probability of achieving higher SVRs in patients when treated with peginterferon plus ribavirin increased compared with other therapies, especially for patients coinfected with HCV genotypes 1 or 4 and HIV. The likelihoods of serious adverse effects and withdrawal rates were similar.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;See also: &lt;/STRONG&gt;&lt;A href="nelh:358122:0" name=internalLink&gt;DARE record&lt;/A&gt; for this article.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Zhao S, Cheng D, Liu E, Yu H, Yang H, Xue X, et al. Peginterferon vs. interferon in the treatment of different HCV genotype infections in HIV patients. &lt;EM&gt;Eur J Clin Microbiol Infect&lt;/EM&gt; Dis 2008 Dec;27(12):1183-92.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323695</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1017/S0266462309090084]]&gt;</url>
    <title>Pegylated and non-pegylated interferon-alfa and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and meta-analysis</title>
    <publicationDate>2009-01-01T00:00:00</publicationDate>
    <publisher>Cambridge University Press</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,RECENT ADDITIONS,AUGUST 2009,CHRONIC HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Patients with histologically mild hepatitis C virus (HCV) infection can be successfully treated with both&amp;nbsp;pegylated (PEG)&amp;nbsp;and non-pegylated interferon (IFN) and ribavirin (RBN) combination therapy, and response rates are broadly comparable with those achieved in patients with advanced disease. Treating patients in the early milder stages of HCV is, therefore, a clinically effective option.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We performed a sensitive search of fourteen electronic bibliographic databases for literature that met criteria defined in a research protocol. Two reviewers independently selected studies, extracted data and assessed methodological quality.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Ten randomized, controlled trials (RCTs) were included. Treatment with PEG + RBV combination therapy resulted in significantly higher sustained virological response (SVR) rates than treatment with IFN + RBV combination therapy. Treatment for 48 weeks with PEG + RBV was significantly more effective than the same treatment for 24 weeks. Significantly higher SVR rates were seen with IFN + RBV compared with either IFN monotherapy or no treatment. In the meta-analysis (four IFN trials), the relative risk of not experiencing an SVR was 0.59 (95 percent CI, 0.51 – 0.69) and was statistically significant (&lt;EM&gt;p&lt;/EM&gt; &amp;lt; .00001). SVRs were higher for patients with genotype non-1 compared with genotype 1 for both PEG + RBV and IFN + RBV treatments.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Hartwell D, Shepherd J. Pegylated and non-pegylated interferon-alfa and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and meta-analysis. &lt;EM&gt;Int J Technol Assess Health Care&lt;/EM&gt; 2009 Jan;25(1):56-62.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public as of 28 August 2009.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>380759</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1002/jmv.21542]]&gt;</url>
    <title>Pegylated interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials</title>
    <publicationDate>2010-05-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,RECENT ADDITIONS,CHRONIC HEPATITIS C,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Pegylated interferon (IFN) does not provide an added benefit in terms of virological response in comparison with standard IFN monotherapy. Tolerance to pegylated-IFN monotherapy was unsatisfactory. Prospective trials are in progress to assess the optimal antiviral therapy for chronic hepatitis C in dialysis patients.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; The efficacy and safety of pegylated-IFN monotherapy in patients with chronic renal failure and chronic hepatitis C remains unclear, although a number of small clinical trials have been published addressing this issue.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A systematic review of the literature with a meta-analysis of clinical trials was performed in order to assess efficacy and safety of initial pegylated interferon monotherapy in chronic renal failure patients with chronic hepatitis C. The primary outcome was sustained virological response (as a measure of efficacy); the secondary outcome was drop-out rate (as a measure of tolerability). The random effects model of Der Simonian and Laird was used, with heterogeneity and sensitivity analyses.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Sixteen clinical trials (254 unique patients) were identified, five (31%) being controlled studies; the majority (15/16 = 94%) regarded patients on long-term dialysis. The summary estimate for sustained virological response and drop-out rate was 33% [95% Confidence Intervals (95%CI) 24-43] and 23% (95%CI, 14-33), respectively. The most frequent side-effects requiring interruption of treatment were haematological (18%) and gastrointestinal (14%). In the group of controlled clinical trials, the summary estimate for sustained viral response and drop-out rate was 38% (95% CI, 18-59), and 15% (95% CI, 3-26), respectively. The studies were heterogeneous with regard to sustained virological response and drop-out rate.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Fabrizi F, Dixit V, Messa P, Martin P. Pegylated interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials. J Med Virol 2010;82(5):768-75.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323678</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2893.2008.00984.x]]&gt;</url>
    <title>Pegylated interferons for chronic hepatitis C virus infection: an indirect analysis of randomized trials</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,RECENT ADDITIONS,AUGUST 2009,CHRONIC HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt;&amp;nbsp;There is insufficient evidence to support conclusions that dual therapy with one pegylated interferon is superior to the other for the treatment of chronic hepatitis C virus infection.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We performed adjusted indirect analysis using trials comparing dual therapy with pegylated interferon alfa-2a or pegylated interferon alfa-2b &lt;SPAN class=i&gt;vs&lt;/SPAN&gt; dual therapy with non-pegylated interferon. We searched for potentially relevant randomized controlled trials using electronic databases and reference lists.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt;&amp;nbsp;A total of 16 trials met inclusion criteria. Adjusted indirect comparisons found no statistically significant differences between dual therapy with pegylated interferon alfa-2a and dual therapy with pegylated interferon alfa-2b on the outcomes sustained virologic response [relative risk (RR)&amp;nbsp;=&amp;nbsp;1.59, 95% CI: 0.56–4.46], withdrawal due to adverse events (RR&amp;nbsp;=&amp;nbsp;0.86, 95% CI: 0.29–2.55), anaemia (RR&amp;nbsp;=&amp;nbsp;1.67, 95% CI: 0.32–8.84), depression (RR&amp;nbsp;=&amp;nbsp;1.09, 95% CI: 0.41–2.90) or flu-like symptoms (RR&amp;nbsp;=&amp;nbsp;1.10, 95% CI: 0.53–2.29). Adjusting for potential publication bias and stratifying analyses by indicators of methodological quality, human immunodeficiency virus infection status, hepatitis C virus genotype, dose of ribavirin or dose of pegylated interferon did not change conclusions.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;See also: &lt;/STRONG&gt;&lt;A href="nelh:331841:0" name=internalLink&gt;DARE record&lt;/A&gt; for this article&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Chou R, Carson S, Chan BKS. Pegylated interferons for chronic hepatitis C virus infection: An indirect analysis of randomized trials. &lt;EM&gt;J Viral Hepat&lt;/EM&gt; 2008;15(8):551-70.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323699</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2893.2008.01019.x]]&gt;</url>
    <title>Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies</title>
    <publicationDate>2008-10-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,NON-ALCOHOLIC,LIVER TRANSPLANTATION,RECENT ADDITIONS,CIRRHOSIS,AUGUST 2009,CHRONIC HEPATITIS C,SURGERY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Pegylated interferon plus ribavirin in full doses is effective for chronic hepatitis C&amp;nbsp;infection&amp;nbsp;pre and post transplant but has a low&amp;nbsp;sustained viral response (SVR)&amp;nbsp;rate. To date no significant histological improvement has been reported.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We evaluated efficacy, tolerability, and safety of Peg/R in liver transplant candidates and recipients with HCV cirrhosis. We searched medical databases and conference proceedings between January 1999 and January 2008 selecting randomized and nonrandomized studies.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Pegylated interferons using either 1–1.5&amp;nbsp;mcg/kg of pegylated interferon alpha-2b or 180&amp;nbsp;µg (pegylated interferon alpha-2a combined with ribavirin 800–1200&amp;nbsp;mg/day were the most effective compared to any other regimen or no therapy. In three pretransplant studies the median SVR was 19.6% (19.6–50%). In six postransplant studies where a meta-analysis was done the cumulative risk difference in SVR was 0.31% (95% CI, 0.18–0.44, &lt;SPAN class=i&gt;p&lt;/SPAN&gt;&amp;nbsp;&amp;lt;&amp;nbsp;0.001). However histological response was not significantly better compared to no therapy or other antiviral regimens. There were no significant differences in discontinuation of therapy, acute or chronic rejection or mortality between optimal Peg/R &lt;SPAN class=i&gt;vs&lt;/SPAN&gt; no treatment or other regimens.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;See also: &lt;/STRONG&gt;&lt;A href="nelh:342890:0" name=internalLink&gt;DARE record&lt;/A&gt; for this article&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Xirouchakis E, Triantos C, Manousou P, Sigalas A, Calvaruso V, Corbani A, et al. Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies. &lt;EM&gt;J Viral Hepat&lt;/EM&gt; 2008 Oct;15(10):699-709.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>330640</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.3748/wjg.15.1613]]&gt;</url>
    <title>Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial</title>
    <publicationDate>2009-04-07T00:00:00</publicationDate>
    <publisher>WJG Press and Beijing Baishideng BioMed Scientific Co.</publisher>
    <publicationType>RANDOMISED CONTROLLED TRIAL</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,ALCOHOLIC LIVER DISEASE,ALCOHOLIC HEPATITIS,STEATOHEPATITIS,ALCOHOLIC,RECENT ADDITIONS,NOVEMBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion: &lt;/STRONG&gt;Reduced mortality, improved risk-benefit profile and renoprotective effects of pentoxifylline compared with prednisolone suggest that pentoxifylline is superior to prednisolone for treatment of severe alcoholic hepatitis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; To compare the efficacy of pentoxifylline and prednisolone in the treatment of severe alcoholic hepatitis, and to evaluate the role of different liver function scores in predicting prognosis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Sixty-eight patients with severe alcoholic hepatitis (Maddrey score = 32) received pentoxifylline (&lt;EM&gt;n &lt;/EM&gt;= 34, group I) or prednisolone (&lt;EM&gt;n&lt;/EM&gt; = 34, group II) for 28 d in a randomized double-blind controlled study, and subsequently in an open study (with a tapering dose of prednisolone) for a total of 3 mo, and were followed up over a period of 12 mo.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Twelve patients in group II died at the end of 3 mo in contrast to five patients in group I. The probability of dying at the end of 3 mo was higher in group II as compared to group I (35.29% &lt;EM&gt;vs &lt;/EM&gt;14.71%, &lt;EM&gt;P&lt;/EM&gt; = 0.04; log rank test). Six patients in group II developed hepatorenal syndrome as compared to none in group I. Pentoxifylline was associated with a significantly lower model for end-stage liver disease (MELD) score at the end of 28 d of therapy (15.53 ± 3.63 &lt;EM&gt;vs &lt;/EM&gt;17.78 ± 4.56, &lt;EM&gt;P&lt;/EM&gt; = 0.04). Higher baseline Maddrey score was associated with increased mortality.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; De BK, Gangopadhyay S, Dutta D, Baksi SD, Pani A, Ghosh P. Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. &lt;EM&gt;World J Gastroenterol&lt;/EM&gt; 2009 Apr 7;15(13):1613-9.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>268544</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.jhep.2005.10.019]]&gt;</url>
    <title>Performance of serum marker panels for liver fibrosis in chronic hepatitis C</title>
    <publicationDate>2006-03-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,CHRONIC HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=abstract&gt;&lt;STRONG&gt;Citation&lt;/STRONG&gt;: Parkes J., Guha I.N., Roderick P. et al. 2006; Journal of Hepatology&lt;/P&gt; &lt;P class=abstract&gt;&lt;STRONG&gt;Abstract: &lt;/STRONG&gt;BACKGROUND/AIMS: Chronic hepatitis C (CHC) is characterised by hepatic fibrosis, used as a proxy measure of prognosis. Liver biopsy is a flawed reference standard and serum markers of fibrosis offer an attractive alternative. METHODS: A systematic review was conducted to assess the performance of panels of serum markers of hepatic fibrosis in CHC, incorporating analyses placing markers in a clinical context. RESULTS: 14 studies were included with 10 different panels. Median AUC in validation populations was 0.77 and training populations 0.81. Likelihood ratios (LR) ranged from -LR 0.1 to 0.9, + LR 1.2 to 33.1, diagnostic odds ratios (DOR) were 9.0 (median) with a range of 5 to 27- mostly below values of robust tests. Tests perform with either high sensitivity with low specificity or vice versa. Cut-off levels that gave clinically relevant predictive values for the presence/absence of significant fibrosis were applicable to 35% of the population. CONCLUSIONS: Serum markers can rule-in or rule-out fibrosis in up to 35% of patients, but cannot differentiate stages of fibrosis reliably. Improvement of index and reference test in needed including evaluation of clinical outcomes as reference. Improved test reporting is needed to derive LR and DOR as performance indicators.&lt;/P&gt; &lt;P class=abstract&gt;&lt;STRONG&gt;See also: &lt;/STRONG&gt;&lt;A href="nelh:297247:0" name=internalLink&gt;DARE record&lt;/A&gt; for this article&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>380565</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/gut.2009.198499]]&gt;</url>
    <title>Peutz–Jeghers syndrome: a systematic review and recommendations for management</title>
    <publicationDate>2010-07-01T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,OESOPHAGUS,CANCER,STOMACH,CANCER,PANCREAS,CANCER,SMALL INTESTINE,CANCER,COLON &amp; RECTUM,POLYPS,NON-MALIGNANT NEOPLASMS,CANCER,RECENT ADDITIONS,POLYPS,NON-MALIGNANT NEOPLASMS,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract:&lt;/STRONG&gt; Peutz-Jeghers syndrome (PJS, MIM175200) is an autosomal dominant condition defined by the development of characteristic polyps throughout the gastrointestinal tract and mucocutaneous pigmentation. The majority of patients that meet the clinical diagnostic criteria have a causative mutation in the STK11 gene, which is located at 19p13.3. The cancer risks in this condition are substantial, particularly for breast and gastrointestinal cancer, although ascertainment and publication bias may have led to overestimates in some publications. Current surveillance protocols are controversial and not evidence-based, due to the relative rarity of the condition. Initially, endoscopies are more likely to be done to detect polyps that may be a risk for future intussusception or obstruction rather than cancers, but surveillance for the various cancers for which these patients are susceptible is an important part of their later management. This review assesses the current literature on the clinical features and management of the condition, genotype-phenotype studies, and suggested guidelines for surveillance and management of individuals with PJS. The proposed guidelines contained in this article have been produced as a consensus statement on behalf of a group of European experts who met in Mallorca in 2007 and who have produced guidelines on the clinical management of Lynch syndrome and familial adenomatous polyposis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Beggs AD, Latchford AR, Vasen HF, Moslein G, Alonso A, Aretz S, Bertario L, Blanco I, Bülow S, Burn J, Capella G, Colas C, Friedl W, Møller P, Hes FJ, Järvinen H, Mecklin JP, Nagengast FM, Parc Y, Phillips RK, Hyer W, Ponz de Leon M, Renkonen-Sinisalo L, Sampson JR, Stormorken A, Tejpar S, Thomas HJ, Wijnen JT, Clark SK, Hodgson SV. Peutz-Jeghers syndrome: a systematic review and recommendations for management. &lt;EM&gt;Gut &lt;/EM&gt;2010;59(7):975-86.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>187037</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.kcl.ac.uk/gsp09/programme/426]]&gt;</url>
    <title>PG Dip/MSc Advanced Practice (Gastrointestinal Nursing)</title>
    <publicationDate></publicationDate>
    <publisher>King's College London</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,ADMIN]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A postgraduate course offered by King's College London, of interest to experienced clinically based healthcare professionals specialising in gastroenterological disorders.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Summary: &lt;/STRONG&gt;This pathway is designed for clinically based experienced healthcare professionals specialising in gastrointestinal disorders who are seeking to extend and expand their clinical practice and develop their professional role. Extensive previous clinical experience is assumed.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323576</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1517/14656566.9.15.2673]]&gt;</url>
    <title>Pharmacoeconomics of entecavir treatment for chronic hepatitis B</title>
    <publicationDate>2008-10-01T00:00:00</publicationDate>
    <publisher>Informa</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,RECENT ADDITIONS,AUGUST 2009,CHRONIC HEPATITIS B]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Entecavir was cost-effective in the treatment of chronic HBV with the incremental cost per QALY (quality-adjusted life-year) gained below the commonly accepted benchmark.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A literature search on Medline and Embase over the period of 1998 – 2008 was performed in April 2008 using keywords ‘entecavir’ and ‘cost’.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Four studies comparing the cost effectiveness of entecavir with lamivudine and/or adefovir for treatment with chronic HBV infection using either decision tree or Markov modeling were reviewed. All four studies showed that entecavir was cost-effective in the treatment of chronic HBV with the incremental cost per QALY gained below the commonly accepted benchmark. The results are mainly due to the lower complication rates and better quality of life of patients using entecavir which can offset the higher acquisition cost of the drug. Patient characteristics, comparing agents and model assumptions were different among the four studies and they should be taken into account when applying the results to real life situations.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; You JH, Chan FW. Pharmacoeconomics of entecavir treatment for chronic hepatitis B. &lt;EM&gt;Expert Opin Pharmacother&lt;/EM&gt; 2008 Oct;9(15):2673-81.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293606</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1007/s10620-007-9945-7]]&gt;</url>
    <title>Phlebotomy improves therapeutic response to interferon in patients with chronic hepatitis C: a meta-analysis of six prospective randomized controlled trials</title>
    <publicationDate>2008-03-01T00:00:00</publicationDate>
    <publisher>Springer</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,CHRONIC HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Desai, TK et al Digestive diseases and sciences 2008 Mar;53(3):815-22. Epub 2007 Sep 12&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract: &lt;/STRONG&gt;Prospective randomized controlled trials (RCTs) comparing phlebotomy and interferon (IFN) treatment to IFN alone in patients with chronic hepatitis C (CHC) have suggested a benefit for the phlebotomy group. However, statistical significance was achieved in only one of these trials. We performed a meta-analysis of RCTs comparing phlebotomy and IFN to IFN alone for the treatment of CHC. The MEDLINE database and Cochrane registry of controlled trials were searched using the key words "phlebotomy" and "treatment of hepatitis C." Reference lists of review articles discussing the interaction between iron and CHC, and prospective RCTs comparing phlebotomy plus IFN therapy to IFN alone were searched to identify additional RCTs that compared phlebotomy plus IFN to IFN alone. Peto odds ratios with their 95% confidence intervals and Forrest plots were generated for each variable to assess the relationships among the studies that had provided that information. Statistical analysis was performed using Comprehensive META-Analysis version 2.0. Six prospective RCTs were identified: all used sustained viral response (SVR) as an endpoint. The three largest RCTs excluded patients with cirrhosis. Two RCTs specifically included only patients with either high ferritin or high hepatic iron content. IFN treatment regimes varied. Length of treatment varied between 6 and 12 months. The phlebotomy plus IFN group and the IFN group did not differ with respect to the percentage of patients with cirrhosis or genotype 1. SVR was attained in 50/182 (27%) patients in the phlebotomy plus IFN group, compared to 22/185 (12%) patients in the IFN group. Peto odds ratio for SVR in phlebotomy plus IFN group was 2.7; 95% CI 1.6-4.5, P &amp;lt; 0.0001. All five RCTs published in manuscript form showed a trend towards a benefit from the phlebotomy plus IFN in attaining SVR, and the results of the meta-analysis were not dependent on any single RCT, since excluding any single RCT did not change the results. Phlebotomy improves the SVR in response to IFN treatment in patients with CHC. Confirmation of this will require RCT with detailed pre-treatment iron studies and appropriately powered to demonstrate a statistically significant benefit.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;See also: &lt;/STRONG&gt;&lt;A href="nelh:312292:0" name=internalLink&gt;DARE record&lt;/A&gt; for this article&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>380739</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2822957/]]&gt;</url>
    <title>Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature</title>
    <publicationDate>2010-03-01T00:00:00</publicationDate>
    <publisher>Springer</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,RECENT ADDITIONS,CHRONIC HEPATITIS C,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Interferon-induced pneumonitis during hepatitis C virus (HCV) treatment is a severe complication and should be recognized in order to prevent further pulmonary damage and/or death.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Combination of peginterferon and ribavirin is the current therapy for chronic HCV infection. Interstitial pneumonitis is a rare side-effect of HCV therapy and is an important cause of dose reduction or discontinuation, impairing success of antiviral therapy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We performed a review of the literature in order to present diagnostic modalities and possible treatments for pneumonitis and to offer guidelines. We searched for cases where pneumonitis as a side-effect of HCV treatment was documented. First we performed a literature search via PubMed and Web of Science interface and second we searched three drug toxicity databases. We systematically analyzed all case reports with respect to clinical manifestations, type of treatment, and outcome.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; A literature search revealed 19 articles, containing 25 case descriptions, while we traced 33 cases from the drug toxicity databases. Pneumonitis presented with any of the combination of fever, dyspnea, and cough and can arise with any type of (conventional or pegylated) interferon. Mortality secondary to pneumonitis was seen in 7% of cases, exclusively with peginterferon alpha-2b. In most cases therapy was discontinued and steroids were started.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Slavenburg S, Heijdra YF, Drenth JP. Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature.&lt;EM&gt; Dig Dis Sci&lt;/EM&gt; 2010;55(3):579-85.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>103353</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.acg.gi.org/physicians/guidelines/NonfamilialColorectalPolyps.pdf]]&gt;</url>
    <title>Polyp guideline: diagnosis, treatment, and surveillance for patients with colorectal polyps</title>
    <publicationDate>2000-11-01T00:00:00</publicationDate>
    <publisher>American College of Gastroenterology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,DISEASE PREVENTION,POLYPS,SCREENING,NON-MALIGNANT NEOPLASMS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims&lt;/STRONG&gt;:&amp;nbsp;&amp;nbsp; This is a revision of a 1993 guideline, intended to document preferable approaches to patient management based on the latest scientific evidence.&amp;nbsp; The most significant change from the original guideline is that, "A large body of recent scientific data discussed in this guideline indicate that clinicians should increasingly shift their focus away from simply detecting and harvesting large numbers of small, simple tubular adenomas toward strategies that allow the reliable detection of most advanced adenomas."&lt;A name=toc3&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience&lt;/STRONG&gt;:&amp;nbsp;Practicing clinicians&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>329674</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1038/ajg.2009.456]]&gt;</url>
    <title>Pouch vs. no pouch following total gastrectomy: meta-analysis and systematic review</title>
    <publicationDate>2009-11-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,STOMACH,CANCER,RECENT ADDITIONS,NOVEMBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion: &lt;/STRONG&gt;Roux-en-Y reconstruction with a pouch is superior to Roux-en-Y reconstruction without&amp;nbsp;one with to&amp;nbsp;respect to postgastrectomy symptoms, eating capability, body weight, and quality of life, without relevantly influencing perioperative parameters.&amp;nbsp; There is not enough data to draw conclusions for the case of jejunal interposition with and without a pouch.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objectives:&lt;/STRONG&gt; Whether reconstruction after total gastrectomy for gastric malignancies should be done with or without a pouch is a controversial issue in clinical research. There is still no consensus on the reconstruction technique of choice. The aim of this report was to assess the value of pouch formation as a gastric substitute after total gastrectomy compared with reconstruction techniques without a pouch.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A systematic literature search of the Medline database and the Cochrane Library was carried out and a meta-analysis executed according to the Quality of Reporting Meta-Analyses (QUOROM) statement. Only randomized controlled trials (RCTs) comparing reconstruction techniques with and without a pouch were eligible for inclusion. All trials were independently assessed by two authors. Data on perioperative parameters, postgastrectomy symptoms, eating capability, body weight, and quality of life were extracted from the RCTs for meta-analysis using random-effects models for the calculation of pooled estimates of treatment effects.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Nine RCTs comparing Roux-en-Y reconstructions with and without pouch and four RCTs comparing jejunal interpositions with and without a pouch were included. The results of the meta-analyses show that additional pouch formation does not significantly increase morbidity or mortality and does not considerably extend the operating time or the hospital stay. Patients with a pouch complained significantly less of dumping and heartburn and showed a significantly better food intake postoperatively. Amongst patients with good chances of survival, quality of life was significantly improved in&amp;nbsp;those with a pouch compared with those without. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Gertler R, Rosenberg R, Feith M, Schuster T, Friess H. Pouch vs. no pouch following total gastrectomy: meta-analysis and systematic review. &lt;EM&gt;Am J Gastroenterol&lt;/EM&gt; 2009 Nov;104(11):2838-51.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309233</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.reprotox.2007.11.010]]&gt;</url>
    <title>Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis</title>
    <publicationDate>2008-02-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Following exposure to 5-ASA drugs, there is no more than an 1.16-fold increase in congenital malformations, an 2.38-fold increase in stillbirth, an 1.14-fold increase in spontaneous abortion, an 1.35-fold increase in preterm delivery, and an 0.93-fold increase in low birth weight.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Bibliographic databases were searched upto June 2007 for studies investigating pregnancy outcomes in women with IBD following exposure to any 5-ASA drugs. The outcomes of interest were congenital abnormalities, stillbirth, spontaneous abortion, preterm delivery, and low birth weight. The odds ratios (OR) and confidence interval (CI) for the individual studies were pooled and heterogeneity analysis was performed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Seven studies with a total of 2200 pregnant women with IBD were included; 642 received 5-ASA drugs (mesalazine, sulfasalazine or olsalazine) and 1158 received no medication. The OR was found 1.16 (95% CI: 0.76–1.77, &lt;I&gt;P&lt;/I&gt;&amp;nbsp;=&amp;nbsp;0.57) for congenital abnormalities, 2.38 (95% CI: 0.65–8.72, &lt;I&gt;P&lt;/I&gt;&amp;nbsp;=&amp;nbsp;0.32) for stillbirth, 1.14 (95% CI: 0.65–2.01, &lt;I&gt;P&lt;/I&gt;&amp;nbsp;=&amp;nbsp;0.74) for spontaneous abortion, 1.35 (95% CI: 0.85–2.13, &lt;I&gt;P&lt;/I&gt;&amp;nbsp;=&amp;nbsp;0.26) for preterm delivery, and 0.93 (95% CI: 0.46–1.85, &lt;I&gt;P&lt;/I&gt;&amp;nbsp;=&amp;nbsp;0.96) for low birth weight.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Rahimi, R., Nikfar, S., Rezaie, A., &amp;amp; Abdollahi, M. (2008) Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis. &lt;I&gt;Reproductive Toxicology&lt;/I&gt;, 25(2):271-275.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;See also: &lt;/STRONG&gt;&lt;A href="nelh:331755:0" name=internalLink&gt;DARE record&lt;/A&gt; for this article.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in February 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309235</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1572-0241.2008.01942.x]]&gt;</url>
    <title>Preoperative steroid use and risk of postoperative complications in patients with inflammatory bowel disease undergoing abdominal surgery</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; There is an increased risk of total as well as infectious complications following the use of steroids in patients with IBD.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We searched medical electronic databases for full journal articles published after 1965 reporting on postoperative complications in patients with IBD undergoing abdominal surgery provided they compared patients treated with steroids with those not on steroids. We hand searched the reference lists of all retrieved articles. Two independent reviewers extracted data from studies meeting the inclusion criteria and any discrepancies were resolved by discussion. We carried out fixed effects meta-analysis, funnel plot and sensitivity analyses.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; A total of seven observational studies involving 1,532 patients met the inclusion criteria for risk of total complications, and five observational studies involving 1,714 patients met the inclusion criteria for risk of infectious complications. Pooled analysis showed an increased risk of all postoperative complications (OR 1.41, 95% confidence interval 1.07–1.87), as well as an increased risk of postoperative infectious complications (OR 1.68, 95% confidence interval 1.24–2.28) among patients on steroids. Patients who received higher doses of perioperative oral steroids (&amp;gt;40 mg) had a higher risk of total complications (OR 2.04 (95% CI 1.28–3.26).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Subramanian, V., Saxena, S., Kang, J. Y., &amp;amp; Pollok, R. C. (2008) Preoperative steroid use and risk of postoperative complications in patients with inflammatory bowel disease undergoing abdominal surgery. &lt;I&gt;American Journal of Gastroenterology&lt;/I&gt;, 103(9):2373-2381.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in September 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>105945</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.pcsg.org.uk/downloads/pcsg-publications/PreventionofColonCancer2003.pdf]]&gt;</url>
    <title>Prevention and early detection of colorectal cancer (CRC) in asymptomatic patients</title>
    <publicationDate>2003-12-31T00:00:00</publicationDate>
    <publisher>Primary Care Society for Gastroenterology</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,DISEASE PREVENTION,POLYPS,CANCER,SCREENING,NON-MALIGNANT NEOPLASMS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;STRONG&gt;Aims&lt;/STRONG&gt;:&amp;nbsp;A brief report one looking at the lifetime risk of getting colorectal cancer based on family and medical history.&amp;nbsp; Includes a summary on how to reduce the risk and the early symptoms. 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience&lt;/STRONG&gt;: General practitioners&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>311427</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1038/ajg.2009.48]]&gt;</url>
    <title>Proton pump inhibitors and bone fractures?</title>
    <publicationDate>2009-03-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,OESOPHAGUS,GASTRO-OESOPHAGEAL REFLUX]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Characteristics of the included studies support a causal association between PPIs and bone fractures;&amp;nbsp;however, there are many factors limiting statements regarding causality.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; The objective of this study was to critically assess studies regarding proton pump inhibitors (PPIs) and fractures. A MEDLINE search was conducted to identify relevant articles.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Three case–control studies assessed fractures and PPI use. A study of all subjects with fracture in Denmark in 2000 revealed adjusted OR=1.18 (1.12–1.43) for PPI use within the last year (hip fracture OR=1.45,1.28–1.65); no dose–response relationship was identified. A study of hip fractures in UK patients greater than or equal to50 years found adjusted OR=1.44 (1.30–1.59) for &amp;gt;1 year of PPIs; duration and average daily dose were significantly associated with fracture risk: adjusted OR for &amp;gt;1.75 times average daily dose for &amp;gt;1 year was 2.65 (1.80–3.90). A study of vertebral, wrist, and hip fractures in Manitoba patients greater than or equal to50 years found adjusted OR=0.99 (0.90–1.11) for greater than or equal to1 year of continuous PPI; association became significant greater than or equal to7 years (OR=1.92, 1.16–3.18).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Laine L.&amp;nbsp;Proton Pump Inhibitors and Bone Fractures? &lt;EM&gt;Am J Gastroenterol &lt;/EM&gt;2009;104(S2):S10-6&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>330636</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18279999]]&gt;</url>
    <title>Quality of life after liver transplantation. A systematic review</title>
    <publicationDate>2007-09-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,TRANSPLANTATION,RECENT ADDITIONS,NOVEMBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; This review suggests that whereas general&amp;nbsp;quality of life (QOL)&amp;nbsp;improves after&amp;nbsp;liver transplantation (LT),&amp;nbsp;when compared with healthy controls, LT recipients have significant deficits in QOL. Consequently, the previously reported QOL benefits after LT may have been overstated.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims: &lt;/STRONG&gt;Although many studies have reported significant improvements in QOL after liver transplantation LT, consistent data on areas of improvement are lacking. To perform a systematic review on medical literature of QOL after LT paying particular attention to studies that utilized the most commonly adopted study instrument, Short Form-36 (SF-36).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; To collect studies focused on QOL in adult LT recipients, from 1963 to 2007, cited in Pub Med, Embase or Cochrane databases. From an initial identification of 613 articles, we selected 44 longitudinal studies with pre- and post-LT data that we assessed using a sign test, and 19 used SF-36, which we analyzed separately.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Longitudinal data showed remarkable improvement of common domains of QOL comparing pre- and post-transplant items. However, analysis of 16 SF-36 cross-sectional studies comparing post-LT patient domains with control population showed significantly higher ratings for controls in six while no differences were found in two.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Tome S, Wells JT, Said A, Lucey MR. Quality of life after liver transplantation. A systematic review. &lt;EM&gt;J Hepatol&lt;/EM&gt; 2008 Apr;48(4):567-77.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>330327</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1002/hep.23045]]&gt;</url>
    <title>Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed</title>
    <publicationDate>2009-09-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>RANDOMISED CONTROLLED TRIAL</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,OESOPHAGUS,OESOPHAGEAL VARICES,LIVER,NON-ALCOHOLIC,ALCOHOLIC LIVER DISEASE,ALCOHOLIC CIRRHOSIS,DISEASE PREVENTION,RECENT ADDITIONS,CIRRHOSIS,ALCOHOLIC,NOVEMBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Carvedilol is effective in preventing the first variceal bleed. Carvedilol is an option for primary prophylaxis in patients with high-risk esophageal varices.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Current therapy for preventing the first variceal bleed includes beta-blocker and variceal band ligation (VBL). VBL has lower bleeding rates, with no differences in survival, whereas beta-blocker therapy can be limited by side effects. Carvedilol, a non-cardioselective vasodilating beta-blocker, is more effective in reducing portal pressure than propranolol; however, there have been no clinical studies assessing the efficacy of carvedilol in primary prophylaxis. The goal of this study was to compare carvedilol and VBL for the prevention of the first variceal bleed in a randomized controlled multicenter trial. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt;&amp;nbsp;One hundred fifty-two cirrhotic patients from five different centers with grade II or larger esophageal varices were randomized to either carvedilol 12.5 mg once daily or VBL performed every 2 weeks until eradication using a multibander device. Seventy-seven patients were randomized to carvedilol and 75 to VBL. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Baseline characteristics did not differ between the groups (alcoholic liver disease, 73%; median Child-Pugh score, 8; median age, 54 years; median follow-up, 20 months). On intention-to-treat analysis, carvedilol had lower rates of the first variceal bleed (10% versus 23%; relative hazard 0.41; 95% confidence interval 0.19-0.96 [&lt;I&gt;P&lt;/I&gt; = 0.04]), with no significant differences in overall mortality (35% versus 37%, &lt;I&gt;P&lt;/I&gt; = 0.71), and bleeding-related mortality (3% versus 1%, &lt;I&gt;P&lt;/I&gt; = 0.26). Six patients in the VBL group bled as a result of banding ulcers. Per-protocol analysis revealed no significant differences in the outcomes. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Tripathi D, Ferguson JW, Kochar N, Leithead JA, Therapondos G, McAvoy NC, Stanley AJ, Forrest EH, Hislop WS, Mills PR, Hayes PC. Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed. &lt;EM&gt;Hepatology &lt;/EM&gt;2009 Sep;50(3):825-33.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281240</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17846837]]&gt;</url>
    <title>Rectovaginal fistula in Crohn's disease</title>
    <publicationDate>2008-03-10T00:00:00</publicationDate>
    <publisher>Springer</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,INFLAMMATORY BOWEL DISEASE,FISTULA,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Andreani, S.&amp;nbsp; &lt;SPAN title="Diseases of the colon and rectum."&gt;&lt;A href="#javascript:AL_get(this," Rectum.?);? Colon ?Dis ?jour?,&gt;Dis Colon Rectum.&lt;/A&gt;&lt;/SPAN&gt; 2007 Dec;50(12):2215-22.&lt;/P&gt;
&lt;P class=abstract&gt;PURPOSE: Crohn's disease is characterized by transmural bowel inflammation and a tendency to form fistulas with adjacent structures. Several different fistulas have been described: enterocutaneous, enteroenteric, enterovesical, enterovaginal, and perineal. Rectovaginal fistulas are difficult to treat despite multimodal therapy. This study was designed to review the current strategic options to best manage this condition. METHODS: We reviewed the English-language literature from 1966 to 2006, using PUBMED, targeting Crohn's disease involving vagina using key words "rectovaginal fistula and CD," "anovaginal fistula and CD," "anovaginal fistula," and "rectovaginal fistula." We excluded the involvement of the vagina from a pouch after a proctectomy. A total of 776 articles were found; 206 articles were identified and judged as being relevant on the basis of title-related articles and links were reviewed. Fifty-three articles were selected after reading the abstract or full manuscript. RESULTS: The management of rectovaginal fistula, representing 9 percent of all fistulas, remains a challenge in the setting of Crohn's disease. Medical treatments are not favorable with low rates of long-term symptomatic control and unacceptable high rates of recurrence. Several novel and new surgical techniques have been described, and rectal advancement flap, in selected patients, seems to have the most successful results. CONCLUSIONS: The management of rectovaginal fistula of Crohn's origin should involve both gastroenterologists and coloproctologists, with the best surgical results being achieved in patients receiving optimum medical therapy. More focused studies targeting these patients with the use of combined medical and surgical therapy are necessary.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>385070</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.jhep.2010.03.013]]&gt;</url>
    <title>Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis</title>
    <publicationDate>2010-08-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,PORTAL HYPERTENSION,RECENT ADDITIONS,CIRRHOSIS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt;&amp;nbsp;&lt;SPAN class=sub_abstract_label&gt;&lt;SPAN&gt;ACE inhibitors&lt;/SPAN&gt; (ACEi) and &lt;SPAN&gt;angiotensin receptor blockers&lt;/SPAN&gt; (&lt;/SPAN&gt;&lt;SPAN&gt;ARB) reduce portal pressure in patients with Child Pugh A cirrhosis without adverse events. The efficacy and safety in this group may be secondary to a targeted effect on the local hepatic r&lt;SPAN&gt;enin-angiotensin-aldosterone&lt;/SPAN&gt; (RAAS) system, as compared to decompensated patients who risk hypotension and renal insufficiency due to activation of the systemic RAAS. Further studies should determine the potential of these drugs as an alternative or adjunct to beta-blockers (BB).&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; &lt;SPAN&gt;Renin-angiotensin-aldosterone antagonists [ACEi, ARB, aldosterone antagonists (AA)] are potential therapies for portal hypertension. We evaluated the efficacy and safety of RAAS inhibitors in hepatic venous pressure gradient (HVPG) reduction.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt;&amp;nbsp;&lt;SPAN&gt;We included full-text controlled trials in patients with cirrhosis and portal hypertension. The primary outcome was mean change in HVPG between treatment and control. Two independent reviewers performed trial selection and quality assessment. An individual patient meta-analysis based on the data of three studies was performed.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;SPAN&gt;From 193 citations, 19 controlled trials (n=678) were included. When compared to placebo, ARB/ACEi resulted in significant HVPG reduction. The best quality trials compared ARB/ACEi to BB. Pooled individual patient data for three of four of these trials showed that BB decreased the HVPG more than ARB/ACEi. In patients with Child Pugh A cirrhosis, the HVPG reduction with ARB/ACEi (-17%; 95% CI: -28 to -6), was similar to that of BB (-21%; 95% CI: -32 to -9). Significant variation in the comparison groups of AA trials precluded pooling. There was no difference in adverse events in any group but selected studies noted adverse hemodynamic effects in decompensated patients on ARB/ACEi.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Tandon P, Abraldes JG, Berzigotti A, Garcia-Pagan JC, Bosch J. Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis. &lt;EM&gt;J Hepatol&lt;/EM&gt; 2010;53(2):273-82.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281275</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17142106]]&gt;</url>
    <title>Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression</title>
    <publicationDate>2008-03-10T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;SPAN title="Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association."&gt;Turner, D. &lt;A href="#javascript:AL_get(this," ?jour?, ?Clin Gastroenterol Hepatol.?);?&gt;Clin Gastroenterol Hepatol.&lt;/A&gt;&lt;/SPAN&gt; 2007 Jan;5(1):103-10. Epub 2006 Dec 4.&lt;/P&gt; &lt;P class=abstract&gt;BACKGROUND &amp;amp; AIMS: Colectomy is a potentially life-saving procedure for patients with severe attacks of UC who fail medical therapy. We aimed to systematically review studies that reported the short-term colectomy rate in severe UC or reported variables that could predict treatment failure. METHODS: We conducted a systematic literature search for cohort studies and controlled trials published between 1974-2006. RESULTS: Thirty-two studies met the inclusion criteria; 16 reported short-term outcome and predictors of therapy failure, 13 only outcome, and 3 only predictors. In the pooled analysis, 581 of 1991 patients required colectomy (weighted mean 27; 95% confidence interval [CI], 26%-28%), and 22 died (1%; 95% CI, 0.7%-1.5%). In a heterogeneity-controlled meta-regression, colectomy rate did not change during the last 30 years (R(2) = 0.07, P = .8). Cyclosporine was used in only 100 patients, with a 51% (95% CI, 41%-60%) short-term success rate. A second meta-regression failed to demonstrate a dose-colectomy response of methylprednisolone therapy beyond 60 mg daily (R(2) &lt; 0.01, P = .98). More than 20 variables were identified in 19 studies to predict medical therapy failure, but only a few were consistently reproduced: disease extent, stool frequency, temperature, heart rate, C-reactive protein, albumin, and radiologic assessment. CONCLUSIONS: The short-term colectomy rate in severe UC has remained stable during the last 30 years, despite the introduction of cyclosporine, which was not used frequently. We could not find any support for administering methylprednisolone at a higher dose than 60 mg/day. Variables that predict outcome of corticosteroid therapy could aid in the development of guidelines for introduction of rescue therapies in severe UC.&lt;/P&gt; &lt;P class=abstract&gt;See also the &lt;A href="nelh:287817:0" name=internalLink&gt;DARE record&lt;/A&gt; for this article.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>380755</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.jhep.2009.06.018]]&gt;</url>
    <title>Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: a meta-analysis</title>
    <publicationDate>2009-10-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,CHRONIC HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Overall modest efficacy argues against an indiscriminate retreatment with pegylated interferon (PEG-IFN) and ribavirin of all non-responders. Restricting retreatment to non-overweight patients or to those with genotype 2 or 3 infection, using a 24-week retreatment stopping rule, would optimize the potential benefit with a scarce likelihood of missing a curative response.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Efficacy of retreatment with PEG-IFN plus ribavirin of non-responders to standard or pegylated IFN plus ribavirin has been assessed in various studies, but sustained virologic response (SVR) rates are variable and factors influencing efficacy and tolerability still remain incompletely defined. We aimed to focus on SVR rates and to identify factors influencing them in this meta-analysis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; MEDLINE as well as a manual search were used. Studies were included if they were controlled or uncontrolled trials, if they had been published as full-length papers and if they included non-responders to standard or pegylated IFN and ribavirin therapy. Fourteen trials were included in the meta-analysis. Data on study populations, interventions, and outcomes were extracted from trials using a random-effects model. Primary outcome was the SVR rate.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The pooled estimate of SVR rate was 16.3% (95% Confidence Interval - 95% CI, 8.3-29.6%). There was a significant heterogeneity among studies (p&amp;lt;0.0001). Heterogeneity was less apparent in studies that included fewer patients with cirrhosis or overweight. By meta-regression, higher SVR rate was observed in trials with a lower prevalence of subjects with genotype 1 infection and with fewer overweight patients. The use of a 24-week retreatment stopping rule did not affect SVR rate. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Cammà C, Cabibbo G, Bronte F, Enea M, Licata A, Attanasio M, Andriulli A, Craxì A. Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: a meta-analysis. &lt;EM&gt;J Hepatol&lt;/EM&gt; 2009;51(4):675-81.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>380662</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2009.04004.x]]&gt;</url>
    <title>Review article: adherence to medication for chronic hepatitis C - building on the model of human immunodeficiency virus antiretroviral adherence research</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,HIV / AIDS,RECENT ADDITIONS,CHRONIC HEPATITIS C,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; As hepatitis C virus (HCV) treatment becomes more complex with new classes of agents, adherence will be increasingly important to treatment success as resistance mutations may develop with suboptimal dosing of HCV enzyme inhibitors. Human immunodeficiency virus (HIV) adherence research can be applied to that on HCV to establish accurate methods to assess adherence, investigate determinants of non-adherence and develop strategies to optimize adherence.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Treatment of HCV infection with pegylated interferon/ribavirin achieves sustained virological response in up to 56% of HCV mono-infected patients and 40% of HCV/human immunodeficiency virus HIV-co-infected patients. The relationship of patient adherence to outcome warrants study. The aim of this paper was to review comprehensively research on patient-missed doses to HCV treatment and discuss applicable research from adherence to HIV antiretroviral therapy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Publications were identified by PubMed searches using the keywords: adherence, compliance, hepatitis C virus, interferon and ribavirin.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The term 'non-adherence' differs in how it is used in the HCV from the HIV literature. In HCV, 'non-adherence' refers primarily to dose reductions by the clinician and early treatment discontinuation. In contrast, in HIV, 'non-adherence' refers primarily to patient-missed doses. Few data have been published on the rates of missed dose adherence to pegylated interferon/ribavirin and its relationship to virological response.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Weiss JJ, Bräu N, Stivala A, Swan T, Fishbein D. Review article: adherence to medication for chronic hepatitis C - building on the model of human immunodeficiency virus antiretroviral adherence research. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2009;30(1):14-27.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>346146</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2009.03955.x]]&gt;</url>
    <title>Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Although anti TNF-a induced psoriasis is extremely rare, understanding the mechanism will be a key step towards better realizing the role played by TNF-a and its pharmacological inhibitors in immune-mediated diseases.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Anti TNF-a agents are used successfully for several autoimmune diseases, including IBD and psoriasis. An emerging challenge is the increasing incidence of anti TNF-a induced psoriasis. A total of 120 cases have been currently reported, of whom 18 patients were treated with biological agents for IBD.&amp;nbsp; The aim of this review was to analyse all cases of anti TNF-a induced psoriasis in patients with IBD in the literature and to investigate potential mechanisms of action.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A literature review was performed in the PubMed, Medline, Cochrane and EMBASE databases, with simple analysis of demographic data, drug administration and psoriasis onset. Risk and incidence patient/year/duration (pyd) was calculated.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; A total of 18 patients with IBD treated by anti TNF-a agents developed drug-induced psoriasis of which, 17 patients developed with infliximab, one with adalimumab. The most frequent time of onset is between 3rd and 4th infusion of infliximab. Withdrawal of infliximab led to regression of lesions in 16 patients. In six patients, infliximab was reintroduced with no further recurrence of psoriasis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Fiorino G, Allez M, Malesci A, Danese S. Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2009;29(9):921-7.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Although anti TNF-a induced psoriasis is extremely rare, understanding the mechanism will be a key step towards better realizing the role played by TNF-a and its pharmacological inhibitors in immune-mediated diseases.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281309</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17635367]]&gt;</url>
    <title>Review article: appropriate use of corticosteroids in Crohn's disease</title>
    <publicationDate>2008-03-10T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic information:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;Irving, PM. &lt;SPAN title="Alimentary pharmacology &amp;amp; therapeutics."&gt;&lt;A href="#javascript:AL_get(this," ?jour?, ?Aliment Pharmacol Ther.?);?&gt;Aliment Pharmacol Ther.&lt;/A&gt;&lt;/SPAN&gt; 2007 Aug 1;26(3):313-29.&lt;/P&gt;
&lt;P class=abstract&gt;BACKGROUND: Corticosteroids are a well-established treatment for active Crohn's disease and have been widely used for decades. It has become apparent, however, that a proportion of patients either fails to respond to corticosteroids or is unable to withdraw from them without relapsing. Furthermore, their use is associated with a range of side effects, such that long-term treatment carries unacceptable risk. AIM: To review the evidence regarding the appropriate use of corticosteroids in Crohn's disease, along with their side effects, safety and alternatives. METHODS: To collect relevant articles, a PubMed search was performed from 1966 to November 2006 using the terms 'steroid', 'corticosteroid', 'glucocorticoid', 'prednisolone', 'prednisone', 'methylprednisolone', 'hydrocortisone', 'dexamethasone' and 'budesonide' in combination with 'Crohn(s) disease'. Relevant articles were reviewed, as were their reference lists to identify further articles. RESULTS: When used correctly, corticosteroids are a highly effective, well tolerated, cheap and generally safe treatment for active Crohn' disease. Nevertheless, approximately 50% of recipients will either fail to respond (steroid-resistant) or will be steroid dependent at 1 year. Newer alternatives to corticosteroids are not, however, without risk themselves and, moreover, are not necessarily available universally. CONCLUSIONS: Steroids are used widely to treat Crohn's disease, a situation that is unlikely to change in the near future. Accordingly, efforts should be made to ensure that they are used correctly and that their side effects are minimized. Reference is made to recently published guidelines and a simplified 'users guide' is presented.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Alimentary Pharmacology and Therapeutics is an international journal concerned with the effects of drugs on the human gastrointestinal and hepato-biliary systems. The journal publishes original research on all aspects of pharmacology, pharmacokinetics and therapeutic use of drugs in the alimentary tract.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is &lt;STRONG&gt;not&lt;/STRONG&gt; available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281297</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17217454]]&gt;</url>
    <title>Review article: biological activity markers in inflammatory bowel disease</title>
    <publicationDate>2008-03-10T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic information:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;Desai, D.&amp;nbsp; &lt;SPAN title="Alimentary pharmacology &amp;amp; therapeutics."&gt;&lt;A href="#javascript:AL_get(this," Ther.?);? Pharmacol ?Aliment ?jour?,&gt;Aliment Pharmacol Ther.&lt;/A&gt;&lt;/SPAN&gt; 2007 Feb 1;25(3):247-55. Epub 2007 Jan 8&lt;/P&gt;
&lt;P&gt;BACKGROUND: Traditionally, inflammatory bowel disease activity is assessed by clinical activity indices that measure clinical symptoms and endoscopic indices that measure endoscopic inflammation. Biological markers are a non-invasive way of objectively measuring inflammation and can play an adjunctive or primary role in the assessment of disease activity. AIM: To review the data on biological markers for assessment of disease activity and prediction of relapse in inflammatory bowel disease. METHODS: To collect relevant articles, a PubMed search was performed from 1980 to 2006 using following search terms in combination: inflammatory bowel disease, biomarkers, inflammation, disease activity, relapse, acute phase reactants cytokines, interleukins, adhesion molecules, integrins, calprotectin and lactoferrin. RESULTS: Biological activity markers can be classified into serological, faecal and miscellaneous categories. Acute phase reactants levels correlate with disease activity and some can be used to help predict relapse. Cytokines and adhesion molecules are elevated in active disease inconsistently. Faecal markers are useful in assessment of disease activity and relapse. CONCLUSIONS: Acute phase reactants and faecal markers are useful to assess the disease activity in clinical practice. More data are required on cytokines and adhesion molecules. C-reactive protein, erythrocyte sedimentation rate, interleukins and faecal markers may be useful in predicting a relapse.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Alimentary Pharmacology and Therapeutics is an international journal concerned with the effects of drugs on the human gastrointestinal and hepato-biliary systems. The journal publishes original research on all aspects of pharmacology, pharmacokinetics and therapeutic use of drugs in the alimentary tract.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is &lt;STRONG&gt;not&lt;/STRONG&gt; available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323584</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2008.03731.x]]&gt;</url>
    <title>Review article: current antiviral therapy of chronic hepatitis B</title>
    <publicationDate>2008-07-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,RECENT ADDITIONS,AUGUST 2009,CHRONIC HEPATITIS B]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Newer agents and modified treatment strategies, especially using combination therapy, hold promise to optimize the management of patients with chronic hepatitis B by achieving the high potency and the lowest rate of resistance.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A systematic review of the literature, with a focus on recent guidelines, was undertaken.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;SPAN class=h5-inline&gt;&lt;/SPAN&gt;Among the six drugs licensed for the treatment of chronic hepatitis B in the US, the preferred agents in 2008 will include entecavir, peginterferon alfa-2a, possibly telbivudine, and tenofovir following licensure. When using an oral agent, a major focus of management is on the selection of a drug with high potency and low rate of resistance, and active on-treatment management to optimize therapy. Preventing the sequelae of antiviral drug resistance and appropriate management when resistance is initially detected are also the major focus of current management. The addition of an antiviral agent that is not cross-resistant is critical to restore suppression of viral replication.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Ayoub WS, Keeffe EB. Review article: current antiviral therapy of chronic hepatitis B. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2008 Jul;28(2):167-77.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>156901</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2006.03010.x]]&gt;</url>
    <title>Review article: evolutionary advances in the delivery of aminosalicylates for the treatment of ulcerative colitis</title>
    <publicationDate>2006-08-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,ULCERATIVE COLITIS,INFLAMMATORY BOWEL DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;H2&gt;Description&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract&lt;/STRONG&gt;:&amp;nbsp;Ulcerative colitis is a chronic and debilitating disease that involves inflammation of the colonic mucosa. Current therapies aim to reduce the symptom burden of ulcerative colitis and maintain disease quiescence. The standard first-line treatment for mild-to-moderate ulcerative colitis is 5-aminosalicylate therapy, which is available in oral and rectal (topical) formulations. While current 5-aminosalicylate formulations are effective in the majority of patients, they are associated with a number of limitations including inconvenient dosing regimens and poor patient acceptability, which may lead to non-compliance with prescribed therapy. A variety of improved delivery mechanisms have been developed in an effort to overcome these limitations. Micropellet formulations and high-dose tablets appear to offer comparable efficacy and tolerability to conventional formulations, although any benefit in terms of long-term patient compliance remains to be proven.&amp;nbsp;Novel methods of delivery, such as those using a combination of hydrophilic and lipophilic matrices, designed to provide once-daily dosing in a high-strength tablet, may offer a significant improvement in the therapy of active and quiescent ulcerative colitis. This review examines the limitations of current 5-aminosalicylate formulations and reports on the evolution of novel oral formulations designed to overcome these limitations, maximize patient compliance during both induction and maintenance of quiescence, and optimize overall clinical outcomes.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Audience&lt;/STRONG&gt;:&amp;nbsp;Health care professionals&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;This article is &lt;STRONG&gt;not&lt;/STRONG&gt; available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>268522</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2006.03073.x]]&gt;</url>
    <title>Review article: management of patients with chronic hepatitis C virus infection and 'normal' alanine aminotransferase activity</title>
    <publicationDate>2006-10-15T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HEPATITIS,HEPATITIS C,LIVER,GASTROENTEROLOGY &amp; LIVER DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation&lt;/STRONG&gt;: Zeuzem S., Alberti A., Rosenberg W., et al. 2006; Alimentary Pharmacology and Therapeutics 24 (8) pp. 1133-49&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;Abstract: &lt;/STRONG&gt;BACKGROUND: Hepatitis C virus infection, a major cause of chronic liver disease, occurs with normal serum alanine aminotransferase activity in approximately 25% of patients. These patients have historically remained untreated but substantial evidence indicates liver damage, progression of disease and impaired quality of life in some individuals. AIM: To review the current management of patients with chronic hepatitis C and normal alanine aminotransferase activity. METHODS: This review represents the summary of discussions at a Clinical Workshop with a comprehensive literature searching of available databases (PubMed and Embase). RESULTS: Current limits defining normal serum alanine aminotransferase activity are not representative of a "healthy" status. Most patients with hepatitis C and normal alanine aminotransferase levels have histologically proven liver damage that, although generally mild, may be significant (&amp;gt; or =F2) in up to 20% of patients and progresses at approximately 50% of the rate in patients with elevated alanine aminotransferase levels. Some patients have persistently normal alanine aminotransferase activity and may have a more benign outcome, but a significant proportion (&amp;gt; or =20%) experience periods of increased serum alanine aminotransferase activity which may be associated with enhanced disease progression. CONCLUSIONS: A treatment approach that considers host and virus-related variables and optimizes patient and cost benefits may therefore provide more effective management of patients with chronic hepatitis C and normal alanine aminotransferase activity.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309203</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18384664]]&gt;</url>
    <title>Review article: medication non-adherence in ulcerative colitis – strategies to improve adherence with mesalazine and other maintenance therapies</title>
    <publicationDate>2008-06-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Educational and behavioural interventions tailored to individual patients can optimize medication adherence. Additional studies combining educational and behavioural interventions may provide further strategies for improving medication adherence rates in UC.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Articles cited were identified via a PubMed search, utilizing the words IBD, adherence, compliance, medication and UC.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Medication non-adherence is multifactorial involving factors other than dosing frequency. Male gender (OR: 2.06), new patient status (OR: 2.14), work and travel pressures (OR: 4.9) and shorter disease duration (OR: 2.1), among others are proven predictors of non-adherence in UC. These indicators can identify 'at-risk' patients and allow an individually tailored treatment approach to be introduced that optimizes medication adherence. A collaborative relationship between physician and patient is important; several strategies for improving adherence have been proven effective including open dialogue that takes into consideration the patient's health beliefs and concerns, providing educational (e.g. verbal/written information, self-management programmes) and behavioural interventions (e.g. calendar blister packs, cues/reminders).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Hawthorne, A. B., Rubin, G., &amp;amp; Ghosh, S. (2008) Review article: medication non-adherence in ulcerative colitis - strategies to improve adherence with mesalazine and other maintenance therapies. &lt;I&gt;Alimentary Pharmacology &amp;amp; Therapeutics&lt;/I&gt;, 27(12):1157-1166.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281274</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17944997]]&gt;</url>
    <title>Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease</title>
    <publicationDate>2008-03-10T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,GASTROENTEROLOGY &amp; LIVER DISEASES,CROHN'S DISEASE,INFECTIOUS DISEASES,TUBERCULOSIS,INFECTIONS,JAN 09,VACCINE PREVENTABLE DISEASES,TUBERCULOSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Tuberculosis following treatment with TNF-alpha inhibitors usually results from reactivation of latent disease. Screening reduces the risk substantially but does not completely eliminate it.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; PubMed searches were performed using search terms that included TB and each of the current anti-TNF-alpha biological agents and also TB and Crohn's disease.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;SPAN class=h5-inline&gt;&lt;/SPAN&gt;Increased susceptibility to TB, often with extrapulmonary or disseminated disease, occurs following treatment with all anti-TNF-alpha biological agents and amounts to a four- to 20-fold increased risk with infliximab. TB usually occurs shortly after anti-TNF-alpha initiation suggesting reactivation of latent infection. Animal studies show that TNF-alpha inhibition impairs inflammatory cell trafficking and granuloma formation. Currently recommended screening for latent TB typically, risk assessment, tuberculin skin testing and chest radiograph used prior to anti-TNF-alpha treatment can reduce TB rates by up to 90% but newer screening interferon gamma assays may enhance screening efficacy. Patients positive on screening who are treated with isoniazid and subsequently receive anti-TNF-alpha treatment still have approximately 19% risk for TB.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Theis, V. S. &amp;amp; Rhodes, J. M. (2008) Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease. &lt;I&gt;Alimentary Pharmacology &amp;amp; Therapeutics&lt;/I&gt;, 27(1):19-30.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309215</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2008.03800.x]]&gt;</url>
    <title>Review article: new drug formulations, chemical entities and therapeutic approaches for the management of ulcerative colitis</title>
    <publicationDate>2008-10-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The evolution of novel oral 5-ASA formulations and dosage regimens, and recent development of new molecules have expanded the therapeutic armamentarium of UC.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Searches for all studies related to UC treatment in Medline and abstracts from major national and international meetings published in the last 10 years.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; 5-Aminosalicylic acids (5-ASA) remain the standard first-line treatment for patients with mild to moderately active UC. New formulations with altered delivery, and new dosing regimens have demonstrated possible improvements in efficacy compared with historically available preparations and dosing patterns. Once-daily dosing, micropellet formulations, and high-dose tablets offer enhanced efficacy and improved compliance. 5-ASA is now recognized as a ligand for peroxisome proliferator-activated receptor-? (PPAR-?) and it has a role as a chemo-preventive agent in long-standing UC. New colonic release corticosteroid formulations help to limit systemic toxicity; turmeric, tacrolimus and infliximab have shown promising results. New anti-inflammatory targeted therapies include an anti-CD3 antibody, selective integrin blockers, anti-IL-2 antibody and PPAR-? agonists.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Ng, S. C. &amp;amp; Kamm, M. A. (2008) Review article: new drug formulations, chemical entities and therapeutic approaches for the management of ulcerative colitis. &lt;I&gt;Alimentary Pharmacology &amp;amp; Therapeutics&lt;/I&gt;, 28(7):815-829.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281308</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17661756]]&gt;</url>
    <title>Review article: reproduction in the patient with inflammatory bowel disease</title>
    <publicationDate>2008-03-10T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic information:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;Heetun, Z. &lt;SPAN title="Alimentary pharmacology &amp;amp; therapeutics."&gt;&lt;A href="#javascript:AL_get(this," Ther.?);? Pharmacol ?Aliment ?jour?,&gt;Aliment Pharmacol Ther.&lt;/A&gt;&lt;/SPAN&gt; 2007 Aug 15;26(4):513-33.&lt;/P&gt;
&lt;P&gt;BACKGROUND: Inflammatory bowel disease (IBD) affects mainly the young population. The effect of IBD and its treatment on fertility and pregnancy is therefore an important clinical consideration. AIM: To review the best management of IBD in the reproductive and pregnant population. METHODS: A MEDLINE and an EMBASE search were performed using mainly the search phrases 'pregnancy AND IBD,''sulphasalazine AND male fertility,''abdominal surgery AND female fertility,''AZA AND placenta' and 'infliximab AND pregnancy.' No language or date restrictions were placed. References of review articles were examined. RESULTS: Overall male and female fertility are not affected by IBD. Sulphasalzine reduces male fertility. No other drugs used in IBD affect significantly fertility in humans. The risk of pregnancy-related complications and the disease behaviour during pregnancy depends mainly on disease activity at time of conception. Proactive treatment for maintenance of disease remission during gestation is recommended. Except for methotrexate, drugs used in IBD appear safe in pregnancy. Breast feeding should be encouraged. CONCLUSION: The management of IBD in the young and pregnant population remains controversial because the literature comes mostly from retrospective studies. Further studies particularly large prospective trials are needed to guide clinicians in decision making.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Alimentary Pharmacology and Therapeutics is an international journal concerned with the effects of drugs on the human gastrointestinal and hepato-biliary systems. The journal publishes original research on all aspects of pharmacology, pharmacokinetics and therapeutic use of drugs in the alimentary tract.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is &lt;STRONG&gt;not&lt;/STRONG&gt; available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>251147</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2005.02424.x]]&gt;</url>
    <title>Review article: smoking cessation as primary therapy to modify the course of Crohn's disease</title>
    <publicationDate>2005-04-15T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This article aims to offer an updated review of the effects of smoking on inflammatory bowel disease, and provide a review of the methods of achieving smoking cessation.</description>
    <body>&lt;![CDATA[ &lt;STRONG&gt;Bibliographic details:&lt;/STRONG&gt; Johnson GJ, Cosnes J and Mansfield JC 2005; Alimentary Pharmacology and Therapeutics 21 (8) pp. 921-931&amp;nbsp; 
&lt;H2&gt;Original article abstract &lt;/H2&gt;
&lt;P class=abstract&gt;This article aims to offer an updated review of the effects of smoking on inflammatory bowel disease, and provide a review of the methods of achieving smoking cessation. A systematic review of Embase and Medline databases was conducted. Smoking causes opposing effects on ulcerative colitis and Crohn's disease. The odds ratio of developing ulcerative colitis for smokers compared with lifetime non-smokers is 0.41. Conversely, smokers with Crohn's disease have a more aggressive disease requiring more therapeutic intervention. Smoking cessation is associated with a 65% reduction in the risk of a relapse as compared with continued smokers, a similar magnitude to that obtained with immunosuppressive therapy. Although difficult to achieve smoking cessation can best be encouraged by accessing appropriate counselling services, nicotine replacement therapy and bupropion. Using a combination of these treatments there is an improved chance of success of up to 20% compared with an unassisted quit attempt. Smoking cessation unequivocally improves the course of Crohn's disease and should be a primary therapeutic aim in smokers with Crohn's disease.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;This article is &lt;STRONG&gt;not&lt;/STRONG&gt; available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281237</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17919275?ordinalpos=2&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Review article: the evidence base for interventions used to maintain remission in Crohn's disease</title>
    <publicationDate>2008-03-10T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic information:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;Akobeng, A.K.&lt;/P&gt;
&lt;P&gt;&lt;SPAN title="Alimentary pharmacology &amp;amp; therapeutics."&gt;&lt;A href="#javascript:AL_get(this," ?jour?, ?Aliment Pharmacol Ther.?);?&gt;Aliment Pharmacol Ther.&lt;/A&gt;&lt;/SPAN&gt; 2008 Jan 1;27(1):11-8.&lt;/P&gt;
&lt;P class=abstract&gt;BACKGROUND: Crohn's disease is characterised by recurrent flare-ups alternating with periods of remission. A number of interventions are currently used in clinical practice to try and maintain remission in Crohn's disease but the evidence base for some of them may be questionable. AIM: To review the available evidence on interventions, which are currently used to maintain remission in Crohn's disease. METHODS: The Cochrane Library and Medline (Pubmed) were searched for level 1 evidence on specific interventions. Search terms included 'Crohn's disease or synonyms', 'remission or synonyms' and the names of specific interventions. RESULTS: Azathioprine, infliximab and adalimumab are effective at maintaining remission in Crohn's disease. Natalizumab is also effective, but there are concerns about its potential association with progressive multifocal leukoencephalopathy. Long-term enteral nutritional supplementation, enteric-coated omega-3 fatty acids and intramuscular methotrexate may also be effective but the evidence for these is based on relatively small studies. The available evidence does not support the use of oral 5-aminosalicylates agents, corticosteroids, anti-mycobacterial agents, probiotics or ciclosporin as maintenance therapy in Crohn's disease. CONCLUSION: A better understanding of the evidence base of existing interventions could result in the use of treatments, which are more likely to lead to improved patient outcomes.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Alimentary Pharmacology and Therapeutics is an international journal concerned with the effects of drugs on the human gastrointestinal and hepato-biliary systems. The journal publishes original research on all aspects of pharmacology, pharmacokinetics and therapeutic use of drugs in the alimentary tract.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is &lt;STRONG&gt;not&lt;/STRONG&gt; available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281276</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18081648?ordinalpos=2&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Review article: the relevance of surveillance endoscopy in long-lasting inflammatory bowel disease</title>
    <publicationDate>2008-03-10T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic information:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;Vleggaar, F.P. &lt;SPAN title="Alimentary pharmacology &amp;amp; therapeutics."&gt;&lt;A href="#javascript:AL_get(this," ?jour?, ?Aliment Pharmacol Ther.?);?&gt;Aliment Pharmacol Ther.&lt;/A&gt;&lt;/SPAN&gt; 2007 Dec;26 Suppl 2:47-52.&lt;/P&gt;
&lt;P class=abstract&gt;BACKGROUND: Development of colitis-associated colorectal cancer is an important clinical problem in patients with colonic inflammatory bowel disease (IBD). British and American guidelines recommend to start surveillance after a disease duration of 8-10 or 15-20 years for patients with extensive or left-sided colitis, respectively. AIM: To assess the evidence level of current surveillance strategies. METHODS: A PubMed-based literature search using the search terms inflammatory bowel disease, ulcerative colitis, Crohn's disease, dysplasia, colorectal cancer and surveillance was performed. RESULTS: Low-grade and high-grade dysplastic lesions progress to cancer in a high percentage of patients. Furthermore, concurrent cancer is found in approximately one-third of the patients with colonic dysplasia. Low-level evidence showing reduced colorectal cancer-related mortality in patients who were undergoing surveillance is available. Patients with concomitant primary sclerosing cholangitis form a subgroup of IBD patients with an even higher risk of colorectal neoplasia. CONCLUSIONS: Colonic surveillance prolongs life expectancy of patients with long-lasting IBD.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Alimentary Pharmacology and Therapeutics is an international journal concerned with the effects of drugs on the human gastrointestinal and hepato-biliary systems. The journal publishes original research on all aspects of pharmacology, pharmacokinetics and therapeutic use of drugs in the alimentary tract.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is &lt;STRONG&gt;not&lt;/STRONG&gt; available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>330598</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2008.03798.x]]&gt;</url>
    <title>Review article: the therapeutic and prognostic benefit of portal pressure reduction in cirrhosis</title>
    <publicationDate>2008-10-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,NON-ALCOHOLIC,ALCOHOLIC LIVER DISEASE,ALCOHOLIC CIRRHOSIS,RECENT ADDITIONS,CIRRHOSIS,ALCOHOLIC,NOVEMBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt;&amp;nbsp;The prognostic and therapeutic value of HVPG is established beyond portal hypertensive bleeding for which there are some clinical surrogates. HVPG measurement should now be part of everyday clinical practice.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Hepatic venous pressure gradient (HVPG) measurement is not a routinely used technique, despite its therapeutic and prognostic value. The aim of this paper is to review the role of HVPG from published literature.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Systematic literature review.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; In acute variceal bleeding, HVPG is prognostic identifying 'difficult to treat' group, which now has defined clinical correlations. In secondary prevention of portal hypertensive bleeding, a reduction to =12&amp;nbsp;mmHg confers near complete protection against rebleeding. The target of =20% HVPG reduction from baseline needs prospective assessment to test a change of therapy, if no reduction occurs. The acute HVPG response to beta-blockade needs further assessment. In primary prevention, the cost-effectiveness of HVPG measurement is not favourable given the efficacy of medical therapy. In chronic liver disease, wedge hepatic venous pressure (WHVP) is prognostic for survival. Pharmacological reduction in portal pressure decreases complications and improves survival, possibly independent of a concomitant improvement in liver function. This latter requires urgent confirmation as it is clinically very relevant. HVPG monitoring can be used to assess anti-viral therapy particularly in cirrhosis, ergonomically combined with transjugular biopsy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Triantos CK, Nikolopoulou V, Burroughs AK. Review article: the therapeutic and prognostic benefit of portal pressure reduction in cirrhosis. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2008 Oct 15;28(8):943-52.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>251141</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2006.02980.x]]&gt;</url>
    <title>Review article: thiopurines in inflammatory bowel disease</title>
    <publicationDate>2006-09-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>In the past 10-20 years, knowledge of both thiopurine pharmacology and -pharmacogenetics has been extended dramatically and used to develop new strategies to improve efficacy and reduce toxicity. This article aimed to review thiopurine efficacy, toxicity, pharmacology, pharmacogenetics, interactions in patients with inflammatory bowel disease. Special attention was paid to new strategies for optimization of pharmacotherapy.</description>
    <body>&lt;![CDATA[ &lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Deriks LJ,&amp;nbsp;Gilissen LP, Hooymans PM&amp;nbsp;et al. 2006; Alimentary Pharmacology and Therapeutics 24 (5) pp. 715-729&amp;nbsp;&amp;nbsp; 
&lt;H2&gt;Original article abstract&lt;/H2&gt;
&lt;P&gt;BACKGROUND: In the past 10-20 years, knowledge of both thiopurine pharmacology and -pharmacogenetics has been extended dramatically and used to develop new strategies to improve efficacy and reduce toxicity. AIM: To review thiopurine efficacy, toxicity, pharmacology, pharmacogenetics, interactions in patients with inflammatory bowel disease. Special attention was paid to new strategies for optimization of pharmacotherapy. METHODS: To collect relevant scientific articles, a Pubmed search was performed from 1966 through January 2006 with the following key words (MeSH terms preferentially) in multiple combinations: 'azathioprine', '6-mercaptopurine', '6-MP', '6-thioguanine', '6-TG', 'thiopurine(s)', 'metabolites', 'level(s)', 'TDM', 'TMPT', 'ITPA', 'genotype(s)', 'phenotype(s)', 'inflammatory bowel disease', 'Crohn('s) disease', 'ulcerative colitis'. RESULTS: Strategies for optimization of pharmacotherapy include therapeutic drug monitoring of thiopurine metabolites, geno- or phenotyping crucial enzymes in thiopurine metabolism like thiopurine S-methyltransferase and inosine triphosphate pyrophosphatase, and the use of thioguanine as such. CONCLUSIONS: Thiopurine S-methyltransferase genotyping and therapeutic drug monitoring are useful instruments for individualizing thiopurine pharmacotherapy of inflammatory bowel disease. Inosine triphosphate pyrophosphatase genotyping may be helpful in case of unexplainable myelotoxicity. In case of azathioprine- or mercaptopurine-intolerance, thioguanine seems a promising alternative. However, more knowledge needs to be gathered about its potential hepatotoxicity.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;This article is &lt;STRONG&gt;not&lt;/STRONG&gt; available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309216</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2008.03753.x]]&gt;</url>
    <title>Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease</title>
    <publicationDate>2008-09-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Conclusion:&lt;/STRONG&gt; &lt;SPAN class=h5-inline&gt;&lt;/SPAN&gt;Treatment strategy algorithms are developed for use of these therapies that maximize remission and minimize corticosteroid dependence in patients with moderate-to-severe CD and UC.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Scientific literature was reviewed using MEDLINE with a specific focus on medical therapies for inducing and maintaining remission of CD and UC. The results were discussed at a roundtable meeting to reach a consensus on key issues.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Several therapies have demonstrated efficacy for the treatment of active, moderate-to-severe CD and UC. These include agents, which induce remission [corticosteroids, infliximab and adalimumab (CD only)] or maintain remission and spare corticosteroids [azathioprine, mercaptopurine, methotrexate (CD only), infliximab and adalimumab (CD only)]. Wide variability exists in the use of these agents.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Panaccione, R., Rutgeerts, P., Sandborn, W. J., Feagan, B., Schreiber, S., &amp;amp; Ghosh, S. (2008) Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. &lt;I&gt;Alimentary Pharmacology &amp;amp; Therapeutics&lt;/I&gt;, 28(6):674-688.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309230</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18284649]]&gt;</url>
    <title>Review article: use of antitumour necrosis factor therapy in inflammatory bowel disease during pregnancy and conception</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Based on available data, biological therapies appear to be safe in pregnancy. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A Medline search was performed and available original research and review articles relating to the use of biological (antitumour necrosis factor-a) therapies in inflammatory bowel disease were reviewed. Where information regarding the use of a drug in inflammatory bowel disease during pregnancy was limited, articles referring to its use for other indications, such as rheumatoid arthritis, were reviewed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Most studies looking at the effects of any one medication on pregnancy in inflammatory bowel disease are confounded by the fact that most patients are on multiple medications and have varying levels of disease activity. Stopping therapy in the third trimester should be considered. Large registries with longer follow-up periods will be necessary before firm conclusions about the safety of antitumour necrosis factor-a therapies during conception and pregnancy can be drawn.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;O'Donnell, S. &amp;amp; O'Morain, C. (2008) Review article: use of antitumour necrosis factor therapy in inflammatory bowel disease during pregnancy and conception. &lt;I&gt;Alimentary Pharmacology &amp;amp; Therapeutics&lt;/I&gt;, 27(10):885-894.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309076</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1007/s10350-008-9310-8]]&gt;</url>
    <title>Review of fecal biomarkers in inflammatory bowel disease</title>
    <publicationDate>2008-06-10T00:00:00</publicationDate>
    <publisher>Springer</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,DIAGNOSTIC PROCEDURES,STOOL TESTING,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Fecal calprotectin and lactoferrin are useful triage tools to differentiate organic intestinal disorders from functional disorders. They also have a role in monitoring inflammatory bowel disease activity and predicting relapse.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; A literature search using PubMed, MEDLINE, and Embase database was performed, locating all language articles on fecal biomarkers, including calprotectin and lactoferrin. The references of these papers were searched manually for further references.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;SPAN class=AbstractSectionHeading&gt;&lt;/SPAN&gt;A wide range of fecal biomarkers have been evaluated in the research setting. Only fecal calprotectin and lactoferrin have translated into useful clinical tools. These biomarkers have demonstrated high sensitivity for organic intestinal disease and good correlation with other measures of disease activity in inflammatory bowel disease.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Sutherland, A. D., Gearry, R. B., &amp;amp; Frizelle, F. A. (2008) Review of fecal biomarkers in inflammatory bowel disease. &lt;I&gt;Diseases of the Colon &amp;amp; Rectum&lt;/I&gt;, 51(8):1283-1291.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>322932</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/ebm.14.4.119]]&gt;</url>
    <title>Review: antidepressants and psychological therapies improve symptoms of irritable bowel syndrome</title>
    <publicationDate>2009-08-01T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,IRRITABLE BOWEL SYNDROME,RECENT ADDITIONS,AUGUST 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Evidence-Based Medicine is a secondary evidence journal, containing informative abstracts and expert commentaries about the best quality research from primary care medicine.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Cash BD. Review: antidepressants and psychological therapies improve symptoms of irritable bowel syndrome. &lt;EM&gt;Evid Based Med &lt;/EM&gt;2009;14(4):119.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt;&amp;nbsp;A review of the original article: Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. &lt;EM&gt;Gut &lt;/EM&gt;2009;58:367–78.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to NHS staff via Athens.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>326349</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/ebm.14.5.138]]&gt;</url>
    <title>Review: bariatric surgery reduces weight and improves type 2 diabetes in adults</title>
    <publicationDate>2009-10-01T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COMMON CLINICAL PRESENTATIONS,STOMACH,OBESITY,RECENT ADDITIONS,OCTOBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Evidence-Based Medicine is a secondary evidence journal, containing informative abstracts and expert commentaries about the best quality research from primary care medicine.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Padwal RS. Review: bariatric surgery reduces weight and improves type 2 diabetes in adults. &lt;EM&gt;Evid Based Med&lt;/EM&gt; 2009;14(5):138.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt; A review of the original article: Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and metaanalysis. &lt;EM&gt;Am J Med &lt;/EM&gt;2009;122:248–256.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to NHS staff via Athens.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>316170</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/ebm.14.3.89]]&gt;</url>
    <title>Review: clinical findings had moderate sensitivity and specificity for diagnosing irritable bowel syndrome</title>
    <publicationDate>2009-06-01T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,IRRITABLE BOWEL SYNDROME,RECENT ADDITIONS,DIAGNOSTIC PROCEDURES,JUNE 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Evidence-Based Medicine is a secondary evidence journal, containing informative abstracts and expert commentaries about the best quality research from primary care medicine.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Bursey F.&amp;nbsp;Diagnosis: Review: clinical findings had moderate sensitivity and specificity for diagnosing irritable bowel syndrome.&amp;nbsp; &lt;EM&gt;Evid Based Med &lt;/EM&gt;2009;14(3):89.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt; A review of the original article: Ford AC, Talley NJ, Veldhuyzen van Zanten SJ, et al. Will the history and physical examination help establish that irritable bowel syndrome is causing this patient’s lower gastrointestinal tract symptoms? JAMA 2008;300:1793–805.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to NHS staff via Athens.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>316173</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/ebm.14.3.84]]&gt;</url>
    <title>Review: fibre, antispasmodics, and peppermint oil are all effective for irritable bowel syndrome</title>
    <publicationDate>2009-06-01T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,IRRITABLE BOWEL SYNDROME,RECENT ADDITIONS,JUNE 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=abstractSummary&gt;
&lt;P&gt;Evidence-Based Medicine is a secondary evidence journal, containing informative abstracts and expert commentaries about the best quality research from primary care medicine.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Veldhuyzen&lt;STRONG&gt; &lt;/STRONG&gt;van Zanten S.&amp;nbsp;Therapeutics:&amp;nbsp;Review: fibre, antispasmodics, and peppermint oil are all effective for irritable bowel syndrome&amp;nbsp; &lt;EM&gt;Evid Based Med &lt;/EM&gt;2009;14(3):84.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt; A review of the original article: Ford AC, Talley NJ, Spiegel BM, et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and metaanalysis. BMJ 2008;337:a2313.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to NHS staff via Athens.&lt;/P&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>326351</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/ebn.12.4.107]]&gt;</url>
    <title>Review: high-quality evidence on the effectiveness of laxatives for functional constipation in children is limited</title>
    <publicationDate>2009-10-01T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COMMON CLINICAL PRESENTATIONS,CONSTIPATION,RECENT ADDITIONS,OCTOBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Evidence-Based Medicine is a secondary evidence journal, containing informative abstracts and expert commentaries about the best quality research from primary care medicine.&amp;nbsp;Evidence-Based Nursing surveys a wide range of international medical journals applying strict criteria for the quality and validity of research. Practising clinicians assess the clinical relevance of the best studies. The key details of these essential studies are presented in a succinct, informative abstract with an expert commentary on its clinical application.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Harkness GE. Review: high-quality evidence on the effectiveness of laxatives for functional constipation in children is limited. &lt;EM&gt;Evid Based Nurs&lt;/EM&gt; 2009;12(4):114.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary:&amp;nbsp;&lt;/STRONG&gt;A review of the original article: Pijpers MA, Tabbers MM, Benninga MA, et al. Currently recommended treatments of childhood constipation are not evidence based: a systematic literature review on the effect of laxative treatment and dietary measures. &lt;EM&gt;Arch Dis Child&lt;/EM&gt; 2009;94:117–31.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to NHS staff via Athens.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>316172</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/ebm.14.3.86]]&gt;</url>
    <title>Review: interferon and nucleoside/tide analogues reduce risk of hepato-cellular cancer in chronic hepatitis B</title>
    <publicationDate>2009-06-01T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,HEPATITIS B,LIVER,HEPATITIS,HEPATOCELLULAR CARCINOMA,RECENT ADDITIONS,JUNE 2009,CANCER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV id=abstractSummary&gt;
&lt;P&gt;Evidence-Based Medicine is a secondary evidence journal, containing informative abstracts and expert commentaries about the best quality research from primary care medicine.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Sherker AH.&amp;nbsp;Therapeutics: Review: interferon and nucleoside/tide analogues reduce risk of hepato-cellular cancer in chronic hepatitis B. &lt;EM&gt;Evid Based Med &lt;/EM&gt;2009;14(3):86.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt; A review of the original article: Sung JJ, Tsoi KK, Wong VW, et al. Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008;28:1067–77.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to NHS staff via Athens.&lt;/P&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>326350</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/ebn.12.4.114]]&gt;</url>
    <title>Review: mechanical bowel preparation before colorectal surgery does not provide any benefit and may be harmful</title>
    <publicationDate>2009-10-01T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,RECENT ADDITIONS,OCTOBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Evidence-Based Medicine is a secondary evidence journal, containing informative abstracts and expert commentaries about the best quality research from primary care medicine.&amp;nbsp;Evidence-Based Nursing surveys a wide range of international medical journals applying strict criteria for the quality and validity of research. Practising clinicians assess the clinical relevance of the best studies. The key details of these essential studies are presented in a succinct, informative abstract with an expert commentary on its clinical application.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Fernell J. Review: mechanical bowel preparation before colorectal surgery does not provide any benefit and may be harmful.&lt;EM&gt; Evid Based Nurs&lt;/EM&gt; 2009;12(4):114.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary:&amp;nbsp;&lt;/STRONG&gt;A review of the original article: Slim K, Vicaut E, Launay-Savary MV, et al. Updated systematic review and meta-analysis of randomized clinical trials on the role of mechanical bowel preparation before colorectal surgery. &lt;EM&gt;Ann Surg&lt;/EM&gt; 2009;249:203–9.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to NHS staff via Athens.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323697</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1440-1746.2008.05398.x]]&gt;</url>
    <title>Ribavirin in the treatment of chronic hepatitis C</title>
    <publicationDate>2008-06-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,RECENT ADDITIONS,AUGUST 2009,CHRONIC HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; &lt;SPAN class=h5-inline&gt;&lt;/SPAN&gt;Treatments of ribavirin toxicities, especially anemia, can allow patients to continue full-dose combination therapy with peginterferon and ribavirin, enhancing their probability of attaining a sustained virologic response (SVR). Treatment of chronic hepatitis C (CHC)should be tailored to individual patients, especially those with renal dysfunction, and should include agents that treat the side-effects of CHC treatment. Monitoring of plasma ribavirin concentrations during treatment may help in the future.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Medline searches were performed using the keywords ribavirin and hepatitis, together with the keywords mechanism, anemia, liver transplant, renal function, pharmacokinetics, and dose reduction. Searches of abstracts of recent Digestive Diseases Week, American Association for the Study of Liver Diseases, and European Association for the Study of Liver Diseases meetings were also performed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;SPAN class=h5-inline&gt;&lt;/SPAN&gt;Ribavirin may be effective in treating CHC by affecting the virus or the host; for example by inducing viral mutations, blocking cellular enzymes, or affecting the host immune response. Although the pegylated interferons are the primary drugs used to treat CHC, a combination with ribavirin is more effective than pegylated interferon alone. Ribavirin-associated&amp;nbsp;adverse events&amp;nbsp;may be lessened by ribavirin dose reductions and by maintenance of the hematocrit.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Martin P, Jensen DM. Ribavirin in the treatment of chronic hepatitis C. &lt;EM&gt;J Gastroenterol Hepatol&lt;/EM&gt; 2008 Jun;23(6):844-55.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>268528</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1572-0241.2006.00505.x]]&gt;</url>
    <title>Ribavirin monotherapy for chronic hepatitis C infection: a Cochrane Hepato-Biliary Group systematic review and meta-analysis of randomized trials</title>
    <publicationDate>2006-04-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,CHRONIC HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation&lt;/STRONG&gt;: Brok J., Gluud L.L., Gluud C. 2006; American Journal of Gastroenterology 101 (4) pp. 842-7&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;Abstract: &lt;/STRONG&gt;OBJECTIVES: Adding ribavirin to interferon improves treatment response for patients with chronic hepatitis C, but the effects of ribavirin monotherapy are unclear. We conducted a systematic review to assess the benefits and harms of ribavirin monotherapy for patients with chronic hepatitis C. METHODS: Randomized trials were identified through the Cochrane Hepato-Biliary Group Controlled Trials Register, The Cochrane Library, MEDLINE, and EMBASE (last search May 2005). The primary outcomes were sustained virological response (loss of HCV RNA) and liver-related morbidity plus all-cause mortality. Secondary outcomes included end-of-treatment virological response, biochemical response (normalization of transaminases), histological response, and adverse events. RESULTS: We included 11 randomized trials with 521 patients. Ten trials had unclear control of bias. Ribavirin had no significant effect on sustained (risk difference (RD), 0%; 95% confidence intervals (CI), -2% to 3%) or end-of-treatment virological response (RD, 0%; 95% CI, -3% to 3%). Ribavirin had no significant effect on liver-related morbidity plus mortality (RD, 0%; 95% CI, -2% to 3%). Ribavirin significantly improved histological response and end-of-treatment biochemical response, but not sustained biochemical response. Ribavirin significantly increased the risk of anemia and treatment discontinuation. CONCLUSIONS: We found no evidence to support ribavirin monotherapy for patients with chronic hepatitis C, but trials were small and type II errors cannot be excluded. Patients intolerant to interferon should not continue treatment with ribavirin alone outside randomized trials.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>380590</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1038/ajg.2009.760]]&gt;</url>
    <title>Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies</title>
    <publicationDate>2010-07-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,OESOPHAGUS,CANCER,STOMACH,CANCER,BILIARY TREE &amp; GALLBLADDER,LIVER,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE,CANCER,RECENT ADDITIONS,CANCER,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Although the overall risk of&amp;nbsp;extra-intestinal cancer (EIC)&amp;nbsp;is not significantly increased among patients with inflammatory bowel disease (IBD), the risk of individual cancer types differs from that of the background population as well as between&amp;nbsp;Crohn's disease (CD)&amp;nbsp;and ulcerative colitis (UC) patients. These findings may primarily be explained by smoking habits, extra-intestinal manifestations of IBD, and involvement of the upper gastrointestinal tract in CD.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Extra-intestinal manifestations of IBD are relatively common, whereas the risk of EIC remains uncertain. The aim of this study was to obtain a reliable estimate of the risk of EIC in CD and UC by performing a meta-analysis of population-based cohort studies.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A systematic literature review was performed using MEDLINE (1966-2009) and abstracts from recent international conferences. Eight population-based cohort studies comprising a total of 17,052 patients with IBD were available. Standardized incidence ratios (SIRs) of EICs were pooled in a meta-analysis approach using STATA software.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Overall, IBD patients were not at increased risk of EIC (SIR, 1.10; 95% confidence interval (CI) 0.96-1.27). However, site-specific analyses revealed that CD patients had an increased risk of cancer of the upper gastrointestinal tract (SIR 2.87, 95% CI 1.66-4.96), lung (SIR 1.82, 95% CI 1.18-2.81), urinary bladder (SIR 2.03, 95% CI 1.14-3.63), and skin (SIR 2.35, 95% CI 1.43-3.86). Patients with UC had a significantly increased risk of liver-biliary cancer (SIR 2.58, 95% CI 1.58-4.22) and leukemia (SIR 2.00, 95% CI 1.31-3.06) but a decreased risk of pulmonary cancer (SIR 0.39, 95% CI 0.20-0.74).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Pedersen N, Duricova D, Elkjaer M, Gamborg M, Munkholm P, Jess T. Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. &lt;EM&gt;Am J Gastroenterol&lt;/EM&gt; 2010;105(7):1480-7.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>346149</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.cgh.2009.01.004]]&gt;</url>
    <title>Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis</title>
    <publicationDate>2009-08-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The use of anti-tumor necrosis factor (anti-TNF)&amp;nbsp;agents with immunomodulators is associated with an increased risk of&amp;nbsp;non-Hodgkin's lymphoma (NHL)&amp;nbsp;in adult Crohn's&amp;nbsp;disease (CD)&amp;nbsp;patients, but the absolute rate of these events remains low and should be weighed against the substantial benefits associated with treatment.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Although anti-TNF therapy can effectively treat CD, there is concern that it might increase the risk of NHL. A meta-analysis was performed to determine the rate of NHL in adult CD patients who have received anti-TNF therapy and to compare this rate with that of a population-based registry and a population of CD patients treated with immunomodulators.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; MEDLINE, EMBASE, Cochrane Collaboration, and Web of Science were searched. Inclusion criteria included randomized controlled trials, cohort studies, or case series reporting on anti-TNF therapy in adult CD patients. Standardized incidence ratios (SIR) were calculated by comparing the pooled rate of NHL with the expected rate of NHL derived from the Surveillance Epidemiology &amp;amp; End Results (SEER) database and a meta-analysis of CD patients treated with immunomodulators.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Twenty-six studies involving 8905 patients and 21,178 patient-years of follow-up were included. Among anti-TNF treated subjects, 13 cases of NHL were reported (6.1 per 10,000 patient-years). The majority of these patients had previous immunomodulator exposure. Compared with the expected rate of NHL in the SEER database (1.9 per 10,000 patient-years), anti-TNF treated subjects had a significantly elevated risk (SIR, 3.23; 95% confidence interval, 1.5-6.9). When compared with the NHL rate in CD patients treated with immunomodulators alone (4 per 10,000 patient-years), the SIR was 1.7 (95% confidence interval, 0.5-7.1).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. &lt;EM&gt;Clin Gastroenterol Hepatol&lt;/EM&gt; 2009;7(8):874-81.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>322934</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/ebm.14.4.111]]&gt;</url>
    <title>Rofecoxib increased risk of CV events in patients with history of colorectal adenomas &gt;=1 year after stopping treatment</title>
    <publicationDate>2009-08-01T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,POLYPS,CANCER,RECENT ADDITIONS,NON-MALIGNANT NEOPLASMS,AUGUST 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Evidence-Based Medicine is a secondary evidence journal, containing informative abstracts and expert commentaries about the best quality research from primary care medicine.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Baron JA. Rofecoxib increased risk of CV events in patients with history of colorectal adenomas &amp;gt;=1 year after stopping treatment. &lt;EM&gt;Evid Based Med &lt;/EM&gt;2009;14(4):111&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary: &lt;/STRONG&gt;A review of the original article: Baron JA, Sandler RS, Bresalier RS, Lanas A, Morton DG, Riddell R, Iverson ER, Demets DL. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. &lt;EM&gt;Lancet&lt;/EM&gt; 2008 Nov 15;372(9651):1756-64.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to NHS staff via Athens.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345480</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1002/ibd.21001]]&gt;</url>
    <title>Role of ATG16L1 Thr300Ala polymorphism in inflammatory bowel disease: a study in the Spanish population and a meta-analysis</title>
    <publicationDate>2009-11-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The Thr300Ala polymorphism is associated with Crohn's disease (CD), regardless of the CARD15 or IL23R status, but not with ulcerative colitis (UC). Stratification by clinical phenotypes did not show definitive results because of the existing heterogeneity among studies.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Thr300Ala polymorphism in ATG16L1 was reported as a susceptibility factor to CD. Inconsistently replicated associations with UC and specifically with ileal CD were also reported. Our aims were: to replicate the ATG16L1 Thr300Ala association with inflammatory bowel disease (IBD) in the Spanish population, to perform a meta-analysis to determine the risk conferred to the different IBD subgroups, and to test for the interaction with CARD15 or IL23R risk loci.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Thr300Ala (rs2241880) single nucleotide polymorphism (SNP) was genotyped in 712 IBD patients and 745 controls by TaqMan technology. Genetic frequencies were compared with chi-square tests. Our findings were pooled in a meta-analysis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; In Spain, we observed an association of rs2241880 with CD (P = 0.008; odds ratio [OR, 95% confidence interval, CI] = 1.28 [1.06-1.54]), but not with UC. No significant differences emerged when patients were stratified by clinical features. Similarly, the meta-analysis demonstrated a significant association only with CD (P &amp;lt; 10(-4); OR [95% CI] = 1.33 [1.28-1.38]). A significant difference between ileal CD patients and controls was observed, but heterogeneity was found in comparisons involving colonic CD patients and definite conclusions cannot be drawn. No interaction between rs2241880 and the established CARD15 or IL23R susceptibility variants was observed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Márquez A, Núñez C, Martínez A, Mendoza JL, Taxonera C, Fernández-Arquero M, Díaz-Rubio M, de la Concha EG, Urcelay E. Role of ATG16L1 Thr300Ala polymorphism in inflammatory bowel disease: a Study in the Spanish population and a meta-analysis. &lt;EM&gt;Inflamm Bowel Dis&lt;/EM&gt; 2009;15(11):1697-704.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>251152</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1097/00054725-200606000-00013]]&gt;</url>
    <title>Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease</title>
    <publicationDate>2006-06-01T00:00:00</publicationDate>
    <publisher>Lippincott Williams &amp; Wilkins</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Calprotectin is an abundant neutrophil protein found in both plasma and stool that is markedly elevated in infectious and inflammatory conditions, including inflammatory bowel disease (IBD). We conducted a systematic review of the published literature regarding fecal calprotectin to evaluate its potential as a noninvasive marker of neutrophilic intestinal inflammation.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Konikoff MR and Denson LA 2006; Inflammatory Bowel Disease 12 (6) pp. 524-534&amp;nbsp; &lt;/P&gt;&lt;BR&gt;
&lt;H2&gt;Article review by Professor David Rampton, Professor of Clinical Gastroenterology, Royal London Hospital.&lt;/H2&gt;&lt;BR&gt;&lt;BR&gt;
&lt;P&gt;The usefulness of measuring the faecal concentration of calprotectin, a neutrophil-derived protein, in the non-invasive diagnosis and management of inflammatory bowel disease and other gut disorders has been investigated for some years both in adults and children. This comprehensive but concise review covers papers published up to the beginning of 2006. After a critical discussion of the calprotectin assay itself, its application to initial diagnosis, assessment of disease activity, prediction of relapse and monitoring of response to treatment in patients with IBD is described. Then follow sections on use of faecal calprotectin assay in the management of pouchitis and a comparison with other biomarkers. The next section makes clear the lack of specificity of a raised faecal calprotectin, causes other than IBD including diverticular disease, micorscopic colitis, coeliac disease and colorectal cancer. Finally, the authors discuss use of faecal calprotectin assay in the outpatient setting to distinguish inflammatory diseases from irritable bowel syndrome, and in the diagnosis of chronic diarrhoea.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;This paper provides a useful overview of the potential value as well as pitfalls of measurement of faecal calprotectin. It is not clear whether the slow uptake of this test, at least in the UK, relates to its cost, the unpleasantness for the patient of providing stool samples, or a feeling that in routine clinical practice the history, conventional laboratory markes and/or endoscopy provide sufficient information. Clinicians are recommended to read this review to see whether their patients' management might be enhanced by introduction of this test.&lt;/P&gt;&lt;BR&gt;
&lt;H2&gt;Original article abstract&lt;/H2&gt;&lt;BR&gt;
&lt;P&gt;Calprotectin is an abundant neutrophil protein found in both plasma and stool that is markedly elevated in infectious and inflammatory conditions, including inflammatory bowel disease (IBD). We conducted a systematic review of the published literature regarding fecal calprotectin to evaluate its potential as a noninvasive marker of neutrophilic intestinal inflammation. Reference ranges for fecal calprotectin have been established in healthy adults and children, and elevated concentrations of fecal calprotectin have been demonstrated in numerous studies of patients with IBD. Fecal calprotectin correlates well with histological inflammation as detected by colonoscopy with biopsies and has been shown successfully to predict relapses and detect pouchitis in patients with IBD. Fecal calprotectin has been shown to consistently differentiate IBD from irritable bowel syndrome because it has excellent negative predictive value in ruling out IBD in undiagnosed, symptomatic patients. Fecal calprotectin also may be useful in determining whether clinical symptoms in patients with known IBD are caused by disease flares or noninflammatory complications/underlying irritable bowel syndrome and in providing objective evidence of response to treatment. Although more studies are needed to define fully the role of fecal calprotectin, convincing studies and growing clinical experience point to an expanded role in the diagnosis and management of IBD.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;This article is &lt;STRONG&gt;not&lt;/STRONG&gt; available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>251142</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://radiology.rsnajnls.org/cgi/reprint/236/1/95]]&gt;</url>
    <title>Role of US in detection of Crohn Disease: meta-analysis</title>
    <publicationDate>2005-07-01T00:00:00</publicationDate>
    <publisher>Radiological Society of North America</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,DIAGNOSTIC PROCEDURES,ULTRASOUND,CROHN'S DISEASE,RADIOLOGY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This article aimed to evaluate the accuracy of ultrasonography (US) in the detection of Crohn disease in adults by systematically reviewing both cohort studies (those including patients whose clinical characteristics were consistent with those caused by an inflammatory bowel disease) and case-control studies (those in which patients with Crohn disease were compared with patients with other bowel diseases or healthy control subjects).</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Fraquelli M, Colli A, Casazza G et al. 2005; Radiology 236 pp. 95-101&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Abstract: &lt;/B&gt;PURPOSE: To evaluate the accuracy of ultrasonography (US) in the detection of Crohn disease in adults by systematically reviewing both cohort studies (those including patients whose clinical characteristics were consistent with those caused by an inflammatory bowel disease) and case-control studies (those in which patients with Crohn disease were compared with patients with other bowel diseases or healthy control subjects). MATERIALS AND METHODS: The MEDLINE, EMBASE, and Cochrane Library databases were used to retrieve all the cross-sectional studies that assessed the diagnostic accuracy of US against that of one of several predefined reference standards (ie, radiologic, endoscopic, or histologic findings). The studies that fulfilled the inclusion criteria were identified, and their methodological quality was evaluated. Of the 2860 primary studies identified, two case-control and five cohort series fulfilled the inclusion criteria. Statistical analysis was performed by using the summary receiver operating characteristic (SROC) model. RESULTS: The ranges of US sensitivity and specificity for the diagnosis of Crohn disease reported for the included series were 75%-94% and 67%-100%, respectively; the heterogeneity of these values prevented the calculation of a cumulative value. The SROC curve revealed a clear cutoff effect that depended on the chosen bowel wall thickness threshold. Sensitivity and specificity of 88% and 93%, respectively, were achieved when a bowel wall thickness threshold greater than 3 mm was used, and sensitivity and specificity of 75% and 97%, respectively, were achieved when a threshold greater than 4 mm was used. CONCLUSION: US examination seems appropriate for confirming or excluding Crohn disease as a diagnosis in a clinical context characterized by a pretest probability of Crohn disease that ranges from 12% to about 60%. In particular, for Crohn disease limited to the ileum, US may represent a valid alternative to the small-bowel series, while for colonic involvement US may be useful in ruling out the diagnosis. &lt;/P&gt;
&lt;H2&gt;&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;Full text available freely online to NHS Athens account holders&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281280</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17762967?ordinalpos=2&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Safety and efficacy of strictureplasty for Crohn's disease: a systematic review and meta-analysis</title>
    <publicationDate>2008-03-10T00:00:00</publicationDate>
    <publisher>Springer</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;SPAN title="Diseases of the colon and rectum."&gt;Yamamoto, T. &lt;A href="#javascript:AL_get(this," Rectum.?);? Colon ?Dis ?jour?,&gt;Dis Colon Rectum.&lt;/A&gt;&lt;/SPAN&gt; 2007 Nov;50(11):1968-86&lt;/P&gt;
&lt;P class=abstract&gt;PURPOSE: This study was designed to review safety and efficacy of strictureplasty for Crohn's disease. METHODS: A literature search was performed to identify studies published between 1975 and 2005 that reported the outcome of strictureplasty. Systematic review was performed on the following subjects separately: 1) overall experience of strictureplasty; 2) postoperative complications; 3) postoperative recurrence and site of recurrence; 4) factors affecting postoperative complications and recurrence; 5) short-bowel syndrome; and 6) cancer risk. Meta-analysis of recurrence rate after strictureplasty was performed by using random-effect model and meta-regressive techniques. RESULTS: A total of 1,112 patients who underwent 3,259 strictureplasties (Heineke-Mikulicz, 81 percent; Finney, 10 percent; side-to-side isoperistaltic, 5 percent) were identified. The sites of strictureplasty were jejunum and/or ileum (94 percent), previous anastomosis (4 percent), duodenum (1 percent), and colon (1 percent). After jejunoileal strictureplasty, including ileocolonic strictureplasty, septic complications (leak/fistula/abscess) occurred in 4 percent of patients. Overall surgical recurrence was 23 percent (95 percent confidence interval, 17-30 percent). Using meta-regressive analysis, the five-year recurrence rate after strictureplasty was 28 percent. In 90 percent of patients, recurrence occurred at nonstrictureplasty sites, and the site-specific recurrence rate was 3 percent. Two patients developed adenocarcinoma at the site of previous jejunoileal strictureplasty. The experience of duodenal or colonic strictureplasty was limited. CONCLUSIONS: Strictureplasty is a safe and effective procedure for jejunoileal Crohn's disease, including ileocolonic recurrence, and it has the advantage of protecting against further small bowel loss. However, the place for strictureplasty is less well defined in duodenal and colonic diseases.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>125509</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[https://www.ecco-ibd.eu/documents/CD_guidelines_2010_current_management.pdf]]&gt;</url>
    <title>Second European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis</title>
    <publicationDate>2010-01-01T00:00:00</publicationDate>
    <publisher>European Crohn's &amp; Colitis Organisation</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,DIAGNOSTIC PROCEDURES,GASTROINTESTINAL ENDOSCOPY,BIOPSY,INTESTINAL,SURGERY,SURGERY,ABDOMEN,SMALL INTESTINE,CROHN'S DISEASE,CROHN’S DISEASE,RECENT ADDITIONS,MAY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; The Consensus endeavours to address the differences in practice in the treatment of Crohn's disease between clinicians in different countries.&amp;nbsp;It is not meant to supersede the guidelines of different countries (such as those from the UK, Germany, or France), which reach broadly the same conclusions since they are, after all, based on the same evidence. Rather, the aim of the Consensus is to promote a European perspective on the management of Crohn's disease and its dilemmas. Since the development of guidelines is an expensive and time-consuming process, it may help to avoid duplication of effort in the future. A Consensus is also considered important because an increasing number of therapeutic trials are based in Europe, especially in eastern European countries where practice guidelines have yet to be published.&lt;/P&gt;
&lt;P&gt;The Consensus is grouped into three parts: definitions and diagnosis; current management; and management of special situations. This first section concerns aims and methods of the Consensus, as well as diagnosis, pathology, and classification of Crohn's disease. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience: &lt;/STRONG&gt;Gastroenterologists&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in January 2010&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>125489</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[https://www.ecco-ibd.eu/documents/CD_guidelines_2010_special_situations.pdf]]&gt;</url>
    <title>Second European evidence based consensus on the diagnosis and management of Crohn's disease: special situations</title>
    <publicationDate>2010-01-01T00:00:00</publicationDate>
    <publisher>European Crohn's &amp; Colitis Organisation</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,SMALL INTESTINE,COLON &amp; RECTUM,INFLAMMATORY BOWEL DISEASE,SURGERY,SURGERY,ABDOMEN,SMALL INTESTINE,FISTULA,CROHN'S DISEASE,PERIANAL,CROHN’S DISEASE,RECENT ADDITIONS,FISTULA,MAY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; The Consensus endeavours to address the differences in practice in the treatment of Crohn's disease between clinicians in different countries.&amp;nbsp;It is not meant to supersede the guidelines of different countries (such as those from the UK, Germany, or France), which reach broadly the same conclusions since they are, after all, based on the same evidence. Rather, the aim of the Consensus is to promote a European perspective on the management of Crohn's disease and its dilemmas. Since the development of guidelines is an expensive and time-consuming process, it may help to avoid duplication of effort in the future. A Consensus is also considered important because an increasing number of therapeutic trials are based in Europe, especially in eastern European countries where practice guidelines have yet to be published.&lt;/P&gt;
&lt;P&gt;The Consensus is grouped into three parts: definitions and diagnosis; current management; and management of special situations.&amp;nbsp;&amp;nbsp;This third section on Special Situations in Crohn's disease includes post-operative recurrence, fistulating disease, paediatrics, pregnancy, psychosomatics, extraintestinal manifestations and alternative therapy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience: &lt;/STRONG&gt;Gastroenterologists&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in January 2010&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>125531</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[https://www.ecco-ibd.eu/documents/CD_guidelines_2010_current_management.pdf]]&gt;</url>
    <title>Second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management</title>
    <publicationDate>2010-01-01T00:00:00</publicationDate>
    <publisher>European Crohn's &amp; Colitis Organisation</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,SURGERY,SURGERY,ABDOMEN,SMALL INTESTINE,CROHN'S DISEASE,CROHN’S DISEASE,RECENT ADDITIONS,MAY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; The Consensus endeavours to address the differences in practice in the treatment of Crohn's disease between clinicians in different countries.&amp;nbsp;It is not meant to supersede the guidelines of different countries (such as those from the UK, Germany, or France), which reach broadly the same conclusions since they are, after all, based on the same evidence. Rather, the aim of the Consensus is to promote a European perspective on the management of Crohn's disease and its dilemmas. Since the development of guidelines is an expensive and time-consuming process, it may help to avoid duplication of effort in the future. A Consensus is also considered important because an increasing number of therapeutic trials are based in Europe, especially in eastern European countries where practice guidelines have yet to be published.&lt;/P&gt;
&lt;P&gt;The Consensus is grouped into three parts: definitions and diagnosis; current management; and management of special situations. This second section on Current Management includes treatment of active disease, maintenance of medically-induced remission and surgery of Crohn's&lt;BR&gt;disease. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience: &lt;/STRONG&gt;Gastroenterologists&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in January 2010&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>295251</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.bsg.org.uk/pdf_word_docs/sedation_elderly.pdf]]&gt;</url>
    <title>Sedation for gastrointestinal endoscopic procedures in the elderly - getting safer but still not nearly safe enough</title>
    <publicationDate>2006-03-19T00:00:00</publicationDate>
    <publisher>British Society of Gastroenterology</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,DIAGNOSTIC PROCEDURES,GASTROINTESTINAL ENDOSCOPY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The British Society of Gastroenterology is an organisation focused on the promotion of gastroenterology within the United Kingdom. It has over three thousand members drawn from the ranks of physicians, surgeons, pathologists, radiologists, scientists, nurses, dietitians, and others interested in the field. Founded in 1937 it has grown from a club to be a major force in British medicine, with representation within the British Royal Colleges and thus to the Department of Health and Government. Internationally it is represented at World and European level. The BSG is a registered charity.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary: &lt;/STRONG&gt;&lt;EM&gt;Background:&lt;/EM&gt; Previously published UK reports showed that excessively large doses of benzodiazepines and opiates were being commonly used to sedate elderly patients for gastrointestinal (GI) endoscopy. This unsafe practice has lead to avoidable morbidity and mortality. We have taken the opportunity provided by recent reports to examine whether GI endoscopy sedation practice in the elderly has improved in the light of this evidence and the publication of guidelines in which specific recommendations on sedation dosage are given.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Methods:&lt;/EM&gt; Using data mining techniques, we have extracted data on the use of benzodiazepines and opiates from a recent NCEPOD report on deaths following GI therapeutic endoscopy and from unpublished data from six East Anglian hospital GI endoscopy databases. We have compared and contrasted these data with re-analysed data from two previously published large audits of upper and lower GI endoscopy carried out in 1991 and 1998 respectively.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Findings:&lt;/EM&gt; Midazolam has largely replaced diazepam as the benzodiazepine of first choice and many more procedures are now carried out without sedation. Improvements have occurred in the use of pulse oximetry, supplemental oxygen and continuous intravenous access. Mean doses of benzodiazepines and opiates given for GI endoscopy sedation in the elderly still exceed published guidelines, although doses have fallen significantly since the 1990’s. The use of flumazenil, a specific benzodiazepine antagonist, appears to be a good marker of over-sedation and cardiopulmonary complications were more common in patients who were given the drug. In the NCEPOD study of patients who died within&lt;BR&gt;30 days after therapeutic endoscopy, the time between endoscopy and death was significantly shorter in those who received flumazenil. In the East Anglian study, there was a two-fold difference in the average doses of both midazolam and pethidine used by individual endoscopists in elderly patients. Despite the well-known synergism between opioids and benzodiazepines, worryingly, those endoscopists who used the highest average doses of midazolam in elderly patients also tended to be those who administered the largest amounts of pethidine.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Interpretation:&lt;/EM&gt; Patient safety would be significantly improved if those GI endoscopists who regularly give unnecessarily high doses of sedative and analgesic drugs to elderly patients changed their sedation practice to conform to published guidelines. Regular audit of sedation dosages and reporting of ‘near misses’ (including flumazenil usage), is recommended.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281304</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.internurse.com/cgi-bin/go.pl/library/article.cgi?uid=23704;article=gn_5_5_34_38]]&gt;</url>
    <title>Self-management in the care of patients with inflammatory bowel disease</title>
    <publicationDate>2008-03-10T00:00:00</publicationDate>
    <publisher>MA Healthcare limited</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ PATIENT AND PUBLIC INVOLVEMENT,PPI IN PRACTICE,GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE,INDIVIDUAL INVOLVEMENT,SELF MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Hall, A. et al.&amp;nbsp; Gastrointestinal Nursing, &lt;A href="http://www.internurse.com/cgi-bin/go.pl/library/contents.html?uid=1745;journal_uid=27" target="_blank"&gt;Vol. 5, Iss. 5&lt;/A&gt;, 21 Jun 2007, pp 34 - 38 &lt;/P&gt;
&lt;P&gt;The cost of managing chronic disease within the NHS has come under increasing focus, along with the issue of self-care of chronic disease. Self-management is one way of addressing these two issues. Self-management is a partnership approach to patient care which involves the patients’ ability to identify worsening symptoms and adjust treatment accordingly. This approach involves changes in service provision to become patient centred with the aim of reducing routine hospital attendance. Guided self-management in inflammatory bowel disease involves the provision of action plans, individualized patient information, open-access clinic appointments, telephone helplines and patient centred consultations. The key focus of self-management is that treatment and management pathways are agreed between the healthcare professional and patient.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>332636</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1038/ajg.2009.555]]&gt;</url>
    <title>Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children</title>
    <publicationDate>2009-12-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,STOMACH,HELICOBACTER PYLORI,RECENT ADDITIONS,INFECTIONS,DECEMBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Sequential therapy (ST) appears to be better than&amp;nbsp;triple therapy (TT)&amp;nbsp;in the eradication of &lt;EM&gt;Helicobacter pylori&lt;/EM&gt;. This is a promising therapy, but further trials are needed in other European countries and North America before it can be recommended as a first-line treatment.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Eradication rates with TT for &lt;EM&gt;H. pylori&lt;/EM&gt; infection have declined to unacceptable levels. ST is a novel treatment that has shown promise in several controlled trials. Our aim was to assess the efficacy of ST in adults and children compared with that of TT by performing a systematic review and meta-analysis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We performed an electronic search of the following: Cochrane Trial Register (until Issue 4, 2008), MEDLINE (1966 to 21 October 2008), EMBASE (1980 to 21 October 2008), and abstracts from the major US, European, and Asian gastroenterology conferences. Randomized controlled trials (RCTs) and controlled clinical trials with a parallel group design comparing the ST with a TT lasting at least 7 days were used.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Ten RCTs enrolled 3,006 adult patients and the odds ratio (OR) for eradication of &lt;EM&gt;H. pylori&lt;/EM&gt; with ST compared with TT was 2.99 (95% confidence interval (CI): 2.47–3.62), giving a number needed to treat (NNT) of 6 (95% CI: 5–7) favoring ST. There was no publication bias. The OR for eradication with ST compared with 10-day TT was 2.92 (95% CI: 1.95–4.38), yielding an NNT of 8 (95% CI: 6–12), favoring ST. In patients with clarithromycin resistance, the OR for eradication with ST was 10.21 (95% CI: 3.01–34.58) compared with TT, but the numbers studied are small. Three RCTs enrolled 260 children and adolescents, and the OR for eradication was 1.98 (95% CI: 0.96–4.07). There was no difference in the rate of side effects between the ST and the TT (OR, 1.01; 95% CI: 0.78–1.30).&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Gatta L, Vakil N, Leandro G, Di Mario F, Vaira D. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. &lt;EM&gt;Am J Gastroenterol&lt;/EM&gt; 2009;104(12):3069-79.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281306</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17481964]]&gt;</url>
    <title>Serious adverse events with infliximab: analysis of spontaneously reported adverse events</title>
    <publicationDate>2008-03-10T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Hansen, RA.&amp;nbsp; &lt;SPAN title="Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association."&gt;&lt;A href="#javascript:AL_get(this," Hepatol.?);? Gastroenterol ?Clin ?jour?,&gt;Clin Gastroenterol Hepatol.&lt;/A&gt;&lt;/SPAN&gt; 2007 Jun;5(6):729-35. Epub 2007 May 4.&lt;/P&gt;
&lt;P class=abstract&gt;BACKGROUND &amp;amp; AIMS: Serious adverse events such as bowel obstruction, heart failure, infection, lymphoma, and neuropathy have been reported with infliximab. The aims of this study were to explore adverse event signals with infliximab by using a long period of post-marketing experience, stratifying by indication. METHODS: The relative reporting of infliximab adverse events to the U.S. Food and Drug Administration (FDA) was assessed with the public release version of the adverse event reporting system (AERS) database from 1968 to third quarter 2005. On the basis of a systematic review of adverse events, Medical Dictionary for Regulatory Activities (MedDRA) terms were mapped to predefined categories of adverse events, including death, heart failure, hepatitis, infection, infusion reaction, lymphoma, myelosuppression, neuropathy, and obstruction. Disproportionality analysis was used to calculate the empiric Bayes geometric mean (EBGM) and corresponding 90% confidence intervals (EB05, EB95) for adverse event categories. RESULTS: Infliximab was identified as the suspect medication in 18,220 reports in the FDA AERS database. We identified a signal for lymphoma (EB05 = 6.9), neuropathy (EB05 = 3.8), infection (EB05 = 2.9), and bowel obstruction (EB05 = 2.8). The signal for granulomatous infections was stronger than the signal for non-granulomatous infections (EB05 = 12.6 and 2.4, respectively). The signals for bowel obstruction and infusion reaction were specific to patients with IBD; this suggests potential confounding by indication, especially for bowel obstruction. CONCLUSIONS: In light of this additional evidence of risk of lymphoma, neuropathy, and granulomatous infections, clinicians should stress this risk in the shared decision-making process.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>380716</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://hepmon.com/pdf/Seroprotection_of_Hepatitis_B_Vaccine_an.pdf]]&gt;</url>
    <title>Seroprotection of hepatitis B vaccine and need for booster dose: a meta-analysis</title>
    <publicationDate>2010-09-01T00:00:00</publicationDate>
    <publisher>Tehran Hepatitis Center</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,DISEASE PREVENTION,VACCINATION,RECENT ADDITIONS,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; According to these findings, the protection provided by hepatitis B (HB)&amp;nbsp;vaccine is dependent on immune memory rather than antibodies to hepatitis B surface antigen (anti-HBs) titer; therefore, recommendations for booster doses should be based on immune memory instead of the persistence of antibody. In addition, a full course of HB vaccination can induce a long-term and strong serologic immunity against hepatitis B virus infection. Nonetheless, the decreasing trend of seroprotection during the first and second decades after immunization indicates that the long-term immunity induced by HB vaccine may diminish over time. This issue raises the possibility of the need for a booster dose, although universal revaccination does not seem necessary during the first and second decades after primary vaccination in healthy individuals with normal immune status who had fully responded to a complete course of the vaccine.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; The duration of protection provided by HB vaccine is still unknown but can be estimated indirectly by measuring the anamnestic immune response to booster doses of the vaccine.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We searched electronic databases and conference databases up to December 2008. We also screened reference lists of articles and contacted the authors and vaccine manufacturers for additional references. We included randomized and nonrandomized studies assessing the anamnestic immune response to the booster of HB vaccine in healthy participants 5 years or more after initial vaccination.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The meta-analysis included 34 studies with 53 intervention groups and 4,479 individuals. The protective antibodies induced by initial vaccination waned over time; however, nonprotected vaccinees who had lost their anti-HBs over time responded strongly to the booster dose. The seroprotection rate of HB vaccine after the primary vaccination was 98.00% [95% confidence interval (CI): 95.32%, 99.52%] after 5 years, 96.88% [95% CI: 94.61%, 98.50%] after 6-10 years, 88.80% [95% CI: 79.84%, 95.08%] after 11-15 years, and 85.12% [95% CI: 82.18%, 88.20%] after 16-20 years.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Poorolajal J, Mahmoodi M, Majdzadeh R, Nasseri-Moghaddam S, Haghdoost A, Ghalichi L, Fotouhi A. Seroprotection of hepatitis B vaccine and need for booster dose:&amp;nbsp;a meta-analysis. &lt;EM&gt;Hep Mon&lt;/EM&gt; 2009;9(4):293-304.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>373099</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.jhep.2009.10.003]]&gt;</url>
    <title>Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis</title>
    <publicationDate>2010-01-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,RECENT ADDITIONS,CHRONIC HEPATITIS C,MAY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt;&amp;nbsp;In hepatitis C virus genotype 1 (HCV-1) patients with a rapid virological response, 24 weeks of combination therapy with pegylated interfron (PEG-IFN) alpha and ribavirin should be considered only in subjects with low baseline viral load. However, the optimal cut-off defining low baseline viral load and the impact of the presence of other factors capable of altering treatment response, remain subject to debate.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; In HCV-1 patients with a rapid viral decline within the first month of therapy, a 24-week course of PEG-IFN alpha and ribavirin treatment has been claimed to be as efficient as the standard 48-week duration.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We performed a meta-analysis of 7 randomized controlled trials comparing less than 48 weeks to 48 weeks PEG-IFN alpha/ribavirin treatment in 807 HCV-1 patients with rapid viral decline.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; SVR was significantly less frequent with short treatment duration than with 48 weeks of therapy, with a mean difference of -13.6% (95% CI: -22.8% to -4.4%, p=0.004). This difference was related to a higher relapse rate (mean difference: 9.9%, 95% CI: 4.1-15.7%, p&amp;lt;0.001). In a sensitivity analysis restricted to studies using only a weight-based ribavirin regimen, shorter therapy was also less efficient. In the subgroup of patients with undetectable HCV-RNA at week 4 and a low baseline HCV-RNA level (400,000 IU/ml), there was no significant difference in SVR rates between 24 and 48 weeks of treatment (mean difference: -3.10%, 95% CI: -8.6% to 2.4%, NS). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Moreno C, Deltenre P, Pawlotsky JM, Henrion J, Adler M, Mathurin P. Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis.&lt;EM&gt; J Hepatol&lt;/EM&gt; 2010;52(1):25-31.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281293</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17504334]]&gt;</url>
    <title>Should ileal pouch-anal anastomosis include mucosectomy?</title>
    <publicationDate>2008-03-10T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Chambers, W. &lt;SPAN title="Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland."&gt;&lt;A href="#javascript:AL_get(this," ?jour?, ?Colorectal Dis.?);?&gt;Colorectal Dis.&lt;/A&gt;&lt;/SPAN&gt; 2007 Jun;9(5):384-92&lt;/P&gt;
&lt;P&gt;OBJECTIVE: Debate exists as to the benefits of performing mucosectomy as part of pouch surgery for ulcerative colitis (UC) and familial adenomatous polyposis (FAP). Whilst mucosectomy results in a more complete removal of diseased mucosa, this benefit may be at the price of poorer function. We examined these issues. METHOD: Using Medline, Embase, Ovid and Cochrane database searches papers were identified relating to the outcome following pouch surgery with and without mucosectomy. Potential reasons for functional problems were investigated, as were rates of 'cuffitis', dysplasia, polyposis and cancer in the ileal pouch and anal canal. RESULTS: The available evidence suggests that performing a mucosectomy leads to a worse functional outcome. Meta-analysis suggested that nighttime seepage of stool and resting and squeeze pressure were worse after mucosectomy. The most likely reason for functional impairment following pouch surgery was the degree of anal manipulation. Mucosectomy does seem to confer benefit in terms of disease control but this benefit does not reach statistical significance. CONCLUSION: Stapled anastomosis avoiding mucosectomy is the approach of choice for ileal pouch anal anastomosis because this leads to superior functional outcome. Performing mucosectomy results in some clinical benefits in terms of lower rates of inflammation and dysplasia in the retained mucosa in UC patients and lower rates of cuff polyposis in FAP patients. However, on the basis of available evidence mucosectomy is only indicated in those cases where the patient is at a high risk of disease in the retained rectal cuff.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>268510</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1038/sj.onc.1209557]]&gt;</url>
    <title>Southern Europe as an example of interaction between various environmental factors: a systematic review of the epidemiologic evidence</title>
    <publicationDate>2006-06-26T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,HEPATITIS C,HEPATOCELLULAR CARCINOMA,CANCER,CHRONIC HEPATITIS B,CHRONIC HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Donato F., Gelatti U., Limina R.M. et al. 2006; Oncogene 25 (27) pp. 3756-70&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract: &lt;/STRONG&gt;Hepatitis B virus (HBV), hepatitis C virus (HCV) and alcohol consumption are major causes of hepatocellular carcinoma (HCC) worldwide. We performed a systematic review of epidemiologic studies carried out on HCC aetiology in Southern Europe, an area with an intermediate-high prevalence of these agents as well as of putative risk factors such as tobacco smoking, diabetes and obesity. To retrieve the articles, we performed a Medline search for titles and abstracts of articles. After the Medline search, we reviewed the papers and reference lists to identify additional articles. A synergism between HCV infection and HBV infection, overt (hepatitis B virus antigen (HbsAg) positivity) or occult (HBsAg negativity with presence of HBV DNA in liver or serum), is suggested by the results of some studies. The pattern of the risk for HCC due to alcohol intake shows a continuous dose-effect curve without a definite threshold, although most studies found that HCC risk increased only for alcohol consumption above 40-60 g of ethanol per day. Some evidence supports a positive interaction of alcohol intake probably with HCV infection and possibly with HBV infection. A few studies found that coffee has a protective effect on HCC risk due to various risk factors. Some data also support a role of tobacco smoking, diabetes and obesity as single agents or preferably co-factors in causing HCC. In countries with a relatively high alcohol consumption and intermediate levels of HCV and HBV infections (1-3% of population infected by each virus), such as Mediterranean countries, the three main risk factors together account for about 85% of the total HCC cases, leaving little space to other known risk factors, such as haemochromatosis, and to new, still unrecognised, factors as independent causes of HCC.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>268545</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2893.2005.00651.x]]&gt;</url>
    <title>Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies</title>
    <publicationDate>2006-01-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,ACUTE HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=abstract&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Micallef J.M., Kaldor J.M., Dore G.J. 2006; Journal of Viral Hepatitis 13 (1) PP. 34-41&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;Abstract: &lt;/STRONG&gt;A large number of studies have reported on spontaneous viral clearance rates in acute hepatitis C infection, however most have been small, and reported rates have varied quite widely. To improve the precision of the estimated rate of spontaneous viral clearance, a systematic review was conducted of longitudinal studies. Factors associated with viral clearance were also examined. Inclusion criteria for studies were: longitudinal assessment from time of acute hepatitis C; hepatitis C virus RNA analysis as determinant of viral clearance; untreated for acute hepatitis C. Information on study population, and factors that may influence viral clearance were extracted from each study. Viral clearance was defined among individuals with at least 6 months follow-up following acute hepatitis C. The number of subjects with viral clearance was expressed as a proportion for each study and a weighted mean for proportion was calculated. A total of 31 studies were examined. Study populations included nine studies of post-transfusion hepatitis, 19 of acute clinical hepatitis, and three of sero-incident cases. In total, data was available for 675 subjects and the mean study population was 22 (range 4-67). The proportion with viral clearance ranged from 0.0 to 0.8, with a weighted mean of 0.26 (95% CI 0.22-0.29). Factors associated with viral clearance were female gender and acute clinical hepatitis C study population. Further studies are required to more clearly define predictors of clearance and guide therapeutic intervention strategies.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>342490</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.sgna.org/Resources/StdofinfectionFINAL1208.pdf]]&gt;</url>
    <title>Standards of infection control in reprocessing of flexible gastrointestinal endoscopes</title>
    <publicationDate>2009-03-09T00:00:00</publicationDate>
    <publisher>Society of Gastroenterology Nurses and Associates</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,DIAGNOSTIC PROCEDURES,GASTROINTESTINAL ENDOSCOPY,RECENT ADDITIONS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; These standards are presented by the Society of Gastroenterology Nurses and Associates, Inc. (SGNA) to be used for all settings where gastrointestinal endoscopy is practiced.&amp;nbsp; A full infection control protocol is included.&amp;nbsp; Also covered are personnel,&amp;nbsp;education and training, quality assurance, procedure and reprocessing rooms, spill containment, and accessories.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Endoscopists, endoscopy nurses and associates.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published March 2009.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>389221</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20804451]]&gt;</url>
    <title>Stem cell therapies for inflammatory bowel disease: efficacy and safety</title>
    <publicationDate>2010-10-01T00:00:00</publicationDate>
    <publisher>Alimentary Pharmacology and Therapeutics</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,RECENT ADDITIONS,OCTOBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Alimentary pharmacology and therapeutics&lt;/EM&gt; is an international journal concerned with the effects of drugs on the human gastrointestinal and hepato-biliary systems. The journal publishes original research on all aspects of pharmacology, pharmacokinetics and therapeutic use of drugs in the alimentary tract.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Garcia-Bosch O, Ricard E, Panes J. (2010) Stem cell therapies for inflammatory bowel disease - efficacy and safety. &lt;EM&gt;Alimentary Pharmacology and Therapeutics&lt;/EM&gt; 32(8):939-952&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background:&lt;/STRONG&gt; Drugs available for the treatment of inflammatory bowel disease fail to induce and maintain remission in a significant number of patients. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aim: &lt;/STRONG&gt;To assess the value of stem cell therapies for treatment of inflammatory bowel disease based on published studies. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Publications were identified through a MEDLINE search using the Medical Subject Heading terms: inflammatory bowel diseases, or Crohn's disease, or ulcerative colitis, and stem cell, or stromal cell or transplant. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Haematopoietic stem cell therapy as a primary treatment for inflammatory bowel disease was originally supported by animal experiments, and by remissions in patients undergoing transplant for haematological disorders. Later, transplantation specifically performed for patients with refractory Crohn's disease showed long-lasting clinical remission and healing of inflammatory intestinal lesions. Use of autologous nonmyeloablative regimens and concentration of the procedures in centres with large experience are key in reducing treatment-related mortality. Initial trials of mesenchymal stem cell therapy with local injection in Crohn's perianal fistulas had positive results. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; Autologous haematopoietic stem cell transplant changes the natural course of Crohn's disease, and may be a therapeutic option in patients with refractory disease if surgery is not feasible due to disease location or extension.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is &lt;STRONG&gt;not&lt;/STRONG&gt; available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>322933</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/ebm.14.4.114]]&gt;</url>
    <title>Step-up and step-down treatment strategies did not differ for symptom relief at 6 months in new onset dyspepsia</title>
    <publicationDate>2009-08-01T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,STOMACH,HELICOBACTER PYLORI,DYSPEPSIA,RECENT ADDITIONS,INFECTIONS,AUGUST 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Evidence-Based Medicine is a secondary evidence journal, containing informative abstracts and expert commentaries about the best quality research from primary care medicine.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Talley NJ. Step-up and step-down treatment strategies did not differ for symptom relief at 6 months in new onset dyspepsia. &lt;EM&gt;Evid Based Med &lt;/EM&gt;2009:14(4):114&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt; A review of the original article: van Marrewijk CJ, Mujakovic S, Fransen GA, Numans ME, de Wit NJ, Muris JW, van Oijen MG, Jansen JB, Grobbee DE, Knottnerus JA, Laheij RJ. Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): a primary-care-based randomised controlled trial. &lt;EM&gt;Lancet&lt;/EM&gt; 2009 Jan 17;373(9659):215-25.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to NHS staff via Athens.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345613</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1002/ibd.20919]]&gt;</url>
    <title>Strategies to improve quality of life in adolescents with inflammatory bowel disease</title>
    <publicationDate>2009-11-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract:&lt;/STRONG&gt; Inflammatory bowel disease (IBD), which encompasses Crohn's disease (CD) and ulcerative colitis (UC), are chronic and debilitating conditions with unpredictable courses and complicated treatment. Pediatric IBD carries implications that extend beyond the health of the gastrointestinal tract. When these lifelong illnesses are diagnosed during adolescence, a critical developmental period, the transition to adulthood can be even more turbulent. Like other chronic diseases of childhood, patients with IBD are at risk for depression, anxiety, social isolation, and altered self-image, which can all negatively affect health-related quality of life (HRQOL). The review will draw from pertinent adult and pediatric literature about HRQOL over the past 10 years using a PubMed literature search to summarize instruments with which HRQOL is measured, and address factors that affect HRQOL in adolescents and young adults with IBD. Psychosocial interventions that have been utilized to improve quality of life in this population will also be covered. Identifying patients with impaired quality of life is of paramount importance, as is implementing strategies that may improve HRQOL, so that they may have an easier transition to adulthood while living with IBD.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Karwowski CA, Keljo D, Szigethy E. Strategies to improve quality of life in adolescents with inflammatory bowel disease. &lt;EM&gt;Inflamm Bowel Dis&lt;/EM&gt; 2009;15(11):1755-64.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281260</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17854290]]&gt;</url>
    <title>Strictureplasty vs resection in small bowel Crohn's disease: an evaluation of short-term outcomes and recurrence</title>
    <publicationDate>2008-03-10T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE,SMALL INTESTINE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;SPAN title="Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland."&gt;Reese, G.E. &lt;A href="#javascript:AL_get(this," ?jour?, ?Colorectal Dis.?);?&gt;Colorectal Dis.&lt;/A&gt;&lt;/SPAN&gt; 2007 Oct;9(8):686-94.&lt;/P&gt;
&lt;P class=abstract&gt;AIM: To compare postoperative adverse events and recurrence following strictureplasty or bowel resection in patients with small bowel Crohn's disease (CD). METHOD: A literature search was performed to identify studies published between 1980 and 2006 comparing outcomes of CD patients undergoing either strictureplasty or bowel resection. Hazard ratios were calculated from Kaplan-Meier plots of cumulative recurrence data. Quality assessment of the included studies was performed. Random-effect meta-analytical techniques were employed. Sensitivity analysis and assessment of heterogeneity were performed. RESULTS: Seven studies comprising 688 CD patients (strictureplasty n = 311, 45%; resection with or without strictureplasty n = 377, 55%) were included. Patients undergoing strictureplasty alone had a lower risk of developing postoperative complications than those who underwent resection (OR = 0.60, 95% CI: 0.31-1.16) although this was not statistically significant (P = 0.13). Surgical recurrence after strictureplasty was more likely than after resection (OR = 1.36, 95% CI: 0.96-1.93, P = 0.09). Patients who had a resection had a significantly longer recurrence-free survival than those undergoing strictureplasty alone (HR = 1.08, 95% CI: 1.02-1.15, P = 0.01). CONCLUSION: Patients with small bowel CD undergoing strictureplasty alone may have fewer postoperative complications than those undergoing a concomitant bowel resection. However, surgical recurrence maybe higher following strictureplasty alone than with a concomitant small bowel resection. Patients may require appropriate preoperative counselling regarding the pros and cons of each operative technique.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345507</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1002/bjs.6454]]&gt;</url>
    <title>Sulphate-reducing bacteria and hydrogen sulphide in the aetiology of ulcerative colitis</title>
    <publicationDate>2009-02-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; There is evidence to implicate&amp;nbsp;sulphate-reducing bacteria (SRB)&amp;nbsp;as an environmental factor in ulcerative colitis. More sophisticated mucosal dissection and molecular techniques using bacteria-directed probes are required to determine an association definitively.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; The aetiology of ulcerative colitis is uncertain but may relate to environmental factors in genetically predisposed individuals. SRB have been implicated through the harmful effects of hydrogen sulphide, a by-product of their respiration. Hydrogen sulphide is freely permeable to cell membranes and inhibits butyrate. This review examines the available evidence relating to SRB as a possible cause of ulcerative colitis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A literature search was conducted using the PubMed database and search terms sulphate reducing bacteria, hydrogen sulphide, ulcerative colitis, mucous gel layer and trans-sulphuration.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Search results were scrutinized and 113 pertinent full-text articles were selected for review. Collected data related to hydrogen sulphide metabolism, SRB respiration, mucous gel layer composition and their association with ulcerative colitis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Rowan FE, Docherty NG, Coffey JC, O'Connell PR. Sulphate-reducing bacteria and hydrogen sulphide in the aetiology of ulcerative colitis. &lt;EM&gt;Br J Surg&lt;/EM&gt; 2009 Feb;96(2):151-8.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102389</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.nzgg.org.nz/guidelines/0048/040624_FINAL_Full_for_Web_Colorectal_Guideline1.pdf]]&gt;</url>
    <title>Surveillance and management of groups at increased risk of colorectal cancer</title>
    <publicationDate>2004-05-01T00:00:00</publicationDate>
    <publisher>New Zealand Guidelines Group</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,DISEASE PREVENTION,CANCER,SCREENING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt;&amp;nbsp; This guideline aims to provide surveillance recomendations for high risk individuals based on the latest evidence.&amp;nbsp; The guideline&amp;nbsp;provides separate information for each of&amp;nbsp;the&amp;nbsp;four main high risk groups within New Zealand: those with a family history, personal history, a colorectal adenoma, or Inflammatory Bowel Disease.&amp;nbsp; The statistics used are specific to New Zealand&amp;nbsp;and the recommendations are based on the country's health care, services, and population, however international&amp;nbsp;guidelines&amp;nbsp;and papers are among those assessed in writing this document.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended Audience&lt;/STRONG&gt;: The guideline is predominantly aimed at primary health care providers, but&amp;nbsp;also intended to be of interest to medical and surgical specialists.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Available to the general public&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>330292</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359641/]]&gt;</url>
    <title>Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis</title>
    <publicationDate>2008-04-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,HEPATITIS C,NON-ALCOHOLIC,ALCOHOLIC LIVER DISEASE,ALCOHOLIC CIRRHOSIS,DISEASE PREVENTION,HEPATOCELLULAR CARCINOMA,SCREENING,RECENT ADDITIONS,CANCER,CIRRHOSIS,ALCOHOLIC,NOVEMBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; In a UK NHS context, surveillance of individuals with cirrhosis for HCC should be considered effective and cost-effective. The economic efficiency of different surveillance strategies is predicted to vary markedly according to cirrhosis aetiology.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Using a decision-analytic model, we evaluated the effectiveness and cost-effectiveness of surveillance for hepatocellular carcinoma (HCC) in individuals with cirrhosis. Separate cohorts with cirrhosis due to alcoholic liver disease, hepatitis B and hepatitis C were simulated. Results were also combined to approximate a mixed aetiology population. Comparisons were made between a variety of surveillance algorithms using alpha-foetoprotein (AFP) assay and/or ultrasound at 6- and 12-monthly intervals. Parameter estimates were obtained from comprehensive literature reviews. Uncertainty was explored using one-way and probabilistic sensitivity analyses. In the mixed aetiology cohort, 6-monthly AFP+ultrasound was predicted to be the most effective strategy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The model estimates that, compared with no surveillance, this strategy may triple the number of people with operable tumours at diagnosis and almost halve the number of people who die from HCC. The cheapest strategy employed triage with annual AFP (incremental cost-effectiveness ratio (ICER): 20,700 pounds per quality-adjusted life-year (QALY) gained). At a willingness-to-pay threshold of 30,000 pounds per QALY the most cost-effective strategy used triage with 6-monthly AFP (ICER: 27,600 pounds per QALY gained). The addition of ultrasound to this strategy increased the ICER to 60,100 pounds per QALY gained. Surveillance appears most cost-effective in individuals with hepatitis B-related cirrhosis, potentially due to younger age at diagnosis of cirrhosis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Thompson Coon J, Rogers G, Hewson P, Wright D, Anderson R, Jackson S, Ryder S, Cramp M, Stein K.&amp;nbsp;Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis.&lt;EM&gt; Br J Cancer&lt;/EM&gt; 2008 Apr 8;98(7):1166-75.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>330290</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.hta.ac.uk/fullmono/mon1134.pdf]]&gt;</url>
    <title>Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis</title>
    <publicationDate>2007-09-01T00:00:00</publicationDate>
    <publisher>National Institute for Health Research</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,HEPATITIS C,NON-ALCOHOLIC,ALCOHOLIC LIVER DISEASE,ALCOHOLIC CIRRHOSIS,DISEASE PREVENTION,HEPATOCELLULAR CARCINOMA,SCREENING,RECENT ADDITIONS,CANCER,CIRRHOSIS,ALCOHOLIC,NOVEMBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; In a mixed-aetiology cohort, the most effective surveillance strategy is to screen each patient with AFP assay and ultrasound imaging on a 6-monthly basis. However, when costs are taken into account it is doubtful whether ultrasound should be routinely offered to those with blood AFP of less than 20 ng/ml, unless policy-makers are prepared to pay over £60,000 per QALY for the benefits achieved. Furthermore, the cost-effectiveness of surveillance for HCC varies considerably depending on the aetiology of cirrhosis; it is much more likely to be cost-effective in those with HBV-related cirrhosis, and much less likely to be cost-effective in those with ALD-related cirrhosis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; To evaluate the effectiveness, cost-effectiveness and cost-utility of surveillance of patients with cirrhosis [alcoholic liver disease (ALD)-, hepatitis B (HBV)- and C virus (HCV)-related], using periodic serum alpha-fetoprotein (AFP) testing and/or liver ultrasound examination, to detect hepatocellular carcinoma (HCC), followed by treatment with liver transplantation or resection, where appropriate.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A systematic review was carried out using standard methodological guidelines. A computerised decision-analytic model was then developed to compare various surveillance strategies. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; No studies were identified that met the criteria of the systematic review. Based on the assumptions used in the model, the most effective surveillance strategy uses a combination of AFP testing and ultrasound at 6-monthly intervals. Compared with no surveillance, this strategy is estimated to more than triple the number of people with operable HCC tumours at time of diagnosis, and almost halves the number of deaths from HCC. On all effectiveness measures and at both testing frequencies, AFP- and ultrasound-led surveillance strategies are very similar. This may be because test sensitivity was varied according to tumour size, which means that AFP testing is capable of identifying many more small tumours than ultrasound. The best available evidence suggests that AFP tests will detect approximately six times as many small tumours as ultrasound. Increasing the frequency of either test to 6-monthly intervals is more effective than performing combined testing on an annual basis. The undiscounted lifetime cost of the surveillance strategies, including all care and treatment costs, ranges from £40,300 (annual AFP triage) to £42,900 (6-monthly AFP and ultrasound). The equivalent discounted costs are £28,400 and £30,400. Only a small proportion of these total costs results from the cost of the screening tests. However, screening test costs, and the cost of liver transplants and caring for people post-transplant, accounted for most of the incremental cost differences between alternative surveillance strategies. The results suggest that different surveillance strategies may provide the best value for money in patient groups of different cirrhosis aetiologies. The surveillance of people with HBV-related cirrhosis for HCC provides the best value for money, while surveillance in people with ALD-related cirrhosis provides the poorest value for money. In people with HBV-related cirrhosis, at an assumed maximum willingness to pay (WTP) for a quality-adjusted life-year (QALY) of £30,000, both the deterministic and probabilistic cost-utility analyses suggest the optimal surveillance strategy would be 6-monthly surveillance with the combination of AFP testing and ultrasound. In contrast, for those with ALD-related cirrhosis, annual screening with AFP as a triage test is the only surveillance strategy that is likely to be considered cost-effective at this WTP. The probabilistic analysis implies that the estimated benefits of a 6-monthly AFP triage strategy will only be worth the cost in those with ALD when society's WTP for a QALY exceeds around £40,000. For people with HCV-related cirrhosis, the model suggests that the most cost-effective surveillance strategy at a WTP threshold of £30,000/QALY would be surveillance with a 6-monthly AFP triage strategy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Thompson Coon J, Rogers G, Hewson P, Wright D, Anderson R, Cramp M, Jackson S, Ryder S, Price A, Stein K.&amp;nbsp;Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis. &lt;EM&gt;Health Technol Assess&lt;/EM&gt; 2007 Sep;11(34):1-206.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>305622</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://learning.bmj.com/learning/search-result.html?moduleId=5003316]]&gt;</url>
    <title>Suspected lower gastrointestinal tract cancer: when you should refer</title>
    <publicationDate></publicationDate>
    <publisher>NICE/BMJ Learning</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,CANCER]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;These online education tools have been developed by NICE in collaboration with BMJ Learning. BMJ Learning offers a wide range of learning resources, commissioned by the BMJ Group. The learning resources deal with everyday issues in primary care and hospital medicine. They are evidence based and peer reviewed. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aims: &lt;/STRONG&gt;This module should help you to:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Be familiar with the typical presenting features of lower gastrointestinal tract cancer 
&lt;LI&gt;Identify unusual presentations of lower gastrointestinal tract cancer 
&lt;LI&gt;Know when to refer patients with suspected lower gastrointestinal tract cancer to a specialist team 
&lt;LI&gt;Know which patients you should refer urgently and which patients you should refer routinely. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&amp;nbsp; Free registration with the site is required.&amp;nbsp; To register, click "Start module" and then "Register here".&amp;nbsp; Do not select the option to log in via Athens as access to BMJ Learning is not currently&amp;nbsp;part of NHS Athens accounts.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293827</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1310/hct0901-43]]&gt;</url>
    <title>Systematic review and meta-analysis of the diagnostic accuracy of fibrosis marker panels in patients with HIV/hepatitis C coinfection</title>
    <publicationDate>2008-01-01T00:00:00</publicationDate>
    <publisher>Thomas Land</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,HIV / AIDS,CHRONIC HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Shaheen, AA et al HIV Clinical Trials 2008 Jan-Feb;9(1):43-51&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract: &lt;/STRONG&gt;BACKGROUND: Accurately staging hepatitis C virus (HCV)-related fibrosis is crucial for treatment decisions and prognostication. Our objective was to systematically review studies describing the accuracy of serum marker panels for predicting fibrosis in HIV/HCV-coinfected patients. METHOD: Studies comparing serum marker panels with biopsy in HIV/HCV-coinfected patients were identified. Random effects meta-analyses and areas under summary receiver operating characteristics curves (AUC) examined test accuracy for detecting significant fibrosis (F2-4) and cirrhosis. Heterogeneity was explored using meta-regression. RESULTS: Five studies (n = 574) including four fibrosis measures (APRI [n = 4 studies], Forns' [n = 2], FibroTest [n = 1], SHASTA [n = 1]) met the inclusion criteria. The prevalence of significant fibrosis and cirrhosis were 51% and 16%, respectively. For the prediction of significant fibrosis, the summary AUC was 0.82 (95% CI 0.78-86) and diagnostic odds ratio was 7.8 (5.1-11.9). For cirrhosis, these figures were 0.83 (0.69-0.97) and 11.0 (4.6-26.2), respectively. Meta-regression including study factors (methodological quality and biopsy adequacy), patient characteristics (age, gender, CD4 count), and fibrosis measure failed to identify important predictors of accuracy. CONCLUSION: Available fibrosis marker panels have acceptable performance for identifying significant fibrosis and cirrhosis in HIV/HCV-coinfected patients but are not yet adequate to replace liver biopsy. Additional studies are necessary to identify the optimal measure.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;See also: &lt;/STRONG&gt;&lt;A href="nelh:352352:0" name=internalLink&gt;DARE record&lt;/A&gt; for this article&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281266</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17443850]]&gt;</url>
    <title>Systematic review of dysplasia after restorative proctocolectomy for ulcerative colitis</title>
    <publicationDate>2008-03-10T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;SPAN title="The British journal of surgery."&gt;Scarpa, M. &lt;A href="#javascript:AL_get(this," ?jour?, ?Br J Surg.?);?&gt;Br J Surg.&lt;/A&gt;&lt;/SPAN&gt; 2007 May;94(5):534-45.&lt;/P&gt;
&lt;P class=abstract&gt;BACKGROUND: The aim of this systematic review was to assess the prevalence and site of dysplasia after restorative proctocolectomy (RPC) for ulcerative colitis (UC), and to identify risk factors that could be used in a surveillance programme. METHODS: Medical databases were searched for potentially relevant publications between 1978 and 2006. Studies that dealt with RPC for UC and postoperative surveillance were included. Two researchers independently performed study selection, quality assessment, data extraction and analysis. RESULTS: Twenty-three observational studies and case series were included, with a total of 2040 patients. The pooled prevalence of confirmed dysplasia in the pouch, anal transitional zone or rectal cuff was 1.13 (range 0-18.75) per cent. The prevalence of high-grade dysplasia, low-grade dysplasia and indefinite for dysplasia was 0.15 (range 0-4.49), 0.98 (range 0-15.62) and 1.23 (range 0-25.28 per cent) respectively. Dysplasia was equally frequent in the pouch and rectal cuff or anal transitional zone. Dysplasia and cancer identified before or at operation seemed to be significant predictors of the development of dysplasia. Pouchitis and duration of follow-up were not of predictive value. CONCLUSION: Although based on low-level evidence from uncontrolled studies, the prevalence of dysplasia observed after RPC was remarkable. A surveillance programme that takes into account the risk factors found is therefore advocated.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>251176</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1002/bjs.5375]]&gt;</url>
    <title>Systematic review of postoperative complications in patients with inflammatory bowel disease treated with immunomodulators</title>
    <publicationDate>2006-07-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This systematic review examined the use of immunomodulators and the risk of postoperative complications after abdominal surgery in patients with inflammatory bowel disease.</description>
    <body>&lt;![CDATA[ &lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Subramanian V, Pollok RC, Kang JY et al. 2006; British Journal of Surgery 93 (7) pp. 793-799 
&lt;H2&gt;Original article abstract&lt;/H2&gt;
&lt;P&gt;BACKGROUND: This systematic review examined the use of immunomodulators and the risk of postoperative complications after abdominal surgery in patients with inflammatory bowel disease. METHODS: Electronic databases (PubMed, Embase, Ingenta, Zetoc and Ovid) were searched and the reference lists in all articles identified were hand-searched for further relevant papers. Studies were included if they evaluated postoperative complications and defined exposure to individual immunomodulators. RESULTS: All 11 studies that met the inclusion criteria were observational studies; two were reported only in abstract form. Five studies reported risks associated with azathioprine, five reported risks associated with cyclosporin and three reported risks associated with infliximab. None showed an increased risk of either total or infectious complications associated with immunomodulator use. However, subgroup analysis in one study, published as an abstract, suggested increased rates of anastomotic complications and reoperation associated with azathioprine. CONCLUSION: Available evidence does not suggest an increased rate of postoperative complications associated with immunomodulator use. Copyright 2006 British Journal of Surgery Society Ltd.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;See also: &lt;/STRONG&gt;&lt;A href="nelh:276355:0" name=internalLink&gt;DARE record&lt;/A&gt; for this article&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;This article is &lt;STRONG&gt;not &lt;/STRONG&gt;available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Other relevant articles&lt;/STRONG&gt;: You may also be interested in the articles covered in the Inflammatory Bowel Disease evidence update 2007 section '&lt;A href="nelh:251406:0" name=internalLink&gt;treatment: corticosteroids, immunosupressants &amp;amp; cytokine inhibitors&lt;/A&gt;' which contains information about articles on a similar topic.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>343365</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1002/hep.23286]]&gt;</url>
    <title>Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome</title>
    <publicationDate>2010-02-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATO-RENAL SYNDROME,RECENT ADDITIONS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Terlipressin plus albumin may prolong short-term survival in type 1 hepato-renal syndrome (HRS). The duration of the response should be considered when making treatment decisions and in the timing of potential liver transplantations. Considering the small number of patients included, the evidence does not allow for treatment recommendations regarding type 2 HRS or any of the remaining treatment comparisons assessed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Vasoconstrictor drugs may improve renal function in HRS, but the effect on mortality has not been established. We therefore performed a systematic review of randomized trials on vasoconstrictor drugs for type 1 or type 2 HRS. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt;&amp;nbsp;Mortality was the primary outcome measure. Eligible trials were identified through electronic and manual searches. Intention-to-treat random effects meta-analyses were performed. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Ten randomized trials on terlipressin alone or with albumin, octreotide plus albumin, and noradrenalin plus albumin were included. The total number of patients was 376. Overall, vasoconstrictor drugs used alone or with albumin reduced mortality compared with no intervention or albumin (relative risk [RR], 0.82; 95% confidence interval [CI], 0.70-0.96). In subgroup analyses, the effect on mortality was seen at 15 days (RR, 0.60; 95% CI, 0.37-0.97) but not at 30 days (RR, 0.74; 95% CI, 0.40-1.39), 90 days (RR, 0.89; 95% CI, 0.66-1.22), or 180 days (RR, 0.83; 95% CI, 0.65-1.05). Subgroup analyses stratified by the treatments assessed showed that terlipressin plus albumin reduced mortality compared with albumin (RR, 0.81; 95% CI, 0.68-0.97). The effect was seen in subgroup analyses of type 1 but not type 2 HRS. The remaining trials were small and found no beneficial or harmful effects of the treatments assessed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Gluud LL, Christensen K, Christensen E, Krag A. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome.&lt;EM&gt; Hepatology&lt;/EM&gt; 2010 Feb;51(2):576-84.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>319807</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.jhep.2009.03.019]]&gt;</url>
    <title>Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis</title>
    <publicationDate>2009-08-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,DIAGNOSTIC PROCEDURES,BIOPSY,LIVER,STEATOHEPATITIS,NON-ALCOHOLIC,RECENT ADDITIONS,JULY 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The presence of inflammation on the initial biopsy and age are independent predictors of progression to advanced fibrosis in patients with non-alcoholic steatohepatitis (NASH).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Our analysis is a systematic review of the medical literature, with all 10 studies published as peer-reviewed case series or retrospective cohort studies. Patients in all studies were identified through pathology database searches using specific diagnostic terms related to NASH. Subjects had to have a histological diagnosis compatible with NASH on their initial biopsy, received no intervention of proven histological benefit, and undergone two liver biopsies with at least an interval of one year between them.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Ten studies were selected comprising 221 patients. 37.6% had progressive fibrosis over a mean follow-up interval of 5.3 years (SD, 4.2 years, median, 3.7 years, range 1.0–21.3 years). Proportional hazards regression analysis demonstrated that age (HR&amp;nbsp;=&amp;nbsp;0.98, &lt;I&gt;p&lt;/I&gt;&amp;nbsp;=&amp;nbsp;0.009) and inflammation on initial biopsy (any inflammation, HR&amp;nbsp;=&amp;nbsp;2.5, &lt;I&gt;p&lt;/I&gt;&amp;nbsp;=&amp;nbsp;0.001; grade 1, HR&amp;nbsp;=&amp;nbsp;2.5, &lt;I&gt;p&lt;/I&gt;&amp;nbsp;=&amp;nbsp;0.001; grade 2, HR&amp;nbsp;=&amp;nbsp;2.4, &lt;I&gt;p&lt;/I&gt;&amp;nbsp;=&amp;nbsp;0.003) are independent predictors of progression to advanced fibrosis. Other traditional parameters (e.g. obesity, diabetes, hypertension) were not statistically significant predictors.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol. 2009 Aug;51(2):371-9.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>251154</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ajcn.org/cgi/reprint/82/3/611]]&gt;</url>
    <title>Systematic review of the effects of n-3 fatty acids in inflammatory bowel disease</title>
    <publicationDate>2005-09-01T00:00:00</publicationDate>
    <publisher>American Society for Nutrition</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>n-3 Fatty acids are purported to have health effects in patients with inflammatory bowel disease (IBD), but studies have reported mixed results. This article aimed to synthesize published and unpublished evidence to determine estimates of the effect of n-3 fatty acids on clinical outcomes in IBD and whether n-3 fatty acids modify the effects of or need for treatment with other agents.</description>
    <body>&lt;![CDATA[ &lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: MacLean CH, Mojica, WA, Newberry SJ et al. 2005; The American Journal of Clinical Nutrition 82 pp. 611-619&amp;nbsp; 
&lt;H2&gt;Original article abstract&lt;/H2&gt;
&lt;P&gt;BACKGROUND: n-3 Fatty acids are purported to have health effects in patients with inflammatory bowel disease (IBD), but studies have reported mixed results. OBJECTIVE: We aimed to synthesize published and unpublished evidence to determine estimates of the effect of n-3 fatty acids on clinical outcomes in IBD and whether n-3 fatty acids modify the effects of or need for treatment with other agents. DESIGN: Computerized databases were searched for studies of n-3 fatty acids in immune-mediated diseases from 1966 to 2003. We also contacted experts in the nutraceutical industry to identify unpublished studies; however, none were identified. RESULTS: Reviewers identified 13 controlled trials that assessed the effects of n-3 fatty acids on clinical, sigmoidoscopic, or histologic scores; rates of induced remission or relapse; or requirements for steroids and other immunosuppressive agents in Crohn disease or ulcerative colitis. Most clinical trials were of good quality. Fewer than 6 were identified that assessed the effects of n-3 fatty acids on any single outcome of clinical, endoscopic, or histologic scores or remission or relapse rates. Consistent across 3 studies was the finding that n-3 fatty acids reduce corticosteroid requirements, although statistical significance was shown in only 1 of these studies. CONCLUSION: The available data are insufficient to draw conclusions about the effects of n-3 fatty acids on clinical, endoscopic, or histologic scores or remission or relapse rates.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;Full text available freely online to NHS Athens account holders&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323677</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.jhep.2008.05.002]]&gt;</url>
    <title>Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,LIVER TRANSPLANTATION,RECENT ADDITIONS,AUGUST 2009,ACUTE HEPATITIS C,CHRONIC HEPATITIS C,SURGERY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Efficacy of antiviral therapy for hepatitis C virus (HCV) in liver transplant recipients is lower than that in the nontransplant population, possibly as a result of the difficulty in maintaining full doses during the treatment period. Maintenance therapy has a potential benefit in post-transplant HCV patients.&amp;nbsp; Predictive factors can&amp;nbsp;be used to identify patients with poor tolerability or those who are candidates for treatment discontinuation.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Data sources included electronic databases and a manual search. Studies evaluating the efficacy and tolerability of PEG-IFN alfa with ribavirin in patients with recurrent hepatitis C were selected for inclusion. The information extracted from each of the selected publications included study design details, patient characteristics, treatment regimens and efficacy and tolerability end points.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Nineteen studies including 611 patients were identified. PEG-IFN alfa-2b was used in 16 studies. The mean rate of SVR was 30.2% (range, 8–50%). Dose reduction and discontinuation of treatment were common in these studies (73% and 27.6%, respectively). The lack of an early virologic response (EVR) at 3&amp;nbsp;months of therapy was the most frequently described predictive factor of nonresponse. Treatment discontinuation and dose reductions due to adverse events were frequent and possibly represent important obstacles to attainment of SVR. EVR at 3&amp;nbsp;months of treatment should be considered an important predictor of treatment outcome.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;See also: &lt;/STRONG&gt;&lt;A href="nelh:357792:0" name=internalLink&gt;DARE record&lt;/A&gt; for this article.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. &lt;EM&gt;J Hepatol&lt;/EM&gt; 2008 Aug;49(2):274-87.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345530</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19293722]]&gt;</url>
    <title>Systematic review on drug and diet-induced endoscopic remission in Crohn's disease</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>Lippincott Williams &amp; Wilkins</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,DIAGNOSTIC PROCEDURES,GASTROINTESTINAL ENDOSCOPY,CROHN'S DISEASE,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Available treatments for Crohn's disease (CD)&amp;nbsp;induce significant endoscopic improvement, which may be associated with a better prognosis.&amp;nbsp;However, pooled results should be cautiously interpreted because of the diversity of measurements. A better definition of endoscopic outcomes and a prospective validation of their relevance in patients with Crohn's disease are needed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Neither the rate of endoscopic remission (ER) in CD after therapy nor its role in patients' prognosis is well defined. The aim of this&amp;nbsp;paper was to systematically review the current evidence on the proportion of ER of different therapies in patients with Crohn's disease and its relation with clinical outcomes. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Databases (MEDLINE and Cochrane) and manual search of manuscripts found 482 titles. Data was extracted from 24 manuscripts.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Ten different methods were used to assess endoscopic outcomes. Corticosteroids induced a pooled proportion of patients with no ulcerations at endoscopic follow-up of 17% (95% confidence interval: 12-22%) lower than that found with infliximab [44% (34-53%)], diet [43% (33-52%)] or azathioprine [54% (38-69%)] (P&amp;lt;0.0001). Enteric diets and infliximab were associated with 61% (52-70%) and 70% (62-78%) reduction in endoscopic scores, respectively, significantly higher than corticosteroids [45% (39-52%)] (P=0.01) and placebo [12% (1-22%)] (P&amp;lt;0.0001). A linear relation between ER and clinical remission was observed with infliximab (r=0.931). Only one study tried to assess the direct correlation between ER and patients' prognosis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Pimentel-Nunes P, Dinis-Ribeiro M, Magro F. Systematic review on drug and diet-induced endoscopic remission in Crohn's disease. &lt;EM&gt;Eur J Gastroenterol Hepatol&lt;/EM&gt; 2009;21(5):491-503.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>251149</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2006.02809.x]]&gt;</url>
    <title>Systematic review: adherence issues in the treatment of ulcerative colitis</title>
    <publicationDate>2006-03-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Ulcerative colitis is a chronic inflammatory and debilitating disease requiring lifelong treatment. First-line therapy for ulcerative colitis is 5-aminosalicylic acid, which suffers from poor patient adherence outside the clinical trial setting.</description>
    <body>&lt;![CDATA[ &lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;:&amp;nbsp;Kane SV 2006; Alimentary Pharmacology and Therapeutics 23 (5) pp. 577-585&amp;nbsp; 
&lt;P&gt;&lt;B&gt;&lt;FONT color=#990000&gt;Review of this article by Isobel Mason, nurse specialist in gastroenterology, Royal Free Hospital, London, March 2007.&lt;/FONT&gt; &lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Adherence to 5-aminosalicylic acid (5-ASA) treatment is good in clinical trial settings (&amp;gt;80%), but is poorer in community based studies (40-60%).&lt;/P&gt;
&lt;P&gt;Two studies examining adherence are discussed. A 41% reduction in adherence was shown over 6 months in patients taking sulphasalazine. 12% patients showed no blood serum sulphasalazine at 4 years. 82% of patients who experienced relapse over a 2 year period were non-adherent to 5 ASA’s. Non-adherence resulted in five times greater risk of relapse.&lt;/P&gt;
&lt;P&gt;Several factors for non-adherence are identified. Reasons patients identify for non-adherence are also discussed.&lt;/P&gt;
&lt;P&gt;One study showing the clinical impact of non-adherence showed 61% chance of relapse in those not taking treatment compared to 11% in those that adhere. 10 year follow up of 175 patients showed an increased colorectal cancer risk in non adherent patients (31%) in comparison to adherent (3%). Case controlled studies show that regular mesalazine reduced colorectal cancer risk by 81%. A recent systematic review of 9 studies (over 2000 patients) confirms that 5 ASA treatment is protective for colorectal cancer.&lt;/P&gt;
&lt;P&gt;Total health care costs and personal economic costs for 5 ASA non-adherence is discussed, but no direct evidence of cost implication is given.&lt;/P&gt;
&lt;P&gt;In 81% of patients who do not adhere, poor compliance has been shown to be non intentional. Methods for improving adherence are discussed, such as open communication, addressing barriers to adherence and providing simple delivery methods.&lt;/P&gt;
&lt;P&gt;Four new formulations that may improve adherence are reviewed. SPD 476 (a once daily dosing oral 5 ASA) has shown 29% remission rates compared to 13% placebo. No data regarding adherence is given, however daily dosing may be useful. Micropellet formulation (granules) are&amp;nbsp; comparable in effectiveness to traditional tablets and may be easier to take. Compliance rates in clinical trials are good (97%). Daily, slow release suppositories for ulcerative proctitis are comparable to twice daily traditional 5 ASA suppositories. Rectal gels (alternatives to suspension / foam enemas) are being developed. They have comparable remission rates and appear to be better tolerated.&lt;/P&gt;
&lt;H2&gt;Original article abstract&lt;/H2&gt;
&lt;P&gt;Ulcerative colitis is a chronic inflammatory and debilitating disease requiring lifelong treatment. First-line therapy for ulcerative colitis is 5-aminosalicylic acid, which suffers from poor patient adherence outside the clinical trial setting. Formulations to deliver 5-aminosalicylic acid to the disease activity site, both orally and topically, are often inconvenient and require multiple daily dosing. Such regimens can interfere with normal life and reduce the overall quality of life, negatively impacting on treatment adherence and leading to poorer long-term outcomes. These include increased morbidity with an elevated risk of symptomatic relapse, possible greater risk of colorectal cancer and higher overall costs of care. Ulcerative colitis patients cite treatment regimen complexity, tablet quantity and dose frequency as key negative influencers of adherence. Solutions to these issues include addressing patient concerns, simplifying daily regimens and utilizing new formulations such as micropellet and multimatrix oral formulations, rectal gel and once-daily suppository formulations. This review examines the prevalence and impact of non-adherence to 5-aminosalicylic acid therapy among patients with ulcerative colitis, as well as drug delivery strategies that may enhance dosing regimens to improve patient acceptability, adherence and long-term clinical outcomes. It is a combination of understanding patient behaviour, recognizing signs of non-adherent behaviour and utilizing management strategies to change behaviour that will improve patient outcomes.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;This article is &lt;STRONG&gt;not &lt;/STRONG&gt;available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>385141</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2009.04148.x]]&gt;</url>
    <title>Systematic review: caspase-cleaved fragments of cytokeratin 18 - the promises and challenges of a biomarker for chronic liver disease</title>
    <publicationDate>2010-12-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,BILIARY TREE &amp; GALLBLADDER,LIVER,HEPATITIS,HEPATITIS B,HEPATITIS C,ALCOHOLIC LIVER DISEASE,ALCOHOLIC HEPATITIS,NON-ALCOHOLIC,DIAGNOSTIC PROCEDURES,DISEASE PREVENTION,HEPATOCELLULAR CARCINOMA,STEATOHEPATITIS,ALCOHOLIC,BLOOD TESTS,SCREENING,RECENT ADDITIONS,CANCER,FATTY LIVER,CHRONIC HEPATITIS B,CHRONIC HEPATITIS C,CHOLECYSTITIS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; &lt;SPAN&gt;Undoubtedly, the most promising application of &lt;SPAN&gt;cytokeratin (CK)&lt;/SPAN&gt; 18 fragments is currently in nonalcoholic fatty liver disease, and especially for distinguishing patients with nonalcoholic steatohepatitis vs. those with simple steatosis. Further investigations and technical improvements are required to cross the boundary from research to the clinical application of CK18 fragments as a marker of chronic liver disease.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; &lt;SPAN&gt;Biomarkers hold great promise for detecting chronic liver disease without the use of liver biopsy. The aim of this study was to &lt;SPAN&gt;review the usefulness of CK18 fragments, a marker of hepatocyte apoptosis, to predict the presence of chronic liver injury.&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; &lt;SPAN&gt;Available literature identified from PubMed was reviewed.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;SPAN&gt;Levels of CK18 fragments have been shown to be elevated in hepatocellular carcinoma, viral hepatitis, alcoholic hepatitis, nonalcoholic fatty liver disease and cholestatic liver disease. In the setting of nonalcoholic fatty liver disease, CK18 fragments may distinguish nonalcoholic steatohepatitis from simple fatty liver.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Yilmaz Y. Systematic review: caspase-cleaved fragments of cytokeratin 18 - the promises and challenges of a biomarker for chronic liver disease. Aliment Pharmacol Ther 2009;30(11-12):1103-9.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>315073</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2009.03959.x]]&gt;</url>
    <title>Systematic review: clinical efficacy of chelator agents and zinc in the initial treatment of Wilson disease</title>
    <publicationDate>2009-02-07T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,WILSON'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; There is lack of high-quality evidence to estimate the relative treatment effects of the available drugs in Wilson disease. Therefore, multicentre prospective randomized controlled comparative trials are necessary.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method: &lt;/STRONG&gt;A systematic literature search of the MEDLINE, EMBASE and COCHRANE databases was performed. Original studies on clinical efficacy of &lt;SPAN class=smallcapitals&gt;d&lt;/SPAN&gt;-penicillamine, trientine, tetrathiomolybdate or zinc monotherapy as initial treatment in Wilson disease were included. A descriptive analysis of the relevant published data was performed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; One randomized trial and 12 observational studies met the inclusion criteria. These studies were quite heterogeneous and generally of low validity. Nevertheless, according to currently available data, patients with hepatic presentation of Wilson disease are probably most effectively treated by &lt;SPAN class=smallcapitals&gt;d&lt;/SPAN&gt;-penicillamine. Zinc seems to be preferred above &lt;SPAN class=smallcapitals&gt;d&lt;/SPAN&gt;-penicillamine for treatment of presymptomatic and neurological patients, as in these subgroups, the tolerance profile is in favour of zinc, while no obvious differences in clinical efficacy could be observed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Wiggelinkhuizen M, Tilanus ME, Bollen CW, Houwen RH. Systematic review: clinical efficacy of chelator agents and zinc in the initial treatment of Wilson disease. Aliment Pharmacol Ther. 2009 May 1;29(9):947-58.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309245</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1007/s00535-008-2246-x]]&gt;</url>
    <title>Systematic review: cytomegalovirus infection in inflammatory bowel disease</title>
    <publicationDate>2008-10-01T00:00:00</publicationDate>
    <publisher>Springer</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,INFECTIONS,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt; This article reviews diagnostic and therapeutic strategies for CMV infection in patients with IBD. Sources for this review were located by using multiple search strategies in MEDLINE and by examination of relevant reference lists, with a particular focus on Englishlanguage articles concentrating on the diagnosis and treatment of CMV infection and IBD.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Nakase, H., Matsumura, K., Yoshino, T., &amp;amp; Chiba, T. (2008) Systematic review: cytomegalovirus infection in inflammatory bowel disease. &lt;I&gt;Journal of Gastroenterology&lt;/I&gt;, 43(10):735-740.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in October 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>385108</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2009.04160.x]]&gt;</url>
    <title>Systematic review: distribution of advanced neoplasia according to polyp size at screening colonoscopy</title>
    <publicationDate>2010-01-15T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,DIAGNOSTIC PROCEDURES,GASTROINTESTINAL ENDOSCOPY,COLONOSCOPY,DISEASE PREVENTION,POLYPS,CANCER,SCREENING,RECENT ADDITIONS,NON-MALIGNANT NEOPLASMS,COLON CANCER,RECTAL CANCER,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; &lt;SPAN&gt;Based on this systematic review, a 6-mm polyp size threshold for polypectomy referral would identify over 95% of subjects with advanced adenomas, whereas a 10-mm threshold would identify 88% of cases.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt;&amp;nbsp;&lt;SPAN class=sub_abstract_label&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;SPAN&gt;The impact of not referring sub-centimetre polyps identified at CT colonography upon the efficacy of colorectal cancer screening remains uncertain.&lt;/SPAN&gt; The aim of this study was&amp;nbsp;t&lt;SPAN&gt;o determine the distribution of advanced neoplasia according to polyp size in a screening setting.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; &lt;SPAN&gt;Published studies reporting the distribution of advanced adenomas in asymptomatic screening cohorts according to polyp size were identified by MEDLINE and EMBASE searches. Predefined outputs were the screening rates of advanced adenomas represented by diminutive (&amp;lt; or =5 mm), small (6-9 mm), sub-centimetre (&amp;lt;10 mm) and large (&amp;gt; or =10 mm) polyp sizes.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;SPAN&gt;Data from four studies with 20 562 screening subjects met the primary inclusion criteria. Advanced adenomas were detected in 1155 (5.6%) subjects (95% CI = 5.3-5.9), corresponding to diminutive, small and large polyps in 4.6% (95% CI = 3.4-5.8), 7.9% (95% CI = 6.3-9.4) and 87.5% (95% CI = 86-89.4) of cases respectively. The frequency of advanced lesions among patients whose largest polyp was diminutive, small, sub-centimetre and large in size was 0.9%, 4.9%, 1.7% and 73.5% respectively.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Hassan C, Pickhardt PJ, Kim DH, Di Giulio E, Zullo A, Laghi A, Repici A, Iafrate F, Osborn J, Annibale B. Systematic review: distribution of advanced neoplasia according to polyp size at screening colonoscopy. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2010;31(2):210-7.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345518</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.meduniwien.ac.at/innere3/gaschelab/files/Andrews_APT2009.pdf]]&gt;</url>
    <title>Systematic review: does concurrent therapy with 5-ASA and immunomodulators in inflammatory bowel disease improve outcomes?</title>
    <publicationDate>2009-03-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CANCER,CROHN'S DISEASE,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; It is unclear whether concurrent 5-aminosalicylic acid (5-ASA) and immunomodulator therapy improves outcomes of disease control, drug toxicity or compliance in inflammatory bowel disease (IBD). Concurrent therapy of 5-ASA and immunomodulators may decrease&amp;nbsp;colorectal cancer (CRC)&amp;nbsp;risk at 'acceptable' cost.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; With greater use of immunomodulators in IBD, it is uncertain whether concurrent therapy with both 5-ASA and an immunomodulator is necessary. The aim of this review was to determine whether concurrent therapy with both 5-ASA and immunomodulator(s) improves outcomes in IBD.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Systematic review with search terms 'azathioprine, 6-mercaptopurine, thiopurine(s), 5 aminosalicylic acid, mesalazine, inflammatory bowel disease, ulcerative colitis, Crohn's disease, immunosuppressant(s), immunomodulator and methotrexate' in November 2007 to identify clinical trials on concurrent 5-ASA and immunomodulator therapy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Two small controlled studies were found. Neither showed a benefit on disease control beyond immunomodulator monotherapy. Potential pharmacological interactions exist between 5-ASA and thiopurines. Whilst circumstantial, epidemiological and laboratory evidence suggests that 5-ASA may assist colorectal cancer (CRC) chemoprevention, it may simply be via anti-inflammatory effects. With changes in practice, ethical issues and the long lead-time needed to demonstrate or disprove an effect, no clinical studies can/will directly answer this. The costs of avoiding one CRC in IBD may be as low as 153 times the annual cost of 5-ASA therapy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Andrews JM, Travis SP, Gibson PR, Gasche C. Systematic review: does concurrent therapy with 5-ASA and immunomodulators in inflammatory bowel disease improve outcomes? &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2009;29(5):459-69.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>385110</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2009.04157.x]]&gt;</url>
    <title>Systematic review: efficacy and safety of pancreatic enzyme supplements for exocrine pancreatic insufficiency</title>
    <publicationDate>2010-01-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COMMON CLINICAL PRESENTATIONS,PANCREAS,DIARRHOEA,RECENT ADDITIONS,EXOCRINE PANCREATIC INSUFFICIENCY,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt;&amp;nbsp;&lt;SPAN&gt;Based on data from randomized cross-over trials, pancreatic enzyme supplements appear to improve fat malabsorption. No specific branded product or specific delivery system is superior for treatment of fat malabsorption in patients with exocrine pancreatic insufficiency.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; &lt;SPAN&gt;Pancreatic enzyme supplements are standard therapy for fat malabsorption in patients with exocrine pancreatic insufficiency. The FDA determined that published data are insufficient to support the efficacy and safety of these agents. The aim of this study was t&lt;SPAN&gt;o determine if pancreatic enzyme supplements are: (i) superior to placebo for treating fat malabsorption and (ii) superior to other supplements based on randomized cross-over trials.&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt;&amp;nbsp;&lt;SPAN&gt;A computer-assisted search of MEDLINE and EMBASE was performed to identify relevant studies. Data extraction on study design, improvement in coefficient of fat absorption, diarrhoea and adverse events using prespecified forms.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;SPAN class=sub_abstract_label&gt;&lt;/SPAN&gt;&lt;SPAN&gt;A total of 12 manuscripts met inclusion criteria. Most studies (10/12) compared pancreatic enzyme supplements that used different delivery systems, while using similar quantities of enzymes. These studies found no consistent difference in fat malabsorption or gastrointestinal symptoms between different active treatments. Two small placebo-controlled trials (n = 65 patients) demonstrate that pancreatic enzyme supplements are superior to placebo for fat absorption. Data are inadequate to determine if pancreatic enzyme supplements lead to weight gain or improvement in diarrhoea.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Taylor JR, Gardner TB, Waljee AK, Dimagno MJ, Schoenfeld PS. Systematic review: efficacy and safety of pancreatic enzyme supplements for exocrine pancreatic insufficiency. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2010;31(1):57-72.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>328312</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2009.04135.x]]&gt;</url>
    <title>Systematic review: endoscopic and imaging-based techniques in the assessment of portal haemodynamics and the risk of variceal bleeding</title>
    <publicationDate>2009-11-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COMMON CLINICAL PRESENTATIONS,OESOPHAGUS,OESOPHAGEAL VARICES,LIVER,PORTAL HYPERTENSION,DIAGNOSTIC PROCEDURES,GASTROINTESTINAL ENDOSCOPY,ENDOSCOPIC ULTRASOUND,ULTRASOUND,BLEEDING,MRI,CT / CAT SCAN,UPPER,LOWER,RECENT ADDITIONS,CIRRHOSIS,RADIOLOGY,GI BLEEDING,OCTOBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Endoscopic and imaging-based measurements of portal haemodynamics provide an alternate means for the assessment of complications of portal hypertension. Further studies are required to validate their use in risk stratification and the evaluation of drug therapies in patients with portal hypertension.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background:&lt;/STRONG&gt; Invasive measurement of the hepatic venous pressure gradient (HVPG) is regarded as the gold standard for risk stratification and the evaluation of pharmaceutical agents in patients with portal hypertension.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; To review the techniques for endoscopic and imaging-based assessment of portal haemodynamics, with particular emphasis on trials where the results were compared with HVPG or direct portal pressure measurement.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Systematic search of the MEDLINE electronic database with keywords: portal hypertension, variceal bleeding, variceal pressure, endoscopic ultrasound, Doppler ultrasonography, magnetic resonance angiography, CT angiography, hepatic venous pressure gradient.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Computed tomography angiography and endoscopic ultrasound (EUS) have been both employed for the diagnosis of complications of portal hypertension and for the evaluation of the efficacy of endoscopic therapy. Colour Doppler ultrasonography and magnetic resonance angiography has given discrepant results. Endoscopic variceal pressure measurements either alone or combined with simultaneous EUS, correlate well with HVPG and risk of variceal bleeding and have a low interobserver variability.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Sgouros SN, Vasiliadis KV, Pereira SP. Systematic review: endoscopic and imaging-based techniques in the assessment of portal haemodynamics and the risk of variceal bleeding. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2009 Nov 15;30(10):965-76. Epub 2009 Sep 4.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281307</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17903236]]&gt;</url>
    <title>Systematic review: endoscopic dilatation in Crohn's disease</title>
    <publicationDate>2008-03-10T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,DIAGNOSTIC PROCEDURES,GASTROINTESTINAL ENDOSCOPY,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic information:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;Hassan,&amp;nbsp;C. &lt;SPAN title="Alimentary pharmacology &amp;amp; therapeutics."&gt;&lt;A href="#javascript:AL_get(this," ?jour?, ?Aliment Pharmacol Ther.?);?&gt;Aliment Pharmacol Ther.&lt;/A&gt;&lt;/SPAN&gt; 2007 Dec;26(11-12):1457-64. Epub 2007 Sep 28&lt;/P&gt;
&lt;P class=abstract&gt;BACKGROUND: Endoscopic dilatation for Crohn's disease has been evaluated only in some small and heterogeneous studies. AIM: To evaluate any association between the main clinical variables and endoscopic variables and the efficacy and safety of endoscopic dilatation in Crohn's disease. METHODS: A Medline search regarding pneumatic dilatation in Crohn's disease was performed. Several technical and clinical variables were extracted from each study to build up a descriptive, pool-data analysis. Data on individual patients were extracted from suitable studies to create a simulated population upon which a multivariate statistical analysis was performed. RESULTS: Thirteen studies enrolling 347 Crohn's disease patients were reviewed. Endoscopic dilatation was mainly applied to postsurgical strictures, being technically successful in 86% of the cases. Long-term clinical efficacy was achieved in 58% of the patients. Mean follow-up was as long as 33 months, corresponding to 800 patient years of follow-up. Major complication rate was 2%, being higher than 10% in two series. At multivariate analysis, a stricture length &amp;lt; or = 4 cm was associated with a surgery-free outcome (OR: 4.01; 95% CI: 1.16-13.8; P &amp;lt; 0.028). CONCLUSIONS: Endoscopic dilatation is an effective and safe treatment for short strictures caused by Crohn's disease, impacting substantially on the natural history of these patients.&lt;/P&gt;
&lt;P&gt;See also the &lt;A href="nelh:324179:0" name=internalLink&gt;DARE record&lt;/A&gt; for this article.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Alimentary Pharmacology and Therapeutics is an international journal concerned with the effects of drugs on the human gastrointestinal and hepato-biliary systems. The journal publishes original research on all aspects of pharmacology, pharmacokinetics and therapeutic use of drugs in the alimentary tract.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is &lt;STRONG&gt;not&lt;/STRONG&gt; available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>384677</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2010.04347.x]]&gt;</url>
    <title>Systematic review: fatigue in inflammatory bowel disease</title>
    <publicationDate>2010-07-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,RECENT ADDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Despite the clinical reality of fatigue, there are few published studies examining fatigue in inflammatory bowel disease (IBD) as a primary outcome. More data are needed on the prevalence, correlation between disease activity and fatigue severity, and putative pathogenic pathways involved in fatigue pathogenesis, before ultimately elucidating targeted therapies for fatigue in IBD patients.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Fatigue is common, disabling yet underappreciated, in patients with chronic diseases, including IBD.&amp;nbsp; The aim of this study was to examine the literature and determine the prevalence and patterns of fatigue in IBD patients, to identify opportunities and directions for future research in this area.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A systematic review using PubMed and Ovid Medline databases was conducted using search terms ‘fatigue’, ‘Crohn’, ‘colitis’ and ‘inflammatory bowel disease’. A review of fatigue in other similar chronic diseases was also performed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Ten studies were found to include data on fatigue in IBD patients; all were conducted between 1999 and 2009. However, only one study (in children) measured fatigue in IBD patients as a primary outcome. In patients in remission, the prevalence of fatigue in IBD patients ranges from 41 to 48%. Data are sparse and conflicting on whether fatigue severity is proportional to disease severity/activity.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; van Langenberg DR, Gibson PR. Systematic review: fatigue in inflammatory bowel disease. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2010;32(2):131-43.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>330643</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18363896]]&gt;</url>
    <title>Systematic review: glucocorticosteroids for alcoholic hepatitis--a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials.</title>
    <publicationDate>2008-06-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,ALCOHOLIC LIVER DISEASE,ALCOHOLIC HEPATITIS,STEATOHEPATITIS,ALCOHOLIC,RECENT ADDITIONS,NOVEMBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The current evidence base of mainly heterogeneous with high bias risk trials does not support the use of glucocorticosteroids in alcoholic hepatitis. Large, low-bias risk placebo-controlled randomized trials are needed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Glucocorticosteroids versus placebo or no intervention for patients with alcoholic hepatitis have been evaluated for more than 35 years. However, the results of randomized trials and meta-analyses differ substantially. The aim of this study was to review all randomized clinical trials of glucocorticosteroids vs. placebo or no intervention for patients with alcoholic hepatitis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We searched for randomized trials published before July 2007. The trials were assessed for risk of bias. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt;&amp;nbsp;We included 15 trials with a total of 721 randomized patients. The overall mortality rate was 39.5%. Twelve of the fifteen trials were at risk of bias. Glucocorticosteroids did not statistically reduce mortality compared with placebo or no intervention (relative risk 0.83, 95% CI 0.63-1.11). Glucocorticosteroids significantly reduced mortality in the subgroup of trials with patients with Maddrey's score of at least 32 or hepatic encephalopathy and with low-bias risk. In all analyses, heterogeneity was significant and substantial. Trial sequential analyses using heterogeneity-adjusted information size demonstrated no significant effect of glucocorticosteroids on mortality. Weighted logistic regression analyses taking prognostic factors at randomization into consideration found no significant effect of glucocorticosteroids on mortality. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Rambaldi A, Saconato HH, Christensen E, Thorlund K, Wetterslev J, Gluud C. Systematic review: glucocorticosteroids for alcoholic hepatitis--a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2008 Jun;27(12):1167-78.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>387981</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2010.04415.x]]&gt;</url>
    <title>Systematic review: Helicobacter pylori and the risk of upper gastrointestinal bleeding risk in patients taking aspirin</title>
    <publicationDate>2010-10-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COMMON CLINICAL PRESENTATIONS,STOMACH,UPPER,HELICOBACTER PYLORI,RECENT ADDITIONS,INFECTIONS,GI BLEEDING,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; &lt;SPAN&gt;The current data are not sufficient to allow meta-analyses. The widely held belief that &lt;EM&gt;Helicobacter pylori&lt;/EM&gt; is a risk factor for upper gastrointestinal bleeding in regular aspirin users is not supported by the very limited evidence available.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; &lt;SPAN&gt;Aspirin is widely used to modify the risk of recurrent vascular events. It is, however, associated with increased upper gastrointestinal bleeding risk. The influence of &lt;EM&gt;H. pylori&lt;/EM&gt; on this risk is uncertain. The aim of this study was to &lt;SPAN&gt;determine the influence of &lt;EM&gt;H. pylori&lt;/EM&gt; on upper gastrointestinal bleeding risk in patients taking aspirin.&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt;&amp;nbsp;&lt;SPAN&gt;MEDLINE and EMBASE databases were searched. All studies providing data regarding &lt;EM&gt;H. pylori&lt;/EM&gt; infection in adults taking aspirin and presenting with upper gastrointestinal bleeding were included.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;SPAN&gt;A total of 13 studies that included 1 case-control, 10 cohort studies and 2 randomized-controlled trials (RCTs) were analysed. The case-control study (n = 245) determined&lt;EM&gt; H. pylori&lt;/EM&gt; to be a significant independent risk factor for upper gastrointestinal bleeding. The cohort studies were heterogeneous, varying in inclusion criteria, doses and duration of aspirin used, mode of &lt;EM&gt;H. pylori&lt;/EM&gt; testing and causative GI pathology considered. Comprising 5465 patients, &lt;EM&gt;H. pylori&lt;/EM&gt; infection was tested for in 163 (0.03%) aspirin users with upper gastrointestinal bleeding. The RCTs yielded no significant results.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Fletcher EH, Johnston DE, Fisher CR, Koerner RJ, Newton JL, Gray CS. Systematic review: Helicobacter pylori and the risk of upper gastrointestinal bleeding risk in patients taking aspirin. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2010;32(7):831-9.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317970</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2008.03906.x]]&gt;</url>
    <title>Systematic review: Heliocobacter pylori infection and impaired drug absorption</title>
    <publicationDate>2009-02-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,STOMACH,HELICOBACTER PYLORI,RECENT ADDITIONS,INFECTIONS,JUNE 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; A plausible mechanism of impaired drug absorption in &lt;SPAN class=i&gt;H. pylori&lt;/SPAN&gt;-gastritis patients&amp;nbsp;is decreased acid secretion. &lt;SPAN class=i&gt;Helicobacter pylori&lt;/SPAN&gt; infection and hypochlorhydria should be considered in prescribing drugs the absorption of which is potentially affected by intragastric pH.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Data sources were the systematic search of MEDLINE/EMBASE/SCOPUS databases (1980–April 2008) for English articles using the keywords: drug malabsorption/absorption, stomach, &lt;SPAN class=i&gt;Helicobacter pylori&lt;/SPAN&gt;, gastritis, gastric acid, gastric pH, hypochlorhydria, gastric hypoacidity. Study selection was made from 2099 retrieved articles, five studies were identified. Data were extracted from selected papers, investigated drugs, study type, main features of subjects, study design, intervention type and results were extracted.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; In all, five studies investigated impaired absorption of &lt;SPAN class=smallcapitals&gt;l&lt;/SPAN&gt;-dopa, thyroxine and delavirdine in &lt;SPAN class=i&gt;H. pylori&lt;/SPAN&gt; infection. Eradication treatment led to 21–54% increase in &lt;SPAN class=smallcapitals&gt;l&lt;/SPAN&gt;-dopa in Parkinon's disease. Thyroxine requirement was higher in hypochlorhydric goitre with &lt;SPAN class=i&gt;H. pylori-&lt;/SPAN&gt;gastritis and thyrotropin levels decreased by 94% after treatment. In &lt;SPAN class=i&gt;H. pylori-&lt;/SPAN&gt; and HIV-positive hypochlorhydric subjects, delavirdine absorption increased by 57% with orange juice administration and by 150% after eradication.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Lahner E, Annibale B, Delle Fave G. Systematic review: Helicobacter pylori infection and impaired drug absorption. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2009;29(4):379-86.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>326235</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2009.04060.x]]&gt;</url>
    <title>Systematic review: hepatitis-associated aplastic anaemia – a syndrome associated with abnormal immunological function</title>
    <publicationDate>2009-09-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Hepatitis-associated bone marrow aplasia is mediated by immunological mechanisms. Treatment options include hematopoietic cell transplantation and immunosuppressive therapy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Literature searches were undertaken on the MEDLINE electronic database up to December 2008. Twenty-four relevant studies were identified. The clinical and laboratory characteristics of the patients were analysed and reviewed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Hepatitis-associated aplastic anemia is a variant of acquired aplastic anemia in which an episode of hepatitis precedes the onset of aplastic anemia. The hepatitis may be acute and severe, even fulminant; it may be self-limiting or chronic. The pathology is often not attributable to a recognized cause of viral hepatitis. The syndrome occurs in 28 percent of young adults after liver transplantation for non-A, non-B, non-C hepatitis. Several features of the syndrome suggest that the marrow aplasia is mediated by immunological mechanisms, possibly mediated by gamma interferon or the cytokine cascade. Survival of patients treated with hematopoietic cell transplantation has been 82%, and the response rate to immunosuppressive therapy 70%.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Gonzalez-Casas R, Garcia-Buey L, Jones EA, Gisbert JP, Moreno-Otero R.&amp;nbsp; Systematic review: hepatitis-associated aplastic anaemia--a syndrome associated with abnormal immunological function.&amp;nbsp;&lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2009 Sep 1;30(5):436-43.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>385092</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2010.04273.x]]&gt;</url>
    <title>Systematic review: impact of constipation on quality of life in adults and children</title>
    <publicationDate>2010-05-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COMMON CLINICAL PRESENTATIONS,CONSTIPATION,RECENT ADDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; &lt;SPAN&gt;The impact of constipation on quality of life&amp;nbsp;(QoL) is significant and comparable with other common chronic conditions. Improving management may prove to be an effective way of improving QoL for a substantial number of patients.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; &lt;SPAN&gt;Comparison of QoL across disease areas requires the use of appropriate tools. Although many studies have investigated QoL in constipation, most used disease-specific tools that are inappropriate for cross-comparisons. The aim of this study was to&amp;nbsp;&lt;SPAN&gt;&amp;nbsp;identify studies of QoL in constipation and to compare these results with other chronic conditions.&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; &lt;SPAN&gt;A comprehensive literature search identified studies in constipation that used a generic QoL tool. Results were statistically pooled where possible and compared with published results using the same tools in other chronic conditions.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;SPAN&gt;A total of 13 qualifying studies were identified, 10 in adults and three in children. Results from eight studies using the SF-36/12 tools were pooled; the remaining five were narratively reported. Mental and physical components of QoL scores were consistently impaired in both adult and child populations, with the greatest impact being seen in secondary care studies. Mental health effects predominated over physical domains. The magnitude of impact was comparable with that seen in patients with allergies, musculoskeletal conditions and inflammatory bowel disease.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Belsey J, Greenfield S, Candy D, Geraint M. Systematic review: impact of constipation on quality of life in adults and children. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2010;31(9):938-49.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>310844</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2008.03865.x]]&gt;</url>
    <title>Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares</title>
    <publicationDate>2009-02-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; &lt;SPAN class=h5-inline&gt;&lt;/SPAN&gt;A substantial proportion of ulcerative colitis (UC) flares and medical costs of UC are attributable to 5-aminosalicylic acid (5-ASA) non-adherence. As non-adherence to 5-ASA medications is common, cost-effective strategies to improve adherence are needed. The impact of adherence on disease activity should be measured in randomized clinical trials (RCTs) of all inflammatory bowel disease treatments.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; UC can be maintained in remission with 5-ASA, but frequent non-adherence by patients who are feeling well has been associated with more frequent flares of colitis. The aim of this study was to perform a systematic review of the published literature and unpublished RCTs regarding the impact of non-adherence with 5-ASA medications on the incidence of UC flares and costs of care.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A search of MEDLINE, EMBASE and the Cochrane databases was performed. Prospective studies of UC maintenance with 5-ASAs in adults were selected if they included data on adherence and disease flares. Studies using insurance claims data to estimate the impact of non-adherence on cost of care were included. Data from unpublished RCTs were obtained from the FDA with a request under the Freedom of Information Act.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The relative risk for flare in non-adherent vs. adherent patients ranged from 3.65 to infinity. Data were obtained from six unpublished 5-ASA RCTs, but none measured the impact of adherence on disease activity. The comorbidity-adjusted annual costs of care in adherent patients were 12.5% less than in non-adherent patients, despite increased medication expenditures.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Higgins PD, Rubin DT, Kaulback K, Schoenfield PS, Kane SV. Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares. &lt;EM&gt;Aliment Pharmacol Ther &lt;/EM&gt;2009;29(3):247-57.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>316440</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2009.03993.x]]&gt;</url>
    <title>Systematic review: impaired drug absorption related to the co-administration of antisecretory therapy</title>
    <publicationDate>2009-03-06T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,OESOPHAGUS,STOMACH,ULCERS,DUODENAL ULCERS,GASTRIC ULCERS,SMALL INTESTINE,GASTRO-OESOPHAGEAL REFLUX,RECENT ADDITIONS,JUNE 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; This is a review of evidence of impaired drug absorption related to the use of co-administered PPIs or H&lt;SUB&gt;&lt;NOBR&gt;2&lt;/NOBR&gt;&lt;/SUB&gt;RAs. In conclusion, gastric pH appears relevant for absorption of some cardiovascular or infectious disease agents. Antisecretory treatment may significantly modify the absorption of co-administered drugs.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt;&amp;nbsp;Systematic search of MEDLINE/EMBASE/SCOPUS databases (1980–September 2008) for English articles with keywords: drug malabsorption and absorption, stomach, anti-secretory/acid inhibitory drugs, histamine H&lt;SUB&gt;&lt;NOBR&gt;2&lt;/NOBR&gt;&lt;/SUB&gt; antagonists, PPIs, gastric acid, pH, hypochlorhydria, gastric hypoacidity. From 2126 retrieved articles, 16 randomized crossover studies were identified investigating impaired absorption of nine different drugs in association with co-administration of PPIs or H&lt;SUB&gt;&lt;NOBR&gt;2&lt;/NOBR&gt;&lt;/SUB&gt;RAs. Information on investigated drug, study type, features of investigated subjects, study design, type of intervention, and study results were extracted.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The identified studies investigated the absorption kinetics of nine drugs. Acid suppression reduced absorption of ketoconazole, itraconazole, atazanavir, cefpodoxime, enoxacin and dipyridamole (median &lt;SPAN class=i&gt;C&lt;/SPAN&gt;&lt;SUB&gt;&lt;NOBR&gt;max&lt;/NOBR&gt;&lt;/SUB&gt; reduction by 66.5%). An increased absorption of nifedipine and digoxin (median &lt;SPAN class=i&gt;AUC&lt;/SPAN&gt; increase by 10%) and a 2-fold-increase in alendronate bioavailability were observed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Lahner E, Annibale B, Delle Fave G. Systematic review: impaired drug absorption related to the co-administration of antisecretory therapy. Aliment Pharmacol Ther. 2009 Jun 15;29(12):1219-29.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281301</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17229218]]&gt;</url>
    <title>Systematic review: infliximab therapy in ulcerative colitis</title>
    <publicationDate>2008-03-10T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic information:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;Gisbert, JP.&amp;nbsp;&lt;SPAN title="Alimentary pharmacology &amp;amp; therapeutics."&gt;&lt;A href="#javascript:AL_get(this," ?jour?, ?Aliment Pharmacol Ther.?);?&gt;Aliment Pharmacol Ther.&lt;/A&gt;&lt;/SPAN&gt; 2007 Jan 1;25(1):19-37.&lt;/P&gt;
&lt;P class=abstract&gt;AIM: To perform a systematic review and meta-analysis on the efficacy and tolerance of infliximab in ulcerative colitis. METHODS: Selection of studies: evaluating efficacy of infliximab in ulcerative colitis. For the meta-analysis, randomized clinical trials comparing infliximab vs. placebo/steroids. Search strategy: electronic and manual. Study quality: independently assessed by two reviewers. Data synthesis: meta-analysis combining the odds ratios (OR). RESULTS: Thirty-four studies (896 patients) evaluated infliximab therapy in UC, with heterogeneous results. Mean short-term (2.3 weeks) response and remission with infliximab was 68% (95% CI 65-71%) and 40% (36-44%). Mean long-term (8.9 months) response and remission was 53% (49-56%) and 39% (35-42%). Five randomized double-blind studies compared infliximab with placebo, the meta-analysis showing an advantage (P &amp;lt; 0.001) of infliximab in all endpoints (short-/long-term response/remission): ORs from 2.7 to 4.6, and number-needed-to-treat (NNT) from 3 to 5. Similar infliximab response was calculated independently of the indication (steroid-refractory/non-steroid-refractory) or the dose (5/10 mg/kg). Adverse effects were reported in 83% and 75% of the infliximab and placebo-treated patients (OR = 1.52; 95% CI 1.03-2.24; number-needed-to-harm (NNH) was 14). CONCLUSION: Infliximab is more effective than placebo, with an NNT from 3 to 5, for the treatment of moderate-to-severe UC, achieving clinical remission in 40% of the patients at approximately 9 months of follow-up. Further studies are necessary to confirm the long-term efficacy of infliximab in ulcerative colitis.&lt;/P&gt;
&lt;P class=abstract&gt;See also the &lt;A href="nelh:283787:0" name=internalLink&gt;DARE record&lt;/A&gt; for this article.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Alimentary Pharmacology and Therapeutics is an international journal concerned with the effects of drugs on the human gastrointestinal and hepato-biliary systems. The journal publishes original research on all aspects of pharmacology, pharmacokinetics and therapeutic use of drugs in the alimentary tract.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is &lt;STRONG&gt;not&lt;/STRONG&gt; available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>268516</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2006.03081.x]]&gt;</url>
    <title>Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection</title>
    <publicationDate>2006-10-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,CHRONIC HEPATITIS B]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt;&amp;nbsp;Kohrt H.E., Ouyang D.L. Keeffe E.B. 2006; Alimentary Pharmacology and Therapeutics 24 (7) pp. 1003-16&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract: &lt;/STRONG&gt;BACKGROUND: Reactivation of hepatitis B virus infection in asymptomatic hepatitis B surface antigen carriers undergoing chemotherapy or immunosuppressive therapy is a well-documented and potentially fatal complication. Data supporting the use of lamivudine for primary prophylaxis have emerged, but its use remains controversial and is not standardized. AIM: To review current randomized-controlled trials, randomized trials and prospective case series to provide a clinically applicable, evidence-based recommendation. METHODS: The published literature was identified using a MEDLINE/PubMed search with secondary review of cited publications, and inclusion of all prospective studies. RESULTS: In nine prospective trials and one randomized-controlled trial, the rate of hepatitis among subjects receiving lamivudine prophylaxis ranged from 0% to 20% (16 of 173, 9.2%), compared with 33-67% among controls. Of patients receiving prophylaxis, 0-24% (15 of 173, 8.7%) developed hepatitis B virus reactivation, compared with 29-56% of controls. Three reactivation-related mortalities were reported (one receiving prophylaxis, two controls). No patients withdrew secondary to toxicity or development of lamivudine-resistant mutations. CONCLUSIONS: The available data show a four- to sevenfold decrease in the rate of hepatitis and hepatitis B virus reactivation in patients who receive lamivudine prophylaxis. It is thus recommended that all hepatitis B surface antigen carriers receive lamivudine, or a comparable anti-viral agent, as prophylaxis from the initiation of chemotherapy until at least 1 year following its completion.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>385109</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2009.04195.x]]&gt;</url>
    <title>Systematic review: molecular chemoprevention of colorectal malignancy by mesalazine</title>
    <publicationDate>2010-01-15T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,DISEASE PREVENTION,CANCER,RECENT ADDITIONS,COLON CANCER,RECTAL CANCER,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt;&lt;SPAN class=sub_abstract_label&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;SPAN&gt;In the recent years, a large amount of molecular data has accumulated supporting the notion that m&lt;SPAN&gt;esalazine (mesalamine)&lt;/SPAN&gt; (5-ASA) biological effects interfere with colorectal cancer development. These molecular pathways are of special interest in the search for 5-ASA's molecular target(s) and development of novel chemopreventive compounds.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN&gt;&lt;/SPAN&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; &lt;SPAN&gt;5-ASA is considered an anti-inflammatory drug for the treatment of inflammatory bowel disease. It is well tolerated by most patients and induces mucosal healing specifically in ulcerative colitis. Besides its anti-inflammatory properties, 5-ASA has been studied for cancer inhibitory activities as it seems to reduce colorectal cancer incidence in patients using this drug for long periods of time. However, detailed molecular mechanisms of drug action are vague. The aim of this study was t&lt;SPAN&gt;o evaluate known molecular mechanisms of 5-ASA on chemoprevention of colorectal malignancy.&lt;/SPAN&gt; &lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; &lt;SPAN&gt;Systematic review with search terms '5 aminosalicylic acid, mesalazine, 5-ASA, mesalazine, molecular mechanisms, chemoprevention' between 2006 and August 2009.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;SPAN class=sub_abstract_label&gt;&lt;/SPAN&gt;&lt;SPAN&gt;A total of 48 studies were retrieved that link 5-ASA chemopreventive properties to five distinct pathways. These include interference with cell cycle progression (12 references), scavenging of reactive oxygen- or nitrogen-derived metabolites (16 references), TNF-alpha/TGF-ss signalling (11 references), WNT/beta-catenin signalling (5 references) and anti-bacterial properties (4 references).&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Lyakhovich A, Gasche C. Systematic review: molecular chemoprevention of colorectal malignancy by mesalazine. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2010;31(2):202-9.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>326238</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2009.04062.x]]&gt;</url>
    <title>Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C</title>
    <publicationDate>2009-09-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,DIAGNOSTIC PROCEDURES,BIOPSY,LIVER,BLOOD TESTS,BREATH TESTS,LIVER FUNCTION TESTS,CHRONIC HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; &lt;SPAN class=h5-inline&gt;&lt;/SPAN&gt;Great strides are being made in the development of accurate non-invasive methods for determination of fibrosis. Although no single non-invasive test or model developed to date can match that information obtained from actual histology (i.e. inflammation, fibrosis, steatosis), combinations of two modalities of non-invasive methods can reliably differentiate between minimal and significant fibrosis, and thereby avoid liver biopsy in a significant percentage of patients.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Accurate determination of the presence and degree of liver fibrosis is essential for prognosis and for planning treatment of patients with chronic hepatitis C virus (HCV). Non-invasive methods of assessing fibrosis have been developed to reduce the need for biopsy. The aims of this study was to perform a review of these non-invasive measures and their ability to replace biopsy for assessing hepatic fibrosis in patients with chronic HCV.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A systematic review of PUBMED and EMBASE was performed through 2008 using the following search terms: HCV, liver, elastography, hepatitis, Fibroscan, SPECT, noninvasive liver fibrosis, ultrasonography, Doppler, MRI, Fibrotest, Fibrosure, Actitest, APRI, Forns and breath tests, alone or in combination.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; We identified 151 studies: 87 using biochemical, 57 imaging and seven breath tests either alone or in combination.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Smith JO, Sterling RK. Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2009;30(6):557-76.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281296</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18045244]]&gt;</url>
    <title>Systematic review: nutritional therapy in paediatric Crohn's disease</title>
    <publicationDate>2008-02-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE,ENTERAL,THERAPEUTIC NUTRITION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Further studies are required to define longer-term effects of nutritional therapy in patients with CD.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A search of PubMed was performed with search terms 'enteral nutrition', 'nutritional therapy', 'Crohn disease' and 'children'. Relevant articles were selected from this search. In addition, the reference lists of available articles were reviewed for further relevant articles.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Nutritional therapy offers numerous benefits in the management of CD. Recent work has begun to elucidate the likely mechanisms of this therapy. These include direct mucosal anti-inflammatory effects and alteration of intestinal microflora.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Day, A. S., Whitten, K. E., Sidler, M., &amp;amp; Lemberg, D. A. (2008) Systematic review: nutritional therapy in paediatric Crohn's disease. &lt;I&gt;Alimentary Pharmacology &amp;amp; Therapeutics&lt;/I&gt;, 27(4):293-307.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317972</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2008.03894.x]]&gt;</url>
    <title>Systematic review: open, small-incision or laparoscopic cholecystectomy for symptomatic cholecystolithiasis</title>
    <publicationDate>2009-02-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,GALLSTONES,BILIARY TREE &amp; GALLBLADDER,RECENT ADDITIONS,JUNE 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; &lt;SPAN class=h5-inline&gt;&lt;/SPAN&gt;No significant differences in mortality and complications were found among the three techniques of laparoscopic, open and small-incision cholecystectomy. Laparoscopic and small-incision cholecystectomy are preferred over open cholecystectomy for quicker convalescence. Laparoscopic and small-incision cholecystectomy show no clear differences on patient outcomes.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; &lt;SPAN class=h5-inline&gt;&lt;/SPAN&gt;We conducted updated searches until January 2007 in multiple databases. We assessed bias risk.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;SPAN class=h5-inline&gt;&lt;/SPAN&gt;&lt;SPAN class=h5-inline&gt;&lt;/SPAN&gt;Fifty-nine trials randomized 5556 patients. No significant differences in primary outcomes (mortality and complications) were found among all three techniques. Both minimal invasive techniques show advantages over open cholecystectomy in terms of convalescence. Small-incision cholecystectomy showed shorter operative time compared with laparoscopic cholecystectomy (random effects, weighted mean difference, 16.4&amp;nbsp;min; 95% confidence interval, 8.9–23.8), but the two techniques did not differ regarding hospital stay and conversions.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Keus F, Gooszen HG, Van Laarhoven CJ. Systematic review: open, small-incision or laparoscopic cholecystectomy for symptomatic cholecystolithiasis. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2009;29(4):359-78.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>384935</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2010.04370.x]]&gt;</url>
    <title>Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection</title>
    <publicationDate>2010-08-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,NON-ALCOHOLIC,HEPATOCELLULAR CARCINOMA,LIVER TRANSPLANTATION,RECENT ADDITIONS,CANCER,CIRRHOSIS,CHRONIC HEPATITIS C,SURGERY,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; &lt;SPAN&gt;The rates of death, transplantation, decompensation and hepatocellular carcinoma (HCC) determined in this study highlight the need for continued vigilance for the occurrence of HCC, while confirming the relatively slow progress of compensated hepatitis C virus (HCV) cirrhosis. Heterogeneity in reporting means that these data may underestimate the rate of disease progression, particularly HCC development. It will be important to ensure clearer distinction between treatment responses in future studies.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; &lt;SPAN&gt;Most studies evaluating chronic HCV natural history have taken the development of cirrhosis as an end-point. The aim of this study was t&lt;SPAN&gt;o perform a systematic review of the literature to establish the outcome of compensated HCV cirrhosis.&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; &lt;SPAN&gt;A systematic literature review was performed. Only data regarding HCV mono-infected patients were included. Weighted mean annual percentage rates for death/transplantation, decompensation of cirrhosis and development of HCC were calculated.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;SPAN&gt;Thirteen papers were included. Despite some heterogeneity, we extracted data relating to 2386 patients. In compensated HCV cirrhosis, the estimated annual rate of death/transplantation is 4.58%, that of decompensation is 6.37% per and that of HCC, 3.36%. When compared with studies of untreated patients, studies that included treated patients reported significantly lower mean annual percentage rates of HCC (2.52% vs. 4.79%, P = 0.02), but not decompensation (5.34% vs. 7.88%, P = 0.026) and death/transplantation (3.79% vs. 4.62%, P = 0.25).&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Alazawi W, Cunningham M, Dearden J, Foster GR. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2010 Aug;32(3):344-55. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>387999</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2010.04406.x]]&gt;</url>
    <title>Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies</title>
    <publicationDate>2010-09-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,OESOPHAGUS,GASTRO-OESOPHAGEAL REFLUX,RECENT ADDITIONS,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; &lt;SPAN&gt;Persistent &lt;SPAN&gt;gastro-oesophageal reflux disease&lt;/SPAN&gt; (GERD) symptoms despite &lt;SPAN&gt;proton pump inhibitor&lt;/SPAN&gt; (PPI) treatment are common in the primary care and community setting. Alternative approaches to management are required.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; &lt;SPAN&gt;Persistent GERD symptoms can occur despite PPI therapy. The aim of this study was to&amp;nbsp;&lt;SPAN&gt;assess the prevalence and potential determinants of persistent GERD symptoms in primary care and community-based studies.&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; &lt;SPAN&gt;Studies were identified by systematic PubMed and Embase searches; pooled prevalence data are shown as sample-size weighted means and 95% confidence intervals.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;SPAN&gt;Nineteen studies in individuals with GERD taking a PPI were included. In interventional, nonrandomized primary care trials, the prevalence of persistent troublesome heartburn and regurgitation was 17% (6-28%) and 28% (26-30%) respectively; in randomized trials, it was 32% (25-39%) and 28% (26-30%), respectively. In observational primary care and community-based studies, 45% (30-60%) of participants reported persistent GERD symptoms. Overall, persistent GERD symptoms despite PPI treatment were more likely in studies with a higher proportion of female participants [&amp;gt;60% vs. &amp;lt;50%, risk ratio (RR): 3.66; P &amp;lt; 0.001], but less likely in studies from Europe than in those from the USA (RR: 0.71; P &amp;lt; 0.001), and were associated with decreased psychological and physical well-being.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; El-Serag H, Becher A, Jones R. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies.&lt;EM&gt; Aliment Pharmacol Ther&lt;/EM&gt; 2010;32(6):720-37.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>334912</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2009.04182.x]]&gt;</url>
    <title>Systematic review: portal vein thrombosis in cirrhosis</title>
    <publicationDate>2010-02-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,VASCULAR DISORDERS,PORTAL VEIN THROMBOSIS,RECENT ADDITIONS,CIRRHOSIS,JANUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Portal vein thrombosis in cirrhosis has many unresolved issues, which are often the critical problems clinicians encounter in their everyday practice. We propose a possible research agenda to address these unresolved issues.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; As current imaging techniques in cirrhosis allow detection of asymptomatic portal vein thrombosis during routine ultrasonography, more patients with cirrhosis are diagnosed with portal vein thrombosis. Although a consensus on noncirrhotic extra-hepatic portal vein thrombosis has been published, no such consensus exists for portal vein thrombosis with cirrhosis. To perform a systematic review of nonmalignant portal vein thrombosis in cirrhosis in terms of prevalence, pathogenesis, diagnosis, clinical course and management.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Studies were identified by a search strategy using MEDLINE and EMBASE.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Portal vein thrombosis is encountered in 10–25% of cirrhotics. In terms of pathophysiology, cirrhosis is no longer considered a hypocoagulable state; rather than a bleeding risk in cirrhosis, various clinical studies support a thrombotic potential. Clinical findings of portal vein thrombosis in cirrhosis vary from asymptomatic disease to a life-threatening condition at first presentation. Optimal management of portal vein thrombosis in cirrhosis is currently not addressed in any consensus publication. Treatment strategies most often include the use of anticoagulation, while thrombectomy and transjugular intrahepatic portosystemic shunts are considered second-line options.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Tsochatzis EA, Senzolo M, Germani G, Gatt A, Burroughs AK. Systematic review: portal vein thrombosis in cirrhosis. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2009;31(3):366-74.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>385082</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2010.04279.x]]&gt;</url>
    <title>Systematic review: prognostic tests of paracetamol-induced acute liver failure</title>
    <publicationDate>2010-05-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,LIVER TRANSPLANTATION,ACUTE LIVER FAILURE,LIVER FAILURE,RECENT ADDITIONS,SURGERY,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; T&lt;SPAN&gt;he original King's College Criteria for listing for emergency liver transplantation remain well-validated criteria with high prognostic accuracy. Other potential prognostic variables should be prospectively assessed in multicentre studies to refine the criteria further.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; &lt;SPAN&gt;Paracetamol (acetaminophen) toxicity remains the leading cause of acute liver failure (ALF) in the developed world. In the UK, the recently modified King's College Criteria are used to list patients for emergency liver transplantation, but these criteria have been criticized for their low sensitivity and for spectrum bias in their application.&lt;/SPAN&gt; The aim of this study was t&lt;SPAN&gt;o evaluate existing prognostic criteria critically for predicting death without transplantation in paracetamol-induced ALF.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; &lt;SPAN&gt;MEDLINE, EMBASE and CINAHL were searched to identify studies containing adult patients with paracetamol-induced ALF. Selected studies were evaluated and data were pooled if appropriate, to calculate sensitivity, specificity and diagnostic odds ratios (DORs) of applied prognostic tests.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;SPAN&gt;Of 6507 studies identified, 14 were eligible for inclusion, evaluating 1960 patients. The original King's College Criteria had a pooled sensitivity of 58.2% and specificity of 94.6%, with a DOR of 27.7. Addition of arterial lactate to the King's College Criteria reduced the DOR to 26.1. Several other clinical and laboratory variables had higher DORs than the King's College Criteria, but were only evaluated in single studies of limited quality.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Craig DG, Ford AC, Hayes PC, Simpson KJ. Systematic review: prognostic tests of paracetamol-induced acute liver failure. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2010;31(10):1064-76.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>384680</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2010.04358.x]]&gt;</url>
    <title>Systematic review: role of acid, weakly acidic and weakly alkaline reflux in gastro-oesophageal reflux disease</title>
    <publicationDate>2010-08-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,OESOPHAGUS,GASTRO-OESOPHAGEAL REFLUX,RECENT ADDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; &lt;SPAN class=sub_abstract_label&gt;&lt;/SPAN&gt;&lt;SPAN&gt;Weakly acidic reflux underlies the majority of reflux episodes in patients with &lt;SPAN&gt;gastro-oesophageal reflux disease&lt;/SPAN&gt; (GERD) on &lt;SPAN&gt;proton pump inhibitor&lt;/SPAN&gt; (PPI) therapy, and is the main cause of reflux symptoms occurring despite PPI therapy.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; &lt;SPAN&gt;The importance of weakly acidic and weakly alkaline reflux in GERD is gaining recognition. The aim of this study was to &lt;SPAN&gt;quantify the proportions of reflux episodes that are acidic (pH &amp;lt;4), weakly acidic (pH 4-7) and weakly alkaline (pH &amp;gt;7) in adult patients with GERD, and to evaluate their correlation with symptoms.&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; &lt;SPAN&gt;Studies were identified by systematic PubMed and Embase searches. Data are presented as sample-size weighted means and 95% confidence intervals.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;SPAN&gt;In patients with GERD taking a PPI, 80% (76-84%) of reflux episodes were weakly acidic or weakly alkaline and 83% (78-88%) of reflux symptom episodes were associated with weakly acidic or weakly alkaline reflux episodes. In patients with GERD not taking a PPI, 63% (59-67%) of reflux episodes were acidic and 72% (57-87%) of reflux symptom episodes were associated with acid reflux episodes. Six studies presented data separately for weakly alkaline reflux, which accounted for &amp;lt;5% of all reflux episodes, both on and off PPI therapy.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Boeckxstaens GE, Smout A. Systematic review: role of acid, weakly acidic and weakly alkaline reflux in gastro-oesophageal reflux disease.&lt;EM&gt; Aliment Pharmacol Ther&lt;/EM&gt; 2010;32(3):334-43.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>326236</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2009.04075.x]]&gt;</url>
    <title>Systematic review: secondary prevention with band ligation, pharmacotherapy or combination therapy after bleeding from oesophageal varices</title>
    <publicationDate>2009-09-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COMMON CLINICAL PRESENTATIONS,OESOPHAGUS,OESOPHAGEAL VARICES,DISEASE PREVENTION,UPPER,GI BLEEDING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Band ligation (BT)&amp;nbsp;and&amp;nbsp;pharmcotherapy (PT)&amp;nbsp;alone are comparable for secondary prevention of rebleeding after oesophageal variceal bleeding (EVB). Further trials with adequate PT dosing are required to determine the efficacy of combination BL+PT therapy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A systematic search of databases, references and meeting abstracts was conducted for randomized trials of BL, PT or BL+PT. The outcomes were mortality, rebleeding and adverse events. A random-effects model was used for meta-analyses.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;SPAN class=h5-inline&gt;&lt;/SPAN&gt;Twelve trials were included (6 BL vs. PT, 4 BL+PT vs. BL, 2 BL+PT vs. PT). All trials used beta-blockers&amp;nbsp;±&amp;nbsp;isosorbide mononitrate (ISMN) as PT. Mortality was not significantly different among trials. Rebleeding was not significantly different for BL vs. PT (RR 1.00, 95% CI 0.73–1.37). BL reduced rebleeding compared with PT for trials with mean beta-blocker dose &amp;lt;80&amp;nbsp;mg/day (RR 0.67, 95% CI 0.49–0.91). There were nonsignificant differences in rebleeding for BL+PT vs. BL (RR 0.57, 95% CI 0.31–1.08) and BL+PT vs. PT (RR 0.76, 95% CI 0.56–1.03). There was no difference in adverse events between BL vs. PT, but was higher with BL+PT vs. BL.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Cheung J, Zeman M, van Zanten SV, Tandon P. Systematic review: secondary prevention with band ligation, pharmacotherapy or combination therapy after bleeding from oesophageal varices. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2009;30(6):577-88.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>384937</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2010.04374.x]]&gt;</url>
    <title>Systematic review: self-management support interventions for irritable bowel syndrome</title>
    <publicationDate>2010-08-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,IRRITABLE BOWEL SYNDROME,RECENT ADDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; &lt;SPAN&gt;Many self-management support interventions appear to benefit patients with irritable bowel syndrome. However, studies were limited by methodological flaws. Furthermore, feasibility in 'real world' clinical practice is uncertain. Thus, practical self-management interventions that can be applied across various clinical settings should be developed, and then tested in well-designed clinical trials.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; &lt;SPAN&gt;Irritable bowel syndrome is an extremely common and costly condition. Because there is no cure, patients must be supported to manage their own condition. The aim of this study was to &lt;SPAN&gt;assess systematically the interventions used to support irritable bowel syndrome patient self-management.&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; &lt;SPAN&gt;A search of PubMed, EMBASE, CINAHL and PsycINFO was performed to identify all studies that involved self-management support interventions for irritable bowel syndrome. Studies that compared the self-management-related intervention to a control group were included.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;SPAN class=sub_abstract_label&gt;&lt;/SPAN&gt;&lt;SPAN&gt;Eleven studies that involved a total of 1657 patients were included. For nearly all studies, the intervention was associated with statistically significant benefits. However, across studies there was significant heterogeneity in terms of sample size, diagnostic criteria, study setting, study design, primary outcome, statistical analyses and study quality. Therefore, individual study results could not be statistically combined.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Dorn SD. Systematic review: self-management support interventions for irritable bowel syndrome.&lt;EM&gt; Aliment Pharmacol Ther&lt;/EM&gt; 2010;32(4):513-21.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>380573</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2010.04373.x]]&gt;</url>
    <title>Systematic review: steroid withdrawal in anti-TNF-treated patients with inflammatory bowel disease</title>
    <publicationDate>2010-08-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE,RECENT ADDITIONS,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Although a consensus on the definition of steroid-sparing is lacking, approximately two-thirds of the inflammatory bowel disease-patients are unable to withdraw corticosteroid treatment during anti-TNF therapy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; The increasing awareness of increased risk for opportunistic infections when combining several immunosuppressant drugs led to new treatment goals for inflammatory bowel disease including limited use of steroids. The aim of this study was&amp;nbsp;to conduct a systematic review to establish figures for steroid withdrawal in anti-TNF treated inflammatory bowel disease-patients.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Medline was searched using the search-terms Ulcerative Colitis (UC) [Mesh], Crohn Disease (CD) [Mesh], IBD [Mesh], crohn, colitis, IBD and steroid sparing, all combined with infliximab and adalimumab. We selected English-language publications that addressed the effect of anti-TNF on steroid withdrawal. Studies had to assess patients with luminal CD or UC. Numbers of patients who were able to withdraw steroids were calculated.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Six studies could be included; five reporting on infliximab and one on adalimumab. Studies were heterogeneously designed. Overall, in the adult population, up to 38% of the patients were able to withdraw corticosteroids during infliximab therapy. In the paediatric population, up to 75% of the patients were able to withdraw corticosteroids during infliximab therapy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Bultman E, Kuipers EJ, van der Woude CJ. Systematic review: steroid withdrawal in anti-TNF-treated patients with inflammatory bowel disease. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2010;32(3):313-23.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>372869</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2010.04271.x]]&gt;</url>
    <title>Systematic review: the association between obesity and hepatocellular carcinoma – epidemiological evidence</title>
    <publicationDate>2010-05-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COMMON CLINICAL PRESENTATIONS,LIVER,HEPATOCELLULAR CARCINOMA,OBESITY,RECENT ADDITIONS,PUBLIC HEALTH,DETERMINANTS,OUTCOMES,BIOLOGICAL COMPOSITION,OBESITY,INDIVIDUAL BEHAVIOUR,EATING HABITS,PHYSICAL ACTIVITY,CANCER,LIVER CANCER,MONTHLY ADDITIONS,CANCER,APRIL 2010,NOVEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; &lt;SPAN class=h5-inline&gt;&lt;/SPAN&gt;Although most studies did not adjust for confounders and most data relate to a single world region, the overall evidence is suggestive of an increased hepatocellular carcinoma risk in obese and overweight individuals.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims: &lt;/STRONG&gt;Evidence increasingly implicates obesity as an independent risk factor for different cancers. The aim of the study was to review the effect of increased levels of body mass index on hepatocellular carcinoma risk.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; &lt;SPAN class=h5-inline&gt;&lt;/SPAN&gt;We reviewed systematically the literature examining the association between increased body mass index and hepatocellular carcinoma risk. For each identified study, relevant data were extracted and appraised.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Ten cohort studies (&amp;gt;90 million person-years), one nested case-control study (244 cases) and two case-control studies (494 cases) were identified. Of the cohort studies, 75% of person-years related to North Americans, 15% to East Asians, and 10% to Europeans. Three cohort studies adjusted for alcohol consumption, only one cohort study adjusted for hepatitis infection status. Seven cohort studies found a positive association between obesity (body mass index =30&amp;nbsp;kg/m&lt;SUP&gt;&lt;NOBR&gt;2&lt;/NOBR&gt;&lt;/SUP&gt;) and hepatocellular carcinoma risk (relative risks ranging from 1.4 to 4.1); two reported no association; and one reported a significant inverse association for a population subgroup (relative risk&amp;nbsp;=&amp;nbsp;0.7, 95% confidence interval: 0.5–0.9).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Saunders D, Seidel D, Allison M, Lyratzopoulos G. Systematic review: the association between obesity and hepatocellular carcinoma – epidemiological evidence. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2010;31(10):1051-63.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>385094</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2010.04234.x]]&gt;</url>
    <title>Systematic review: the costs of ulcerative colitis in Western countries</title>
    <publicationDate>2010-04-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,RECENT ADDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; &lt;SPAN&gt;Ulcerative colitis is a costly disease. Hospitalizations contribute significantly to direct medical costs, and indirect costs are considerable, having previously been substantially underestimated.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; &lt;SPAN&gt;Early onset and complications such as hospitalization and surgery contribute to the economic burden of ulcerative colitis.&amp;nbsp; The aim of this study was to &lt;SPAN&gt;review systematically the literature on costs of ulcerative colitis in Western countries.&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; &lt;SPAN&gt;Studies estimating costs of ulcerative colitis in Western countries were identified using Medline, EMBASE and ISI Web of Science and were rated based on relevance and reliability of estimates. All costs were adjusted to 2008 currency values. A parallel review focused on the impact of disease severity on costs, hospitalizations and surgeries.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;SPAN&gt;Estimated annual per-patient direct medical costs of ulcerative colitis ranged from $6217 to $11,477 in the United States and from euro8949 to euro10,395 in Europe. Hospitalizations accounted for 41-55% of direct medical costs. Indirect costs accounted for approximately one-third of total costs in the United States and 54-68% in Europe. Total economic burden of ulcerative colitis was estimated at $8.1-14.9 billion annually in the United States and at euro12.5-29.1 billion in Europe; total direct costs were $3.4-8.6 billion in the United States and euro5.4-12.6 billion in Europe. Direct costs, hospitalizations and surgeries increased with worsening disease severity.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Cohen RD, Yu AP, Wu EQ, Xie J, Mulani PM, Chao J. Systematic review: the costs of ulcerative colitis in Western countries. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2010;31(7):693-707.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293623</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=2729097&amp;blobtype=pdf]]&gt;</url>
    <title>Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy</title>
    <publicationDate>2008-04-01T00:00:00</publicationDate>
    <publisher>American College of Physicians</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Loomba, R Annals of Internal Medicine 2008 Apr 1;148(7):519-28&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract: &lt;/STRONG&gt;BACKGROUND: Lamivudine is increasingly being used to prevent hepatitis B reactivation in patients with cancer who test positive for hepatitis B surface antigen (HBsAg) and are undergoing chemotherapy. PURPOSE: To determine whether preventive lamivudine reduces chemotherapy-induced hepatitis B virus (HBV)-related morbidity and mortality in patients with cancer who test positive for HBsAg. DATA SOURCES: MEDLINE, Ovid MEDLINE, TOXNET, Scopus, Web of Science, and Cochrane Central Register of Controlled Trials were searched in all languages until June 2007. STUDY SELECTION: Clinical trials and cohort studies that reported the efficacy of preventive lamivudine versus control on HBV reactivation in patients who tested positive for HBsAg and were receiving chemotherapy were included. Additional requirements included minimum sample size (&amp;gt;5 participants per treatment group) and reported HBV-related morbidity and mortality data. DATA EXTRACTION: Two investigators independently did literature searches and data extraction, and 2 other investigators independently confirmed study eligibility and data retrieval. DATA SYNTHESIS: Fourteen studies (2 randomized, controlled trials; 8 prospective cohort studies; and 4 retrospective cohort studies) met the predefined criteria for analysis. There were 275 patients in the preventive lamivudine group and 475 control participants for the primary end point of HBV reactivation. With preventive lamivudine, the relative risk for both HBV reactivation and HBV-related hepatitis ranged from 0.00 to 0.21. None of the patients in the preventive lamivudine group developed HBV-related hepatic failure (0 of 108 patients vs. 21 of 162 patients), and only 4 deaths were attributable to HBV (4 of 208 patients vs. 27 of 394 patients) in the preventive lamivudine group. Lamivudine was well tolerated, and no adverse effects were noted. LIMITATIONS: The studies included in the meta-analysis did not consistently report all of the outcomes of interest. Sample sizes were small and only 2 studies had a randomized, controlled design. CONCLUSION: Preventive therapy with lamivudine for patients who test positive for HBsAg and are undergoing chemotherapy may reduce the risk for HBV reactivation and HBV-associated morbidity and mortality.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;See also:&lt;/STRONG&gt; &lt;A href="nelh:297392:0" name=internalLink&gt;DARE record&lt;/A&gt; for this article&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>385106</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2010.04232.x]]&gt;</url>
    <title>Systematic review: the effects of carbonated beverages on gastro-oesophageal reflux disease</title>
    <publicationDate>2010-03-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,OESOPHAGUS,GASTRO-OESOPHAGEAL REFLUX,RECENT ADDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; &lt;SPAN&gt;Based on the currently available literature, it appears that there is no direct evidence that carbonated beverages promote or exacerbate &lt;SPAN&gt;gastro-oesophageal reflux disease&lt;/SPAN&gt; (GERD).&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; &lt;SPAN&gt;Carbonated beverages have unique properties that may potentially exacerbate GERD, such as high acidity and carbonation. Cessation of carbonated beverage consumption is commonly recommended as part of lifestyle modifications for patients with GERD. &lt;SPAN class=sub_abstract_label&gt;&lt;/SPAN&gt;&lt;SPAN&gt;To evaluate the relationship of carbonated beverages with oesophageal pH, oesophageal motility, oesophageal damage, GERD symptoms and GERD complications.&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt;&amp;nbsp;&lt;SPAN&gt;A systematic review.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;SPAN&gt;Carbonated beverage consumption results in a very short decline in intra-oesophageal pH. In addition, carbonated beverages may lead to a transient reduction in lower oesophageal sphincter basal pressure. There is no evidence that carbonated beverages directly cause oesophageal damage. Carbonated beverages have not been consistently shown to cause GERD-related symptoms. Furthermore, there is no evidence that these popular drinks lead to GERD complications or oesophageal cancer.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Johnson T, Gerson L, Hershcovici T, Stave C, Fass R. Systematic review: the effects of carbonated beverages on gastro-oesophageal reflux disease. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2010;31(6):607-14.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>385133</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2009.04146.x]]&gt;</url>
    <title>Systematic review: the effects of conservative and surgical treatment for obesity on gastro-oesophageal reflux disease</title>
    <publicationDate>2009-12-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,OESOPHAGUS,GASTRO-OESOPHAGEAL REFLUX,RECENT ADDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt;&lt;SPAN class=sub_abstract_label&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;SPAN&gt;Dietary and lifestyle intervention may improve&amp;nbsp;&lt;SPAN&gt;gastro-oesophageal reflux disease (&lt;/SPAN&gt;GERD) in obese patients; however, the most favourable effect is likely to be found after bariatric surgery, especially after Roux-en-Y gastric bypass. Future studies need to elucidate for which GERD patients laparoscopic adjustable gastric banding might have a beneficial effect and how they can be identified preoperatively.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; &lt;SPAN&gt;Incidence rates of both obesity and gastro-oesophageal reflux disease (GERD) are increasing, particularly in the Western world. It has been suggested that GERD symptoms may be improved by weight reduction. The aim of this study was to &lt;SPAN&gt;review the literature on the effect of various weight reducing modalities on manifestations of GERD in obese patients.&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; &lt;SPAN&gt;A literature search was performed using PubMed, EMBASE and the Cochrane Library, combining the words obesity and gastro-oesophageal reflux with bariatric surgery, diet, lifestyle intervention and weight loss.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;SPAN&gt;With regard to diet/lifestyle intervention (conservative), four of seven studies reported an improvement of GERD. For Roux-en-Y gastric bypass, a positive effect on GERD was found in all studies, although this was mainly evaluated by questionnaires. In contrast, for vertical banded gastroplasty, no change or even an increase of GERD was noted, whereas the results for laparoscopic adjustable gastric banding were conflicting.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; De Groot NL, Burgerhart JS, Van De Meeberg PC, de Vries DR, Smout AJ, Siersema PD. Systematic review: the effects of conservative and surgical treatment for obesity on gastro-oesophageal reflux disease. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2009;30(11-12):1091-102.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>388003</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2010.04411.x]]&gt;</url>
    <title>Systematic review: the epidemiology of eosinophilic oesophagitis in adults</title>
    <publicationDate>2010-09-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,OESOPHAGUS,OESOPHAGITIS,RECENT ADDITIONS,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; &lt;SPAN&gt;The prevalence of &lt;SPAN&gt;eosinophilic oesophagitis&lt;/SPAN&gt; (EoE) in adults varies considerably based on the study sampling frame: high in dysphagia patients, quite low in population-based studies and intermediate among unselected endoscopy patients.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt;&lt;SPAN class=sub_abstract_label&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;SPAN&gt;The epidemiology of EoE in adults remains unclear. The aim of this study was to &lt;SPAN&gt;estimate the prevalence and incidence of EoE through a systematic review of published literature.&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; &lt;SPAN&gt;We conducted systematic literature searches in PubMed in September 2009. Studies were excluded if they contained any participants below 18 years of age, published in languages other than English, or had no exact reporting of prevalence or incidence rates.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;SPAN&gt;Nine studies fulfilled the criteria; one evaluated a population-based sample, one examined patients referred from a defined geographical region and seven studies examined the prevalence in a total of 6018 patients in clinic or hospital settings. The lowest prevalence was reported in population-based studies (4 and 0.23 per 1000), followed by studies of unselected patients (1.0%, 6.5%) and highest in the other five clinic/hospital based studies (2.2-48.2%). Men were more affected in seven of eight studies (64.5-100%). The sample size weighted average prevalence from the population-based studies was 0.03%. For studies evaluating symptomatic patients, it was 2.8%.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Sealock RJ, Rendon G, El-Serag HB. Systematic review: the epidemiology of eosinophilic oesophagitis in adults. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2010;32(6):712-9.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>320160</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2008.03901.x]]&gt;</url>
    <title>Systematic review: the epidemiology of gastro-oesophageal reflux disease in primary care, using the UK General Practice Research Database</title>
    <publicationDate>2009-03-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,OESOPHAGUS,GASTRO-OESOPHAGEAL REFLUX,RECENT ADDITIONS,JULY 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The General Practice Research Database is an effective way of studying the epidemiology of gastro-oesophageal reflux disease (GERD) in a large population-based primary care setting.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Systematic literature searches using PubMed and EMBASE.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;SPAN class=h5-inline&gt;&lt;/SPAN&gt;Seventeen articles fulfilled the inclusion criteria. The incidence of GERD in primary care was 4.5 new diagnoses per 1000&amp;nbsp;person-years in 1996 (95% CI: 4.4–4.7). A new diagnosis of GERD was associated with being overweight, obese or an ex-smoker. Prior diagnoses of ischaemic heart disease, peptic ulcer disease, nonspecific chest pain, nonspecific abdominal pain, chronic obstructive pulmonary disease and asthma were associated with a subsequent new GERD diagnosis. A first diagnosis of GERD was associated with an increased risk of a subsequent diagnosis of oesophageal adenocarcinoma, oesophageal stricture, chronic cough, sinusitis, chest pain, angina, gallbladder disease, irritable bowel syndrome or sleep problems. Mortality may be higher in patients with a GERD diagnosis than in those without in the first year after diagnosis, but not long term.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; El-Serag H, Hill C, Jones R. Systematic review: the epidemiology of gastro-oesophageal reflux disease in primary care, using the UK General Practice Research Database. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2009;29(5):470-80.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>312624</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2009.03960.x]]&gt;</url>
    <title>Systematic review: the global incidence and prevalence of peptic ulcer disease</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,STOMACH,ULCERS,DUODENAL ULCERS,GASTRIC ULCERS,SMALL INTESTINE,HELICOBACTER PYLORI,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Peptic ulcer disease remains a common condition, although reported incidence and prevalence are decreasing. This decrease may be due to a decrease in &lt;SPAN class=i&gt;&lt;EM&gt;H. pylori&lt;/EM&gt;&lt;/SPAN&gt;-associated PUD.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; &lt;SPAN class=h5-inline&gt;&lt;/SPAN&gt;Systematic searches of PubMed, EMBASE and the Cochrane library.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;SPAN class=h5-inline&gt;&lt;/SPAN&gt;The annual incidence rates of PUD were 0.10–0.19% for physician-diagnosed PUD and 0.03–0.17% when based on hospitalization data. The 1-year prevalence based on physician diagnosis was 0.12–1.50% and that based on hospitalization data was 0.10–0.19%. The majority of studies reported a decrease in the incidence or prevalence of PUD over time.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Sung JJY, Kuipers EJ, El-Serag HB. Systematic review: the global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther 2009 May;29(9):938-46.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>251159</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2006.02884.x]]&gt;</url>
    <title>Systematic review: the management of pouchitis</title>
    <publicationDate>2006-04-15T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Pouchitis is the most common complication following proctocolectomy and ileal pouch-anal anastomosis in patients with ulcerative colitis. We aim at discussing relevant information on epidemiology, clinical features, risk factors, diagnostic testing, differential diagnosis and treatment of this idiopathic inflammatory condition.</description>
    <body>&lt;![CDATA[ &lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Pardi DS and Sandborn WJ 2006; Alimentary Pharmacology and Therapeutics 23 (8) pp. 1087-1096 
&lt;H2&gt;Original article abstract&lt;/H2&gt;
&lt;P&gt;Pouchitis is the most common complication following proctocolectomy and ileal pouch-anal anastomosis in patients with ulcerative colitis. We aim at discussing relevant information on epidemiology, clinical features, risk factors, diagnostic testing, differential diagnosis and treatment of this idiopathic inflammatory condition. A computerized search of PubMed was performed with the search term 'pouchitis', limited to English papers on humans. This strategy identified 514 references. Relevant articles were selected from this list. In addition, the reference list for each of the selected articles was reviewed to identify any additional references. Pouchitis occurs in up to 60% of patients after ileal pouch-anal anastomosis for ulcerative colitis, and has characteristic clinical, endoscopic and histological features. The most important test for diagnosis is pouch endoscopy with biopsy. Antibiotics remain the mainstay of treatment, and other options are discussed for those patients who are refractory to antibiotic therapy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;This article is &lt;STRONG&gt;not&lt;/STRONG&gt; available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281271</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17539978]]&gt;</url>
    <title>Systematic review: the potential influence of mesalazine formulation on maintenance of remission in Crohn's disease</title>
    <publicationDate>2008-03-10T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic information:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;Steinhart, A.H.&amp;nbsp;&lt;SPAN title="Alimentary pharmacology &amp;amp; therapeutics."&gt;&lt;A href="#javascript:AL_get(this," ?Aliment Pharmacol Ther.?);? ?jour?,&gt;Aliment Pharmacol Ther.&lt;/A&gt;&lt;/SPAN&gt; 2007 Jun 15;25(12):1389-99.&lt;/P&gt;
&lt;P&gt;AIM: To evaluate the effectiveness of pH 6-/pH 7-dependent and controlled-release mesalazines in maintaining medically and surgically induced Crohn's disease remission. METHODS: A systematic search identified 13 randomized controlled trials (RCTs). The rate of symptomatic relapse (Crohn's disease activity index &amp;gt;150, or an increase in baseline by at least 60-100 points) was extracted from each randomized controlled trial. Pooled odds ratios (OR), the number needed to treat (NNT), and percentage therapeutic benefit (absolute risk reduction) were calculated. RESULTS: Treatment with pH 7-dependent mesalazine significantly reduced the risk of relapse in patients with either surgically [OR 0.28; 95% confidence interval (CI) 0.12-0.65; P = 0.0032] or medically induced remission (OR 0.38; 95% CI 0.17-0.85; P = 0.0113). However, treatment with controlled-release mesalazine and pH 6-dependent mesalazine failed to show any significant advantage over placebo. The NNT to maintain surgically or medically induced remission was lowest for pH 7-dependent mesalazine (NNT = 4 and 5, respectively; NNT = 15 and 16 for controlled-release mesalazine and NNT = 11 and 23 for pH 6-dependent mesalazine). Therapeutic benefit was highest for pH 7-dependent mesalazine (surgical = 30.6%, medical = 22.8%). This compared with 6.9% (surgical) and 6.4% (medical) for controlled-release mesalazine, and 9.8% and 4.4%, respectively, for pH 6-dependent mesalazine. CONCLUSION: Further trials of pH 7-dependent mesalazine formulations are warranted in the maintenance of remission in Crohn's disease.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Alimentary Pharmacology and Therapeutics is an international journal concerned with the effects of drugs on the human gastrointestinal and hepato-biliary systems. The journal publishes original research on all aspects of pharmacology, pharmacokinetics and therapeutic use of drugs in the alimentary tract.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is &lt;STRONG&gt;not&lt;/STRONG&gt; available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>326239</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2009.04081.x]]&gt;</url>
    <title>Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome</title>
    <publicationDate>2009-10-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COMMON CLINICAL PRESENTATIONS,COLON &amp; RECTUM,IRRITABLE BOWEL SYNDROME,DIARRHOEA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Idiopathic adult-onset bile acid malabsorption is not rare and is an important cause of diarrhoea-predominant IBS type symptoms.&amp;nbsp;Improved access to diagnostic tools and increased awareness amongst clinicians will result in the condition being more readily diagnosed and treated.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A systematic search was performed of publications reporting patients presenting with IBS-D type symptoms, who were subsequently confirmed as having I-BAM by SeHCAT scanning.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Eighteen relevant studies, 15 prospective, comprising 1223 patients were identified. Five studies (429 patients) indicated that 10% (CI: 7–13) patients had severe bile acid malabsorption (SeHCAT 7&amp;nbsp;day retention &amp;lt;5% of baseline value). 17 studies (1073 patients) indicated that 32% (CI: 29–35) patients had moderate bile acid malabsorption (SeHCAT &amp;lt;10%). 7 studies (618 patients) indicated that 26% (CI: 23–30) patients had mild (SeHCAT &amp;lt;15%) bile acid malabsorption. Pooled data from 15 studies showed a dose-response relationship according to severity of malabsorption to treatment with a bile acid binder: response to colestyramine occurred in 96% of patients with &amp;lt;5% retention, 80% at &amp;lt;10% retention and 70% at &amp;lt;15% retention.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Wedlake L, A'Hern R, Russell D, Thomas K, Walters JR, Andreyev HJ. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2009;30(7):707-17.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345481</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.jpeds.2009.03.017]]&gt;</url>
    <title>Systematic review: the role of breastfeeding in the development of pediatric inflammatory bowel disease</title>
    <publicationDate>2009-09-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The current evidence demonstrates a possible protective effect for breast milk in the development of early onset inflammatory bowel disease (IBD). However, the quality of existing data is generally poor. These findings need to be investigated in well-designed prospective studies&lt;STRONG&gt;.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; To assess the current evidence for the role of breastfeeding in the development of early onset IBD with a systematic review. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; An electronic database search was performed (January 1966-January 2008) with keywords related to IBD and breastfeeding, looking specifically for studies that reported outcome in early-onset disease (&amp;lt;16 years of age) and "any exposure" to breast milk as the variables. Meta-analysis of studies included for review was then performed by using a random effects model, and results were expressed as odds ratios (OR) with 95% CIs. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; A total of 79 articles were identified, 20 of which were found describing breastfeeding in relation to the development of IBD; 8 of these articles included separate early-onset groups. One study did not describe "any exposure" to breast milk for the early onset group, so 7 studies were included in the meta-analysis. Breast milk exposure had a significant protective effect (OR, 0.69; 95% CI, 0.51-0.94; P = .02) in developing early-onset IBD. A non-significant difference was demonstrated for ulcerative colitis and Crohn's disease individually (OR, 0.72; 95% CI, 0.51-1.02; P = .06; OR, 0.64; 95% CI, 0.38-1.07; P = .09, respectively).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Barclay AR, Russell RK, Wilson ML, Gilmour WH, Satsangi J, Wilson DC. Systematic review: the role of breastfeeding in the development of pediatric inflammatory bowel disease. &lt;EM&gt;J Pediatr&lt;/EM&gt; 2009;155(3):421-6. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>380620</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2010.04301.x]]&gt;</url>
    <title>Systematic review: the role of self-expanding plastic stents for benign oesophageal strictures</title>
    <publicationDate>2010-06-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,OESOPHAGUS,STRICTURES,DYSPHAGIA,RECENT ADDITIONS,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Our pooled-data analysis showed a favourable risk/benefit ratio when self-expanding plastic stents&amp;nbsp;(SEPS) are applied in patients with recurrent or refractory benign oesophageal strictures. This supports the use of SEPS before referring patients to surgery, and they are a valuable alternative to repeat endoscopic dilation.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Treatment of refractory or recurrent benign oesophageal strictures is demanding and surgery may be the only available option. The role of SEPS in the treatment of these strictures is still controversial because of the conflicting results of various studies.&amp;nbsp;The aim of this study was&amp;nbsp;to analyse with regard to SEPS: technical and clinical success, factors associated with outcome, and safety.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt;&amp;nbsp;Pooled-data analysis of a systematic review of the literature. Clinical success was defined as no need for further endoscopic or surgical treatment after SEPS removal. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt;&amp;nbsp;Data of 10 studies with 130 treated patients were included. SEPS insertion was technically successful in 128 of 130 patients (98%, 95% CI = 96-100%). Clinical success was achieved in 68 patients (52%, 95% CI = 44-61%) and this was found to be lower in those with a cervical localization of the stricture (33% vs. 54%; P &amp;lt; 0.05). Early (&amp;lt;4 weeks) migration of the stent was reported in 19 (24%, 95% CI = 14-32%) cases, while post-insertion endoscopic re-intervention was required in 25 (21%, 95% CI = 14-28%). Major clinical complications occurred in 12 patients (9%, 95% CI = 4-14%), resulting in death of one (0.8%) patient.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Repici A, Hassan C, Sharma P, Conio M, Siersema P. Systematic review: the role of self-expanding plastic stents for benign oesophageal strictures. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2010;31(12):1268-75. Epub 2010 Mar 17.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345595</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2009.04101.x]]&gt;</url>
    <title>Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab</title>
    <publicationDate>2009-11-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Current randomized-controlled trial (RCT) and open-label cohort (OLC) evidence suggest that adalimumab is an efficacious therapy for Crohn's&amp;nbsp;disease (CD)&amp;nbsp;patients who discontinue infliximab.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Therapy with adalimumab has been shown to be effective in CD patients who have lost response or are intolerant to infliximab. The aim of this paper was to determine the efficacy of adalimumab in CD patients who discontinued infliximab through a systematic review.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Electronic searches of EMBASE and MEDLINE databases up to May 1, 2009, as well as abstracts from the AGA (2006-2008), ACG (2006-2007), UEGW (2006-2008) and CDDW (2006-2009) identified RCTs or OLCs evaluating the short-term and/or long-term efficacy of adalimumab in infliximab failures. The response rates for short-term (clinical response and remission at 4 weeks) and long-term (remission at 6 and 12 months) efficacy were considered.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; A total of 1810 CD patients were identified among the 15 studies (2 RCT and 13 OLC). The majority of studies evaluated CD patients who either lost response or were intolerable to infliximab, although five OLCs permitted patients refractory to infliximab. Short-term clinical response (n = 9 articles) ranged from 41% to 83%. Long-term clinical remission at 12 months (n = 8 articles) ranged from 19% to 68%. The occurrence of severe adverse events ranged from 0% to 19% and four patients died.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Ma C, Panaccione R, Heitman SJ, Devlin SM, Ghosh S, Kaplan GG. Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2009;30(10):977-86.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>251139</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2006.02846.x]]&gt;</url>
    <title>Systematic review: the use of mesalazine in inflammatory bowel disease</title>
    <publicationDate>2006-04-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Mesalazine is among the medications most commonly prescribed by gastroenterologists, having to a large extent superseded sulfasalazine (sulphasalazine). However, there are still a number of aspects regarding its use which provoke debate and controversy.</description>
    <body>&lt;![CDATA[ &lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Bergman R and Parkes M 2006; Alimentary Pharmacology and Therapeutics 23 (7) pp. 841-855&amp;nbsp; 
&lt;H2&gt;Original article abstract&lt;/H2&gt;
&lt;P&gt;Background: Mesalazine is among the medications most commonly prescribed by gastroenterologists, having to a large extent superseded sulfasalazine (sulphasalazine). However, there are still a number of aspects regarding its use which provoke debate and controversy. Aims: To provide a systematic assessment of the evidence for the use of mesalazine in ulcerative colitis and Crohn's disease. Methods: References were identified using PubMed database. Additional references were identified with related article searches. RESULTS: Mesalazine has a clear role in the maintenance of remission in ulcerative colitis and management of mild to moderately active disease, although the efficacy of topical preparations or combined topical and oral is clearly superior to oral alone. Evidence that increasing the dose of oral mesalazine improves efficacy is not clear-cut. The benefits of mesalazine in the management of acute Crohn's disease and the maintenance of remission are questionable and alternative treatments are usually more appropriate. Emerging evidence suggests that maintenance mesalazine reduces the risk of neoplastic progression in chronic ulcerative colitis. Compliance with therapy is thus important, as is an understanding of individuals most likely to default on this. CONCLUSION: Evidence for a beneficial effect of mesalazine is largely confined to the management of ulcerative colitis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;This article is &lt;STRONG&gt;not&lt;/STRONG&gt; available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>384679</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2010.04359.x]]&gt;</url>
    <title>Systematic review: the use of nitrous oxide gas for lower gastrointestinal endoscopy</title>
    <publicationDate>2010-08-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,DIAGNOSTIC PROCEDURES,GASTROINTESTINAL ENDOSCOPY,COLONOSCOPY,RECENT ADDITIONS,FLEXIBLE SIGMOIDOSCOPY,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; &lt;SPAN&gt;For patients undergoing colonoscopy, n&lt;SPAN&gt;itrous oxide gas (&lt;/SPAN&gt;N(2)O) provides comparable analgesia to i.v. sedation. The rapid psychomotor recovery with N(2)O enables quicker patient discharge and removes the need for a patient to be chaperoned. Benefit was not seen from N(2)O in patients undergoing flexible sigmoidoscopy possibly because it was delivered on demand rather than continuously.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; &lt;SPAN&gt;N(2)O has been proposed as an alternative to intravenous (i.v.) analgesia in patients undergoing lower gastrointestinal endoscopy. The aim of this study was&amp;nbsp;t&lt;SPAN&gt;o perform a systematic review of randomized studies where N(2)O was compared against control in patients undergoing either flexible sigmoidoscopy or colonoscopy.&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt;&amp;nbsp;&lt;SPAN&gt;Electronic databases were searched; reference lists were checked and letters were sent to authors requesting data. Methodological quality was assessed. Data were tabulated on the duration and difficulty of the procedure, quality of sedation and speed of patient recovery.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;SPAN class=sub_abstract_label&gt;&lt;/SPAN&gt;&lt;SPAN&gt;A total of 11 studies were identified containing 623 patients. No differences were seen between groups for duration, difficulty of procedure or complications. Patient-reported pain was similar for N(2)O when undergoing flexible sigmoidoscopy vs. no sedation and when undergoing colonoscopy vs. i.v. sedation. Differences in delivery of N(2)O were identified. In all studies, N(2)O was associated with a more rapid recovery than i.v. sedation.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Welchman S, Cochrane S, Minto G, Lewis S. Systematic review: the use of nitrous oxide gas for lower gastrointestinal endoscopy. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2010;32(3):324-33.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323640</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1007/s12325-009-0004-y]]&gt;</url>
    <title>Telbivudine in the treatment of chronic hepatitis B</title>
    <publicationDate>2009-02-01T00:00:00</publicationDate>
    <publisher>Springer</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,RECENT ADDITIONS,AUGUST 2009,CHRONIC HEPATITIS B]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Telbivudine is a new antiviral agent joining the armamentarium against HBV. It is superior to lamivudine in terms of therapeutic response and resistance profile. However, concerns about resistance with long-term use, along with inferior cost-effective analyses, have relegated telbivudine to a second-line agent in the management of chronic HBV infection.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Relevant publications were identified from searches of Medline and PubMed between 2000 and 2008, using the search terms “hepatitis B/HBV,” “telbivudine/LdT,” “ß-L-thymidine,” “pharmacokinetics,” “safety,” “adverse events,” and “resistance.” The reference lists of retrieved articles were searched for relevant studies.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Phase 3 clinical studies demonstrate that telbivudine is superior to lamivudine over a 2-year period in hepatitis B e-antigen (HBeAg)-positive and HBeAg-negative patients. Telbivudine was associated with a statistically signficantly greater reduction in HBV DNA, greater proportion of alanine aminotransferase normalization, and greater histological response than lamivudine. Furthermore, telbivudine use resulted in fewer cases of treatment failure and less virological resistance than lamivudine. However, after 2 years of therapy, telbivudine resistance was appreciable (25%) and considerably higher than that seen with other new antivirals such as tenofovir and entecavir. Overall, telbivudine was found to be safe, although grade 3 or 4 adverse events, including elevations in creatine kinase, were more commonly found in patients receiving telbivudine than lamivudine. Telbivudine is not active against lamivudine-resistant HBV.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Nash K. Telbivudine in the treatment of chronic hepatitis B. &lt;EM&gt;Adv Ther&lt;/EM&gt; 2009 Feb;26(2):155-69.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>268519</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1345/aph.1G027]]&gt;</url>
    <title>Telbivudine: a novel nucleoside analog for chronic hepatitis B</title>
    <publicationDate>2006-03-01T00:00:00</publicationDate>
    <publisher>Harvey Whitney Books Co.</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,CHRONIC HEPATITIS B]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=abstract&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Kim J.W., Park S.H., Louie S.G 2006; The Annals of Pharmacotherapy 40(3) pp. 472-8&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;Abstract: &lt;/STRONG&gt;OBJECTIVE: To review available literature on the pharmacology, pharmacokinetics, dosing and administration, efficacy, and safety of the antiviral nucleoside analog telbivudine. DATA SOURCES: Information was obtained from searching MEDLINE (1966-December 2005), International Pharmaceutical Abstracts (1970-December 2005), and the Cochrane Database of Systematic Reviews (4th quarter 2005) using the search words telbivudine, L-dT, L-deoxythymidine, L-nucleosides, and nucleosides. Abstracts from the Annual Meeting of the American Association for the Study of Liver Diseases and European Association for the Study of the Liver were also searched, including bibliographies from the identified articles. STUDY SELECTION AND DATA EXTRACTION: Data from double-blind, placebo-controlled clinical trials and unpublished information were extracted. DATA SYNTHESIS: Telbivudine is a novel, orally administered nucleoside analog under development for use in the treatment of chronic hepatitis B. In contrast to other nucleoside analogs, telbivudine has not been associated with inhibition of mammalian DNA polymerase with mitochondrial toxicity. Telbivudine demonstrated potent activity against hepatitis B with significantly higher rate of response and superior viral suppression compared with lamivudine, the standard treatment. Telbivudine has been generally well tolerated, with low adverse effect profile, and at its effective dose, no dose-limiting toxicity has been observed. CONCLUSIONS: Telbivudine is a novel oral nucleoside analog effective in the treatment of chronic hepatitis B infection.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>389213</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.gastrojournal.org/article/PIIS0016508510009017/abstract]]&gt;</url>
    <title>Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and bayesian meta-analyses</title>
    <publicationDate>2010-06-21T00:00:00</publicationDate>
    <publisher>Gastroenterology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,RECENT ADDITIONS,CHRONIC HEPATITIS B,OCTOBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Woo G, Tomlinson G, Nishikawa Y, Kowgier M, Sherman M, Wong DKH, Pham B, Ungar WJ, Einarson TR, Heathcote EJ, Krahn M. (2010) Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and bayesian meta-analyses. &lt;STRONG&gt;Gastroenterology&lt;/STRONG&gt; 139(4): 1218-1229 e5&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background &amp;amp; Aims:&lt;/STRONG&gt; The relative efficacies of licensed antiviral therapies for treatment-naive chronic hepatitis B (CHB) infection in randomized controlled trials have not been determined. We evaluated the relative efficacies of the first 12 months of CHB treatments.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Drugs evaluated were lamivudine, pegylated interferon, adefovir, entecavir, telbivudine, and tenofovir, as monotherapies and combination therapies, in treatment-naive individuals. Databases were searched for randomized controlled trials of the first 12 months of therapy in hepatitis B e antigen (HBeAg)-positive and/or HBeAg-negative patients with CHB published in English before October 31, 2009. Bayesian mixed treatment comparisons were used to calculate the odds ratios, including 95% credible intervals and predicted probabilities of surrogate outcomes to determine the relative effects of each treatment.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; In HBeAg-positive patients, tenofovir was most effective in inducing undetectable levels of HBV DNA (predicted probability, 88%), normalization of alanine aminotransferase (ALT) levels (66%), HBeAg seroconversion (20%), and hepatitis B surface antigen loss (5%); it ranked third in histologic improvement of the liver (53%). Entecavir was most effective in improving liver histology (56%), second for inducing undetectable levels of HBV DNA (61%) and normalization of ALT levels (70%), and third in loss of hepatitis B surface antigen (1%). In HBeAg-negative patients, tenofovir was the most effective in inducing undetectable levels of HBV DNA (94%) and improving liver histology (65%); it ranked second for normalization of ALT levels (73%).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; In the first year of treatment for CHB, tenofovir and entecavir are the most potent oral antiviral agents for HBeAg-positive patients; tenofovir is most effective for HBeAg-negative patients.&lt;/P&gt;
&lt;P&gt;Gastroenterology is the official journal of the American Gastroenterological Association Institute. It publishes reports on the latest treatments for diseases, and has an exculusive correspondence section.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>396510</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20074149]]&gt;</url>
    <title>Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials</title>
    <publicationDate>2010-01-14T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>RANDOMISED CONTROLLED TRIAL</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATO-RENAL SYNDROME,ALCOHOLIC LIVER DISEASE,RECENT ADDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Terlipressin is effective in reversing HRS type 1. Recurrence of HRS is rare with at least 14 days of therapy. Serious side-effects requiring discontinuation of therapy are less common. There appears to be a survival benefit in patients with HRS treated with terlipressin.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Hepatorenal syndrome (HRS) is a serious complication of advanced liver disease and carries a poor prognosis. Recent trials have indicated that terlipressin may be effective in reversing HRS. Our aim was to evaluate the efficacy of terlipressin therapy in reversing type 1 HRS defined as a serum creatinine &amp;lt;1.5 mg/dL during treatment.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Randomized controlled trials in which patients with type 1 HRS received at least 3 days of terlipressin therapy and albumin in the intervention arm were included after a systematic search of the published English reports. Studies with other vasoconstrictor therapies in the control group were excluded.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; A total of 223 patients with HRS type 1 in four different trials, were included in the final analysis. Alcohol-related cirrhosis was the most common underlying etiology. The risk ratio for reversal in type 1 HRS with terlipressin therapy was 3.66 (95% confidence interval 2.15-6.23). Recurrence of HRS was low (8%). Serious side-effects requiring discontinuation of therapy were seen only in 6.8% of patients on terlipressin therapy. There was a trend towards improved transplant-free survival at 90 days in the terlipressin group (relative risk 1.86 95% confidence interval 1.0-3.4, P = 0.05).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Sagi SV, Mittal S, Kasturi KS, Sood GK. Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol. 2010 May;25(5):880-5. Epub 2010 Jan 14.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers; ask your local healthcare library if they have a local subscription. However, abstracts and tables of contents are free for all to view.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>388023</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.cghjournal.org/article/S1542-3565(10)00440-4/abstract]]&gt;</url>
    <title>The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's Disease: one size does not fit all</title>
    <publicationDate>2010-05-07T00:00:00</publicationDate>
    <publisher>Clinical Gastroenterology and Hepatology</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE,RECENT ADDITIONS,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The mission of &lt;EM&gt;Clinical Gastroenterology and Hepatology (CGH)&lt;/EM&gt; is to provide readers with a broad spectrum of themes in clinical gastroenterology and hepatology, including the diagnostic , endoscopic, interventional, and therapeutic advances in cancer, inflammatory diseases, functional gastrointestinal disorders, nutrition, absorption, and secretion. &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Melmed GY; Speigel BM; Bressler B; Cheifetz AS, Devlin SM, Harrell LE, Irving PM, Jones J, Kaplan GG, Kozuch PL, Velayos FS, Baidoo L, Sparrow MP, Siegel CA. (2010) The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's Disease: one size does not fit all. &lt;EM&gt;Clinical Gastroenterology and Hepatology&lt;/EM&gt; 8(8):655-659&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background &amp;amp; Aims:&lt;/STRONG&gt; There is no consensus on the appropriateness of concomitant immunomodulators with anti–tumor necrosis factor (TNF) therapy for Crohn's disease. Some patients benefit from concomitant immunomodulators, but concerns related to infections and lymphoma risk have dampened enthusiasm for this approach. We applied the RAND/University of California Los Angeles Appropriateness Method toward establishing appropriateness of concomitant immunomodulators and anti-TNF therapies for Crohn's disease.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; A literature review was conducted regarding efficacy and safety of concomitant immunomodulators in the setting of anti-TNF therapy for Crohn's disease and presented to the Building Research in Inflammatory Bowel Disease Globally group, a globally diverse panel of 13 gastroenterologists clinically experienced in inflammatory bowel disease. A total of 134 scenarios were constructed using several clinical variables. Panelists used a modified Delphi method to rate the appropriateness of concomitant immunomodulators, and met to discuss and re-rate appropriateness. Disagreement was assessed using a validated index.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Concomitant immunomodulators were generally rated appropriate for 63 scenarios, uncertain for 60 scenarios, and inappropriate for 11 scenarios. In general, concomitant immunomodulators were appropriate for those with extensive disease, shorter duration of disease, perianal involvement, prior surgery, females, and older patients (&amp;gt;26 y). Concomitant immunomodulators were generally rated inappropriate for young males, and in some scenarios involving uncomplicated disease. Smoking and the particular anti-TNF medication did not influence ratings. Disagreement was observed in 6 of 134 scenarios.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; The appropriateness of concomitant immunomodulators with anti-TNF therapy for Crohn's disease was determined through a modified Delphi panel approach based on expert interpretation of the available literature. Clinicians should consider multiple factors when considering concomitant immunomodulators with anti-TNF treatment.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is &lt;STRONG&gt;not&lt;/STRONG&gt; available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>251144</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.semarthrit.2004.11.006]]&gt;</url>
    <title>The benefit/risk profile of TNF-blocking agents: findings of a consensus panel</title>
    <publicationDate>2005-06-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This article aimed to review the benefits and risks associated with the use of the tumor necrosis factor (TNF)-blockers in various indications (eg, rheumatoid arthritis [RA], Crohn's disease [CD], psoriasis).</description>
    <body>&lt;![CDATA[ &lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Hochberg MC, Lebwohl MG, Plevy SE&amp;nbsp;et al. 2006; Seminars in Arthritis and&amp;nbsp;Rheumatism&amp;nbsp;34 (6) pp. 819-836 
&lt;H2&gt;Original article abstract&lt;/H2&gt;
&lt;P class=abstract&gt;OBJECTIVE: To review the benefits and risks associated with the use of the tumor necrosis factor (TNF)-blockers in various indications (eg, rheumatoid arthritis [RA], Crohn's disease [CD], psoriasis). METHODS: The members of the consensus panel were selected based on their expertise. Centocor, Inc provided an educational grant to the Center for Health Care Education to facilitate the consensus panel. Peer-reviewed articles discussing clinical studies and clinical experiences with TNF-blockers form the basis of this review. Emerging data that have not been peer-reviewed are also included. RESULTS: The TNF-blockers infliximab, etanercept, and adalimumab are all approved for treatment of RA. All 3 are effective, and there are currently no published data from head-to-head clinical trials to support using 1 agent over another. Preliminary data from small, retrospective studies indicate that switching among agents to overcome inadequate efficacy or poor tolerability is beneficial in some patients. The only TNF-blocker currently approved for the induction and maintenance of remission in CD is infliximab. Preliminary data indicate that etanercept and infliximab are effective in treating psoriasis. Some risks associated with TNF-blockers have become apparent, including congestive heart failure, demyelinating diseases, and systemic lupus erythematosus, but in most cases can be identified and managed. Several of these risks (eg, lymphoma and serious infections) are associated with either the condition per se or the concomitant medication use. Simple screening procedures help manage the risk of tuberculosis infection; however, it is recommended that physicians and patients be alert to the development of any new infection so that appropriate treatment may be initiated promptly. Rare infusion reactions, particularly with infliximab, may also be effectively managed. CONCLUSION: TNF-blockers are effective and may be safely used for short- and long-term management of RA or CD. TNF-blockers also show efficacy in other emerging indications.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;This article is &lt;STRONG&gt;not&lt;/STRONG&gt; available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>236044</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.pcsg.org.uk/downloads/pcsg-publications/PCSGReport-CareofGIDisordersOutsideHospital.pdf]]&gt;</url>
    <title>The care of gastrointestinal disorders outside hospital</title>
    <publicationDate>2006-03-01T00:00:00</publicationDate>
    <publisher>Primary Care Society for Gastroenterology</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COMMON CLINICAL PRESENTATIONS,ANAEMIA,OESOPHAGUS,STOMACH,ULCERS,DUODENAL ULCERS,GASTRIC ULCERS,CANCER,LIVER,SMALL INTESTINE,COELIAC DISEASE,COLON &amp; RECTUM,IRRITABLE BOWEL SYNDROME,INFLAMMATORY BOWEL DISEASE,DIAGNOSTIC PROCEDURES,GASTROINTESTINAL ENDOSCOPY,COLONOSCOPY,UPPER ENDOSCOPY,DISEASE PREVENTION,LOWER,GASTRO-OESOPHAGEAL REFLUX,HELICOBACTER PYLORI,CANCER,SCREENING,DYSPEPSIA,INFECTIONS,LIVER FUNCTION TESTS,GI BLEEDING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A report from the Primary Care Society for Gastroenterology summarising the current state of care for patients with gastroenterological conditions in the primary care setting.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Summary: &lt;/STRONG&gt;This report from the Primary Care Society for Gastroenterology summarises the current state of care for patients with gastroenterological conditions in the primary care setting. The report outlines current models of service provision and practice at the primary care level, and provides examples of successful use of guidelines for care of patients suffering from gastroenterological disorders, and new initiatives that may benefit patients and practitioners. &lt;/P&gt;
&lt;P&gt;General practitioners perceptions of gastroenterology are also discussed, including the learning needs of GPs with regard to gastroenterological conditions, as is the use of endoscopy in primary care. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293836</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1097/MEG.0b013e3282748f1f]]&gt;</url>
    <title>The cost-effectiveness of the new protocol reflecting rapid virologic response to peginterferon alpha-2b and ribavirin for chronic hepatitis C</title>
    <publicationDate>2007-09-01T00:00:00</publicationDate>
    <publisher>Lippincott Williams &amp; Wilkins</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,CHRONIC HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Nakamura J, Kobayashi K, Toyabe S, Aoyagi Y, Akazawa K.&amp;nbsp; European Journal of&amp;nbsp;Gastroenterology and&amp;nbsp;Hepatology. 2007 Sep;19(9):733-9.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract: &lt;/STRONG&gt;OBJECTIVE: Recent studies have reported the effectiveness of shorter courses of treatment with peginterferon alpha-2b plus ribavirin for patients with chronic hepatitis C, who achieved a rapid virologic response (RVR), defined as undetectable hepatitis C virus (HCV-) RNA at week 4. The aim of this study was to evaluate the cost-effectiveness of the new protocol for treatment, from the perspective of RVR. METHODS: A cost-effectiveness analysis based on the rate of sustained virologic response was performed. A Markov cohort model of hepatitis C was constructed to demonstrate the clinical states on the basis of the assigned transition probabilities over 30 years. The treatment strategies were classified into five subgroups taking into consideration the viral genotypes, viral load, and RVR. The lifetime costs and quality-adjusted life years (QALYs) were compared between the new and standard protocols for treatment. RESULTS: Genotype 1-infected patients in the new protocol for treatment compared with the standard one could prolong QALYs by 0.33 and reduce lifetime cost by euro 5993. Genotype 2 or 3-infected patients in the new protocol for treatment compared with the standard one could prolong QALYs by 0.02 and reduce lifetime cost by euro2851. CONCLUSION: Treatment strategies that consider viral load and RVR for patients with a low viral load infected with genotype 1 and those infected with genotype 2 or 3 are more cost-effective compared with the standard protocol for treatment.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293617</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=1831797&amp;blobtype=pdf]]&gt;</url>
    <title>The costs and impacts of testing for hepatitis C virus antibody in public STD clinics</title>
    <publicationDate>2007-09-01T00:00:00</publicationDate>
    <publisher>Association of Schools of Public Health</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,DIAGNOSTIC PROCEDURES,BLOOD TESTS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Honeycutt, AA et al Public health reports 2007;122 Suppl 2:55-62&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract: &lt;/STRONG&gt;OBJECTIVES: To estimate the cost and cost-effectiveness of testing sexually transmitted disease (STD) clinic subgroups for antibodies to hepatitis C virus (HCV). METHODS: HCV counseling, testing, and referral (CTR) costs were estimated using data from two STD clinics and the literature, and are reported in 2006 dollars. Effectiveness of HCV CTR was defined as the estimated percentage of clinic clients in subgroups targeted for HCV antibody (anti-HCV) testing who had a true positive test and returned for their test results. We estimated the cost per true positive injection drug user (IDU) who returned for anti-HCV test results and the cost-effectiveness of expanding HCV CTR to non-IDU subgroups. RESULTS: The estimated cost per true positive IDU who returned for test results was $54. The cost-effectiveness of expanding HCV CTR to non-IDU subgroups ranged from $179 to $2,986. Our estimates were most sensitive to variations in HCV prevalence, the cost of testing, and the rate of client return. CONCLUSIONS: Based on national data, testing IDUs in the STD clinic setting is highly cost-effective. Some clinics may find that it is cost-effective to expand testing to non-IDU men older than 40 who report more than 100 lifetime sex partners. STD clinics can use study estimates to assess the feasibility and desirability of expanding HCV CTR beyond IDUs.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;See also:&amp;nbsp;&lt;/STRONG&gt;&lt;A href="nelh:283905:0" name=internalLink&gt;NHS EED&amp;nbsp;record&lt;/A&gt; for this article&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309256</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1185/030079908X260790]]&gt;</url>
    <title>The costs of Crohn's disease in the United States and other Western countries: a systematic review</title>
    <publicationDate>2008-02-01T00:00:00</publicationDate>
    <publisher>Informa</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; This updated literature synthesis demonstrated the substantial total cost burden of CD, of which hospitalizations accounted for more than half of direct medical costs.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Studies published in English that described the cost of CD in Western industrialized countries were identified using three major databases (Medline, EMBASE, and ISI Web of Science). Studies were reviewed and rated based on their relevance to cost of illness and the reliability of the estimates. All costs were adjusted for inflation to 2006 values.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Estimated direct medical costs were $18 022-18 932 per patient with CD per year in the United States, and €2898-6960 in other Western countries. Hospitalizations accounted for 53-66% of direct medical costs, with an average cost-per-hospitalization of $37 459 in the United States. Estimated indirect costs accounted for 28% of the total cost in the United States and 64-69% in Europe. Costs differed greatly by disease severity. Costs of patients with severe disease were 3- to 9-fold higher than patients in remission. Direct medical costs in the United States for patients in the top 25% of total costs averaged $60 582 per year; costs of patients in the top 2% averaged more than $300 000 per year. Combining prevalence rates, the total economic burden of CD was $10.9-15.5 billion in the United States and €2.1-16.7 billion in Europe.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Yu, A. P., Cabanilla, L. A., Wu, E. Q., Mulani, P. M., &amp;amp; Chao, J. (2008) The costs of CD in the United States and other Western countries: a systematic review. &lt;I&gt;Current Medical Research &amp;amp; Opinion&lt;/I&gt;, 24(2):319-328.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in February 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345570</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2036.2008.03856.x]]&gt;</url>
    <title>The cost-utility of high dose oral mesalazine for moderately active ulcerative colitis</title>
    <publicationDate>2008-12-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; This study suggests that&amp;nbsp;high dose (HD)&amp;nbsp;mesalazine represents a cost-effective alternative to&amp;nbsp;standard dose (SD)&amp;nbsp;mesalazine for moderately active ulcerative colitis (UC), while potentially reducing the need for hospitalization.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Mesalazine (mesalamine) is standard first line treatment for moderately active UC. Recently, doubling the mesalazine dose (Asacol 4.8 g/day) was shown to improve efficacy with no increase in adverse events. The cost-effectiveness of this strategy remains unknown. AIM: To assess the cost-utility of HD mesalazine (Asacol 4.8 g/day) compared with SD mesalazine (Asacol 2.4 g/day) as first line treatment for moderately active UC.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; The costs and benefits associated with a treatment pathway beginning with HD or SD mesalazine were determined over 12 weeks using a decision tree analytical model.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; A 12-week treatment pathway starting with HD mesalazine cost an average of 2382 pounds per patient compared with 2474 pounds for SD mesalazine and generated 0.0016 more quality adjusted life years (QALYs). HD mesalazine dominated SD mesalazine, being both more effective and less costly. HD mesalazine treatment resulted in fewer patients requiring surgery or hospitalization for intensive pharmacological treatment. Probabilistic sensitivity analysis indicated a 72% chance that HD mesalazine was cost effective, based on a cost/QALY threshold of 30,000 pounds.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Buckland A, Bodger K. The cost-utility of high dose oral mesalazine for moderately active ulcerative colitis. &lt;EM&gt;Aliment Pharmacol Ther&lt;/EM&gt; 2008;28(11-12):1287-96.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;See also:&lt;/STRONG&gt; &lt;A href="nelh:316868:0" name=internalLink&gt;NHS EED record&lt;/A&gt; for this paper.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>125560</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://daveproject.org/]]&gt;</url>
    <title>The DAVE Project - Gastroenterology</title>
    <publicationDate></publicationDate>
    <publisher>Harvard University</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COMMON CLINICAL PRESENTATIONS,OESOPHAGUS,STOMACH,BILIARY TREE &amp; GALLBLADDER,PANCREAS,LIVER,SMALL INTESTINE,COLON &amp; RECTUM,INFLAMMATORY BOWEL DISEASE,DIAGNOSTIC PROCEDURES,GASTROINTESTINAL ENDOSCOPY,SURGERY,SURGERY,ABDOMEN,OESOPHAGUS,STOMACH &amp; DUODENUM,GALL BLADDER &amp; BILIARY TREE,SMALL INTESTINE,LIVER &amp; SPLEEN,PANCREAS,COLON &amp; RECTUM,ANAL CANAL &amp; PERIANAL]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This e-learning website provides access to an Endoscopy Atlas, and teaching materials (Pathology Slide Box, Grand Rounds and Clinical Journals Club) developed and compiled by the Gastrointestinal Unit, Massachusetts General Hospital.</description>
    <body>&lt;![CDATA[ &lt;P&gt;This e-learning website provides access to teaching materials developed and delivered by senior clinicians at the Massechusetts General Hospital &amp;amp; Harvard Medical School.&lt;/P&gt;
&lt;P&gt;Endoscopy Atlas:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://dave1.mgh.harvard.edu/SearchResults.cfm?portal=presentation&amp;amp;module=Esophagus" target="_blank"&gt;Esophagus&lt;/A&gt;, 
&lt;LI&gt;&lt;A href="http://dave1.mgh.harvard.edu/SearchResults.cfm?portal=presentation&amp;amp;module=Stomach" target="_blank"&gt;Stomach,&lt;/A&gt; 
&lt;LI&gt;&lt;A href="http://dave1.mgh.harvard.edu/SearchResults.cfm?portal=presentation&amp;amp;module=Duodenum" target="_blank"&gt;Duodenum&lt;/A&gt;, 
&lt;LI&gt;&lt;A href="http://dave1.mgh.harvard.edu/SearchResults.cfm?portal=presentation&amp;amp;module=Liver" target="_blank"&gt;Liver,&lt;/A&gt; 
&lt;LI&gt;&lt;A href="http://dave1.mgh.harvard.edu/SearchResults.cfm?portal=presentation&amp;amp;module=Intestine" target="_blank"&gt;Intestine&lt;/A&gt;, 
&lt;LI&gt;&lt;A href="http://dave1.mgh.harvard.edu/SearchResults.cfm?portal=presentation&amp;amp;module=Colon" target="_blank"&gt;Colon&lt;/A&gt;, 
&lt;LI&gt;&lt;A href="http://dave1.mgh.harvard.edu/SearchResults.cfm?portal=presentation&amp;amp;module=Biliary" target="_blank"&gt;Biliary&lt;/A&gt;, 
&lt;LI&gt;&lt;A href="http://dave1.mgh.harvard.edu/SearchResults.cfm?portal=presentation&amp;amp;module=Pancreas" target="_blank"&gt;Pancreas&lt;/A&gt;, and 
&lt;LI&gt;Other. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Other e-learnng materials include:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Pathology Slide Box, 
&lt;LI&gt;Grand Rounds, and 
&lt;LI&gt;Clinical Journal Club.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Downloadable file types include: images, video and podcasts.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; All, particularly those in training or involved in continual profesional devlopemnt.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Ongoing since 2003&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Freely accessible to all. Materials can be copied for educational purposes but must be credited.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>330284</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1186/1741-7015-5-13]]&gt;</url>
    <title>The effect of acetaminophen (four grams a day for three consecutive days) on hepatic tests in alcoholic patients--a multicenter randomized study</title>
    <publicationDate>2007-05-30T00:00:00</publicationDate>
    <publisher>BioMed Central</publisher>
    <publicationType>RANDOMISED CONTROLLED TRIAL</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,ALCOHOLIC LIVER DISEASE,RECENT ADDITIONS,NOVEMBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Alcoholic patients treated with the maximum recommended daily dose of acetaminophen for 3 consecutive days did not develop increases in serum transaminase or other measures of liver injury. Treatment of pain or fever for 3 days with acetaminophen appears safe in newly-abstinent alcoholic patients, such as those presenting for acute medical care.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Hepatic failure has been associated with reported therapeutic use of acetaminophen by alcoholic patients. The highest risk period for alcoholic patients is immediately after discontinuation of alcohol intake. This period exhibits the largest increase in CYP2E1 induction and lowest glutathione levels. Our hypothesis was that common liver tests would be unaffected by administration of the maximum recommended daily dosage of acetaminophen for 3 consecutive days to newly-abstinent alcoholic subjects.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Adult alcoholic subjects entering two alcohol detoxification centers were enrolled in a prospective double-blind, randomized, placebo-controlled trial. Subjects were randomized to acetaminophen, 4 g/day, or placebo for 3 consecutive days. The study had 95% probability of detecting a 15 IU/L difference in serum ALT.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; A total of 443 subjects were enrolled: 308 (258 completed) received acetaminophen and 135 subjects (114 completed) received placebo. Study groups did not differ in demographics, alcohol consumption, nutritional status or baseline laboratory assessments. The peak mean ALT activity was 57 ± 45 IU/L and 55 ± 48 IU/L in the acetaminophen and placebo groups, respectively. Subgroup analyses for subjects presenting with an elevated ALT, subjects fulfilling a diagnosis of alcoholic hepatitis and subjects attaining a peak ALT greater than 200 IU/L showed no statistical difference between the acetaminophen and control groups. The one participant developing an increased international normalized ratio was in the placebo group.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Kuffner EK, Green JL, Bogdan GM, Knox PC, Palmer RB, Heard K, Slattery JT, Dart RC. The effect of acetaminophen (four grams a day for three consecutive days) on hepatic tests in alcoholic patients--a multicenter randomized study. &lt;EM&gt;BMC Med&lt;/EM&gt; 2007 May 30;5:13.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281261</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17180251?ordinalpos=5&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>The effect of Crohn's disease on outcomes after restorative proctocolectomy</title>
    <publicationDate>2008-03-10T00:00:00</publicationDate>
    <publisher>Springer</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;SPAN title="Diseases of the colon and rectum."&gt;Reese, G.E. &lt;A href="#javascript:AL_get(this," ?jour?, ?Dis Colon Rectum.?);?&gt;Dis Colon Rectum.&lt;/A&gt;&lt;/SPAN&gt; 2007 Feb;50(2):239-50.&lt;/P&gt;
&lt;P class=abstract&gt;PURPOSE: This study was designed to compare postoperative adverse events and functional outcomes after ileal pouch-anal anastomosis between patients with Crohn's disease and those with non-Crohn's disease diagnoses. METHODS: A literature search was performed to identify studies published between 1980 and 2005 comparing outcomes of patients undergoing ileal pouch-anal anastomosis for Crohn's disease, ulcerative colitis, and indeterminate colitis. Random-effect, meta-analytical techniques were used and sensitivity analysis was performed. RESULTS: Ten studies comprising 3,103 patients (Crohn's disease=225; ulcerative colitis=2,711; indeterminate colitis=167) were included. Patients with Crohn's disease developed more anastomotic strictures than non-Crohn's disease diagnoses (odds ratio, 2.12; P=0.05) and experienced pouch failure more frequently than patients with ulcerative colitis (Crohn's disease vs. ulcerative colitis: 32 vs. 4.8 percent, P&amp;lt;0.001; Crohn's disease vs. indeterminate colitis: 38 vs. 5 percent, P&amp;lt;0.001). Urgency was more common in Crohn's disease compared with non-Crohn's disease: 19 vs. 11 percent (P=0.02). Incontinence occurred more frequently in Crohn's disease compared with non-Crohn's disease patients: 19 vs. 10 percent (odds ratio, 2.4; P=0.01). Twenty-four-hour stool frequency did not differ significantly between Crohn's disease, ulcerative colitis, or indeterminate colitis. Patients with isolated colonic Crohn's disease were not significantly at increased risk of postoperative complications or pouch failure (P=0.06). CONCLUSIONS: Patients with Crohn's disease undergoing ileal pouch-anal anastomosis should be appropriately counseled toward poorer functional outcomes and higher failure compared with non-Crohn's disease patients. It maybe possible to preoperatively select patients with isolated colonic Crohn's disease who may benefit from ileal pouch-anal anastomosis with acceptable adverse outcomes.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281295</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17588223?ordinalpos=1&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>The effect of restorative proctocolectomy on sexual function, urinary function, fertility, pregnancy and delivery: a systematic review</title>
    <publicationDate>2008-03-10T00:00:00</publicationDate>
    <publisher>Springer</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Cornish, J.A. &lt;SPAN title="Diseases of the colon and rectum."&gt;&lt;A href="#javascript:AL_get(this," ?jour?, ?Dis Colon Rectum.?);?&gt;Dis Colon Rectum.&lt;/A&gt;&lt;/SPAN&gt; 2007 Aug;50(8):1128-38&lt;/P&gt;
&lt;P class=abstract&gt;PURPOSE: This study was designed to evaluate the effect of restorative proctocolectomy on sexual function, urinary function, fertility, pregnancy, and delivery in patients with ulcerative colitis. METHODS: A systematic literature search was performed of articles published between 1980 and 2005 on patients undergoing restorative proctocolectomy for ulcerative colitis reporting data on the outcomes of interest. A random-effect, meta-analytical model was used for pooled estimates and 95 percent confidence intervals. RESULTS: A total of 22 studies, with 1,852 females, were included. Infertility rate was 12 percent before restorative proctocolectomy and 26 percent after, among 945 patients in seven studies. The incidence of sexual dysfunction was 8 percent preoperatively and 25 percent postoperatively (7 studies, n = 419). Two studies (n = 62) reported no urinary dysfunction in patients undergoing restorative proctocolectomy. There was an increased incidence of cesarean section after restorative proctocolectomy. During the third trimester of pregnancy, there was an increase in stool frequency by 1.15 stools per day compared with before pregnancy frequency (n = 49 95 percent confidence interval, 0.28-2.03 P = 0.01 chi-squared statistic, 0.04 P = 0.84). No significant differences were seen in pouch function after vaginal delivery (n = 456; weighted mean difference, 0.23; 95 percent confidence interval, 0.43-0.88; P = 0.49; chi-squared statistic, 1.29; P = 0.26). CONCLUSIONS: The incidence of dyspareunia increases after restorative proctocolectomy. There was a decrease in fertility after restorative proctocolectomy. Pregnancy after restorative proctocolectomy was not associated with an increase in complications. There was an increase in stool frequency and pad usage during the third trimester. Vaginal delivery is safe after restorative proctocolectomy. Pouch function after delivery returns to pregestational function within six months.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309249</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1007/s00384-008-0542-9]]&gt;</url>
    <title>The effect of smoking after surgery for Crohn's disease: a meta-analysis of observational studies</title>
    <publicationDate>2008-12-01T00:00:00</publicationDate>
    <publisher>Springer</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,DISEASE PREVENTION,SMOKING CESSATION,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Patients with Crohn’s disease who smoke have a 2.5-fold increased risk of surgical recurrence and a twofold risk of clinical recurrence compared to non-smokers. Patients with Crohn’s disease should be encouraged to stop smoking since the risk of disease relapse is minimised upon its cessation.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; &lt;SPAN class=AbstractSectionHeading&gt;&lt;/SPAN&gt;A literature search was performed to identify studies published between 1966 and 2007 comparing outcomes of smokers, ex-smokers and non-smokers with Crohn’s disease. Random-effect meta-analytical techniques were employed to assess the risk of medical or surgical recurrence.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Sixteen studies encompassing 2,962 patients including 1,425 non-smokers (48.1%), 1,393 smokers (47.0%) and 137 ex-smokers (4.6%) were included. Smokers had significantly higher clinical post-operative recurrence than non-smokers (odds ratio [OR]?=?2.15; 95%CI?=?1.42, 3.27; &lt;I&gt;p&lt;/I&gt;?&lt;?0.001). Smokers were also more likely to experience surgical recurrence by 5 (OR?=?1.06; 95%CI?=?0.32; 3.53, &lt;I&gt;p&lt;/I&gt;?=?0.04) and 10&amp;nbsp;years of follow-up (OR?=?2.56; 95%CI?=?1.79, 3.67; &lt;I&gt;p&lt;/I&gt;? &lt;?0.001) compared to non-smokers, although the crude re-operation rate was not statistically significant. When matched for operation and disease site, smokers had significantly higher re-operation rates to non-smokers (OR?=?2.3; 95%CI?=?1.29, 4.08; &lt;I&gt;p&lt;/I&gt;?=?0.005). There was no significant difference between ex-smokers and non-smokers in re-operation rate at 10&amp;nbsp;years (OR?=?0.30; 95%CI?=?0.09, 1.07; &lt;I&gt;p&lt;/I&gt;?=?0.10) or in post-operative acute relapses (OR?=?1.54; 95%CI?=?0.78, 3.02; &lt;I&gt;p&lt;/I&gt;?=?0.21). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Reese, G. E., Nanidis, T., Borysiewicz, C., Yamamoto, T., Orchard, T., &amp;amp; Tekkis, P. P. (2008) The effect of smoking after surgery for Crohn's disease: a meta-analysis of observational studies. &lt;I&gt;International Journal of Colorectal Disease&lt;/I&gt;, 23(12):1213-1221.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in December 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>381429</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.contraception.2009.04.007]]&gt;</url>
    <title>The effects of hormonal contraceptive use among women with viral hepatitis or cirrhosis of the liver: a systematic review</title>
    <publicationDate>2009-10-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,HEPATITIS C,RECENT ADDITIONS,CIRRHOSIS,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Data from one study suggest that combined oral contraceptives (COCs) do not affect the course of acute hepatitis. Limited data from studies on chronic hepatitis or its sequelae suggest that COC use does not affect the rate of progression or severity of cirrhotic fibrosis, the risk of hepatocellular carcinoma in women with chronic hepatitis, or the risk of liver dysfunction in hepatitis B virus carriers.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims: &lt;/STRONG&gt;This report evaluates the effects of hormonal contraceptive use among women with viral hepatitis or cirrhosis of the liver.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; PubMed and Cochrane databases were searched from inception to June 2008 for publications that examined the use of hormonal contraceptives among women with viral hepatitis or cirrhosis of the liver.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Six studies met the inclusion criteria. In one study of acute hepatitis, COC use did not affect duration of hospitalization or successful disease resolution. The remainder of the studies examined chronic hepatitis or its sequelae. Women recovered from hepatitis experienced transaminase elevation with COC use which resolved after 4 weeks in one study or increased slightly over 6 months in another study. Hepatitis B virus carriers using COCs had similar transaminase levels as nonusing carriers over 6 months. Studies of chronic hepatitis C infection demonstrated no influence of COC use on progression or severity of liver fibrosis or development of hepatocellular carcinoma.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Kapp N, Tilley IB, Curtis KM. The effects of hormonal contraceptive use among women with viral hepatitis or cirrhosis of the liver: a systematic review. &lt;EM&gt;Contraception&lt;/EM&gt; 2009;80(4):381-6.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>396343</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20491750]]&gt;</url>
    <title>The effects of paracetamol (acetaminophen) on hepatic tests in patients who chronically abuse alcohol - a randomized study</title>
    <publicationDate>2010-08-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>RANDOMISED CONTROLLED TRIAL</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,ALCOHOLIC LIVER DISEASE,RECENT ADDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Alimentary pharmacology and therapeutics&lt;/EM&gt; is an international journal concerned with the effects of drugs on the human gastrointestinal and hepato-biliary systems. The journal publishes original research on all aspects of pharmacology, pharmacokinetics and therapeutic use of drugs in the alimentary tract.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Dart, R. C., Green, J. L., Kuffner, E. K., Heard, K., Sproule, B., &amp;amp; Brands, B. 2010. The effects of paracetamol (acetaminophen) on hepatic tests in patients who chronically abuse alcohol - a randomized study. Alimentary Pharmacology &amp;amp; Therapeutics 32(3) 478-486.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;AIM:&lt;/STRONG&gt; To determine the effect of paracetamol on serum liver tests of newly abstinent subjects who abuse alcohol, including subjects with hepatitis C infection. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; A randomized, double-blind, placebo-controlled study. Adult alcohol abusers with a current drinking episode longer than 7 days received either placebo or paracetamol 4 g/day for 5 days. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Of 142 subjects enrolled, 74 received paracetamol and 68 received placebo. Mean ALT activity during treatment increased from 48 to 62 IU/L in the paracetamol group and from 47 to 49 IU/L in the placebo group. Maximum ALT was 238 and 249 IU/L in the paracetamol and control groups respectively. The INR remained unchanged and serum bilirubin decreased in both groups. Subgroup analyses for subjects with alcoholic hepatitis, hepatitis C virus antibody and other subgroups showed no statistical difference between groups. &lt;/P&gt;
&lt;P&gt;CONCLUSION: Administration of paracetamol 4 g/day appears safe in newly abstinent patients who abuse alcohol. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is &lt;STRONG&gt;not&lt;/STRONG&gt; available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>380653</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1517/13543780903501505]]&gt;</url>
    <title>The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus</title>
    <publicationDate>2010-01-01T00:00:00</publicationDate>
    <publisher>Informa</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,RECENT ADDITIONS,CHRONIC HEPATITIS C,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Telaprevir has an acceptable pharmacokinetic profile and seems to be a potent antiviral drug against hepatitis C virus (HCV), although, owing to a low genetic barrier, resistant variants emerge within a few days when used in monotherapy, thereby decreasing its efficacy. Consequently, telaprevir has been combined with pegylated-interferon and ribavirin in clinical trials. This triple combination is more effective but has a higher rate of adverse events (notably rash) than the standard of care, despite the shorter duration of therapy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; HCV is the main agent of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma in the western world. It affects more than 170 million people worldwide. HCV treatment, based on the combination of Peg-interferon and ribavirin, is effective in about 50% of treated patients. Therefore, there is a need to develop new drugs active against HCV.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Data were obtained by searching for all full articles on Medline and abstracts presented at major international congresses on viral hepatitis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; A review of clinical data about the efficacy and safety of telaprevir (VX-950), the HCV protease inhibitor that is in the most advanced phase of clinical development is presented.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Gentile I, Carleo MA, Borgia F, Castaldo G, Borgia G. The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus. &lt;EM&gt;Expert Opin Investig Drugs&lt;/EM&gt; 2010;19(1):151-9.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>346882</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/gut.2008.167270]]&gt;</url>
    <title>The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review</title>
    <publicationDate>2010-03-01T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,IRRITABLE BOWEL SYNDROME,DISEASE PREVENTION,PROBIOTICS,DIETARY SUPPLEMENTS,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Probiotics appear to be efficacious in irritable bowel syndrome (IBS), but the magnitude of benefit and the most effective species and strain are uncertain.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Probiotics may benefit IBS symptoms, but randomised controlled trials (RCTs) have been conflicting; therefore a systematic review was conducted.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; MEDLINE (1966 to May 2008), EMBASE (1988 to May 2008) and the Cochrane Controlled Trials Register (2008) electronic databases were searched, as were abstracts from DDW (Digestive Diseases Week) and UEGW (United European Gastroenterology Week), and authors were contacted for extra information. Only parallel group RCTs with at least 1 week of treatment comparing probiotics with placebo or no treatment in adults with IBS according to any acceptable definition were included. Studies had to provide improvement in abdominal pain or global IBS symptoms as an outcome. Eligibility assessment and data extraction were performed by two independent researchers. Data were synthesised using relative risk (RR) of symptoms not improving for dichotomous data and standardised mean difference (SMD) for continuous data using random effects models.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; 19 RCTs (18 papers) in 1650 patients with IBS were identified. Trial quality was generally good, with nine reporting adequate methods of randomisation and six a method of concealment of allocation. There were 10 RCTs involving 918 patients providing outcomes as a dichotomous variable. Probiotics were statistically significantly better than placebo (RR of IBS not improving=0.71; 95% CI 0.57 to 0.88) with a number needed to treat (NNT)=4 (95% CI 3 to 12.5). There was significant heterogeneity (chi(2)=28.3, p=0.001, I(2)=68%) and possible funnel plot asymmetry. Fifteen trials assessing 1351 patients reported on improvement in IBS score as a continuous outcome (SMD=-0.34; 95% CI -0.60 to -0.07). There was statistically significant heterogeneity (chi(2)=67.04, p&amp;lt;0.001, I(2)=79%), but this was explained by one outlying trial.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein AE, Brandt LJ, Quigley EM. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. &lt;EM&gt;Gut&lt;/EM&gt; 2010;59(3):325-32.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>295246</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.bsg.org.uk/pdf_word_docs/ercp_stakeholders_08.doc]]&gt;</url>
    <title>The future of service and training in ERCP in the UK - a strategy</title>
    <publicationDate>2007-08-01T00:00:00</publicationDate>
    <publisher>British Society of Gastroenterology</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,DIAGNOSTIC PROCEDURES,GASTROINTESTINAL ENDOSCOPY,ERCP]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The British Society of Gastroenterology is an organisation focused on the promotion of gastroenterology within the United Kingdom. It has over three thousand members drawn from the ranks of physicians, surgeons, pathologists, radiologists, scientists, nurses, dietitians, and others interested in the field. Founded in 1937 it has grown from a club to be a major force in British medicine, with representation within the British Royal Colleges and thus to the Department of Health and Government. Internationally it is represented at World and European level. The BSG is a registered charity.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt; The current place and the future of ERCP (endoscopic retrograde cholangio-pancreatography) began to emerge as major issues at national level in 2005. At that time, the British Society of Gastroenterology (BSG) Endoscopy Committee considered that attention should be urgently directed towards ERCP for a number of reasons.&amp;nbsp; This document is the result of the work of the stakeholder's group set up by the BSG Endoscopy Committee to address the issue.&amp;nbsp; The Strategy covers service (needs, provision and delivery), training (number and selection of trainees, mode of training, and trainers), and next steps.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323541</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1097/QAD.0b013e32830e0152]]&gt;</url>
    <title>The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis</title>
    <publicationDate>2008-09-12T00:00:00</publicationDate>
    <publisher>Lippincott Williams &amp; Wilkins</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,HIV / AIDS,RECENT ADDITIONS,AUGUST 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Hepatitis C coinfection is associated with a significant increase in the risk of HIV-related kidney disease.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Two investigators identified English-language citations in MEDLINE and Web of Science from 1989 through 1 July 2007. References of selected articles were reviewed. Observational studies and clinical trials of HIV-related kidney disease and antiretroviral nephrotoxicity were eligible if they included at least 50 subjects and reported hepatitis C status. Data on study characteristics, population, and kidney disease outcomes were abstracted by two independent reviewers.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; After screening 2516 articles, 27 studies were eligible and 24 authors confirmed or provided data. Separate meta-analyses were performed for chronic kidney disease outcomes (&lt;SPAN class=fulltext-IT&gt;n&lt;/SPAN&gt; = 10), proteinuria (&lt;SPAN class=fulltext-IT&gt;n&lt;/SPAN&gt; = 4), acute renal failure (&lt;SPAN class=fulltext-IT&gt;n&lt;/SPAN&gt; = 2), and indinavir toxicity (&lt;SPAN class=fulltext-IT&gt;n&lt;/SPAN&gt; = 5). The pooled incidence of chronic kidney disease was higher in patients with hepatitis C coinfection [6.2 versus 4.0%; relative risk 1.49, 95% confidence interval (CI) 1.08–2.06]. In meta-regression, prevalence of black race and the proportion of patients with documented hepatitis C status were independently associated with the risk of chronic kidney disease. The relative risk associated with hepatitis C coinfection was significantly increased for proteinuria (1.15; 95% CI 1.02–1.30) and acute renal failure (1.64; 95% CI 1.21–2.23), with no significant statistical heterogeneity. The relative risk of indinavir toxicity was 1.59 (95% CI 0.99–2.54) with hepatitis C coinfection.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Wyatt CM, Malvestutto C, Coca SG, Klotman PE, Parikh CR. The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis. &lt;EM&gt;AIDS&lt;/EM&gt; 2008 Sep 12;22(14):1799-807.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor generally via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293612</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2893.2007.00868.x]]&gt;</url>
    <title>The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies</title>
    <publicationDate>2007-10-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Fabrizi, F et al Journal of Viral Hepatitis 2007 Oct;14(10):697-703&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract: &lt;/STRONG&gt;The impact of hepatitis C virus (HCV) infection on mortality of patients receiving regular dialysis remains unclear. The assessment of the natural history of HCV in dialysis population is difficult because of the low progression of HCV-related liver disease over time and the reduced life expectancy in patients with end-stage renal disease. The aim of the study was to conduct a systematic review of the published medical literature concerning the impact of HCV infection on the survival of patients undergoing maintenance dialysis. The relative risk of mortality was regarded as the most reliable outcome end-point. Study-specific relative risks were weighted by the inverse of their variance to obtain fixed- and random-effects pooled estimates for mortality with HCV across the published studies. We identified seven studies involving 11 589 unique patients on maintenance dialysis; two (29%) were case-control studies. Pooling of study results demonstrated that presence of anti-HCV antibody was an independent and significant risk factor for death in patients on maintenance dialysis. The summary estimate for adjusted relative risk (aRR) (all-cause mortality) was 1.34 with a 95% confidence interval (CI) of 1.13-1.59. Heterogeneity statistics, R(i) = 0.48 (P-value by Q-test = 0.13). In a sensitivity analysis including only (n = 5) cohort studies, the pooled aRR was 1.38 (95% CI, 1.20-1.59); heterogeneity statistics R(i) = 0.46. As a cause of death, hepatocellular carcinoma and liver cirrhosis were significantly more frequent among anti-HCV-positive than -negative dialysis patients. Our meta-analysis indicates that anti-HCV-positive patients on dialysis have an increased risk of mortality compared with HCV-negative patients. The excess risk of death in HCV-positive patients may be at least partially attributed to chronic liver disease with its attendant complications.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>381430</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1177/1049732309341656]]&gt;</url>
    <title>The lived experience of hepatitis C and its treatment among injecting drug users: qualitative synthesis</title>
    <publicationDate>2009-09-01T00:00:00</publicationDate>
    <publisher>Sage Publications</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,RECENT ADDITIONS,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract:&lt;/STRONG&gt; Hepatitis C virus infection is a stigmatized condition because of its close association with injecting drug use. There is a need to explore how people who inject drugs (IDUs) perceive hepatitis C, including in relation to treatment experience. We undertook a review, using a qualitative synthesis approach, of English-language qualitative research focusing on the lived experience of hepatitis C among IDUs. The review included 25 published articles representing 20 unique studies. A synthesis of this literature generated three interplaying themes: social stigma, biographical adaptation, and medical and treatment encounters. Interactions with health systems can reproduce stigma linked to drug injecting and hepatitis C, as well as trivialize the lived experience of diagnosis and illness. Hepatitis C can be biographically reinforcing of socially accommodated risk and spoiled identity, as well as disruptive to everyday life. We hypothesize hepatitis C as a liminal illness experience, oscillating between trivial and serious, normalized and stigmatized, public and personal. We conclude by emphasizing the disconnects between the lived experience of hepatitis C among IDUs and Western health care system responses.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Treloar C, Rhodes T. The lived experience of hepatitis C and its treatment among injecting drug users: qualitative synthesis. &lt;EM&gt;Qual Health Res&lt;/EM&gt; 2009;19(9):1321-34.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>393921</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.bsg.org.uk/images/stories/clinical/bsg_coeliac_10.pdf]]&gt;</url>
    <title>The management of adults with Coeliac Disease</title>
    <publicationDate>2010-07-01T00:00:00</publicationDate>
    <publisher>British Society of Gastroenterology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,SMALL INTESTINE,COELIAC DISEASE,RECENT ADDITIONS,NOVEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Ciclitira PJ, Dewar DH, McLaughlin SD, Sanders DS (2010) The Management of Adults with Coeliac Disease. British Society of Gastroenterology&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt; There is clear evidence that coeliac disease is a common gastrointestinal disease affecting up to 1% of the adult population. Individuals may go undetected for many years. This is despite multiple presentations to both primary and secondary care. This may reflect that fact that affected individuals have subtle gastrointestinal symptoms or no gastrointestinal symptoms. An active case finding strategy will increase the number of patients detected with coeliac disease. Testing for coeliac disease should incorporate an IgA level, Tissue Transglutaminase antibody and/or Endomysial antibody (depending on what is locally available). In patients with a positive antibody a duodenal biopsy should be undertaken to confirm the presence of villous atrophy. In patients who are antibody negative but the clinician is suspicious then a duodenal biopsy should still be undertaken having ensured that the patient is not on a self-imposed gluten-free diet (GFD). The cornerstone of treatment is a GFD. Patients require regular diete tic support with the opportunity or access to a gastroenterologist should further problems arise. Follow-up may be in primary or secondary care as long as the support is adequate (as noted previously). In patients with persisting symptoms they should be investigated carefully with particular reference to ensuring that refractory coeliac disease is excluded.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publisher information:&lt;/STRONG&gt;&amp;nbsp; The British Society of Gastroenterology is an organisation focused on the promotion of gastroenterology within the United Kingdom. It has over three thousand members drawn from the ranks of physicians, surgeons, pathologists, radiologists, scientists, nurses, dietitians, and others interested in the field. Founded in 1937 it has grown from a club to be a major force in British medicine, with representation within the British Royal Colleges and thus to the Department of Health and Government. Internationally it is represented at World and European level. The BSG is a registered charity.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>391546</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.bsg.org.uk/images/stories/clinical/man_gastric_polyps_10.pdf]]&gt;</url>
    <title>The management of gastric polyps</title>
    <publicationDate>2010-02-24T00:00:00</publicationDate>
    <publisher>British Society of Gastroenterology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,STOMACH,NON-MALIGNANT NEOPLASMS,RECENT ADDITIONS,POLYPS,OCTOBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Goddard AF, Badreldin R, Pritchard DM, Walker MM, Warren B. (2010) &lt;EM&gt;Gut&lt;/EM&gt; 59:1270-1276&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background:&lt;/STRONG&gt; Gastric polyps are important as some have malignant potential. If such polyps are left untreated,gastric cancer may result. The malignant potential depends on the histological type of the polyp. The literature base is relatively weak and any recommendations made must be viewed in light of this.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Definition:&lt;/STRONG&gt; Gastric polyps are sessile or pedunculated lesions that originate in the gastric epithelium or submucosa and protrude into the stomach lumen. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Malignant potential:&lt;/STRONG&gt; Depending on histological type,some gastric polyps (adenomas and hyperplastic polyps) have malignant potential and are precursors of early gastric cancer. They may also indicate an increased risk of intestinal or extra-intestinal malignancy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publisher information:&lt;/STRONG&gt;&amp;nbsp; The British Society of Gastroenterology is an organisation focused on the promotion of gastroenterology within the United Kingdom. It has over three thousand members drawn from the ranks of physicians, surgeons, pathologists, radiologists, scientists, nurses, dietitians, and others interested in the field. Founded in 1937 it has grown from a club to be a major force in British medicine, with representation within the British Royal Colleges and thus to the Department of Health and Government. Internationally it is represented at World and European level. The BSG is a registered charity.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344542</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1038/ajg.2009.579]]&gt;</url>
    <title>The natural history of adult Crohn's disease in population-based cohorts</title>
    <publicationDate>2010-02-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE,RECENT ADDITIONS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Crohn's disease is a disabling condition over time. The impact of changing treatment paradigms with increased use of immunosuppressants and biological agents on its natural history is poorly known.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Natural history studies provide invaluable data on the disease course. First, they help define the end points for clinical trials that are designed to test drugs for the end point of disease modification in chronic disabling diseases. Natural history studies can also help to identify subsets of patients in whom the disease prognosis can be stratified according to clinical features. This comprehensive review summarizes our current knowledge of the natural history of Crohn's disease in adults as reported in population-based studies that include long-term follow-up results.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We conducted a literature search of English and non-English language publications listed in the electronic databases of MEDLINE (source PUBMED, 1935 to December 2008).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; One-third of the patients had ileitis, colitis, or ileocolitis at the time of diagnosis. Disease location remained broadly stable over time. Up to one-third of the patients had evidence of a stricturing or penetrating intestinal complication at diagnosis, and half of all patients had experienced an intestinal complication within 20 years after diagnosis. Ten percent of the patients had prolonged clinical remission. Steroid dependency occurred in one-third of the patients, and surgery was required in one-third after initiation of steroid therapy. The annual incidence of hospitalizations was 20%. Half of the patients required surgery within 10 years after diagnosis. The risk of postoperative recurrence was 44-55% after 10 years.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ. The natural history of adult Crohn's disease in population-based cohorts. &lt;EM&gt;Am J Gastroenterol&lt;/EM&gt; 2010 Feb;105(2):289-97.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>385069</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.jhep.2010.03.015]]&gt;</url>
    <title>The natural history of hepatitis C infection acquired through injection drug use: meta-analysis and meta-regression</title>
    <publicationDate>2010-08-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,NON-ALCOHOLIC,HIV / AIDS,RECENT ADDITIONS,CIRRHOSIS,CHRONIC HEPATITIS C,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; &lt;SPAN&gt;Analysis of aggregate level data suggests that for patients who contracted hepatitis C virus (HCV) through injection drug use prognosis is poor in populations with many male patients and high levels of alcohol consumption.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; &lt;SPAN&gt;Our aim was to estimate the rate of progression to cirrhosis for those infected with HCV through injection drug use.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; &lt;SPAN&gt;We searched the published literature for articles assessing cirrhosis in this population and abstracted data on cirrhosis prevalence, mean duration of infection, mean age, mean alanine aminotransferase (ALT) enzyme levels, proportion of males, proportion HIV co-infected, proportion consuming excessive alcohol, and study setting. Summary progression rates were estimated using weighted averages and random effects Poisson meta-regression. The impact of co-variates was assessed by estimating the posterior probability that the relative risk (RR) of progression exceeded 1.0.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;SPAN&gt;A total of 47 published articles were identified. After adjusting for covariates in 44 studies representing 6457 patients, the estimated rate of progression to cirrhosis, was 8.1 per 1000 person-years (95% credible region (CR), 3.9-14.7). This corresponds to a 20-year cirrhosis prevalence of 14.8% (95% CR, 7.5-25.5). A 5% increase in the proportion of male participants and a 5% increase in the proportion consuming excessive alcohol were associated with faster progression (probability RR&amp;gt;1=0.97 and 0.92, respectively). A 5% increase in the proportion of HIV co-infected, an increase in ALT of 5 IU/L and studies in settings with a high risk of referral bias were not associated with faster progression (probability RR&amp;gt;1=0.42, 0.65, and 0.43, respectively).&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; John-Baptiste A, Krahn M, Heathcote J, Laporte A, Tomlinson G. The natural history of hepatitis C infection acquired through injection drug use: meta-analysis and meta-regression. &lt;EM&gt;J Hepatol&lt;/EM&gt; 2010;53(2):245-51.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281278</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17308939]]&gt;</url>
    <title>The risk of cancer in patients with Crohn's disease</title>
    <publicationDate>2008-03-10T00:00:00</publicationDate>
    <publisher>Springer</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,SMALL INTESTINE,CANCER,COLON &amp; RECTUM,INFLAMMATORY BOWEL DISEASE,CANCER,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;SPAN title="Diseases of the colon and rectum."&gt;Von Roon, A.C. &lt;A href="#javascript:AL_get(this," ?jour?, ?Dis Colon Rectum.?);?&gt;Dis Colon Rectum.&lt;/A&gt;&lt;/SPAN&gt; 2007 Jun;50(6):839-55.&lt;/P&gt;
&lt;P class=abstract&gt;PURPOSE: The risk of cancer in patients with Crohn's disease is not well defined. Using meta-analytical techniques, the present study was designed to quantify the risk of intestinal, extraintestinal, and hemopoietic malignancies in such patients. METHODS: A literature search identified 34 studies of 60,122 patients with Crohn's disease. The incidence and relative risk of cancer were calculated for patients with Crohn's disease and compared with the baseline population of patients without Crohn's disease. Overall pooled estimates, with 95 percent confidence intervals, were obtained, using a random-effects model. RESULTS: The relative risk of small bowel, colorectal, extraintestinal cancer, and lymphoma compared with the baseline population was 28.4 (95 percent confidence interval, 14.46-55.66), 2.4 (95 percent confidence interval, 1.56-4.36), 1.27 (95 percent confidence interval, 1.1-1.47), and 1.42 (95 percent confidence interval, 1.16-1.73), respectively. On subgroup analysis, patients with Crohn's disease had an increased risk of colon cancer (relative risk, 2.59; 95 percent confidence interval, 1.54-4.36) but not of rectal cancer (relative risk, 1.46; 95 percent confidence interval, 0.8-2.55). There was significant association between the anatomic location of the diseased bowel and the risk of cancer in that segment. The risk of small bowel cancer and colorectal cancer was found to be higher in North America and the United Kingdom than in Scandinavian countries with no evidence of temporal changes in the cancer incidence. CONCLUSIONS: The present meta-analysis demonstrated an increased risk of small bowel, colon, extraintestinal cancers, and lymphoma in patients with Crohn's disease. Patients with extensive colonic disease that has been present from a young age should be candidates for endoscopic surveillance; however, further data are required to evaluate the risk of neoplasia over time.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309034</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1572-0241.2008.02118.x]]&gt;</url>
    <title>The risk of developing Crohn's disease after an appendectomy: a meta-analysis.</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE,APPENDICITIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The meta-analysis demonstrated a significant risk of CD following an appendectomy, though heterogeneity was observed between the studies. The elevated risk early after an appendectomy, which diminishes thereafter, likely reflects diagnostic problems in patients with incipient CD.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; MEDLINE was used to identify observational studies evaluating the association between appendectomy and CD. Authors were contacted when data were insufficient. Relative risks (RR) with 95% confidence intervals (CI) were calculated using a random effects model. Studies that analyzed their data by the interval between the appendectomy and the diagnosis of CD were assessed separately. The Woolf chi2 statistic was used to test for homogeneity. Egger's test was used to evaluate publication bias.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The summary RR estimate for CD following an appendectomy was significantly elevated (RR 1.61, 95% CI 1.28–2.02), though heterogeneity was observed (P &amp;lt; 0.0001). The risk was elevated within the first year following the operation (RR 6.69, 95% CI 5.42–8.25). The risk of CD was also significantly increased 1–4 yr following an appendectomy (RR 1.99, 95% CI 1.66– 2.38); however, after 5 yr or more, the risk fell to baseline levels (RR 1.08, 95% CI 0.99–1.18). Publication bias was not detected (P = 0.2).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Kaplan, G. G., Jackson, T., Sands, B. E., Frisch, M., Andersson, R. E., &amp;amp; Korzenik, J. (2008) The risk of developing Crohn's disease after an appendectomy: a meta-analysis. &lt;I&gt;American Journal of Gastroenterology&lt;/I&gt;, 103(11):2925-31.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in November 2008&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309028</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1572-0241.2008.02064.x]]&gt;</url>
    <title>The risk of oral contraceptives in the etiology of inflammatory bowel disease: a meta-analysis</title>
    <publicationDate>2008-09-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; This study provides evidence of an association between the use of oral contraceptive agents and development of IBD, in particular CD. The study also suggests that the risk for patients who stop using the OCP reverts to that of the nonexposed population.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A literature search was performed to identify comparative studies reporting on the association of oral contraceptive use in the etiology of UC and CD between 1983 and 2007. A random-effect meta-analysis was used to compare the incidence of UC or CD between the patients exposed to the OCP and nonexposed patients. The results were adjusted for smoking.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; A total of 75,815 patients were reported on by 14 studies, with 36,797 exposed to OCP and 39,018 nonexposed women. The pooled relative risk (RR) for CD for women currently taking the OCP was 1.51 (95% confidence interval [CI] 1.17–1.96, &lt;I&gt;P&lt;/I&gt; = 0.002), and 1.46 (95% CI 1.26–1.70, &lt;I&gt;P&lt;/I&gt; &amp;lt; 0.001), adjusted for smoking. The RR for UC in women currently taking the OCP was 1.53 (95% CI 1.21–1.94, &lt;I&gt;P&lt;/I&gt; = 0.001), and 1.28 (95% CI 1.06–1.54, &lt;I&gt;P&lt;/I&gt; = 0.011), adjusted for smoking. The RR for CD increased with the length of exposure to OCP. Moreover, although the RR did not reduce once the OCP was stopped, it was no longer significant once the OCP was stopped (CI contains 1), both for CD and for UC.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Cornish, J. A., Tan, E., Simillis, C., Clark, S. K., Teare, J., &amp;amp; Tekkis, P. P. (2008) The risk of oral contraceptives in the etiology of inflammatory bowel disease:&amp;nbsp;a meta-analysis. &lt;I&gt;American Journal of Gastroenterology&lt;/I&gt;, 103(9):2394-2400.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in September 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345471</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.crohns.2009.03.002]]&gt;</url>
    <title>The role of CMV in steroid-resistant ulcerative colitis: a systematic review</title>
    <publicationDate>2009-09-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,INFECTIONS,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; A distinction between cytomegalovirus (CMV)&amp;nbsp;disease (CMV colitis) and CMV infection is necessary. CMV disease increases the biological severity of&amp;nbsp; colitis and is the cause of acute severe colitis in a small minority, not all of whom are on immunosuppressants. CMV&amp;nbsp;infection may be associated with steroid-resistance, but may also be a self-limiting marker of viral reactivation.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Steroid-resistance presents a management challenge in ulcerative colitis. How steroid-resistance occurs is unknown, but cytomegalovirus infection, often unrecognised, may be the cause in some patients. Current evidence and therapeutic recommendations are examined.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A systematic review of PubMed and EMBASE databases was performed. Search and exclusion criteria are defined in the text.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Heterogeneity of experimental design and definitions of key terms were notable. Criteria for cytomegalovirus disease, infection or detection varied, as did definitions of steroid-resistance. CMV infection defined by antigenaemia or serology was common in patients on steroids and associated with a higher rate of steroid-resistance (41.66–61% versus 0–68% in steroid-responsive patients). Colonic mucosal cytomegalovirus disease detected by histopathology was associated with intravenous steroid-resistance in 5&lt;STRONG&gt;–&lt;/STRONG&gt;36%, compared to 0–10% of steroid-responsive patients. CMV colitis has rarely been reported in association with ulcerative colitis without steroids or other immunomodulators. CMV colitis in healthy individuals is so exceptional as to be the topic of case reports.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Ayre K, Warren BF, Jeffery K, Travis SPL. The role of CMV in steroid-resistant ulcerative colitis: A systematic review. &lt;EM&gt;J Crohn's Colitis &lt;/EM&gt;2009;3(3):141-8.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309042</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.2174/156652408784533832]]&gt;</url>
    <title>The role of stress in the development and clinical course of inflammatory bowel disease: epidemiological evidence</title>
    <publicationDate>2008-06-01T00:00:00</publicationDate>
    <publisher>Ingenta</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusions:&lt;/STRONG&gt; There is consistent evidence for a contribution of psychological factors to IBD disease course, especially stress in UC and depressive symptoms in CD. More rigorous tests of psychological interventions in IBD are needed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A Medline search identified prospective studies of the effects of stress on subsequent disease activity and randomized controlled studies of the effects of psychological interventions on disease course in IBD. Controlled retrospective studies were included in the review of aspects of the stress-inflammatory relationship for which few prospective studies are available (e.g. the link between stress and disease onset). Studies were assessed qualitatively.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; A Medline search identified prospective studies of the effects of stress on subsequent disease activity and randomized controlled studies of the effects of psychological interventions on disease course in IBD. Controlled retrospective studies were included in the review of aspects of the stress-inflammatory relationship for which few prospective studies are available (e.g. the link between stress and disease onset). Studies were assessed qualitatively.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Maunder, R. G. &amp;amp; Levenstein, S. (2008) The role of stress in the development and clinical course of inflammatory bowel disease: epidemiological evidence. &lt;I&gt;Current Molecular Medicine&lt;/I&gt;, 8(4):247-52.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in June 2008&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317089</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1038/ajg.2009.122]]&gt;</url>
    <title>The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis</title>
    <publicationDate>2009-06-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,OESOPHAGUS,STOMACH,ULCERS,DUODENAL ULCERS,GASTRIC ULCERS,ZOLLINGER-ELLISON SYNDROME,SMALL INTESTINE,GASTRO-OESOPHAGEAL REFLUX,HELICOBACTER PYLORI,DYSPEPSIA,RECENT ADDITIONS,INFECTIONS,JUNE 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; On the basis of these results,&amp;nbsp;proton pump inhibitors (PPIs)&amp;nbsp;are not associated with an increased risk for major congenital birth defects, spontaneous abortions, or preterm delivery. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; All original research assessing the safety of PPIs in pregnancy was sought from inception to July 2008. Two independent reviewers identified articles, compared results, and settled differences through consensus. The Downs–Black scale was used to assess quality. Data assessed included congenital malformations, spontaneous abortions, and preterm delivery. A random effects meta-analysis combined the results from included studies.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Of the 60 articles identified, 7 met our inclusion criteria. Using data from 134,940 patients, including 1,530 exposed and 133,410 not exposed to PPIs, the overall odds ratio (OR) for major malformations was 1.12 (95% confidence interval, CI: 0.86–1.45). Further analysis revealed no increased risk for spontaneous abortions (OR=1.29, 95% CI: 0.84–1.97); similarly, there was no increased risk for preterm delivery (OR=1.13, 95% CI: 0.96–1.33). In the secondary analysis of 1,341 exposed and 120,137 not exposed to omeprazole alone, the OR and 95% CI for major malformations were 1.17 and 0.90–1.53, respectively.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Gill SK, O'Brien L, Einarson TR, Koren G. The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis. Am J Gastroenterol. 2009 Jun;104(6):1541-5. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;See also: &lt;/STRONG&gt;&lt;A href="nelh:331873:0" name=internalLink&gt;DARE record&lt;/A&gt; for this article&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293621</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1468-1293.2007.00476.x]]&gt;</url>
    <title>The treatment of chronic hepatitis C in HIV-infected patients: a meta-analysis</title>
    <publicationDate>2007-07-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,HIV / AIDS,CHRONIC HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Kim, AI et al HIV medicine 2007 Jul;8(5):312-21&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract: &lt;/STRONG&gt;OBJECTIVE: Hepatitis C virus (HCV) disease progression appears to be accelerated in patients coinfected with HIV. The impact of HCV on coinfected patients is being realized as patients are now living longer. The objective of our study was to further elucidate incremental improvement and safety concerns with combinations of pegylated interferon (peginterferon), interferon and ribavirin based on data obtained from prospective randomized controlled trials. METHODS: A search of MEDLINE and the Cochrane database for material published between 1966 and 29 August 2005 and a hand search of abstracts from national meetings held between 2001 and August 2005 were performed. Trials comparing the use of peginterferon plus ribavirin vs peginterferon or interferon plus ribavirin were assessed. RESULTS: In six randomized controlled trials, 1756 patients were randomized. Sustained virological response was greater for patients treated with peginterferon plus ribavirin compared with patients treated with interferon plus ribavirin [odds ratio (OR) 3.00; 95% confidence interval (CI) 2.27-3.96]. This increased sustained virological response with peginterferon and ribavirin was found for patients with HCV genotype 1 or 4 (OR 4.40; 95% CI 2.75-7.03) and genotype 2 or 3 (OR 2.56; 95% CI 1.71-3.85). Sustained virological responses were also higher with peginterferon and ribavirin as compared with peginterferon monotherapy (OR 2.60; 95% CI 1.84-3.67). Severe adverse effects (OR 1.09; 95% CI 0.74-1.4) and withdrawal rates (OR 0.97; 95% CI 0.75-1.25) were similar between patients treated with peginterferon plus ribavirin and patients treated with interferon plus ribavirin. CONCLUSIONS: Patients with chronic HCV/HIV coinfection have a greater likelihood of achieving a sustained virological response with peginterferon plus ribavirin. The likelihoods of serious adverse effects and study withdrawal were similar.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>126590</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.hepctrust.org.uk/Resources/HepC/Migrated%20Resources/Documents/Other/213_The%20UK%20vs.%20Europe.pdf]]&gt;</url>
    <title>The UK vs. Europe: losing the fight against Hepatitis C</title>
    <publicationDate>2005-09-30T00:00:00</publicationDate>
    <publisher>Hepatitis C Trust</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This interim report compares hepatits care in France, Germany, Italy and Spain to the UK.</description>
    <body>&lt;![CDATA[ &lt;P&gt;This report is a summary of&amp;nbsp;interim findings. Full report in link below.&lt;/P&gt;
&lt;P&gt;Urgent action is required to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Increase diagnosis of hepatitis C 
&lt;LI&gt;Increase the number of patients that are treated, and bring the UK in line with the rest of Europe&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The report looks at what our European neighbours have achieved and advocates that we learn from their successes.&lt;FONT face="Times New Roman,Times New Roman"&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Audience:&lt;/STRONG&gt;&amp;nbsp;All those affected by Hepatitis C care&amp;nbsp;within the NHS,&amp;nbsp;especially&amp;nbsp;healthcare professionals and&amp;nbsp;managers.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Freely available.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Related links:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:126586:0" name=internalLink&gt;&lt;/A&gt;Full report &lt;A href="nelh:126678:0" name=internalLink&gt;&lt;A href="nelh:126678:0" name=internalLink&gt;The UK vs. Europe: ready to fight back?&lt;/A&gt;&lt;/A&gt; The Hepatitis C Trust.&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:126586:0" name=internalLink&gt;&lt;A href="ttp://www.hepcuk.info/data/news/280_A%20MATTER%20OF%20CHANCE%2023-5-06.pdf" target="_blank"&gt;A matter of chance: an audit of the Department of Health 2005 Hepatitis C Action Plan for England&lt;/A&gt;&lt;A href="ttp://www.hepcuk.info/data/news/280_A%20MATTER%20OF%20CHANCE%2023-5-06.pdf" target="_blank"&gt;&lt;/A&gt;&lt;/A&gt;&lt;A href="ttp://www.hepcuk.info/data/news/280_A%20MATTER%20OF%20CHANCE%2023-5-06.pdf" target="_blank"&gt;&lt;/A&gt;&lt;/A&gt;&lt;A href="ttp://www.hepcuk.info/data/news/280_A%20MATTER%20OF%20CHANCE%2023-5-06.pdf" target="_blank"&gt;&lt;/A&gt;&lt;/A&gt;, Department of Health.&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:126589:0" name=internalLink&gt;&lt;A href="nelh:126589:0" name=internalLink&gt;&lt;A href="nelh:126589:0" name=internalLink&gt;Hepatitis C Action Plan for England&lt;/A&gt;&lt;A href="nelh:126589:0" name=internalLink&gt;&lt;/A&gt;&lt;/A&gt;&lt;A href="nelh:126589:0" name=internalLink&gt;&lt;/A&gt;&lt;/A&gt;, Department for Health.&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:126588:0" name=internalLink&gt;&lt;A href="nelh:126588:0" name=internalLink&gt;&lt;A href="nelh:126588:0" name=internalLink&gt;&lt;A href="http://www.dh.gov.uk/assetRoot/04/05/95/10/04059510.pdf" target="_blank"&gt;Hepatitis C Strategy for England&lt;/A&gt;&lt;A href="http://www.dh.gov.uk/assetRoot/04/05/95/10/04059510.pdf" target="_blank"&gt;&lt;/A&gt;&lt;EM&gt;&lt;/A&gt;&lt;/EM&gt;&lt;A href="http://www.dh.gov.uk/assetRoot/04/05/95/10/04059510.pdf" target="_blank"&gt;&lt;/A&gt;&lt;/A&gt;&lt;A href="http://www.dh.gov.uk/assetRoot/04/05/95/10/04059510.pdf" target="_blank"&gt;&lt;/A&gt;&lt;/A&gt;, Department for Health.&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:126587:0" name=internalLink&gt;&lt;A href="nelh:126588:0" name=internalLink&gt;&lt;A href="nelh:126587:0" name=internalLink&gt;&lt;A href="http://www.hepcuk.info/data/usercontentroot/home/" target="_blank"&gt;The Hepatitis C Trust&lt;/A&gt;&lt;A href="http://www.hepcuk.info/data/usercontentroot/home/" target="_blank"&gt;&lt;/A&gt;&lt;/A&gt;&lt;A href="http://www.hepcuk.info/data/usercontentroot/home/" target="_blank"&gt;&lt;/A&gt;&lt;/A&gt;&lt;A href="http://www.hepcuk.info/data/usercontentroot/home/" target="_blank"&gt;&lt;/A&gt;&lt;/A&gt; website.&lt;/FONT&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>126678</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.hepctrust.org.uk/Resources/HepC/Migrated%20Resources/Documents/Other/281_Euro%20Report%20final.pdf]]&gt;</url>
    <title>The UK vs. Europe: ready to fight back?</title>
    <publicationDate>2006-05-24T00:00:00</publicationDate>
    <publisher>Hepatitis C Trust</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Hepatitis C infection is a serious public health issue that is being actively confronted in many European countries. Sadly, the UK is poorly prepared to address it.</description>
    <body>&lt;![CDATA[ &lt;P&gt;This report,&amp;nbsp;commissioned by&amp;nbsp;The Hepatitis C Trust,&amp;nbsp;sets out recommendations, that the UK Government and healthcare policymakers must consider if we are to stand any chance of effectively controlling this insidious disease.&lt;/P&gt;
&lt;P&gt;A concensus panel of UK hepatologists was assembled to consider the barriers to effective detection and treatment of hepatitis C. Their &lt;STRONG&gt;7 recommendations&lt;/STRONG&gt; were (headline only):&lt;/P&gt;
&lt;P&gt;1. Develop a detailed strategy for the management of HCV, with detailed targets for detection and treatment&lt;/P&gt;
&lt;P&gt;2. Appoint an individual to lead strategy development within the Department of Health&lt;/P&gt;
&lt;P&gt;3. Develop and implement an awareness campaign using multiple media channels and parient representation&lt;/P&gt;
&lt;P&gt;4. Improve diagnostic services for HCV&lt;/P&gt;
&lt;P&gt;5. Build an appropriate infrastructure for diagnosis and treatment&lt;/P&gt;
&lt;P&gt;6. Establish a "diagnosis to treatment highway" for rapid refeeral abd initiation of treatment&lt;/P&gt;
&lt;P&gt;7. Link clinical activity to a research programme, targetting epidemiology, evaluation of these programmes plus clinical and basic science research into diagnosis and more effective treatment of HCV&lt;FONT face="Times New Roman,Times New Roman"&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Audience:&lt;/STRONG&gt;&amp;nbsp;All those affected by Hepatitis C care&amp;nbsp;within the NHS,&amp;nbsp;especially&amp;nbsp;healthcare professionals and&amp;nbsp;managers.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Freely available.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Related links:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:126586:0" name=internalLink&gt;&lt;/A&gt;Interim report &lt;A href="nelh:126590:0" name=internalLink&gt;&lt;A href="nelh:126678:0" name=internalLink&gt;The UK vs. Europe: losing the fight&amp;nbsp;against Hepatitis C&lt;/A&gt;&lt;/A&gt;&lt;/A&gt;. The Hepatitis C Trust.&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:126586:0" name=internalLink&gt;&lt;A href="ttp://www.hepcuk.info/data/news/280_A%20MATTER%20OF%20CHANCE%2023-5-06.pdf" target="_blank"&gt;A matter of chance: an audit of the Department of Health 2005 Hepatitis C Action Plan for England&lt;/A&gt;&lt;A href="ttp://www.hepcuk.info/data/news/280_A%20MATTER%20OF%20CHANCE%2023-5-06.pdf" target="_blank"&gt;&lt;/A&gt;&lt;/A&gt;&lt;A href="ttp://www.hepcuk.info/data/news/280_A%20MATTER%20OF%20CHANCE%2023-5-06.pdf" target="_blank"&gt;&lt;/A&gt;&lt;/A&gt;&lt;A href="ttp://www.hepcuk.info/data/news/280_A%20MATTER%20OF%20CHANCE%2023-5-06.pdf" target="_blank"&gt;&lt;/A&gt;&lt;/A&gt;, Department of Health.&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:126589:0" name=internalLink&gt;&lt;A href="nelh:126589:0" name=internalLink&gt;&lt;A href="nelh:126589:0" name=internalLink&gt;Hepatitis C Action Plan for England&lt;/A&gt;&lt;A href="nelh:126589:0" name=internalLink&gt;&lt;/A&gt;&lt;/A&gt;&lt;A href="nelh:126589:0" name=internalLink&gt;&lt;/A&gt;&lt;/A&gt;, Department&amp;nbsp;of Health.&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:126588:0" name=internalLink&gt;&lt;A href="nelh:126588:0" name=internalLink&gt;&lt;A href="nelh:126588:0" name=internalLink&gt;&lt;A href="http://www.dh.gov.uk/assetRoot/04/05/95/10/04059510.pdf" target="_blank"&gt;Hepatitis C Strategy for England&lt;/A&gt;&lt;A href="http://www.dh.gov.uk/assetRoot/04/05/95/10/04059510.pdf" target="_blank"&gt;&lt;/A&gt;&lt;/A&gt;&lt;A href="http://www.dh.gov.uk/assetRoot/04/05/95/10/04059510.pdf" target="_blank"&gt;&lt;/A&gt;&lt;/A&gt;&lt;A href="http://www.dh.gov.uk/assetRoot/04/05/95/10/04059510.pdf" target="_blank"&gt;&lt;/A&gt;&lt;/A&gt;, Department of Health.&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:126587:0" name=internalLink&gt;&lt;A href="nelh:126587:0" name=internalLink&gt;&lt;A href="http://www.hepcuk.info/data/usercontentroot/home/" target="_blank"&gt;The Hepatitis C Trust&lt;/A&gt;&lt;A href="http://www.hepcuk.info/data/usercontentroot/home/" target="_blank"&gt;&lt;/A&gt;&lt;/A&gt;&lt;A href="http://www.hepcuk.info/data/usercontentroot/home/" target="_blank"&gt;&lt;/A&gt;&lt;/A&gt; website.&lt;/FONT&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309190</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.dld.2008.03.016]]&gt;</url>
    <title>The use of thiopurines for the treatment of inflammatory bowel diseases in clinical practice</title>
    <publicationDate>2008-10-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,INDETERMINATE COLITIS,ULCERATIVE COLITIS,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Thiopurines confirm their clinical usefulness and acceptable safety profile in managing complicated IBD patients. The majority of patients treated for longer than 4 years maintain response. No clinical and demographic predictive factors for efficacy and side effects were identified.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; To evaluate the use, the therapeutic and safety profiles of thiopurines in a large sample of IBD patients.We reviewed 3641 case histories of IBD patients. Thiopurines were prescribed in 582 patients (16.0%); the analysis was performed on the 553 (267 ulcerative colitis, 286 Crohn's disease) with exhaustive clinical data.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The main indications for treatment were steroid-dependence (328/553, 59.3%) and steroid-resistance (113/553, 20.7%). Thiopurines were started when CD were younger than UC patients (&lt;I&gt;p&lt;/I&gt;&amp;nbsp;&amp;lt;&amp;nbsp;0.001) but earlier from diagnosis in UC than in CD patients (&lt;I&gt;p&lt;/I&gt;&amp;nbsp;=&amp;nbsp;0.003). Efficacy was defined as optimal (258/553, 46.6%), partial (108/553, 19.5%), absent (85/553, 15.4%) and not assessable (102/553, 18.4%). Efficacy was independent of disease type, location/extension or duration and age at starting. Side effects were observed in 151/553 (27.3%) patients, leading to drug discontinuation in 101 (18.3%). 15 out of the 130 (11.5%) patients who took thiopurines for more than 4 years relapsed, more frequently in CD than in UC (OR&amp;nbsp;=&amp;nbsp;3.67 95% C.I. 0.98–13.69; &lt;I&gt;p&lt;/I&gt;&amp;nbsp;=&amp;nbsp;0.053).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Saibeni, S., Virgilio, T., D'Inca, R., Spina, L., Bortoli, A., Paccagnella, M., Peli, M., Sablich, R., Meucci, G., Colombo, E., Benedetti, G., Girelli, C. M., Casella, G., Grasso, G., de Franchis, R., &amp;amp; Vecchi, M. (2008) The use of thiopurines for the treatment of inflammatory bowel diseases in clinical practice. &lt;I&gt;Digestive and Liver Disease&lt;/I&gt;, 40(10):814-820.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in September 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>311565</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1038/ajg.2009.25]]&gt;</url>
    <title>The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review</title>
    <publicationDate>2009-04-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COLON &amp; RECTUM,IRRITABLE BOWEL SYNDROME]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion: &lt;/STRONG&gt;&lt;EM&gt;B. infantis&lt;/EM&gt; 35624 has shown efficacy for improvement of IBS symptoms. Most RCTs about the utility of probiotics in IBS have not used an appropriate study design and do not adequately report adverse events. Therefore, there is inadequate data to comment on the efficacy of other probiotics. Future probiotic studies should follow Rome II recommendations for appropriate design of an RCT.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Comprehensive literature searches of multiple databases were performed. Study selection criteria were as follows: (i) RCTs, (ii) adults with IBS defined by Manning or Rome II criteria, (iii) single or combination probiotic vs. placebo, and (iv) improvement in IBS symptoms and/or decrease in frequency of adverse events reported. Data about study design and results were extracted in duplicate using standardized data extraction forms. Owing to variability in outcome measures, quantitative pooling of data was not feasible.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; A total of 16 RCTs met selection criteria. Of those, 11 studies showed suboptimal study design with inadequate blinding, inadequate trial length, inadequate sample size, and/or lack of intention-to-treat analysis. None of the studies provided quantifiable data about both tolerability and adverse events. &lt;I&gt;Bifidobacterium infantis&lt;/I&gt; 35624 showed significant improvement in the composite score for abdominal pain/discomfort, bloating/distention, and/or bowel movement difficulty compared with placebo (&lt;I&gt;P&lt;/I&gt;&amp;lt;0.05) in two appropriately designed studies. No other probiotic showed significant improvement in IBS symptoms in an appropriately designed study.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS.&amp;nbsp;The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review.&amp;nbsp;Am J Gastroenterol 2009;104(4):1033-1049.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>380650</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1345/aph.1M225]]&gt;</url>
    <title>The utility of therapeutic drug monitoring for ribavirin in patients with chronic hepatitis C--a critical review</title>
    <publicationDate>2009-12-01T00:00:00</publicationDate>
    <publisher>Harvey Whitney Books Co.</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,RECENT ADDITIONS,CHRONIC HEPATITIS C,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; There is conflicting evidence about the existence of a correlation between ribavirin concentrations and virologic response or development of toxicity. This inconsistent evidence, coupled with the currently employed effective strategies that maximize sustained virologic response and minimize development of anemia, precludes the utility of TDM for ribavirin.Background and aims:&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; To evaluate the utility of therapeutic drug monitoring (TDM) for ribavirin in chronic hepatitis C.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Literature searches were conducted through PubMed (1949-June 2009), EMBASE (1980-June 2009), BIOSIS Previews (1969-June 2009), International Pharmaceutical Abstracts (1970-June 2009), Google, and www.clinicaltrials.gov using the terms ribavirin, therapeutic monitoring, hepatitis C, and drug levels. In addition, pertinent reference citations from identified publications were reviewed. Studies were limited to English language, adult age, and human subjects. All articles identified from the data sources were evaluated. Studies that measured ribavirin concentrations or dose and treatment response were included in the review. While monitoring of ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C has been described in the literature, the utility of TDM for ribavirin in this group of patients has not been systematically studied. Thus, a previously published 9-step decision-making algorithm was employed to help determine whether TDM is warranted, based on currently available evidence.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt;&amp;nbsp; Thirty articles involving patients with chronic hepatitis C mono-infection, 12 for hepatitis C-HIV coinfection, 5 for renal dysfunction, and 5 for post-liver transplant patients were reviewed. In all subpopulations, studies exist that either support or refute the usefulness of ribavirin TDM. Additionally, the majority of the included studies had methodologic limitations, such as small sample size, retrospective analyses, and lack of p value adjustment for multiple analyses. Large randomized controlled trials would help to definitively answer this question.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Chan AH, Partovi N, Ensom MH. The utility of therapeutic drug monitoring for ribavirin in patients with chronic hepatitis C--a critical review. &lt;EM&gt;Ann Pharmacother &lt;/EM&gt;2009;43(12):2044-63.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309053</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://journal.cpha.ca/index.php/cjph/article/view/1613/1802]]&gt;</url>
    <title>The zoonotic potential of Mycobacterium avium spp. paratuberculosis: a systematic review</title>
    <publicationDate>2008-04-01T00:00:00</publicationDate>
    <publisher>Canadian Public Health Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Evidence for the zoonotic potential of MAP is not strong, but should not be ignored. Interdisciplinary collaboration among medical, veterinary and other public health officials may contribute to a better understanding of the potential routes of human exposure to MAP.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; The search strategy included 19 bibliographic databases, 8 conference proceedings, reference lists of 15 articles and contacting 28 topic-related scientists. Two independent reviewers performed relevance screening, quality assessment and data extraction stages of the review.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Seventy-five articles were included. Among 60 case-control studies that investigated the association between MAP and CD, 37 were of acceptable quality. Twenty-three studies reported significant positive associations, 23 reported non-significant associations, and 14 did not detect MAP in any sample. Different laboratory tests, test protocols, types of samples and source populations were used in these studies resulting in large variability among studies. Seven studies investigated the association between CD and JD, two challenge trials reported contradictory results, one cross-sectional study did not support the association, and four descriptive studies suggested that isolated MAP is often closely related to cattle isolates. MAP detection in raw and pasteurized milk was reported in several studies.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Waddell, L. A., Rajic, A., Sargeant, J., Harris, J., Amezcua, R., Downey, L., Read, S., &amp;amp; McEwen, S. A. (2008) The zoonotic potential of Mycobacterium avium spp. paratuberculosis: a systematic review. &lt;I&gt;Canadian Journal of Public Health/Revue Canadienne de Sante Publique&lt;/I&gt;, 99(2):145-55.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; Published in March 2008&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Availability: &lt;/STRONG&gt;Available to the general public&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281302</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17391318?ordinalpos=2&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review</title>
    <publicationDate>2008-03-10T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: &lt;/P&gt;
&lt;P&gt;Gisbert, JP. &lt;SPAN title="The American journal of gastroenterology."&gt;&lt;A href="#javascript:AL_get(this," ?jour?, ?Am J Gastroenterol.?);?&gt;Am J Gastroenterol.&lt;/A&gt;&lt;/SPAN&gt; 2007 Jul;102(7):1518-27. Epub 2007 Mar 27.&lt;/P&gt;
&lt;P class=abstract&gt;The mean prevalence of azathioprine (AZA) or 6-mercaptopurine (MP)-induced liver injury in patients with inflammatory bowel disease was approximately 3%, and the mean annual drug-induced liver disorder rate was only 1.4%. However, this low figure calculated from retrospective studies contrasts with a much higher incidence (&amp;gt;10%) reported by a prospective study. Thiopurine-induced hepatotoxicity can be grouped into three syndromes: hypersensitivity, idiosyncratic cholestatic reaction, and endothelial cell injury (with resultant raised portal pressures, veno-occlusive disease, or peliosis hepatis). A small percentage of patients present with a slight elevation of liver tests (LTs) that do not have clinical implications and LTs return to normal values during the follow-up, indicating that it is not always necessary to adjust the dose of the immunomodulator. However, when abnormalities in LTs are more marked, the dose of AZA/MP may be reduced 50%, with posterior clinical and analytical controls. With this strategy, LTs frequently normalize spontaneously, and the initial AZA/MP dose may be cautiously prescribed again. Thiopurines may induce an unusual severe cholestatic jaundice that may not regress but even progress despite thiopurine withdrawal. Therefore, these drugs should be completely withdrawn, and not only tapered, in those patients presenting clinically significant jaundice. Despite a lack of evidence that monitoring of LTs is necessary in patients receiving AZA/MP, routinely performed laboratory controls including LTs seem recommendable. However, the optimal monitoring schedule remains to be established. As long-term hepatotoxicity seems to be an unpredictable and potentially severe adverse drug reaction of 6-thioguanine, this drug should not be administered outside a clinical trial setting. (Am J Gastroenterol 2007;102:1518-527).&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;The American Journal of Gastroenterology is the official journal of the American College of Gastroenterology and publishes a variety of material including editorials, clinical reviews, correspondance and research articles.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: This article is &lt;STRONG&gt;not&lt;/STRONG&gt; available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309224</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1572-0241.2008.01848.x]]&gt;</url>
    <title>Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review</title>
    <publicationDate>2008-07-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The incidence rate of myelotoxicity in IBD patients receiving AZA/MP is approximately 3% per patient and year of treatment. Although bone marrow toxicity may develop at any time after starting the therapy, this happens more frequently during the first months. The incidence rate of severe myelotoxicity is less than 1% per patient and year of treatment, and the mortality risk is less than 0.1% (which means that the risk of death among IBD patients who develop myelotoxicity is approximately 1%).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Bibliographical searches were performed in MEDLINE/EMBASE. The studies evaluating thiopurine-induced myelotoxicity in patients with IBD were reviewed. The cumulative incidence and the incidence rate of AZA/MP-induced myelotoxicity were calculated by a meta-analysis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; In total, 66 studies (8,302 patients) were included. The cumulative incidence of AZA/MP-induced myelotoxicity was 7% (95% confidence interval [CI] 6–8%). The incidence rate (per patient and year of treatment) of the drug-induced myelotoxicity was 3% (95% CI 3–4%). The risk was roughly similar with AZA and with MP (7% vs 9%). The duration of AZA/MP treatment in patients with myelotoxicity ranged from 12 days to 27 yr. The cumulative incidence of infections among AZA/MP-induced myelotoxicity patients was 6.5%. The cumulative incidence of severe myelotoxicity was 1.1% (incidence rate 0.9%). Three deaths were reported due to myelotoxicity (cumulative incidence 0.06%, 95% CI 0.02–0.17%). The risk of death among patients who developed myelotoxicity was 0.94% (95% CI 0.32–2.70%).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Gisbert, J. P. &amp;amp; Gomollon, F. (2008) Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. &lt;I&gt;American Journal of Gastroenterology&lt;/I&gt;, 103(7):1783-1800.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;See also: &lt;/STRONG&gt;&lt;A href="nelh:342846:0" name=internalLink&gt;DARE record&lt;/A&gt; for this article.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in July 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>177108</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.clnu.2005.03.004]]&gt;</url>
    <title>To screen or not to screen for adult malnutrition</title>
    <publicationDate>2005-12-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COMMON CLINICAL PRESENTATIONS,DIAGNOSTIC PROCEDURES,NUTRITION ASSESSMENT,MALNUTRITION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A systematic review examining whether malnourished patients are remaining unidentified and untreated, and nutritional screening interventions in populations of malnourished and well-nourished subjects. 
</description>
    <body>&lt;![CDATA[ &lt;H2&gt;Description&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;Bibliographic details:&lt;/STRONG&gt; Elia, M., Zellipour, L., Stratton, R.J., Clinical Nutrition, 2005 Dec; 24(6): 867-84.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background&lt;/STRONG&gt;:&amp;nbsp;There is some controversy about whether all adults receiving healthcare should be routinely screened for nutritional problems. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt;&amp;nbsp;(i) A systematic review examined the proposition that malnutrition is under-recognised and under-treated, and that nutritional interventions in malnourished patients, identified through a screening procedure produce clinical benefits (assessed using randomised controlled trials, RCTs). (ii) A systematic review of nutritional screening interventions in populations of malnourished and well-nourished subjects (RCTs and non-RCTs). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; The frequent failure to recognise and treat malnutrition, especially where it is common, is unacceptable. In such circumstances, the routine use of a simple screening procedure is recommended. Each health care setting should have a transparent policy about nutritional screening, which may vary according to the 'care gap', available resources, and specific populations of patients, in which the prevalence of malnutrition may vary widely.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience&lt;/STRONG&gt;:&amp;nbsp;Healthcare professionals&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>377690</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/ebm1073]]&gt;</url>
    <title>Training paediatricians to follow guidelines for the management of acute gastroenteritis improves guideline adherence and reduces the duration of diarrhoea in young children</title>
    <publicationDate>2010-06-01T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,COMMON CLINICAL PRESENTATIONS,STOMACH,GASTRITIS,SMALL INTESTINE,DIARRHOEA,INFECTIONS,RECENT ADDITIONS,INFECTIONS,ENTERITIS,JUNE 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Evidence-Based Medicine is a secondary evidence journal, containing informative abstracts and expert commentaries about the best quality research from primary care medicine.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Tieder JS. Training paediatricians to follow guidelines for the management of acute gastroenteritis improves guideline adherence and reduces the duration of diarrhoea in young children. &lt;EM&gt;Evid Based Med&lt;/EM&gt; 2010;15(3):83-4.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt; A review of the original article: Albano F, Lo Vecchio A, Guarino A. The applicability and efficacy of guidelines for the management of acute gastroenteritis in outpatient children: a field-randomized trial on primary care pediatricians. &lt;EM&gt;J Pediatr&lt;/EM&gt; 2010;156:226–30.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to NHS staff via Athens.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323561</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1002/hep.22509]]&gt;</url>
    <title>Treating hepatitis C in the prison population is cost-saving</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,DISEASE PREVENTION,VACCINATION,RECENT ADDITIONS,AUGUST 2009,CHRONIC HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Treatment of chronic hepatitis C with PEG IFN and ribavirin in U.S. prisons results in both improved quality of life and savings in cost for almost all segments of the inmate population. If the decision to treat hepatitis C is based on pharmaco-economic measures, this significant proportion of infected individuals should not be denied access to therapy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; The aim of this study was to determine the cost-effectiveness of hepatitis C treatment with PEG IFN and ribavirin in the U.S. prison population. Cost-effectiveness was determined via a decision analysis model employing Markov simulation. The cohort of prisoners had a distribution of genotypes and stages of fibrosis in accordance with prior studies evaluating inmate populations. The probability of transitioning from one health state to another, reinfection rates, in-prison and out-of-prison mortality rates, sustained viral response rates, costs, and quality of life weights were also obtained from the literature. Sensitivity analysis was performed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; In a strategy without a pretreatment liver biopsy, treatment was cost-effective for all ages and genotypes. This model was robust to rates of disease progression, mortality rates, reinfection rates, sustained viral response rates, and costs. In a strategy employing a pretreatment liver biopsy, treatment was also cost-saving for prisoners of all ages and genotypes with portal fibrosis, bridging fibrosis, or compensated cirrhosis. Treatment was not cost-effective in patients between the ages of 40 and 49 with no fibrosis and genotype 1.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Tan JA, Joseph TA, Saab S. Treating hepatitis C in the prison population is cost-saving. &lt;EM&gt;Hepatology&lt;/EM&gt; 2008;48(5):1387-95.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293614</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1093/jac/dkn119]]&gt;</url>
    <title>Treatment of chronic hepatitis C in haemophilic patients with interferon and ribavirin: a meta-analysis</title>
    <publicationDate>2008-06-01T00:00:00</publicationDate>
    <publisher>Oxford University</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,CHRONIC HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Franchini, M et al. Journal of antimicrobial chemotherapy 2008 Jun;61(6):1191-200. Epub 2008 Mar 19&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract: &lt;/STRONG&gt;BACKGROUND: Hepatitis C virus (HCV) infection is a major cause of morbidity and mortality among haemophilic patients who were treated with clotting factor concentrates before the availability of virus-inactivated factors in the mid 1980s. In order to analyse the effect of the current combination anti-HCV treatment [i.e. ribavirin plus interferon (IFN)] in this subset of HCV-infected patients, we performed a systematic review with meta-analysis of the available literature. METHODS: The outcome was sustained viral suppression. When trials included for the main predictors two arms (positive and negative), the effect size was described as a comparative index [odds ratio (OR)] and a standard meta-analytical procedure was applied. However, when trials did not report the outcome in separate study arms, the effect size was a non-comparative index (success rate) and comparisons between predictor-positive and -negative studies were performed by meta-regression. RESULTS: Data involving 824 haemophilic HCV-infected patients treated with IFN plus ribavirin were collected from 18 articles (14 prospective cohort studies, 1 retrospective study and 3 randomized controlled trials). The higher rate of sustained viral response was observed in human immunodeficiency virus (HIV)-negative naive haemophiliacs treated with pegylated-IFN in combination with ribavirin (61%, ranging from 45% for genotype 1 to 79% for non-1 genotypes). Genotype 1 (OR, 0.15; 95% CI, 0.09-0.25) and co-infection with HIV (OR, 0.25; 95% CI, 0.08-0.81) were strong predictors of worse response to IFN therapy. CONCLUSIONS: Our meta-analysis shows that the pattern of response to combination anti-HCV therapy of chronically HCV-infected haemophiliacs is similar to that achieved in the general HCV-infected population.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;See also: &lt;/STRONG&gt;&lt;A href="nelh:312330:0" name=internalLink&gt;DARE record&lt;/A&gt; for this article&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>268521</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1345/aph.1G427]]&gt;</url>
    <title>Treatment of hepatitis C in HIV-coinfected patients</title>
    <publicationDate>2006-03-01T00:00:00</publicationDate>
    <publisher>Harvey Whitney Books Co.</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,HIV / AIDS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Hughes C.A. Shafran S.D. 2006; The Annals of Pharmacotherapy 40 (3) pp. 479-89&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;Abstract: &lt;/STRONG&gt;OBJECTIVE: To review the current management of hepatitis C virus (HCV) in persons coinfected with HIV. DATA SOURCES: A MEDLINE search (1966-February 2006) was conducted, using key words such as HIV, human immunodeficiency virus, hepatitis C, interferon, pegylated interferon, and therapy. Article bibliographies and conference abstracts were also reviewed to identify relevant studies. STUDY SELECTION AND DATA EXTRACTION: Studies that examined HCV treatment in individuals coinfected with HIV and articles that focused on HCV/HIV coinfection were considered for this review. DATA SYNTHESIS: Coinfection with HIV leads to a more rapid and severe course of HCV-related liver disease. Treatment of HCV with pegylated interferon (PEG-IFN) and ribavirin therapy is relatively well tolerated in individuals coinfected with HIV, with overall sustained virologic response (SVR) rates of 27-40%. High relapse rates and poor response in HCV-genotype 1 contribute to the lower SVR in coinfected individuals compared with HCV monoinfection. Treatment of HCV is more complicated in HIV-infected persons due to increased risk of myelosuppression, drug interactions, hepatotoxicity of antiretroviral therapy, and the relative contraindication to interferon therapy in advanced HIV disease. Current guidelines recommend that all HIV-positive patients with chronic HCV infection be considered as treatment candidates for anti-HCV therapy due to the higher risk of liver disease progression. Further studies are needed, however, to define the appropriate dose and duration of therapy in HCV/HIV-coinfected individuals. CONCLUSIONS: Response to treatment with PEG-IFN and ribavirin is poorer in patients coinfected with HCV/HIV than in those infected with HCV alone. The benefits of anti-HCV therapy, including viral eradication, need to be weighed against the risks of adverse effects and drug-drug interactions between anti-HCV and antiretroviral medications.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>268418</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1601-5215.2006.00136.x]]&gt;</url>
    <title>Treatment of hepatitis C virus infection in intravenous drug users</title>
    <publicationDate>2006-10-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,ACUTE HEPATITIS C,CHRONIC HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Cowan ML, Maxwell JD 2006; Acta Neuropsychiatrica 18 pp.183-192&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract: &lt;/STRONG&gt;Background:&amp;nbsp;Hepatitis C virus (HCV) infection is common among intravenous drug users, and because of the long latent period, HCV liver disease is set to increase. Objectives:&amp;nbsp;We sought to examine practice guidelines regarding treatment of HCV in drug users and to review the evidence for current practices. Methods:&amp;nbsp;A structured search of the Pubmed database, websites of the National Institute for Clinical Excellence and national and international expert groups and opinion of independent experts in the field. Results and Conclusions:&amp;nbsp;All those infected with HCV need to be assessed to ascertain whether they have active ongoing viral replication and the extent of liver damage. HCV-infected individuals should be educated about the modes of transmission and means of reducing the risk of infecting others. They should also be advised to avoid cofactors (especially alcohol) that accelerate the progression of liver disease. Specific treatment with antivirals can cause viral clearance and prevent the progression of liver disease. Therapy is effective in those on opiate-replacement treatments and also in motivated individuals who continue to use intravenous drugs. The decision whether to treat drug users should be made jointly by specialists in the management of viral hepatitis and addiction on a case-by-case basis. Current combination drug regimens are expensive but are claimed to be cost-effective, and are certainly much less costly than managing end-stage liver disease. In addition to satisfactory sustained viral response rates, other benefits such as a beneficial effect on drug habit, self-esteem and rehabilitation have been reported. Encouraging suitable drug users to take-up and comply with treatment seems to be more easily achieved in supportive drug dependency unit settings (rather than the more formal surroundings of a hospital clinic).&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>380730</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.jaad.2009.03.044]]&gt;</url>
    <title>Treatment of psoriasis in patients with hepatitis C: from the Medical Board of the National Psoriasis Foundation</title>
    <publicationDate>2009-12-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,RECENT ADDITIONS,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; There are no large double-blind clinical trials addressing the treatment of psoriasis in patients with&amp;nbsp;hepatitis C virus (HCV)&amp;nbsp;infection and more studies are needed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Treating psoriasis in patients with concomitant HCV infection presents a special challenge. Not only is psoriasis exacerbated by interferon therapy, the standard of care for HCV, but many psoriasis therapies are potentially hepatotoxic, immunosuppressive, or both, which has been generally thought to be a contraindication in chronic infections such as HCV. The objective of this study was to arrive at a consensus on treating psoriasis in patients with concomitant HCV infection. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Reports in the literature were reviewed regarding common psoriasis therapies and liver toxicity. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Topical therapies are first-line therapy for patients with limited psoriasis and HCV. Ultraviolet B phototherapy may be considered as a second-line treatment when needed. Ultraviolet B phototherapies in combination with topical therapies are first line for patients with moderate to severe psoriasis, and are considered safe in those patients with concomitant HCV infection. Other systemic therapies, such as acitretin, etanercept, and, possibly, other tumor necrosis factor inhibitors, are considered second line. Psoralen plus ultraviolet A should also be considered a second-line therapy. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Frankel AJ, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Bebo BF Jr, Gottlieb AB, National Psoriasis Foundation. Treatment of psoriasis in patients with hepatitis C: from the Medical Board of the National Psoriasis Foundation. &lt;EM&gt;J Am Acad Dermatol&lt;/EM&gt; 2009;61(6):1044-55.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>381391</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1517/14656561003642006]]&gt;</url>
    <title>Treatment of viral hepatitis B in children</title>
    <publicationDate>2010-04-01T00:00:00</publicationDate>
    <publisher>Informa</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,RECENT ADDITIONS,CHRONIC HEPATITIS B,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The decision to treat&amp;nbsp;chronic hepatitis B&amp;nbsp;(CHB) in children demands that the possibility of favorable spontaneous viral clearance has been considered and must be made on the bases of the extent of liver damage.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Treatment of CHB in children is aimed at reducing viral replication and at minimizing liver injury and related consequences in children with chronic active viral liver infection.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; In this review, treatment options available for both adults and children are summarized, together with suggestions from our own experience. The most relevant works published between 1982 and 2009 on PubMed/Medline database search were used.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; At present, standardized treatment is available in only a few therapeutic options, such as IFN-alpha and lamivudine; it is hoped that these will be complemented in the future by new, encouraging drugs still under study in pediatric age patients. Moreover, current treatment approaches have their limitations: although IFN-alpha has been shown to be effective in patients with non-vertically-transmitted infection, HBeAg clearance while on treatment is similar to spontaneous seroconversion after long-term follow-up. IFN-alpha-induced side effects are frequent rarely severe in children. Lamivudine achieves similar results in children with active viral replication. However, despite good compliance to oral administration, this treatment can lead to the development of drug-resistant mutations.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Giacchino R, Cappelli B. Treatment of viral hepatitis B in children. Expert Opin Pharmacother 2010;11(6):889-903.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>378387</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.jhep.2010.01.037]]&gt;</url>
    <title>Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials</title>
    <publicationDate>2010-07-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,AUTOIMMUNE CHRONIC HEPATITIS,RECENT ADDITIONS,JUNE 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Based on available randomised controlled trials (RCTs), predniso(lo)ne&amp;nbsp;(PRED) monotherapy and PRED + azathioprine (AZA) combination therapy are both viable induction therapies for&amp;nbsp;autoimmune hepatitis (AIH)&amp;nbsp;treatment naives and relapsers, while for maintenance therapy PRED + AZA and AZA therapy are superior to PRED monotherapy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; PRED with or without&amp;nbsp;AZA is considered the mainstay in the treatment of AIH, but many therapeutic options are available. The primary objective of this review was to explore the published literature on the optimal induction and subsequent maintenance therapy for AIH.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method: &lt;/STRONG&gt;We performed a systematic search on electronic databases MEDLINE (1950-07.2009), Web of Science, Cochrane, and the website www.clinicaltrials.gov. RCTs on apparent beneficial treatment regimens as induction or maintenance treatment in AIH were included. Pediatric studies were excluded. We calculated relative risks (RR) for comparison of treatment options on the primary outcome measure, which was defined as clinical, biochemical and histological remission.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Eleven RCTs were included, of which 7 studies evaluated the induction therapy in AIH patients: 3 treatment naive (n=253), 2 relapse (n=53), 2 combination of naive and relapse (n=110). The remaining 4 studies (n=162) assessed maintenance therapy. All but one maintenance study (thymostimulin versus no therapy) studied PRED, AZA or combination PRED+AZA. We found no differences in primary outcome between induction therapy with PRED and PRED+AZA in treatment naive patients (RR=0.98; 95% CI 0.65-1.47). AZA monotherapy as induction was considered as not viable because of a high mortality rate (30%). This was similar in AIH patients who relapsed: RR for PRED versus PRED+AZA for inducing remission was not different: 0.71 (95% CI 0.37-1.39). PRED+AZA maintained remission more often than PRED (RR=1.40; 95% CI 1.13-1.73). Also AZA maintained a higher remission rate than PRED (RR=1.35; 95% CI 1.07-1.70). Maintenance of remission was not different between PRED+AZA and AZA (RR=1.06; 95% CI 0.94-1.20). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Lamers MM, van Oijen MG, Pronk M, Drenth JP. Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials. &lt;EM&gt;J Hepatol&lt;/EM&gt; 2010;53(1):191-8.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309208</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=2605852&amp;blobtype=pdf]]&gt;</url>
    <title>Treatment regimen adherence in pediatric gastroenterology</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>Lippincott Williams &amp; Wilkins</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,CROHN'S DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Future research should focus on refining assessment method, examining adherence and concomitant behavioral factors longitudinally, testing theoretical models of adherence, and developing efficacious treatments for nonadherence.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A literature search with no date restriction was conducted using PubMed and PsychInfo electronic databases and bibliographies of relevant articles.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Adherence rates in inflammatory bowel disease and celiac disease range considerably from 16% to 62% and 5% to 70%, respectively, across treatments and assessment method; nonadherence frequency was generally not reported. Measures used to assess adherence included self-report, interview, diet record, and bioassay methods, and each measure demonstrated strengths and limitations. Limited evidence suggests that adherence in both disease populations is related to patient and family behavioral factors and that nonadherence is related to poor disease outcome. Treatment outcome research for nonadherence is scant in the current literature.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Hommel, K. A., Mackner, L. M., Denson, L. A., &amp;amp; Crandall, W. V. (2008) Treatment regimen adherence in pediatric gastroenterology. &lt;I&gt;Journal of Pediatric Gastroenterology &amp;amp; Nutrition&lt;/I&gt;, 47(5):526-543.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in November 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>381272</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.virologyj.com/content/6/1/63]]&gt;</url>
    <title>Treatment with lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B patients: a meta-analysis</title>
    <publicationDate>2009-05-25T00:00:00</publicationDate>
    <publisher>BioMed Central</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,RECENT ADDITIONS,CHRONIC HEPATITIS B,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Among hepatitis B e antigen (HBeAg)-positive patients, thymosin alpha-1 and lamivudine combination therapy may be more effective than lamivudine monotherapy, providing superior rates of biochemical response, virological response, and HBeAg seroconversion.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Currently, there is no evidence on the combination of lamivudine and thymosin alpha-1 on chronic hepatitis B patients. The aim of this study was to compare the effect of lamivudine monotherapy with that of lamivudine and thymosin alpha-1 combination therapy for the treatment of HBeAg-positive hepatitis B patients.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We searched PUBMED (from 1966 onwards), EMBASE (from 1966), CBMdisk (Chinese Biomedical Database, from 1978), CNKI (National Knowledge Infrastructure, from 1980), the Cochrane Central Register of Controlled Trials and the Cochrane Database of Systematic Reviews.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Eight trials (583 patients in total) were identified. The lamivudine and thymosin alpha-1 combination treatment was significantly superior to lamivudine treatment in terms of ALT normalization rate (80.2% vs. 68.8%, P = 0.01), virological response rate (84.7% vs. 74.9%, P = 0.002), and HBeAg seroconversion rate (45.1% vs. 15.2%, P &amp;lt; 0.00001).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Zhang YY, Chen EQ, Yang J, Duan YR, Tang H. Treatment with lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B patients: a meta-analysis. &lt;EM&gt;Virol J&lt;/EM&gt; 2009;6:63.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>380664</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1742-1241.2009.02082.x]]&gt;</url>
    <title>Treatment with peginterferon plus ribavirin vs. interferon plus ribavirin for 48 weeks in Chinese patients with chronic hepatitis C</title>
    <publicationDate>2009-09-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C,RECENT ADDITIONS,CHRONIC HEPATITIS C,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Like Caucasian patients, Chinese patients with&amp;nbsp;chronic hepatitis C (CHC)&amp;nbsp;have a greater likelihood of achieving an&amp;nbsp;sustained virological response (SVR)&amp;nbsp;with&amp;nbsp;pegylated interferon (peg-IFN)&amp;nbsp;plus ribavirin than with interferon (IFN) plus ribavirin.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Virological responses to IFN treatment for CHC have been found to be correlated with racial differences. Furthermore, higher SVR rates were obtained in many randomised clinical trials (RCT) in Caucasian patients with CHC after treating with peg-IFN than those with IFN. However, it is not clear whether this conclusion can be adapted to patients of Chinese descent.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A search of MEDLINE and China National Knowledge Infrastructure between 1966 and 2008 was performed. Trials comparing the use of peg-IFN plus ribavirin vs. IFN plus ribavirin in treating Chinese patients with CHC were assessed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Of the 94 studies screened, seven RCTs including 398 patients (peg-IFN therapy 232, IFN therapy 166) were analysed. The SVRs obtained in patients treated with peg-IFN plus ribavirin were significantly higher than in patients treated with IFN plus ribavirin [70% vs. 35%, relative risk, 1.76; 95% confidence interval: 1.21-2.56; p (0.01)]. Withdrawal rates were similar between patients treated with peg-IFN plus ribavirin and IFN plus ribavirin.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Zhao SH, Chu YL, Cheng DX, Waqar AB, Yu Q, Yang PH, Xue X, Yang HJ, Liu EQ. Treatment with peginterferon plus ribavirin vs. interferon plus ribavirin for 48 weeks in Chinese patients with chronic hepatitis C. &lt;EM&gt;Int J Clin Pract&lt;/EM&gt; 2009;63(9):1334-9.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>377681</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1002/lt.22070]]&gt;</url>
    <title>T-Tube or no T-tube in the reconstruction of the biliary tract during orthotopic liver transplantation: systematic review and meta-analysis</title>
    <publicationDate>2010-06-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,BILIARY TREE &amp; GALLBLADDER,LIVER,LIVER TRANSPLANTATION,RECENT ADDITIONS,SURGERY,JUNE 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Although reconstruction of the biliary tree with a T-tube prevents the occurrence of biliary strictures and may have the potential to reduce long-term morbidity with respect to late strictures, there is no clear evidence in favor of using a T-tube during orthotopic liver transplantation (OLT).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; The routine use of a T-tube in reconstruction of the biliary tree during OLT is controversial.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A systematic review of the literature on the use of a T-tube in reconstruction of the biliary tree was performed. Retrospective studies were only reviewed, whereas prospective randomized studies were included in the meta-analysis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; An analysis of 196 studies revealed that 91 studies investigated the use of a T-tube in OLT. Fifteen retrospective studies compared different groups and were thus considered relevant; 6 prospective studies were identified, of which 5 were randomized controlled trials with a total of 639 patients. The results of the randomized controlled trials were meta-analyzed. The odds ratio (OR) for biliary complications was 1.15 [95% confidence interval (CI) = 0.28-4.72], and this revealed that there were no differences in the rate of overall biliary complications whether or not a T-tube was used (&lt;I&gt;Z&lt;/I&gt; = 0.19, &lt;I&gt;P&lt;/I&gt; = 0.85). A detailed analysis of the biliary complications revealed that biliary leaks developed in 24 patients in the T-tube group versus 22 patients in the no-T-tube group (OR = 1.17, 95% CI = 0.4-3.47, &lt;I&gt;Z&lt;/I&gt; = 0.29, &lt;I&gt;P&lt;/I&gt; = 0.77). Biliary strictures were significantly more common in the group of patients who underwent reconstruction without a T-tube (14 versus 31 events; OR = 0.46, 95% CI = 0.23-0.9, &lt;I&gt;Z&lt;/I&gt; = 2.26, &lt;I&gt;P&lt;/I&gt; = 0.02). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Riediger C, Müller MW, Michalski CW, Hüser N, Schuster T, Kleeff J, Friess H. T-Tube or no T-tube in the reconstruction of the biliary tract during orthotopic liver transplantation: systematic review and meta-analysis. &lt;EM&gt;Liver Transpl&lt;/EM&gt; 2010;16(6):705-17.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>322992</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1002/lt.21709]]&gt;</url>
    <title>Tuberculosis in liver transplant recipients: a systematic review and meta-analysis of individual patient data</title>
    <publicationDate>2009-08-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,TUBERCULOSIS,BACTERIAL INFECTIONS,LIVER TRANSPLANTATION,RECENT ADDITIONS,AUGUST 2009,SURGERY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt;&amp;nbsp;Compared with the general population, liver transplant recipients have an 18-fold increase in the prevalence of active &lt;EM&gt;Mycobacterium tuberculosis&lt;/EM&gt; (MTB) infection and a 4-fold increase in the case-fatality rate. For high-risk transplant candidates, isoniazid appears safe and is probably effective at reducing MTB reactivation.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We examined the efficacy of isoniazid latent &lt;I&gt;Mycobacterium tuberculosis&lt;/I&gt; infection (LTBI) treatment in liver transplant recipients and reviewed systematically all cases of active infection in this population.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; We found 7 studies that evaluated LTBI treatment and 139 cases of active MTB infection in liver transplant recipients. Isoniazid LTBI treatment was associated with reduced MTB reactivation in transplant patients with latent MTB risk factors (0.0% versus 8.2%, &lt;I&gt;P&lt;/I&gt; = 0.02), and isoniazid-related hepatotoxicity occurred in 6% of treated patients, with no reported deaths. The prevalence of active MTB infection in transplant recipients was 1.3%. Nearly half of all recipients with active MTB infection had an identifiable pretransplant MTB risk factor. Among recipients who developed active MTB infection, extrapulmonary involvement was common (67%), including multiorgan disease (27%). The short-term mortality rate was 31%. Surviving patients were more likely to have received 3 or more drugs for MTB induction therapy (&lt;I&gt;P&lt;/I&gt; = 0.003) and to have been diagnosed within 1 month of symptom onset (&lt;I&gt;P&lt;/I&gt; = 0.01) and were less likely to have multiorgan disease (&lt;I&gt;P&lt;/I&gt; = 0.01) or to have experienced episodes of acute transplant rejection (&lt;I&gt;P&lt;/I&gt; = 0.02).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Holty JE, Gould MK, Meinke L, Keeffe EB, Ruoss SJ. Tuberculosis in liver transplant recipients: a systematic review and meta-analysis of individual patient data. &lt;EM&gt;Liver Transpl&lt;/EM&gt; 2009 Aug;15(8):894-906.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>396346</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://aje.oxfordjournals.org/content/170/8/948.full.pdf]]&gt;</url>
    <title>Tumor necrosis factor polymorphisms and alcoholic liver disease: a HuGE review and meta-analysis</title>
    <publicationDate>2009-10-15T00:00:00</publicationDate>
    <publisher>Oxford Journals</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,ALCOHOLIC LIVER DISEASE,RECENT ADDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The &lt;EM&gt;American Journal of Epidemiology&lt;/EM&gt; is an epidemiological journal devoted to the publication of empirical research findings, methodological developments in the field of epidemiological research, and opinion pieces. It is aimed at both epidemiologists and those who use epidemiological data, including public health workers and clinicians. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Marcos, M., Gomez-Munuera, M., Pastor, I., Gonzalez-Sarmiento, R., &amp;amp; Laso, F. J. (2009). Tumor necrosis factor polymorphisms and alcoholic liver disease: a HuGE review and meta-analysis. American &lt;EM&gt;Journal of Epidemiology&lt;/EM&gt; 170(8): 948-956.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aim:&lt;/STRONG&gt; The main purpose of this study was to integrate previous findings and explore whether these polymorphisms are associated with susceptibility to ALD. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods: &lt;/STRONG&gt;The authors surveyed studies on the relation between TNFA gene polymorphisms and ALD by means of an electronic database search. A meta-analysis was conducted in a random-effects model. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The association between ALD and the -238G&amp;gt;A or -308G&amp;gt;A polymorphism of the TNFA gene has been analyzed in 11 studies. Concerning the -238G&amp;gt;A polymorphism, the authors found a significant association between possession of the A allele and risk of alcoholic liver cirrhosis (odds ratio = 1.47, 95% confidence interval: 1.05, 2.07). Meta-analysis of the relation between the -308G&amp;gt;A polymorphism and ALD did not show any significant association. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusion:&lt;/STRONG&gt; Given the limited number of studies and the potential biases, more data are needed to confirm the association described for the -238A allele.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is&amp;nbsp;freely available through the publisher's website.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>103349</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.acg.gi.org/physicians/guidelines/UlcerativeColitis.pdf]]&gt;</url>
    <title>Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee</title>
    <publicationDate>2010-03-01T00:00:00</publicationDate>
    <publisher>American College of Gastroenterology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,RECENT ADDITIONS,MAY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims&lt;/STRONG&gt;:&amp;nbsp;Published in the American Journal of Gastroenterology in March 2010, this guideline looks at the diagnosis, assessment, and&amp;nbsp;management of colitis.&amp;nbsp;&amp;nbsp; The guideline&amp;nbsp;methodology included a comprehensive&amp;nbsp;literature search, and a stated quality of evidence hierarchy for guideline recommendation.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience&lt;/STRONG&gt;:&amp;nbsp;Gastroenterologists&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published March 2010; update of previous version published in 2004.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;Available to the general public&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309212</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1517/14656566.9.5.741]]&gt;</url>
    <title>Ulcerative proctitis: a review of pharmacotherapy and management</title>
    <publicationDate>2008-04-01T00:00:00</publicationDate>
    <publisher>Informa</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,PROCTITIS &amp; DISTIL COLITIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Topical medication with rectally administered 5-aminosalicylic acid (5-ASA)/corticosteroid suppositories or enemas is effective treatment for most UP patients. Locally administered 5-ASA is more efficacious than oral compounds. The combination of topical 5-ASA and oral 5-ASA or topical steroids should be considered for escalation of treatment. Maintenance treatment is indicated in all UC cases. 5-ASA suppositories are suggested as first-line maintenance therapy if accepted by patients, although oral 5-ASA as maintenance therapy might prevent proximal extension of the disease. After re-assessment, chronically active patients refractory or intolerant to 5-ASAs and corticosteroids may require immunomodulators or biological therapy. Exceptional cases may require a proctocolectomy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Extensive Medline/Embase literature search was performed to identify relevant articles.&lt;STRONG&gt; &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Lakatos, P. L. &amp;amp; Lakatos, L. (2008) Ulcerative proctitis: a review of pharmacotherapy and management. &lt;I&gt;Expert Opinion on Pharmacotherapy&lt;/I&gt;, 9(5):741-749.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in April 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317186</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.acg.gi.org/physicians/guidelines/BarrettsEsophagus08.pdf]]&gt;</url>
    <title>Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett’s esophagus</title>
    <publicationDate>2008-03-01T00:00:00</publicationDate>
    <publisher>American College of Gastroenterology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,OESOPHAGUS,DIAGNOSTIC PROCEDURES,GASTROINTESTINAL ENDOSCOPY,UPPER ENDOSCOPY,DISEASE PREVENTION,BARRETT'S OESOPHAGUS,CAPSULE ENDOSCOPY,SCREENING,RECENT ADDITIONS,JUNE 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; Significant advances have occurred in the area of Barrett’s esophagus over the past four years leading to another revision of the prior guidelines. These advances include the potential use of esophageal capsule endoscopy for the diagnosis and screening of Barrett’s esophagus, data regarding the outcome of low-grade dysplasia, the treatment of high-grade dysplasia using photodynamic therapy, and the development of new ablation techniques such as radiofrequency ablation.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience: &lt;/STRONG&gt;Gastroenterologists, endoscopists&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published March 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>103401</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.acg.gi.org/physicians/guidelines/GERDTreatment.pdf]]&gt;</url>
    <title>Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease</title>
    <publicationDate>2005-01-01T00:00:00</publicationDate>
    <publisher>American College of Gastroenterology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,OESOPHAGUS,GASTRO-OESOPHAGEAL REFLUX]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims&lt;/STRONG&gt;: This clear evidence-based document is an update of previously published GERD guidelines by the College.&amp;nbsp; Different diagnostic and treatment considerations are addressed.&amp;nbsp; United Kingdom professionals should be aware that there is a slight leaning towards the US bias of the risk of Barrett's disease being a reason for early endoscopic intervention, but this is not overstated&amp;nbsp;in the guideline.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience&lt;/STRONG&gt;: All health care providers who address GERD&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in June 2005.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>268533</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1345/aph.1H169]]&gt;</url>
    <title>Use of hematopoietic growth factors as adjuvant therapy for anemia and neutropenia in the treatment of hepatitis C</title>
    <publicationDate>2007-02-01T00:00:00</publicationDate>
    <publisher>Harvey Whitney Books Co.</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS C]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt;&amp;nbsp;Dar Santos A.E., Partovi N., Ford J.A. et al. 2007; The Annals of Pharmacotherapy&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract: &lt;/STRONG&gt;OBJECTIVE: To review the hematologic adverse effects of hepatitis C virus (HCV) therapy and adjuvant treatment with epoetin alfa and granulocyte colony-stimulating factor (ie, filgrastim). DATA SOURCES: Medical literature indexed in MEDLINE (1966-January 2007) and EMBASE (1980-January 2007) was searched, and published conference abstracts were reviewed. STUDY SELECTION AND DATA EXTRACTION: Peer-reviewed articles and relevant conference abstracts regarding the use of epoetin alfa and granulocyte colony-stimulating factor were reviewed. DATA SYNTHESIS: Ribavirin induces a dose-dependent hemolytic anemia. Studies using epoetin alfa 40 000 units subcutaneously once weekly have demonstrated efficacy in maintaining hemoglobin, ribavirin dose, and quality of life scores, but clear benefit shown with sustained virologic response (SVR) is lacking. The hemoglobin threshold for initiation of epoetin alfa used in studies may not adequately reflect values used in clinical practice. Treatment-related neutropenia is caused primarily by interferon or peginterferon. Few studies have investigated the impact of granulocyte or granulocyte-macrophage colony-stimulating factor derivatives on neutropenia. Results of dose maintenance evaluation vary, and studies reporting data on SVR showed no effect from growth factor therapy. The frequency of bacterial infections was not reported. CONCLUSIONS: The role and benefit of hematopoietic growth factors in HCV therapy have not been conclusively determined to date. However, the possibility of a benefit to individual patients seen on an outpatient basis remains, and an individualized treatment approach is recommended.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>389219</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20815021]]&gt;</url>
    <title>Use of sirolimus in liver transplant recipients with renal insufficiency: a systematic review and meta-analysis</title>
    <publicationDate>2010-10-01T00:00:00</publicationDate>
    <publisher>Hepatology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,LIVER TRANSPLANTATION,RECENT ADDITIONS,SURGERY,OCTOBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Hepatology &lt;/EM&gt;publishes original, peer reviewed articles cocerning all aspects of liver structure, function and disease. It is published on behalf of the American Association for the Study of Liver Diseases.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Asrani SK, Leise MD, West CP, Murad MH, Pedersen RA, Erwin PJ, Tian J, Wiesner RH, Kim WR. (2010) Use of sirolimus in liver transplant recipients with renal insufficiency: a systematic review and meta-analysis. &lt;EM&gt;Hepatology&lt;/EM&gt; 52(4):1360-1370&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract:&lt;/STRONG&gt; Sirolimus is used in patients with renal insufficiency after liver transplantation (LT) and especially in those with calcineurin inhibitor (CNI)-associated nephrotoxicity. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; We conducted a systematic review of all randomized controlled trials and observational studies to test the hypothesis that the use of sirolimus is associated with an improvement in renal function at 1 year in LT recipients with renal insufficiency [glomerular filtration rate (GFR) &amp;lt; 60 mL/minute or creatinine level = 1.5 mg/dL]. We performed a search of all major databases, conference proceedings, and relevant journals through December 2009 and contacted content experts, corresponding authors, and the pharmaceutical manufacturer. A random effects model was used to determine the pooled estimate of the change in renal function and pooled risk estimates of adverse events that may be associated with sirolimus-based therapy at 1 year. Eleven studies (three randomized controlled trials and eight observational studies) met the final inclusion criteria. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; A nonsignificant improvement of 3.38 mL/minute [95% confidence interval (CI) = -2.93 to 9.69] was observed in methodologically sound observational studies and controlled trials reporting the primary outcome. In controlled trials, baseline GFR &amp;gt;50 mL/min sirolimus use was associated with an improvement of 10.35 mL/minute (95% CI = 3.98-16.77) in GFR or creatinine clearance. Sirolimus was not significantly associated with death [relative risk (RR) = 1.12, 95% CI = 0.66-1.88] or graft failure (RR = 0.80, 95% CI = 0.45-1.41), although reporting was incomplete. It was associated with a statistically significant risk of infection (RR = 2.47, 95% CI = 1.14-5.36), rash (RR = 7.57, 95% CI = 1.75-32.70), ulcers (RR = 7.44, 95% CI = 2.03-27.28), and discontinuation of therapy (RR = 3.61, 95% CI = 1.32-9.89). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusion:&lt;/STRONG&gt;&amp;nbsp;Conversion to sirolimus from CNIs is associated with a nonsignificant improvement in renal function in LT recipients with renal insufficiency, although the results are limited by heterogeneity, a risk of bias, and a lack of standardized reporting.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: This article is &lt;STRONG&gt;not&lt;/STRONG&gt; available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of this journal&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>381428</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://hepmon.com/pdf/Viral_Hepatitis_D_among_Hemodialysis_Pat.pdf]]&gt;</url>
    <title>Viral hepatitis D among hemodialysis patients: a worldwide underestimated problem</title>
    <publicationDate>2009-09-01T00:00:00</publicationDate>
    <publisher>Tehran Hepatitis Center</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,LIVER,HEPATITIS,HEPATITIS B,HEPATITIS D,RECENT ADDITIONS,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract:&lt;/STRONG&gt; Hepatitis D virus (HDV) infection is a major concern among hemodialysis (HD i) subjects, particularly the hepatitis B surface antigen (HBsAg) positive patients; in HBsAg-positive subjects HDV can be transmitted at serum dilutions as high as 10 -11 (1) and HBsAg-positive HD i patients stand therefore a very high risk of becoming infected with HDV through blood contamination of the hemodialysis machinery or through transfusions. Despite the importance of the problem studies of HDV in HD i are limited, the reported frequency of HDV infection among HD i patients is different throughout the world and there is no definite standard protocol to manage disease in these patients. The following represent important issues when considering HDV infection among HD i subjects: 1) High risk of HDV/ hepatitis B virus (HBV) transmission due to chronic transfusion or blood exchanges during dialysis 2) High mortality and morbidity rates 3) difficulties in the diagnosis of HDV in HD i patients 4) Irreversible complications 5) Uncertain methods for treatments. Clearly the absence of a definite standard protocol for effective management of HDV infection in HD i subjects stems from limited research on this matter. As HDV infection in HD patients has been largely neglected globally, in order to gain knowledge on this issue we carried out a world-wide investigation to determine the magnitude as well as the disease burden of HDV infection among HD i subjects with the ultimate goal to provide guidelines to manage HDV infection in this setting. We reviewed all the related studies on “HDV and hemodialysis” “renal failure” by searching the MEDLINE. Forty-seven manuscripts were retrieved in total. After a preliminary evaluation, we found only 18 articles that seemed relevant. These articles were analyzed in detail and the relevant data were gathered and summarized.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Hosseini-Moghaddam SM, Imani AA, Rizzetto M, Alavian SM. Viral hepatitis D among hemodialysis patients: a worldwide underestimated problem. &lt;EM&gt;Hep Mon&lt;/EM&gt; 2009;9(4):305-9.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>387991</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20625354]]&gt;</url>
    <title>Visceral Kaposi's sarcoma remission after intestinal transplant: first case report and systematic literature review</title>
    <publicationDate>2010-09-15T00:00:00</publicationDate>
    <publisher>Lippincott Williams &amp; Wilkins</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,SMALL INTESTINE,CANCER,RECENT ADDITIONS,TRANSPLANTATION,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; &lt;SPAN&gt;Treatment of Karposi's sarcoma (KS) in posttransplant patients should be designed aiming to obtain a complete response, irrespective of the organ affected. Only recipients who are able to achieve a sustained response would be able to obtain long-term disease-free survival.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; &lt;SPAN&gt;KS is an infrequent vascular neoplasm commonly diagnosed as an isolated cutaneous lesion that can involve other organs. So far, there are no data in the literature about the development of KS after intestinal transplant.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; &lt;SPAN class=sub_abstract_label&gt;&lt;/SPAN&gt;&lt;SPAN&gt;In this study, the authors describe a case of "visceral KS" with pulmonary and intestinal involvement and perform a systematic literature review of case reports and single-center series identified in MEDLINE.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; &lt;SPAN&gt;This case was a 42-year-old man, diagnosed with visceral KS 9 months after receiving an isolated intestinal transplant. He was successfully treated with a combination of sirolimus and liposomal doxorubicin and achieved an 18-month disease-free survival. A total of 54 cases from 27 manuscripts and the present case were analyzed in this study. The mean time from transplant to diagnosis was 17.2 months. Lungs and gastrointestinal tract were the main organs involved. Immunosuppressants were discontinued in two of the three (66.7%) cases, and sirolimus was added in eight cases. Doxorubicin was used in 12 cases. In a univariate analysis, the use of Tacrolimus, type of transplant, and presence of cutaneous KS seem to be the significant predictors of response to therapy and survival; the addition of doxorubicin showed a reduction in graft loss.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; D'Amico F, Fuxman C, Nachman F, Bitetti L, Fauda M, Echevarria C, Solar H, Politi P, Cabanne A, Mauriño E, Ruf A, Gondolesi GE. Visceral Kaposi's sarcoma remission after intestinal transplant. First case report and systematic literature review. &lt;EM&gt;Transplantation&lt;/EM&gt; 2010;90(5):547-54.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely or via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note: &lt;/STRONG&gt;This article has been included in the Specialist Collection as it is a systematic review published in a reputable journal in the field.&amp;nbsp; It has not been appraised for quality by NHS Evidence staff.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345632</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1002/ibd.20786]]&gt;</url>
    <title>Voting With their Feet (VWF) endpoint: a meta-analysis of an alternative endpoint in clinical trials, using 5-ASA induction studies in ulcerative colitis</title>
    <publicationDate>2009-03-01T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,INFLAMMATORY BOWEL DISEASE,ULCERATIVE COLITIS,RECENT ADDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The VWF (Voting With their Feet) endpoint, the percentage of subjects leaving a randomized controlled trial (RCT) arm for lack of efficacy, is inexpensive, intuitive, and has similar statistical power to clinical remission (CR).&amp;nbsp; VWF can confirm the validity of outcome measures in clinical trials, and estimate real-world clinical efficacy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aims:&lt;/STRONG&gt; Strict clinical remission endpoints in ulcerative colitis (UC) trials produce low remission rates and do not reflect the good outcomes of UC therapy. We proposed the use of the VWF endpoint. The aims were 1) to determine if the VWF endpoint can be extracted from 5-aminosalicylate (5-ASA) RCTs in UC; 2) to perform meta-analyses of VWF and CR endpoints; and 3) to determine the statistical power of the VWF endpoint.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; Fixed effects meta-analysis and power calculations were used.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; In 5 studies, including 1048 subjects, 9.5% of patients left 5-ASA study arms for lack of efficacy, versus 28.3% leaving placebo. The rate of failure to achieve CR was 68.2% with 5-ASA, versus 86.9% with placebo. The relative risk (RR) of treatment failure for 5-ASA using the VWF endpoint was 0.33 (95% confidence interval [CI] 0.24-0.44), which was significantly smaller than with the CR endpoint (RR 0.81, 95% CI 0.76-0.88). The statistical power of VWF was slightly greater than CR.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Rangwalla SC, Waljee AK, Higgins PD. Voting With their Feet (VWF) endpoint: a meta-analysis of an alternative endpoint in clinical trials, using 5-ASA induction studies in ulcerative colitis. &lt;EM&gt;Inflamm Bowel Dis&lt;/EM&gt; 2009;15(3):422-8.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is not available freely nor via NHS Athens username and password. NHS professionals are advised to check their local library to access the fulltext of&amp;nbsp;this journal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>311345</id>
    <name>&lt;![CDATA[ Gastroenterology &amp; Liver Diseases]]&gt;</name>
    <rootDirectory>/gastroliver</rootDirectory>
    <url>&lt;![CDATA[http://www.attract.wales.nhs.uk/answer.aspx?qid=6120]]&gt;</url>
    <title>What is the evidence for Gaviscon in reflux in infants?</title>
    <publicationDate>2009-04-06T00:00:00</publicationDate>
    <publisher>ATTRACT</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ GASTROENTEROLOGY &amp; LIVER DISEASES,OESOPHAGUS,GASTRO-OESOPHAGEAL REFLUX]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The ATTRACT service is based in Wales, and performs pragmatic reviews of the evidence-base for questions suggested by clinicians within the UK.&amp;nbsp; The following answer is given to this question:&lt;/P&gt;
&lt;P&gt;&lt;U&gt;Answer:&lt;/U&gt; We found very little recent evidence on the use of Gaviscon in reflux in infants. We did find one small placebo controlled randomised, double blind study which investigated the influence of Gaviscon Infant on GOR in infants. (Full details &lt;A href="http://www.attract.wales.nhs.uk/question_answers.cfm?question_id=2739" target="_blank"&gt;here&lt;/A&gt;)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&lt;/P&gt;]]&gt;</body>
  </document>
</documents>